FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Gladwell, W
Middleton, L
Cook, D
Ciencewicki, J
Kleeberger, SR
AF Gladwell, W.
Middleton, L.
Cook, D.
Ciencewicki, J.
Kleeberger, S. R.
TI Susceptibility And Response To Respiratory Syncytial Virus Infection
Enhanced By Exposure To Hyperoxic Conditions
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Gladwell, W.; Cook, D.; Ciencewicki, J.; Kleeberger, S. R.] NIEHS, Res Triangle Pk, NC 27709 USA.
[Middleton, L.] Stanford Univ Sch, Stanford, CA USA.
EM gladwell@niehs.nih.gov
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A2728
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838202006
ER
PT J
AU Habgood, A
Tatler, AL
John, AE
Laurent, GJ
Wahl, SM
Johnson, SR
Jenkins, RG
AF Habgood, A.
Tatler, A. L.
John, A. E.
Laurent, G. J.
Wahl, S. M.
Johnson, S. R.
Jenkins, R. G.
TI Investigating The Role Of Secretory Leukocyte Protease Inhibitor On The
Development Of Pulmonary Fibrosis
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Habgood, A.; Tatler, A. L.; John, A. E.; Johnson, S. R.; Jenkins, R. G.] Univ Nottingham, Nottingham, England.
[Laurent, G. J.] UCL, London, England.
[Wahl, S. M.] NIH, Bethesda, MD 20892 USA.
EM anthony.habgood@nottingham.ac.uk
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A1955
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838201115
ER
PT J
AU Habibi, M
Smith, BM
Parikh, M
Chahal, H
Shimbo, D
Prince, MR
Michos, ED
Gomes, A
Watson, KE
Hoffman, EA
Bluemke, DA
Lima, JA
Barr, RG
AF Habibi, M.
Smith, B. M.
Parikh, M.
Chahal, H.
Shimbo, D.
Prince, M. R.
Michos, E. D.
Gomes, A.
Watson, K. E.
Hoffman, E. A.
Bluemke, D. A.
Lima, J. A.
Barr, R. G.
TI Left Atrial Strain And Volume On Magnetic Resonance Imaging (mri) In
Patients With COPD And Emphysema: The Multi-Ethnic Study Of
Atherosclerosis (MESA) COPD Study
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Habibi, M.; Chahal, H.; Michos, E. D.; Lima, J. A.] Johns Hopkins Univ, Baltimore, MD USA.
[Smith, B. M.; Parikh, M.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
[Shimbo, D.] Columbia Univ, New York, NY USA.
[Prince, M. R.; Barr, R. G.] Columbia Univ, Presbyterian Hosp, New York, NY USA.
[Gomes, A.; Watson, K. E.] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA.
[Hoffman, E. A.] Univ Iowa, Iowa City, IA USA.
[Bluemke, D. A.] NIH, Bethesda, MD 20892 USA.
EM mhabibi3@jhmi.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A4357
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838203711
ER
PT J
AU Haney, C
Leung, JM
Szymanski, E
Olivier, KN
Holland, SM
AF Haney, C.
Leung, J. M.
Szymanski, E.
Olivier, K. N.
Holland, S. M.
CA NIAID NIH
TI Familial Bronchiectasis: A Case For Autosomal Dominant Mounier-Kuhn
Syndrome?
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
CT 108th International Congress of the American-Thoracic-Society
CY MAY 16-21, 2014
CL San Diego, CA
SP Amer Thorac Soc
C1 [Haney, C.; Leung, J. M.] NIH, Bethesda, MD 20892 USA.
[Szymanski, E.; Holland, S. M.] NIAID, NIH, Bethesda, MD 20892 USA.
[Olivier, K. N.] NIAID, Bethesda, MD 20892 USA.
EM haneyc@niaid.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A1751
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838200739
ER
PT J
AU Hussain, S
Sangtian, S
Rice, A
George, M
Snyder, RJ
Garantziotis, S
AF Hussain, S.
Sangtian, S.
Rice, A.
George, M.
Snyder, R. J.
Garantziotis, S.
TI Modulation Of Pre-Existing Inflammation In Peripheral Blood Monocytes
From Healthy And Diabetic Subjects After Nanomaterial Exposures
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Hussain, S.; Sangtian, S.; Rice, A.; George, M.; Snyder, R. J.; Garantziotis, S.] NIEHS, Res Triangle Pk, NC 27709 USA.
EM salik.hussain@nih.gov
RI Garantziotis, Stavros/A-6903-2009
OI Garantziotis, Stavros/0000-0003-4007-375X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A3807
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838203179
ER
PT J
AU Hussain, S
Sangtian, S
Snyder, RJ
Marshburn, J
Rice, A
Bonner, JC
Garantziotis, S
AF Hussain, S.
Sangtian, S.
Snyder, R. J.
Marshburn, J.
Rice, A.
Bonner, J. C.
Garantziotis, S.
TI Human Bronchial Epithelia Exposure To Multi-Walled Carbon Nanotubes
Induces Inflammasome-Dependent Pyroptosis And A Profibrotic Response
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Hussain, S.; Sangtian, S.; Snyder, R. J.; Marshburn, J.; Rice, A.; Garantziotis, S.] NIEHS, Res Triangle Pk, NC 27709 USA.
[Bonner, J. C.] North Carolina State Univ, Raleigh, NC USA.
EM salik.hussain@nih.gov
RI Garantziotis, Stavros/A-6903-2009
OI Garantziotis, Stavros/0000-0003-4007-375X
NR 0
TC 0
Z9 0
U1 3
U2 3
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A3806
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838203178
ER
PT J
AU Jaswal, DS
Leung, JM
Sun, J
Cui, X
Li, Y
Kern, S
Welsh, J
Natanson, C
Eichacker, PQ
AF Jaswal, D. S.
Leung, J. M.
Sun, J.
Cui, X.
Li, Y.
Kern, S.
Welsh, J.
Natanson, C.
Eichacker, P. Q.
TI Tidal Volume Practices In Acute Lung Injury And Acute Respiratory
Distress Syndrome Since 2000: A Systematic Literature Review
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Jaswal, D. S.; Leung, J. M.; Sun, J.; Cui, X.; Li, Y.; Kern, S.; Welsh, J.; Natanson, C.; Eichacker, P. Q.] NIH, Bethesda, MD 20892 USA.
EM dharmvir.jaswal@nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A3067
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838202344
ER
PT J
AU Jaswal, DS
Cui, X
Suffredini, AF
Eichacker, PQ
AF Jaswal, D. S.
Cui, X.
Suffredini, A. F.
Eichacker, P. Q.
TI A Systematic Review Of Literature Provided To The National Quality Forum
(nqf) To Validate The "severe Sepsis And Septic Shock: Management Bundle
Performance Measure (pm)"
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Jaswal, D. S.; Cui, X.; Suffredini, A. F.; Eichacker, P. Q.] NIH, Bethesda, MD 20892 USA.
EM dharmvir.jaswal@nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A2197
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838201356
ER
PT J
AU Javaheri, S
Sharma, R
Weng, J
Wang, R
Rosen, BD
Bluemke, DA
Lima, JA
Redline, S
AF Javaheri, S.
Sharma, R.
Weng, J.
Wang, R.
Rosen, B. D.
Bluemke, D. A.
Lima, J. A.
Redline, S.
TI Association Of Left Ventricular Structure And Function With Obstructive
Sleep Apnea (osa)
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Javaheri, S.; Weng, J.; Wang, R.; Redline, S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Javaheri, S.; Sharma, R.; Rosen, B. D.; Lima, J. A.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
[Bluemke, D. A.] NIH, Bethesda, MD 20892 USA.
EM sjavaheri@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A2404
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838201563
ER
PT J
AU Jones, AM
Yao, J
Taveira-DaSilva, AM
Moss, J
AF Jones, A. M.
Yao, J.
Taveira-DaSilva, A. M.
Moss, J.
TI Effect Of Sirolimus In Patients With Lymphangioleiomyomatosis On The
Progression Of Lung Disease By High-Resolution Computed Tomography Scans
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Jones, A. M.; Yao, J.; Taveira-DaSilva, A. M.; Moss, J.] NIH, Bethesda, MD 20892 USA.
EM jonesam@mail.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A2122
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838201281
ER
PT J
AU Kadri, S
Hohmann, S
Danner, RL
AF Kadri, S.
Hohmann, S.
Danner, R. L.
TI Multi-Drug Resistant Gram Negative Bacterial Infections: A Comparison Of
Mortality Estimation Strategies (colistrack Vs. Cdc)
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Kadri, S.; Danner, R. L.] NIH, Bethesda, MD 20892 USA.
[Hohmann, S.] Univ Hlth Syst Consortium, Chicago, IL USA.
EM sameer.kadri@nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A3781
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838203153
ER
PT J
AU Kadri, S
Remy, KE
Strich, J
Gea-Banacloche, J
Leitman, S
AF Kadri, S.
Remy, K. E.
Strich, J.
Gea-Banacloche, J.
Leitman, S.
TI G-Csf Stimulated Donor Granulocyte Infusions Increase Resolution Of
Invasive Fusarium Infection In Immunocompromised Hosts
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Kadri, S.; Remy, K. E.; Gea-Banacloche, J.; Leitman, S.] NIH, Bethesda, MD 20892 USA.
[Strich, J.] Georgetown Sch Med, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A2711
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838201869
ER
PT J
AU Karnekar, R
Malur, A
Butt, A
Jacob, M
Rehman, Z
Bowling, M
Shaw, R
Fessler, MB
Barna, BP
Thomassen, M
AF Karnekar, R.
Malur, A.
Butt, A.
Jacob, M.
Rehman, Z.
Bowling, M.
Shaw, R.
Fessler, M. B.
Barna, B. P.
Thomassen, M.
TI Reduced Abca1 Expression In Alveolar Macrophages From Obese Individuals:
Possible Ivolvement Of Mir33a
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Karnekar, R.; Malur, A.; Butt, A.; Jacob, M.; Rehman, Z.; Bowling, M.; Shaw, R.; Barna, B. P.; Thomassen, M.] East Carolina Univ, Greenville, NC USA.
[Fessler, M. B.] Natl Inst Environm Hlth, Res Triangle Pk, NC USA.
EM thomassenm@ecu.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A3679
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838203051
ER
PT J
AU Lee, M
Jeong, I
Choi, H
Song, T
Chen, R
Joh, J
Han, S
Kim, Y
Cho, R
Via, LE
Barry, CE
AF Lee, M.
Jeong, I.
Choi, H.
Song, T.
Chen, R.
Joh, J.
Han, S.
Kim, Y.
Cho, R.
Via, L. E.
Barry, C. E.
TI The Efficacy Of Linezolid For The Treatment Of Chronic Extensively
Drug-Resistant Tuberculosis In Korea
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Lee, M.; Choi, H.; Song, T.; Han, S.; Kim, Y.; Cho, R.] Int TB Res Ctr, Seoul, South Korea.
[Lee, M.; Jeong, I.; Joh, J.] Natl Med Ctr, Seoul, South Korea.
[Chen, R.; Via, L. E.; Barry, C. E.] NIAID, NIH, Bethesda, MD 20892 USA.
EM drsunny21c@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A2561
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838201719
ER
PT J
AU Li, Y
Cui, X
Malide, DA
Yu, Z
Fitz, Y
Eichacker, PQ
AF Li, Y.
Cui, X.
Malide, D. A.
Yu, Z.
Fitz, Y.
Eichacker, P. Q.
TI Nitric Oxide Contributes To The Arterial Relaxant Effects Of B.
Anthracis Edema Toxin In The Rat Aortic Ring Model
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
CT 108th International Congress of the American-Thoracic-Society
CY MAY 16-21, 2014
CL San Diego, CA
SP Amer Thorac Soc
C1 [Li, Y.; Cui, X.; Fitz, Y.; Eichacker, P. Q.] NIH, Dept Crit Care Med, Bethesda, MD 20892 USA.
[Malide, D. A.; Yu, Z.] NHLBI, NIH, Bethesda, MD 20892 USA.
EM yli@mail.cc.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A1655
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838200643
ER
PT J
AU Madenspacher, JH
Gowdy, KM
Azzam, KM
Fessler, MB
AF Madenspacher, J. H.
Gowdy, K. M.
Azzam, K. M.
Fessler, M. B.
TI A Role For Cholesterol 25-Hydroxylase In Resolution Of Inflammation
Following Pulmonary Innate Immune Challenge
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Madenspacher, J. H.; Gowdy, K. M.; Azzam, K. M.; Fessler, M. B.] NIEHS, Res Triangle Pk, NC 27709 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A4007
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838203361
ER
PT J
AU McCaw, ZR
Klimczak, L
Burkholder, A
Wiltshire, T
Fargo, D
Kleeberger, SR
Verhein, KC
AF McCaw, Z. R.
Klimczak, L.
Burkholder, A.
Wiltshire, T.
Fargo, D.
Kleeberger, S. R.
Verhein, K. C.
TI Gene Expression Profiling Predicts Response To Respiratory Syncytial
Virus (rsv) In Inbred Strains Of Mice
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [McCaw, Z. R.; Klimczak, L.; Burkholder, A.; Fargo, D.; Kleeberger, S. R.; Verhein, K. C.] NIEHS, Res Triangle Pk, NC 27709 USA.
[Wiltshire, T.] Univ North Carolina Chapel Hill, Chapel Hill, NC USA.
EM zrmacc@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A3820
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838203192
ER
PT J
AU Mushaben, E
Dai, C
Keeran, K
Nugent, G
Yu, ZX
Levine, SJ
AF Mushaben, E.
Dai, C.
Keeran, K.
Nugent, G.
Yu, Z. -X.
Levine, S. J.
TI The Macrophage Scavenger Receptor Cd163 Suppresses Airway
Hyperreactivity In A Murine Model Of Experimental Cockroach-Induced
Asthma
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Mushaben, E.; Dai, C.; Keeran, K.; Nugent, G.; Yu, Z. -X.; Levine, S. J.] NIH, Bethesda, MD 20892 USA.
EM Elizabeth.Mushaben@nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A4194
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838203548
ER
PT J
AU Nannes, CE
Remy, KE
AF Nannes, C. E.
Remy, K. E.
TI Romiplostim-Associated Acute Coronary Thrombosis With
Auto-Revascularization
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Nannes, C. E.] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA.
[Remy, K. E.] NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A6199
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838205819
ER
PT J
AU Narute, PS
Machado, RF
Cai, R
Sun, J
Logun, C
Shelhamer, JH
Suffredini, AF
AF Narute, P. S.
Machado, R. F.
Cai, R.
Sun, J.
Logun, C.
Shelhamer, J. H.
Suffredini, A. F.
TI Effects Of Inhaled Nitric Oxide Or Carbon Monoxide On Micrornas In
Bronchoalveolar Lavage Of Healthy Humans After Segmental Challenge With
Saline Or Endotoxin
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Narute, P. S.; Cai, R.; Sun, J.; Logun, C.; Shelhamer, J. H.; Suffredini, A. F.] NIH, Bethesda, MD 20892 USA.
[Machado, R. F.] Univ Illinois, Chicago, IL USA.
EM asuffredini@cc.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A5768
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838205388
ER
PT J
AU Narute, PS
Seam, N
Tropea, M
Logun, C
Cai, R
Sun, J
Shelhamer, JH
Meduri, GU
Suffredini, AF
AF Narute, P. S.
Seam, N.
Tropea, M.
Logun, C.
Cai, R.
Sun, J.
Shelhamer, J. H.
Meduri, G. U.
Suffredini, A. F.
TI Microrna Expression In Peripheral Blood Mononuclear Cells From Patients
With Acute Respiratory Distress Syndrome Treated With Corticosteroids
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Narute, P. S.; Tropea, M.; Logun, C.; Cai, R.; Sun, J.; Shelhamer, J. H.; Suffredini, A. F.] NIH, Bethesda, MD 20892 USA.
[Seam, N.] VA Med Ctr Washington DC, Washington, DC USA.
[Meduri, G. U.] VA Med Ctr, Memphis, TN USA.
EM asuffredini@cc.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A5017
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838204509
ER
PT J
AU Narute, PS
Logun, C
Cai, R
Sun, J
Shelhamer, JH
Suffredini, AF
AF Narute, P. S.
Logun, C.
Cai, R.
Sun, J.
Shelhamer, J. H.
Suffredini, A. F.
TI The Secretion Of Mirna From Normal Human Bronchial Epithelial Cells:
Effects Of Endotoxin, Nitric Oxide Or Carbon Monoxide
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Narute, P. S.; Logun, C.; Cai, R.; Sun, J.; Suffredini, A. F.] NIH, Bethesda, MD 20892 USA.
[Shelhamer, J. H.] NIH, Ctr Clin, Bethesda, MD 20892 USA.
EM asuffredini@cc.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A4220
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838203574
ER
PT J
AU Nichols, JL
McCaw, ZR
Verhein, KC
Gladwell, W
Bushel, P
Kleeberger, S
AF Nichols, J. L.
McCaw, Z. R.
Verhein, K. C.
Gladwell, W.
Bushel, P.
Kleeberger, S.
TI Genomic Analysis Of Postnatal Lung Development And Characterization Of
Susceptibility To Hyperoxic Lung Injury
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Nichols, J. L.] US EPA, Natl Ctr Environm Assessment, Res Triangle Pk, NC 27711 USA.
[McCaw, Z. R.; Verhein, K. C.; Gladwell, W.; Bushel, P.; Kleeberger, S.] NIEHS, Res Triangle Pk, NC 27709 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A6631
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838206429
ER
PT J
AU Nwankwor, O
Garber, NA
Rosenthal, GL
Remy, KE
AF Nwankwor, O.
Garber, N. A.
Rosenthal, G. L.
Remy, K. E.
TI Dexmedetomidine Infusion In Young Critically Ill Children Has
Significant Negative Chronotropic Effects In Absence Of Defined
Bradycardia
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Nwankwor, O.; Garber, N. A.; Rosenthal, G. L.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Remy, K. E.] NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A3247
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838202523
ER
PT J
AU Obeidat, M
Hao, K
Bosse, Y
Laviolette, M
Nickle, DC
Postma, DS
Timens, W
Gharib, SA
Tobin, MD
Hall, IP
London, SJ
Sin, DD
Pare, PD
AF Obeidat, M.
Hao, K.
Bosse, Y.
Laviolette, M.
Nickle, D. C.
Postma, D. S.
Timens, W.
Gharib, S. A.
Tobin, M. D.
Hall, I. P.
London, S. J.
Sin, D. D.
Pare, P. D.
CA CHARGE SpiroMeta Consortia
TI Integrative Genomics Approach To Unravel The Molecular Mechanisms
Underlying Variations In Lung Function Measures
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Obeidat, M.; Sin, D. D.; Pare, P. D.] Univ British Columbia, St Pauls Hosp, Ctr Heart Lung Innovat, Vancouver, BC, Canada.
[Hao, K.] Mt Sinai Sch Med, New York, NY USA.
[Bosse, Y.; Laviolette, M.] Univ Laval, Quebec City, PQ, Canada.
[Nickle, D. C.] Merck Res Labs, Boston, MA USA.
[Postma, D. S.; Timens, W.] Univ Groningen, Groningen, Netherlands.
[Gharib, S. A.] Univ Washington, Seattle, WA 98195 USA.
[Tobin, M. D.] Univ Leicester, Leicester, Leics, England.
[Hall, I. P.] Univ Nottingham, Nottingham, England.
[London, S. J.] NIEHS, Res Triangle Pk, NC 27709 USA.
EM maen.obeidat@hli.ubc.ca
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A6363
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838206162
ER
PT J
AU Olivier, KN
Gupta, R
Daley, CL
Winthrop, KL
Ruoss, S
Addrizzo-Harris, DJ
Flume, P
Dorgan, D
Salathe, MA
Brown-Elliott, BA
Wallace, RJ
Griffith, DE
AF Olivier, K. N.
Gupta, R.
Daley, C. L.
Winthrop, K. L.
Ruoss, S.
Addrizzo-Harris, D. J.
Flume, P.
Dorgan, D.
Salathe, M. A.
Brown-Elliott, B. A.
Wallace, R. J.
Griffith, D. E.
CA Arikace NTM Study Grp
TI A Randomized, Double-Blind, Placebo-Controlled Study Of Liposomal
Amikacin For Inhalation (arikace (R)) In Patients With Recalcitrant
Nontuberculous Mycobacterial Lung Disease
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Olivier, K. N.] NIAID, Bethesda, MD 20892 USA.
[Gupta, R.] Insmed Inc, Monmouth Jct, NJ USA.
[Daley, C. L.] Natl Jewish Hlth, Denver, CO USA.
[Winthrop, K. L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Ruoss, S.] Stanford Univ, Stanford, CA 94305 USA.
[Addrizzo-Harris, D. J.] NYU, Sch Med, New York, NY USA.
[Flume, P.] Med Coll South Carolina, Charleston, SC USA.
[Dorgan, D.] Univ Penn, Philadelphia, PA 19104 USA.
[Salathe, M. A.] Univ Miami, Miami, FL USA.
[Brown-Elliott, B. A.; Wallace, R. J.; Griffith, D. E.] Univ Texas Hlth Ctr Tyler, Tyler, TX USA.
EM olivierk@niaid.nih.gov
NR 0
TC 6
Z9 7
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A4126
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838203480
ER
PT J
AU Pino-Yanes, M
Thakur, N
Gignoux, CR
Galanter, JM
Roth, LA
Eng, C
Nishimura, KK
Oh, SS
Huntsman, S
Nguyen, EA
Hu, D
Drake, KA
Conti, DV
Moreno-Estrada, A
Sandoval, K
Winkler, CA
Borrell, LN
Lurmann, F
Islam, T
Davis, A
Farber, HJ
Meade, K
Avila, PC
Serebrisky, D
Bibbins-Domingo, K
Lenoir, MA
Ford, JG
Brigino-Buenaventura, E
Rodriguez-Cintron, W
Thyne, S
Sen, S
Rodriguez-Santana, JR
Bustamante, C
Williams, L
Gilliland, FD
Gauderman, WJ
Kumar, R
Torgerson, DG
Burchard, EG
AF Pino-Yanes, M.
Thakur, N.
Gignoux, C. R.
Galanter, J. M.
Roth, L. A.
Eng, C.
Nishimura, K. K.
Oh, S. S.
Huntsman, S.
Nguyen, E. A.
Hu, D.
Drake, K. A.
Conti, D. V.
Moreno-Estrada, A.
Sandoval, K.
Winkler, C. A.
Borrell, L. N.
Lurmann, F.
Islam, T.
Davis, A.
Farber, H. J.
Meade, K.
Avila, P. C.
Serebrisky, D.
Bibbins-Domingo, K.
Lenoir, M. A.
Ford, J. G.
Brigino-Buenaventura, E.
Rodriguez-Cintron, W.
Thyne, S.
Sen, S.
Rodriguez-Santana, J. R.
Bustamante, C.
Williams, L.
Gilliland, F. D.
Gauderman, W. J.
Kumar, R.
Torgerson, D. G.
Burchard, E. G.
TI Genetic Ancestry Influences Asthma Susceptibility And Lung Function
Among LatINOS
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Pino-Yanes, M.; Thakur, N.; Gignoux, C. R.; Galanter, J. M.; Roth, L. A.; Eng, C.; Nishimura, K. K.; Oh, S. S.; Huntsman, S.; Nguyen, E. A.; Hu, D.; Drake, K. A.; Bibbins-Domingo, K.; Sen, S.; Torgerson, D. G.; Burchard, E. G.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Conti, D. V.; Islam, T.; Gilliland, F. D.; Gauderman, W. J.] Univ Southern Calif, Los Angeles, CA USA.
[Moreno-Estrada, A.; Sandoval, K.; Bustamante, C.] Stanford Univ, Palo Alto, CA 94304 USA.
[Winkler, C. A.] NCI, Ctr Canc Res, Frederick, MD 21701 USA.
[Borrell, L. N.] CUNY, Bronx, NJ USA.
[Lurmann, F.] Sonoma Technol Inc, Petaluma, CA USA.
[Davis, A.; Meade, K.] Childrens Hosp & Res Ctr, Oakland, CA USA.
[Farber, H. J.] Baylor Coll Med, Houston, TX 77030 USA.
[Avila, P. C.] Northwestern Univ, Chicago, IL 60611 USA.
[Serebrisky, D.] Jacobi Med Ctr, Bronx, NY USA.
[Lenoir, M. A.] Bay Area Pediat, Oakland, CA USA.
[Ford, J. G.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Brigino-Buenaventura, E.] Kaiser Permanente, Vallejo Med Ctr, Vallejo, CA USA.
[Rodriguez-Cintron, W.] Vet Caribbean Hlth Care Syst, San Juan, PR USA.
[Thyne, S.] San Francisco Gen Hosp, San Francisco, CA 94110 USA.
[Rodriguez-Santana, J. R.] Ctr Neumol Pediat, San Juan, PR USA.
[Williams, L.] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA.
[Kumar, R.] Childrens Mem Hosp, Chicago, IL 60614 USA.
[Kumar, R.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
EM mdelpino@ull.es
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A3834
PG 2
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838203206
ER
PT J
AU Qiu, P
Cui, X
Li, Y
Fitz, Y
Ferreyra, G
Wang, S
Wang, H
Moayeri, M
Leppla, S
Suffredini, AF
Danner, R
Eichacker, PQ
AF Qiu, P.
Cui, X.
Li, Y.
Fitz, Y.
Ferreyra, G.
Wang, S.
Wang, H.
Moayeri, M.
Leppla, S.
Suffredini, A. F.
Danner, R.
Eichacker, P. Q.
TI Treatment With 3-MorpholINOSydnoime (sin-1), An No And O2-Donor Agent,
Improves Survival In Bacillus Anthracis Lethal Toxin-Challenged Rats
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
CT 108th International Congress of the American-Thoracic-Society
CY MAY 16-21, 2014
CL San Diego, CA
SP Amer Thorac Soc
C1 [Qiu, P.; Cui, X.; Li, Y.; Fitz, Y.; Ferreyra, G.; Wang, S.; Wang, H.; Suffredini, A. F.; Danner, R.; Eichacker, P. Q.] NIH, Ctr Clin, Bethesda, MD 20892 USA.
[Moayeri, M.; Leppla, S.] NIAID, NIH, Bethesda, MD 20892 USA.
EM qiup@cc.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A1652
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838200640
ER
PT J
AU Remy, KE
Baird, JS
AF Remy, K. E.
Baird, J. S.
TI An 18 Year Old Presenting With Acute, Severe Hypercalcemia Causing
Direct Myocardial Injury
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Remy, K. E.] NIH, Bethesda, MD 20892 USA.
[Baird, J. S.] Columbia Univ, Sch Med, New York, NY USA.
EM kenneth.remy@nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A6133
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838205753
ER
PT J
AU Remy, KE
Cui, X
Solomon, SB
Sun, J
Li, Y
Eichacker, PQ
AF Remy, K. E.
Cui, X.
Solomon, S. B.
Sun, J.
Li, Y.
Eichacker, P. Q.
TI Raxibacumab Treatment Improves Survival In A Fluid And Vasopressor
Supported Canine Model Of B. Anthracis Lethal And Edema Toxin Associated
Shock
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Remy, K. E.; Cui, X.; Solomon, S. B.; Sun, J.; Li, Y.; Eichacker, P. Q.] NIH, Bethesda, MD 20892 USA.
EM kenneth.remy@nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A3113
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838202390
ER
PT J
AU Shaffer, RK
Haney, C
Freeman, AM
Prevots, DR
Holland, SM
Olivier, KN
AF Shaffer, R. K.
Haney, C.
Freeman, A. M.
Prevots, D. R.
Holland, S. M.
Olivier, K. N.
TI Prevalence And Clinical Significance Of Nocardia And Cryptococcus
Species In Pulmonary Nontuberculous Mycobacteria (p-Ntm) Patients
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Shaffer, R. K.; Haney, C.; Freeman, A. M.; Prevots, D. R.; Holland, S. M.; Olivier, K. N.] NIAID, Bethesda, MD 20892 USA.
EM robyn.shaffer@nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A4116
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838203470
ER
PT J
AU Snyder, RJ
Hussain, S
Sangtian, S
Rice, A
Marshburn, J
George, M
Garantziotis, S
AF Snyder, R. J.
Hussain, S.
Sangtian, S.
Rice, A.
Marshburn, J.
George, M.
Garantziotis, S.
TI Prevention Of Terminal Differentiation In Primary Human Bronchial
Epithelial Cells Exposed To Multi-Walled Carbon Nanotubes
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Snyder, R. J.; Hussain, S.; Sangtian, S.; Rice, A.; Marshburn, J.; George, M.; Garantziotis, S.] NIEHS, Durham, NC USA.
EM snyder3@niehs.nih.gov
RI Garantziotis, Stavros/A-6903-2009
OI Garantziotis, Stavros/0000-0003-4007-375X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A3805
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838203177
ER
PT J
AU Stober, V
Majors, A
Wisniewski, HG
Aronica, MA
Garantziotis, S
AF Stober, V.
Majors, A.
Wisniewski, H. -G.
Aronica, M. A.
Garantziotis, S.
TI Tsg-6 Promotes Hyperresponsiveness Of Naive Tracheal Rings
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Stober, V.; Garantziotis, S.] NIEHS, Res Triangle Pk, NC 27709 USA.
[Majors, A.; Aronica, M. A.] Cleveland Clin, Dept Pathobiol, Cleveland, OH 44106 USA.
[Majors, A.; Aronica, M. A.] Cleveland Clin, Resp Inst, Cleveland, OH 44106 USA.
[Wisniewski, H. -G.] NYU, Langone Med Ctr, New York, NY USA.
RI Garantziotis, Stavros/A-6903-2009
OI Garantziotis, Stavros/0000-0003-4007-375X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A5601
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838205221
ER
PT J
AU Taveira-DaSilva, AM
Jones, AM
Julien-Williams, P
Haughey, M
Stylianou, M
Glasgow, CG
Moss, J
AF Taveira-DaSilva, A. M.
Jones, A. M.
Julien-Williams, P.
Haughey, M.
Stylianou, M.
Glasgow, C. G.
Moss, J.
TI Fasting Decreases The Size Of Abdomino-Pelvic Lymphangioleiomyomas
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Taveira-DaSilva, A. M.; Jones, A. M.; Julien-Williams, P.; Haughey, M.; Glasgow, C. G.; Moss, J.] NIH, Bethesda, MD 20892 USA.
[Stylianou, M.] NHLBI, NIH, Bethesda, MD 20892 USA.
EM dasilvaa@nhlbi.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A2124
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838201283
ER
PT J
AU Taveira-DaSilva, AM
Jones, AM
Julien-Williams, P
Stylianou, M
Moss, J
AF Taveira-DaSilva, A. M.
Jones, A. M.
Julien-Williams, P.
Stylianou, M.
Moss, J.
TI Retrospective Review Of Combined Sirolimus And Simvastatin Therapy In
Lymphangioleiomyomatosis
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Taveira-DaSilva, A. M.; Jones, A. M.; Julien-Williams, P.; Moss, J.] NHLBI, NIH, Bethesda, MD 20892 USA.
[Stylianou, M.] NIH, Bethesda, MD 20892 USA.
EM mossj@nhlbi.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A2123
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838201282
ER
PT J
AU Trempus, C
Garantziotis, S
AF Trempus, C.
Garantziotis, S.
TI Extracellular Matrix Interactions With Primary Cilia In Human Airway
Smooth Muscle Cells
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Trempus, C.; Garantziotis, S.] NIEHS, NIH, Res Triangle Pk, NC 27709 USA.
RI Garantziotis, Stavros/A-6903-2009
OI Garantziotis, Stavros/0000-0003-4007-375X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A2671
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838201829
ER
PT J
AU Verhein, KC
Nichols, JL
Panduri, V
Gladwell, W
Marzec, J
McCaw, Z
Reeves, N
Malphurs, J
Solomon, G
Wiltshire, T
Burkholder, A
Fargo, D
Bell, D
Van Houten, B
Kleeberger, SR
AF Verhein, K. C.
Nichols, J. L.
Panduri, V.
Gladwell, W.
Marzec, J.
McCaw, Z.
Reeves, N.
Malphurs, J.
Solomon, G.
Wiltshire, T.
Burkholder, A.
Fargo, D.
Bell, D.
Van Houten, B.
Kleeberger, S. R.
TI Genetic Determinants Of Oxidant-Induced Nuclear And Mitochondrial Dna
Lesions In A Neonatal Inbred Mouse Model Of Acute Lung Injury
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Verhein, K. C.; Panduri, V.; Gladwell, W.; Marzec, J.; McCaw, Z.; Reeves, N.; Malphurs, J.; Solomon, G.; Burkholder, A.; Fargo, D.; Bell, D.; Kleeberger, S. R.] NIEHS, Res Triangle Pk, NC 27709 USA.
[Nichols, J. L.] US EPA, Res Triangle Pk, NC 27711 USA.
[Wiltshire, T.] Univ N Carolina, Chapel Hill, NC USA.
[Van Houten, B.] Univ Pittsburgh, Pittsburgh, PA USA.
EM verheinkc@niehs.nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A3816
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838203188
ER
PT J
AU Wang, TW
Lan, Q
Rothman, N
Wei, H
Steiling, K
Liu, G
Alekseyev, Y
Hosgood, H
Downward, G
Reiss, B
Wei, F
Xu, J
Lenburg, M
Vermeulen, R
Spira, A
AF Wang, T. W.
Lan, Q.
Rothman, N.
Wei, H.
Steiling, K.
Liu, G.
Alekseyev, Y.
Hosgood, H., III
Downward, G.
Reiss, B.
Wei, F.
Xu, J.
Lenburg, M.
Vermeulen, R.
Spira, A.
TI Buccal Epithelial Gene-Expression Reflects The Physiological Response To
Smoky Vs. Smokeless Coal Exposure
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Wang, T. W.; Steiling, K.; Liu, G.; Alekseyev, Y.; Lenburg, M.; Spira, A.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Lan, Q.; Rothman, N.; Wei, H.] NCI, Rockville, MD USA.
[Hosgood, H., III] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Downward, G.; Vermeulen, R.] Univ Utrecht, Utrecht, Netherlands.
[Reiss, B.] Univ Washington, Seattle, WA 98195 USA.
[Wei, F.] China Natl Environm Monitoring Ctr, Beijing, Peoples R China.
[Xu, J.] Univ Hong Kong, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China.
EM wateresa@bu.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A3822
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838203194
ER
PT J
AU Yang, IV
Pedersen, B
Liu, A
O'Connor, GT
Teach, SJ
Kattan, M
Misiak, RT
Gruchalla, R
Steinbach, SF
Szefler, SJ
Gill, MA
Calatroni, A
David, G
Hennessy, C
Davidson, EJ
Gergen, P
Togias, A
Busse, WW
Schwartz, DA
AF Yang, I. V.
Pedersen, B.
Liu, A.
O'Connor, G. T.
Teach, S. J.
Kattan, M.
Misiak, R. T.
Gruchalla, R.
Steinbach, S. F.
Szefler, S. J.
Gill, M. A.
Calatroni, A.
David, G.
Hennessy, C.
Davidson, E. J.
Gergen, P.
Togias, A.
Busse, W. W.
Schwartz, D. A.
CA Inner City Asthma Consortium ICAC
TI Nasal Epithelial Dna Methylation And Gene Expression Profiles Of
Allergic Asthma In The Inner City
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Yang, I. V.; Pedersen, B.; Hennessy, C.; Davidson, E. J.; Schwartz, D. A.] Univ Colorado, Aurora, CO USA.
[Liu, A.; Szefler, S. J.] Natl Jewish Hlth, Denver, CO USA.
[O'Connor, G. T.; Steinbach, S. F.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Teach, S. J.] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Kattan, M.] Columbia Univ, Med Ctr, New York, NY USA.
[Misiak, R. T.] Henry Ford Hosp, Detroit, MI 48202 USA.
[Gruchalla, R.; Gill, M. A.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA.
[Calatroni, A.; David, G.] Rho Fed Syst Inc, Chapel Hill, NC USA.
[Gergen, P.; Togias, A.] NIAID, Bethesda, MD 20892 USA.
[Busse, W. W.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
EM ivana.yang@ucdenver.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A3375
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838202651
ER
PT J
AU Yao, X
Gao, M
Meyer, K
Keeran, K
Nugent, G
Jeffries, K
Qu, X
Yu, ZX
Yang, Y
Raghavachari, N
Levine, SJ
AF Yao, X.
Gao, M.
Meyer, K.
Keeran, K.
Nugent, G.
Jeffries, K.
Qu, X.
Yu, Z. -X.
Yang, Y.
Raghavachari, N.
Levine, S. J.
TI Disabled-1 Attenuates House Dust Mite-Induced Airway Inflammation By
Suppressing The Recruitment Of Intraepithelial Mast Cells
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Yao, X.; Gao, M.; Meyer, K.; Keeran, K.; Nugent, G.; Jeffries, K.; Qu, X.; Yu, Z. -X.; Yang, Y.; Raghavachari, N.; Levine, S. J.] NHLBI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A5355
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838204839
ER
PT J
AU Young, MT
Sandler, DP
Deroo, LA
Vedal, S
Kaufman, JD
London, S
AF Young, M. T.
Sandler, D. P.
Deroo, L. A.
Vedal, S.
Kaufman, J. D.
London, S.
TI Traffic-Related Air Pollution Exposure And Adult Incident Asthma In A
Cohort Of Us Women
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Young, M. T.; Vedal, S.; Kaufman, J. D.] Univ Washington, Seattle, WA 98195 USA.
[Sandler, D. P.; Deroo, L. A.; London, S.] NIEHS, Res Triangle Pk, NC 27709 USA.
EM myoung3@uw.edu
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A2298
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838201457
ER
PT J
AU Zhou, Y
Herzog, E
He, CH
Peng, X
Lee, CM
Gulati, M
Gochuico, BR
Gahl, WA
Lee, CG
Elias, JA
AF Zhou, Y.
Herzog, E.
He, C-H
Peng, X.
Lee, C-M
Gulati, M.
Gochuico, B. R.
Gahl, W. A.
Lee, C. G.
Elias, J. A.
TI Elevated Chitinase-3-Like-1 And Impaired Trafficking Of Il-13r alpha 2
Contribute To Pulmonary Injury And Fibroproliferative Repair In
Hermansky-Pudlak Syndrome
SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
LA English
DT Meeting Abstract
C1 [Zhou, Y.; Herzog, E.; He, C-H; Peng, X.; Lee, C-M; Gulati, M.; Lee, C. G.] Yale Univ, Sch Med, New Haven, CT USA.
[Gochuico, B. R.; Gahl, W. A.] NHGRI, NIH, Bethesda, MD 20892 USA.
[Elias, J. A.] Brown Univ, Providence, RI 02912 USA.
EM y.zhou@yale.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1073-449X
EI 1535-4970
J9 AM J RESP CRIT CARE
JI Am. J. Respir. Crit. Care Med.
PY 2014
VL 189
MA A1245
PG 1
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA V45TF
UT WOS:000209838200235
ER
PT J
AU Goldman, D
Rosser, AA
AF Goldman, David
Rosser, Alexandra A.
TI MAOA-Environment Interactions: Results May Vary
SO BIOLOGICAL PSYCHIATRY
LA English
DT Editorial Material
ID MONOAMINE OXIDASE-A; BEHAVIOR; CHILDREN; GENE
C1 [Goldman, David; Rosser, Alexandra A.] NIAAA, Rockville, MD 20852 USA.
RP Goldman, D (reprint author), NIAAA, 5625 Fishers Lane, Rockville, MD 20852 USA.
EM david.goldman@nih.hhs.gov
RI Goldman, David/F-9772-2010
OI Goldman, David/0000-0002-1724-5405
NR 9
TC 5
Z9 5
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD JAN 1
PY 2014
VL 75
IS 1
BP 2
EP 3
DI 10.1016/j.biopsych.2013.09.015
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 269TW
UT WOS:000328265800001
PM 24314060
ER
PT J
AU Sutin, AR
Cutler, RG
Camandola, S
Uda, M
Feldman, NH
Cucca, F
Zonderman, AB
Mattson, MP
Ferrucci, L
Schlessinger, D
Terracciano, A
AF Sutin, Angelina R.
Cutler, Roy G.
Camandola, Simonetta
Uda, Manuela
Feldman, Neil H.
Cucca, Francesco
Zonderman, Alan B.
Mattson, Mark P.
Ferrucci, Luigi
Schlessinger, David
Terracciano, Antonio
TI Impulsivity is Associated with Uric Acid: Evidence from Humans and Mice
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Excitement seeking; impulse control; impulsivity; mouse model;
personality traits; uric acid
ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; LOW REARING ACTIVITY;
LESCH-NYHAN-DISEASE; PERSONALITY-TRAITS; 5-FACTOR MODEL; BODY-WEIGHT;
RATS; HYPERURICEMIA; POPULATION; LEVEL
AB Background: The ability to control impulses varies greatly, and difficulty with impulse control can have severe consequences; in the extreme, it is the defining feature of many psychiatric disorders. Evidence from disparate lines of research suggests that uric acid is elevated in psychiatric disorders characterized by high impulsivity, such as attention-deficit/hyperactivity disorder and bipolar disorder. The present research tests the hypothesis that impulsivity is associated with higher uric acid in humans and mice.
Methods: Using two longitudinal, nonclinical community samples (total n = 6883), we tested whether there is an association between uric acid and normal variation in trait impulsivity measured with the Revised NEO Personality Inventory. We also examined the effect of uric acid on behavior by comparing wild-type mice, which naturally have low levels of uric acid, with mice genetically modified to accumulate high levels of uric acid.
Results: In both human samples, the emotional aspects of trait impulsivity, specifically impulsiveness and excitement seeking, were associated with higher levels of uric acid concurrently and when uric acid was measured 3 to 5 years later. Consistent with the human data, the genetically modified mice displayed significantly more exploratory and novelty-seeking behavior than the wild-type mice.
Conclusions: Higher uric acid was associated with impulsivity in both humans and mice. The identification of biological markers of impulsivity may lead to a better understanding of the physiological mechanisms involved in impulsivity and may suggest potential targets for therapeutic intervention.
C1 [Sutin, Angelina R.] Florida State Univ, Coll Med, Dept Med Humanities & Social Sci, Tallahassee, FL 32306 USA.
[Terracciano, Antonio] Florida State Univ, Coll Med, Dept Geriatr, Tallahassee, FL 32306 USA.
[Sutin, Angelina R.; Zonderman, Alan B.; Terracciano, Antonio] NIA, Lab Behav Neurosci, NIH, Bethesda, MD 20892 USA.
[Cutler, Roy G.; Camandola, Simonetta; Feldman, Neil H.; Mattson, Mark P.] NIA, Neurosci Lab, NIH, Bethesda, MD 20892 USA.
[Schlessinger, David] NIA, Genet Lab, NIH, Bethesda, MD 20892 USA.
[Ferrucci, Luigi] NIA, Clin Res Branch, NIH, Bethesda, MD 20892 USA.
[Uda, Manuela; Cucca, Francesco] CNR, Ist Neurogenet & Neurofarmacol, Cagliari, Italy.
[Mattson, Mark P.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.
RP Sutin, AR (reprint author), Florida State Univ, Coll Med, 1115 W Call St, Tallahassee, FL 32306 USA.
EM angelina.sutin@med.fsu.edu
OI Zonderman, Alan B/0000-0002-6523-4778
FU Intramural Research Program of the National Institute on Aging, National
Institutes of Health
FX This research was supported, in part, by the Intramural Research Program
of the National Institute on Aging, National Institutes of Health.
NR 52
TC 15
Z9 15
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD JAN 1
PY 2014
VL 75
IS 1
BP 31
EP 37
DI 10.1016/j.biopsych.2013.02.024
PG 7
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 269TW
UT WOS:000328265800007
PM 23582268
ER
PT J
AU Bondi, CO
Taha, AY
Tock, JL
Totah, NKB
Cheon, Y
Torres, GE
Rapoport, SI
Moghaddam, B
AF Bondi, Corina O.
Taha, Ameer Y.
Tock, Jody L.
Totah, Nelson K. B.
Cheon, Yewon
Torres, Gonzalo E.
Rapoport, Stanley I.
Moghaddam, Bita
TI Adolescent Behavior and Dopamine Availability Are Uniquely Sensitive to
Dietary Omega-3 Fatty Acid Deficiency
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Addiction; anxiety; nutrition; cognition; fatty acids; schizophrenia
ID POLYUNSATURATED FATTY-ACIDS; BRAIN DOCOSAHEXAENOIC ACID; MEDIAL
PREFRONTAL CORTEX; RAT-BRAIN; DOCOSAPENTAENOIC ACID;
PSYCHIATRIC-DISORDERS; PSYCHOTIC DISORDERS; RECEPTOR BLOCKADE;
FRONTAL-CORTEX; SCHIZOPHRENIA
AB Background: Understanding the nature of environmental factors that contribute to behavioral health is critical for successful prevention strategies in individuals at risk for psychiatric disorders. These factors are typically experiential in nature, such as stress and urbanicity, but nutrition-in particular dietary deficiency of omega-3 polyunsaturated fatty acids (n-3 PUFAs)-has increasingly been implicated in the symptomatic onset of schizophrenia and mood disorders, which typically occurs during adolescence to early adulthood. Thus, adolescence might be the critical age range for the negative impact of diet as an environmental insult.
Methods: A rat model involving consecutive generations of n-3 PUFA deficiency was developed on the basis of the assumption that dietary trends toward decreased consumption of these fats began 4-5 decades ago when the parents of current adolescents were born. Behavioral performance in a wide range of tasks as well as markers of dopamine-related neurotransmission was compared in adolescents and adults fed n-3 PUFA adequate and deficient diets.
Results: In adolescents, dietary n-3 PUFA deficiency across consecutive generations produced a modality-selective and task-dependent impairment in cognitive and motivated behavior distinct from the deficits observed in adults. Although this dietary deficiency affected expression of dopamine-related proteins in both age groups in adolescents but not adults, there was an increase in tyrosine hydroxylase expression that was selective to the dorsal striatum.
Conclusions: These data support a nutritional contribution to optimal cognitive and affective functioning in adolescents. Furthermore, they suggest that n-3 PUFA deficiency disrupts adolescent behaviors through enhanced dorsal striatal dopamine availability.
C1 [Bondi, Corina O.; Tock, Jody L.; Totah, Nelson K. B.; Moghaddam, Bita] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA.
[Torres, Gonzalo E.] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15260 USA.
[Taha, Ameer Y.; Cheon, Yewon; Rapoport, Stanley I.] NIA, Brain Physiol & Metab Sect, Neurosci Lab, NIH, Bethesda, MD 20892 USA.
RP Moghaddam, B (reprint author), Univ Pittsburgh, Dept Neurosci, A210 Langley Hall, Pittsburgh, PA 15260 USA.
EM bita@pitt.edu
FU United States National Institutes of Health [R21 (MH097219)]; National
Institute on Aging Intramural Research Program
FX This research was supported by Grant R21 (MH097219) from the United
States National Institutes of Health, and the National Institute on
Aging Intramural Research Program.
NR 66
TC 22
Z9 23
U1 3
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD JAN 1
PY 2014
VL 75
IS 1
BP 38
EP 46
DI 10.1016/j.biopsych.2013.06.007
PG 9
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 269TW
UT WOS:000328265800008
PM 23890734
ER
PT S
AU Miller, DS
AF Miller, David S.
BE Fricker, G
Ott, M
Mahringer, A
TI ABC Transporters at the Blood-Brain Barrier
SO BLOOD BRAIN BARRIER (BBB)
SE Topics in Medicinal Chemistry Series
LA English
DT Article; Book Chapter
DE BCRP; Blood-brain barrier; Brain capillary endothelium; Disease; Drug
delivery; MRP; P-glycoprotein; Regulation
ID CANCER RESISTANCE PROTEIN; P-GLYCOPROTEIN EXPRESSION;
PREGNANE-X-RECEPTOR; BINDING CASSETTE TRANSPORTERS; CONSTITUTIVE
ANDROSTANE RECEPTOR; XENOBIOTIC EFFLUX TRANSPORTERS;
CENTRAL-NERVOUS-SYSTEM; MEDIATED UP-REGULATION; NECROSIS-FACTOR-ALPHA;
SPINAL CORD BARRIER
AB In the blood-brain barrier several ABC transporters are expressed at the luminal, blood-facing, plasma membrane of the brain capillary endothelial cells. There they function as ATP-driven efflux pumps for xenobiotics and endogenous metabolites, thus providing an important element of the barrier. When these transporters limit neurotoxicant entry into the CNS, they are neuroprotective; when they limit therapeutic drug entry, they become major obstacles to drug delivery to treat CNS diseases. Here I review function and regulation of ABC transporters at the blood-brain barrier, with an emphasis on recently disclosed mechanisms that alter transporter expression and transport activity.
C1 [Miller, David S.] NIEHS, Lab Toxicol & Pharmacol, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
RP Miller, DS (reprint author), NIEHS, Lab Toxicol & Pharmacol, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
NR 79
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 1862-2461
BN 978-3-662-43787-2; 978-3-662-43786-5
J9 TOP MED CHEM SER
JI Top. Med. Chem.
PY 2014
VL 10
BP 49
EP 69
DI 10.1007/7355_2013_31
D2 10.1007/978-3-662-43787-2
PG 21
WC Chemistry, Medicinal; Neurosciences; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy; Neurosciences & Neurology
GA BE9ZC
UT WOS:000378380100004
ER
PT S
AU Kovac, P
AF Kovac, Pavol
BE VanDerMarel, G
Codee, J
TI In Lieu of an Introduction
SO CARBOHYDRATE CHEMISTRY: PROVEN SYNTHETIC METHODS, VOL 2
SE Carbohydrate Chemistry-Proven Synthetic Methods
LA English
DT Editorial Material; Book Chapter
ID URONIC-ACID DERIVATIVES; STEREOSELECTIVE-SYNTHESIS; CHEMICAL-SYNTHESIS
C1 [Kovac, Pavol] NIDDK, LBC, NIH, Bethesda, MD 20892 USA.
RP Kovac, P (reprint author), NIDDK, LBC, NIH, Bethesda, MD 20892 USA.
NR 17
TC 0
Z9 0
U1 1
U2 1
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
SN 2372-9163
BN 978-1-4398-7595-7; 978-1-4398-7594-0
J9 CARBOHYD CHEM
PY 2014
VL 2
BP XI
EP XXV
PG 15
WC Biochemical Research Methods; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA BE0XL
UT WOS:000367295900001
ER
PT S
AU Xu, P
Castelli, R
Kovac, P
AF Xu, Peng
Castelli, Riccardo
Kovac, Pavol
BE VanDerMarel, G
Codee, J
TI Synthesis and Characterization of Tetra-O-propargyl Pentaerythritol
SO CARBOHYDRATE CHEMISTRY: PROVEN SYNTHETIC METHODS, VOL 2
SE Carbohydrate Chemistry-Proven Synthetic Methods
LA English
DT Article; Book Chapter
C1 [Xu, Peng; Kovac, Pavol] NIDDK, LBC, NIH, Bethesda, MD 20892 USA.
[Castelli, Riccardo] Leiden Univ, Leiden Inst Chem, NL-2300 RA Leiden, Netherlands.
RP Kovac, P (reprint author), NIDDK, LBC, NIH, Bethesda, MD 20892 USA.
EM kpn@helix.nih.gov
NR 10
TC 2
Z9 2
U1 1
U2 1
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
SN 2372-9163
BN 978-1-4398-7595-7; 978-1-4398-7594-0
J9 CARBOHYD CHEM
PY 2014
VL 2
BP 213
EP 216
PG 4
WC Biochemical Research Methods; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA BE0XL
UT WOS:000367295900025
ER
PT S
AU Soliman, SE
Chinoy, Z
Kovac, P
AF Soliman, Sameh E.
Chinoy, Zoeisha
Kovac, Pavol
BE VanDerMarel, G
Codee, J
TI Improved Synthesis of Ethyl
(2,3,4,6-Tetra-beta-D-acetyl-beta-D-galactopyranosyI)-(1 ->
3)-4,6-O-benzylidene-2-deoxy-1-thio-2-trichloroacetamido-D-beta-glucopyr
anoside
SO CARBOHYDRATE CHEMISTRY: PROVEN SYNTHETIC METHODS, VOL 2
SE Carbohydrate Chemistry-Proven Synthetic Methods
LA English
DT Article; Book Chapter
C1 [Soliman, Sameh E.; Kovac, Pavol] NIDDK, LBC, NIH, Bethesda, MD 20892 USA.
[Chinoy, Zoeisha] Univ Georgia, Athens, GA 30602 USA.
RP Kovac, P (reprint author), NIDDK, LBC, NIH, Bethesda, MD 20892 USA.
EM kpn@helix.nih.gov
NR 6
TC 0
Z9 0
U1 1
U2 1
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
SN 2372-9163
BN 978-1-4398-7595-7; 978-1-4398-7594-0
J9 CARBOHYD CHEM
PY 2014
VL 2
BP 217
EP 221
PG 5
WC Biochemical Research Methods; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA BE0XL
UT WOS:000367295900026
ER
PT J
AU Benavente, OR
Pearce, LA
McClure, LA
Conwit, R
Hart, RG
AF Benavente, O. R.
Pearce, L. A.
McClure, L. A.
Conwit, R.
Hart, R. G.
TI Effect of Blood Pressure Lowering on Cognition in Patients with Lacunar
Stroke. The Secondary Prevention of Small Subcortical Strokes (SPS3)
trial.
SO CEREBROVASCULAR DISEASES
LA English
DT Meeting Abstract
C1 [Benavente, O. R.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[McClure, L. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Conwit, R.] NINDS, NIH, Bethesda, MD 20892 USA.
[Hart, R. G.] McMaster Univ, Hamilton, ON, Canada.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-9770
EI 1421-9786
J9 CEREBROVASC DIS
JI Cerebrovasc. Dis.
PY 2014
VL 37
SU 1
BP 33
EP 33
PG 1
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA V43ZE
UT WOS:000209718500042
ER
PT J
AU Parides, MK
Overbey, JR
Stapf, C
Moskowitz, AJ
Moy, C
Salman, RA
Vicaut, EC
Mohr, JP
AF Parides, M. K.
Overbey, J. R.
Stapf, C.
Moskowitz, A. J.
Moy, C.
Salman, R. Al-Shahi
Vicaut, E. C.
Mohr, J. P.
TI Projecting longer term results in the ARUBA trial
SO CEREBROVASCULAR DISEASES
LA English
DT Meeting Abstract
C1 [Parides, M. K.; Overbey, J. R.; Moskowitz, A. J.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Stapf, C.; Vicaut, E. C.] Hop Lariboisiere, F-75475 Paris, France.
[Moy, C.] NINDS, Bethesda, MD 20892 USA.
[Salman, R. Al-Shahi] Univ Edinburgh, Edinburgh, Midlothian, Scotland.
[Mohr, J. P.] Columbia Univ, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-9770
EI 1421-9786
J9 CEREBROVASC DIS
JI Cerebrovasc. Dis.
PY 2014
VL 37
SU 1
BP 190
EP 191
PG 2
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA V43ZE
UT WOS:000209718501105
ER
PT J
AU Lynch, J
Benson, R
Hsia, A
Nadareishvilli, Z
Merino, J
Latour, L
Luby, M
AF Lynch, J.
Benson, R.
Hsia, A.
Nadareishvilli, Z.
Merino, J.
Latour, L.
Luby, M.
TI Stroke in Multiple Vascular Territories
SO CEREBROVASCULAR DISEASES
LA English
DT Meeting Abstract
C1 [Lynch, J.; Latour, L.; Luby, M.] NINDS, NIH, Bethesda, MD 20892 USA.
[Benson, R.; Hsia, A.] Washington Hosp Ctr, NIH Stroke Program, Washington, DC 20010 USA.
[Nadareishvilli, Z.] Suburban Hosp, NIH Stroke Program, Bethesda, MD USA.
[Merino, J.] Johns Hopkins Community Phys, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-9770
EI 1421-9786
J9 CEREBROVASC DIS
JI Cerebrovasc. Dis.
PY 2014
VL 37
SU 1
MA B1917
BP 501
EP 501
PG 1
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA V43ZE
UT WOS:000209718504017
ER
PT J
AU Boja, ES
Kinsinger, CR
Rodriguez, H
Srinivas, P
AF Boja, Emily S.
Kinsinger, Christopher R.
Rodriguez, Henry
Srinivas, Pothur
CA Omics Integration Workshop
TI Integration of omics sciences to advance biology and medicine
SO CLINICAL PROTEOMICS
LA English
DT Article
DE Omics integration; Omics science; Clinical application; Risk prediction;
Proteomics; Metabolomics; Genomics
AB In the past two decades, our ability to study cellular and molecular systems has been transformed through the development of omics sciences. While unlimited potential lies within massive omics datasets, the success of omics sciences to further our understanding of human disease and/or translating these findings to clinical utility remains elusive due to a number of factors. A significant limiting factor is the integration of different omics datasets (i.e., integromics) for extraction of biological and clinical insights. To this end, the National Cancer Institute (NCI) and the National Heart, Lung and Blood Institute (NHLBI) organized a joint workshop in June 2012 with the focus on integration issues related to multi-omics technologies that needed to be resolved in order to realize the full utility of integrating omics datasets by providing a glimpse into the disease as an integrated "system". The overarching goals were to (1) identify challenges and roadblocks in omics integration, and (2) facilitate the full maturation of 'integromics' in biology and medicine. Participants reached a consensus on the most significant barriers for integrating omics sciences and provided recommendations on viable approaches to overcome each of these barriers within the areas of technology, bioinformatics and clinical medicine.
C1 [Boja, Emily S.; Kinsinger, Christopher R.; Rodriguez, Henry] NCI, Off Canc Clin Prote Res, NIH, Bethesda, MD 20892 USA.
[Srinivas, Pothur] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA.
RP Boja, ES (reprint author), NCI, Off Canc Clin Prote Res, NIH, Bethesda, MD 20892 USA.
EM bojae@mail.nih.gov; kinsingc@mail.nih.gov
NR 45
TC 3
Z9 3
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1542-6416
EI 1559-0275
J9 CLIN PROTEOM
JI Clin. Proteom.
PY 2014
VL 11
AR 45
DI 10.1186/1559-0275-11-45
PG 12
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA V42YR
UT WOS:000209649600040
ER
PT J
AU Boja, ES
Rodriguez, H
AF Boja, Emily S.
Rodriguez, Henry
TI Proteogenomic convergence for understanding cancer pathways and networks
SO CLINICAL PROTEOMICS
LA English
DT Review
DE Protein identification and quantitation; Post-translational
modification; Targeted proteomics; Proteogenomics; Protein networks;
Signaling pathways; Mathematical and computational modeling; Omics
integration; Systems biology
AB During the past several decades, the understanding of cancer at the molecular level has been primarily focused on mechanisms on how signaling molecules transform homeostatically balanced cells into malignant ones within an individual pathway. However, it is becoming more apparent that pathways are dynamic and crosstalk at different control points of the signaling cascades, making the traditional linear signaling models inadequate to interpret complex biological systems. Recent technological advances in high throughput, deep sequencing for the human genomes and proteomic technologies to comprehensively characterize the human proteomes in conjunction with multiplexed targeted proteomic assays to measure panels of proteins involved in biologically relevant pathways have made significant progress in understanding cancer at the molecular level. It is undeniable that proteomic profiling of differentially expressed proteins under many perturbation conditions, or between normal and "diseased" states is important to capture a first glance at the overall proteomic landscape, which has been a main focus of proteomics research during the past 15-20 years. However, the research community is gradually shifting its heavy focus from that initial discovery step to protein target verification using multiplexed quantitative proteomic assays, capable of measuring changes in proteins and their interacting partners, isoforms, and post-translational modifications (PTMs) in response to stimuli in the context of signaling pathways and protein networks. With a critical link to genotypes (i.e., high throughput genomics and transcriptomics data), new and complementary information can be gleaned from multi-dimensional omics data to (1) assess the effect of genomic and transcriptomic aberrations on such complex molecular machinery in the context of cell signaling architectures associated with pathological diseases such as cancer (i.e., from genotype to proteotype to phenotype); and (2) target pathway-and network-driven changes and map the fluctuations of these functional units (proteins) responsible for cellular activities in response to perturbation in a spatiotemporal fashion to better understand cancer biology as a whole system.
C1 [Boja, Emily S.; Rodriguez, Henry] NCI, Off Canc Clin Prote Res, NIH, 31 Ctr Dr,MSC 2580, Bethesda, MD 20892 USA.
RP Boja, ES (reprint author), NCI, Off Canc Clin Prote Res, NIH, 31 Ctr Dr,MSC 2580, Bethesda, MD 20892 USA.
EM bojae@mail.nih.gov
NR 146
TC 12
Z9 12
U1 1
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1542-6416
EI 1559-0275
J9 CLIN PROTEOM
JI Clin. Proteom.
PY 2014
VL 11
AR 22
DI 10.1186/1559-0275-11-22
PG 17
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA V42YR
UT WOS:000209649600015
PM 24994965
ER
PT J
AU Norheim, OF
Baltussen, R
Johri, M
Chisholm, D
Nord, E
Brock, DW
Carlsson, P
Cookson, R
Daniels, N
Danis, M
Fleurbaey, M
Johansson, KA
Kapiriri, L
Littlejohns, P
Mbeeli, T
Rao, KD
Edejer, TTT
Wikler, D
AF Norheim, Ole F.
Baltussen, Rob
Johri, Mira
Chisholm, Dan
Nord, Erik
Brock, Dan W.
Carlsson, Per
Cookson, Richard
Daniels, Norman
Danis, Marion
Fleurbaey, Marc
Johansson, Kjell A.
Kapiriri, Lydia
Littlejohns, Peter
Mbeeli, Thomas
Rao, Krishna D.
Edejer, Tessa Tan-Torres
Wikler, Dan
TI Guidance on priority setting in health care (GPS-Health): the inclusion
of equity criteria not captured by cost-effectiveness analysis
SO COST EFFECTIVENESS AND RESOURCE ALLOCATION
LA English
DT Article
DE Priority setting; Resource allocation; Cost-effectiveness; Equity;
Population health
AB This Guidance for Priority Setting in Health Care (GPS-Health), initiated by the World Health Organization, offers a comprehensive map of equity criteria that are relevant to health care priority setting and should be considered in addition to cost-effectiveness analysis. The guidance, in the form of a checklist, is especially targeted at decision makers who set priorities at national and sub-national levels, and those who interpret findings from cost-effectiveness analysis. It is also targeted at researchers conducting cost-effectiveness analysis to improve reporting of their results in the light of these other criteria.
The guidance was develop through a series of expert consultation meetings and involved three steps: i) methods and normative concepts were identified through a systematic review; ii) the review findings were critically assessed in the expert consultation meetings which resulted in a draft checklist of normative criteria; iii) the checklist was validated though an extensive hearing process with input from a range of relevant stakeholders.
The GPS-Health incorporates criteria related to the disease an intervention targets (severity of disease, capacity to benefit, and past health loss); characteristics of social groups an intervention targets (socioeconomic status, area of living, gender; race, ethnicity, religion and sexual orientation); and non-health consequences of an intervention (financial protection, economic productivity, and care for others).
C1 [Norheim, Ole F.; Johansson, Kjell A.] Univ Bergen, Dept Global Publ Hlth & Primary Care, N-5020 Bergen, Norway.
[Baltussen, Rob] Radboud Univ Nijmegen, Med Ctr, Nijmegen Int Ctr Hlth Syst Res & Educ NICHE, Nijmegen, Netherlands.
[Johri, Mira] CRCHUM, Quebec City, PQ, Canada.
[Chisholm, Dan] WHO, Dept Hlth Syst Financing, Geneva, Switzerland.
[Nord, Erik] Norwegian Inst Publ Hlth, Oslo, Norway.
[Brock, Dan W.] Harvard Univ, Harvard Med Sch, Cambridge, MA USA.
[Carlsson, Per] Linkoping Univ, Natl Ctr Prior Setting Hlth Care, Linkoping, Sweden.
[Cookson, Richard] Univ York, Hlth Econ, York, N Yorkshire, England.
[Daniels, Norman] Harvard Univ, Harvard Sch Publ Hlth, Cambridge, MA USA.
[Danis, Marion] NIH Clin Ctr, Sect Ethics & Hlth Policy, Bethesda, MD USA.
[Fleurbaey, Marc] Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Princeton, NJ USA.
[Kapiriri, Lydia] McMaster Univ, Dept Hlth, Hamilton, MT USA.
[Littlejohns, Peter] Kings Coll London, Previous affiliat Natl Inst Hlth & Care Excellenc, Div Hlth & Social Care Res, Dept Primary Care & Publ Hlth Sci, London, England.
[Rao, Krishna D.] Kings Coll London, Previous affiliat Natl Inst Hlth & Care Excellenc, Div Hlth & Social Care Res, Dept Primary Care & Publ Hlth Sci, London, England.
[Carlsson, Per; Johansson, Kjell A.] Publ Hlth Fdn India, New Delhi, India.
RP Norheim, OF (reprint author), Univ Bergen, Dept Global Publ Hlth & Primary Care, N-5020 Bergen, Norway.
EM ole.norheim@igs.uib.no
RI Baltussen, R.M.P.M./L-4181-2015;
OI Johri, Mira/0000-0001-5642-787X; Norheim, Ole F./0000-0002-5748-5956
FU Young Investigator Grant for Ole F. Norheim, Norwegian Research Council
[611720]; Brocher Foundation; Canadian Institutes for Health Research
(CIHR)
FX The first meeting to develop the guidance document in Geneva September
2010 was funded by a Young Investigator Grant for Ole F. Norheim,
Norwegian Research Council (grant no 611720). The Brocher Foundation
provided support for the second meeting of experts in June 2011. MJ
acknowledges a New Investigator Award from the Canadian Institutes for
Health Research (CIHR). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 66
TC 16
Z9 16
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1478-7547
J9 COST EFFECT RESOUR A
JI Cost Effect. Resour Alloc.
PY 2014
VL 12
AR 18
DI 10.1186/1478-7547-12-18
PG 8
WC Health Policy & Services
SC Health Care Sciences & Services
GA V45UD
UT WOS:000209840600018
PM 25246855
ER
PT J
AU Trabert, B
Chodick, G
Shalev, V
Sella, T
Longnecker, MP
McGlynn, KA
AF Trabert, Britton
Chodick, Gabriel
Shalev, Varda
Sella, Tal
Longnecker, Matthew P.
McGlynn, Katherine A.
TI Gestational Diabetes and the Risk of Cryptorchidism and Hypospadias
SO EPIDEMIOLOGY
LA English
DT Letter
ID CONGENITAL-MALFORMATIONS; INFANTS
C1 [Trabert, Britton; McGlynn, Katherine A.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Chodick, Gabriel; Shalev, Varda; Sella, Tal] Maccabi Healthcare Serv, Div Med, Tel Aviv, Israel.
[Chodick, Gabriel; Shalev, Varda; Sella, Tal] Tel Aviv Univ, Sackler Fac, IL-69978 Tel Aviv, Israel.
[Longnecker, Matthew P.] NIEHS, Epidemiol Branch, NIH, Res Triangle Pk, NC 27709 USA.
RP Trabert, B (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
EM britton.trabert@nih.gov
RI Trabert, Britton/F-8051-2015;
OI Longnecker, Matthew/0000-0001-6073-5322
FU Intramural NIH HHS [Z01 CP010126-13]
NR 8
TC 3
Z9 3
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1044-3983
EI 1531-5487
J9 EPIDEMIOLOGY
JI Epidemiology
PD JAN
PY 2014
VL 25
IS 1
BP 152
EP 153
DI 10.1097/EDE.0000000000000014
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 268XW
UT WOS:000328205200025
PM 24296929
ER
PT J
AU Ghosh, SK
Bond, MR
Love, DC
Ashwell, GG
Krause, MW
Hanover, JA
AF Ghosh, Salil K.
Bond, Michelle R.
Love, Dona C.
Ashwell, G. Gilbert
Krause, Michael W.
Hanover, John A.
TI Disruption of O-GIcNAc cycling in C. elegans perturbs nucleotide sugar
pools and complex glycans
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE O-GIcNAcylation; nucleotide sugars; hexosamines; C. elegans/nematode;
glycogen; trehalose
AB The carbohydrate modification of serine and threonine residues with O-linked beta-N-acetylglucosamine (O-GIcNAc) is ubiquitous and governs cellular processes ranging from cell signaling to apoptosis. The O-GIcNAc modification along with other carbohydrate modifications, including N-linked and O-linked glycans, glycolipids, and sugar polymers, all require the use of the nucleotide sugar UDP-GIcNAc, the end product of the hexosamine biosynthetic pathway (HBP). In this paper, we describe the biochemical consequences resulting from perturbation of the O-GIcNAc pathway in C. elegans lacking O-GIcNAc transferase and O-GIcNAcase activities. In ogt-1 null animals, steady-state levels of UDP-GIcNAc/UDP-GaINAc and UDP-glucose were substantially elevated. Transcripts of genes encoding for key members in the HBP (gfat-2, gna-2, C36A4.4) and trehalose metabolism (tre-1, tre-2, tps-2) were elevated in ogt-1 null animals. While there is no evidence to suggest changes in the profile of N-linked glycans in the ogt-1 and oga-1 mutants, glycans insensitive to PNGase digestion (including O-linked glycans, glycolipids, and glycopolymers) were altered in these strains. Our data support that changes in O-GIcNAcylation alters nucleotide sugar production, overall glycan composition, and transcription of genes encoding glycan processing enzymes. These data along with our previous findings that disruption in O-GIcNAc cycling alters macronutrient storage underscores the noteworthy influence this posttranslational modification plays in nutrient sensing.
C1 [Ghosh, Salil K.; Bond, Michelle R.; Love, Dona C.; Ashwell, G. Gilbert; Hanover, John A.] NIDDK, Lab Cell & Mol Biol, NIH, Bldg 8 Room B127,9000 Rockville Pike, Bethesda, MD 20892 USA.
[Krause, Michael W.] NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
RP Hanover, JA (reprint author), NIDDK, Lab Cell & Mol Biol, NIH, Bldg 8 Room B127,9000 Rockville Pike, Bethesda, MD 20892 USA.
EM jah@helix.nih.gov
NR 44
TC 4
Z9 4
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PY 2014
VL 5
AR 197
DI 10.3389/fendo.2014.00197
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V44LF
UT WOS:000209749800195
PM 25505447
ER
PT J
AU Janssens, J
Etienne, H
Idriss, S
Azmi, A
Martin, B
Maudsley, S
AF Janssens, Jonathan
Etienne, Harmonie
Idriss, Sherif
Azmi, Abdelkrim
Martin, Bronwen
Maudsley, Stuart
TI Systems-level G protein-coupled receptor therapy across a
neurodegenerative continuum by the GLP-1 receptor system
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Review
DE transcriptomics and proteomics; pharmacotherapeutics; pathophysiology;
heptahelical G protein-coupled receptor
AB With our increasing appreciation of the true complexity of diseases and pathophysiologies, it is clear that this knowledge needs to inform the future development of pharmacotherapeutics. For many disorders, the disease mechanism itself is a complex process spanning multiple signaling networks, tissues, and organ systems. Identifying the precise nature and locations of the pathophysiology is crucial for the creation of systemically effective drugs. Diseases once considered constrained to a limited range of organ systems, e.g., central neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington' disease (HD), the role of multiple central and peripheral organ systems in the etiology of such diseases is now widely accepted. With this knowledge, it is increasingly clear that these seemingly distinct neurodegenerative disorders (AD, PD, and HD) possess multiple pathophysiological similarities thereby demonstrating an inter-related continuum of disease-related molecular alterations. With this systems-level appreciation of neurodegenerative diseases, it is now imperative to consider that pharmacotherapeutics should be developed specifically to address the systemic imbalances that create the disorders. Identification of potential systems-level signaling axes may facilitate the generation of therapeutic agents with synergistic remedial activity across multiple tissues, organ systems, and even diseases. Here, we discuss the potentially therapeutic systems-level interaction of the glucagon-like peptide 1 (GLP-1) ligand receptor axis with multiple aspects of the AD, PD, and HD neurodegenerative continuum.
C1 [Janssens, Jonathan; Etienne, Harmonie; Idriss, Sherif; Azmi, Abdelkrim; Maudsley, Stuart] Univ Antwerp VIB, Translat Neurobiol Grp, Dept Mol Genet, Univ Pl 1,Bldg V, B-2020 Antwerp, Belgium.
[Martin, Bronwen] NIA, Metab Unit, NIH, Bethesda, MD 20892 USA.
RP Maudsley, S (reprint author), Univ Antwerp VIB, Translat Neurobiol Grp, Dept Mol Genet, Univ Pl 1,Bldg V, B-2020 Antwerp, Belgium.
EM stuart.maudsley@molgen.vib-ua.be
NR 208
TC 6
Z9 6
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PY 2014
VL 5
AR 142
DI 10.3389/fendo.2014.00142
PG 15
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V44LF
UT WOS:000209749800142
PM 25225492
ER
PT J
AU Kimura, S
AF Kimura, Shioko
TI Thyroid regeneration: how stem cells play a role?
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Review
DE adult-resident thyroid stem/progenitor cells; partial thyroidectomy;
solid cell nest; ultimobranchial body cyst; side population;
sphere/spheroid culture; OCT4 expression
AB Many tissues if not all are thought to contain stem cells that are responsible for regeneration and repair of the tissue after injury. Dysregulation of tissue regeneration may result in various pathological conditions, among which cancer is the most extensively studied. Notably, the so-called cancer stem cells or tumor-initiating cells, have been studied in order to understand the mechanisms of carcinogenesis and/or metastasis. However, the nature of cancer stem cells, let alone normal stem/progenitor cells, particularly those of the thyroid remains elusive. There remains a gap in knowledge between adult thyroid stem/progenitor cells and cancer stem cells of the thyroid, and if and/or how they are related to each other. Understanding of the mechanism for thyroid regeneration and mode of participation of normal adult thyroid stem/progenitor cells in this process will hopefully yield a more complete understanding of the nature of thyroid cancer stem cells, and/or help understand the pathogenesis of other thyroid diseases. This review summarizes the current understanding of adult thyroid stem/progenitor cells, with particular emphasis on how they contribute to thyroid regeneration.
C1 [Kimura, Shioko] NCI, Lab Metab, NIH, Bldg 37,Room 3106, Bethesda, MD 20892 USA.
RP Kimura, S (reprint author), NCI, Lab Metab, NIH, Bldg 37,Room 3106, Bethesda, MD 20892 USA.
EM kimuras@mail.nih.gov
FU National Cancer Institute Intramural Research Program [1ZIABC005522]
FX This work was supported by the National Cancer Institute Intramural
Research Program (Grant 1ZIABC005522).
NR 97
TC 1
Z9 1
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PY 2014
VL 5
AR 55
DI 10.3389/fendo.2014.00055
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V44LF
UT WOS:000209749800057
PM 24782833
ER
PT J
AU Wang, R
van Keeken, NMA
Siddiqui, S
Dijksman, LM
Maudsley, S
Derval, D
van Dam, PS
Martin, B
AF Wang, Rui
van Keeken, Nika M. A.
Siddiqui, Sana
Dijksman, Lea M.
Maudsley, Stuart
Derval, Diana
van Dam, P. Sytze
Martin, Bronwen
TI Higher TNF-alpha IGF-1, and leptin levels are found in tasters than
non-tasters
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE taste; TNF-alpha; leptin; IGF-1; BMI
AB Taste perception is controlled by taste cells that are present in the tongue that produce and secrete various metabolic hormones. Recent studies have demonstrated that taste receptors in tongue, gut, and pancreas are associated with local hormone secretion. The aim of this study was to determine whether there is a link between taste sensitivity and levels of circulating metabolic hormones in humans and whether taste sensitivity is potentially related to peripheral metabolic regulation. Thirty-one subjects were recruited and separated into tasters and non-tasters based on their phenol thiocarbamide (PTC) bitter taste test results. Fasting plasma and saliva were collected and levels of hormones and cytokines were assayed. We observed significant differences in both hormone levels and hormone body mass index (BMI) correlation between tasters and non-tasters. Tasters had higher plasma levels of leptin (p = 0.05), tumor necrosis factor-alpha (INF-alpha) (p = 0.04), and insulin-like growth factor 1 (IGF-1) (p = 0.03). There was also a trend toward increased IGF-1 levels in the saliva of tasters (p = 0.06). We found a positive correlation between plasma levels of glucose and BMI (R = 0.4999, p = 0.04) exclusively in non-tasters. In contrast, plasma C-peptide levels were found to be positively correlated to BMI (R = 0.5563, p = 0.03) in tasters. Saliva INF-alpha levels were negatively correlated with BMI in tasters (R = 0.5908, p = 0.03). Our findings demonstrate that there are differences in circulating levels of leptin, INF-alpha, and IGF-1 between tasters and non -tasters. These findings indicate that in addition to the regulation of food consumption, taste perception also appears to be tightly linked to circulating metabolic hormone levels. People with different taste sensitivity may respond differently to the nutrient stimulation. Further work investigating the link between taste perception and peripheral metabolic control could potentially lead to the development of novel therapies for obesity or Type 2 diabetes.
C1 [Wang, Rui; Martin, Bronwen] NIA, Metab Unit, NIH, Baltimore, MD 21224 USA.
[van Keeken, Nika M. A.; van Dam, P. Sytze] Onze Lieve Vrouw Hosp, Dept Internal Med, Amsterdam, Netherlands.
[Siddiqui, Sana; Maudsley, Stuart] NIA, Receptor Pharmacol Unit, NIH, Baltimore, MD 21224 USA.
[Dijksman, Lea M.] Onze Lieve Vrouw Hosp, Teaching Hosp, Amsterdam, Netherlands.
[Maudsley, Stuart] Univ Antwerp VIB, Dept Mol Genet, Antwerp, Belgium.
[Derval, Diana] Better Immune Syst Fdn, Amsterdam, Netherlands.
RP Martin, B (reprint author), NIA, Metab Unit, 251 Bayview Blvd,Suite 100 Room 08C009, Baltimore, MD 21224 USA.
EM martinbro@mail.nih.gov
FU Better Immune System Foundation; Onze Lieve Vrouwe Gasthuis; HDSA COE
grant; Intramural Research Program of the National Institute on Aging,
National Institutes of Health; NINDS [16375]; [AG000915-01];
[AG000917-01]
FX This work was supported by the Intramural Research Program of the
National Institute on Aging, National Institutes of Health, the Better
Immune System Foundation, and Onze Lieve Vrouwe Gasthuis. We would like
to thank the volunteers that took part in this study for their time and
dedication. We would like to thank Better Immune System volunteers who
helped recruit the subjects. We also thank the NIH fellows' editorial
board for their help with manuscript editing. Supporting grants:
AG000915-01, AG000917-01, NINDS 16375, HDSA COE grant.
NR 46
TC 3
Z9 3
U1 1
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PY 2014
VL 5
AR 125
DI 10.3389/fendo.2014.00125
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA V44LF
UT WOS:000209749800125
PM 25120532
ER
PT J
AU Bielekova, B
Vodovotz, Y
An, G
Hallenbeck, J
AF Bielekova, Bibiana
Vodovotz, Yoram
An, Gary
Hallenbeck, John
TI How implementation of systems biology into clinical trials accelerates
understanding of diseases
SO FRONTIERS IN NEUROLOGY
LA English
DT Review
DE systems biology; clinical trials; clinical trials methodology; multiple
sclerosis; polygenic diseases
AB Systems biology comprises a series of concepts and approaches that have been used successfully both to delineate novel biological mechanisms and to drive translational advances. The goal of systems biology is to re-integrate putatively critical elements extracted from multi-modality datasets in order to understand how interactions among multiple components form functional networks at the organism/patient-level, and how dysfunction of these networks underlies a particular disease. Due to the genetic and environmental diversity of human subjects, identification of critical elements related to a particular disease process from cross-sectional studies requires prohibitively large cohorts. Alternatively, implementation of systems biology principles to interventional clinical trials represents a unique opportunity to gain predictive understanding of complex diseases in comparatively small cohorts of patients. This paper reviews systems biology principles applicable to translational research, focusing on lessons from systems approaches to inflammation applied to multiple sclerosis. We suggest that employing systems biology methods in the design and execution of biomarker-supported, proof-of-principle clinical trials provides a singular opportunity to merge therapeutic development with a basic understanding of disease processes. The ultimate goal is to develop predictive computational models of the disease, which will revolutionize diagnostic process and provide mechanistic understanding necessary for personalized therapeutic approaches. Added, biologically meaningful information can be derived from diagnostic tests, if they are interpreted in functional relationships, rather than as independent measurements. Such systems biology based diagnostics will transform disease taxonomies from phenotypical to molecular and will allow physicians to select optimal therapeutic regimens for individual patients.
C1 [Bielekova, Bibiana] NINDS, Neuroimmunol Dis Unit, NIH, Bethesda, MD 20892 USA.
[Bielekova, Bibiana] NIH, Ctr Human Immunol, Bethesda, MD 20892 USA.
[Vodovotz, Yoram] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA.
[Vodovotz, Yoram; An, Gary] McGowan Inst Regenerat Med, Ctr Inflammat & Regenerat Modeling, Pittsburgh, PA USA.
[An, Gary] Northwestern Univ, Dept Surg, Chicago, IL 60611 USA.
[Hallenbeck, John] NINDS, Stroke Branch, NIH, Bethesda, MD 20892 USA.
RP Bielekova, B (reprint author), NINDS, NIH, NIB, Bld10-R,5C103,10 Ctr Dr,MSC1400, Bethesda, MD 20892 USA.
EM bibi.bielekova@nih.gov
OI An, Gary/0000-0003-4549-9004
FU US National Institute of Neurological Disorders and Stroke (NINDS)/US
National Institutes of Health (NIH); National Science Foundation (NSF)
[0830-370-V601]; National Institute of Disability and Rehabilitation
Research (NIDRR) [H133E070024]; National Institutes of Health (NIH)
[P50GM053789]
FX The study was supported by the intramural research program of the US
National Institute of Neurological Disorders and Stroke (NINDS)/US
National Institutes of Health (NIH) and by National Science Foundation
(NSF) 0830-370-V601, National Institute of Disability and Rehabilitation
Research (NIDRR) H133E070024 and National Institutes of Health (NIH)
P50GM053789. The authors are grateful to Ronald Germain, Henry
McFarland, Dorian McGovern, Walter Koroshetz and Irene Cortese (all NIH)
for their critical review of the manuscript and helpful suggestions. The
authors also acknowledge that the imposed word limit requirements
precluded inclusion of other mechanistically supported Phase I/II trials
in MS that provided equally informative knowledge about MS disease
process.
NR 60
TC 8
Z9 8
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PY 2014
VL 5
AR 102
DI 10.3389/fneur.2014.00102
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA V42QW
UT WOS:000209629300099
PM 25018747
ER
PT J
AU Heinzelmann, M
Reddy, SY
French, LM
Wang, D
Lee, H
Barr, T
Baxter, T
Mysliwiec, V
Gill, J
AF Heinzelmann, Morgan
Reddy, Swarnalatha Y.
French, Louis M.
Wang, Dan
Lee, Hyunhwa
Barr, Taura
Baxter, Tristin
Mysliwiec, Vincent
Gill, Jessica
TI Military personnel with chronic symptoms following blast traumatic brain
injury have differential expression of neuronal recovery and epidermal
growth factor receptor genes
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE traumatic brain injury; military; post-concussive disorder;
gene-expression
AB Objective: Approximately one-quarter of military personnel who deployed to combat stations sustained one or more blast-related, closed-head injuries. Blast injuries result from the detonation of an explosive device. The mechanisms associated with blast exposure that give rise to traumatic brain injury (TBI), and place military personnel at high risk for chronic symptoms of post-concussive disorder (PCD), post-traumatic stress disorder (PTSD), and depression are not elucidated.
Methods:To investigate the mechanisms of persistent blast-related symptoms, we examined expression profiles of transcripts across the genome to determine the role of gene activity in chronic symptoms following blast-TBI. Active duty military personnel with (1) a medical record of a blast-TBI that occurred during deployment (n= 19) were compared to control participants without TBI (n = 17). Controls were matched to cases on demographic factors including age, gender, and race, and also in diagnoses of sleep disturbance, and symptoms of PTSD and depression. Due to the high number of PCD symptoms in the TBI+ group, we did not match on this variable. Using expression profiles of transcripts in microarray platform in peripheral samples of whole blood, significantly differentially expressed gene lists were generated. Statistical threshold is based on criteria of 1.5 magnitude fold-change (up or down) and p-values with multiple test correction (false discovery rate <0.05).
Results:There were 34 transcripts in 29 genes that were differentially regulated in blast-TBI participants compared to controls. Up-regulated genes included epithelial cell transforming sequence and zinc finger proteins, which are necessary for astrocyte differentiation following injury. Tensin-1, which has been implicated in neuronal recovery in pre-clinical TBI models, was down-regulated in blast-TBI participants. Protein ubiquitination genes, such as epidermal growth factor receptor, were also down-regulated and identified as the central regulators in the gene network determined by interaction pathway analysis.
Conclusion: In this study, we identified a gene-expression pathway of delayed neuronal recovery in military personnel a blast-TBI and chronic symptoms. Future work is needed to determine if therapeutic agents that regulate these pathways may provide novel treatments for chronic blast-TBI-related symptoms.
C1 [Heinzelmann, Morgan; Reddy, Swarnalatha Y.; Wang, Dan; Lee, Hyunhwa; Gill, Jessica] NINR, NIH, Bethesda, MD 20892 USA.
[French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA.
[French, Louis M.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA.
[Barr, Taura] W Virginia Univ, Hlth Sci Ctr, Morgantown, WV 26506 USA.
[Baxter, Tristin; Mysliwiec, Vincent] Madigan Army Med Ctr, Sleep Med Clin, Tacoma, WA 98431 USA.
RP Gill, J (reprint author), NINR, 1 Cloister Court,Room 256, Bethesda, MD 20814 USA.
EM gillj@mail.nih.gov
RI Reddy, Swarna/G-5349-2013
FU Center for Neuroscience and Regenerative Medicine [60855]
FX This study was funded, in part, by the Center for Neuroscience and
Regenerative Medicine (Grant 60855).
NR 54
TC 4
Z9 5
U1 2
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PY 2014
VL 5
AR 198
DI 10.3389/fneur.2014.00198
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA V42QW
UT WOS:000209629300186
PM 25346719
ER
PT J
AU Leigh, R
Urrutia, VC
Llinas, RH
Gottesman, RF
Krakauer, JW
Hillis, AE
AF Leigh, Richard
Urrutia, Victor C.
Llinas, Rafael H.
Gottesman, Rebecca F.
Krakauer, John W.
Hillis, Argye E.
TI A comparison of two methods for MRI classification of at-risk tissue and
core infarction
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE MR RESCUE; DEFUSE 2; MRI; penumbra; DWI; PWI; at-risk tissue; core
infarction
AB Objective: To compare how at-risk tissue and core infarction were defined in two major trials that tested the use of MRI in selecting acute stroke patients for endovascular recanalization therapy.
Methods: MRIs from 12 patients evaluated for possible endovascular therapy were processed using the methods published from two major trials, MR RESCUE and DEFUSE 2. Specifically, volumes of at-risk tissue and core infarction were generated from each patient's MRI. MRIs were then classified as whether or not they met criteria for salvageable tissue: "penumbral pattern" for MR RESCUE and/or "target profile" for DEFUSE 2 as defined by each trial.
Results: Volumes of at-risk tissue measured by the two definitions were correlated (p = 0.017) while the volumes of core infarct were not (p = 0.059). The volume of at-risk tissue was consistently larger when defined by the penumbral pattern than the target profile while the volume of core infarct was consistently larger when defined by the target profile than the penumbral pattern. When these volumes were used to classify the MRI scans, 9 out of 12 patients (75%) were classified as having a penumbral pattern, while only 4 out of 12 patients (33%) were classified as having a target profile. Of the 9 patients classified as penumbral pattern, 5 (55%) were classified differently by the target profile.
Interpretation: Our analysis found that the MR RESCUE trial defined salvageable tissue in a way that made it more likely for patients be labeled as favorable for treatment. For the cohort of patients examined in this study, had they been enrolled in both trials, most of the patients identified as having salvageable tissue by the MR RESCUE trial would not have been considered to have salvageable tissue in the DEFUSE 2 trial. Caution should be taken in concluding that MRI selection for endovascular therapy is not effective as imaging selection criteria were substantially different between the two trials.
C1 [Leigh, Richard; Urrutia, Victor C.; Llinas, Rafael H.; Gottesman, Rebecca F.; Krakauer, John W.; Hillis, Argye E.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
RP Leigh, R (reprint author), NINDS, Sect Stroke Diagnost & Therapeut, NIH, 10 Ctr Dr,Bldg 10,Room B1D-733,MSC 1063, Bethesda, MD 20892 USA.
EM richard.leigh@nih.gov
OI Urrutia, Victor/0000-0002-4995-6949
FU NINDS NIH HHS [R01 NS047691]
NR 12
TC 2
Z9 2
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PY 2014
VL 5
AR 155
DI 10.3389/fneur.2014.00155
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA V42QW
UT WOS:000209629300148
PM 25232348
ER
PT J
AU Christopher, AB
Ochoa, S
Krushansky, E
Francis, R
Tian, X
Zahid, M
Munoz, R
Lo, CW
AF Christopher, Adam B.
Ochoa, Sebastian
Krushansky, Evonne
Francis, Richard
Tian, Xin
Zahid, Maliha
Munoz, Ricardo
Lo, Cecilia W.
TI The effects temperature and anesthetic agents on ciliary function in
murine respiratory epithelia
SO FRONTIERS IN PEDIATRICS
LA English
DT Article
DE ciliary beat frequency; dexmedetomidine; fentanyl; isoflurane;
hypothermia
AB Background: Mucus transport mediated by motile cilia in the airway is an important defense mechanism for prevention of respiratory infections. As cilia motility can be depressed by hypothermia or exposure to anesthetics, in this study, we investigated the individual and combined effects of dexmedetomidine (dex), fentanyl (fen), and/or isoflurane (iso) at physiologic and low temperatures on cilia motility in mouse tracheal airway epithelia. These anesthetic combinations and low temperature conditions are often used in the setting of cardiopulmonary bypass surgery, surgical repair of congenital heart disease, and cardiac intensive care.
Methods: C57BL/6J mouse tracheal epithelia were excised and cilia dynamics were captured by videomicroscopy following incubation at 15, 22-24, and 37 degrees C with different combinations of therapeutic concentrations of dex (10 nM), fen (10 nM), and iso (0.01 %). Airway ciliary motion was assessed and compared across conditions by measuring ciliary beat frequency and ciliary flow velocity. Statistical analysis was carried out using unpaired t-tests, analysis of variance, and multivariate linear regression.
Results:There was a linear correlation between cilia motility and temperature. Fen exerted cilia stimulatory effects, while dex and iso each had ciliodepressive effects. When added together, fen + iso, dex + iso, and dex+ fen + iso were all cilia inhibitory. In contrast fenl + dex did not significantly alter ciliary function.
Conclusion: We show that ciliary motility is stimulated by fen, but depressed by dex or iso. However, when used in combination, ciliary motility showed changes indicative of complex drug drug and drug temperature interactions not predicted by simple summation of their individual effects. Similar studies are needed to examine the human airway epithelia and its response to anesthetics.
C1 [Christopher, Adam B.; Francis, Richard; Zahid, Maliha; Lo, Cecilia W.] Univ Pittsburgh, Sch Med, Dept Dev Biol, Pittsburgh, PA USA.
[Ochoa, Sebastian; Krushansky, Evonne; Tian, Xin; Munoz, Ricardo; Lo, Cecilia W.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA.
[Tian, Xin] NHLBI, Off Biostat Res, Bethesda, MD 20892 USA.
RP Lo, CW (reprint author), Univ Pittsburgh, Dept Dev Biol, Rangos Res Ctr 8120, 530 45th St, Pittsburgh, PA 15201 USA.
EM cel36@pitt.edu
RI Francis, Richard/P-2524-2015
NR 28
TC 6
Z9 6
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
SWITZERLAND
SN 2296-2360
J9 FRONT PEDIATR
JI Front. Pediatr.
PY 2014
VL 2
AR 111
DI 10.3389/fped.2014.00111
PG 9
WC Pediatrics
SC Pediatrics
GA V46PX
UT WOS:000209897200110
PM 25360434
ER
PT S
AU Rees, MG
Gloyn, AL
AF Rees, Matthew G.
Gloyn, Anna L.
BE Gloyn, AL
McCarthy, MI
TI Translating Genetic Association Signals for Diabetes and Metabolic
Traits into Molecular Mechanisms for Disease
SO GENETICS IN DIABETES: TYPE 2 DIABETES AND RELATED TRAITS
SE Frontiers in Diabetes
LA English
DT Article; Book Chapter
ID GENOME-WIDE ASSOCIATION; GLUCOKINASE REGULATORY PROTEIN; HUMAN
PANCREATIC-ISLETS; INSULIN-SECRETION; SUSCEPTIBILITY LOCI; PROVIDES
INSIGHTS; P446L VARIANT; TRANSFER-RNA; CELL LINE; TYPE-2
AB More than 80 genetic loci affecting type 2 diabetes (T2D) risk have been published to date. However, the causative variant(s) and biology underlying the associations at the vast majority of these loci remain elusive, in part due to an incomplete understanding of the genes and pathways involved in T2D development and progression. This highlights two interrelated challenges: the need for functional elucidation of the effects of individual variants, and the need to broadly and comprehensively investigate the function of implicated genes to understand how their modulation contributes to disease risk. This chapter discusses the approaches beginning to bear fruit in addressing both of these challenges, including the characterization of nonsynonymous common variants or collections of rare variants (e.g. GCKR, MTNR1B), the assignment of novel gene function relevant to disease processes (e.g. CDKAL1), the value of integrating genetic association results with datasets for expression or epigenetic factors (e.g. TCF7L2, KLF14), and emerging systems genetics approaches focusing on pathways, protein-protein interactions, and gene-gene interactions. These instructive studies suggest a template for future functional investigations into the variants and genes underlying T2D risk. (C) 2014 S. Karger AG, Basel
C1 [Rees, Matthew G.; Gloyn, Anna L.] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England.
[Gloyn, Anna L.] Churchill Hosp, Oxford Univ Hosp Trust, NIHR Oxford Biomed Res Ctr, Oxford, England.
[Rees, Matthew G.] NHGRI, NIH, Bethesda, MD 20892 USA.
RP Gloyn, AL (reprint author), Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7LE, England.
EM anna.gloyn@drl.ox.ac.uk
NR 50
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA POSTFACH, CH-4009 BASEL, SWITZERLAND
SN 0251-5342
BN 978-3-318-02700-6; 978-3-318-02699-3
J9 FRONT DIABETES
JI Front.Diabetes
PY 2014
VL 23
BP 133
EP 145
DI 10.1159/000362473
D2 10.1159/isbn.978-3-318-02700-6
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA BG2UO
UT WOS:000387711300012
ER
PT B
AU Bindewald, E
Shapiro, BA
AF Bindewald, Eckart
Shapiro, Bruce A.
BE Poptsova, MS
TI Comparative Methods for RNA Structure Prediction
SO GENOME ANALYSIS: CURRENT PROCEDURES AND APPLICATIONS
LA English
DT Article; Book Chapter
ID SECONDARY STRUCTURE PREDICTION; SELECTIVE 2'-HYDROXYL ACYLATION;
CONTEXT-FREE GRAMMARS; DYNAMIC-PROGRAMMING ALGORITHM; COMPARATIVE
SEQUENCE-ANALYSIS; SINGLE NUCLEOTIDE RESOLUTION; BASE-PAIRING
PROBABILITIES; FREE-ENERGY MINIMIZATION; PRIMER EXTENSION SHAPE;
INCLUDING PSEUDOKNOTS
AB The appreciation of the pervasiveness of RNA biology continues to increase. The vastness of available sequence information calls for computational tools that aid in a variety of prediction problems, such as RNA structure prediction, RNA-RNA interaction prediction and genomic scans for conserved RNA structural elements. Comparative methods for RNA structure prediction employ a set of homologous RNA sequences; this additional information can then be used to not only estimate energy contributions, but also information in the form of compensatory base changes. Different software tools make use of this information in a fascinating variety of ways. This paper surveys current comparative approaches for RNA structure predictions and discusses a variety of future trends.
C1 [Bindewald, Eckart] SAIC Frederick Inc, Basic Sci Program, Ctr Canc Res, Nanobiol Program,Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.
[Shapiro, Bruce A.] NCI, Ctr Canc Res, Nanobiol Program, Frederick, MD 21701 USA.
RP Bindewald, E (reprint author), SAIC Frederick Inc, Basic Sci Program, Ctr Canc Res, Nanobiol Program,Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.
EM eckart@mail.nih.gov; shapirbr@mail.nih.gov
NR 131
TC 0
Z9 0
U1 0
U2 0
PU CAISTER ACADEMIC PRESS
PI WYMONDHAM
PA 32 HEWITTS LANE, WYMONDHAM NR 18 0JA, ENGLAND
BN 978-1-908230-68-3; 978-1-908230-29-4
PY 2014
BP 287
EP 305
PG 19
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Genetics
& Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA BF7MU
UT WOS:000384249900015
ER
PT J
AU Miettinen, M
AF Miettinen, Markku
TI Immunohistochemistry of soft tissue tumours - review with emphasis on 10
markers
SO HISTOPATHOLOGY
LA English
DT Review
DE CD31; CD34; desmin; DOG1; EMA; ERG; immunohistochemistry; IT; keratins;
S100 protein; sarcoma; SMA
ID GASTROINTESTINAL STROMAL TUMORS; CELL ANTIGEN CD34; POSITIVE EPITHELIOID
ANGIOSARCOMA; MALIGNANT FIBROUS HISTIOCYTOMA; GRADE FIBROMYXOID SARCOMA;
DIFFERENTIAL-DIAGNOSIS; ENDOTHELIAL-CELLS; VASCULAR TUMORS; H-CALDESMON;
C-KIT
AB Immunohistochemistry is an integral component in the proper analysis of soft tissue tumours, and a simple panel of six markers is useful in practical triage: CD34, desmin, epithelial membrane antigen (EMA), keratin cocktail AE1/AE3, S100 protein and alpha smooth muscle actin (SMA). These markers frequently assist in the differential diagnosis of fibroblastic, myoid, nerve sheath and perineurial cell tumours, synovial and epithelioid sarcoma and others. However, they all are multispecific, so that one has to be cognizant of their distribution in normal and neoplastic tissues. Four additional useful markers for specific tumour types are discussed here: CD31 and ERG for vascular endothelial tumours, and KIT and DOG1/Ano-1 for gastrointestinal stromal tumours (GISTs). However, hardly any marker is totally monospecific for any one type of tumour. Furthermore, variably lineage-specific markers do not usually distinguish between benign and malignant proliferations, so that this distinction has to be made on histological grounds. Immunohistochemical evaluation is most useful, efficient and cost-effective when used in the context of careful histological evaluation by an experienced pathologist, aware of all diagnostic entities and their histological spectra. Additional diagnostic steps that must be considered in difficult cases include clinicoradiological correlation and additional sampling of remaining wet tissue, if possible.
C1 NCI, Pathol Lab, Bethesda, MD 20892 USA.
RP Miettinen, M (reprint author), NCI, Pathol Lab, 9000 Rockville Pike,Bldg 10,Room 2B50, Bethesda, MD 20892 USA.
EM miettinenmm@mail.nih.gov
FU NCI
FX This work was supported as a part of NCI's intramural research
programme. The author reports no conflicts of interest regarding the
contents of this paper.
NR 86
TC 16
Z9 17
U1 2
U2 20
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0309-0167
EI 1365-2559
J9 HISTOPATHOLOGY
JI Histopathology
PD JAN
PY 2014
VL 64
IS 1
BP 101
EP 118
DI 10.1111/his.12298
PG 18
WC Cell Biology; Pathology
SC Cell Biology; Pathology
GA 269CU
UT WOS:000328219100009
PM 24111893
ER
PT J
AU Berl, MM
Mayo, J
Parks, EN
Rosenberger, LR
VanMeter, J
Ratner, NB
Vaidya, CJ
Gaillard, WD
AF Berl, Madison M.
Mayo, Jessica
Parks, Erin N.
Rosenberger, Lisa R.
VanMeter, John
Ratner, Nan Bernstein
Vaidya, Chandan J.
Gaillard, William Davis
TI Regional Differences in the Developmental Trajectory of Lateralization
of the Language Network
SO HUMAN BRAIN MAPPING
LA English
DT Article
DE language; fMRI; pediatric; lateralization
ID HUMAN CEREBRAL-CORTEX; FUNCTIONAL MRI; NORMAL-CHILDREN; YOUNG-CHILDREN;
METHODOLOGICAL ISSUES; PARTIAL EPILEPSY; NEURAL-NETWORKS; BRAIN-LESIONS;
FMRI LANGUAGE; DOMINANCE
AB The timing and developmental factors underlying the establishment of language dominance are poorly understood. We investigated the degree of lateralization of traditional frontotemporal and modulatory prefrontal-cerebellar regions of the distributed language network in children (n = 57) ages 4 to 12a critical period for language consolidation. We examined the relationship between the strength of language lateralization and neuropsychological measures and task performance. The fundamental language network is established by four with ongoing maturation of language functions as evidenced by strengthening of lateralization in the traditional frontotemporal language regions; temporal regions were strongly and consistently lateralized by age seven, while frontal regions had greater variability and were less strongly lateralized through age 10. In contrast, the modulatory prefrontal-cerebellar regions were the least strongly lateralized and degree of lateralization was not associated with age. Stronger core language skills were significantly correlated with greater right lateralization in the cerebellum. Hum Brain Mapp 35:270-284, 2014. (c) 2012 Wiley Periodicals, Inc.
C1 [Berl, Madison M.; Mayo, Jessica; Parks, Erin N.; Rosenberger, Lisa R.; Vaidya, Chandan J.; Gaillard, William Davis] Childrens Natl Med Ctr, Dept Neurosci, Washington, DC 20010 USA.
[VanMeter, John] Georgetown Univ, Ctr Funct & Mol Imaging, Washington, DC USA.
[Ratner, Nan Bernstein] Univ Maryland, Dept Hearing & Speech Sci, College Pk, MD 20742 USA.
[Vaidya, Chandan J.] Georgetown Univ, Dept Psychol, Washington, DC 20057 USA.
[Gaillard, William Davis] NINDS, Clin Epilepsy Sect, NIH, Bethesda, MD 20892 USA.
[Gaillard, William Davis] Georgetown Univ, Sch Med, Dept Neurol, Washington, DC USA.
RP Berl, MM (reprint author), Childrens Natl Med Ctr, Div Pediat Neuropsychol, 111 Michigan Ave NW, Washington, DC 20010 USA.
EM mberl@childrensnational.org
FU National Institutes of Health (NIH) [NINDS R01 NS44280, NCRR
M01RR020359]; Epilepsy Foundation; Children's Research Institute; NINDS
Clinical Epilepsy Section Division of Intramural Research, Intellectual
and Developmental Research Center [HD040677-07]
FX Contract grant sponsor: National Institutes of Health (NIH); Contract
grant number: NINDS R01 NS44280 (to W. D. G.) NCRR M01RR020359; Contract
grant sponsors: Epilepsy Foundation (Partnership for Pediatric Research
to M. M. B.); Children's Research Institute (Avery Award to M. M. B.);
NINDS Clinical Epilepsy Section Division of Intramural Research,
Intellectual and Developmental Research Center; Contract grant number:
HD040677-07.
NR 86
TC 18
Z9 18
U1 2
U2 26
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1065-9471
EI 1097-0193
J9 HUM BRAIN MAPP
JI Hum. Brain Mapp.
PD JAN
PY 2014
VL 35
IS 1
BP 270
EP 284
DI 10.1002/hbm.22179
PG 15
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 264EN
UT WOS:000327859900022
PM 23033058
ER
PT J
AU Lanuza, MA
Santafe, MM
Garcia, N
Besalduch, N
Tomas, M
Obis, T
Priego, M
Nelson, PG
Tomas, J
AF Lanuza, Maria A.
Santafe, Manel M.
Garcia, Neus
Besalduch, Nuria
Tomas, Marta
Obis, Teresa
Priego, Mercedes
Nelson, Phillip G.
Tomas, Josep
TI Protein kinase C isoforms at the neuromuscular junction: localization
and specific roles in neurotransmission and development
SO JOURNAL OF ANATOMY
LA English
DT Review
DE electrical stimulation; immunofluorescence; isoforms; neuromuscular
junction; neurotransmission; protein kinase C; synapse elimination
ID MOTOR-NERVE TERMINALS; HUMAN SKELETAL-MUSCLE; PRESYNAPTIC MUSCARINIC
RECEPTORS; NICOTINIC ACETYLCHOLINE-RECEPTOR; MODULATE TRANSMITTER
RELEASE; RAT PHRENIC-NERVE; SYNAPSE ELIMINATION; PHORBOL ESTER;
ADULT-RAT; IN-VITRO
AB The protein kinase C family (PKC) regulates a variety of neural functions including neurotransmitter release. The selective activation of a wide range of PKC isoforms in different cells and domains is likely to contribute to the functional diversity of PKC phosphorylating activity. In this review, we describe the isoform localization, phosphorylation function, regulation and signalling of the PKC family at the neuromuscular junction. Data show the involvement of the PKC family in several important functions at the neuromuscular junction and in particular in the maturation of the synapse and the modulation of neurotransmission in the adult.
C1 [Lanuza, Maria A.; Santafe, Manel M.; Garcia, Neus; Besalduch, Nuria; Tomas, Marta; Obis, Teresa; Priego, Mercedes; Tomas, Josep] Univ Rovira & Virgili, UHN, Fac Med & Ciencies Salut, Reus 43201, Spain.
[Nelson, Phillip G.] NICHHD, NIH, Bethesda, MD 20892 USA.
RP Lanuza, MA (reprint author), Univ Rovira & Virgili, UHN, Fac Med & Ciencies Salut, Carrer St Llorenc 21, Reus 43201, Spain.
EM mariaangel.lanuza@urv.cat
OI Santafe, Manel/0000-0002-5462-5108; OBIS IBANEZ,
TERESA/0000-0003-1569-1070
FU MEC [SAF2011-23711]; Catalan Government (Generalitat) [2009SGR0 1248]
FX This work was supported by a grant from MEC (SAF2011-23711) and a grant
from the Catalan Government (Generalitat) (2009SGR0 1248).
NR 94
TC 3
Z9 3
U1 1
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-8782
EI 1469-7580
J9 J ANAT
JI J. Anat.
PD JAN
PY 2014
VL 224
IS 1
SI SI
BP 61
EP 73
DI 10.1111/joa.12106
PG 13
WC Anatomy & Morphology
SC Anatomy & Morphology
GA 268PC
UT WOS:000328182000008
PM 24102585
ER
PT J
AU Stampalija, T
Chaiworapongsa, T
Romero, R
Tarca, AL
Bhatti, G
Chiang, PJ
Than, NG
Ferrazzi, E
Hassan, SS
Yeo, L
AF Stampalija, Tamara
Chaiworapongsa, Tinnakorn
Romero, Roberto
Tarca, Adi L.
Bhatti, Gaurav
Chiang, Po Jen
Than, Nandor Gabor
Ferrazzi, Enrico
Hassan, Sonia S.
Yeo, Lami
TI Soluble ST2, a modulator of the inflammatory response, in preterm and
term labor
SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
LA English
DT Article
DE Acute histologic chorioamnionitis; amniotic fluid; IL-33; intra-amniotic
infection/inflammation; mRNA expression
ID TUMOR-NECROSIS-FACTOR; AMNIOTIC-FLUID INTERLEUKIN-6;
TOLL-LIKE-RECEPTORS; MONOCYTE CHEMOTACTIC PROTEIN-1;
POLYMERASE-CHAIN-REACTION; CHRONIC LUNG-DISEASE; HUMAN FETAL MEMBRANES;
WHITE-MATTER LESIONS; BLOOD-CELL COUNT; EXPERIMENTAL INTRAUTERINE
INFECTION
AB Objective: Intra-amniotic infection/inflammation (IAI) is causally linked with spontaneous preterm labor and delivery. The ST2L receptor and its soluble form (sST2) are capable of binding to interleukin (IL)-33, a member of the IL-1 superfamily. Members of this cytokine family have been implicated in the onset of spontaneous preterm labor in the context of infection. Soluble ST2 has anti-inflammatory properties, and plasma concentrations are elevated in systemic inflammation, such as sepsis, acute pyelonephritis in pregnancy and the fetal inflammatory response syndrome. The aims of this study were to examine: (1) whether amniotic fluid concentrations of sST2 change with IAI, preterm, and term parturition; and (2) if mRNA expression of ST2 in the chorioamniotic membranes changes with acute histologic chorioamnionitis in women who deliver preterm.
Method: A cross-sectional study was conducted to determine amniotic fluid concentrations of sST2 in: (1) women with preterm labor (PTL) who delivered at term (n = 49); (2) women with PTL who delivered preterm without IAI (n = 21); (3) women with PTL who delivered preterm with IAI (n = 31); (4) term pregnancies not in labor (n = 13); and (5) term pregnancies in labor (n = 43). The amniotic fluid concentration of sST2 was determined by ELISA. The mRNA expression of ST2 in the chorioamniotic membranes of women who delivered preterm with (n = 24), and without acute histologic chorioamnionitis (n = 19) was determined by qRT-PCR.
Results: (1) Patients with PTL who delivered preterm with IAI had a lower median amniotic fluid concentration of sST2 compared to those with PTL who delivered preterm without IAI [median 410 ng/mL, inter-quartile range (IQR) 152-699 ng/mL versus median 825 ng/mL, IQR 493-1216 ng/mL; p = 0.0003] and those with PTL who delivered at term [median 410 ng/mL, IQR 152-699 ng/mL versus median 673 ng/mL, IQR 468-1045 ng/mL; p = 0.0003]; (2) no significant differences in the median amniotic fluid concentration of sST2 were observed between patients with PTL who delivered at term and those who delivered preterm without IAI (p = 0.4), and between women at term in labor and those at term not in labor (p = 0.9); (3) the mean mRNA expression of ST2 was 4-fold lower in women who delivered preterm with acute histologic chorioamnionitis than in those without this lesion (p = 0.008).
Conclusions: The median sST2 amniotic fluid concentration and mRNA expression of ST2 by chorioamniotic membranes is lower in PTL associated with IAI and acute histologic chorioamnionitis than in PTL without these conditions. Changes in the median amniotic fluid sST2 concentration are not observed in preterm and term parturition without IAI. Thus, amniotic fluid sST2 in the presence of IAI behaves differently when compared to sST2 in the plasma of individuals affected by fetal inflammatory response syndrome, acute pyelonephritis in pregnancy, and adult sepsis. Decreased concentrations of sST2 in IAI are likely to promote a pro-inflammatory response, which is important for parturition in the context of infection.
C1 [Stampalija, Tamara; Chaiworapongsa, Tinnakorn; Romero, Roberto; Tarca, Adi L.; Bhatti, Gaurav; Chiang, Po Jen; Than, Nandor Gabor; Hassan, Sonia S.; Yeo, Lami] NICHD, Perinatol Res Branch, NIH, DHHS, Bethesda, MD USA.
[Stampalija, Tamara; Chaiworapongsa, Tinnakorn; Romero, Roberto; Tarca, Adi L.; Bhatti, Gaurav; Chiang, Po Jen; Than, Nandor Gabor; Hassan, Sonia S.; Yeo, Lami] NICHD, Perinatol Res Branch, NIH, DHHS, Detroit, MI USA.
[Stampalija, Tamara; Chaiworapongsa, Tinnakorn; Than, Nandor Gabor; Hassan, Sonia S.; Yeo, Lami] Wayne State Univ, Dept Obstet Gynecol, Detroit, MI 48201 USA.
[Stampalija, Tamara; Ferrazzi, Enrico] Univ Milan, Childrens Hosp V Buzzi, Dept Obstet Gynecol, Milan, Italy.
[Tarca, Adi L.] Wayne State Univ, Dept Comp Sci, Detroit, MI 48201 USA.
RP Romero, R (reprint author), Wayne State Univ, Hutzel Womens Hosp, Perinatol Res Branch, NICHD,NIH,DHHS, 3990 John R,Box 4, Detroit, MI 48201 USA.
EM tchaiwor@med.wayne.edu; romeror@maih.nih.gov
RI Stampalija, Tamara/K-4900-2014
FU Perinatology Research Branch, Division of Intramural Research, Eunice
Kennedy Shriver National Institute of Child Health and Human
Development, National Institutes of Health, Department of Health and
Human Services (NICHD/NIH); Federal funds from NICHD, NIH
[HSN275201300006C]
FX This research was supported, in part, by the Perinatology Research
Branch, Division of Intramural Research, Eunice Kennedy Shriver National
Institute of Child Health and Human Development, National Institutes of
Health, Department of Health and Human Services (NICHD/NIH); and, in
part, with Federal funds from NICHD, NIH under Contract No.
HSN275201300006C.
NR 217
TC 5
Z9 5
U1 1
U2 6
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1476-7058
EI 1476-4954
J9 J MATERN-FETAL NEO M
JI J. Matern.-Fetal Neonatal Med.
PD JAN
PY 2014
VL 27
IS 2
BP 111
EP 121
DI 10.3109/14767058.2013.806894
PG 11
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 269RL
UT WOS:000328259500001
PM 23688338
ER
PT J
AU Chaiworapongsa, T
Romero, R
Korzeniewski, SJ
Cortez, JM
Pappas, A
Tarca, AL
Chaemsaithong, P
Dong, Z
Yeo, L
Hassan, SS
AF Chaiworapongsa, Tinnakorn
Romero, Roberto
Korzeniewski, Steven J.
Cortez, Josef M.
Pappas, Athina
Tarca, Adi L.
Chaemsaithong, Piya
Dong, Zhong
Yeo, Lami
Hassan, Sonia S.
TI Plasma concentrations of angiogenic/anti-angiogenic factors have
prognostic value in women presenting with suspected preeclampsia to the
obstetrical triage area: a prospective study
SO JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
LA English
DT Article
DE Maternal outcome; neonatal outcome; placental growth factor; pregnancy;
soluble endoglin; soluble vascular endothelial growth factor receptor-1
ID ELEVATED LIVER-ENZYMES; PREGNANCY-INDUCED HYPERTENSION; GROWTH-FACTOR
RECEPTOR-1; LOW PLATELET COUNT; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME;
LATE-ONSET PREECLAMPSIA; FOR-GESTATIONAL-AGE; SERUM URIC-ACID; SOLUBLE
ENDOGLIN; MATERNAL COMPLICATIONS
AB Objective: To prospectively determine the prognostic value of maternal plasma concentrations of placental growth factor (PlGF), soluble endoglin (sEng) and soluble vascular endothelial growth factor receptors-1 and -2 (sVEGFR-1 and -2) in identifying patients with suspected preeclampsia (PE), who require preterm delivery (PTD) or develop adverse outcomes.
Study design: This prospective cohort study included 85 consecutive patients who presented to the obstetrical triage area at 20-36 weeks with a diagnosis of "rule out PE." Patients were classified as: 1) those who remained stable until term (n = 37); and 2) those who developed severe PE and required PTD (n = 48). Plasma concentrations of PlGF, sEng and sVEGFR-1 and -2 were determined by ELISA.
Results: Patients with PlGF/sVEGFR-1 <= 0.05 multiples of the median (MoM) or PlGF/sEng <= 0.07 MoM were more likely to deliver preterm due to PE [adjusted odd ratio (aOR) 7.4 and 8.8], and to develop maternal (aOR 3.7 and 2.4) or neonatal complications (aOR 10.0 and 10.1). Among patients who presented <34 weeks of gestation, PlGF/sVEGFR-1 <= 0.035 MoM or PlGF/sEng <= 0.05 MoM had a sensitivity of 89% (16/18), specificity of 96% (24/25) and likelihood ratio for a positive test of 22 to identify patients who delivered within 2 weeks. The addition of the PlGF/sVEGFR-1 ratio to standard clinical tests improved the sensitivity at a fixed false-positive rate of 3% (p = 0.004) for the identification of patients who were delivered due to PE within 2 weeks. Among patients who had a plasma concentration of PlGF/sVEGFR-1 ratio <= 0.035 MoM, 0.036-0.34 MoM and >= 0.35 MoM, the rates of PTD <34 weeks were 94%, 27% and 7%, respectively.
Conclusions: The determination of angiogenic/anti-angiogenic factors has prognostic value in patients presenting to the obstetrical triage area with suspected PE for the identification of those requiring preterm delivery and at risk for adverse maternal/neonatal outcomes.
C1 [Chaiworapongsa, Tinnakorn; Romero, Roberto; Korzeniewski, Steven J.; Tarca, Adi L.; Chaemsaithong, Piya; Dong, Zhong; Yeo, Lami; Hassan, Sonia S.] NICHD, Perinatol Res Branch, NIH, DHHS, Detroit, MI USA.
[Chaiworapongsa, Tinnakorn; Korzeniewski, Steven J.; Chaemsaithong, Piya; Yeo, Lami; Hassan, Sonia S.] Wayne State Univ, Dept Obstet Gynecol, Detroit, MI 48201 USA.
[Cortez, Josef M.; Pappas, Athina] Wayne State Univ, Dept Pediat, Detroit, MI 48201 USA.
[Tarca, Adi L.] Wayne State Univ, Dept Comp Sci, Detroit, MI 48201 USA.
RP Chaiworapongsa, T (reprint author), Wayne State Univ, Hutzel Womens Hosp, Perinatol Res Branch, NICHD,NIH,DHHS, 3990 John R,Box 4, Detroit, MI 48201 USA.
EM tchaiwor@med.wayne.edu; romeror@mail.nih.gov
FU Perinatology Research Branch, Division of Intramural Research, Eunice
Kennedy Shriver National Institute of Child Health and Human
Development, National Institutes of Health, Department of Health and
Human Services (NICHD/NIH); Federal funds from NICHD, NIH
[HHSN275201300006C]
FX This research was supported, in part, by the Perinatology Research
Branch, Division of Intramural Research, Eunice Kennedy Shriver National
Institute of Child Health and Human Development, National Institutes of
Health, Department of Health and Human Services (NICHD/NIH); and, in
part, with Federal funds from NICHD, NIH under Contract No.
HHSN275201300006C.
NR 123
TC 22
Z9 22
U1 1
U2 8
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1476-7058
EI 1476-4954
J9 J MATERN-FETAL NEO M
JI J. Matern.-Fetal Neonatal Med.
PD JAN
PY 2014
VL 27
IS 2
BP 132
EP 144
DI 10.3109/14767058.2013.806905
PG 13
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 269RL
UT WOS:000328259500004
PM 23687930
ER
PT S
AU Perera, L
Beard, WA
Pedersen, LG
Wilson, SH
AF Perera, Lalith
Beard, William A.
Pedersen, Lee G.
Wilson, Samuel H.
BE Christov, CZ
TI Applications of Quantum Mechanical/Molecular Mechanical Methods to the
Chemical Insertion Step of DNA and RNA Polymerization
SO METAL-CONTAINING ENZYMES
SE Advances in Protein Chemistry and Structural Biology
LA English
DT Review; Book Chapter
ID BIOMOLECULAR SIMULATION PROGRAM; NUCLEOTIDYL TRANSFER-REACTION;
ERROR-FREE BYPASS; POLYMERASE-BETA; ACTIVE-SITE; CATALYTIC MECHANISM;
CONFORMATIONAL-CHANGES; MOLECULAR-DYNAMICS; ENZYME CATALYSIS; QM/MM
METHODS
AB We review theoretical attempts to model the chemical insertion reactions of nucleoside triphosphates catalyzed by the nucleic acid polymerases using combined quantum mechanical/molecular mechanical methodology. Due to an existing excellent database of high-resolution X-ray crystal structures, the DNA polymerase beta system serves as a useful template for discussion and comparison. The convergence of structures of high-quality complexes and continued developments of theoretical techniques suggest a bright future for understanding the global features of nucleic acid polymerization.
C1 [Perera, Lalith; Beard, William A.; Wilson, Samuel H.] NIEHS, Struct Biol Lab, POB 12233, Res Triangle Pk, NC 27709 USA.
[Pedersen, Lee G.] Univ North Carolina Chapel Hill, Dept Chem, Chapel Hill, NC USA.
RP Perera, L (reprint author), NIEHS, Struct Biol Lab, POB 12233, Res Triangle Pk, NC 27709 USA.
EM pereral2@niehs.nih.gov
FU Intramural NIH HHS; NHLBI NIH HHS [HL-06350]; NIEHS NIH HHS
[Z01-ES043010, Z01-ES050158, Z01-ES050161]
NR 77
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1876-1623
BN 978-0-12-800012-0
J9 ADV PROTEIN CHEM STR
JI Adv. Protein Chem. Struct. Biol.
PY 2014
VL 97
BP 83
EP 113
DI 10.1016/bs.apcsb.2014.10.001
PG 31
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BF5HT
UT WOS:000382006500005
PM 25458356
ER
PT S
AU Zhou, B
Lin, MY
Sun, T
Knight, AL
Sheng, ZH
AF Zhou, Bing
Lin, Mei-Yao
Sun, Tao
Knight, Adam L.
Sheng, Zu-Hang
BE Murphy, AN
Chan, DC
TI Characterization of Mitochondrial Transport in Neurons
SO MITOCHONDRIAL FUNCTION
SE Methods in Enzymology
LA English
DT Review; Book Chapter
ID AMYOTROPHIC-LATERAL-SCLEROSIS; AXONAL-TRANSPORT; CORTICAL-NEURONS;
IN-VIVO; SYNAPSES; TRAFFICKING; ENDOCYTOSIS; MORPHOLOGY; MECHANISM;
MOTILITY
AB Mitochondria are cellular power plants that supply ATP to power various biological activities essential for neuronal growth, survival, and function. Due to extremely varied morphological features, neurons face exceptional challenges to maintain energy homeostasis. Neurons require specialized mechanisms distributing mitochondria to distal synapses where energy is in high demand. Axons and synapses undergo activity-dependent remodeling, thereby altering mitochondrial distribution. The uniform microtubule polarity has made axons particularly useful for exploring mechanisms regulating mitochondrial transport. Mitochondria alter their motility under stress conditions or when their integrity is impaired. Therefore, research into the mechanisms regulating mitochondrial motility in healthy and diseased neurons is an important emerging frontier in neurobiology. In this chapter, we discuss the current protocols in the characterization of axonal mitochondrial transport in primary neuron cultures isolated from embryonic rats and adult mice. We also briefly discuss new procedures developed in our lab in analyzing mitochondrial motility patterns at presynaptic terminals and evaluate their impact on synaptic vesicle release.
C1 [Zhou, Bing; Lin, Mei-Yao; Sun, Tao; Knight, Adam L.; Sheng, Zu-Hang] NINDS, Synapt Funct Sect, Porter Neurosci Res Ctr, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
RP Sheng, ZH (reprint author), NINDS, Synapt Funct Sect, Porter Neurosci Res Ctr, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
EM shengz@ninds.nih.gov
FU Intramural NIH HHS
NR 36
TC 0
Z9 0
U1 4
U2 5
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0076-6879
BN 978-0-12-801415-8
J9 METHOD ENZYMOL
JI Methods Enzymol.
PY 2014
VL 547
BP 75
EP 96
DI 10.1016/B978-0-12-801415-8.00005-9
PG 22
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Cell
Biology; Neurosciences
SC Biochemistry & Molecular Biology; Cell Biology; Neurosciences &
Neurology
GA BF4XK
UT WOS:000381757800006
PM 25416353
ER
PT S
AU Holmes-Hampton, GP
Tong, WH
Rouault, TA
AF Holmes-Hampton, Gregory P.
Tong, Wing-Hang
Rouault, Tracey A.
BE Murphy, AN
Chan, DC
TI Biochemical and Biophysical Methods for Studying Mitochondrial Iron
Metabolism
SO MITOCHONDRIAL FUNCTION
SE Methods in Enzymology
LA English
DT Review; Book Chapter
ID RAY-FLUORESCENCE MICROSCOPY; PERFUSION-TURNBULL METHODS;
ELECTRON-PARAMAGNETIC-RES; CLUSTER SCAFFOLD PROTEIN; FIELD EPR
SPECTROSCOPY; HUMAN JURKAT CELLS; FRIEDREICHS-ATAXIA; FERROUS IRON;
PAROXYSMAL MYOGLOBINURIA; SUCCINATE-DEHYDROGENASE
AB Iron is a heavily utilized element in organisms and numerous mechanisms accordingly regulate the trafficking, metabolism, and storage of iron. Despite the high regulation of iron homeostasis, several diseases and mutations can lead to the misregulation and often accumulation of iron in the cytosol or mitochondria of tissues. To understand the genesis of iron overload, it is necessary to employ various techniques to quantify iron in organisms and mitochondria. This chapter discusses techniques for determining the total iron content of tissue samples, ranging from colorimetric determination of iron concentrations, atomic absorption spectroscopy, inductively coupled plasma-optical emission spectroscopy, and inductively coupled plasma-mass spectrometry. In addition, we discuss in situ techniques for analyzing iron including electron microscopic non-heme iron histochemistry, electron energy loss spectroscopy, synchrotron X-ray fluorescence imaging, and confocal Raman microscopy. Finally, we discuss biophysical methods for studying iron in isolated mitochondria, including ultraviolet-visible, electron paramagnetic resonance, X-ray absorbance, and Mossbauer spectroscopies. This chapter should aid researchers to select and interpret mitochondrial iron quantifications.
C1 [Holmes-Hampton, Gregory P.; Tong, Wing-Hang; Rouault, Tracey A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Mol Med, Bethesda, MD 20892 USA.
RP Rouault, TA (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Mol Med, Bethesda, MD 20892 USA.
EM rouault@mail.nih.gov
FU Intramural NIH HHS
NR 146
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0076-6879
BN 978-0-12-801415-8
J9 METHOD ENZYMOL
JI Methods Enzymol.
PY 2014
VL 547
BP 275
EP 307
DI 10.1016/B978-0-12-801415-8.00015-1
PG 33
WC Biochemical Research Methods; Biochemistry & Molecular Biology; Cell
Biology; Neurosciences
SC Biochemistry & Molecular Biology; Cell Biology; Neurosciences &
Neurology
GA BF4XK
UT WOS:000381757800016
PM 25416363
ER
PT J
AU Geguchadze, R
Wang, ZM
Zourelias, L
Perez-Riveros, P
Edwards, PC
Machen, L
Passineau, MJ
AF Geguchadze, Ramaz
Wang, Zhimin
Zourelias, Lee
Perez-Riveros, Paola
Edwards, Paul C.
Machen, Laurie
Passineau, Michael J.
TI Proteomic profiling of salivary gland after nonviral gene transfer
mediated by conventional plasmids and minicircles
SO MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
LA English
DT Article
AB In this study, we compared gene transfer efficiency and host response to ultrasound-assisted, nonviral gene transfer with a conventional plasmid and a minicircle vector in the submandibular salivary glands of mice. Initially, we looked at gene transfer efficiency with equimolar amounts of the plasmid and minicircle vectors, corroborating an earlier report showing that minicircle is more efficient in the context of a physical method of gene transfer. We then sought to characterize the physiological response of the salivary gland to exogenous gene transfer using global proteomic profiling. Somewhat surprisingly, we found that sonoporation alone, without a gene transfer vector present, had virtually no effect on the salivary gland proteome. However, when a plasmid vector was used, we observed profound perturbations of the salivary gland proteome that compared in magnitude to that seen in a previous report after high doses of adeno-associated virus. Finally, we found that gene transfer with a minicircle induces only minor proteomic alterations that were similar to sonoporation alone. Using mass spectrometry, we assigned protein IDs to 218 gel spots that differed between plasmid and minicircle. Bioinformatic analysis of these proteins demonstrated convergence on 68 known protein interaction pathways, most notably those associated with innate immunity, cellular stress, and morphogenesis.
C1 [Geguchadze, Ramaz; Wang, Zhimin; Zourelias, Lee; Machen, Laurie; Passineau, Michael J.] Allegheny Hlth Network, Gene Therapy Program, Pittsburgh, PA 15212 USA.
[Perez-Riveros, Paola] Natl Inst Dent & Craniofacial Res, Bethesda, MD USA.
[Edwards, Paul C.] Indiana Univ, Sch Dent, Dept Oral Pathol Med & Radiol, Indianapolis, IN USA.
RP Passineau, MJ (reprint author), Allegheny Hlth Network, Gene Therapy Program, Pittsburgh, PA 15212 USA.
EM mpassine@wpahs.org
OI Edwards, Paul/0000-0001-7884-8480
FU National Institutes of Health grants [5R03DE020118, 1R01DE022973]
FX This work was supported by National Institutes of Health grants
5R03DE020118 and 1R01DE022973 (to M.J.P.). The authors wish to thank
Alexander Zambon and Nathan Salomonis for their assistance with the
GO-Elite pathway analysis software.
NR 31
TC 4
Z9 4
U1 0
U2 0
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2329-0501
J9 MOL THER-METH CLIN D
JI Mol.Ther.-Methods Clin. Dev.
PY 2014
VL 1
AR UNSP 14007
DI 10.1038/mtm.2014.7
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA V46YD
UT WOS:000209918600019
PM 25414909
ER
PT J
AU Wu, CF
Hong, SG
Winkler, T
Spencer, DM
Jares, A
Ichwan, B
Nicolae, A
Guo, V
Larochelle, A
Dunbar, CE
AF Wu, Chuanfeng
Hong, So Gun
Winkler, Thomas
Spencer, David M.
Jares, Alexander
Ichwan, Brian
Nicolae, Alina
Guo, Vicky
Larochelle, Andre
Dunbar, Cynthia E.
TI Development of an inducible caspase-9 safety switch for pluripotent stem
cell-based therapies
SO MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
LA English
DT Article
AB Induced pluripotent stem cell (iPSC) therapies offer a promising path for patient-specific regenerative medicine. However, tumor formation from residual undifferentiated iPSC or transformation of iPSC or their derivatives is a risk. Inclusion of a suicide gene is one approach to risk mitigation. We introduced a dimerizable-"inducible caspase-9" (iCasp9) suicide gene into mouse iPSC (miPSC) and rhesus iPSC (RhiPSC) via a lentivirus, driving expression from either a cytomegalovirus (CMV), elongation factor-1 alpha (EF1 alpha) or pluripotency-specific EOS-C(3+) promoter. Exposure of the iPSC to the synthetic chemical dimerizer, AP1903, in vitro induced effective apoptosis in EF1 alpha-iCasp9-expressing (EF1 alpha)-iPSC, with less effective killing of EOS-C(3+)-iPSC and CMV-iPSC, proportional to transgene expression in these cells. AP1903 treatment of EF1 alpha-iCasp9 miPSC in vitro delayed or prevented teratomas. AP1903 administration following subcutaneous or intravenous delivery of EF1 alpha-iPSC resulted in delayed teratoma progression but did not ablate tumors. EF1 alpha-iCasp9 expression was downregulated during in vitro and in vivo differentiation due to DNA methylation at CpG islands within the promoter, and methylation, and thus decreased expression, could be reversed by 5-azacytidine treatment. The level and stability of suicide gene expression will be important for the development of suicide gene strategies in iPSC regenerative medicine.
C1 [Wu, Chuanfeng; Hong, So Gun; Winkler, Thomas; Jares, Alexander; Ichwan, Brian; Guo, Vicky; Larochelle, Andre; Dunbar, Cynthia E.] NHLBI, Hematol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.
[Spencer, David M.] Bellicum Pharmaceut Inc, Houston, TX USA.
[Nicolae, Alina] NCI, Lab Pathol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Dunbar, CE (reprint author), NHLBI, Hematol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM dunbarc@nhlbi.nih.gov
RI Wu, Chuanfeng/A-1109-2016;
OI Jares, Alexander/0000-0001-8387-2362
FU National Heart, Lung, and Blood Institute (NHLBI); National Center for
Regenerative Medicine (NCRM)
FX This work was supported by intramural funding from the National Heart,
Lung, and Blood Institute (NHLBI) and the National Center for
Regenerative Medicine (NCRM). We thank Jichun Chen and Marie Desierto
from the Hematology Branch, and ZuXi Yu from the NHLBI pathology core
facility for their assistance with teratoma assays, and Vivian Diaz from
NIH Mouse Imaging Facility (MIF) for GFP live cell imaging. We thank
Gianpietro Dotti for providing the pCDH-iCasp9-2A-h. CD19 lentiviral
vector. D.M.S. is employed by Bellicum Pharmaceuticals. The other
authors declare no conflict of interest.
NR 48
TC 12
Z9 12
U1 0
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2329-0501
J9 MOL THER-METH CLIN D
JI Mol.Ther.-Methods Clin. Dev.
PY 2014
VL 1
AR UNSP 14053
DI 10.1038/mtm.2014.53
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA V46YD
UT WOS:000209918600065
PM 26052521
ER
PT S
AU Pryde, DC
Groft, SC
AF Pryde, David C.
Groft, Stephen C.
BE Pryde, DC
Palmer, MJ
TI Definitions, History and Regulatory Framework for Rare Diseases and
Orphan Drugs
SO ORPHAN DRUGS AND RARE DISEASES
SE RSC Drug Discovery Series
LA English
DT Article; Book Chapter
ID INNOVATION; GENE
C1 [Pryde, David C.] Pfizer Neusentis, Worldwide Med Chem, Portway Bldg,Granta Pk, Cambridge CB21 6GS, England.
[Groft, Stephen C.] NIH, Natl Ctr Adv Translat Sci, Off Rare Dis Res, Bethesda, MD 20892 USA.
RP Pryde, DC (reprint author), Pfizer Neusentis, Worldwide Med Chem, Portway Bldg,Granta Pk, Cambridge CB21 6GS, England.
EM David.Pryde@pfizer.com
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, CAMBRIDGE CB4 4WF, CAMBS, ENGLAND
SN 2041-3203
BN 978-1-78262-420-2; 978-1-84973-806-4
J9 RSC DRUG DISCOV
JI RSC Drug Discov.
PY 2014
VL 38
BP 3
EP 31
D2 10.1039/9781782624202
PG 29
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA BG0WH
UT WOS:000386536600003
ER
PT B
AU Merril, CR
AF Merril, Carl R.
BE Borysowski, J
Miedzybrodzki, R
Gorski, A
TI Phage Therapy Current Research and Applications Foreword
SO PHAGE THERAPY: CURRENT RESEARCH AND APPLICATIONS
LA English
DT Editorial Material; Book Chapter
ID BACTERIOPHAGE
C1 [Merril, Carl R.] NIH, Bldg 10, Bethesda, MD 20892 USA.
RP Merril, CR (reprint author), NIH, Bldg 10, Bethesda, MD 20892 USA.
NR 6
TC 0
Z9 0
U1 2
U2 2
PU CAISTER ACADEMIC PRESS
PI WYMONDHAM
PA 32 HEWITTS LANE, WYMONDHAM NR 18 0JA, ENGLAND
BN 978-1-908230-74-4; 978-1-908230-40-9
PY 2014
BP XI
EP XII
PG 2
WC Biotechnology & Applied Microbiology; Infectious Diseases; Microbiology;
Pharmacology & Pharmacy
SC Biotechnology & Applied Microbiology; Infectious Diseases; Microbiology;
Pharmacology & Pharmacy
GA BF7MX
UT WOS:000384251600001
ER
PT S
AU Zhang, JW
Ferre-D'Amare, AR
AF Zhang, Jinwei
Ferre-D'Amare, Adrian R.
BE BurkeAguero, DH
TI A Flexible, Scalable Method for Preparation of Homogeneous Aminoacylated
tRNAs
SO RIBOSWITCH DISCOVERY, STRUCTURE AND FUNCTION
SE Methods in Enzymology
LA English
DT Review; Book Chapter
ID MISACYLATED TRANSFER-RNAS; EF-TU; CRYSTAL-STRUCTURE; PROTECTING GROUP;
AMINO-ACID; RIBOZYME; MUTANTS; COMPLEX; DOMAIN; GTP
AB Transfer RNAs (tRNAs) are cellular courier molecules that decipher the genetic code in messenger RNAs and enable the transfer of appropriate esterified amino acids to the growing peptide chain. The preparation of biophysical quantities of homogeneous aminoacylated tRNAs has remained a significant technical challenge. This is primarily due to the difficulty in removing contaminating nonaminoacylated tRNAs that are have very similar properties overall, as well as the hydrolytic instability of the aminoacyl linkage. We describe a flexible, scalable method to prepare homogeneous aminoacylated tRNAs that is also broadly compatible with mutant, misacylated, or otherwise aberrant tRNAs and other RNAs. This method combines ribozyme-mediated aminoacylation with reversible N-pentenoylation of the esterified amino acid, which not only protects against spontaneous deacylation but also provides a hydrophobic purification handle. This protocol makes it straightforward to produce biophysical quantities of natural and unnatural aminoacylated tRNAs and has proven essential for mechanistic investigations of the T-box riboswitches.
C1 [Zhang, Jinwei; Ferre-D'Amare, Adrian R.] NHLBI, Bldg 10, Bethesda, MD 20892 USA.
RP Ferre-D'Amare, AR (reprint author), NHLBI, Bldg 10, Bethesda, MD 20892 USA.
EM adrian.ferre@nih.gov
FU Intramural NIH HHS [Z99 HL999999, ZIA HL006102-04, ZIA HL006150-03, ZIA
HL006188-01]
NR 24
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0076-6879
BN 978-0-12-801122-5
J9 METHOD ENZYMOL
JI Methods Enzymol.
PY 2014
VL 549
BP 105
EP 113
DI 10.1016/B978-0-12-801122-5.00005-2
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BF4XX
UT WOS:000381763600006
PM 25432746
ER
PT S
AU Warner, KD
Ferre-D'Amare, AR
AF Warner, Katherine Deigan
Ferre-D'Amare, Adrian R.
BE BurkeAguero, DH
TI Crystallographic Analysis of TPP Riboswitch Binding by Small-Molecule
Ligands Discovered Through Fragment-Based Drug Discovery Approaches
SO RIBOSWITCH DISCOVERY, STRUCTURE AND FUNCTION
SE Methods in Enzymology
LA English
DT Review; Book Chapter
ID STRUCTURAL BASIS; GLMS RIBOZYME; RNA; TOOL; CRYOCRYSTALLOGRAPHY
AB Riboswitches are structured mRNA elements that regulate gene expression in response to metabolite or second-messenger binding and are promising targets for drug discovery. Fragment-based drug discovery methods have identified weakly binding small molecule "fragments" that bind a thiamine pyrophosphate (TPP) riboswitch. However, these fragments require substantial chemical elaboration into more potent, drug-like molecules. Structure determination of the fragments bound to the riboswitch is the necessary next step. In this chapter, we describe the methods for co-crystallization and structure determination of fragment-bound TPP riboswitch structures. We focus on considerations for screening crystallization conditions across multiple crystal forms and provide guidance for building the fragment into the refined crystallographic model. These methods are broadly applicable for crystallographic analyses of any small molecules that bind structured RNAs.
C1 [Warner, Katherine Deigan; Ferre-D'Amare, Adrian R.] NHLBI, Bldg 10, Bethesda, MD 20892 USA.
[Warner, Katherine Deigan] Univ Cambridge, Dept Chem, Cambridge, England.
RP Ferre-D'Amare, AR (reprint author), NHLBI, Bldg 10, Bethesda, MD 20892 USA.
EM adrian.ferre@nih.gov
FU Intramural NIH HHS [Z99 HL999999, ZIA HL006102-04, ZIA HL006150-03, ZIA
HL006188-01]
NR 33
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0076-6879
BN 978-0-12-801122-5
J9 METHOD ENZYMOL
JI Methods Enzymol.
PY 2014
VL 549
BP 221
EP 233
DI 10.1016/B978-0-12-801122-5.00010-6
PG 13
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA BF4XX
UT WOS:000381763600011
PM 25432751
ER
PT J
AU Gong, BS
Wang, C
Su, ZQ
Hong, HX
Thierry-Mieg, J
Thierry-Mieg, D
Shi, LM
Auerbach, SS
Tong, WD
Xu, J
AF Gong, Binsheng
Wang, Charles
Su, Zhenqiang
Hong, Huixiao
Thierry-Mieg, Jean
Thierry-Mieg, Danielle
Shi, Leming
Auerbach, Scott S.
Tong, Weida
Xu, Joshua
TI Transcriptomic profiling of rat liver samples in a comprehensive study
design by RNA-Seq
SO SCIENTIFIC DATA
LA English
DT Article
AB RNA-Seq provides the capability to characterize the entire transcriptome in multiple levels including gene expression, allele specific expression, alternative splicing, fusion gene detection, and etc. The US FDA-led SEQC (i.e., MAQC-III) project conducted a comprehensive study focused on the transcriptome profiling of rat liver samples treated with 27 chemicals to evaluate the utility of RNA-Seq in safety assessment and toxicity mechanism elucidation. The chemicals represented multiple chemogenomic modes of action (MOA) and exhibited varying degrees of transcriptional response. The paired-end 100 bp sequencing data were generated using Illumina HiScanSQ and/or HiSeq 2000. In addition to the core study, six animals (i.e., three aflatoxin B1 treated rats and three vehicle control rats) were sequenced three times, with two separate library preparations on two sequencing machines. This large toxicogenomics dataset can serve as a resource to characterize various aspects of transcriptomic changes (e.g., alternative splicing) that are byproduct of chemical perturbation.
C1 [Gong, Binsheng; Su, Zhenqiang; Hong, Huixiao; Shi, Leming; Tong, Weida; Xu, Joshua] US FDA, Div Bioinformat & Biostat, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
[Wang, Charles] Loma Linda Univ, Sch Med, Ctr Genom, Loma Linda, CA 92350 USA.
[Wang, Charles] Loma Linda Univ, Sch Med, Div Microbiol & Mol Genet, Loma Linda, CA 92350 USA.
[Thierry-Mieg, Jean; Thierry-Mieg, Danielle] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20814 USA.
[Shi, Leming] Fudan Univ, State Key Lab Genet Engn, Shanghai 201203, Peoples R China.
[Shi, Leming] Fudan Univ, MOE Key Lab Contemporary Anthropol, Sch Life Sci, Shanghai 201203, Peoples R China.
[Shi, Leming] Fudan Univ, MOE Key Lab Contemporary Anthropol, Sch Pharm, Shanghai 201203, Peoples R China.
[Auerbach, Scott S.] NIEHS, Biomol Screening Branch, Div Natl Toxicol Program, POB 12233, Res Triangle Pk, NC 27709 USA.
RP Auerbach, SS (reprint author), NIEHS, Biomol Screening Branch, Div Natl Toxicol Program, POB 12233, Res Triangle Pk, NC 27709 USA.
EM auerbachs@niehs.nih.gov; weida.tong@fda.hhs.gov; zhihua.xu@fda.hhs.gov
RI THIERRY-MIEG, Jean/F-1975-2017
OI THIERRY-MIEG, Jean/0000-0002-0396-6789
FU Intramural Research Program of the NIH, National Library of Medicine
FX This dataset was generated for the SEQC toxicogenomics study and the
related research manuscript8. The authors would like to thank
Philippe Rocca-Serra for his guidance and assistance in sample metadata
collection and coding with ISA-TAB. This research was supported in part
by the Intramural Research Program of the NIH, National Library of
Medicine. The views presented in this article do not necessarily reflect
current or future opinion or policy of the US Food and Drug
Administration. Any mention of commercial products is for clarification
and not intended as an endorsement.
NR 24
TC 3
Z9 3
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2052-4463
J9 SCI DATA
JI Sci. Data
PY 2014
VL 1
AR 140021
DI 10.1038/sdata.2014.21
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V45VG
UT WOS:000209843500014
ER
PT J
AU Harpaz, R
Odgers, D
Gaskin, G
DuMouchel, W
Winnenburg, R
Bodenreider, O
Ripple, A
Szarfman, A
Sorbello, A
Horvitz, E
White, RW
Shah, NH
AF Harpaz, Rave
Odgers, David
Gaskin, Greg
DuMouchel, William
Winnenburg, Rainer
Bodenreider, Olivier
Ripple, Anna
Szarfman, Ana
Sorbello, Alfred
Horvitz, Eric
White, Ryen W.
Shah, Nigam H.
TI A time-indexed reference standard of adverse drug reactions
SO SCIENTIFIC DATA
LA English
DT Article
AB Undetected adverse drug reactions (ADRs) pose a major burden on the health system. Data mining methodologies designed to identify signals of novel ADRs are of deep importance for drug safety surveillance. The development and evaluation of these methodologies requires proper reference benchmarks. While progress has recently been made in developing such benchmarks, our understanding of the performance characteristics of the data mining methodologies is limited because existing benchmarks do not support prospective performance evaluations. We address this shortcoming by providing a reference standard to support prospective performance evaluations. The reference standard was systematically curated from drug labeling revisions, such as new warnings, which were issued and communicated by the US Food and Drug Administration in 2013. The reference standard includes 62 positive test cases and 75 negative controls, and covers 44 drugs and 38 events. We provide usage guidance and empirical support for the reference standard by applying it to analyze two data sources commonly mined for drug safety surveillance.
C1 [Harpaz, Rave; Odgers, David; Gaskin, Greg; Shah, Nigam H.] Stanford Univ, Ctr Biomed Informat Res, Stanford, CA 94305 USA.
[DuMouchel, William] Oracle Hlth Sci, Bedford, MA 01730 USA.
[Winnenburg, Rainer; Bodenreider, Olivier; Ripple, Anna] NIH, Natl Lib Med, Bethesda, MD 20894 USA.
[Szarfman, Ana; Sorbello, Alfred] US FDA, Silver Spring, MD 20993 USA.
[Horvitz, Eric; White, Ryen W.] Microsoft Res, Redmond, WA 98052 USA.
RP Harpaz, R (reprint author), Stanford Univ, Ctr Biomed Informat Res, Stanford, CA 94305 USA.
EM rharpaz@stanford.edu
FU NIH [U54-HG004028]; NIGMS [GM101430- 01A1]; Med Scholars fellowship from
the Stanford School of Medicine; Intramural Research Program of the NIH,
National Library of Medicine; Microsoft Research
FX R.H. and N.H.S. acknowledge support by NIH grant U54-HG004028 for the
National Center for Biomedical Ontology and by NIGMS grant GM101430-
01A1. D.O. acknowledges support by NIGMS grant GM101430- 01A1. G.G. is
supported by a Med Scholars fellowship from the Stanford School of
Medicine. This work was supported in part by the Intramural Research
Program of the NIH, National Library of Medicine, and Microsoft
Research.
NR 29
TC 6
Z9 6
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2052-4463
J9 SCI DATA
JI Sci. Data
PY 2014
VL 1
AR 140043
DI 10.1038/sdata.2014.43
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V45VG
UT WOS:000209843500039
ER
PT J
AU Messina, JP
Brady, OJ
Pigott, DM
Brownstein, JS
Hoen, AG
Hay, SI
AF Messina, Jane P.
Brady, Oliver J.
Pigott, David M.
Brownstein, John S.
Hoen, Anne G.
Hay, Simon I.
TI A global compendium of human dengue virus occurrence
SO SCIENTIFIC DATA
LA English
DT Article
AB A global geographic database of human dengue virus occurrence was produced to generate a global risk map and associated burden estimates(1). Herein we present the database, which comprises occurrence data linked to point or polygon locations, derived from peer-reviewed literature and case reports as well as informal online sources. Entries date from 1960 to 2012. We describe all data collection processes in full, as well as geo-positioning, database management and quality-control procedures. This is the most comprehensive database of confirmed human dengue infection to-date, consisting of 8,309 geo-positioned occurrences in total.
C1 [Messina, Jane P.; Brady, Oliver J.; Pigott, David M.; Hay, Simon I.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, South Pk Rd, Oxford OX1 3PS, England.
[Brownstein, John S.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.
[Brownstein, John S.] Boston Childrens Hosp, Childrens Hosp Informat Program, Boston, MA 02115 USA.
[Hoen, Anne G.] Dartmouth Coll, Geisel Sch Med, Dept Community & Family Med, Hanover, NH 03755 USA.
[Hay, Simon I.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
RP Messina, JP (reprint author), Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, South Pk Rd, Oxford OX1 3PS, England.
EM jane.messina@zoo.ox.ac.uk
OI Brady, Oliver/0000-0002-3235-2129; Hay, Simon/0000-0002-0611-7272
FU Wellcome Trust [095066]; BBSRC Industrial CASE studentship;
International Research Consortium on Dengue Risk Assessment Management
and Surveillance (IDAMS) [21803]; Sir Richard Southwood Graduate
Scholarship from the Department of Zoology at the University of Oxford;
RAPIDD program of the Science & Technology Directorate, Department of
Homeland Security; Fogarty International Center, National Institutes of
Health
FX S.I.H. is funded by a Senior Research Fellowship from the Wellcome Trust
(095066). O.J.B. is funded by a BBSRC Industrial CASE studentship.
J.P.M. is funded by the International Research Consortium on Dengue Risk
Assessment Management and Surveillance (IDAMS, 21803,
http://www.idams.eu). D.M.P. is funded by a Sir Richard Southwood
Graduate Scholarship from the Department of Zoology at the University of
Oxford. S.I.H. also acknowledges funding support from the RAPIDD program
of the Science & Technology Directorate, Department of Homeland
Security, and the Fogarty International Center, National Institutes of
Health.
NR 6
TC 16
Z9 17
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2052-4463
J9 SCI DATA
JI Sci. Data
PY 2014
VL 1
AR 140004
DI 10.1038/sdata.2014.4
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V45VG
UT WOS:000209843500035
ER
PT J
AU Mylne, A
Brady, OJ
Huang, Z
Pigott, DM
Golding, N
Kraemer, MUG
Hay, SI
AF Mylne, Adrian
Brady, Oliver J.
Huang, Zhi
Pigott, David M.
Golding, Nick
Kraemer, Moritz U. G.
Hay, Simon I.
TI A comprehensive database of the geographic spread of past human Ebola
outbreaks
SO SCIENTIFIC DATA
LA English
DT Article
AB Ebola is a zoonotic filovirus that has the potential to cause outbreaks of variable magnitude in human populations. This database collates our existing knowledge of all known human outbreaks of Ebola for the first time by extracting details of their suspected zoonotic origin and subsequent human-to-human spread from a range of published and non-published sources. In total, 22 unique Ebola outbreaks were identified, composed of 117 unique geographic transmission clusters. Details of the index case and geographic spread of secondary and imported cases were recorded as well as summaries of patient numbers and case fatality rates. A brief text summary describing suspected routes and means of spread for each outbreak was also included. While we cannot yet include the ongoing Guinea and DRC outbreaks until they are over, these data and compiled maps can be used to gain an improved understanding of the initial spread of past Ebola outbreaks and help evaluate surveillance and control guidelines for limiting the spread of future epidemics.
C1 [Mylne, Adrian; Brady, Oliver J.; Huang, Zhi; Pigott, David M.; Golding, Nick; Kraemer, Moritz U. G.; Hay, Simon I.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford OX1 3PS, England.
[Hay, Simon I.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
RP Hay, SI (reprint author), Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford OX1 3PS, England.
EM simon.hay@zoo.ox.ac.uk
OI Golding, Nick/0000-0001-8916-5570; Brady, Oliver/0000-0002-3235-2129;
Hay, Simon/0000-0002-0611-7272
FU BBSRC; Wellcome Trust [095066]; Bill & Melinda Gates Foundation
[OPP1093011, OPP1106023, OPP1053338]; RAPIDD program of the Science &
Technology Directorate, Department of Homeland Security; Fogarty
International Center, National Institutes of Health; Sir Richard
Southwood Graduate Scholarship from the Department of Zoology at the
University of Oxford; German Academic Exchange Service (DAAD)
FX O.J.B. is funded by a BBSRC studentship. S.I.H. is funded by a Senior
Research Fellowship from the Wellcome Trust (#095066) which also
supports A.M. and a grant from the Bill & Melinda Gates Foundation
(#OPP1093011). S.I.H. would also like to acknowledge funding support
from the RAPIDD program of the Science & Technology Directorate,
Department of Homeland Security, and the Fogarty International Center,
National Institutes of Health. Z.H. is funded by the Bill & Melinda
Gates Foundation (#OPP1106023). D.M.P. is funded by a Sir Richard
Southwood Graduate Scholarship from the Department of Zoology at the
University of Oxford. N.G. is funded by a grant from the Bill & Melinda
Gates Foundation (#OPP1053338). M.U.G.K. is funded by the German
Academic Exchange Service (DAAD) through a graduate scholarship. Funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 48
TC 13
Z9 13
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2052-4463
J9 SCI DATA
JI Sci. Data
PY 2014
VL 1
AR 140042
DI 10.1038/sdata.2014.42
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V45VG
UT WOS:000209843500038
ER
PT J
AU Pigott, DM
Golding, N
Messina, JP
Battle, KE
Duda, KA
Balard, Y
Bastien, P
Pratlong, F
Brownstein, JS
Freifeld, CC
Mekaru, SR
Madoff', LC
George, DB
Myers, MF
Hay, SI
AF Pigott, David M.
Golding, Nick
Messina, Jane P.
Battle, Katherine E.
Duda, Kirsten A.
Balard, Yves
Bastien, Patrick
Pratlong, Francine
Brownstein, John S.
Freifeld, Clark C.
Mekaru, Sumiko R.
Madoff', Lawrence C.
George, Dylan B.
Myers, Monica F.
Hay, Simon I.
TI Global database of leishmaniasis occurrence locations, 1960-2012
SO SCIENTIFIC DATA
LA English
DT Article
AB The leishmaniases are neglected tropical diseases of significant public health importance. However, information on their global occurrence is disparate and sparse. This database represents an attempt to collate reported leishmaniasis occurrences from 1960 to 2012. Methodology for the collection of data from the literature, abstraction of case locations and data processing procedures are described here. In addition, strain archives and online data resources were accessed. A total of 12,563 spatially and temporally unique occurrences of both cutaneous and visceral leishmaniasis comprise the database, ranging in geographic scale from villages to states. These data can be used for a variety of mapping and spatial analyses covering multiple resolutions.
C1 [Pigott, David M.; Golding, Nick; Messina, Jane P.; Battle, Katherine E.; Duda, Kirsten A.; Myers, Monica F.; Hay, Simon I.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Tinbergen Bldg,South Pk Rd, Oxford OX1 3PS, England.
[Balard, Yves; Bastien, Patrick; Pratlong, Francine] Univ Montpellier I, UFR Med, F-34295 Montpellier, France.
[Balard, Yves; Bastien, Patrick; Pratlong, Francine] CNRS 5290 IRD 224, UMR MiVEGEC, Lab Parasitol Mycol, F-34295 Montpellier, France.
[Bastien, Patrick; Pratlong, Francine] CHRU Montpellier, Dept Parasitol Mycol, Ctr Natl Reference Leishmanioses, F-34295 Montpellier, France.
[Brownstein, John S.; Freifeld, Clark C.; Mekaru, Sumiko R.] Boston Childrens Hosp, Childrens Hosp Informat Program, Boston, MA USA.
[Brownstein, John S.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.
[Madoff', Lawrence C.] Int Soc Infect Dis, ProMED Mail, Worcester, MA 01655 USA.
[Madoff', Lawrence C.] Univ Massachusetts, Sch Med, Worcester, MA 01655 USA.
[George, Dylan B.; Hay, Simon I.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
RP Pigott, DM (reprint author), Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Tinbergen Bldg,South Pk Rd, Oxford OX1 3PS, England.
EM david.pigott@zoo.ox.ac.uk
OI Hay, Simon/0000-0002-0611-7272; Golding, Nick/0000-0001-8916-5570;
Battle, Katherine/0000-0003-2401-2615
FU Sir Richard Southwood Graduate Scholarship from the Department of
Zoology at the University of Oxford; Wellcome trust [095066]; Bill &
Melinda gates Foundation [OPP1053338]; International Research Consortium
on Dengue Risk Assessment Management and Surveillance (IDAMS, European
Commission 7th Framework Programme) [21803]; French Institut de Veille
Sanitaire (InVS); NIH National Library of Medicine [R01LM010812]
FX D.M.P. is funded by a Sir Richard Southwood Graduate Scholarship from
the Department of Zoology at the University of Oxford. S.I.H. is funded
by a Senior Research Fellowship from the Wellcome trust (095066) which
also supports K.A.D. and K.E.B., N.G. is funded by a grant from the Bill
& Melinda gates Foundation (#OPP1053338). J.P.M. is funded by, and
S.I.H. acknowledges the support of, the International Research
Consortium on Dengue Risk Assessment Management and Surveillance (IDAMS,
European Commission 7th Framework Programme (#21803)
http://www.idams.eu). Y.B., F.P. and P.B. acknowledge financial support
by the French Institut de Veille Sanitaire (InVS). J.S.B., S.R.M. and
C.F. acknowledge the funding from NIH National Library of Medicine
(R01LM010812). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
S.I.H. had full access to all the data in the study and takes
responsibility for the integrity of the data and the accuracy of the
data analysis.
NR 20
TC 8
Z9 8
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2052-4463
J9 SCI DATA
JI Sci. Data
PY 2014
VL 1
AR 140036
DI 10.1038/sdata.2014.36
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V45VG
UT WOS:000209843500031
ER
PT J
AU Xu, J
Su, ZQ
Hong, HX
Thierry-Mieg, J
Thierry-Mieg, D
Kreil, DP
Mason, CE
Tong, WD
Shi, LM
AF Xu, Joshua
Su, Zhenqiang
Hong, Huixiao
Thierry-Mieg, Jean
Thierry-Mieg, Danielle
Kreil, David P.
Mason, Christopher E.
Tong, Weida
Shi, Leming
TI Cross-platform ultradeep transcriptomic profiling of human reference RNA
samples by RNA-Seq
SO SCIENTIFIC DATA
LA English
DT Article
AB Whole-transcriptome sequencing ('RNA-Seq') has been drastically changing the scale and scope of genomic research. In order to fully understand the power and limitations of this technology, the US Food and Drug Administration (FDA) launched the third phase of the MicroArray Quality Control (MAQC-III) project, also known as the SEquencing Quality Control (SEQC) project. Using two well-established human reference RNA samples from the first phase of the MAQC project, three sequencing platforms were tested across more than ten sites with built-in truths including spike-in of external RNA controls (ERCC), titration data and qPCR verification. The SEQC project generated over 30 billion sequence reads representing the largest RNA-Seq data ever generated by a single project on individual RNA samples. This extraordinarily ultradeep transcriptomic data set and the known truths built into the study design provide many opportunities for further research and development to advance the improvement and application of RNA-Seq.
C1 [Xu, Joshua; Su, Zhenqiang; Hong, Huixiao; Tong, Weida; Shi, Leming] US FDA, Div Bioinformat cs & Biostat, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
[Thierry-Mieg, Jean; Thierry-Mieg, Danielle] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20814 USA.
[Kreil, David P.] Boku Univ Vienna, Chair Bioinformat Res Grp, Vienna, Austria.
[Kreil, David P.] Univ Warwick, Coventry CV4 7AL, W Midlands, England.
[Mason, Christopher E.] Weill Cornell Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA.
[Mason, Christopher E.] Weill Cornell Med Coll, Inst Computat Biomed, New York, NY 10021 USA.
[Shi, Leming] Fudan Univ, State Key Lab Genet Engn, Shanghai 201203, Peoples R China.
[Shi, Leming] Fudan Univ, MOE Key Lab Contemporary Anthropol, Sch Life Sci, Shanghai 201203, Peoples R China.
[Shi, Leming] Fudan Univ, MOE Key Lab Contemporary Anthropol, Sch Pharm, Shanghai 201203, Peoples R China.
RP Tong, WD (reprint author), US FDA, Div Bioinformat cs & Biostat, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
EM leming.shi@gmail.com
RI THIERRY-MIEG, Jean/F-1975-2017
OI THIERRY-MIEG, Jean/0000-0002-0396-6789
FU Intramural Research Program of the NIH, National Library of Medicine
FX The authors would like to acknowledge all the participants of the SEQC
project, particularly the sequencing sites for generating the
high-quality data set. This research was supported in part by the
Intramural Research Program of the NIH, National Library of Medicine.
The views presented in this article do not necessarily reflect current
or future opinion or policy of the US Food and Drug Administration. Any
mention of commercial products is for clarification and not intended as
an endorsement.
NR 22
TC 1
Z9 1
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2052-4463
J9 SCI DATA
JI Sci. Data
PY 2014
VL 1
AR 140020
DI 10.1038/sdata.2014.20
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V45VG
UT WOS:000209843500013
ER
PT B
AU Lever, C
Kaplan, R
Burgess, N
AF Lever, Colin
Kaplan, Raphael
Burgess, Neil
BE Derdikman, D
Knierim, JJ
TI The Function of Oscillations in the Hippocampal Formation
SO SPACE, TIME AND MEMORY IN THE HIPPOCAMPAL FORMATION
LA English
DT Article; Book Chapter
ID IRREGULAR ACTIVITY STATE; LONG-TERM POTENTIATION; MEDIAL TEMPORAL-LOBE;
HIGH-FREQUENCY OSCILLATIONS; GAMMA-BAND SYNCHRONIZATION; HUMAN SPATIAL
NAVIGATION; HUMAN THETA-OSCILLATIONS; WORKING-MEMORY TASK; FREELY MOVING
RATS; CAT VISUAL-CORTEX
AB Some of the strongest experimental and computational links between oscillations and cognition concern the oscillations in the hippocampal formation supporting spatial and mnemonic processing. We review experimental and theoretical work concerning well-established hippocampal oscillations such as theta, gamma, and high-frequency ripples and how they relate to spatial, mnemonic, and anxiety-related representation and behaviour. We specifically consider the following computational roles for oscillations: organising processing into discrete chunks, as seen in encoding versus retrieval scheduling; ordinal and metric coding by oscillatory phase; temporal integration by oscillatory phase; and interregional communication. The literature on oscillations has typically been concerned with changes in band-specific power. Here, focusing on the theta oscillation, we summarise how key variables are linked not only to power but also to frequency and to coherence. We conclude that the hippocampal formation provides an invaluable model system for understanding the functional roles of neuronal oscillations and the interaction between oscillations.
C1 [Lever, Colin] Univ Durham, Dept Psychol, Durham DH1 3LE, England.
[Kaplan, Raphael] NIMH, Lab Brain & Cognit, Bethseda, MD USA.
[Kaplan, Raphael; Burgess, Neil] UCL Inst Cognit Neurosci, London WC1N 3AR, England.
[Burgess, Neil] UCL Inst Neurol, London WC1N 3BG, England.
RP Lever, C (reprint author), Univ Durham, Dept Psychol, Durham DH1 3LE, England.
EM colin.lever@durham.ac.uk; n.burgess@ucl.ac.uk
NR 247
TC 7
Z9 7
U1 1
U2 1
PU SPRINGER-VERLAG WIEN
PI VIENNA
PA SACHSENPLATZ 4-6, A-1201 VIENNA, AUSTRIA
BN 978-3-7091-1292-2; 978-3-7091-1291-5
PY 2014
BP 303
EP 350
DI 10.1007/978-3-7091-1292-2_12
D2 10.1007/978-3-7091-1292-2
PG 48
WC Neurosciences
SC Neurosciences & Neurology
GA BE6BF
UT WOS:000373804400013
ER
PT B
AU Kuhn, JH
Clawson, AN
Radoshitzky, SR
Wahl-Jensen, V
Bavari, S
Jahrling, PB
AF Kuhn, Jens H.
Clawson, Anna N.
Radoshitzky, Sheli R.
Wahl-Jensen, Victoria
Bavari, Sina
Jahrling, Peter B.
BE Singh, SK
Ruzek, D
TI Viral Hemorrhagic Fevers History and Definitions
SO VIRAL HEMORRHAGIC FEVERS
LA English
DT Article; Book Chapter
ID LASSA FEVER; SWINE-FEVER; VIRUS
C1 [Kuhn, Jens H.; Clawson, Anna N.; Wahl-Jensen, Victoria; Jahrling, Peter B.] NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD 20852 USA.
[Radoshitzky, Sheli R.; Bavari, Sina] US Army, Med Res Inst Infect Dis, Frederick, MD USA.
RP Kuhn, JH (reprint author), NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD 20852 USA.
NR 34
TC 0
Z9 0
U1 0
U2 0
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-4398-8431-7; 978-1-4398-8429-4
PY 2014
BP 3
EP 13
PG 11
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA BF0KX
UT WOS:000379007900003
ER
PT B
AU Huzella, LM
Cann, JA
Lackemeyer, M
Wahl-Jensen, V
Jahrling, PB
Kuhn, JH
Perry, DL
AF Huzella, Louis M.
Cann, Jennifer A.
Lackemeyer, Matthew
Wahl-Jensen, Victoria
Jahrling, Peter B.
Kuhn, Jens H.
Perry, Donna L.
BE Singh, SK
Ruzek, D
TI General Disease Pathology in Filoviral and Arenaviral Infections
SO VIRAL HEMORRHAGIC FEVERS
LA English
DT Article; Book Chapter
ID EBOLA HEMORRHAGIC-FEVER; MARBURG-VIRUS-DISEASE; I INTERFERON INDUCTION;
CYNOMOLGUS MACAQUES; LASSA FEVER; ELECTRON-MICROSCOPY;
ENDOTHELIAL-CELLS; RHESUS-MONKEY; PATHOGENESIS; ZAIRE
C1 [Huzella, Louis M.; Cann, Jennifer A.; Lackemeyer, Matthew; Wahl-Jensen, Victoria; Jahrling, Peter B.; Kuhn, Jens H.; Perry, Donna L.] NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD 21702 USA.
RP Huzella, LM (reprint author), NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD 21702 USA.
NR 78
TC 0
Z9 0
U1 0
U2 0
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-4398-8431-7; 978-1-4398-8429-4
PY 2014
BP 15
EP 29
PG 15
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA BF0KX
UT WOS:000379007900004
ER
PT B
AU Shurtleff, AC
Warren, TK
Morrow, D
Radoshitzky, SR
Kuhn, JH
Bavari, S
AF Shurtleff, Amy C.
Warren, Travis K.
Morrow, Derek
Radoshitzky, Sheli R.
Kuhn, Jens H.
Bavari, Sina
BE Singh, SK
Ruzek, D
TI Animal Models of Viral Hemorrhagic Fevers
SO VIRAL HEMORRHAGIC FEVERS
LA English
DT Article; Book Chapter
ID EBOLA-VIRUS-INFECTION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; KNOCKOUT
MOUSE MODEL; GUINEA-PIGS; MARBURG VIRUS; LASSA-VIRUS; JUNIN VIRUS;
CYNOMOLGUS MACAQUES; RHESUS MACAQUES; PERIPHERAL-BLOOD
C1 [Shurtleff, Amy C.] US Army, Integrated Toxicol Div, Med Res Inst Infect Dis, Ft Detrick, MD USA.
[Warren, Travis K.; Morrow, Derek; Radoshitzky, Sheli R.] US Army, Med Res Inst Infect Dis, Frederick, MD USA.
[Kuhn, Jens H.] NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD USA.
[Bavari, Sina] US Army, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA.
RP Shurtleff, AC (reprint author), US Army, Integrated Toxicol Div, Med Res Inst Infect Dis, Ft Detrick, MD USA.
NR 132
TC 0
Z9 0
U1 0
U2 0
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-4398-8431-7; 978-1-4398-8429-4
PY 2014
BP 81
EP 98
PG 18
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA BF0KX
UT WOS:000379007900008
ER
PT B
AU Wahl-Jensen, V
Radoshitzky, SR
de Kok-Mercado, F
Taylor, SL
Bavari, S
Jahrling, PB
Kuhn, JH
AF Wahl-Jensen, Victoria
Radoshitzky, Sheli R.
de Kok-Mercado, Fabian
Taylor, Shannon L.
Bavari, Sina
Jahrling, Peter B.
Kuhn, Jens H.
BE Singh, SK
Ruzek, D
TI Role of Rodents and Bats in Human Viral Hemorrhagic Fevers
SO VIRAL HEMORRHAGIC FEVERS
LA English
DT Article; Book Chapter
ID HANTAVIRUS-PULMONARY-SYNDROME; GUANARITO VIRUS ARENAVIRIDAE;
MASTOMYS-NATALENSIS; JUNIN VIRUS; EBOLA-VIRUS; RENAL SYNDROME;
LASSA-VIRUS; WEST-AFRICA; MACHUPO VIRUS; CALOMYS-MUSCULINUS
C1 [Wahl-Jensen, Victoria; de Kok-Mercado, Fabian; Jahrling, Peter B.; Kuhn, Jens H.] NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD 21702 USA.
[Radoshitzky, Sheli R.] US Army, Med Res Inst Infect Dis, Frederick, MD USA.
[Taylor, Shannon L.] US Army, Div Virol, Med Res Inst Infect Dis, Ft Detrick, MD USA.
[Bavari, Sina] US Army, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA.
RP Wahl-Jensen, V (reprint author), NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD 21702 USA.
NR 156
TC 3
Z9 3
U1 2
U2 2
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-4398-8431-7; 978-1-4398-8429-4
PY 2014
BP 99
EP 127
PG 29
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA BF0KX
UT WOS:000379007900009
ER
PT B
AU Risi, GF
Arminio, T
AF Risi, George F.
Arminio, Thomas
BE Singh, SK
Ruzek, D
TI Biosafety Issues and Clinical Management of Hemorrhagic Fever Virus
Infections
SO VIRAL HEMORRHAGIC FEVERS
LA English
DT Article; Book Chapter
ID ANTICOAGULANT PROTEIN C2; FACTOR VIIA/TISSUE FACTOR; DENGUE SHOCK
SYNDROME; RIFT-VALLEY FEVER; EBOLA-VIRUS; SEVERE SEPSIS; LASSA FEVER;
POSTEXPOSURE PROTECTION; NEMATODE ANTICOAGULANT; NONHUMAN-PRIMATES
C1 [Risi, George F.] NIAID, Rocky Mt Labs, Hamilton, MT 59840 USA.
[Risi, George F.] Infect Dis Specialists PC, Missoula, MT USA.
[Arminio, Thomas] NIH, Integrated Res Facil, Div Occupat Hlth & Safety, Rocky Mt Labs, Hamilton, MT USA.
RP Risi, GF (reprint author), NIAID, Rocky Mt Labs, Hamilton, MT 59840 USA.
NR 128
TC 0
Z9 0
U1 0
U2 0
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-4398-8431-7; 978-1-4398-8429-4
PY 2014
BP 129
EP 147
PG 19
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA BF0KX
UT WOS:000379007900010
ER
PT B
AU Radoshitzky, SR
de Kok-Mercado, F
Jahrling, PB
Bavari, S
Kuhn, JH
AF Radoshitzky, Sheli R.
de Kok-Mercado, Fabian
Jahrling, Peter B.
Bavari, Sina
Kuhn, Jens H.
BE Singh, SK
Ruzek, D
TI Bolivian Hemorrhagic Fever
SO VIRAL HEMORRHAGIC FEVERS
LA English
DT Article; Book Chapter
ID LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NEW-WORLD ARENAVIRUSES;
FINGER-Z-PROTEIN; VIRAL-RNA SYNTHESIS; I INTERFERON INDUCTION; STABLE
SIGNAL PEPTIDE; PH-INDUCED ACTIVATION; GLYCOPROTEIN GP-C; JUNIN VIRUS;
LASSA-VIRUS
C1 [Radoshitzky, Sheli R.] US Army, Med Res Inst Infect Dis, Frederick, MD 21702 USA.
[de Kok-Mercado, Fabian; Jahrling, Peter B.; Kuhn, Jens H.] NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD USA.
[Bavari, Sina] US Army, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA.
RP Radoshitzky, SR (reprint author), US Army, Med Res Inst Infect Dis, Frederick, MD 21702 USA.
NR 162
TC 1
Z9 1
U1 0
U2 0
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-4398-8431-7; 978-1-4398-8429-4
PY 2014
BP 339
EP 358
PG 20
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA BF0KX
UT WOS:000379007900021
ER
PT B
AU Radoshitzky, SR
de Kok-Mercado, F
Jahrling, PB
Bavari, S
Kuhn, JH
AF Radoshitzky, Sheli R.
de Kok-Mercado, Fabian
Jahrling, Peter B.
Bavari, Sina
Kuhn, Jens H.
BE Singh, SK
Ruzek, D
TI "Venezuelan" Hemorrhagic Fever
SO VIRAL HEMORRHAGIC FEVERS
LA English
DT Article; Book Chapter
ID LYMPHOCYTIC CHORIOMENINGITIS VIRUS; FINGER-Z-PROTEIN; NEW-WORLD
ARENAVIRUSES; VIRAL-RNA SYNTHESIS; ENVELOPE GLYCOPROTEIN COMPLEX; STABLE
SIGNAL PEPTIDE; PH-INDUCED ACTIVATION; LASSA-VIRUS; JUNIN VIRUS;
GUANARITO VIRUS
C1 [Radoshitzky, Sheli R.] US Army, Med Res Inst Infect Dis, Frederick, MD 21702 USA.
[de Kok-Mercado, Fabian; Jahrling, Peter B.; Kuhn, Jens H.] NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD USA.
[Bavari, Sina] US Army, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA.
RP Radoshitzky, SR (reprint author), US Army, Med Res Inst Infect Dis, Frederick, MD 21702 USA.
NR 148
TC 0
Z9 0
U1 0
U2 0
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-4398-8431-7; 978-1-4398-8429-4
PY 2014
BP 359
EP 377
PG 19
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA BF0KX
UT WOS:000379007900022
ER
PT B
AU Bradfute, SB
Bavari, S
Jahrling, PB
Kuhn, JH
AF Bradfute, Steven B.
Bavari, Sina
Jahrling, Peter B.
Kuhn, Jens H.
BE Singh, SK
Ruzek, D
TI Marburg Virus Disease
SO VIRAL HEMORRHAGIC FEVERS
LA English
DT Article; Book Chapter
ID PROTECTS NONHUMAN-PRIMATES; VERVET MONKEY DISEASE; ATTENUATED
RECOMBINANT VACCINE; LAKE-VICTORIA-MARBURGVIRUS; HEMORRHAGIC-FEVER;
EBOLA-VIRUS; FILOVIRUS INFECTION; MATRIX PROTEIN; GUINEA-PIGS;
POSTEXPOSURE PROTECTION
C1 [Bradfute, Steven B.] Univ New Mexico, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA.
[Bavari, Sina] US Army Med Res Inst Infect Dis, Ft Detrick, MD USA.
[Jahrling, Peter B.; Kuhn, Jens H.] NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD USA.
RP Bradfute, SB (reprint author), Univ New Mexico, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA.
NR 115
TC 0
Z9 0
U1 1
U2 1
PU CRC PRESS-TAYLOR & FRANCIS GROUP
PI BOCA RATON
PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA
BN 978-1-4398-8431-7; 978-1-4398-8429-4
PY 2014
BP 457
EP 479
PG 23
WC Infectious Diseases; Virology
SC Infectious Diseases; Virology
GA BF0KX
UT WOS:000379007900027
ER
PT J
AU Yoshinaga, K
PrabhuDas, M
Davies, C
White, K
Caron, K
Golos, T
Fazleabas, A
Paria, B
Mor, G
Paul, S
Ye, XQ
Dey, SK
Spencer, T
Roberts, RM
AF Yoshinaga, Koji
PrabhuDas, Mercy
Davies, Christopher
White, Kenneth
Caron, Kathleen
Golos, Thaddeus
Fazleabas, Asgerally
Paria, Bibhash
Mor, Gil
Paul, Soumen
Ye, Xiaoqin
Dey, Sudhansu K.
Spencer, Thomas
Roberts, Robert Michael
TI Interdisciplinary Collaborative Team for Blastocyst Implantation
Research: inception and perspectives
SO AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY
LA English
DT Letter
C1 [Yoshinaga, Koji] NICHD, Fertil & Infertil Branch, NIH, DHHS, Bethesda, MD 20892 USA.
[PrabhuDas, Mercy] NIAID, Basic Immunol Branch, NIH, DHHS, Bethesda, MD 20892 USA.
[Davies, Christopher; White, Kenneth] Utah State Univ, Coll Agr, Dept Anim Dairy & Vet Sci, Logan, UT 84322 USA.
[Caron, Kathleen] Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC USA.
[Golos, Thaddeus] Univ Wisconsin, Dept Comparat Biosci, Madison, WI 53706 USA.
[Golos, Thaddeus] Univ Wisconsin, Dept Obstet & Gynecol, Madison, WI 53706 USA.
[Fazleabas, Asgerally] Michigan State Univ, Coll Human Med, Dept Obstet Gynecol & Reprod Biol, Grand Rapids, MI USA.
[Paria, Bibhash] Vanderbilt Univ, Sch Med, Dept Pediat Neonatol, Nashville, TN 37212 USA.
[Mor, Gil] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA.
[Paul, Soumen] Univ Kansas, Med Ctr, Inst Reprod Biol & Med, Kansas City, KS 66103 USA.
[Ye, Xiaoqin] Univ Georgia, Dept Physiol & Pharmacol, Athens, GA 30602 USA.
[Dey, Sudhansu K.] Cincinnati Childrens Hosp Med Ctr, Dept Reprod Sci, Cincinnati, OH 45229 USA.
[Spencer, Thomas] Washington State Univ, Dept Anim Sci, Pullman, WA 99164 USA.
[Roberts, Robert Michael] Univ Missouri, Life Sci Ctr, Columbia, MO USA.
RP Yoshinaga, K (reprint author), NICHD, Fertil & Infertil Branch, NIH, DHHS, Bldg 6100,Room 8B01, Bethesda, MD 20892 USA.
EM ky6a@nih.gov
OI Spencer, Thomas/0000-0003-2815-766X
FU NICHD NIH HHS [R01 HD067759, R01 HD042280, R01 HD062546, R01 HD065939];
NIH HHS [P51 OD011106]
NR 3
TC 1
Z9 1
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1046-7408
EI 1600-0897
J9 AM J REPROD IMMUNOL
JI Am. J. Reprod. Immunol.
PD JAN
PY 2014
VL 71
IS 1
BP 1
EP 11
DI 10.1111/aji.12173
PG 11
WC Immunology; Reproductive Biology
SC Immunology; Reproductive Biology
GA 267DO
UT WOS:000328077100001
PM 24286196
ER
PT J
AU Castillo-Castrejon, M
Meraz-Cruz, N
Gomez-Lopez, N
Flores-Pliego, A
Beltran-Montoya, J
Viveros-Alcaraz, M
Vadillo-Ortega, F
AF Castillo-Castrejon, Marisol
Meraz-Cruz, Noemi
Gomez-Lopez, Nardhy
Flores-Pliego, Arturo
Beltran-Montoya, Jorge
Viveros-Alcaraz, Martin
Vadillo-Ortega, Felipe
TI Choriodecidual Cells From Term Human Pregnancies Show Distinctive
Functional Properties Related to the Induction of Labor
SO AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY
LA English
DT Article
DE Amniochorion; choriodecidua; fetal membranes; inflammation; labor
ID PRETERM PARTURITION; FETAL MEMBRANES; LEUKOCYTES;
MATRIX-METALLOPROTEINASE-9; MYOMETRIUM; CERVIX; INTERLEUKIN-8;
AMNIOCHORION; EXPRESSION; CYTOKINES
AB ProblemHuman parturition is associated with an intrauterine pro-inflammatory environment in the choriodecidua. Evidence that some mediators of this signaling cascade also elicit responses leading to labor prompted us to characterize the cellular sources of these mediators in the human choriodecidua.
Method of studyLeukocyte-enriched preparations from human choriodecidua (ChL) and intervillous placental blood leukocytes (PL) were maintained in culture. Secretions of inflammatory cytokines, chemokines, and MMP-9 were documented. Leukocyte phenotype of ChL and PL was determined by flow cytometry using specific fluorochrome-conjugated antibodies.
Results and ConclusionsChL showed a distinct pro-inflammatory secretion pattern of cytokines and chemokines when compared with PL, including higher amounts of TNF- and IL-6, and decreased secretions of IL-4 and IL-1ra. ChL also secreted more MIP-1 and MCP-1 and MMP-9 than PL. No significant differences were found in leukocytes subsets between compartments. Based on our findings, we propose that ChL isolated from fetal membranes at term are functionally different from PL and may collaborate to modulate the microenvironment linked to induction and progression of human labor.
C1 [Castillo-Castrejon, Marisol; Meraz-Cruz, Noemi; Vadillo-Ortega, Felipe] Inst Nacl Med Genom, UNAM, Fac Med, Unidad Vinculac, Mexico City 14610, DF, Mexico.
[Castillo-Castrejon, Marisol] Univ Nacl Autonoma Mexico, Programa Posgrad Ciencias Biol, Mexico City 04510, DF, Mexico.
[Gomez-Lopez, Nardhy] Wayne State Univ, NICHD, Dept Obstet & Gynecol, Sch Med,Perinatol Res Branch,NIH, Detroit, MI USA.
[Gomez-Lopez, Nardhy] Wayne State Univ, NICHD, Dept Immunol & Microbiol, Sch Med,Perinatol Res Branch,NIH, Detroit, MI USA.
[Flores-Pliego, Arturo; Beltran-Montoya, Jorge] Inst Nacl Perinatol Isidro Espinosa de los Reyes, Mexico City, DF, Mexico.
[Viveros-Alcaraz, Martin] Secretaria Salud DF, Hosp Materno Infantil Inguaran, Mexico City, DF, Mexico.
RP Vadillo-Ortega, F (reprint author), Inst Nacl Med Genom, UNAM, Fac Med, Unidad Vinculac, Perifer Sur 4809, Mexico City 14610, DF, Mexico.
EM felipe.vadillo@gmail.com
RI Gomez-Lopez, Nardhy/R-7664-2016;
OI Gomez-Lopez, Nardhy/0000-0002-3406-5262; Flores Pliego,
Arturo/0000-0001-7876-6098
FU U.S. National Institute for Environmental Health Sciences [R01
ES016932]; National Institutes of Health; National Council of Science
and Technology (CONACyT); U.N.A.M. [PAPIIT IA200612-2]; Consejo Nacional
de Ciencia y Tecnologia (CONACyT) [203418]; Wayne State University
Research Initiative in Maternal, Perinatal, and Child health (Eunice
Kennedy Shriver National Institute of Child Health and Human Development
of the National Institutes of Health)
FX Support for this work was provided partially by Grant No: R01 ES016932
from the U.S. National Institute for Environmental Health Sciences and
the National Institutes of Health. M.C.C. received a scholarship and
financial support provided by the National Council of Science and
Technology (CONACyT) and U.N.A.M. (PAPIIT IA200612-2). This paper
constitutes a partial fulfillment of the Graduate Program in Biological
Sciences of the National Autonomous University of Mexico (UNAM). Marisol
Castillo-Castrejon acknowledges the scholarship provided by the Consejo
Nacional de Ciencia y Tecnologia (CONACyT No. 203418). N.G-L is funded
by Wayne State University Research Initiative in Maternal, Perinatal,
and Child health (Eunice Kennedy Shriver National Institute of Child
Health and Human Development of the National Institutes of Health). The
authors thank Marie O'Neill for reviewing the manuscript prior to the
submission.
NR 38
TC 10
Z9 10
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1046-7408
EI 1600-0897
J9 AM J REPROD IMMUNOL
JI Am. J. Reprod. Immunol.
PD JAN
PY 2014
VL 71
IS 1
BP 86
EP 93
DI 10.1111/aji.12179
PG 8
WC Immunology; Reproductive Biology
SC Immunology; Reproductive Biology
GA 267DO
UT WOS:000328077100009
PM 24286217
ER
PT J
AU Schuck, P
Gillis, RB
Besong, TMD
Almutairi, F
Adams, GG
Rowe, AJ
Harding, SE
AF Schuck, Peter
Gillis, Richard B.
Besong, Tabot M. D.
Almutairi, Fahad
Adams, Gary G.
Rowe, Arthur J.
Harding, Stephen E.
TI SEDFIT-MSTAR: molecular weight and molecular weight distribution
analysis of polymers by sedimentation equilibrium in the ultracentrifuge
SO ANALYST
LA English
DT Article
ID INTEGRAL-EQUATIONS; MUCUS GLYCOPROTEINS; INTERFERENCE OPTICS; SYSTEMS;
MACROMOLECULES; COEFFICIENTS; PROGRAM; MODEL
AB Sedimentation equilibrium (analytical ultracentrifugation) is one of the most inherently suitable methods for the determination of average molecular weights and molecular weight distributions of polymers, because of its absolute basis (no conformation assumptions) and inherent fractionation ability (without the need for columns or membranes and associated assumptions over inertness). With modern instrumentation it is also possible to run up to 21 samples simultaneously in a single run. Its application has been severely hampered because of difficulties in terms of baseline determination (incorporating estimation of the concentration at the air/solution meniscus) and complexity of the analysis procedures. We describe a new method for baseline determination based on a smart-smoothing principle and built into the highly popular platform SEDFIT for the analysis of the sedimentation behavior of natural and synthetic polymer materials. The SEDFIT-MSTAR procedure - which takes only a few minutes to perform - is tested with four synthetic data sets (including a significantly non-ideal system), a naturally occurring protein (human IgG1) and two naturally occurring carbohydrate polymers (pullulan and l-carrageenan) in terms of (i) weight average molecular weight for the whole distribution of species in the sample (ii) the variation in "point" average molecular weight with local concentration in the ultracentrifuge cell and (iii) molecular weight distribution.
C1 [Schuck, Peter] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD 20892 USA.
[Gillis, Richard B.; Besong, Tabot M. D.; Almutairi, Fahad; Adams, Gary G.; Rowe, Arthur J.; Harding, Stephen E.] Univ Nottingham, Natl Ctr Macromol Hydrodynam, Sch Biosci, Loughborough LE12 5RD, England.
RP Schuck, P (reprint author), Natl Inst Biomed Imaging & Bioengn, NIH, Bldg 13,Rm 3N17,13 South Dr, Bethesda, MD 20892 USA.
EM schuckp@mail.nih.gov; steve.harding@nottingham.ac.uk
OI Schuck, Peter/0000-0002-8859-6966; Harding, Stephen
E./0000-0002-7798-9692
FU National Institute of Biomedical Imaging and Bioengineering, National
Institutes of Health; Royal Society; Biotechnology and Biological
Sciences Research Council
FX This work was supported by the Intramural Research Programs of the
National Institute of Biomedical Imaging and Bioengineering, National
Institutes of Health (PS), the Royal Society (SEH) and the Biotechnology
and Biological Sciences Research Council (SEH, GGA and RG).
NR 38
TC 19
Z9 20
U1 0
U2 22
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
ENGLAND
SN 0003-2654
EI 1364-5528
J9 ANALYST
JI Analyst
PY 2014
VL 139
IS 1
BP 79
EP 92
DI 10.1039/c3an01507f
PG 14
WC Chemistry, Analytical
SC Chemistry
GA 259TE
UT WOS:000327548400011
PM 24244936
ER
PT J
AU Qi, YC
Li, XL
Ma, XR
Xu, LY
Zhang, XF
Jiang, XH
Hong, J
Cui, B
Ning, G
Wang, S
AF Qi, Yicheng
Li, Xiaoli
Ma, Xinran
Xu, Lingyan
Zhang, Xiaofang
Jiang, Xiaohua
Hong, Jie
Cui, Bin
Ning, Guang
Wang, Shu
TI The role of osteopontin in the induction of the CD40 ligand in Graves'
disease
SO CLINICAL ENDOCRINOLOGY
LA English
DT Article
ID AUTOIMMUNE THYROID-DISEASE; CELL-ACTIVATION; T-CELLS; EXPRESSION;
RECEPTOR; TNF; PATHOGENESIS; GENERATION; CYTOKINE
AB ObjectiveGraves' disease (GD) is a common autoimmune disease involved autoantibody production. Although we previously reported that osteopontin (OPN), a proinflammatory protein, affected development of GD through NF-B activation, little is known about the role of OPN in regulating immunoglobulin production in GD. CD40 Ligand (CD40L) is expressed on the surface of activated CD4+T cells and costimulates CD40 on B cells, stimulating production of immunoglobulins, a process which has been reported to play a vital role in immunological signalling transduction in several autoimmune diseases. This study sought to characterize the relationship between CD40L and GD development, as well as investigating the role of OPN in modulating immunoglobulin production in GD via CD40L.
MethodsForty incident patients with GD, twenty-one patients with GD in remission and twenty-seven healthy controls were recruited. Both membrane-bound and soluble forms of CD40L were measured, and their correlations with clinical parameters were studied. In addition, correlation between OPN and CD40L level was also examined. Furthermore, we studied the regulatory effect of OPN on CD40L in CD4+T cells.
ResultsWe demonstrated that the CD40L levels were enhanced in patients with GD and recovered in patients with GD in remission. CD40L levels correlated with clinical GD diagnostic parameters and OPN concentration. Moreover, human recombinant OPN and plasma samples from patients with GD increased CD40L expression, which could be significantly suppressed by OPN monoclonal antibody. In addition, CD40L antibody blocked the immunoglobulin production augmented by OPN in cultured peripheral blood mononuclear cells (PBMCs), isolated from patients with GD and healthy subjects.
ConclusionThese results indicate that CD40L is induced by OPN and serves as the downstream effector of OPN for immunoglobulin production in GD development.
C1 [Qi, Yicheng; Li, Xiaoli; Zhang, Xiaofang; Jiang, Xiaohua; Hong, Jie; Cui, Bin; Ning, Guang; Wang, Shu] Shanghai Jiao Tong Univ, Sch Med, Shanghai Clin Ctr Endocrine & Metab Dis, Dept Endocrinol & Metab,Ruijin Hosp, Shanghai 200025, Peoples R China.
[Qi, Yicheng; Li, Xiaoli; Ma, Xinran; Xu, Lingyan; Cui, Bin; Ning, Guang; Wang, Shu] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Lab Endocrinol & Metab, Shanghai, Peoples R China.
[Qi, Yicheng; Li, Xiaoli; Ma, Xinran; Xu, Lingyan; Cui, Bin; Ning, Guang; Wang, Shu] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China.
[Ma, Xinran; Xu, Lingyan] NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA.
RP Ning, G (reprint author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Clin Ctr Endocrine & Metab Dis, Rui Jin Hosp, 197 Rui Jin 2nd Rd, Shanghai 200025, Peoples R China.
EM guangning@medmail.com.cn; shuwang9999@163.com
FU National Natural Science Foundation of China [81270872]; Shanghai
Municipal Natural Science Foundation [11495803400]; Sector Funds of
Ministry of Health [201002002, 201202008]; National Key New Drug
Creation and Manufacturing Program of Ministry of Science and Technology
[2012ZX09303006-001]
FX This study was supported by the grants from the National Natural Science
Foundation of China (No. 81270872), Shanghai Municipal Natural Science
Foundation (No. 11495803400), the Sector Funds of Ministry of Health
(No. 201002002, No. 201202008) and The National Key New Drug Creation
and Manufacturing Program of Ministry of Science and Technology (No.
2012ZX09303006-001).
NR 35
TC 2
Z9 3
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-0664
EI 1365-2265
J9 CLIN ENDOCRINOL
JI Clin. Endocrinol.
PD JAN
PY 2014
VL 80
IS 1
BP 128
EP 134
DI 10.1111/cen.12229
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 263IJ
UT WOS:000327801300018
PM 23617736
ER
PT S
AU O'Connell, KF
Golden, A
AF O'Connell, Kevin F.
Golden, Andy
BE Paddock, SW
TI Confocal Imaging of the Microtubule Cytoskeleton in C. elegans Embryos
and Germ Cells
SO CONFOCAL MICROSCOPY: METHODS AND PROTOCOLS, 2ND EDITION
SE Methods in Molecular Biology
LA English
DT Article; Book Chapter
DE Microtubules; Centrosomes; C. elegans; Immunofluorescence; GFP
ID CAENORHABDITIS-ELEGANS; IMMUNOFLUORESCENCE MICROSCOPY; PROTEINS;
NEMATODE; SPINDLE; SPERM
AB The microtubule cytoskeleton plays important roles in a number of cellular processes including cell division, establishing and maintaining cell architecture and polarity, and intracellular trafficking. The identification and characterization of factors required for the proper functioning of the microtubule cytoskeleton have been aided by approaches that combine sensitive and rapid methods for high-resolution optical imaging, such as confocal microscopy, with the powerful genetics available in model organisms. Here we present methods for confocal imaging of live and fixed tissues of the nematode C. elegans, a model organism that has been employed with great success to study the microtubule cytoskeleton and its roles in cell division and cell polarity.
C1 [O'Connell, Kevin F.; Golden, Andy] NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA.
RP O'Connell, KF (reprint author), NIDDK, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA.
NR 16
TC 1
Z9 1
U1 0
U2 18
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
SN 1064-3745
BN 978-1-58829-351-0; 978-1-60761-847-8
J9 METHODS MOL BIOL
JI Methods Mol. Biol.
PY 2014
VL 1075
BP 257
EP 272
DI 10.1007/978-1-60761-847-8_13
D2 10.1007/978-1-60761-847-8
PG 16
WC Microscopy; Radiology, Nuclear Medicine & Medical Imaging
SC Microscopy; Radiology, Nuclear Medicine & Medical Imaging
GA BIE12
UT WOS:000327800100014
PM 24052357
ER
PT B
AU Schlom, J
Palena, C
Gulley, JL
Greiner, JW
Tsang, KY
Madan, RA
Hodge, JW
AF Schlom, Jeffrey
Palena, Claudia
Gulley, James L.
Greiner, John W.
Tsang, Kwong-Yok
Madan, Ravi A.
Hodge, James W.
BE Lattime, EC
Gerson, SL
TI The Use of T Cell Costimulation to Enhance the Immunogenicity of Tumors
SO GENE THERAPY OF CANCER: TRANSLATIONAL APPROACHES FROM PRECLINICAL
STUDIES TO CLINICAL IMPLEMENTATION, 3RD EDITION
LA English
DT Article; Book Chapter
DE Cancer; vaccines; poxviruses; TRICOM; immunotherapy; intratumoral
vaccination; immunostimulatory molecules; costimulatory molecules
ID RECOMBINANT VACCINIA VIRUS; DIVERSIFIED SUBCUTANEOUS/INTRATUMORAL
VACCINATION; INDEPENDENT PROSTATE-CANCER; COLONY-STIMULATING FACTOR;
LYMPHOCYTIC-LEUKEMIA CLL; ANTITUMOR IMMUNITY; PHASE-I; COMBINATION
THERAPY; INTRATUMORAL VACCINATION; POXVIRUS VECTORS
AB The use of recombinant poxviral vectors containing transgenes for tumor-associated antigens, along with transgenes directed against one or more costimulatory molecules or other immunostimulatory entities, as "conventional" vaccines for cancer therapy is now well documented in numerous preclinical studies and completed and ongoing clinical studies. This chapter reviews the status of the use of recombinant poxviral vectors containing multiple costimulatory molecules to enhance the immunogenicity of tumor cells. This can be accomplished by the ex vivo infection of tumor cells with recombinant poxviral vectors containing immunostimulatory molecules and the subsequent use of these tumor cells as vaccines or by the direct intratumoral injection of recombinant poxviral vectors containing immunostimulatory molecules. Preclinical studies have reported the successful use of these modalities to enhance both antigen-specific T cell responses and antitumor effects. To date, however, few clinical trials have actually been carried out to further evaluate these potentially efficacious modalities in the management of a range of cancers.
C1 [Schlom, Jeffrey; Palena, Claudia; Gulley, James L.; Greiner, John W.; Tsang, Kwong-Yok; Madan, Ravi A.; Hodge, James W.] NIH, Bethesda, MD 20892 USA.
RP Schlom, J (reprint author), NIH, Bldg 10, Bethesda, MD 20892 USA.
RI Hodge, James/D-5518-2015; Gulley, James/K-4139-2016
OI Hodge, James/0000-0001-5282-3154; Gulley, James/0000-0002-6569-2912
NR 50
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
BN 978-0-12-394632-4; 978-0-12-394295-1
PY 2014
BP 315
EP 334
DI 10.1016/B978-0-12-394295-1.00022-6
PG 20
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
Research & Experimental Medicine
GA BIE16
UT WOS:000327801200025
ER
PT J
AU Sneller, MC
Lane, HC
AF Sneller, M. C.
Lane, H. C.
TI HIV/IL-2 and EBV-associated lymphoproliferative diseases: cause and
effect or coincidence?
SO HIV MEDICINE
LA English
DT Editorial Material
ID REGULATORY T-CELLS; HODGKIN-LYMPHOMA; HIV-INFECTION; INTERLEUKIN-2;
THERAPY; AIDS
C1 [Sneller, M. C.; Lane, H. C.] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA.
RP Sneller, MC (reprint author), NIAID, Immunoregulat Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
NR 12
TC 3
Z9 3
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-2662
EI 1468-1293
J9 HIV MED
JI HIV Med.
PD JAN
PY 2014
VL 15
IS 1
BP 1
EP 2
DI 10.1111/hiv.12092
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA 262LC
UT WOS:000327735700001
PM 24299219
ER
PT J
AU Madan, I
Than, NG
Romero, R
Chaemsaithong, P
Miranda, J
Tarca, AL
Bhatti, G
Draghici, S
Yeo, L
Mazor, M
Hassan, SS
Chaiworapongsa, T
AF Madan, Ichchha
Than, Nandor Gabor
Romero, Roberto
Chaemsaithong, Piya
Miranda, Jezid
Tarca, Adi L.
Bhatti, Gaurav
Draghici, Sorin
Yeo, Lami
Mazor, Moshe
Hassan, Sonia S.
Chaiworapongsa, Tinnakorn
TI The peripheral whole-blood transcriptome of acute pyelonephritis in
human pregnancy
SO JOURNAL OF PERINATAL MEDICINE
LA English
DT Article
DE Adaptive immunity; high-dimensional biology; infection during pregnancy;
innate immunity; mRNA; PAX gene; urinary tract infection
ID RESPIRATORY-DISTRESS-SYNDROME; URINARY-TRACT-INFECTIONS; REGULATORY
T-CELLS; UROPATHOGENIC ESCHERICHIA-COLI; GENERALIZED SHWARTZMAN
REACTION; HOST-PATHOGEN INTERACTIONS; GENE-EXPRESSION PROFILES;
MATERNAL-FETAL INTERFACE; MICROARRAY ANALYSIS; IMMUNE TOLERANCE
AB Objective: Human pregnancy is characterized by activation of the innate immune response and suppression of adaptive immunity. The former is thought to provide protection against infection for the mother, and the latter, tolerance against paternal antigens expressed in fetal cells. Acute pyelonephritis is associated with an increased risk of acute respiratory distress syndrome and sepsis in pregnant (vs. nonpregnant) women. The objective of this study was to describe the gene expression profile (transcriptome) of maternal whole blood in acute pyelonephritis.
Method: A case-control study was conducted to include pregnant women with acute pyelonephritis (n=15) and women with a normal pregnancy (n=34). Affymetrix HG-U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA, USA) were used for gene expression profiling. A linear model was used to test the association between the presence of pyelonephritis and gene expression levels while controlling for white blood cell count and gestational age. A fold change of 1.5 was considered significant at a false discovery rate of 0.1. A subset of differentially expressed genes (n=56) was tested with real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) (cases, n=19; controls, n=59). Gene ontology and pathway analyses were applied.
Results: A total of 983 genes were differentially expressed in acute pyelonephritis: 457 were upregulated and 526 were downregulated. Significant enrichment of 300 biological processes and 63 molecular functions was found in pyelonephritis. Significantly impacted pathways in pyelonephritis included (a) cytokine-cytokine receptor interaction, (b) T-cell receptor signaling, (c) Jak-STAT signaling, and (d) complement and coagulation cascades. Of 56 genes tested by qRT-PCR, 48 (85.7%) had confirmation of differential expression.
Conclusion: This is the first study of the transcriptomic signature of whole blood in pregnant women with acute pyelonephritis. Acute infection during pregnancy is associated with the increased expression of genes involved in innate immunity and the decreased expression of genes involved in lymphocyte function.
C1 [Romero, Roberto] Wayne State Univ, Hutzel Womens Hosp, Perinatol Res Branch, NICHD,NIH,DHHS, Detroit, MI 48201 USA.
[Madan, Ichchha; Than, Nandor Gabor; Romero, Roberto; Chaemsaithong, Piya; Miranda, Jezid; Tarca, Adi L.; Yeo, Lami; Hassan, Sonia S.; Chaiworapongsa, Tinnakorn] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Perinatol Res Branch, NIH, Dept Hlth & Human Serv, Detroit, MI USA.
[Madan, Ichchha; Than, Nandor Gabor; Romero, Roberto; Chaemsaithong, Piya; Miranda, Jezid; Tarca, Adi L.; Yeo, Lami; Hassan, Sonia S.; Chaiworapongsa, Tinnakorn] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Perinatol Res Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD USA.
[Madan, Ichchha; Than, Nandor Gabor; Chaemsaithong, Piya; Miranda, Jezid; Yeo, Lami; Hassan, Sonia S.; Chaiworapongsa, Tinnakorn] Wayne State Univ, Dept Obstet & Gynecol, Sch Med, Detroit, MI 48201 USA.
[Romero, Roberto] Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA.
[Romero, Roberto] Michigan State Univ, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA.
[Tarca, Adi L.; Bhatti, Gaurav; Draghici, Sorin] Wayne State Univ, Dept Comp Sci, Detroit, MI 48201 USA.
[Mazor, Moshe] Ben Gurion Univ Negev, Dept Obstet & Gynecol, Soroka Univ Med Ctr, Sch Med, IL-84105 Beer Sheva, Israel.
RP Romero, R (reprint author), Wayne State Univ, Hutzel Womens Hosp, Perinatol Res Branch, NICHD,NIH,DHHS, 3990 John R,Box 4, Detroit, MI 48201 USA.
EM romeror@mail.nih.gov
OI Draghici, Sorin/0000-0002-0786-8377
FU Perinatology Research Branch, Division of Intramural Research, Eunice
Kennedy Shriver National Institute of Child Health and Human
Development, National Institutes of Health, Department of Health and
Human Services (NICHD/NIH); NICHD/NIH [HHSN275201300006C]
FX This research was supported, in part, by the Perinatology Research
Branch, Division of Intramural Research, Eunice Kennedy Shriver National
Institute of Child Health and Human Development, National Institutes of
Health, Department of Health and Human Services (NICHD/NIH), and, in
part, with federal funds from NICHD/NIH under contract no.
HHSN275201300006C.
NR 148
TC 4
Z9 4
U1 1
U2 7
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 0300-5577
EI 1619-3997
J9 J PERINAT MED
JI J. Perinat. Med.
PD JAN
PY 2014
VL 42
IS 1
BP 31
EP 53
DI 10.1515/jpm-2013-0085
PG 23
WC Obstetrics & Gynecology; Pediatrics
SC Obstetrics & Gynecology; Pediatrics
GA 262VE
UT WOS:000327765200005
PM 24293448
ER
PT J
AU Kent, EE
Mitchell, SA
Oakley-Girvan, I
Arora, NK
AF Kent, Erin E.
Mitchell, Sandra A.
Oakley-Girvan, Ingrid
Arora, Neeraj K.
TI The importance of symptom surveillance during follow-up care of
leukemia, bladder, and colorectal cancer survivors
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Cancer survivorship; Symptom burden; Symptom management; Late effects;
Health-related quality of life
ID QUALITY-OF-LIFE; PATIENT-REPORTED OUTCOMES; LONG-TERM; MANAGEMENT;
DIAGNOSIS; DISTRESS; SURGERY; BURDEN; SYSTEM; NEEDS
AB We examined cancer survivors' experience of bothersome symptoms, association of symptom bother with health-related quality of life (HRQOL), survivors' perception of symptom care, and their symptom-related information needs.
Using self-report survey measures, survivors of leukemia, bladder, or colorectal cancer who were 2-5 years post-diagnosis and received follow-up care in the past year (N = 623) provided information about the presence of bothersome symptoms, symptom-related information needs, adequacy of symptom-related care, and their physical and mental HRQOL. Multivariable statistical analyses were conducted to identify correlates of symptom bother, inadequate care, and symptom information needs and to examine the association between symptom bother and HRQOL.
Twenty-eight percent of the 606 respondents experienced symptom bother in the past year (46 % of leukemia, 24 % of bladder, and 26 % of colorectal cancer survivors). Younger survivors, those of Hispanic ethnicity, with low income, those with recurrent cancer, and chemotherapy recipients were more likely to report symptom bother (all p < 0.05). Symptom bother was associated with lower physical and mental HRQOL (p < 0.001). While 92 % of survivors with symptoms discussed them with their follow-up care physician, 52 % of these reported receiving inadequate symptom care. Survivors reporting inadequate symptom care were 2.5 times as likely to identify symptom information needs compared to those who received adequate care (p < 0.05).
One in four cancer survivors report symptoms 2-5 years post-diagnosis, and only half of these survivors receive adequate care to address those symptoms. Research that refines and tests symptom care interventions for this population is warranted.
C1 [Kent, Erin E.; Mitchell, Sandra A.; Arora, Neeraj K.] Natl Canc Inst, Div Canc Control & Populat Sci, Outcomes Res Branch, Appl Res Program, Rockville, MD 20850 USA.
[Oakley-Girvan, Ingrid] Canc Prevent Inst Calif, Fremont, CA 94538 USA.
RP Kent, EE (reprint author), Natl Canc Inst, Div Canc Control & Populat Sci, Outcomes Res Branch, Appl Res Program, 9609 Med Ctr Dr, Rockville, MD 20850 USA.
EM erin.kent@nih.gov
FU National Cancer Institute [N01-PC-35136]
FX Support for data collection was provided by the National Cancer
Institute (Contract No. N01-PC-35136) as a contract to the Cancer
Prevention Institute of California (formerly known as the Northern
California Cancer Center).
NR 46
TC 5
Z9 5
U1 3
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JAN
PY 2014
VL 22
IS 1
BP 163
EP 172
DI 10.1007/s00520-013-1961-x
PG 10
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 264QL
UT WOS:000327895000021
PM 24018909
ER
PT J
AU de Jong, LW
Forsberg, LE
Vidal, JS
Sigurdsson, S
Zijdenbos, AP
Garcia, M
Eiriksdottir, G
Gudnason, V
van Buchem, MA
Launer, LJ
AF de Jong, Laura W.
Forsberg, Lars E.
Vidal, Jean-Sebastien
Sigurdsson, Sigurdur
Zijdenbos, Alex P.
Garcia, Melissa
Eiriksdottir, Gudny
Gudnason, Vilmundur
van Buchem, Mark A.
Launer, Lenore J.
TI Different susceptibility of medial temporal lobe and basal ganglia
atrophy rates to vascular risk factors
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Medial temporal lobe; Hippocampus; Basal ganglia; Thalamus; Atrophy;
Aging; Vascular risk factor
ID SMALL-VESSEL DISEASE; APOLIPOPROTEIN-E GENOTYPE; VIRCHOW-ROBIN SPACES;
WHITE-MATTER LESIONS; BLOOD-PRESSURE; ALZHEIMERS-DISEASE; HIPPOCAMPAL
ATROPHY; AGES-REYKJAVIK; MIDLIFE; POPULATION
AB Atrophy of the medial temporal lobe (MTL) and basal ganglia (BG) are characteristic of various neurodegenerative diseases in older people. In search of potentially modifiable factors that lead to atrophy in these structures, we studied the association of vascular risk factors with atrophy of the MTL and BG in 368 nondemented men and women (born, 1907-1935) who participated in the Age, Gene/Environment, Susceptibility-Reykjavik Study. A fully automated segmentation pipeline estimated volumes of the MTL and BG from whole-brain magnetic resonance imaging performed at baseline and 2.4 years later. Linear regression models showed higher systolic and diastolic blood pressures and the presence of Apo E epsilon 4 were independently associated with increased atrophy of the MTL but no association of vascular risk factors with atrophy of the BG. The different susceptibility of MTL and BG atrophy to the vascular risk factors suggests perfusion of the BG is relatively preserved when vascular risk factors are present. (C) 2014 Elsevier Inc. All rights reserved.
C1 [de Jong, Laura W.; van Buchem, Mark A.] Leiden Univ, Med Ctr, Dept Radiol, Leiden, Netherlands.
[Forsberg, Lars E.] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.
[Vidal, Jean-Sebastien] Hop Broca, AP HP, Serv Gerontol 2, Paris, France.
[Vidal, Jean-Sebastien] Univ Paris 05, Sorbonne Paris 5, EA 4468, Paris, France.
[Sigurdsson, Sigurdur; Eiriksdottir, Gudny; Gudnason, Vilmundur] Iceland Heart Assoc, Kopavogur, Iceland.
[Zijdenbos, Alex P.] Biospective Inc, Montreal, PQ, Canada.
[Garcia, Melissa; Launer, Lenore J.] NIA, Intramural Res Program, Bethesda, MD 20892 USA.
RP Launer, LJ (reprint author), Lab Epidemiol Demog & Biometry, Gateway Bldg,3C309,7201 Wisconsin Ave, Bethesda, MD 20892 USA.
EM launerl@nia.nih.gov
RI Gudnason, Vilmundur/K-6885-2015; Vidal, Jean-Sebastien/D-1941-2016
OI Gudnason, Vilmundur/0000-0001-5696-0084; Vidal,
Jean-Sebastien/0000-0001-6770-0720
FU National Institutes of Health [N01-AG-1-2100]; National Institute on
Aging Intramural Research Program,; Althingi (Icelandic Parliament);
Netherlands Organisation for Health Research and Development (AGIKO)
[92003536]; Dutch Genomics Initiative [NCHA 050-060-810]; Hjartavernd
(Icelandic Heart Association)
FX The authors thank the participants of the AGES-Reykjavik Study and the
Icelandic Heart Association clinic staff for their invaluable
contribution. This work was supported by the National Institutes of
Health (N01-AG-1-2100), National Institute on Aging Intramural Research
Program, the Hjartavernd (Icelandic Heart Association), and the Althingi
(Icelandic Parliament). Dr de Jong is supported by the Netherlands
Organisation for Health Research and Development (AGIKO grant number
92003536). Prof van Buchem is supported by an unrestricted grant from
the Dutch Genomics Initiative (NCHA 050-060-810).
NR 41
TC 5
Z9 5
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD JAN
PY 2014
VL 35
IS 1
BP 72
EP 78
DI 10.1016/j.neurobiolaging.2013.07.009
PG 7
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 251AI
UT WOS:000326898400008
PM 23992618
ER
PT J
AU Wang, Y
Mattson, MP
AF Wang, Yue
Mattson, Mark P.
TI L-type Ca2+ currents at CA1 synapses, but not CA3 or dentate granule
neuron synapses, are increased in 3xTgAD mice in an age-dependent manner
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE 3xTgAD mice; Aging; L-type Ca2+ currents; CA1
ID ALZHEIMERS-DISEASE MICE; CALCIUM-CHANNEL BLOCKER; AMYLOID-BETA; MOUSE
MODEL; HIPPOCAMPAL-NEURONS; SYNAPTIC PLASTICITY; PYRAMIDAL NEURONS;
CELL-DEATH; IN-VIVO; NEUROFIBRILLARY TANGLES
AB Abnormal neuronal excitability and impaired synaptic plasticity might occur before the degeneration and death of neurons in Alzheimer's disease (AD). To elucidate potential biophysical alterations underlying aberrant neuronal network activity in AD, we performed whole-cell patch clamp analyses of L-type (nifedipine-sensitive) Ca2+ currents (L-VGCC), 4-eaminopyridine-sensitive K+ currents, and AMPA (2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid) and NMDA (N-methyl-D-aspartate) currents in CA1, CA3, and dentate granule neurons in hippocampal slices from young, middle-age, and old 3xTgAD mice and age-matched wild type mice. 3xTgAD mice develop progressive widespread accumulation of amyloid beta-peptide, and selective hyperphosphorylated tau pathology in hippocampal CA1 neurons, which are associated with cognitive deficits, but independent of overt neuronal degeneration. An age-related elevation of L-type Ca2+ channel current density occurred in CA1 neurons in 3xTgAD mice, but not in wild type mice, with the magnitude being significantly greater in older 3xTgAD mice. The NMDA current was also significantly elevated in CA1 neurons of old 3xTgAD mice compared with in old wild type mice. There were no differences in the amplitude of K+ or AMPA currents in CA1 neurons of 3xTgAD mice compared with wild type mice at any age. There were no significant differences in Ca2+, K+, AMPA, or NMDA currents in CA3 and dentate neurons from 3xTgAD mice compared with wild type mice at any age. Our results reveal an age-related increase of L-VGCC density in CA1 neurons, but not in CA3 or dentate granule neurons, of 3xTgAD mice. These findings suggest a potential contribution of altered L-VGCC to the selective vulnerability of CA1 neurons to tau pathology in the 3xTgAD mice and to their degeneration in AD patients. Published by Elsevier Inc.
C1 [Wang, Yue; Mattson, Mark P.] NIA, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA.
[Mattson, Mark P.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.
RP Wang, Y (reprint author), NIA, Intramural Res Program, Dept Neurosci, Baltimore, MD 21224 USA.
EM wangyu@grc.nia.nih.gov
FU Intramural Research Program of the National Institute on Aging of the
National Institutes of Health
FX This research was supported by the Intramural Research Program of the
National Institute on Aging of the National Institutes of Health. The
authors thank the Comparative Medicine Section of the National Institute
on Aging for technical support.
NR 69
TC 12
Z9 13
U1 1
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD JAN
PY 2014
VL 35
IS 1
BP 88
EP 95
DI 10.1016/j.neurobiolaging.2013.07.007
PG 8
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 251AI
UT WOS:000326898400010
PM 23932880
ER
PT B
AU Walsh, ER
Bolland, S
AF Walsh, Elizabeth R.
Bolland, Silvia
BA Ackerman, ME
Nimmerjahn, F
BF Ackerman, ME
Nimmerjahn, F
TI B Cells Development, Differentiation, and Regulation by Fc gamma
Receptor IIB in the Humoral Immune Response
SO ANTIBODY FC: LINKING ADAPTIVE AND INNATE IMMUNITY
LA English
DT Article; Book Chapter
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; FOLLICULAR DENDRITIC CELLS; COATED PIT
LOCALIZATION; RIIB-DEFICIENT MICE; MOUSE BONE-MARROW; GERMINAL-CENTER;
T-CELLS; PLASMA-CELLS; LYMPH-NODES; SUBCAPSULAR SINUS
C1 [Walsh, Elizabeth R.; Bolland, Silvia] NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA.
RP Bolland, S (reprint author), NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA.
NR 100
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
BN 978-0-12-394818-2; 978-0-12-394802-1
PY 2014
BP 115
EP 129
PG 15
WC Immunology
SC Immunology
GA BHU43
UT WOS:000326685100006
ER
PT B
AU Sun, P
AF Sun, Peter
BA Ackerman, ME
Nimmerjahn, F
BF Ackerman, ME
Nimmerjahn, F
TI Structural Recognition of Immunoglobulins by Fc gamma Receptors
SO ANTIBODY FC: LINKING ADAPTIVE AND INNATE IMMUNITY
LA English
DT Article; Book Chapter
ID C-REACTIVE PROTEIN; AMYLOID-P COMPONENT; SMALL NUCLEAR
RIBONUCLEOPROTEIN; AFFINITY IGE RECEPTOR; EPSILON-RI-ALPHA;
CRYSTAL-STRUCTURE; BINDING-SITE; 3-DIMENSIONAL STRUCTURE;
RHEUMATOID-ARTHRITIS; EFFECTOR FUNCTIONS
C1 NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA.
RP Sun, P (reprint author), NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA.
NR 89
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
BN 978-0-12-394818-2; 978-0-12-394802-1
PY 2014
BP 131
EP 144
PG 14
WC Immunology
SC Immunology
GA BHU43
UT WOS:000326685100007
ER
PT B
AU Clatworthy, MR
AF Clatworthy, Menna R.
BA Ackerman, ME
Nimmerjahn, F
BF Ackerman, ME
Nimmerjahn, F
TI Fc gamma Receptor Polymorphisms and Susceptibility to Infection
SO ANTIBODY FC: LINKING ADAPTIVE AND INNATE IMMUNITY
LA English
DT Article; Book Chapter
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; IIA CD32 POLYMORPHISM; C-REACTIVE PROTEIN;
STREPTOCOCCUS-PNEUMONIAE INFECTION; PLASMODIUM-FALCIPARUM MALARIA;
DENGUE VIRUS-INFECTION; ANTIBODY-DEPENDENT ENHANCEMENT;
NECROSIS-FACTOR-ALPHA; MENINGOCOCCAL DISEASE; HUMAN MONOCYTES
C1 [Clatworthy, Menna R.] Univ Cambridge, Sch Clin Med, Cambridge Inst Med Res, Cambridge, England.
[Clatworthy, Menna R.] Univ Cambridge, Sch Clin Med, Dept Med, Cambridge, England.
[Clatworthy, Menna R.] NIAID, Lab Syst Biol, NIH, Bethesda, MD 20892 USA.
RP Clatworthy, MR (reprint author), Univ Cambridge, Sch Clin Med, Cambridge Inst Med Res, Cambridge, England.
NR 135
TC 2
Z9 2
U1 0
U2 5
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
BN 978-0-12-394818-2; 978-0-12-394802-1
PY 2014
BP 217
EP 237
PG 21
WC Immunology
SC Immunology
GA BHU43
UT WOS:000326685100012
ER
PT J
AU Shah, NN
Wayne, AS
Wilson, WH
AF Shah, Nirali N.
Wayne, Alan S.
Wilson, Wyndham H.
BE Marcus, R
Sweetenham, JW
Williams, ME
TI Burkitt and lymphoblastic lymphoma: clinical therapy and outcome
SO LYMPHOMA: PATHOLOGY, DIAGNOSIS, AND TREATMENT, 2ND EDITION
LA English
DT Article; Book Chapter
ID FRANKFURT-MUNSTER GROUP; CHILDRENS CANCER GROUP; HIGH-DOSE METHOTREXATE;
CRANIAL RADIOTHERAPY; ONCOLOGY-GROUP; BFM 90; LEUKEMIA; CHILDHOOD;
PROTOCOL; TRIAL
C1 [Shah, Nirali N.] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Wayne, Alan S.] Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA USA.
[Wilson, Wyndham H.] NCI, Lymphoma Therapeut Sect, Metab Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.
RP Shah, NN (reprint author), NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
NR 34
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA THE PITT BUILDING, TRUMPINGTON ST, CAMBRIDGE CB2 1RP, CAMBS, ENGLAND
BN 978-1-107-01059-8
PY 2014
BP 172
EP 190
PG 19
WC Oncology; Hematology
SC Oncology; Hematology
GA BIA08
UT WOS:000327127000013
ER
PT J
AU Gorlick, R
Kolb, EA
Keir, ST
Maris, JM
Reynolds, CP
Kang, MH
Carol, H
Lock, R
Billups, CA
Kurmasheva, RT
Houghton, PJ
Smith, MA
AF Gorlick, Richard
Kolb, E. Anders
Keir, Stephen T.
Maris, John M.
Reynolds, C. Patrick
Kang, Min H.
Carol, Hernan
Lock, Richard
Billups, Catherine A.
Kurmasheva, Raushan T.
Houghton, Peter J.
Smith, Malcolm A.
TI Initial Testing (Stage 1) of the Polo-Like Kinase Inhibitor Volasertib
(BI 6727), by the Pediatric Preclinical Testing Program
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article
DE developmental therapeutics; Plk inhibitor; preclinical testing
ID ANTITUMOR-ACTIVITY; TUMOR-GROWTH; IN-VITRO; OSTEOSARCOMA; SCREEN; CELLS;
TARGET; CANCER; POLO-LIKE-KINASE-1; EXPRESSION
AB BackgroundVolasertib (BI 6727) is a potent inhibitor of Polo-like kinase 1 (Plk1), that is overexpressed in several childhood cancers and cell lines. Because of its novel mechanism of action, volasertib was evaluated through the PPTP.
ProceduresVolasertib was tested against the PPTP in vitro cell line panel at concentrations from 0.1nM to 1.0M and against the PPTP in vivo xenograft panels administered IV at a dose of 30mg/kg (solid tumors) or 15mg/kg (ALL models) using a q7dx3 schedule.
ResultsIn vitro volasertib demonstrated cytotoxic activity, with a median relative IC50 value of 14.1nM, (range 6.0-135nM). Volasertib induced significant differences in EFS in 19 of 32 (59%) of the evaluable solid tumor xenografts and in 2 of 4 (50%) of the evaluable ALL xenografts. Volasertib induced tumor growth inhibition meeting criteria for intermediate EFS T/C (>2) activity in 11 of 30 (37%) evaluable solid tumor xenografts, including neuroblastoma (4 of 6) and glioblastoma (2 of 3) panels, and 2 of 4 ALL models. Objective responses (CR's) were observed for 4 of 32 solid tumor (two neuroblastoma, one glioblastoma, and one rhabdomyosarcoma) and one of four ALL xenografts.
ConclusionsVolasertib shows potent in vitro activity against the PPTP cell lines with no histotype selectivity. In vivo, volasertib induced regressions in several xenograft models. However, pharmacokinetic data suggest that mice tolerate higher systemic exposure to volasertib than humans, suggesting that the current results may over-estimate potential clinical efficacy against the childhood cancers studied. Pediatr Blood Cancer 2014;61:158-164. (c) 2013 Wiley Periodicals, Inc.
C1 [Gorlick, Richard] Childrens Hosp Montefiore, Bronx, NY USA.
[Kolb, E. Anders] Alfred I DuPont Hosp Children, Wilmington, DE USA.
[Keir, Stephen T.] Duke Univ, Med Ctr, Durham, NC USA.
[Maris, John M.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA.
[Maris, John M.] Abramson Family Canc Res Inst, Philadelphia, PA USA.
[Reynolds, C. Patrick; Kang, Min H.] Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USA.
[Carol, Hernan; Lock, Richard] Childrens Canc Inst Australia Med Res, Randwick, NSW, Australia.
[Billups, Catherine A.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
[Kurmasheva, Raushan T.; Houghton, Peter J.] Nationwide Childrens Hosp, Columbus, OH USA.
[Smith, Malcolm A.] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA.
RP Gorlick, R (reprint author), Montefiore Med Ctr, Dept Pediat, 3415 Bainbridge Ave, Bronx, NY 10467 USA.
EM rgorlick@montefiore.org
RI Houghton, Peter/E-3265-2011; Lock, Richard/G-4253-2013;
OI Reynolds, C. Patrick/0000-0002-2827-8536
FU National Cancer Institute [NO1-CM-42216, CA21765, CA108786]
FX National Cancer Institute; Grant numbers: NO1-CM-42216; CA21765;
CA108786
NR 25
TC 24
Z9 24
U1 3
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
EI 1545-5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JAN
PY 2014
VL 61
IS 1
BP 158
EP 164
DI 10.1002/pbc.24616
PG 7
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 249GG
UT WOS:000326765100026
PM 23956067
ER
PT B
AU Resnik, DB
AF Resnik, David B.
BE Curd, M
Psillos, S
TI ETHICS OF SCIENCE
SO ROUTLEDGE COMPANION TO PHILOSOPHY OF SCIENCE. 2ND EDITION
SE Routledge Philosophy Companion
LA English
DT Article; Book Chapter
C1 NIEHS, NIH, Res Triangle Pk, NC 27709 USA.
RP Resnik, DB (reprint author), NIEHS, NIH, Res Triangle Pk, NC 27709 USA.
NR 7
TC 0
Z9 0
U1 1
U2 4
PU ROUTLEDGE
PI LONDON
PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND
BN 978-1-135-01109-3; 978-0-415-51874-1
J9 ROUTL PHILOS COMPAN
PY 2014
BP 181
EP 190
PG 10
WC History & Philosophy Of Science
SC History & Philosophy of Science
GA BIB84
UT WOS:000327316600018
ER
PT J
AU Colbert, RA
Tran, TM
Layh-Schmitt, G
AF Colbert, Robert A.
Tran, Tri M.
Layh-Schmitt, Gerlinde
TI HLA-B27 misfolding and ankylosing spondylitis
SO MOLECULAR IMMUNOLOGY
LA English
DT Review
DE MHC class I; Protein misfolding; Endoplasmic reticulum stress; Unfolded
protein response; Autophagy; Ankylosing spondylitis; Spondyloarthritis
ID UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS;
TUMOR-NECROSIS-FACTOR; IFN-BETA INDUCTION; I HEAVY-CHAINS; TRANSGENIC
RATS; INFLAMMATORY DISEASE; TRANSCRIPTION FACTOR; HLA-B27-TRANSGENIC
RATS; CELL-SURVIVAL
AB Understanding how HLA-B27 contributes to the pathogenesis of spondyloarthritis continues to be an important goal. Current efforts are aimed largely on three areas of investigation; peptide presentation to CD8T cells, abnormal forms of the HLA-B27 heavy chain and their recognition by leukocyte immunoglobulin-like receptors on immune effector cells, and HLA-B27 heavy chain misfolding and intrinsic biological effects on affected cells. In this chapter we review our current understanding of the causes and consequences of HLA-B27 misfolding, which can be defined biochemically as a propensity to oligomerize and form complexes in the endoplasmic reticulum (ER) with the chaperone BiP (HSPA5/GRP78). HLA-B27 misfolding is linked to an unusual combination of polymorphisms that identify this allele, and cause the heavy chain to fold and load peptides inefficiently. Misfolding can result in ER-associated degradation (ERAD) of heavy chains, which is mediated in part by the E3 ubiquitin ligase HRD1 (SYVN1), and the ubiquitin conjugating enzyme UBE2JL. Upregulation of HLA-B27 and accumulation of misfolded heavy chains can activate ER stress signaling pathways that orchestrate the unfolded protein response. In transgenic rats where HLA-B27 is overexpressed, UPR activation is prominent. However, it is specific for heavy chain misfolding, since overexpression of HLA-B7, an allele that does not misfold, fails to generate ER stress. UPR activation has been linked to cytokine dysregulation, promoting IL-23, IFN beta, and IL-1 alpha production, and may activate the IL-23/IL-17 axis in these rats. IL-l alpha and IFN beta are pro- and anti-osteoclastogenic cytokines, respectively, that modulate osteoclast development in HLA-B27-expressing transgenic rat monocytes. Translational studies of patient derived cells expressing HLA-B27 at physiologic levels have provided evidence that ER stress and UPR activation can occur in peripheral blood, but this has not been reported to date in isolated macrophages. Inflamed gastrointestinal tissue reveals evidence for HLA-B27 misfolding, ERAD, and autophagy, without acute UPR activation. A more complete picture of conditions that impact HLA-B27 folding and misfolding, the full spectrum and time course of consequences of ER stress, and critical cell types involved is needed to understand the role of HLA-B27 misfolding in spondyloarthritis pathogenesis. Published by Elsevier Ltd.
C1 [Colbert, Robert A.; Tran, Tri M.; Layh-Schmitt, Gerlinde] NIAMSD, Pediat Translat Res Branch, NIH, Bethesda, MD 20892 USA.
RP Colbert, RA (reprint author), NIAMS, NIH, Bldg 10 CRC,Room 1-5142,10 Ctr Dr,MSC 1102, Bethesda, MD 20892 USA.
EM colbertr@mail.nih.gov
FU Intramural NIH HHS [ZIA AR041184-04]
NR 78
TC 45
Z9 50
U1 2
U2 44
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD JAN
PY 2014
VL 57
IS 1
SI SI
BP 44
EP 51
DI 10.1016/j.molimm.2013.07.013
PG 8
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 248AG
UT WOS:000326665500007
PM 23993278
ER
PT S
AU Cicala, C
Arthos, J
AF Cicala, Claudia
Arthos, James
BE Vicenzi, E
Poli, G
TI Virion Attachment and Entry: HIV gp120 Env Biotinylation, gp120 Env, or
Integrin Ligand-Binding Assay
SO HUMAN RETROVIRUSES: METHODS AND PROTOCOLS
SE Methods in Molecular Biology
LA English
DT Article; Book Chapter
DE HIV-1 gp120; Integrin; gp120 biotinylation; Binding assay; Retinoic
acid; MAdCAM
ID RETINOIC ACID; CELLS; ALPHA(4)BETA(7)
AB The HIV-1 entry receptors are CD4 and a chemokine receptor (CCR5 or CXCR4). In addition it has recently been demonstrated that HIV-1 gp120 binds to and signals through integrin alpha(4)beta(7), the gut-homing receptor (Arthos et al., Nat Immunol 9(3):301-309, 2008). Integrin alpha(4)beta(7) is not an entry receptor for HIV-1, although it can facilitate virion attachment to target cells (Arthos et al., Nat Immunol 9(3):301-309, 2008; Cicala et al., Proc Natl Acad Sci U S A 106:20877-20882, 2009). Recombinant HIV-1 gp120s bind to integrin alpha(4)beta(7) in a manner similar to its natural ligands (MAdCAM-1, V-CAM-1, fibronectin) (Andrew et al., J Immunol 153:3847-3861, 1994). gp120-alpha(4)beta(7) interactions are detected in a manner similar to assays developed for the natural ligands of alpha(4)beta(7). In this chapter we describe a method for the analysis of integrin-gp120 binding via a cell-based binding assay. In vitro ligand-integrin affinity can be modified by the presence of divalent cations (Mn2+, Mg2+, Ca2+) (Leitinger et al., Leitinger Biochim Biophys Acta 1498:91-98, 2000). Here we describe a protocol to detect biotinylated recombinant HIV-1 gp120 binding to integrin alpha(4)beta(7) in both primary cells and cell lines expressing the gut-homing receptor.
C1 [Cicala, Claudia; Arthos, James] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA.
RP Cicala, C (reprint author), NIAID, Immunoregulat Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
NR 13
TC 2
Z9 2
U1 0
U2 7
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
SN 1064-3745
BN 978-1-62703-670-2; 978-1-62703-669-6
J9 METHODS MOL BIOL
JI Methods Mol. Biol.
PY 2014
VL 1087
BP 3
EP 12
DI 10.1007/978-1-62703-670-2_1
D2 10.1007/978-1-62703-670-2
PG 10
WC Immunology; Virology
SC Immunology; Virology
GA BHR82
UT WOS:000326509000003
PM 24158809
ER
PT S
AU Andrew, A
Strebel, K
AF Andrew, Amy
Strebel, Klaus
BE Vicenzi, E
Poli, G
TI HIV-1 Accessory Proteins: Vpu and Vif
SO HUMAN RETROVIRUSES: METHODS AND PROTOCOLS
SE Methods in Molecular Biology
LA English
DT Article; Book Chapter
DE Vif; Vpu; Accessory protein; Restriction factor; Virus-host interactions
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD4
AB HIV-1 Vif and Vpu are accessory factors involved in late stages of viral replication. Vif regulates viral infectivity by preventing virion incorporation of APOBEC3G and other members of the family of cytidine deaminases, while Vpu causes degradation of CD4 and promotes virus release by functionally inactivating the host factor BST-2. This chapter described techniques used for the characterization of Vif and Vpu and their functional interaction with host factors. Many of the techniques are, however, applicable to the functional analysis of other viral proteins.
C1 [Andrew, Amy; Strebel, Klaus] NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA.
RP Andrew, A (reprint author), NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA.
FU Intramural NIH HHS [ZIA AI000669-21]
NR 5
TC 1
Z9 1
U1 0
U2 3
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
SN 1064-3745
BN 978-1-62703-670-2; 978-1-62703-669-6
J9 METHODS MOL BIOL
JI Methods Mol. Biol.
PY 2014
VL 1087
BP 135
EP 158
DI 10.1007/978-1-62703-670-2_12
D2 10.1007/978-1-62703-670-2
PG 24
WC Immunology; Virology
SC Immunology; Virology
GA BHR82
UT WOS:000326509000014
PM 24158820
ER
PT S
AU Arakelyan, A
Fitzgerald, W
Grivel, JC
Vanpouille, C
Margolis, L
AF Arakelyan, Anush
Fitzgerald, Wendy
Grivel, Jean-Charles
Vanpouille, Christophe
Margolis, Leonid
BE Vicenzi, E
Poli, G
TI Histocultures(Tissue Explants) in Human Retrovirology
SO HUMAN RETROVIRUSES: METHODS AND PROTOCOLS
SE Methods in Molecular Biology
LA English
DT Article; Book Chapter
DE Human tissue; HIV; Histoculture; Explants; Pathogenesis; Flow cytometry
ID HUMAN LYMPHOID-TISSUE; IMMUNODEFICIENCY-VIRUS TYPE-1; EX-VIVO;
MEASLES-VIRUS; HIV TYPE-1; INFECTION; CULTURE; PATHOGENESIS;
REPLICATION; PHENOTYPE
AB Viral pathogenesis is studied predominantly in cultures of primary isolated cells or cell lines. Many retroviruses efficiently replicate only in activated cells. Therefore, in order to become efficient viral producers cells should be artificially activated, a procedure which significantly changes cell physiology. However, for many viral diseases, like HIV-1 and other retroviruses' diseases, critical pathogenic events occur in tissues. Therefore, cell isolation from their native microenvironment prevents single-cell cultures from faithfully reflecting important aspects of cell-cell and cell-pathogen interactions that occur in the context of complex tissue cytoarchitecture. Tissue explants (histocultures) that retain tissue cytoarchitecture and many aspects of cell-cell interactions more faithfully represent in vivo tissue features. Human histocultures constitute an adequate model for studying viral pathogenesis under controlled laboratory conditions. Protocols for various human histocultures as applied to study retroviral pathogenesis, in particular of HIV-1, have been refined by our laboratory and are described in the present publication. Histocultures of human tonsils and lymph nodes, as well as of recto-sigmoid and cervicovaginal tissues can be used to study viral transmission, pathogenesis and as a preclinical platform for antivirals evaluation.
C1 [Arakelyan, Anush; Fitzgerald, Wendy; Grivel, Jean-Charles; Vanpouille, Christophe; Margolis, Leonid] NICHHD, Sect Intercellular Interact, Program Phys Biol, NIH, Bethesda, MD 20892 USA.
RP Arakelyan, A (reprint author), NICHHD, Sect Intercellular Interact, Program Phys Biol, NIH, Bethesda, MD 20892 USA.
FU Intramural NIH HHS [ZIA HD001416-21, ZIA HD001416-20]
NR 30
TC 2
Z9 2
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
SN 1064-3745
BN 978-1-62703-670-2; 978-1-62703-669-6
J9 METHODS MOL BIOL
JI Methods Mol. Biol.
PY 2014
VL 1087
BP 233
EP 248
DI 10.1007/978-1-62703-670-2_19
D2 10.1007/978-1-62703-670-2
PG 16
WC Immunology; Virology
SC Immunology; Virology
GA BHR82
UT WOS:000326509000021
PM 24158827
ER
PT S
AU Wiegand, A
Maldarelli, F
AF Wiegand, Ann
Maldarelli, Frank
BE Vicenzi, E
Poli, G
TI Single-Copy Quantification of HIV-1 in Clinical Samples
SO HUMAN RETROVIRUSES: METHODS AND PROTOCOLS
SE Methods in Molecular Biology
LA English
DT Article; Book Chapter
DE HIV; RNA; PCR; Single-copy assay
ID ACTIVE ANTIRETROVIRAL THERAPY; LOW-LEVEL VIREMIA; VIRUS TYPE-1 RNA;
RALTEGRAVIR INTENSIFICATION; PROGNOSTIC VALUE; PLASMA SAMPLES; MONITOR
V1.5; PCR ASSAY; T-CELLS; REPLICATION
AB HIV replication in humans proceeds with substantial viral RNA levels in plasma. Antiretroviral therapy results in suppression but not eradication of HIV infection. Continuous therapy is essential for durable clinical responses. Discontinuing antiretroviral therapy results in prompt rebound in viremia. The source of HIV during suppressive therapy and mechanisms of persistence remain uncertain. Sensitive assays for HIV have been useful in quantifying viremia in response to antiretroviral therapy and in experimental studies of drug intensification, drug simplification, and potential anatomic sanctuary site investigations. As clinical eradication strategies move forward, robust, sensitive quantitative assays for HIV at low levels represent essential laboratory support modalities. Here we describe in detail an assay for HIV-1 RNA with single-copy sensitivity.
C1 [Wiegand, Ann; Maldarelli, Frank] NCI, HIV Drug Resistance Program, Frederick Natl Lab Canc Res, NIH, Frederick, MD 21701 USA.
RP Wiegand, A (reprint author), NCI, HIV Drug Resistance Program, Frederick Natl Lab Canc Res, NIH, Frederick, MD 21701 USA.
NR 33
TC 0
Z9 0
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
SN 1064-3745
BN 978-1-62703-670-2; 978-1-62703-669-6
J9 METHODS MOL BIOL
JI Methods Mol. Biol.
PY 2014
VL 1087
BP 251
EP 260
DI 10.1007/978-1-62703-670-2_20
D2 10.1007/978-1-62703-670-2
PG 10
WC Immunology; Virology
SC Immunology; Virology
GA BHR82
UT WOS:000326509000022
PM 24158828
ER
PT S
AU Klase, ZA
Houzet, L
Jeang, KT
AF Klase, Zachary A.
Houzet, Laurent
Jeang, Kuan-Teh
BE Vicenzi, E
Poli, G
TI Quantification of miRNA by Poly(A)-RT-qPCR Arrays and Verification of
Target Sites in HIV-1 Using a One-LTR Infectious Molecular Clone
SO HUMAN RETROVIRUSES: METHODS AND PROTOCOLS
SE Methods in Molecular Biology
LA English
DT Article; Book Chapter
DE miRNA; qPCR array; RNA isolation; Small RNA labeling; One-LTR molecular
clone
ID VIRUS-REPLICATION; MICRORNAS; RNAI; IDENTIFICATION; SUPPRESSOR; ELEMENT;
PROTEIN; PATHWAY; DICER
AB Quantitative PCR (qPCR) provides a robust method for quantifying DNA species. By combining modern qPCR techniques with the isolation of small RNA, the polyadenylation of the RNA, and the use of reverse transcriptase to create miRNA derived cDNA, it is now possible to use qPCR to quantify miRNA. This method is scalable and provides a useful addition to the retrovirologists' toolbox. Here, we also describe the use of one-LTR infectious molecular clones to verify miRNA target sites within the retroviral LTR.
C1 [Klase, Zachary A.; Houzet, Laurent] NIAID, NIH, Bethesda, MD 20892 USA.
[Jeang, Kuan-Teh] NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA.
RP Klase, ZA (reprint author), NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
FU Intramural NIH HHS
NR 22
TC 1
Z9 1
U1 1
U2 9
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
SN 1064-3745
BN 978-1-62703-670-2; 978-1-62703-669-6
J9 METHODS MOL BIOL
JI Methods Mol. Biol.
PY 2014
VL 1087
BP 285
EP 296
DI 10.1007/978-1-62703-670-2_23
D2 10.1007/978-1-62703-670-2
PG 12
WC Immunology; Virology
SC Immunology; Virology
GA BHR82
UT WOS:000326509000025
PM 24158831
ER
PT J
AU Li, YY
Parker, LE
AF Li, YuanYuan
Parker, Lynne E.
TI Nearest neighbor imputation using spatial-temporal correlations in
wireless sensor networks
SO INFORMATION FUSION
LA English
DT Article
DE Wireless sensor networks; kd-Tree; Missing data imputation; Nearest
neighbor imputation
ID CLASSIFICATION
AB Missing data is common in Wireless Sensor Networks (WSNs), especially with multi-hop communications. There are many reasons for this phenomenon, such as unstable wireless communications, synchronization issues, and unreliable sensors. Unfortunately, missing data creates a number of problems for WSNs. First, since most sensor nodes in the network are battery-powered, it is too expensive to have the nodes retransmit missing data across the network. Data re-transmission may also cause time delays when detecting abnormal changes in an environment. Furthermore, localized reasoning techniques on sensor nodes (such as machine learning algorithms to classify states of the environment) are generally not robust enough to handle missing data. Since sensor data collected by a WSN is generally correlated in time and space, we illustrate how replacing missing sensor values with spatially and temporally correlated sensor values can significantly improve the network's performance. However, our studies show that it is important to determine which nodes are spatially and temporally correlated with each other. Simple techniques based on Euclidean distance are not sufficient for complex environmental deployments. Thus, we have developed a novel Nearest Neighbor (NN) imputation method that estimates missing data in WSNs by learning spatial and temporal correlations between sensor nodes. To improve the search time, we utilize a kd-tree data structure, which is a non-parametric, data-driven binary search tree. Instead of using traditional mean and variance of each dimension for kd-tree construction, and Euclidean distance for kd-tree search, we use weighted variances and weighted Euclidean distances based on measured percentages of missing data. We have evaluated this approach through experiments on sensor data from a volcano dataset collected by a network of Crossbow motes, as well as experiments using sensor data from a highway traffic monitoring application. Our experimental results show that our proposed K-NN imputation method has a competitive accuracy with state-of-the-art Expectation-Maximization (EM) techniques, while using much simpler computational techniques, thus making it suitable for use in resource-constrained WSNs. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Li, YuanYuan] NIEHS, Biostat Branch, NIH, DHHS, Res Triangle Pk, NC 27709 USA.
[Parker, Lynne E.] Univ Tennessee, Dept Elect Engn & Comp Sci, Distributed Intelligence Lab, Knoxville, TN 37996 USA.
RP Li, YY (reprint author), NIEHS, Biostat Branch, NIH, DHHS, Res Triangle Pk, NC 27709 USA.
EM yuanyuan.li@nih.gov
NR 24
TC 15
Z9 15
U1 2
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1566-2535
EI 1872-6305
J9 INFORM FUSION
JI Inf. Fusion
PD JAN
PY 2014
VL 15
SI SI
BP 64
EP 79
DI 10.1016/j.inffus.2012.08.007
PG 16
WC Computer Science, Artificial Intelligence; Computer Science, Theory &
Methods
SC Computer Science
GA 244UE
UT WOS:000326414900008
ER
PT J
AU Sadjadi, A
Derakhshan, MH
Yazdanbod, A
Boreiri, M
Parsaeian, M
Babaei, M
Alimohammadian, M
Samadi, F
Etemadi, A
Pourfarzi, F
Ahmadi, E
Delavari, A
Islami, F
Farzadfar, F
Sotoudeh, M
Nikmanesh, A
Alizadeh, BZ
de Bock, GH
Malekzadeh, R
AF Sadjadi, Alireza
Derakhshan, Mohammad H.
Yazdanbod, Abbas
Boreiri, Majid
Parsaeian, Mahbubeh
Babaei, Masoud
Alimohammadian, Masoomeh
Samadi, Fatemeh
Etemadi, Arash
Pourfarzi, Farhad
Ahmadi, Emad
Delavari, Alireza
Islami, Farhad
Farzadfar, Farshad
Sotoudeh, Masoud
Nikmanesh, Arash
Alizadeh, Behrooz Z.
de Bock, Geertruida H.
Malekzadeh, Reza
TI Neglected role of hookah and opium in gastric carcinogenesis: A cohort
study on risk factors and attributable fractions
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE gastric cancer; precancerous lesions; Helicobacter pylori; smoking;
hookah; opium
ID HELICOBACTER-PYLORI INFECTION; CANCER INCIDENCE; INTESTINAL METAPLASIA;
WATERPIPE SMOKE; SALT INTAKE; POPULATION; IRAN; METAANALYSIS; REGISTRY;
CONSUMPTION
AB A recent study showed an association between hookah/opium use and gastric cancer but no study has investigated the relationship with gastric precancerous lesions. We examined the association between hookah/opium and gastric precancerous lesions and subsequent gastric cancer. In a population-based cohort study, 928 randomly selected, healthy, Helicobacter pylori-infected subjects in Ardabil Province, Iran, were followed for 10 years. The association between baseline precancerous lesions and lifestyle risk factors (including hookah/opium) was analyzed using logistic regression and presented as odds ratios (ORs) and 95% confidence intervals (CIs). We also calculated hazard ratios (HRs) and 95% CIs for the associations of lifestyle risk factors and endoscopic and histological parameters with incident gastric cancers using Cox regression models. Additionally, the proportion of cancers attributable to modifiable risk factors was calculated. During 9,096 person-years of follow-up, 36 new cases of gastric cancer were observed (incidence rate: 3.96/1,000 persons-years). Opium consumption was strongly associated with baseline antral (OR: 3.2; 95% CI: 1.2-9.1) and body intestinal metaplasia (OR: 7.3; 95% CI: 2.5-21.5). Opium (HR: 3.2; 95% CI: 1.4-7.7), hookah (HR: 3.4; 95% CI: 1.7-7.1) and cigarette use (HR: 3.2; 95% CI: 1.4-7.5), as well as high salt intake, family history of gastric cancer, gastric ulcer and histological atrophic gastritis and intestinal metaplasia of body were associated with higher risk of gastric cancer. The fraction of cancers attributable jointly to high salt, low fruit intake, smoking (including hookah) and opium was 93% (95% CI: 83-98). Hookah and opium use are risk factors for gastric cancer as well as for precancerous lesions. Hookah, opium, cigarette and high salt intake are important modifiable risk factors in this high-incidence gastric cancer area.
What's new? Gastric cancer strikes Iranian men more often than any other cancer, and previous studies report a connection between gastric cancer and hookah, a traditional smoking device in the region. This study probed the factors associated with precancerous lesions and gastric cancer, including hookah and opium use. They found that both hookah and opium use increased the likelihood of developing cancer, as did high salt intake and cigarette smoking.
C1 [Sadjadi, Alireza; Derakhshan, Mohammad H.; Boreiri, Majid; Etemadi, Arash; Ahmadi, Emad; Delavari, Alireza; Islami, Farhad; Sotoudeh, Masoud; Nikmanesh, Arash; Alizadeh, Behrooz Z.; Malekzadeh, Reza] Univ Tehran Med Sci, Digest Dis Res Ctr, Tehran 1411713135, Iran.
[Sadjadi, Alireza; Alizadeh, Behrooz Z.; de Bock, Geertruida H.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands.
[Derakhshan, Mohammad H.] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
[Yazdanbod, Abbas; Babaei, Masoud; Samadi, Fatemeh; Pourfarzi, Farhad] Ardabil Univ Med Sci, Gastrointestinal Canc Res Ctr, Ardebil, Iran.
[Parsaeian, Mahbubeh; Farzadfar, Farshad] Univ Tehran Med Sci, Endocrinol & Metab Res Inst, Noncommunicable Dis Res Ctr, Tehran 1411713135, Iran.
[Alimohammadian, Masoomeh] Univ Tehran Med Sci, Sch Publ Hlth, Tehran 1411713135, Iran.
[Etemadi, Arash] NCI, Div Canc Epidemiol & Genet, Bethesda, MA USA.
[Islami, Farhad] Mt Sinai Sch Med, Inst Translat Epidemiol, New York, NY USA.
RP Malekzadeh, R (reprint author), Univ Tehran Med Sci, Shariati Hosp, Digest Dis Res Ctr, Tehran 1411713135, Iran.
EM g.h.de.bock@umcg.nl; malek@tums.ac.ir
RI Etemadi, Arash/C-1386-2016; Derakhshan, Mohammad/K-8694-2016; de Bock,
Geertruida/F-6529-2014;
OI Etemadi, Arash/0000-0002-3458-1072; de Bock,
Geertruida/0000-0003-3104-4471; Ziad Alizadeh,
Behrooz/0000-0002-1415-8007; Malekzadeh, Reza/0000-0003-1043-3814
FU Digestive Disease Research Center of Tehran, University of Medical
Sciences; Iran's National Elites Foundation; National Cancer Institute
at the National Institutes of Health, USA
FX Grant sponsor: Digestive Disease Research Center of Tehran, University
of Medical Sciences; Grant sponsor: Iran's National Elites Foundation;
Grant sponsor: National Cancer Institute at the National Institutes of
Health, USA
NR 40
TC 17
Z9 17
U1 0
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JAN 1
PY 2014
VL 134
IS 1
BP 181
EP 188
DI 10.1002/ijc.28344
PG 8
WC Oncology
SC Oncology
GA 238WI
UT WOS:000325982000019
PM 23797606
ER
PT J
AU Fleming, JL
Dworkin, AM
Allain, DC
Fernandez, S
Wei, L
Peters, SB
Iwenofu, OH
Ridd, K
Bastian, BC
Toland, AE
AF Fleming, Jessica L.
Dworkin, Amy M.
Allain, Dawn C.
Fernandez, Soledad
Wei, Lai
Peters, Sara B.
Iwenofu, O. Hans
Ridd, Katie
Bastian, Boris C.
Toland, Amanda Ewart
TI Allele-specific imbalance mapping identifies HDAC9 as a candidate gene
for cutaneous squamous cell carcinoma
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE HDAC9; cutaneous squamous cell carcinoma; allelic-specific imbalance;
Skts5
ID REGULATORY T-CELLS; SUSCEPTIBILITY GENE; SKIN; MICE; EXPRESSION;
SURVIVAL; LOCI
AB More than 3.5 million nonmelanoma skin cancers were treated in 2006; of these 700,000 were cutaneous squamous cell carcinomas (cSCCs). Despite clear environmental causes for cSCC, studies also suggest genetic risk factors. A cSCC susceptibility locus, Skts5, was identified on mouse chromosome 12 by linkage analysis. The orthologous locus to Skts5 in humans maps to 7p21 and 7q31. These loci show copy number increases in approximate to 10% of cSCC tumors. Here, we show that an additional 15-22% of tumors exhibit copy-neutral loss of heterozygosity. Furthermore, our previous data identified microsatellite markers on 7p21 and 7q31 that demonstrate preferential allelic imbalance (PAI) in cSCC tumors. On the basis of these results, we hypothesized that the human orthologous locus to Skts5 would house a gene important in human cSCC development and that tumors would demonstrate allele-specific somatic alterations. To test this hypothesis, we performed quantitative genotyping of 108 single nucleotide polymorphisms (SNPs) mapping to candidate genes at human SKTS5 in paired normal and tumor DNAs. Nine SNPs in HDAC9 (rs801540, rs1178108, rs1178112, rs1726610, rs10243618, rs11764116, rs1178355, rs10269422 and rs12540872) showed PAI in tumors. These data suggest that HDAC9 variants may be selected for during cSCC tumorigenesis.
What's new? While inherited risk factors have been suggested to play a role in cutaneous squamous cell carcinomas (cSCC) in addition to environmental causes, so far few well-validated genetic risk variants exist. Human 7p21 however shows evidence of preferential allelic imbalance (PAI) and copy neutral loss of heterozygosity in cSCCs. 7p21 is orthologous to a mouse skin cancer susceptibility locus, Skts5. Here, candidate genes at Skts5 identified from the mouse were assessed for evidence of PAI in human cSCCs. Multiple variants in HDAC9 were identified that show evidence of allele-specific gains in cSCC, suggesting that HDAC9 may be important in cSCC development.
C1 [Fleming, Jessica L.; Toland, Amanda Ewart] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
[Fleming, Jessica L.; Allain, Dawn C.; Toland, Amanda Ewart] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Dworkin, Amy M.] NHGRI, NIH, Bethesda, MD 20892 USA.
[Allain, Dawn C.] Arthur G James Canc Hosp, Clin Canc Genet Program, Columbus, OH USA.
[Allain, Dawn C.] Arthur G James Canc Hosp, Human Canc Genet Program, Columbus, OH USA.
[Allain, Dawn C.] Ohio State Univ, Wexner Med Ctr, Richard J Solove Res Inst, Columbus, OH 43210 USA.
[Allain, Dawn C.; Toland, Amanda Ewart] Ohio State Univ, Dept Internal Med, Div Human Genet, Med Ctr, Columbus, OH 43210 USA.
[Fernandez, Soledad; Wei, Lai] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA.
[Peters, Sara B.; Iwenofu, O. Hans] Ohio State Univ, Dept Pathol & Lab Med, Columbus, OH 43210 USA.
[Ridd, Katie; Bastian, Boris C.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
[Ridd, Katie; Bastian, Boris C.] Univ Calif San Francisco, UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Bastian, Boris C.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA.
RP Toland, AE (reprint author), 998 Biomed Res Tower,460 W 12th Ave, Columbus, OH 43210 USA.
EM amanda.toland@osumc.edu
RI Allain, Dawn/E-2634-2011; Iwenofu, Obiajulu/E-3293-2011;
OI Toland, Amanda/0000-0002-0271-1792
FU American Cancer Society [RSG-07-083 MGO]; National Cancer Institute
[CA134461]; National Institutes of Arthritis and Musculoskeletal and
Skin, Ohio State University Comprehensive Cancer Center
FX Grant sponsor: American Cancer Society; Grant number: RSG-07-083 MGO;
Grant sponsor: National Cancer Institute; Grant number: CA134461; Grant
sponsors: National Institutes of Arthritis and Musculoskeletal and Skin,
Ohio State University Comprehensive Cancer Center
NR 23
TC 4
Z9 4
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JAN 1
PY 2014
VL 134
IS 1
BP 244
EP 248
DI 10.1002/ijc.28339
PG 5
WC Oncology
SC Oncology
GA 238WI
UT WOS:000325982000026
PM 23784969
ER
PT B
AU Makareeva, E
Leikin, S
AF Makareeva, Elena
Leikin, Sergey
BE Shapiro, JR
TI Collagen Structure, Folding and Function
SO OSTEOGENESIS IMPERFECTA: A TRANSLATIONAL APPROACH TO BRITTLE BONE
DISEASE
LA English
DT Article; Book Chapter
ID EHLERS-DANLOS-SYNDROME; RECESSIVE OSTEOGENESIS IMPERFECTA;
EPITHELIUM-DERIVED FACTOR; SYNDROME TYPE-VII; CARBOXYL-TERMINAL
PROPEPTIDE; CONNECTIVE-TISSUE DISORDERS; HYPEROSTOSIS CAFFEY-DISEASE;
TRIPLE-HELIX FORMATION; RETICULUM EXIT SITES; CIS-TRANS-ISOMERASE
C1 [Makareeva, Elena; Leikin, Sergey] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
RP Makareeva, E (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
RI Leikin, Sergey/A-5518-2008
OI Leikin, Sergey/0000-0001-7095-0739
NR 172
TC 6
Z9 6
U1 0
U2 10
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
BN 978-0-12-397789-2; 978-0-12-397165-4
PY 2014
BP 71
EP 84
DI 10.1016/B978-0-12-397165-4.00007-1
PG 14
WC Orthopedics
SC Orthopedics
GA BHP54
UT WOS:000326245700009
ER
PT B
AU Kram, V
Young, MF
AF Kram, Vardit
Young, Marian F.
BE Shapiro, JR
TI Bone Matrix Proteoglycans in Skeletal Function
SO OSTEOGENESIS IMPERFECTA: A TRANSLATIONAL APPROACH TO BRITTLE BONE
DISEASE
LA English
DT Article; Book Chapter
ID HEPARAN-SULFATE PROTEOGLYCANS; LEUCINE-RICH PROTEOGLYCANS; COLLAGEN
TYPE-I; GROWTH-FACTOR-BETA; LARGE AGGREGATING PROTEOGLYCAN;
FIBROMODULIN-DEFICIENT MICE; REPEAT PROTEIN FAMILY; AGGRECAN GENE AGC1;
OSTEOGENESIS IMPERFECTA; EXTRACELLULAR-MATRIX
C1 [Kram, Vardit; Young, Marian F.] Natl Inst Dent & Craniofacial Res, Mol Biol Bones & Teeth Sect, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD USA.
RP Kram, V (reprint author), Natl Inst Dent & Craniofacial Res, Mol Biol Bones & Teeth Sect, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD USA.
NR 142
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
BN 978-0-12-397789-2; 978-0-12-397165-4
PY 2014
BP 85
EP 95
DI 10.1016/B978-0-12-397165-4.00008-3
PG 11
WC Orthopedics
SC Orthopedics
GA BHP54
UT WOS:000326245700010
ER
PT J
AU Choi, HJ
Shung, KK
AF Choi, Hojong
Shung, K. Kirk
TI Novel power MOSFET-based expander for high frequency ultrasound systems
SO ULTRASONICS
LA English
DT Article
DE Protection devices; Expander; Power MOSFET; High frequency ultrasound
system; Ultrasonic transducers
AB The function of an expander is to obstruct the noise signal transmitted by the pulser so that it does not pass into the transducer or receive electronics, where it can produce undesirable ring-down in an ultrasound imaging application. The most common type is a diode-based expander, which is essentially a simple diode-pair, is widely used in pulse-echo measurements and imaging applications because of its simple architecture. However, diode-based expanders may degrade the performance of ultrasonic transducers and electronic components on the receiving and transmitting sides of the ultrasound systems, respectively. Since they are non-linear devices, they cause excessive signal attenuation and noise at higher frequencies and voltages. In this paper, a new type of expander that utilizes power MOSFET components, which we call a power MOSFET-based expander, is introduced and evaluated for use in high frequency ultrasound imaging systems. The performance of a power MOSFET-based expander was evaluated relative to a diode-based expander by comparing the noise figure (NF), insertion loss (IL), total harmonic distortion (THD), response time (RT), electrical impedance (EI) and dynamic power consumption (DPC). The results showed that the power MOSFET-based expander provided better NF (0.76 dB), IL (-0.3 dB) and THD (-62.9 dB), and faster RT (82 ns) than did the diode-based expander (NF (2.6 dB), IL (-1.4 dB), THD (-56.0 dB) and RT (119 ns)) at 70 MHz. The -6 dB bandwidth and the peak-to-peak voltage of the echo signal received by the transducer using the power MOSFET-based expander improved by 17.4% and 240% compared to the diode-based expander, respectively. The new power MOSFET-based expander was shown to yield lower NF, IL and THD, faster RT and lower ring down than the diode-based expander at the expense of higher dynamic power consumption. (C) 2013 Elsevier B. V. All rights reserved.
C1 [Choi, Hojong] Univ So Calif, NIH Transducer Resource Ctr, Los Angeles, CA USA.
Univ So Calif, Dept Biomed Engn, Los Angeles, CA USA.
RP Choi, HJ (reprint author), Univ So Calif, NIH Transducer Resource Ctr, Los Angeles, CA USA.
EM hojongch@usc.edu
FU National Institute of Health [P41-EB002182]
FX This research was supported by National Institute of Health Grant
#P41-EB002182. The authors thank Mr. Thomas Cummins and Dr. Jay Mung for
their English correction and editing contribution.
NR 37
TC 4
Z9 4
U1 1
U2 31
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0041-624X
J9 ULTRASONICS
JI Ultrasonics
PD JAN
PY 2014
VL 54
IS 1
BP 121
EP 130
DI 10.1016/j.ultras.2013.04.018
PG 10
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA 215XJ
UT WOS:000324244100015
PM 23835308
ER
PT J
AU Kuka, M
Ashwell, JD
AF Kuka, Mirela
Ashwell, Jonathan D.
TI A method for high purity sorting of rare cell subsets applied to T-DC
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE Flow cytometry; Sorting; T-DC; Purification
ID DENDRITIC CELLS; FLOW-CYTOMETRY; IDENTIFICATION; EXPRESSION; VARIANTS;
ZBTB46
AB T-DC are a recently described subset of polyclonal alpha beta T-cells with dendritic cell properties. Because of their low number in peripheral immune compartments, isolation and characterization of T-DC with existing purification methods are technically challenging. Here we describe a customized gating strategy and a flow cytometry-based cell sorting protocol for isolation of T-DC. The protocol was developed because, despite very conservative gating for dead-cell and doublet exclusion, cells obtained with normal sorting procedures were enriched for T-DC but not pure. Re-sorting the output of the first round of sorting results in highly pure T-DC. Cells obtained with this method are viable and can be used for in vitro characterization. Moreover, this double-round sorting strategy can be universally applied to the isolation of other rare cell subsets. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Kuka, Mirela; Ashwell, Jonathan D.] NCI, Lab Immune Cell Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Kuka, M (reprint author), Ist Sci San Raffaele, Div Immunol Transplantat & Infect Dis, Via Olgettina 58, I-20132 Milan, Italy.
EM kuka.mirela@hsr.it; jda@pop.nci.nih.gov
OI KUKA, MIRELA/0000-0001-9418-1559
FU Center for Cancer Research, National Cancer Institute, National
Institutes of Health
FX This work was supported by the Intramural Research Program of the Center
for Cancer Research, National Cancer Institute, National Institutes of
Health. We thank Ivana Munitic, Barbara J. Taylor, and Karen M. Wolcott
for helpful suggestions.
NR 12
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
EI 1872-7905
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD DEC 31
PY 2013
VL 400
SI SI
BP 111
EP 116
DI 10.1016/j.jim.2013.10.002
PG 6
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 287JS
UT WOS:000329538700014
PM 24120843
ER
PT J
AU Gu, S
Cheung, HH
Lee, TL
Lu, G
Poon, WS
Chan, WY
AF Gu, Shen
Cheung, Hoi Hung
Lee, Tin Lap
Lu, Gang
Poon, Wai Sang
Chan, Wai Yee
TI Molecular Mechanisms of Regulation and Action of microRNA-199a in
Testicular Germ Cell Tumor and Glioblastomas
SO PLOS ONE
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA; CANCER CELLS; EXPRESSION; GENES; METHYLATION;
RNAS; IDENTIFICATION; PROLIFERATION; MIR-199A; REVEALS
AB MicroRNA-199a (miRNA-199a) has been shown to have comprehensive functions and behave differently in different systems and diseases. It is encoded by two loci in the human genome, miR-199a-1 in chromosome 19 and miR-199a-2 in chromosome 1. Both loci give rise to the same miRNAs (miR-199a-5p and miR-199a-3p). The cause of the diverse action of the miRNA in different systems is not clear. However, it is likely due to different regulation of the two genomic loci and variable targets of the miRNA in different cells and tissues. Here we studied promoter methylation of miR-199a in testicular germ cell tumors (TGCTs) and glioblastomas (gliomas) and discovered that hypermethylation in TGCTs of both miR-199a-1 and -2 resulted in its reduced expression, while hypomethylation of miR-199a-2 but not -1 in gliomas may be related to its elevated expression. We also identified a common regulator, REST, which preferentially bound to the methylated promoters of both miR-199a-1 and miR-199a-2. The action of miR-199a is dependent on its downstream targets. We identified MAFB as a putative target of miRNA-199a-5p in TGCTs and confirmed that the tumor suppression activity of the microRNA is mediated by its target MAFB. By studying the mechanisms that control the expressions of miR-199a and its various downstream targets, we hope to use miR-199a as a model to understand the complexity of miRNA biology.
C1 [Gu, Shen; Lee, Tin Lap; Lu, Gang; Chan, Wai Yee] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.
[Cheung, Hoi Hung] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Clin & Dev Genom, NIH, Bethesda, MD USA.
[Lu, Gang; Poon, Wai Sang] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
RP Chan, WY (reprint author), Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.
EM chanwy@cuhk.edu.hk
RI Poon, Wai Sang/F-1558-2011; Lee, Tin-Lap/A-7853-2009
OI Lee, Tin-Lap/0000-0002-6654-0988
FU Chinese University of Hong Kong; Vigconic International project fund;
RGC GRF [475910]
FX This study is partially supported by the start-up fund provided to WYC
by the Chinese University of Hong Kong, the Vigconic International
project fund, and RGC GRF No: 475910. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 40
TC 9
Z9 9
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2013
VL 8
IS 12
AR e83980
DI 10.1371/journal.pone.0083980
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 284NF
UT WOS:000329325200154
PM 24391856
ER
PT J
AU de Maturana, EL
Ye, YQ
Calle, ML
Rothman, N
Urrea, V
Kogevinas, M
Petrus, S
Chanock, SJ
Tardon, A
Garcia-Closas, M
Gonzalez-Neira, A
Vellalta, G
Carrato, A
Navarro, A
Lorente-Galdos, B
Silverman, DT
Real, FX
Wu, XF
Malats, N
AF Lopez de Maturana, Evangelina
Ye, Yuanqing
Luz Calle, M.
Rothman, Nathaniel
Urrea, Victor
Kogevinas, Manolis
Petrus, Sandra
Chanock, Stephen J.
Tardon, Adonina
Garcia-Closas, Montserrat
Gonzalez-Neira, Anna
Vellalta, Gemma
Carrato, Alfredo
Navarro, Arcadi
Lorente-Galdos, Belen
Silverman, Debra T.
Real, Francisco X.
Wu, Xifeng
Malats, Nuria
TI Application of Multi-SNP Approaches Bayesian LASSO and AUC-RF to Detect
Main Effects of Inflammatory-Gene Variants Associated with Bladder
Cancer Risk
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; B SIGNALING PATHWAY; SUSCEPTIBILITY LOCI;
COLORECTAL-CANCER; REGRESSION; POLYMORPHISM; SELECTION; MARKERS;
PREDISPOSITION; IDENTIFICATION
AB The relationship between inflammation and cancer is well established in several tumor types, including bladder cancer. We performed an association study between 886 inflammatory-gene variants and bladder cancer risk in 1,047 cases and 988 controls from the Spanish Bladder Cancer (SBC)/EPICURO Study. A preliminary exploration with the widely used univariate logistic regression approach did not identify any significant SNP after correcting for multiple testing. We further applied two more comprehensive methods to capture the complexity of bladder cancer genetic susceptibility: Bayesian Threshold LASSO (BTL), a regularized regression method, and AUC-Random Forest, a machine-learning algorithm. Both approaches explore the joint effect of markers. BTL analysis identified a signature of 37 SNPs in 34 genes showing an association with bladder cancer. AUC-RF detected an optimal predictive subset of 56 SNPs. 13 SNPs were identified by both methods in the total population. Using resources from the Texas Bladder Cancer study we were able to replicate 30% of the SNPs assessed. The associations between inflammatory SNPs and bladder cancer were reexamined among non-smokers to eliminate the effect of tobacco, one of the strongest and most prevalent environmental risk factor for this tumor. A 9 SNP-signature was detected by BTL. Here we report, for the first time, a set of SNP in inflammatory genes jointly associated with bladder cancer risk. These results highlight the importance of the complex structure of genetic susceptibility associated with cancer risk.
C1 [Lopez de Maturana, Evangelina; Petrus, Sandra; Gonzalez-Neira, Anna; Real, Francisco X.; Malats, Nuria] Spanish Natl Canc Res Ctr CNIO, Genet & Mol Epidemiol Grp, Madrid, Spain.
[Ye, Yuanqing; Wu, Xifeng] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
[Luz Calle, M.; Urrea, Victor; Petrus, Sandra] Univ Vic, Dept Syst Biol, Vic, Spain.
[Rothman, Nathaniel; Chanock, Stephen J.; Garcia-Closas, Montserrat; Silverman, Debra T.] NCI, Div Canc Epidemiol & Genet, US Dept HHS, Bethesda, MD 20892 USA.
[Kogevinas, Manolis] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain.
[Kogevinas, Manolis; Vellalta, Gemma] Inst Municipal Invest Med Hosp del Mar, Barcelona, Spain.
[Tardon, Adonina] Univ Oviedo, Oviedo, Spain.
[Carrato, Alfredo] Hosp Univ Elche, Elche, Spain.
[Carrato, Alfredo] Hosp Univ Ramon y Cajal, Madrid, Spain.
[Navarro, Arcadi; Lorente-Galdos, Belen; Real, Francisco X.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain.
[Navarro, Arcadi; Lorente-Galdos, Belen] Inst Biol Evolutiva UPF CSIC, Barcelona, Spain.
[Navarro, Arcadi] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain.
[Navarro, Arcadi; Lorente-Galdos, Belen] Inst Nacl Bioinformat, Barcelona, Spain.
RP Malats, N (reprint author), Spanish Natl Canc Res Ctr CNIO, Genet & Mol Epidemiol Grp, Madrid, Spain.
EM nmalats@cnio.es
RI Navarro, Arcadi/F-1592-2011; Gonzalez-Neira, Anna/C-5791-2015; Calle,
M.Luz/D-2704-2015; Garcia-Closas, Montserrat /F-3871-2015; Malats,
Nuria/H-7041-2015; Real Arribas, Francisco/H-5275-2015; Kogevinas,
Manolis/C-3918-2017;
OI Lorente-Galdos, Belen/0000-0001-5390-2452; Navarro,
Arcadi/0000-0003-2162-8246; Urrea Gales, Victor/0000-0002-2577-856X;
Calle, M.Luz/0000-0001-9334-415X; Garcia-Closas, Montserrat
/0000-0003-1033-2650; Malats, Nuria/0000-0003-2538-3784; Real Arribas,
Francisco/0000-0001-9501-498X; Lopez de Maturana,
Evangelina/0000-0001-9425-3911
FU Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III
[G03/174, 00/0745, PI051436, PI061614, PI09-02102]; Ministry of Science
and Innovation, Spain [MTM2008-06747-C02-02]; AGAUR-Generalitat de
Catalunya [2009SGR-581]; Fundaciola Maratode TV3; Red Tematica de
Investigacion Cooperativa en Cancer (RTICC); Asociacion Espanola Contra
el Cancer (AECC); Spanish National Institute for Bioinformatics;
Division of Cancer Epidemiology and Genetics, National Cancer Institute,
USA; MD Anderson [U01 CA 127615, R01 CA 74880, P50 CA 91846]; Betty B.
Marcus Chair fund in Cancer Prevention; UT Research Trust;
[EU-FP7-201663]; [RO1-CA089715]; [CA34627]; [R01 CA 131335]
FX The work was partially supported by the Fondo de Investigacion
Sanitaria, Instituto de Salud Carlos III (G03/174, 00/0745, PI051436,
PI061614, PI09-02102, G03/174 and Sara Borrell fellowship to ELM) and
Ministry of Science and Innovation (MTM2008-06747-C02-02 and FPU
fellowship award to VU), Spain; AGAUR-Generalitat de Catalunya (Grant
2009SGR-581); Fundaciola Maratode TV3; Red Tematica de Investigacion
Cooperativa en Cancer (RTICC); Asociacion Espanola Contra el Cancer
(AECC); EU-FP7-201663; and RO1-CA089715 and CA34627; the Spanish
National Institute for Bioinformatics (www.inab.org); and by the
Intramural Research Program of the Division of Cancer Epidemiology and
Genetics, National Cancer Institute, USA. MD Anderson support for this
project included U01 CA 127615 (XW); R01 CA 74880 (XW); P50 CA 91846
(XW, CPD); Betty B. Marcus Chair fund in Cancer Prevention (XW); UT
Research Trust fund (XW) and R01 CA 131335 (JG). The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 60
TC 7
Z9 7
U1 2
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2013
VL 8
IS 12
AR e83745
DI 10.1371/journal.pone.0083745
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 284NF
UT WOS:000329325200116
PM 24391818
ER
PT J
AU Polston, JE
Pritchett, CE
Tomasko, JM
Rogers, AM
Leggio, L
Thanos, PK
Volkow, ND
Hajnal, A
AF Polston, James E.
Pritchett, Carolyn E.
Tomasko, Jonathan M.
Rogers, Ann M.
Leggio, Lorenzo
Thanos, Panayotis K.
Volkow, Nora D.
Hajnal, Andras
TI Roux-en-Y Gastric Bypass Increases Intravenous Ethanol
Self-Administration in Dietary Obese Rats
SO PLOS ONE
LA English
DT Article
ID STIMULATES LOCOMOTOR-ACTIVITY; BARIATRIC SURGERY; NUCLEUS-ACCUMBENS;
ALCOHOL METABOLISM; ENERGY-EXPENDITURE; GHRELIN LEVELS; FOOD REWARD;
SWEET TASTE; DOPAMINE; CONSUMPTION
AB Roux-en-Y gastric bypass surgery (RYGB) is an effective treatment for severe obesity. Clinical studies however have reported susceptibility to increased alcohol use after RYGB, and preclinical studies have shown increased alcohol intake in obese rats after RYGB. This could reflect a direct enhancement of alcohol's rewarding effects in the brain or an indirect effect due to increased alcohol absorption after RGYB. To rule out the contribution that changes in alcohol absorption have on its rewarding effects, here we assessed the effects of RYGB on intravenously (IV) administered ethanol (1%). For this purpose, high fat (60% kcal from fat) diet-induced obese male Sprague Dawley rats were tested similar to 2 months after RYGB or sham surgery (SHAM) using both fixed and progressive ratio schedules of reinforcement to evaluate if RGYB modified the reinforcing effects of IV ethanol. Compared to SHAM, RYGB rats made significantly more active spout responses to earn IV ethanol during the fixed ratio schedule, and achieved higher breakpoints during the progressive ratio schedule. Although additional studies are needed, our results provide preliminary evidence that RYGB increases the rewarding effects of alcohol independent of its effects on alcohol absorption.
C1 [Polston, James E.; Pritchett, Carolyn E.; Hajnal, Andras] Penn State Univ, Dept Neural & Behav Sci, Coll Med, Hershey, PA 17033 USA.
[Tomasko, Jonathan M.; Rogers, Ann M.; Hajnal, Andras] Penn State Univ, Dept Surg, Coll Med, Hershey, PA USA.
[Leggio, Lorenzo] NIAAA, Sect Clin Psychoneuroendocrinol & Neuropsychophar, Lab Clin & Translat Studies, NIH, Bethesda, MD USA.
[Leggio, Lorenzo] NIDA, Intramural Res Program, NIH, Baltimore, MD USA.
[Leggio, Lorenzo] Brown Univ, Dept Behav & Social Sci, Providence, RI 02912 USA.
[Thanos, Panayotis K.] SUNY Stony Brook, Dept Psychol, Stony Brook, NY 11794 USA.
[Volkow, Nora D.] NIAAA Intramural Program, Lab Neuroimaging, NIH, Bethesda, MD USA.
RP Hajnal, A (reprint author), Penn State Univ, Dept Neural & Behav Sci, Coll Med, Hershey, PA 17033 USA.
EM ahajnal@psu.edu
RI Leggio, Lorenzo/M-2972-2016;
OI Hajnal, Andras/0000-0001-7297-7134
FU National Institute of Diabetes and Digestive and Kidney Diseases
[DK080899]
FX This research was supported by National Institute of Diabetes and
Digestive and Kidney Diseases Grant DK080899 (to AH). The funder had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 52
TC 11
Z9 11
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2013
VL 8
IS 12
AR e83741
DI 10.1371/journal.pone.0083741
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 284NF
UT WOS:000329325200114
PM 24391816
ER
PT J
AU Qi, LN
Li, LQ
Chen, YY
Chen, ZH
Bai, T
Xiang, BD
Qin, X
Xiao, KY
Peng, MH
Liu, ZM
Liu, TW
Qin, X
Li, S
Han, ZG
Mo, ZN
Santella, RM
Winkler, CA
O'Brien, SJ
Peng, T
AF Qi, Lu-Nan
Li, Le-Qun
Chen, Yuan-Yuan
Chen, Zhao-Hong
Bai, Tao
Xiang, Bang-De
Qin, Xiao
Xiao, Kai-Yin
Peng, Min-Hao
Liu, Zhi-Ming
Liu, Tang-Wei
Qin, Xue
Li, Shan
Han, Ze-Guang
Mo, Zeng-Nan
Santella, Regina M.
Winkler, Cheryl A.
O'Brien, Stephen J.
Peng, Tao
TI Genome-Wide and Differential Proteomic Analysis of Hepatitis B Virus and
Aflatoxin B1 Related Hepatocellular Carcinoma in Guangxi, China
SO PLOS ONE
LA English
DT Article
ID HEAT-SHOCK PROTEINS; LIVER-CANCER; RISK-FACTORS; LUNG-CANCER; DNA
DOMAIN; CELL-DEATH; AKR1B10; EXPRESSION; OVEREXPRESSION; HYBRIDIZATION
AB Both hepatitis B virus (HBV) and aflatoxin B1 (AFB1) exposure can cause liver damage as well as increase the probability of hepatocellular carcinoma (HCC). To investigate the underlying genetic changes that may influence development of HCC associated with HBV infection and AFB1 exposure, HCC patients were subdivided into 4 groups depending upon HBV and AFB1 exposure status: (HBV(+)/AFB1(+), HBV(+)/AFB1(-), HBV(-)/AFB1(+), HBV(-)/AFB1(-)). Genetic abnormalities and protein expression profiles were analyzed by array-based comparative genomic hybridization and isobaric tagging for quantitation. A total of 573 chromosomal aberrations (CNAs) including 184 increased and 389 decreased were detected in our study population. Twenty-five recurrently altered regions (RARs; chromosomal alterations observed in >= 10 patients) in chromosomes were identified. Loss of 4q13.3-q35.2, 13q12.1-q21.2 and gain of 7q11.2-q35 were observed with a higher frequency in the HBV(+)/AFB1(+), HBV(+)/AFB1(-) and HBV(-)/AFB1(+) groups compared to the HBV(-)/AFB(-) group. Loss of 8p12-p23.2 was associated with high TNM stage tumors (P = 0.038) and was an unfavorable prognostic factor for tumor-free survival (P =0.045). A total of 133 differentially expressed proteins were identified in iTRAQ proteomics analysis, 69 (51.8%) of which mapped within identified RARs. The most common biological processes affected by HBV and AFB1 status in HCC tumorigenesis were detoxification and drug metabolism pathways, antigen processing and anti-apoptosis pathways. Expression of AKR1B10 was increased significantly in the HBV(+)/AFB1(+) and HBV(-)/AFB1(+) groups. A significant correlation between the expression of AKR1B10 mRNA and protein levels as well as AKR1B10 copy number was observered, which suggest that AKR1B10 may play a role in AFB1-related hepatocarcinogenesis. In summary, a number of genetic and gene expression alterations were found to be associated with HBV and AFB1- related HCC. The possible synergistic effects of HBV and AFB1 in hepatocarcinogenesis warrant further investigations.
C1 [Qi, Lu-Nan; Li, Le-Qun; Chen, Zhao-Hong; Bai, Tao; Xiang, Bang-De] Guangxi Med Univ, Tumor Hosp, Dept Hepatobiliary Surg, Nanning, Guangxi Provinc, Peoples R China.
[Chen, Yuan-Yuan] Guangxi Med Univ, Affiliated Hosp 1, Dept Ultrasound, Nanning, Guangxi Provinc, Peoples R China.
[Qin, Xiao; Xiao, Kai-Yin; Peng, Min-Hao; Liu, Zhi-Ming; Liu, Tang-Wei; Peng, Tao] Guangxi Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Nanning, Guangxi Provinc, Peoples R China.
[Qin, Xue; Li, Shan] Guangxi Med Univ, Affiliated Hosp 1, Dept Clin Lab, Nanning, Guangxi Provinc, Peoples R China.
[Han, Ze-Guang] China Natl Human Genome Ctr Shanghai, Shanghai, Peoples R China.
[Mo, Zeng-Nan] Guangxi Med Univ, Affiliated Hosp 1, Dept Urol & Nephrol Surg, Nanning, Guangxi Provinc, Peoples R China.
[Santella, Regina M.] Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, New York, NY USA.
[Winkler, Cheryl A.; O'Brien, Stephen J.; Peng, Tao] NCI, Lab Genom Divers, NIH, Frederick, MD 21701 USA.
RP Peng, T (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Nanning, Guangxi Provinc, Peoples R China.
EM pengtaocn@hotmail.com
OI O'Brien, Stephen J./0000-0001-7353-8301
FU National Nature Science Foundation of China [NSFC 81072321, 30960021,
30460143, 30560133]; Program for New Century Excellent Talents in
University (NCET, Chinese Ministry of Educationministry of
educationministry of education); Guangxi Nature Sciences [GKJ 0236030,
0632007-1E, 0640101, GKG 0592007-1A]; Guangxi Health Ministry Medicine
[Z2010108]; USA National Institutes of Health [ES05116, ES09089]
FX This work was supported in part by the National Nature Science
Foundation of China (NSFC 81072321, 30960021, 30460143, and 30560133),
Program for New Century Excellent Talents in University (NCET, 2009
Chinese Ministry of Educationministry of educationministry of
education), Guangxi Nature Sciences Grant (GKJ 0236030,0632007-1E,
0640101, GKG 0592007-1A), Guangxi Health Ministry Medicine Grant
(Z2010108), and the USA National Institutes of Health Grants (ES05116
and ES09089). The authors thank Ms. Li Guan and Yu-Chun Zhou (Laboratory
of Genomic Diversity, National Cancer Institute at Frederick, USA) and
Mr. Li Jia Quan (Laboratory Center, GMU, China) for their laboratory
assistance. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 49
TC 8
Z9 8
U1 2
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2013
VL 8
IS 12
AR e83465
DI 10.1371/journal.pone.0083465
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 284NF
UT WOS:000329325200068
PM 24391771
ER
PT J
AU Renner, LD
Eswaramoorthy, P
Ramamurthi, KS
Weibel, DB
AF Renner, Lars D.
Eswaramoorthy, Prahathees
Ramamurthi, Kumaran S.
Weibel, Douglas B.
TI Studying Biomolecule Localization by Engineering Bacterial Cell Wall
Curvature
SO PLOS ONE
LA English
DT Article
ID LIQUID-CRYSTALLINE DROPLETS; ESCHERICHIA-COLI; BACILLUS-SUBTILIS;
PROTEIN LOCALIZATION; MEMBRANE CURVATURE; ACTIN MREB; SHAPE;
CARDIOLIPIN; PEPTIDOGLYCAN; CYTOSKELETON
AB In this article we describe two techniques for exploring the relationship between bacterial cell shape and the intracellular organization of proteins. First, we created microchannels in a layer of agarose to reshape live bacterial cells and predictably control their mean cell wall curvature, and quantified the influence of curvature on the localization and distribution of proteins in vivo. Second, we used agarose microchambers to reshape bacteria whose cell wall had been chemically and enzymatically removed. By combining microstructures with different geometries and fluorescence microscopy, we determined the relationship between bacterial shape and the localization for two different membrane-associated proteins: i) the cell-shape related protein MreB of Escherichia coli, which is positioned along the long axis of the rod-shaped cell; and ii) the negative curvature-sensing cell division protein DivIVA of Bacillus subtilis, which is positioned primarily at cell division sites. Our studies of intracellular organization in live cells of E. coli and B. subtilis demonstrate that MreB is largely excluded from areas of high negative curvature, whereas DivIVA localizes preferentially to regions of high negative curvature. These studies highlight a unique approach for studying the relationship between cell shape and intracellular organization in intact, live bacteria.
C1 [Renner, Lars D.; Weibel, Douglas B.] Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA.
[Renner, Lars D.] Tech Univ Dresden, D-01062 Dresden, Germany.
[Renner, Lars D.] Max Bergmann Ctr Biomat, Dresden, Germany.
[Eswaramoorthy, Prahathees; Ramamurthi, Kumaran S.] NCI, NIH, Bethesda, MD 20892 USA.
[Weibel, Douglas B.] Univ Wisconsin, Dept Biomed Engn, Madison, WI USA.
RP Weibel, DB (reprint author), Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53705 USA.
EM weibel@biochem.wisc.edu
RI Renner, Lars/D-6291-2012; Ramamurthi, Kumaran/P-3516-2015
OI Renner, Lars/0000-0003-0178-1788;
FU National Science Foundation [DMR-1121288]; National Institutes of Health
[1DP2OD008735-01]; Intramural Research Program of the NIH, National
Cancer Institute, Center for Cancer Research; University of Wisconsin
Materials Research Science and Engineering Center [DMR-1121288]; DFG;
Alfred P. Sloan Foundation
FX This research was funded by the National Science Foundation
(DMR-1121288; L. D. R., D. B. W.,
http://www.nsf.gov/mps/dmr/highlights.jsp), the National Institutes of
Health (1DP2OD008735-01; L. D. R., D. B. W., http://www.nih.gov/), and
the Intramural Research Program of the NIH, National Cancer Institute,
Center for Cancer Research (K. S. R. and P. E., http://www.nih.gov/).
The authors gratefully acknowledge use of facilities and instrumentation
supported by the University of Wisconsin Materials Research Science and
Engineering Center (DMR-1121288, http://mrsec.wisc.edu/), and
acknowledge support from a DFG Postdoctoral Fellowship (to L. D. R.,
http://www.dfg.de/) and an Alfred P. Sloan Foundation Fellowship (to D.
B. W., http://www.sloan.org/sloan-research-fellowships/). The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 55
TC 8
Z9 8
U1 0
U2 34
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2013
VL 8
IS 12
AR e84143
DI 10.1371/journal.pone.0084143
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 284MV
UT WOS:000329323900048
PM 24391905
ER
PT J
AU Wang, Y
Goh, JO
Resnick, SM
Davatzikos, C
AF Wang, Ying
Goh, Joshua O.
Resnick, Susan M.
Davatzikos, Christos
TI Imaging-Based Biomarkers of Cognitive Performance in Older Adults
Constructed via High- Dimensional Pattern Regression Applied to MRI and
PET
SO PLOS ONE
LA English
DT Article
ID FMRI TIME-SERIES; ALZHEIMERS-DISEASE; MEMORY; BRAIN; AGE;
CLASSIFICATION; IMPAIRMENT; DIAGNOSIS; MACHINE; SEGMENTATION
AB In this study, we used high-dimensional pattern regression methods based on structural (gray and white matter; GM and WM) and functional (positron emission tomography of regional cerebral blood flow; PET) brain data to identify cross-sectional imaging biomarkers of cognitive performance in cognitively normal older adults from the Baltimore Longitudinal Study of Aging (BLSA). We focused on specific components of executive and memory domains known to decline with aging, including manipulation, semantic retrieval, long-term memory (LTM), and short-term memory (STM). For each imaging modality, brain regions associated with each cognitive domain were generated by adaptive regional clustering. A relevance vector machine was adopted to model the nonlinear continuous relationship between brain regions and cognitive performance, with cross-validation to select the most informative brain regions (using recursive feature elimination) as imaging biomarkers and optimize model parameters. Predicted cognitive scores using our regression algorithm based on the resulting brain regions correlated well with actual performance. Also, regression models obtained using combined GM, WM, and PET imaging modalities outperformed models based on single modalities. Imaging biomarkers related to memory performance included the orbito-frontal and medial temporal cortical regions with LTM showing stronger correlation with the temporal lobe than STM. Brain regions predicting executive performance included orbito-frontal, and occipito-temporal areas. The PET modality had higher contribution to most cognitive domains except manipulation, which had higher WM contribution from the superior longitudinal fasciculus and the genu of the corpus callosum. These findings based on machine-learning methods demonstrate the importance of combining structural and functional imaging data in understanding complex cognitive mechanisms and also their potential usage as biomarkers that predict cognitive status.
C1 [Wang, Ying; Davatzikos, Christos] Univ Penn, Dept Radiol, Sect Biomed Image Anal, Philadelphia, PA 19104 USA.
[Goh, Joshua O.; Resnick, Susan M.] NIA, Lab Behav Neurosci, Baltimore, MD 21224 USA.
[Goh, Joshua O.] Natl Taiwan Univ, Coll Med, Grad Inst Brain & Mind Sci, Taipei 10764, Taiwan.
RP Wang, Y (reprint author), Univ Penn, Dept Radiol, Sect Biomed Image Anal, Philadelphia, PA 19104 USA.
EM ying.wang@uphs.upenn.edu
RI GOH, JOSHUA/C-8063-2016
OI GOH, JOSHUA/0000-0001-7808-5452
FU National Institutes of Health (NIH) [R01AG14971]; Intramural Research
Program, National Institute on Aging, NIH; [N01-AG-3-124]
FX This work was supported by the National Institutes of Health (NIH) grant
R01AG14971, by N01-AG-3-124, and by the Intramural Research Program,
National Institute on Aging, NIH. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 58
TC 2
Z9 2
U1 2
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 31
PY 2013
VL 8
IS 12
AR UNSP e85460
DI 10.1371/journal.pone.0085460
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 284MV
UT WOS:000329323900154
PM 24392010
ER
PT J
AU Bosch, FX
Broker, TR
Forman, D
Moscicki, AB
Gillison, ML
Doorbar, J
Stern, PL
Stanley, M
Arbyn, M
Poljak, M
Cuzick, J
Castle, PE
Schiller, JT
Markowitz, LE
Fisher, WA
Canfell, K
Denny, LA
Franco, EL
Steben, M
Kane, MA
Schiffman, M
Meijer, CJLM
Sankaranarayanan, R
Castellsague, X
Kim, JJ
Brotons, M
Alemany, L
Albero, G
Diaz, M
de Sanjose, S
AF Xavier Bosch, F.
Broker, Thomas R.
Forman, David
Moscicki, Anna-Barbara
Gillison, Maura L.
Doorbar, John
Stern, Peter L.
Stanley, Margaret
Arbyn, Marc
Poljak, Mario
Cuzick, Jack
Castle, Philip E.
Schiller, John T.
Markowitz, Lauri E.
Fisher, William A.
Canfell, Karen
Denny, Lynette A.
Franco, Eduardo L.
Steben, Marc
Kane, Mark A.
Schiffman, Mark
Meijer, Chris J. L. M.
Sankaranarayanan, Rengaswamy
Castellsague, Xavier
Kim, Jane J.
Brotons, Maria
Alemany, Laia
Albero, Ginesa
Diaz, Mireia
de Sanjose, Silvia
CA ICO Monograph 'Comprehensive Conto
TI Comprehensive Control of Human Papillomavirus Infections and Related
Diseases
SO VACCINE
LA English
DT Review
DE HPV; Cervical cancer; Anal cancer; Penile cancer; Vaginal cancer
ID CERVICAL-CANCER; PREVENTION; COUNTRIES; VACCINES; WORLD
AB Infection with human papillomavirus (HPV) is recognized as one of the major causes of infection-related cancer worldwide, as well as the causal factor in other diseases. Strong evidence for a causal etiology with HPV has been stated by the International Agency for Research on Cancer for cancers of the cervix uteri, penis, vulva, vagina, anus and oropharynx (including base of the tongue and tonsils). Of the estimated 12.7 million new cancers occurring in 2008 worldwide, 4.8% were attributable to HPV infection, with substantially higher incidence and mortality rates seen in developing versus developed countries. In recent years, we have gained tremendous knowledge about HPVs and their interactions with host cells, tissues and the immune system; have validated and implemented strategies for safe and efficacious prophylactic vaccination against HPV infections; have developed increasingly sensitive and specific molecular diagnostic tools for HPV detection for use in cervical cancer screening; and have substantially increased global awareness of HPV and its many associated diseases in women, men, and children. While these achievements exemplify the success of biomedical research in generating important public health interventions, they also generate new and daunting challenges: costs of HPV prevention and medical care, the implementation of what is technically possible, socio-political resistance to prevention opportunities, and the very wide ranges of national economic capabilities and health care systems. Gains and challenges faced in the quest for comprehensive control of HPV infection and HPV-related cancers and other disease are summarized in this review. The information presented may be viewed in terms of a reframed paradigm of prevention of cervical cancer and other HPV-related diseases that will include strategic combinations of at least four major components: 1) routine introduction of HPV vaccines to women in all countries, 2) extension and simplification of existing screening programs using HPV-based technology, 3) extension of adapted screening programs to developing populations, and 4) consideration of the broader spectrum of cancers and other diseases preventable by HPV vaccination in women, as well as in men. Despite the huge advances already achieved, there must be ongoing efforts including international advocacy to achieve widespread optimally universal implementation of HPV prevention strategies in both developed and developing countries.
This article summarizes information from the chapters presented in a special ICO Monograph 'Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012. Additional details on each subtopic and full information regarding the supporting literature references may be found in the original chapters. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Xavier Bosch, F.; Castellsague, Xavier; Brotons, Maria; Alemany, Laia; Albero, Ginesa; Diaz, Mireia; de Sanjose, Silvia] IDIBELL, Catalan Inst Oncol, Canc Epidemiol Res Program, Lhospitalet De Llobregat, Barcelona, Spain.
[Broker, Thomas R.] Univ Alabama Birmingham, Birmingham, AL USA.
[Forman, David] Int Agcy Res Canc, Sect Canc Informat, F-69372 Lyon, France.
[Moscicki, Anna-Barbara] Univ Calif San Francisco, Dept Pediat, Div Adolescent Med, San Francisco, CA USA.
[Gillison, Maura L.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Doorbar, John] Natl Inst Med Res, Div Virol, London NW7 1AA, England.
[Stern, Peter L.] Univ Manchester, Paterson Inst Canc Res, Manchester, Lancs, England.
[Stanley, Margaret] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England.
[Arbyn, Marc] Sci Inst Publ Hlth, Canc Epidemiol Unit, Brussels, Belgium.
[Arbyn, Marc] Univ Antwerp, Lab Cell Biol & Histol, B-2020 Antwerp, Belgium.
[Poljak, Mario] Univ Ljubljana, Fac Med, Inst Microbiol & Immunol, Ljubljana, Slovenia.
[Cuzick, Jack] Queen Mary Univ London, Wolfson Inst Prevent Med, London, England.
[Castle, Philip E.] Global Canc Initiat, Chestertown, MD USA.
[Schiller, John T.] NCI, Ctr Canc Res, Bethesda, MD 20892 USA.
[Markowitz, Lauri E.] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA.
[Fisher, William A.] Univ Western Ontario, Dept Psychol, Social Sci Ctr 7428, London, ON, Canada.
[Fisher, William A.] Univ Western Ontario, Dept Obstet & Gynaecol, Social Sci Ctr 7428, London, ON, Canada.
[Canfell, Karen] Univ NSW, Prince Wales Clin Sch, Lowy Canc Res Ctr, Newcastle, NSW, Australia.
[Canfell, Karen] NSW Canc Council, Canc Epidemiol Res Unit, Sydney, NSW, Australia.
[Denny, Lynette A.] Univ Cape Town, Groote Schuur Hosp, Dept Obstet & Gynaecol, ZA-7925 Cape Town, South Africa.
[Denny, Lynette A.] Univ Cape Town, Groote Schuur Hosp, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
[Franco, Eduardo L.] McGill Univ, Div Canc Epidemiol, Montreal, PQ, Canada.
[Steben, Marc] Inst Natl Sante Publ Quebec, Montreal, PQ, Canada.
[Kane, Mark A.] Consultant Immunizat Policy, Mercer Isl, WA USA.
[Schiffman, Mark] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Meijer, Chris J. L. M.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands.
[Sankaranarayanan, Rengaswamy] Int Agcy Res Canc, Screening Grp, F-69372 Lyon, France.
[Castellsague, Xavier; Alemany, Laia; Albero, Ginesa; de Sanjose, Silvia] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain.
[Kim, Jane J.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA 02115 USA.
RP Bosch, FX (reprint author), IDIBELL, Catalan Inst Oncol, Canc Epidemiol Res Program, Lhospitalet De Llobregat, Barcelona, Spain.
EM admincerp@iconcologia.net
RI Albero, Ginesa/G-7248-2015; de Sanjose Llongueras, Silvia/H-6339-2014;
Bruni, Laia/N-5816-2014; BOSCH JOSE, FRANCESC XAVIER/J-6339-2012;
Castellsague Pique, Xavier/N-5795-2014; DIAZ SANCHIS,
MIREIA/H-6335-2014;
OI Bruni, Laia/0000-0003-3943-0326; Albero, Ginesa/0000-0002-9400-1914;
Kjaer, Susanne/0000-0002-8347-1398; BOSCH JOSE, FRANCESC
XAVIER/0000-0002-7172-3412; Castellsague Pique,
Xavier/0000-0002-0802-3595; Franco, Eduardo/0000-0002-4409-8084
FU European Commission [HEALTH-F3-2010-242061, HEALTH-F2-2011-282562,
242061]; Instituto de Salud Carlos III (Spanish Government) [FIS
PI08/1535, FIS PI10/02995, FIS PI11/02090, FIS PI11/02096, FIS
PI11/02104, RCESP C03/09, RTICESP C03/10, RTIC RD06/0020/0095,
RD12/0036/0056, CIBERESP]; Agencia de Gestio d'Ajuts Universitaris i de
Recerca Generalitat de Catalunya (Catalonian Government) [AGAUR
2005SGR00695, AGAUR 2009SGR126]; USPHS/NIH/National Cancer Institute
[CA36200, CA83679]; US Public Health Service (National Cancer Institute,
National Institutes of Health, Department of Health and Human Services)
[R37 CA51323]; National Institute of AIDS and Infectious Disease [RC1
AI86051]; UK Medical Research Council [MC_U117584278]; Belgian
Foundation Against Cancer (Brussels, Belgium); International Agency for
Research on Cancer (Lyon, France); Cancer Research UK [A10404]; National
Health and Medical Research Council, Australia [CDF APP1007994,
1007518]; Bill and Melinda Gates Foundation, USA [35537]; U.S. National
Cancer Institute [U54 CA164336, R01 CA160744-01A1]; Bill and Melinda
Gates Foundation [30505]; Cancer Council NSW, Australia
FX The work was partially supported by public grants from the European
Commission (7th Framework Programme grants HEALTH-F3-2010-242061,
PREHDICT and HEALTH-F2-2011-282562, HPV AHEAD), from the Instituto de
Salud Carlos III (Spanish Government) (grants FIS PI08/1535, FIS
PI10/02995, FIS PI11/02090, FIS PI11/02096, FIS PI11/02104, RCESP
C03/09, RTICESP C03/10, RTIC RD06/0020/0095, RD12/0036/0056 and
CIBERESP) and from the Agencia de Gestio d'Ajuts Universitaris i de
Recerca Generalitat de Catalunya (Catalonian Government) (grants AGAUR
2005SGR00695 and AGAUR 2009SGR126), who had no role in data collection,
analysis or interpretation of results. Thomas R. Broker receives
research support from the USPHS/NIH/National Cancer Institute (grants
"Human Papillomavirus Gene Expression" CA36200 and "Mechanisms of Human
Papillomavirus DNA Replication" CA83679). Anna-Barbara Moscicki's work
is supported by US Public Health Service grant R37 CA51323 (National
Cancer Institute, National Institutes of Health, Department of Health
and Human Services) and National Institute of AIDS and Infectious
Disease RC1 AI86051. John Doorbar is funded by the UK Medical Research
Council through program grant MC_U117584278 (Molecular Biology of Human
Papillomavirus Infection). Marc Arbyn received financial support from:
(1) the 7th Framework Programme of DG Research of the European
Commission through the PREHDICT project (grant No. 242061, coordinated
by the Vrije Universiteit Amsterdam, the Netherlands) and through the
HPV AHEAD Network (FP7-HEALTH-2011-282562); (2) the Belgian Foundation
Against Cancer (Brussels, Belgium); and (3) the International Agency for
Research on Cancer (Lyon, France). Jack Cuzick was supported in part by
Cancer Research UK programme grant A10404. Karen Canfell is supported by
grants from the National Health and Medical Research Council, Australia
(CDF APP1007994 and Project Grant #1007518), by non-commercial
government and academic consulting agreements in Australia, New Zealand
and the UK, and by Cancer Council NSW, Australia. Lynette A. Denny was
partially supported by Bill and Melinda Gates Foundation, USA (35537).
The work of Chris J.L.M. Meijer received support via the 7th Framework
Programme of DG Research of the European commission through the PREHDICT
project (grant 242061, coordinated via the Vrije Universiteit
Amsterdam). Jane J. Kim is supported in part by grants from the U.S.
National Cancer Institute (U54 CA164336, R01 CA160744-01A1) and the Bill
and Melinda Gates Foundation (30505) for modeling of HPV and cervical
cancer in developing countries.
NR 20
TC 15
Z9 20
U1 9
U2 43
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD DEC 31
PY 2013
VL 31
SU 7
BP H1
EP H31
DI 10.1016/j.vaccine.2013.10.003
PG 31
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 288HM
UT WOS:000329602600003
PM 24332295
ER
PT J
AU Desrosiers, M
DeWerd, L
Deye, J
Lindsay, P
Murphy, MK
Mitch, M
Macchiarini, F
Stojadinovic, S
Stone, H
AF Desrosiers, Marc
DeWerd, Larry
Deye, James
Lindsay, Patricia
Murphy, Mark K.
Mitch, Michael
Macchiarini, Francesca
Stojadinovic, Strahinja
Stone, Helen
TI The Importance of Dosimetry Standardization in Radiobiology
SO JOURNAL OF RESEARCH OF THE NATIONAL INSTITUTE OF STANDARDS AND
TECHNOLOGY
LA English
DT Article
DE dosimetry; dosimetry protocols; dosimetry standards; radiobiology;
radiobiology protocols; radiobiology standards
ID RADIOTHERAPY; PROTOCOL; PHOTON; ENERGY
AB Radiation dose is central to much of radiobiological research. Precision and accuracy of dose measurements and reporting of the measurement details should be sufficient to allow the work to be interpreted and repeated and to allow valid comparisons to be made, both in the same laboratory and by other laboratories. Despite this, a careful reading of published manuscripts suggests that measurement and reporting of radiation dosimetry and setup for radiobiology research is frequently inadequate, thus undermining the reliability and reproducibility of the findings. To address these problems and propose a course of action, the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Diseases (NIAID), and the National Institute of Standards and Technology (NIST) brought together representatives of the radiobiology and radiation physics communities in a workshop in September, 2011. The workshop participants arrived at a number of specific recommendations as enumerated in this paper and they expressed the desirability of creating dosimetry standard operating procedures (SOPs) for cell culture and for small and large animal experiments. It was also felt that these SOPs would be most useful if they are made widely available through mechanism(s) such as the web, where they can provide guidance to both radiobiologists and radiation physicists, be cited in publications, and be updated as the field and needs evolve. Other broad areas covered were the need for continuing education through tutorials at national conferences, and for journals to establish standards for reporting dosimetry. This workshop did not address issues of dosimetry for studies involving radiation focused at the sub-cellular level, internally-administered radionuclides, biodosimetry based on biological markers of radiation exposure, or dose reconstruction for epidemiological studies.
C1 [Desrosiers, Marc; Mitch, Michael] NIST, Gaithersburg, MD 20899 USA.
[DeWerd, Larry] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
[Deye, James; Stone, Helen] NCI, NIH, Bethesda, MD 20892 USA.
[Lindsay, Patricia] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada.
[Murphy, Mark K.] Battelle Pacific Northwest Natl Lab, Richland, WA USA.
[Macchiarini, Francesca] Natl Inst Allergy & Infect Dis, NIH, Bethesda, MD USA.
[Stojadinovic, Strahinja] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
RP Desrosiers, M (reprint author), NIST, Gaithersburg, MD 20899 USA.
EM marc.desrosiers@nist.gov; ladewerd@facstaff.wisc.edu;
deyej@mail.nih.gov; Patricia.Lindsay@rmp.uhn.on.ca;
michael.mitch@nist.gov; michael.mitch@nist.gov;
fmacchiarini@niaid.nih.gov; Strahinja.Stojadinovic@UTSouthwestern.edu;
stoneh@mail.nih.gov
NR 16
TC 7
Z9 7
U1 1
U2 7
PU US GOVERNMENT PRINTING OFFICE
PI WASHINGTON
PA SUPERINTENDENT DOCUMENTS,, WASHINGTON, DC 20402-9325 USA
SN 1044-677X
J9 J RES NATL INST STAN
JI J. Res. Natl. Inst. Stand. Technol.
PD DEC 30
PY 2013
VL 118
DI 10.6028/jres.118.021
PG 16
WC Instruments & Instrumentation; Physics, Applied
SC Instruments & Instrumentation; Physics
GA 289TC
UT WOS:000329704000001
PM 26401441
ER
PT J
AU Bosch, FX
Broker, TR
Forman, D
Moscicki, AB
Gillison, ML
Doorbar, J
Stern, PL
Stanley, M
Arbyn, M
Poljak, M
Cuzick, J
Castle, PE
Schiller, JT
Markowitz, LE
Fisher, WA
Canfell, K
Denny, LA
Franco, EL
Steben, M
Kane, MA
Schiffman, M
Meijer, CJLM
Sankaranarayanan, R
Castellsague, X
Kim, JJ
Brotons, M
Alemany, L
Albero, G
Diaz, M
de Sanjose, S
AF Xavier Bosch, F.
Broker, Thomas R.
Forman, David
Moscicki, Anna-Barbara
Gillison, Maura L.
Doorbar, John
Stern, Peter L.
Stanley, Margaret
Arbyn, Marc
Poljak, Mario
Cuzick, Jack
Castle, Philip E.
Schiller, John T.
Markowitz, Lauri E.
Fisher, William A.
Canfell, Karen
Denny, Lynette A.
Franco, Eduardo L.
Steben, Marc
Kane, Mark A.
Schiffman, Mark
Meijer, Chris J. L. M.
Sankaranarayanan, Rengaswamy
Castellsague, Xavier
Kim, Jane J.
Brotons, Maria
Alemany, Laia
Albero, Ginesa
Diaz, Mireia
de Sanjose, Silvia
CA ICO Monograph 'Comprehensive Contr
TI Comprehensive Control of Human Papillomavirus Infections and Related
Diseases
SO VACCINE
LA English
DT Review
DE HPV; Cervical cancer; Anal cancer; Penile cancer; Vaginal cancer; Vulvar
cancer; Oropharyngeal cancer; Screening; HPV vaccination; HPV testing;
Prevention
ID CERVICAL-CANCER; PREVENTION; COUNTRIES; VACCINES; WORLD
AB Infection with human papillomavirus (HPV) is recognized as one of the major causes of infection-related cancer worldwide, as well as the causal factor in other diseases. Strong evidence for a causal etiology with HPV has been stated by the International Agency for Research on Cancer for cancers of the cervix uteri, penis, vulva, vagina, anus and oropharynx (including base of the tongue and tonsils). Of the estimated 12.7 million new cancers occurring in 2008 worldwide, 4.8% were attributable to HPV infection, with substantially higher incidence and mortality rates seen in developing versus developed countries. In recent years, we have gained tremendous knowledge about HPVs and their interactions with host cells, tissues and the immune system; have validated and implemented strategies for safe and efficacious prophylactic vaccination against HPV infections; have developed increasingly sensitive and specific molecular diagnostic tools for HPV detection for use in cervical cancer screening; and have substantially increased global awareness of HPV and its many associated diseases in women, men, and children. While these achievements exemplify the success of biomedical research in generating important public health interventions, they also generate new and daunting challenges: costs of HPV prevention and medical care, the implementation of what is technically possible, socio-political resistance to prevention opportunities, and the very wide ranges of national economic capabilities and health care systems. Gains and challenges faced in the quest for comprehensive control of HPV infection and HPV-related cancers and other disease are summarized in this review. The information presented may be viewed in terms of a reframed paradigm of prevention of cervical cancer and other HPV-related diseases that will include strategic combinations of at least four major components: 1) routine introduction of HPV vaccines to women in all countries, 2) extension and simplification of existing screening programs using HPV-based technology, 3) extension of adapted screening programs to developing populations, and 4) consideration of the broader spectrum of cancers and other diseases preventable by HPV vaccination in women, as well as in men. Despite the huge advances already achieved, there must be ongoing efforts including international advocacy to achieve widespread-optimally universal-implementation of HPV prevention strategies in both developed and developing countries.
This article summarizes information from the chapters presented in a special ICO Monograph 'Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012. Additional details on each subtopic and full information regarding the supporting literature references may be found in the original chapters. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Xavier Bosch, F.; Castellsague, Xavier; Kim, Jane J.; Brotons, Maria; Alemany, Laia; Albero, Ginesa; Diaz, Mireia; de Sanjose, Silvia] IDIBELL, Catalan Inst Oncol ICO, Canc Epidemiol Res Program, Lhospitalet De Llobregat, Barcelona, Spain.
[Broker, Thomas R.] Univ Alabama Birmingham, Birmingham, AL USA.
[Forman, David] Int Agcy Res Canc, Sect Canc Informat, F-69372 Lyon, France.
[Moscicki, Anna-Barbara] Univ Calif San Francisco, Dept Pediat, Div Adolescent Med, San Francisco, CA USA.
[Gillison, Maura L.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA.
[Doorbar, John] Natl Inst Med Res, Div Virol, London NW7 1AA, England.
[Stern, Peter L.] Univ Manchester, Paterson Inst Canc Res, Manchester, Lancs, England.
[Stanley, Margaret] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England.
[Arbyn, Marc] Sci Inst Publ Hlth, Canc Epidemiol Unit, Brussels, Belgium.
[Arbyn, Marc] Univ Antwerp, Lab Cell Biol & Histol, B-2020 Antwerp, Belgium.
[Poljak, Mario] Univ Ljubljana, Fac Med, Inst Microbiol & Immunol, Ljubljana, Slovenia.
[Cuzick, Jack] Queen Mary Univ London, Wolfson Inst Prevent Med, London, England.
[Castle, Philip E.] Global Canc Initiat, Chestertown, MD USA.
[Schiller, John T.] NCI, Ctr Canc Res, Bethesda, MD 20892 USA.
[Markowitz, Lauri E.] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA.
[Fisher, William A.] Univ Western Ontario, Dept Psychol, Social Sci Ctr, London, ON, Canada.
[Fisher, William A.] Univ Western Ontario, Dept Obstet & Gynaecol, Social Sci Ctr, London, ON, Canada.
[Canfell, Karen] Univ NSW, Prince Wales Clin Sch, Lowy Canc Res Ctr, Sydney, NSW, Australia.
[Canfell, Karen] NSW Canc Council, Canc Epidemiol Res Unit, Sydney, NSW, Australia.
[Denny, Lynette A.] Univ Cape Town, Groote Schuur Hosp, Dept Obstet & Gynaecol, ZA-7925 Cape Town, South Africa.
[Denny, Lynette A.] Univ Cape Town, Groote Schuur Hosp, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
[Franco, Eduardo L.] McGill Univ, Div Canc Epidemiol, Montreal, PQ, Canada.
[Steben, Marc] Inst Natl Sante Publ Quebec, Montreal, PQ, Canada.
[Kane, Mark A.] Consultant Immunizat Policy, Mercer Isl, WA USA.
[Schiffman, Mark] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Meijer, Chris J. L. M.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands.
[Sankaranarayanan, Rengaswamy] Int Agcy Res Canc, Screening Grp, F-69372 Lyon, France.
[Castellsague, Xavier; Alemany, Laia; Albero, Ginesa; de Sanjose, Silvia] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain.
[Kim, Jane J.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA 02115 USA.
RP Bosch, FX (reprint author), IDIBELL, Catalan Inst Oncol ICO, Canc Epidemiol Res Program, Lhospitalet De Llobregat, Barcelona, Spain.
EM admincerp@iconcologia.net
RI de Sanjose Llongueras, Silvia/H-6339-2014; Bruni, Laia/N-5816-2014;
BOSCH JOSE, FRANCESC XAVIER/J-6339-2012; Castellsague Pique,
Xavier/N-5795-2014; DIAZ SANCHIS, MIREIA/H-6335-2014; Albero,
Ginesa/G-7248-2015;
OI BOSCH JOSE, FRANCESC XAVIER/0000-0002-7172-3412; Castellsague Pique,
Xavier/0000-0002-0802-3595; Albero, Ginesa/0000-0002-9400-1914; Kjaer,
Susanne/0000-0002-8347-1398; Bruni, Laia/0000-0003-3943-0326; Franco,
Eduardo/0000-0002-4409-8084
FU European Commission [HEALTH-F3-2010-242061, HEALTH-F2-2011-282562];
Instituto de Salud Carlos III (Spanish Government) [FIS PI08/1535, FIS
PI10/02995, FIS PI11/02090, FIS PI11/02096, FIS PI11/02104, RCESP
C03/09, RTICESP C03/10, RTIC RD06/0020/0095, RD12/0036/0056, CIBERESP];
Agencia de Gestio d'Ajuts Universitaris i de Recerca - Generalitat de
Catalunya (Catalonian Government) [AGAUR 2005SGR00695, AGAUR
2009SGR126]; USPHS/NIH/National Cancer Institute [CA36200, CA83679]; US
Public Health Service grant (National Cancer Institute, National
Institutes of Health, Department of Health and Human Services) [R37
CA51323]; National Institute of AIDS and Infectious Disease [RC1
AI86051]; UK Medical Research Council [MC_U117584278]; European
Commission through the PREHDICT project [242061]; European Commission
through HPV AHEAD Network [FP7-HEALTH-2011-282562]; Belgian Foundation
Against Cancer (Brussels, Belgium); International Agency for Research on
Cancer (Lyon, France); Cancer Research UK [A10404]; National Health and
Medical Research Council, Australia [CDF APP1007994, 1007518]; Cancer
Council NSW, Australia; Bill and Melinda Gates Foundation, USA [35537];
U.S. National Cancer Institute [U54 CA164336, R01 CA160744-01A1]; Bill
and Melinda Gates Foundation [30505]
FX The work was partially supported by public grants from the European
Commission (7th Framework Programme grants HEALTH-F3-2010-242061,
PREHDICT and HEALTH-F2-2011-282562, HPV AHEAD), from the Instituto de
Salud Carlos III (Spanish Government) (grants FIS PI08/1535, FIS
PI10/02995, FIS PI11/02090, FIS PI11/02096, FIS PI11/02104, RCESP
C03/09, RTICESP C03/10, RTIC RD06/0020/0095, RD12/0036/0056 and
CIBERESP) and from the Agencia de Gestio d'Ajuts Universitaris i de
Recerca - Generalitat de Catalunya (Catalonian Government) (grants AGAUR
2005SGR00695 and AGAUR 2009SGR126), who had no role in data collection,
analysis or interpretation of results. Thomas R. Broker receives
research support from the USPHS/NIH/National Cancer Institute (grants
"Human Papillomavirus Gene Expression" CA36200 and "Mechanisms of Human
Papillomavirus DNA Replication" CA83679). Anna-Barbara Moscicki's work
is supported by US Public Health Service grant R37 CA51323 (National
Cancer Institute, National Institutes of Health, Department of Health
and Human Services) and National Institute of AIDS and Infectious
Disease RC1 AI86051. John Doorbar is funded by the UK Medical Research
Council through program grant MC_U117584278 (Molecular Biology of Human
Papillomavirus Infection). Marc Arbyn received financial support from:
(1) the 7th Framework Programme of DG Research of the European
Commission through the PREHDICT project (grant No. 242061, coordinated
by the Vrije Universiteit Amsterdam, the Netherlands) and through the
HPV AHEAD Network (FP7-HEALTH-2011-282562); (2) the Belgian Foundation
Against Cancer (Brussels, Belgium); and (3) the International Agency for
Research on Cancer (Lyon, France). Jack Cuzick was supported in part by
Cancer Research UK programme grant A10404. Karen Canfell is supported by
grants from the National Health and Medical Research Council, Australia
(CDF APP1007994 and Project Grant #1007518), by non-commercial
government and academic consulting agreements in Australia, New Zealand
and the UK, and by Cancer Council NSW, Australia. Lynette A. Denny was
partially supported by Bill and Melinda Gates Foundation, USA (35537).
The work of Chris J.L.M. Meijer received support via the 7th Framework
Programme of DG Research of the European commission through the PREHDICT
project (grant 242061, coordinated via the Vrije Universiteit
Amsterdam). Jane J. Kim is supported in part by grants from the U.S.
National Cancer Institute (U54 CA164336, R01 CA160744-01A1) and the Bill
and Melinda Gates Foundation (30505) for modeling of HPV and cervical
cancer in developing countries.
NR 20
TC 0
Z9 1
U1 1
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD DEC 30
PY 2013
VL 31
SU 6
BP G1
EP G31
DI 10.1016/j.vaccine.2013.10.002
PG 31
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 289LR
UT WOS:000329684500003
PM 24331817
ER
PT J
AU Peer, CJ
Brown, JL
Martin, TJ
Roth, J
Spencer, SD
Brassil, P
McNeill, KA
Kreisl, TN
Fine, HA
Figg, WD
AF Peer, Cody J.
Brown, Jeffrey L.
Martin, Timothy J.
Roth, Jeffrey
Spencer, Shawn D.
Brassil, Patrick
McNeill, Katharine A.
Kreisl, Teri N.
Fine, Howard A.
Figg, William D.
TI A novel uHPLC-MS/MS method for the quantitation of AZD7451 (AZ12607092)
in human plasma
SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL
AND LIFE SCIENCES
LA English
DT Article
DE Tropomyosin-related kinase; Ultra-high performance liquid;
chromatography; Tandem mass spectrometry
ID RECEPTORS
AB Tropomyosin-related kinases (Trk) are tyrosine kinase receptors implicated in tumor proliferation, invasion, and survival signaling across a number of tumors, making them potentially attractive targets for the treatment of cancer. AZD7451 is a potent and selective inhibitor of Trk kinases currently undergoing a Phase I dose escalation in glioblastoma multiforme at the National Cancer Institute. A key part of early clinical testing for AZD7451 involves demonstrating that pharmacokinetic half-life and clinical exposures of AZD7451 are sufficient to inhibit Trk receptors in preclinical models. To address this need, an ultra sensitive analytical method was developed to measure the AZD7451 profile in human plasma. A liquid-liquid extraction recovered >80% of AZD7451 before quantitative analysis by ultra HPLC-MS/MS. A Varian Polaris (R) C18-A column and a mass transition of m/z 383.5 -> 340.5 (m/z 389.6 -> 342.0 for the internal standard [H-2(6)]-AZD7451) was used, and a dynamic calibration range of 0.5-1000 ng/mL was established, which provided a sensitive (<8.5% deviation), and precise (<6%) quantitative assay for AZD7451. AZD7451 demonstrated stability in human plasma at room temperature for 24 h (<7% change) and after extraction at 4 degrees C for 24 h (<8% change), and was stable through 4 freeze/thaw cycles (<8% change). This method was used to measure AZD7451 plasma levels in clinical samples to confirm the sensitivity at several time points following AZD7451 treatment in subjects with glioblastoma. Published by Elsevier B.V.
C1 [Peer, Cody J.; Martin, Timothy J.; Roth, Jeffrey; Figg, William D.] NCI, Clin Pharmacol Program, Off Clin Director, Bethesda, MD 20892 USA.
[Brown, Jeffrey L.; Brassil, Patrick] AstraZeneca, Waltham, MA USA.
[Spencer, Shawn D.] Fairleigh Dickinson Univ, Sch Pharm, Div Pharmaceut Sci, Florham Pk, NJ USA.
[McNeill, Katharine A.; Kreisl, Teri N.; Fine, Howard A.] NCI, Neurooncol Branch, Bethesda, MD 20892 USA.
[McNeill, Katharine A.; Fine, Howard A.] NYU, Brain Tumor Ctr, Langone Med Ctr, New York, NY USA.
[McNeill, Katharine A.; Fine, Howard A.] NYU, Inst Canc, Langone Med Ctr, New York, NY USA.
RP Figg, WD (reprint author), Clin Pharmacol Program, 9000 Rockville Pike,Bldg 10,Room 5A01, Bethesda, MD 20892 USA.
EM figgw@helix.nih.gov
RI Figg Sr, William/M-2411-2016
FU Intramural Research Program of the NIH; National Cancer Institute and in
part by a CRADA between the National Cancer Institute and AstraZeneca
[02429]
FX This study was funded in part the Intramural Research Program of the
NIH, National Cancer Institute and in part by a CRADA between the
National Cancer Institute and AstraZeneca (#02429). This is a US
Government work. There are no restrictions on its use. The views
expressed within this paper do not necessarily reflect those of the US
Government. We thank the nursing staff of the National Cancer Institute
and the fellows of the Medical Oncology Branch at the National Cancer
Institute for their care of our patients; Cynthia Graves for data
management assistance; and Cancer Therapy and Evaluation Program for
sponsoring the trial. Most importantly, we appreciate the patients with
cancer who enroll in investigational trials to advance the knowledge of
this disease.
NR 10
TC 1
Z9 1
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1570-0232
EI 1873-376X
J9 J CHROMATOGR B
JI J. Chromatogr. B
PD DEC 30
PY 2013
VL 942
BP 107
EP 112
DI 10.1016/j.jchromb.2013.10.023
PG 6
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 270FH
UT WOS:000328303800015
PM 24239935
ER
PT J
AU Bosch, FX
Broker, TR
Forman, D
Moscicki, AB
Gillison, ML
Doorbar, J
Stern, PL
Stanley, M
Arbyn, M
Poljak, M
Cuzick, J
Castle, PE
Schiller, JT
Markowitz, LE
Fisher, WA
Canfell, K
Denny, LA
Franco, EL
Steben, M
Kane, MA
Schiffman, M
Meijer, CJLM
Sankaranarayanan, R
Castellsague, X
Kim, JJ
Brotons, M
Alemanya, L
Albero, G
Diaz, M
de Sanjose, S
AF Bosch, F. Xavier
Broker, Thomas R.
Forman, David
Moscicki, Anna-Barbara
Gillison, Maura L.
Doorbar, John
Stern, Peter L.
Stanley, Margaret
Arbyn, Marc
Poljak, Mario
Cuzick, Jack
Castle, Philip E.
Schiller, John T.
Markowitz, Lauri E.
Fisher, William A.
Canfell, Karen
Denny, Lynette A.
Franco, Eduardo L.
Steben, Marc
Kane, Mark A.
Schiffman, Mark
Meijer, Chris J. L. M.
Sankaranarayanan, Rengaswamy
Castellsague, Xavier
Kim, Jane J.
Brotons, Maria
Alemanya, Laia
Albero, Ginesa
Diaz, Mireia
de Sanjose, Silvia
CA ICO Monograph Comprehensive Contro
TI Comprehensive Control of Human Papillomavirus Infections and Related
Diseases
SO VACCINE
LA English
DT Review
DE HPV; Cervical cancer; Anal cancer; Penile cancer; Vaginal cancer; Vulvar
cancer; Oropharyngeal cancer; Screening; HPV vaccination; HPV testing;
Prevention
ID CERVICAL-CANCER; PREVENTION; COUNTRIES; VACCINES; WORLD
AB Infection with human papillomavirus (HPV) is recognized as one of the major causes of infection-related cancer worldwide, as well as the causal factor in other diseases. Strong evidence for a causal etiology with HPV has been stated by the International Agency for Research on Cancer for cancers of the cervix uteri, penis, vulva, vagina, anus and oropharynx (including base of the tongue and tonsils). Of the estimated 12.7 million new cancers occurring in 2008 worldwide, 4.8% were attributable to HPV infection, with substantially higher incidence and mortality rates seen in developing versus developed countries. In recent years, we have gained tremendous knowledge about HPVs and their interactions with host cells, tissues and the immune system; have validated and implemented strategies for safe and efficacious prophylactic vaccination against HPV infections; have developed increasingly sensitive and specific molecular diagnostic tools for HPV detection for use in cervical cancer screening; and have substantially increased global awareness of HPV and its many associated diseases in women, men, and children. While these achievements exemplify the success of biomedical research in generating important public health interventions, they also generate new and daunting challenges: costs of HPV prevention and medical care, the implementation of what is technically possible, socio-political resistance to prevention opportunities, and the very wide ranges of national economic capabilities and health care systems. Gains and challenges faced in the quest for comprehensive control of HPV infection and HPV-related cancers and other disease are summarized in this review. The information presented may be viewed in terms of a reframed paradigm of prevention of cervical cancer and other HPV-related diseases that will include strategic combinations of at least four major components: 1) routine introduction of HPV vaccines to women in all countries, 2) extension and simplification of existing screening programs using HPV-based technology, 3) extension of adapted screening programs to developing populations, and 4) consideration of the broader spectrum of cancers and other diseases preventable by HPV vaccination in women, as well as in men. Despite the huge advances already achieved, there must be ongoing efforts including international advocacy to achieve widespread-optimally universal-implementation of HPV prevention strategies in both developed and developing countries.
This article summarizes information from the chapters presented in a special ICO Monograph 'Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012. Additional details on each subtopic and full information regarding the supporting literature references may be found in the original chapters. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Bosch, F. Xavier; Castellsague, Xavier; Brotons, Maria; Alemanya, Laia; Albero, Ginesa; Diaz, Mireia; de Sanjose, Silvia] IDIBELL, Inst Catala Oncol Catalan Inst Oncol ICO, Canc Epidemiol Res Program, Lhospitalet De Llobregat, Barcelona, Spain.
[Broker, Thomas R.] Univ Alabama Birmingham, Birmingham, AL USA.
[Forman, David] Int Agcy Res Canc, Sect Canc Informat, F-69372 Lyon, France.
[Moscicki, Anna-Barbara] Univ Calif San Francisco, Dept Pediat, Div Adolescent Med, San Francisco, CA USA.
[Gillison, Maura L.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Doorbar, John] Natl Inst Med Res, Div Virol, London NW7 1AA, England.
[Stern, Peter L.] Univ Manchester, Paterson Inst Canc Res, Manchester, Lancs, England.
[Stanley, Margaret] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England.
[Arbyn, Marc] Sci Inst Publ Hlth, Canc Epidemiol Unit, Brussels, Belgium.
[Arbyn, Marc] Univ Antwerp, Lab Cell Biol & Histol, B-2020 Antwerp, Belgium.
[Poljak, Mario] Univ Ljubljana, Fac Med, Inst Microbiol & Immunol, Ljubljana, Slovenia.
[Cuzick, Jack] Queen Mary Univ London, Wolfson Inst Prevent Med, London, England.
[Castle, Philip E.] Global Canc Initiat, Chestertown, MD USA.
[Schiller, John T.] NCI, Ctr Canc Res, Bethesda, MD 20892 USA.
[Markowitz, Lauri E.] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA.
[Fisher, William A.] Univ Western Ontario, Dept Psychol, Social Sci Ctr, London, ON, Canada.
[Fisher, William A.] Univ Western Ontario, Dept Obstet & Gynaecol, Social Sci Ctr, London, ON, Canada.
[Canfell, Karen] Univ NSW, Prince Wales Clin Sch, Lowy Canc Res Ctr, Sydney, NSW, Australia.
[Canfell, Karen] NSW Canc Council, Canc Epidemiol Res Unit, Sydney, NSW, Australia.
[Denny, Lynette A.] Univ Cape Town, Dept Obstet & Gynaecol, Groote Schuur Hosp, Cape Town, South Africa.
[Denny, Lynette A.] Univ Cape Town, Inst Infect Dis & Mol Med, Groote Schuur Hosp, Cape Town, South Africa.
[Franco, Eduardo L.] McGill Univ, Div Canc Epidemiol, Montreal, PQ, Canada.
[Steben, Marc] Inst Natl Sante Publ Quebec, Montreal, PQ, Canada.
[Schiffman, Mark] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Meijer, Chris J. L. M.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands.
[Sankaranarayanan, Rengaswamy] Int Agcy Res Canc, Screening Grp, F-69372 Lyon, France.
[Castellsague, Xavier; Alemanya, Laia; Albero, Ginesa; de Sanjose, Silvia] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain.
[Kim, Jane J.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA 02115 USA.
RP Bosch, FX (reprint author), IDIBELL, Inst Catala Oncol Catalan Inst Oncol ICO, Canc Epidemiol Res Program, Lhospitalet De Llobregat, Barcelona, Spain.
EM admincerp@iconcologia.net
RI Castellsague Pique, Xavier/N-5795-2014; de Sanjose Llongueras,
Silvia/H-6339-2014; DIAZ SANCHIS, MIREIA/H-6335-2014; Albero,
Ginesa/G-7248-2015; BOSCH JOSE, FRANCESC XAVIER/J-6339-2012
OI Castellsague Pique, Xavier/0000-0002-0802-3595; Albero,
Ginesa/0000-0002-9400-1914; Franco, Eduardo/0000-0002-4409-8084; BOSCH
JOSE, FRANCESC XAVIER/0000-0002-7172-3412
FU European Commission [HEALTH-F3-2010-242061, HEALTH-F2-2011-282562];
Instituto de Salud Carlos III (Spanish Government) [FIS PI08/1535, FIS
PI10/02995, FIS PI11/02090, FIS PI11/02096, FIS PI11/02104, RCESP
C03/09, RTICESP C03110, RTIC RD06/0020/0095, RD12/0036/0056, CIBERESP];
Agenda de Gestio d'Ajuts Universitaris i de Recerca - Generalitat de
Catalunya (Catalonian Government) [AGAUR 2005SGR00695, AGAUR
2009SGR126]; USPHS/NIH/National Cancer Institute [CA36200, CA83679]; US
Public Health Service (National Cancer Institute, National Institutes of
Health, Department of Health and Human Services) [R37 CA51323]; National
Institute of AIDS and Infectious Disease [RC1 AI86051]; UK Medical
Research Council [MC_U117584278]; European Commission through PREHDICT
[242061]; European Commission through HPV AHEAD Network
[FP7-HEALTH-2011-282562]; Belgian Foundation Against Cancer (Brussels,
Belgium); International Agency for Research on Cancer (Lyon, France);
Cancer Research UK [A10404]; National Health and Medical Research
Council, Australia [CDF APP1007994, 1007518]; non-commercial government
and academic consulting agreements in Australia, New Zealand;
non-commercial government and academic consulting agreements in
Australia, New Zealand, UK; Cancer Council NSW, Australia; Bill and
Melinda Gates Foundation, USA [35537]; U.S. National Cancer Institute
[U54 CA164336, R01 CA160744-01A1]; Bill and Melinda Gates Foundation
[30505]
FX The work was partially supported by public grants from the European
Commission (7th Framework Programme grants HEALTH-F3-2010-242061,
PREHDICT and HEALTH-F2-2011-282562, HPV AHEAD), from the Instituto de
Salud Carlos III (Spanish Government) (grants FIS PI08/1535, FIS
PI10/02995, FIS PI11/02090, FIS PI11/02096, FIS PI11/02104, RCESP
C03/09, RTICESP C03110, RTIC RD06/0020/0095, RD12/0036/0056 and
CIBERESP) and from the Agenda de Gestio d'Ajuts Universitaris i de
Recerca - Generalitat de Catalunya (Catalonian Government) (grants AGAUR
2005SGR00695 and AGAUR 2009SGR126), who had no role in data collection,
analysis or interpretation of results. Thomas R. Broker receives
research support from the USPHS/NIH/National Cancer Institute (grants
"Human Papillomavirus Gene Expression" CA36200 and "Mechanisms of Human
Papillomavirus DNA Replication" CA83679). Anna-Barbara Moscicki's work
is supported by US Public Health Service grant R37 CA51323 (National
Cancer Institute, National Institutes of Health, Department of Health
and Human Services) and National Institute of AIDS and Infectious
Disease RC1 AI86051. John Doorbar is funded by the UK Medical Research
Council through program grant MC_U117584278 (Molecular Biology of Human
Papillomavirus Infection). Marc Arbyn received financial support from:
(1) the 7th Framework Programme of DG Research of the European
Commission through the PREHDICT project (grant No. 242061, coordinated
by the Vrije Universiteit Amsterdam, the Netherlands) and through the
HPV AHEAD Network (FP7-HEALTH-2011-282562); (2) the Belgian Foundation
Against Cancer (Brussels, Belgium); and (3) the International Agency for
Research on Cancer (Lyon, France). Jack Cuzick was supported in part by
Cancer Research UK programme grant A10404. Karen Canfell is supported by
grants from the National Health and Medical Research Council, Australia
(CDF APP1007994 and Project Grant #1007518), by non-commercial
government and academic consulting agreements in Australia, New Zealand
and the UK, and by Cancer Council NSW, Australia. Lynette A. Denny was
partially supported by Bill and Melinda Gates Foundation, USA (35537).
The work of Chris J.L.M. Meijer received support via the 7th Framework
Programme of DG Research of the European commission through the PREHDICT
project (grant 242061, coordinated via the Vrije Universiteit
Amsterdam). Jane J. Kim is supported in part by grants from the U.S.
National Cancer Institute (U54 CA164336, R01 CA160744-01A1) and the Bill
and Melinda Gates Foundation (30505) for modeling of HPV and cervical
cancer in developing countries.
NR 20
TC 0
Z9 0
U1 2
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD DEC 29
PY 2013
VL 31
SU 5
BP F1
EP F31
DI 10.1016/j.vaccine.2013.10.001
PG 31
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 289LQ
UT WOS:000329684400003
PM 24331745
ER
PT J
AU De Vuyst, H
Alemany, L
Lacey, C
Chibwesha, CJ
Sahasrabuddhe, V
Banura, C
Denny, L
Parham, GP
AF De Vuyst, Hugo
Alemany, Laia
Lacey, Charles
Chibwesha, Carla J.
Sahasrabuddhe, Vikrant
Banura, Cecily
Denny, Lynette
Parham, Groesbeck P.
TI The Burden of Human Papillomavirus Infections and Related Diseases in
Sub-Saharan Africa
SO VACCINE
LA English
DT Review
DE HPV epidemiology; Cervical cancer; Anogenital cancers; Genital warts;
Sub-Saharan Africa
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SQUAMOUS INTRAEPITHELIAL LESIONS; INVASIVE
CERVICAL-CARCINOMA; RISK HUMAN-PAPILLOMAVIRUS; HIV-SEROPOSITIVE MEN;
SOUTH-AFRICA; HPV INFECTION; ANTIRETROVIRAL THERAPY; CODON-72
POLYMORPHISM; MALE CIRCUMCISION
AB Despite the scarcity of high quality cancer registries and lack of reliable mortality data, it is clear that human papillomavirus (HPV)-associated diseases, particularly cervical cancer, are major causes of morbidity and mortality in sub-Saharan Africa (SSA). Cervical cancer incidence rates in SSA are the highest in the world and the disease is the most common cause of cancer death among women in the region. The high incidence of cervical cancer is a consequence of the inability of most countries to either initiate or sustain cervical cancer prevention services. In addition, it appears that the prevalence of HPV in women with normal cytology is higher than in more developed areas of the world, at an average of 24%. There is, however, significant regional variation in SSA, with the highest incidence of HPV infection and cervical cancer found in Eastern and Western Africa. It is expected that, due to aging and growth of the population, but also to lack of access to appropriate prevention services and the concomitant human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) epidemic, cervical cancer incidence and mortality rates in SSA will rise over the next 20 years. HPV16 and 18 are the most common genotypes in cervical cancer in SSA, although other carcinogenic HPV types, such as HPV45 and 35, are also relatively more frequent compared with other world regions. Data on other HPV-related anogenital cancers including those of the vulva, vagina, anus, and penis, are limited. Genital warts are common and associated with HPV types 6 and 11. HIV infection increases incidence and prevalence of all HPV-associated diseases. Sociocultural determinants of HPV-related disease, as well as the impact of forces that result in social destabilization, demand further study. Strategies to reduce the excessive burden of HPV-related diseases in SSA include age-appropriate prophylactic HPV vaccination, cervical cancer prevention services for women of the reproductive ages, and control of HIV/AIDS.
This article forms part of a regional report entitled "Comprehensive Control of HPV Infections and Related Diseases in the Sub-Saharan Africa Region"Vaccine Volume 31, Supplement 5, 2013. Updates of the progress in the field are presented in a separate monograph entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012. (C) 2013 Published by Elsevier Ltd.
C1 [De Vuyst, Hugo] Int Agcy Res Canc WHO IARC, Infect & Canc Epidemiol Grp, Lyon, France.
[Alemany, Laia] Inst Catala Oncol Catalan Inst Oncol ICO, Canc Epidemiol Res Program, Unit Infect & Canc UNIC, Lhospitalet De Llobregat, Barcelona, Spain.
[Alemany, Laia] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain.
[Lacey, Charles] Univ York, Hull York Med Sch, Ctr Immunol & Infect, York YO10 5DD, N Yorkshire, England.
[Chibwesha, Carla J.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
[Chibwesha, Carla J.] Ctr Infect Dis Res Zambia, Lusaka, Zambia.
[Sahasrabuddhe, Vikrant] NCI, Hormonal & Reprod Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Banura, Cecily] Makerere Univ, Coll Hlth Sci, Dept Child Hlth & Dev Ctr, Kampala, Uganda.
[Denny, Lynette] Univ Cape Town, Dept Obstet & Gynaecol, Groote Schuur Hosp, Cape Town, South Africa.
[Denny, Lynette] Univ Cape Town, Inst Infect Dis & Mol Med, Groote Schuur Hosp, Cape Town, South Africa.
[Parham, Groesbeck P.] Univ N Carolina, Dept Obstet & Gynecol, UNC Global Womens Hlth, Chapel Hill, NC USA.
RP Parham, GP (reprint author), Univ N Carolina, Dept Obstet & Gynecol, UNC Global Womens Hlth, Chapel Hill, NC USA.
EM groesbeckparham@cidrz.org
FU Bill & Melinda Gates Foundation (BMGF), USA [35537]; Instituto de Salud
Carlos III (Spanish Government) [RCESP C03/09, RTICESP C03/10, RTIC
RD06/0020/0095, RD12/0036/0056, CIBERESP]; Agencia de Gestio d'Ajuts
Universitaris i de Recerca - Generalitat de Catalunya (Catalonian
Government) [AGAUR 2005SGR00695, AGAUR 2009SGR126]
FX This work was supported by the Bill & Melinda Gates Foundation (BMGF),
USA (grant number 35537). Laia Alemany's work was partially supported by
public grants from the Instituto de Salud Carlos III (Spanish
Government) (grants RCESP C03/09, RTICESP C03/10, RTIC RD06/0020/0095,
RD12/0036/0056 and CIBERESP) and from the Agencia de Gestio d'Ajuts
Universitaris i de Recerca - Generalitat de Catalunya (Catalonian
Government) (grants AGAUR 2005SGR00695 and AGAUR 2009SGR126).
NR 97
TC 27
Z9 27
U1 4
U2 22
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD DEC 29
PY 2013
VL 31
SU 5
BP F32
EP F46
DI 10.1016/j.vaccine.2012.07.092
PG 15
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 289LQ
UT WOS:000329684400004
PM 24331746
ER
PT J
AU Prentice, RL
Zhao, SS
Johnson, M
Aragaki, A
Hsia, J
Jackson, RD
Rossouw, JE
Manson, JE
Hanash, SM
AF Prentice, Ross L.
Zhao, Shanshan
Johnson, Melissa
Aragaki, Aaron
Hsia, Judith
Jackson, Rebecca D.
Rossouw, Jacques E.
Manson, JoAnn E.
Hanash, Samir M.
TI Proteomic risk markers for coronary heart disease and stroke: validation
and mediation of randomized trial hormone therapy effects on these
diseases
SO GENOME MEDICINE
LA English
DT Article
ID GROWTH-FACTOR-I; CONJUGATED EQUINE ESTROGENS; C-REACTIVE PROTEIN;
ISCHEMIC-STROKE; CARDIOVASCULAR-DISEASE; POSTMENOPAUSAL WOMEN; PLUS
PROGESTIN; BETA-2-MICROGLOBULIN; PREDICTION; BETA(2)-MICROGLOBULIN
AB Background: We previously reported mass spectrometry-based proteomic discovery research to identify novel plasma proteins related to the risk of coronary heart disease (CHD) and stroke, and to identify proteins with concentrations affected by the use of postmenopausal hormone therapy. Here we report CHD and stroke risk validation studies for highly ranked proteins, and consider the extent to which protein concentration changes relate to disease risk or provide an explanation for hormone therapy effects on these outcomes.
Methods: Five proteins potentially associated with CHD (beta-2 microglobulin (B2M), alpha-1-acid glycoprotein 1 (ORM1), thrombospondin-1(THBS1), complement factor D pre-protein (CFD), and insulin-like growth factor binding protein 1 (IGFBP1)) and five potentially associated with stroke (B2M, IGFBP2, IGFBP4, IGFBP6, and hemopexin (HPX)) had high discovery phase significance level ranking and an available ELISA assay, and were included in case-control validation studies within the Women's Health Initiative (WHI) hormone therapy trials. Protein concentrations, at baseline and 1 year following randomization, were assessed for 358 CHD cases and 362 stroke cases, along with corresponding disease-free controls. Disease association, and mediation of estrogen-alone and estrogen plus progestin effects on CHD and stroke risk, were assessed using logistic regression.
Results: B2M, THBS1, and CFD were confirmed (P < 0.05) as novel CHD risk markers, and B2M, IGFBP2, and IGFBP4 were confirmed as novel stroke disease risk markers, while the assay for HPX proved to be unreliable. The change from baseline to 1 year in B2M was associated (P < 0.05) with subsequent stroke risk, and trended similarly with subsequent CHD risk. Change from baseline to 1 year in IGFBP1 was also associated with CHD risk, and this change provided evidence of hormone therapy effect mediation.
Conclusions: Plasma B2M is confirmed to be an informative risk marker for both CHD and stroke. The B2M increase experienced by women during the first year of hormone therapy trial participation conveys cardiovascular disease risk. The increase in IGFBP1 similarly conveys CHD risk, and the magnitude of the IGFBP1 increase following hormone therapy may be a mediator of hormone therapy effects. Plasma THBS1 and CFD are confirmed as CHD risk markers, and plasma IGFBP4 and IGFBP2 are confirmed as stroke risk markers.
C1 [Prentice, Ross L.; Zhao, Shanshan; Johnson, Melissa; Aragaki, Aaron] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
[Hsia, Judith] AstraZeneca LP, Res & Dev, Wilmington, DE 19803 USA.
[Jackson, Rebecca D.] Ohio State Univ, Div Endocrinol, Columbus, OH 43210 USA.
[Rossouw, Jacques E.] NHLBI, WHI Project Off, NIH, Bethesda, MD 20892 USA.
[Manson, JoAnn E.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA.
[Hanash, Samir M.] Univ Texas MD Anderson Canc Ctr, Red & Charline McCombs Inst Early Detect & Treatm, Dept Clin Canc Prevent, Houston, TX 77030 USA.
RP Prentice, RL (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave N,POB 19024, Seattle, WA 98109 USA.
EM rprentic@whi.org
FU National Heart, Lung and Blood Institute, National Institutes of Health,
U.S. Department of Health and Human Services [R21HL105927]; National
Heart, Lung and Blood Institute [HHSN268201100046C, HHSN268201100001C,
HHSN268201100002C, HHSN268201100003C, HHSN268201100004C,
HHSN271201100004C]; National Cancer Institute [P01CA53996]
FX This work was supported by National Heart, Lung and Blood Institute,
National Institutes of Health, U.S. Department of Health and Human
Services grant R21HL105927 (Prentice). The Women's Health Initiative
Program (all investigators) is also supported by the National Heart,
Lung and Blood Institute under contracts HHSN268201100046C,
HHSN268201100001C, HHSN268201100002C, HHSN268201100003C,
HHSN268201100004C, and HHSN271201100004C. Dr. Prentice's work was also
partially supported by grant P01CA53996 from the National Cancer
Institute.
NR 41
TC 7
Z9 7
U1 3
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-994X
J9 GENOME MED
JI Genome Med.
PD DEC 27
PY 2013
VL 5
AR 112
DI 10.1186/gm517
PG 15
WC Genetics & Heredity
SC Genetics & Heredity
GA 295JA
UT WOS:000330111200001
PM 24373343
ER
PT J
AU Harel, A
Kravitz, D
Baker, CI
AF Harel, Assaf
Kravitz, Dwight
Baker, Chris I.
TI Beyond perceptual expertise: revisiting the neural substrates of expert
object recognition
SO FRONTIERS IN HUMAN NEUROSCIENCE
LA English
DT Review
DE expertise; object recognition; visual perception; fMRI; review; visual
cortex
ID FUSIFORM FACE AREA; HUMAN EXTRASTRIATE CORTEX; PRIMARY VISUAL-CORTEX;
CHESS EXPERTS; HUMAN BRAIN; TEXTURE-DISCRIMINATION; ACTION ANTICIPATION;
DOMAIN SPECIFICITY; BASKETBALL PLAYERS; TASK CONSTRAINTS
AB Real-world expertise provides a valuable opportunity to understand how experience shapes human behavior and neural function. In the visual domain, the study of expert object recognition, such as in car enthusiasts or bird watchers, has produced a large, growing, and often-controversial literature. Here, we synthesize this literature, focusing primarily on results from functional brain imaging, and propose an interactive framework that incorporates the impact of high-level factors, such as attention and conceptual knowledge, in supporting expertise. This framework contrasts with the perceptual view of object expertise that has concentrated largely on stimulus driven processing in visual cortex. One prominent version of this perceptual account has almost exclusively focused on the relation of expertise to face processing and, in terms of the neural substrates, has centered on face-selective cortical regions such as the Fusiform Face Area (FFA). We discuss the limitations of this face-centric approach as well as the more general perceptual view, and highlight that expert related activity is CO found throughout visual cortex, not just FFA, with a strong relationship between neural response and behavioral expertise even in the earliest stages of visual processing, (ii) found outside visual cortex in areas such as parietal and prefrontal cortices, and (iii) modulated by the attentional engagement of the observer suggesting that it is neither automatic nor driven solely by stimulus properties. These findings strongly support a framework in which object expertise emerges from extensive interactions within and between the visual system and other cognitive systems, resulting in widespread, distributed patterns of expertise-related activity across the entire cortex.
C1 [Harel, Assaf; Kravitz, Dwight; Baker, Chris I.] NIMH, Lab Brain & Cognit, NIH, Bethesda, MD 20892 USA.
RP Harel, A (reprint author), NIMH, Lab Brain & Cognit, NIH, 10 Ctr Dr, Bethesda, MD 20892 USA.
EM assaf.harel@nih.gov
OI Baker, Chris/0000-0001-6861-8964; Harel, Assaf/0000-0002-4899-6156
FU Intramural Research Program of the US National Institutes of Health
(NIH), National Institute of Mental Health (NIMH)
FX The authors thank Hans Op de Beeck, Marlene Behrmann, and Alex Martin
for helpful discussions. This research was supported by the Intramural
Research Program of the US National Institutes of Health (NIH), National
Institute of Mental Health (NIMH).
NR 144
TC 18
Z9 18
U1 8
U2 55
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-5161
J9 FRONT HUM NEUROSCI
JI Front. Hum. Neurosci.
PD DEC 27
PY 2013
VL 7
AR 885
DI 10.3389/fnhum.2013.00885
PG 12
WC Neurosciences; Psychology
SC Neurosciences & Neurology; Psychology
GA 283LF
UT WOS:000329246900001
PM 24409134
ER
PT J
AU Boone-Heinonen, J
Diez-Roux, AV
Goff, DC
Loria, CM
Kiefe, CI
Popkin, BM
Gordon-Larsen, P
AF Boone-Heinonen, Janne
Diez-Roux, Ana V.
Goff, David C.
Loria, Catherine M.
Kiefe, Catarina I.
Popkin, Barry M.
Gordon-Larsen, Penny
TI The Neighborhood Energy Balance Equation: Does Neighborhood Food Retail
Environment plus Physical Activity Environment = Obesity? The CARDIA
Study
SO PLOS ONE
LA English
DT Article
ID BODY-MASS INDEX; RESIDENTIAL SELF-SELECTION; ARTERY RISK DEVELOPMENT;
BUILT ENVIRONMENT; LONGITUDINAL-ASSOCIATIONS; HEALTHY FOODS; WEIGHT
STATUS; DIET QUALITY; URBAN SPRAWL; YOUNG-ADULTS
AB Background: Recent obesity prevention initiatives focus on healthy neighborhood design, but most research examines neighborhood food retail and physical activity (PA) environments in isolation. We estimated joint, interactive, and cumulative impacts of neighborhood food retail and PA environment characteristics on body mass index (BMI) throughout early adulthood.
Methods and Findings: We used cohort data from the Coronary Artery Risk Development in Young Adults (CARDIA) Study [n=4,092; Year 7 (24-42 years, 1992-1993) followed over 5 exams through Year 25 (2010-2011); 12,921 person-exam observations], with linked time-varying geographic information system-derived neighborhood environment measures. Using regression with fixed effects for individuals, we modeled time-lagged BMI as a function of food and PA resource density (counts per population) and neighborhood development intensity (a composite density score). We controlled for neighborhood poverty, individual-level sociodemographics, and BMI in the prior exam; and included significant interactions between neighborhood measures and by sex. Using model coefficients, we simulated BMI reductions in response to single and combined neighborhood improvements. Simulated increase in supermarket density (from 25th to 75th percentile) predicted inter-exam reduction in BMI of 0.09 kg/m(2) [estimate (95% CI): -0.09 (-0.16, -0.02)]. Increasing commercial PA facility density predicted BMI reductions up to 0.22 kg/m(2) in men, with variation across other neighborhood features [estimate (95% CI) range: -0.14 (-0.29, 0.01) to -0.22 (-0.37, -0.08)]. Simultaneous increases in supermarket and commercial PA facility density predicted inter-exam BMI reductions up to 0.31 kg/m(2) in men [estimate (95% CI) range: -0.23 (-0.39, -0.06) to -0.31 (-0.47, -0.15)] but not women. Reduced fast food restaurant and convenience store density and increased public PA facility density and neighborhood development intensity did not predict reductions in BMI.
Conclusions: Findings suggest that improvements in neighborhood food retail or PA environments may accumulate to reduce BMI, but some neighborhood changes may be less beneficial to women.
C1 [Boone-Heinonen, Janne] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA.
[Diez-Roux, Ana V.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Goff, David C.] Wake Forest Univ, Bowman Gray Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC USA.
[Loria, Catherine M.] NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA.
[Kiefe, Catarina I.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA.
[Popkin, Barry M.; Gordon-Larsen, Penny] Univ N Carolina, Carolina Populat Ctr, Dept Nutr, Chapel Hill, NC 27599 USA.
RP Gordon-Larsen, P (reprint author), Univ N Carolina, Carolina Populat Ctr, Dept Nutr, Chapel Hill, NC 27599 USA.
EM gordon_larsen@unc.edu
FU National Heart, Lung, and Blood Institute (NHLBI); University of Alabama
at Birmingham [HHSN268201300025C, HHSN268201300026C]; Northwestern
University [HHSN268201300027C]; University of Minnesota
[HHSN268201300028C]; Kaiser Foundation Research Institute
[HHSN268201300029C]; Johns Hopkins University School of Medicine
[HHSN268200900041C]; Intramural Research Program of the National
Institute on Aging (NIA); NIA [AG0005]; NHLBI [AG0005]; National
Institutes of Health [R01 HL104580, R01- HL114091]; UNC-CH Clinic
Nutrition Research Center [NIH DK56350]; Carolina Population Center
[R24HD050924]; University of Alabama at Birmingham Coordinating Center
[N01-HC-95095]; University of Alabama at Birmingham Field Center
[N01-HC-48047]; University of Minnesota Field Center [N01-HC-48048];
Northwestern University Field Center [N01-HC-48049]; Kaiser Foundation
Research Institute from the National Heart, Lung and Blood Institute
[N01-HC-48050]; Interdisciplinary Obesity Training postdoctoral
fellowship [T32MH075854-04]
FX The Coronary Artery Risk Development in Young Adults Study (CARDIA) is
conducted and supported by the National Heart, Lung, and Blood Institute
(NHLBI) in collaboration with the University of Alabama at Birmingham
(HHSN268201300025C & HHSN268201300026C), Northwestern University
(HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser
Foundation Research Institute (HHSN268201300029C), and Johns Hopkins
University School of Medicine (HHSN268200900041C). CARDIA is also
partially supported by the Intramural Research Program of the National
Institute on Aging (NIA) and an intra-agency agreement between NIA and
NHLBI (AG0005). This manuscript has been reviewed by CARDIA for
scientific content. Funding for this study comes from the National
Institutes of Health: (R01 HL104580, R01- HL114091). Additional funding
has come from the UNC-CH Clinic Nutrition Research Center (NIH DK56350)
and the Carolina Population Center (R24HD050924); from contracts with
the University of Alabama at Birmingham Coordinating Center,
N01-HC-95095; University of Alabama at Birmingham Field Center,
N01-HC-48047; University of Minnesota Field Center, N01-HC-48048;
Northwestern University Field Center, N01-HC-48049; and Kaiser
Foundation Research Institute, N01-HC-48050 from the National Heart,
Lung and Blood Institute. Analysis was supported by the
Interdisciplinary Obesity Training postdoctoral fellowship
(T32MH075854-04). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 73
TC 17
Z9 17
U1 6
U2 31
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 27
PY 2013
VL 8
IS 12
AR e85141
DI 10.1371/journal.pone.0085141
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 281RE
UT WOS:000329117900126
PM 24386458
ER
PT J
AU Deng, C
He, XM
Hsueh, AJW
AF Deng, Cheng
He, Ximiao
Hsueh, Aaron J. W.
TI A Single-Nucleotide Polymorphism of Human Neuropeptide S Gene Originated
from Europe Shows Decreased Bioactivity
SO PLOS ONE
LA English
DT Article
ID INHIBITS FOOD-INTAKE; HUMAN GENOME; RAT-BRAIN; IN-VITRO; PHARMACOLOGICAL
CHARACTERIZATION; RECEPTOR ACTIVATION; EXPRESSING NEURONS;
COCAINE-SEEKING; MICE; POPULATION
AB Using accumulating SNP (Single-Nucleotide Polymorphism) data, we performed a genome-wide search for polypeptide hormone ligands showing changes in the mature regions to elucidate genotype/phenotype diversity among various human populations. Neuropeptide S (NPS), a brain peptide hormone highly conserved in vertebrates, has diverse physiological effects on anxiety, fear, hyperactivity, food intake, and sleeping time through its cognate receptor-NPSR. Here, we report a SNP rs4751440 (L-6-NPS) causing non-synonymous substitution on the 6th position (V to L) of the NPS mature peptide region. L-6-NPS has a higher allele frequency in Europeans than other populations and probably originated from European ancestors similar to 25,000 yrs ago based on haplotype analysis and Approximate Bayesian Computation. Functional analyses indicate that L-6-NPS exhibits a significant lower bioactivity than the wild type NPS, with similar to 20-fold higher EC50 values in the stimulation of NPSR. Additional evolutionary and mutagenesis studies further demonstrate the importance of the valine residue in the 6th position for NPS functions. Given the known physiological roles of NPS receptor in inflammatory bowel diseases, asthma pathogenesis, macrophage immune responses, and brain functions, our study provides the basis to elucidate NPS evolution and signaling diversity among human populations.
C1 [Deng, Cheng; Hsueh, Aaron J. W.] Stanford Univ, Sch Med, Dept Ob Gyn, Program Reprod & Stem Cell Biol, Stanford, CA 94305 USA.
[He, Ximiao] NCI, NIH, Bethesda, MD 20892 USA.
RP Deng, C (reprint author), Stanford Univ, Sch Med, Dept Ob Gyn, Program Reprod & Stem Cell Biol, Stanford, CA 94305 USA.
EM cdeng@stanford.edu; aaron.hsueh@stanford.edu
NR 72
TC 0
Z9 0
U1 2
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 27
PY 2013
VL 8
IS 12
AR e83009
DI 10.1371/journal.pone.0083009
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 281RE
UT WOS:000329117900017
PM 24386135
ER
PT J
AU Harmon, QE
Laughlin, SK
Baird, DD
AF Harmon, Quaker E.
Laughlin, Shannon K.
Baird, Donna D.
TI Keloids and Ultrasound Detected Fibroids in Young African American Women
SO PLOS ONE
LA English
DT Article
ID UTERINE LEIOMYOMAS; PATHOGENESIS; PREVALENCE; EXPRESSION; SCARS; RISK
AB Objective: Keloids and fibroids share a number of biologic and demographic similarities however there are no published reports of the association between them. The objective of this study was to investigate the association between self-reported keloids and ultrasound detected fibroids in a population of young African American women.
Study Design: The Study of Environment, Life-style & Fibroids (SELF), is a volunteer cohort of over 1600 African American women aged 23-34 years recruited in Detroit, Michigan. Enrollment occurred between December 2010 and December 2012. Data are available for the first 1196 participants. Participants self-reported a history of raised (hypertrophic) scars or scars extending beyond the limits of the original injury (keloid) and had an enrollment pelvic ultrasound examination to detect prevalent fibroids. Log linear regression was used to model the association between abnormal scars and prevalent fibroids controlling for possible covariates. Among women with fibroids, associations between particular fibroid characteristics (tumor location, size or number) and scarring were assessed using chi-square and Mann Whitney U-tests.
Results: Both abnormal scarring (keloids, 9.0%; hypertrophic scars, 28.3%) and fibroids (23.3%) were common in this cohort. There was no indication [ adjusted Risk Ratio (95% Confidence Interval): 0.7 (0.5-1.1)] of an association between self-reported keloids and prevalent fibroids. Nor was there any association with hypertrophic scars. Specific characteristics of the prevalent fibroids were not associated with abnormal scarring.
Conclusion: Despite similarly dysregulated extracellular matrices in keloids and fibroids, these conditions did not tend to co-occur in this young African American population.
C1 [Harmon, Quaker E.; Baird, Donna D.] NIEHS, Epidemiol Branch, NIH, Res Triangle Pk, NC 27709 USA.
[Laughlin, Shannon K.] Mayo Clin, Dept Obstet & Gynecol, Rochester, MN USA.
RP Harmon, QE (reprint author), NIEHS, Epidemiol Branch, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
EM quaker.harmon@nih.gov
RI Baird, Donna/D-5214-2017;
OI Baird, Donna/0000-0002-5544-2653; Harmon, Quaker/0000-0002-5866-848X
FU Intramural Research Program of the NIH; National Institute of
Environmental Health Sciences; American Recovery and Reinvestment Act
funds designated for National Institute of Health research
FX This research was supported in part by the Intramural Research Program
of the NIH, National Institute of Environmental Health Sciences. Funding
also came from the American Recovery and Reinvestment Act funds
designated for National Institute of Health research. SELF website:
detroitself.org. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 19
TC 4
Z9 4
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 27
PY 2013
VL 8
IS 12
AR e84737
DI 10.1371/journal.pone.0084737
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 281RE
UT WOS:000329117900108
PM 24386410
ER
PT J
AU Kainerstorfer, JM
Polizzotto, MN
Uldrick, TS
Rahman, R
Hassan, M
Najafizadeh, L
Ardeshirpour, Y
Wyvill, KM
Aleman, K
Smith, PD
Yarchoan, R
Gandjbakhche, AH
AF Kainerstorfer, Jana M.
Polizzotto, Mark N.
Uldrick, Thomas S.
Rahman, Rafa
Hassan, Moinuddin
Najafizadeh, Laleh
Ardeshirpour, Yasaman
Wyvill, Kathleen M.
Aleman, Karen
Smith, Paul D.
Yarchoan, Robert
Gandjbakhche, Amir H.
TI Evaluation of Non-Invasive Multispectral Imaging as a Tool for Measuring
the Effect of Systemic Therapy in Kaposi Sarcoma
SO PLOS ONE
LA English
DT Article
ID INDEPENDENT-COMPONENT ANALYSIS; GROWTH-FACTOR; AIDS; RECOGNITION;
HERPESVIRUS; MODEL; PCA; HIV
AB Diffuse multi-spectral imaging has been evaluated as a potential non-invasive marker of tumor response. Multi-spectral images of Kaposi sarcoma skin lesions were taken over the course of treatment, and blood volume and oxygenation concentration maps were obtained through principal component analysis (PCA) of the data. These images were compared with clinical and pathological responses determined by conventional means. We demonstrate that cutaneous lesions have increased blood volume concentration and that changes in this parameter are a reliable indicator of treatment efficacy, differentiating responders and non-responders. Blood volume decreased by at least 20% in all lesions that responded by clinical criteria and increased in the two lesions that did not respond clinically. Responses as assessed by multi-spectral imaging also generally correlated with overall patient clinical response assessment, were often detectable earlier in the course of therapy, and are less subject to observer variability than conventional clinical assessment. Tissue oxygenation was more variable, with lesions often showing decreased oxygenation in the center surrounded by a zone of increased oxygenation. This technique could potentially be a clinically useful supplement to existing response assessment in KS, providing an early, quantitative, and non-invasive marker of treatment effect.
C1 [Kainerstorfer, Jana M.; Rahman, Rafa; Hassan, Moinuddin; Najafizadeh, Laleh; Ardeshirpour, Yasaman; Gandjbakhche, Amir H.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Analyt & Funct Biophoton, NIH, Bethesda, MD USA.
[Polizzotto, Mark N.; Uldrick, Thomas S.; Wyvill, Kathleen M.; Aleman, Karen; Yarchoan, Robert] NCI, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA.
[Smith, Paul D.] Natl Inst Biomed Imaging & Bioengn, Biomed Instrumentat & Multiscale Imaging Sect, Lab Cellular Imaging & Macromol Biophys, NIH, Bethesda, MD USA.
RP Gandjbakhche, AH (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Analyt & Funct Biophoton, NIH, Bethesda, MD USA.
EM amir@helix.nih.gov
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development; National Institute of Biomedical Imaging and
Bioengineering; National Cancer Institute; NCI, National Institutes of
Health [HHSN26120080001E]
FX The research was funded by the Intramural Research Programs of the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development, the National Institute of Biomedical Imaging and
Bioengineering, and the National Cancer Institute. Additional funding
provided by the NCI, National Institutes of Health under Contract No.
HHSN26120080001E. Bevacizumab was provided to the NCI through a
Cooperative Research and Development Agreements with Genentech. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 33
TC 3
Z9 3
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 27
PY 2013
VL 8
IS 12
AR e83887
DI 10.1371/journal.pone.0083887
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 281RE
UT WOS:000329117900066
PM 24386302
ER
PT J
AU Konikoff, J
Brookmeyer, R
Longosz, AF
Cousins, MM
Celum, C
Buchbinder, SP
Seage, GR
Kirk, GD
Moore, RD
Mehta, SH
Margolick, JB
Brown, J
Mayer, KH
Koblin, BA
Justman, JE
Hodder, SL
Quinn, TC
Eshleman, SH
Laeyendecker, O
AF Konikoff, Jacob
Brookmeyer, Ron
Longosz, Andrew F.
Cousins, Matthew M.
Celum, Connie
Buchbinder, Susan P.
Seage, George R., III
Kirk, Gregory D.
Moore, Richard D.
Mehta, Shruti H.
Margolick, Joseph B.
Brown, Joelle
Mayer, Kenneth H.
Koblin, Beryl A.
Justman, Jessica E.
Hodder, Sally L.
Quinn, Thomas C.
Eshleman, Susan H.
Laeyendecker, Oliver
TI Performance of a Limiting-Antigen Avidity Enzyme Immunoassay for
Cross-Sectional Estimation of HIV Incidence in the United States
SO PLOS ONE
LA English
DT Article
ID INCIDENCE RATES; TYPE-1 SEROCONVERSION; INFECTION; COHORT; ASSAYS;
CHALLENGES; ACCURACY; EPIDEMIC; THERAPY; PLASMA
AB Background: A limiting antigen avidity enzyme immunoassay (HIV-1 LAg-Avidity assay) was recently developed for cross-sectional HIV incidence estimation. We evaluated the performance of the LAg-Avidity assay alone and in multi-assay algorithms (MAAs) that included other biomarkers.
Methods and Findings: Performance of testing algorithms was evaluated using 2,282 samples from individuals in the United States collected 1 month to >8 years after HIV seroconversion. The capacity of selected testing algorithms to accurately estimate incidence was evaluated in three longitudinal cohorts. When used in a single-assay format, the LAg-Avidity assay classified some individuals infected >5 years as assay positive and failed to provide reliable incidence estimates in cohorts that included individuals with long-term infections. We evaluated >500,000 testing algorithms, that included the LAg-Avidity assay alone and MAAs with other biomarkers (BED capture immunoassay [BED-CEIA], BioRad-Avidity assay, HIV viral load, CD4 cell count), varying the assays and assay cutoffs. We identified an optimized 2-assay MAA that included the LAg-Avidity and BioRad-Avidity assays, and an optimized 4-assay MAA that included those assays, as well as HIV viral load and CD4 cell count. The two optimized MAAs classified all 845 samples from individuals infected >5 years as MAA negative and estimated incidence within a year of sample collection. These two MAAs produced incidence estimates that were consistent with those from longitudinal follow-up of cohorts. A comparison of the laboratory assay costs of the MAAs was also performed, and we found that the costs associated with the optimal two assay MAA were substantially less than with the four assay MAA.
Conclusions: The LAg-Avidity assay did not perform well in a single-assay format, regardless of the assay cutoff. MAAs that include the LAg-Avidity and BioRad-Avidity assays, with or without viral load and CD4 cell count, provide accurate incidence estimates.
C1 [Konikoff, Jacob; Brookmeyer, Ron; Laeyendecker, Oliver] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA.
[Longosz, Andrew F.] NIAID, NIH, Bethesda, MD 20892 USA.
[Cousins, Matthew M.; Eshleman, Susan H.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
[Celum, Connie] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
[Celum, Connie] Univ Washington, Dept Med, Seattle, WA USA.
[Buchbinder, Susan P.] San Francisco Dept Hlth, San Francisco, CA USA.
[Laeyendecker, Oliver] UCSF, Dept Epidemiol, San Francisco, CA USA.
[Laeyendecker, Oliver] UCSF, Dept Med, San Francisco, CA USA.
[Seage, George R., III] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Kirk, Gregory D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Moore, Richard D.; Mehta, Shruti H.; Laeyendecker, Oliver] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Margolick, Joseph B.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA.
[Brown, Joelle] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA.
[Mayer, Kenneth H.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
[Koblin, Beryl A.] New York Blood Ctr, New York, NY 10021 USA.
[Justman, Jessica E.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
[Hodder, Sally L.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA.
[Quinn, Thomas C.] NIAID, NIH, Bethesda, MD 20892 USA.
RP Laeyendecker, O (reprint author), Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA.
EM olaeyen1@jhmi.edu
OI Laeyendecker, Oliver/0000-0002-6429-4760
FU HIV Prevention Trials Network (HPTN); National Institute of Allergy and
Infectious Diseases (NIAID), National Institute on Drug Abuse (NIDA),
National Institute of Mental Health (NIMH); Office of AIDS Research of
the National Institutes of Health (NIH), Department of Health and Human
Services [UM1-AI068613, R01-AI095068]; Division of Intramural Research,
NIAID, NIH; HIV Network for Prevention Trials (HIVNET); NIAID, NIH, DHHS
[N01-AI35176, N01-AI-45200, AI-45202]; NIDA [R01-DA-04334, R01-DA12568,
R01-DA011602]; NIAID; National Cancer Institute; National Heart, Lung
and Blood Institute [U01-AI35042, U01-AI35043, U01-AI35039, U01-AI35040,
U01-AI35041, UL1-RR025005]; National Institute of Alcohol Abuse and
Alcoholism [R01-AA016893]; NIH [UM1-AI068613, HPTN 061, HPTN 064,
UM1-AI068619, UM1-AI068617]
FX This work was supported by: (1) the HIV Prevention Trials Network (HPTN)
sponsored by the National Institute of Allergy and Infectious Diseases
(NIAID), National Institute on Drug Abuse (NIDA), National Institute of
Mental Health (NIMH), and the Office of AIDS Research of the National
Institutes of Health (NIH), Department of Health and Human Services
(UM1-AI068613 to SE); (2) R01-AI095068 (to SE and RB); and (3) the
Division of Intramural Research, NIAID, NIH. The funders had no role in
the design and conduct of the study, data collection and analysis,
preparation of the manuscript, or the decision to publish. Support for
the studies that provided samples for this project was as follows: the
HIVNET 001/001.1 study was funded by the HIV Network for Prevention
Trials (HIVNET) and sponsored by the NIAID, NIH, DHHS (N01-AI35176,
N01-AI-45200, and AI-45202); the ALIVE study is funded by NIDA
(R01-DA-04334 and R01-DA12568; the MACS is funded by the NIAID, with
additional supplemental funding from the National Cancer Institute and
the National Heart, Lung and Blood Institute (U01-AI35042, U01-AI35043,
U01-AI35039, U01-AI35040, U01-AI35041, and UL1-RR025005); the JHHCC is
funded by NIDA (R01-DA011602 to RDM) and the National Institute of
Alcohol Abuse and Alcoholism (R01-AA016893 to RDM); HPTN 061 and HPTN
064 were funded by the NIH (see above; UM1-AI068619, UM1-AI068617, and
UM1-AI068613). Role of the funders: None of the funders had a role in
the design and conduct of the study; collection, management, analysis
and interpretation of the data; or preparation, review, or approval of
the manuscript.
NR 40
TC 17
Z9 17
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 27
PY 2013
VL 8
IS 12
AR e82772
DI 10.1371/journal.pone.0082772
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 281RE
UT WOS:000329117900015
PM 24386116
ER
PT J
AU Steuerwald, NM
Foureau, DM
Norton, HJ
Zhou, J
Parsons, JC
Chalasani, N
Fontana, RJ
Watkins, PB
Lee, WM
Reddy, KR
Stolz, A
Talwalkar, J
Davern, T
Saha, D
Bell, LN
Barnhart, H
Gu, JZ
Serrano, J
Bonkovsky, HL
AF Steuerwald, Nury M.
Foureau, David M.
Norton, H. James
Zhou, Jie
Parsons, Judith C.
Chalasani, Naga
Fontana, Robert J.
Watkins, Paul B.
Lee, William M.
Reddy, K. Rajender
Stolz, Andrew
Talwalkar, Jayant
Davern, Timothy
Saha, Dhanonjoy
Bell, Lauren N.
Barnhart, Huiman
Gu, Jiezhun
Serrano, Jose
Bonkovsky, Herbert L.
TI Profiles of Serum Cytokines in Acute Drug-Induced Liver Injury and Their
Prognostic Significance
SO PLOS ONE
LA English
DT Article
ID SEVERE ALCOHOLIC HEPATITIS; UNITED-STATES; THERAPY; FAILURE;
INTERLEUKIN-10; HEPATOTOXICITY; IL-10; POLYMORPHISMS; BIOMARKERS;
FEATURES
AB Drug-induced liver injury (DILI) is the most common cause of acute liver failure in the United-States. The aim of the study was to describe serum immune profiles associated with acute DILI, to investigate whether there are profiles associated with clinical features or types of DILI and/or with prognosis, and to assess temporal changes in levels. Twenty-seven immune analytes were measured in the sera of 78 DILI subjects in the Drug-Induced Liver Injury Network (DILIN) and compared with 40 healthy controls. Immune analytes (14 cytokines, 7 chemokines and 6 growth factors) were measured by BioPlex multiplex ELISA at DILI onset and after 6 months. A modeling process utilizing immune principles was used to select a final set of variables among 27 immune analytes and several additional clinical lab values for prediction of early death (within 6 months of DILI onset). Nineteen of the 27 immune analytes were differentially expressed among healthy control, DILI onset and 6-month cohorts. Disparate patterns of immune responses, especially innate and adaptive cellular (mostly TH17) immunity were evident. Low values of four immune analytes (IL-9, IL-17, PDGF-bb and RANTES) and serum albumin are predictive of early death [PPV = 88% (95% CI, 65%-100%), NPV = 97% (95% CI, 93%-100%), accuracy = 96% (95% CI, 92%-100%)].
Conclusions: Acute DILI is associated with robust and varying immune responses. High levels of expression of cytokines associated with innate immunity are associated with a poor prognosis, whereas high levels of expression of adaptive cytokines are associated with good long-term prognosis and eventual recovery. Serum immune analyte profiles at DILI onset appear to be of prognostic, and perhaps, diagnostic significance.
C1 [Steuerwald, Nury M.; Foureau, David M.; Norton, H. James; Zhou, Jie; Parsons, Judith C.; Saha, Dhanonjoy; Bonkovsky, Herbert L.] Carolinas Med Ctr, Liver Biliary Pancreat Ctr, Charlotte, NC 28203 USA.
[Steuerwald, Nury M.; Foureau, David M.; Norton, H. James; Zhou, Jie; Parsons, Judith C.; Saha, Dhanonjoy; Bonkovsky, Herbert L.] Carolinas Med Ctr, Dept Internal Med, Charlotte, NC 28203 USA.
[Steuerwald, Nury M.; Foureau, David M.; Norton, H. James; Zhou, Jie; Parsons, Judith C.; Saha, Dhanonjoy; Bonkovsky, Herbert L.] Carolinas Med Ctr, Dept Gen Surg, Charlotte, NC 28203 USA.
[Steuerwald, Nury M.; Foureau, David M.; Norton, H. James; Zhou, Jie; Parsons, Judith C.; Saha, Dhanonjoy; Bonkovsky, Herbert L.] Carolinas Med Ctr, Dept Res, Charlotte, NC 28203 USA.
[Steuerwald, Nury M.; Foureau, David M.; Norton, H. James; Zhou, Jie; Parsons, Judith C.; Saha, Dhanonjoy; Bonkovsky, Herbert L.] Carolinas Med Ctr, Dept Dickson Adv Analyt, Charlotte, NC 28203 USA.
[Chalasani, Naga; Bell, Lauren N.] IUPUI, Dept Internal Med, Indianapolis, IN USA.
[Fontana, Robert J.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Watkins, Paul B.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
[Watkins, Paul B.] Univ N Carolina, Sch Pharm, Chapel Hill, NC USA.
[Lee, William M.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA.
[Reddy, K. Rajender] Univ Penn, Dept Internal Med, Philadelphia, PA 19104 USA.
[Stolz, Andrew] Univ So Calif, Dept Internal Med, Los Angeles, CA USA.
[Talwalkar, Jayant] Mayo Clin, Dept Internal Med, Rochester, MN USA.
[Davern, Timothy] Pacific Med Ctr, Dept Internal Med, San Francisco, CA USA.
[Barnhart, Huiman; Gu, Jiezhun] Duke Clin Res Inst, Durham, NC USA.
[Serrano, Jose] NIDDK, NIH, Bethesda, MD 20892 USA.
RP Steuerwald, NM (reprint author), Carolinas Med Ctr, Liver Biliary Pancreat Ctr, Charlotte, NC 28203 USA.
EM nury.steuerwald@carolinas.org
FU National Institute of Diabetes and Digestive and Kidney Diseases
[1U01DK065193, U01DK065211, U01DK065238, U01DK065184, U01DK065201,
U01DK83023, U01DK083020, U01DK08992, U01DK083027]
FX Supported by The DILIN (Drug Induced Liver Injury Network) is supported
by the National Institute of Diabetes and Digestive and Kidney Diseases.
Numbers of the cooperative agreements are as follows: 1U01DK065193,
U01DK065211, U01DK065238, U01DK065184, U01DK065201, U01DK83023,
U01DK083020, U01DK08992, U01DK083027. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 50
TC 19
Z9 20
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 27
PY 2013
VL 8
IS 12
AR UNSP e81974
DI 10.1371/journal.pone.0081974
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 281RE
UT WOS:000329117900007
PM 24386086
ER
PT J
AU Bies, J
Sramko, M
Wolff, L
AF Bies, Juraj
Sramko, Marek
Wolff, Linda
TI Stress-induced Phosphorylation of Thr(486) in c-Myb by p38
Mitogen-activated Protein Kinases Attenuates Conjugation of SUMO-2/3
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Apoptosis; p38 MAPK; Phosphorylation; Protein Degradation; Protein
Stability; Stress; Sumoylation; Transcription; Myb
ID NEGATIVE REGULATORY DOMAIN; INDUCED TRANSCRIPTION ACTIVATION; T-CELL
DEVELOPMENT; V-MYB; LEUKEMIA; PROLIFERATION; DEGRADATION; GENE;
DIFFERENTIATION; INTEGRATION
AB c-Myb plays an essential role in regulation of properly balanced hematopoiesis through transcriptional regulation of genes directly controlling cellular processes such as proliferation, differentiation, and apoptosis. The transcriptional activity and protein levels of c-Myb are strictly controlled through post-translational modifications such as phosphorylation, acetylation, ubiquitination, and SUMOylation. Conjugation of small ubiquitin-like modifier (SUMO) proteins has been shown to suppress the transcriptional activity of c-Myb. SUMO-1 modifies c-Myb under physiological conditions, whereas SUMO-2/3 conjugation was reported in cells under stress. Because stress also activates several cellular protein kinases, we investigated whether phosphorylation of c-Myb changes in stressed cells and whether a mutual interplay exists between phosphorylation and SUMOylation of c-Myb. Here we show that several types of environmental stress induce a rapid change in c-Myb phosphorylation. Interestingly, the phosphorylation of Thr(486), located in close proximity to SUMOylation site Lys(499) of c-Myb, is detected preferentially in nonSUMOylated protein and has a negative effect on stress-induced SUMOylation of c-Myb. Stress-activated p38 MAPKs phosphorylate Thr(486) in c-Myb, attenuate its SUMOylation, and increase its proteolytic turnover. Stressed cells expressing a phosphorylation-deficient T486A mutant demonstrate decreased expression of c-Myb target genes Bcl-2 and Bcl-xL and accelerated apoptosis because of increased SUMOylation of the mutant protein. These results suggest that phosphorylation-dependent modulation of c-Myb SUMOylation may be important for proper response of cells to stress. In summary, we have identified a novel regulatory interplay between phosphorylation and SUMOylation of c-Myb that regulates its activity in stressed cells.
C1 [Bies, Juraj; Sramko, Marek; Wolff, Linda] NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Bies, J (reprint author), NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bldg 37-4124,37 Convent Dr,MSC 4263, Bethesda, MD 20892 USA.
EM biesj@mail.nih.gov
FU Intramural Research Program of the National Cancer Institute, Center for
Cancer Research, National Institutes of Health
FX This work was supported, in whole or in part, by the Intramural Research
Program of the National Cancer Institute, Center for Cancer Research,
National Institutes of Health.
NR 54
TC 1
Z9 1
U1 0
U2 3
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 27
PY 2013
VL 288
IS 52
BP 36983
EP 36993
DI 10.1074/jbc.M113.500264
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 282RH
UT WOS:000329189700020
PM 24257756
ER
PT J
AU Quintero, OA
Unrath, WC
Stevens, SM
Manor, U
Kachar, B
Yengo, CM
AF Quintero, Omar A.
Unrath, William C.
Stevens, Stanley M., Jr.
Manor, Uri
Kachar, Bechara
Yengo, Christopher M.
TI Myosin 3A Kinase Activity Is Regulated by Phosphorylation of the Kinase
Domain Activation Loop
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Actin; Hearing; Molecular Motors; Myosin; Phosphorylation
ID CLASS-III MYOSIN; PROTEIN-KINASE; STATISTICAL-MODEL; ATPASE ACTIVITY;
MST1 KINASE; ACTIN; MECHANISM; AUTOPHOSPHORYLATION; LOCALIZATION; MOTOR
AB Class III myosins are unique members of the myosin superfamily in that they contain both a motor and kinase domain. We have found that motor activity is decreased by autophosphorylation, although little is known about the regulation of the kinase domain. We demonstrate by mass spectrometry that Thr-178 and Thr-184 in the kinase domain activation loop and two threonines in the loop 2 region of the motor domain are autophosphorylated (Thr-908 and Thr-919). The kinase activity of MYO3A 2IQ with the phosphomimic (T184E) or phosphoblock (T184A) mutations demonstrates that kinase activity is reduced 30-fold as a result of the T184A mutation, although the Thr-178 site only had a minor impact on kinase activity. Interestingly, the actin-activated ATPase activity of MYO3A 2IQ is slightly reduced as a result of the T178A and T184A mutations suggesting coupling between motor and kinase domains. Full-length GFP-tagged T184A and T184E MYO3A constructs transfected into COS7 cells do not disrupt the ability of MYO3A to localize to filopodia structures. In addition, we demonstrate that T184E MYO3A reduces filopodia elongation in the presence of espin-1, whereas T184A enhances filopodia elongation in a similar fashion to kinase-dead MYO3A. Our results suggest that as MYO3A accumulates at the tips of actin protrusions, autophosphorylation of Thr-184 enhances kinase activity resulting in phosphorylation of the MYO3A motor and reducing motor activity. The differential regulation of the kinase and motor activities allows for MYO3A to precisely self-regulate its concentration in the actin bundle-based structures of cells.
C1 [Quintero, Omar A.; Unrath, William C.; Yengo, Christopher M.] Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA.
[Stevens, Stanley M., Jr.] Univ S Florida, Dept Cell Biol Microbiol & Mol Biol, Tampa, FL 33620 USA.
[Manor, Uri; Kachar, Bechara] NIDCD, Lab Cell Struct & Dynam, NIH, Bethesda, MD 20894 USA.
RP Yengo, CM (reprint author), Penn State Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.
EM cmy11@psu.edu
OI Quintero, Omar/0000-0002-9314-1704
FU National Institutes of Health [EY0181416, K01CA160667]; Penn State
College of Medicine
FX This work was supported, in whole or in part, by National Institutes of
Health Grants EY0181416 (to C. M. Y.) and K01CA160667 (to O. A. Q.).
This work was also supported by start-up funds from Penn State College
of Medicine.
NR 54
TC 10
Z9 10
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 27
PY 2013
VL 288
IS 52
BP 37126
EP 37137
DI 10.1074/jbc.M113.511014
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 282RH
UT WOS:000329189700032
PM 24214986
ER
PT J
AU Shinomiya, K
Sato, K
Yoshida, K
Tokura, K
Maruyama, H
Yanagidaira, K
Ito, Y
AF Shinomiya, Kazufusa
Sato, Kazuki
Yoshida, Kazunori
Tokura, Koji
Maruyama, Hiroshi
Yanagidaira, Kazuhiro
Ito, Yoichiro
TI Partition efficiencies of newly fabricated universal high-speed
counter-current chromatograph for separation of two different types of
sugar derivatives with organic-aqueous two-phase solvent systems
SO JOURNAL OF CHROMATOGRAPHY A
LA English
DT Article
DE Counter-current chromatography; Instrumentation; Sugar derivatives
ID COIL PLANET CENTRIFUGE; POLYMER PHASE SYSTEMS; COLUMN; PURIFICATION;
PERFORMANCE; PROTEINS
AB A new design of universal high-speed counter-current chromatograph (HSCCC) was fabricated in our laboratory. It holds a set of four column holders symmetrically around the rotary frame at a distance of 11.2 cm from the central axis. By engaging the stationary gear on the central axis of the centrifuge to the planetary gears on the column holder shaft through a set of idle gears, two pairs of diagonally located column holders simultaneously rotate about their own axes in the opposite directions: one forward (type-J planetary motion) and the other backward (type-I planetary motion) each synchronously with the revolution. Using the eccentric coil assembly, partition efficiencies produced by these two planetary motions were compared on the separation of two different types of sugar derivatives (4-methylumbelliferyl and 5-bromo-4-chloro-3-indoxyl sugar derivatives) using organic-aqueous two-phase solvent systems composed of n-hexane/ethyl acetate/1-butanol/methanollwater and aqueous 0.1 M sodium tetraborate, respectively. With lower phase mobile, better peak resolution was obtained by the type-J forward rotation for both samples probably due to higher retention of the stationary phase. With upper phase mobile, however, similar peak resolutions were obtained between these two planetary motions for both sugar derivatives. The overall results indicate that the present universal HSCCC is useful for counter-current chromatographic separation since each planetary motion has its specific applications: e.g., vortex CCC by the type-I planetary motion and HSCCC by the type-J planetary motion both for separation of various natural and synthetic products. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Shinomiya, Kazufusa; Sato, Kazuki] Nihon Univ, Sch Pharm, Funabashi, Chiba 2748555, Japan.
[Yoshida, Kazunori; Tokura, Koji; Maruyama, Hiroshi; Yanagidaira, Kazuhiro] Nihon Univ, Coll Sci & Technol, Funabashi, Chiba 2748501, Japan.
[Ito, Yoichiro] NHLBI, Lab Bioseparat Technol, Biochem & Biophys Ctr, NIH, Bethesda, MD 20892 USA.
RP Shinomiya, K (reprint author), Nihon Univ, Sch Pharm, 7-7-1 Narashinodai, Funabashi, Chiba 2748555, Japan.
EM shinomiya.kazufusa@nihon-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
FX The present study was supported in part by a grant from the Ministry of
Education, Culture, Sports, Science and Technology of Japan.
NR 18
TC 9
Z9 9
U1 0
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0021-9673
EI 1873-3778
J9 J CHROMATOGR A
JI J. Chromatogr. A
PD DEC 27
PY 2013
VL 1322
BP 74
EP 80
DI 10.1016/j.chroma.2013.10.096
PG 7
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 275ZF
UT WOS:000328717200010
PM 24267319
ER
PT J
AU Pena-Cruz, V
Etemad, B
Chatziandreou, N
Nyein, PH
Stock, S
Reynolds, SJ
Laeyendecker, O
Gray, RH
Serwadda, D
Lee, SJ
Quinn, TC
Sagar, M
AF Pena-Cruz, Victor
Etemad, Behzad
Chatziandreou, Nikolaos
Phyu Hninn Nyein
Stock, Shannon
Reynolds, Steven J.
Laeyendecker, Oliver
Gray, Ronald H.
Serwadda, David
Lee, Sandra J.
Quinn, Thomas C.
Sagar, Manish
TI HIV-1 envelope replication and alpha 4 beta 7 utilization among newly
infected subjects and their corresponding heterosexual partners
SO RETROVIROLOGY
LA English
DT Article
DE HIV-1; Envelope; Transmission; Receptor; Replication; Alpha4 beta7;
Dendritic cells; Langerhans cells; Selection
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN LANGERHANS CELLS; FUSION INHIBITOR
T-20; DENDRITIC CELLS; T-CELLS; CORECEPTOR USAGE; TRANS-INFECTION;
GENITAL-TRACT; NEUTRALIZATION SENSITIVITY; INTEGRIN ALPHA(4)BETA(7)
AB Background: Previous studies suggest that active selection limits the number of HIV-1 variants acquired by a newly infected individual from the diverse variants circulating in the transmitting partner. We compared HIV-1 envelopes from 9 newly infected subjects and their linked transmitting partner to explore potential mechanisms for selection.
Results: Recipient virus envelopes had significant genotypic differences compared to those present in the transmitting partner. Recombinant viruses incorporating pools of recipient and transmitter envelopes showed no significant difference in their sensitivity to receptor and fusion inhibitors, suggesting they had relatively similar entry capacity in the presence of low CD4 and CCR5 levels. Aggregate results in primary cells from up to 4 different blood or skin donors showed that viruses with envelopes from the transmitting partner as compared to recipient envelopes replicated more efficiently in CD4+ T cells, monocyte derived dendritic cell (MDDC) - CD4+ T cell co-cultures, Langerhans cells (LCs) - CD4+ T cell co-cultures and CD4+ T cells expressing high levels of the gut homing receptor, alpha 4 beta 7, and demonstrated greater binding to alpha 4 beta 7 high / CD8+ T cells. These transmitter versus recipient envelope virus phenotypic differences, however, were not always consistent among the primary cells from all the different blood or skin donation volunteers.
Conclusion: Although genotypically unique variants are present in newly infected individuals compared to the diverse swarm circulating in the chronically infected transmitting partner, replication in potential early target cells and receptor utilization either do not completely dictate this genetic selection, or these potential transmission phenotypes are lost very soon after HIV-1 acquisition.
C1 [Pena-Cruz, Victor; Etemad, Behzad; Chatziandreou, Nikolaos; Phyu Hninn Nyein; Sagar, Manish] Boston Univ, Dept Med, Div Infect Dis, Boston, MA 02215 USA.
[Stock, Shannon] Coll Holy Cross, Dept Math & Comp Sci, Worcester, MA 01610 USA.
[Reynolds, Steven J.; Laeyendecker, Oliver; Quinn, Thomas C.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Reynolds, Steven J.; Laeyendecker, Oliver; Quinn, Thomas C.] NIAID, Div Intramural Res, NIH, Bethesda, MD 20892 USA.
[Gray, Ronald H.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Serwadda, David] Makerere Univ, Sch Publ Hlth, Kampala, Uganda.
[Lee, Sandra J.] Dana Farber Canc Ctr, Dept Biostat, Boston, MA USA.
[Lee, Sandra J.] Dana Farber Canc Ctr, Dept Computat Biol, Boston, MA USA.
[Sagar, Manish] Boston Univ, Boston, MA 02118 USA.
RP Sagar, M (reprint author), Boston Univ, Dept Med, Div Infect Dis, Boston, MA 02215 USA.
EM msagar@bu.edu
OI Laeyendecker, Oliver/0000-0002-6429-4760
FU NIH [AI077473]; Division of Intramural Research, NIAID, NIH
FX We thank all the subjects who have contributed samples for these studies
as part of the Rakai Health Sciences Program. We thank Drs. Andrew Redd,
James Arthos, and Suryaram Gummuluru for insightful comments on the
manuscript. This study was supported by NIH grants AI077473 (MS) and by
the Division of Intramural Research, NIAID, NIH. The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 112
TC 10
Z9 10
U1 2
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD DEC 26
PY 2013
VL 10
AR 162
DI 10.1186/1742-4690-10-162
PG 16
WC Virology
SC Virology
GA AB3OC
UT WOS:000331699100001
PM 24369910
ER
PT J
AU Claxton, JS
Sandoval, PC
Liu, G
Chou, CL
Hoffert, JD
Knepper, MA
AF Claxton, J'Neka S.
Sandoval, Pablo C.
Liu, Gary
Chou, Chung-Lin
Hoffert, Jason D.
Knepper, Mark A.
TI Endogenous Carbamylation of Renal Medullary Proteins
SO PLOS ONE
LA English
DT Article
ID LOW-DENSITY-LIPOPROTEIN; HEMOGLOBIN CARBAMYLATION; WATER DIURESIS;
IN-VIVO; UREA; IDENTIFICATION; ACETYLATION; EXCRETION; PEPTIDES; UREMIA
AB Protein carbamylation is a post-translational modification that can occur in the presence of urea. In solution, urea is in equilibrium with ammonium cyanate, and carbamylation occurs when cyanate ions react with the amino groups of lysines, arginines, protein N-termini, as well as sulfhydryl groups of cysteines. The concentration of urea is elevated in the renal inner medulla compared with other tissues. Due to the high urea concentration, we hypothesized that carbamylation can occur endogenously within the rat inner medulla. Using immunoblotting of rat kidney cortical and medullary homogenates with a carbamyl-lysine specific antibody, we showed that carbamylation is present in a large number of inner medullary proteins. Using protein mass spectrometry (LC-MS/MS) of rat renal inner medulla, we identified 456 unique carbamylated sites in 403 proteins, including many that play important physiological roles in the renal medulla [Data can be accessed at https://helixweb.nih.gov/ESBL/Database/Carbamylation/Carbamylation_peptide_sorted.html]. We conclude that protein carbamylation occurs endogenously in the kidney, modifying many physiologically important proteins.
C1 [Claxton, J'Neka S.; Sandoval, Pablo C.; Liu, Gary; Chou, Chung-Lin; Hoffert, Jason D.; Knepper, Mark A.] NHLBI, Epithelial Syst Biol Lab, NIH, Bethesda, MD 20892 USA.
RP Knepper, MA (reprint author), NHLBI, Epithelial Syst Biol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM knepperm@nhlbi.nih.gov
FU Intramural budget of NHLBI [ZO1-HL001285]
FX This work was supported by the Intramural budget of NHLBI (Project
ZO1-HL001285, M. A. K.). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 32
TC 3
Z9 4
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 26
PY 2013
VL 8
IS 12
AR e82655
DI 10.1371/journal.pone.0082655
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 281QS
UT WOS:000329116700011
PM 24386107
ER
PT J
AU Shindo, S
Moore, R
Flake, G
Negishi, M
AF Shindo, Sawako
Moore, Rick
Flake, Gordon
Negishi, Masahiko
TI Serine 216 Phosphorylation of Estrogen Receptor alpha in Neutrophils:
Migration and Infiltration into the Mouse Uterus
SO PLOS ONE
LA English
DT Article
ID LACTOFERRIN; EXPRESSION; GENE; RAT
AB Background: Whereas estrogen receptors are present in immune cells, it is not known if they are phosphorylated to regulate immune cell functions. Here we determined the phosphorylation status of estrogen receptor alpha (ER alpha) at residue serine 216 in mouse neutrophils and examined its role in migration and infiltration. Serine 216 is the conserved phosphorylation site within the DNA binding domains found in the majority of nuclear receptors.
Methodology/Principal Findings: A phospho-peptide antibody specific to phosphorylated serine 216 and ER alpha KO mice were utilized in immunohistochemistry, double immuno-staining or Western blot to detect phosphorylation of ER alpha in peripheral blood as well as infiltrating neutrophils in the mouse uterus. Transwell assays were performed to examine migration of neutrophils. An anti-Ly6G antibody identified neutrophils. About 20% of neutrophils expressed phosphorylated ER alpha at serine 216 in peripheral white blood cells (WBC) from C3H/HeNCrIBR females. Phosphorylation was additively segregated between C3H/HeNCrIBR and C57BL/6 females. Only neutrophils that expressed phosphorylated ER alpha migrated in Transwell assays as well as infiltrated the mouse uterus during normal estrous cycles.
Conclusions/Significance: ER alpha was phosphorylated at serine 216 in about 20% of mouse peripheral blood neutrophils. Only those that express phosphorylated ER alpha migrate and infiltrate the mouse uterus. This phosphorylation was the first to be characterized in endogenous ER alpha found in normal tissues and cells. Phosphorylated ER alpha may have opened a novel research direction for biological roles of phosphorylation in ER alpha actions and can be developed as a drug target for treatment of immune-related diseases.
C1 [Shindo, Sawako; Moore, Rick; Negishi, Masahiko] NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA.
[Flake, Gordon] NIEHS, Pathol Lab, NIH, Res Triangle Pk, NC 27709 USA.
RP Negishi, M (reprint author), NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.
EM negishi@niehs.nih.gov
FU Intramural Research Program of the NIH, National Institute of
Environmental Health [Z01ES1005-01]
FX This study was supported by the Intramural Research Program of the NIH,
National Institute of Environmental Health: Z01ES1005-01. The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 22
TC 4
Z9 4
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 26
PY 2013
VL 8
IS 12
AR e84462
DI 10.1371/journal.pone.0084462
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 281QS
UT WOS:000329116700109
PM 24386386
ER
PT J
AU Yu, Y
Walia, V
Elble, RC
AF Yu, Yang
Walia, Vijay
Elble, Randolph C.
TI Loss of CLCA4 Promotes Epithelial-to-Mesenchymal Transition in Breast
Cancer Cells
SO PLOS ONE
LA English
DT Article
ID STEM-CELLS; TUMOR PROGRESSION; EXPRESSION; METASTASIS; PROTEIN; FAMILY;
METALLOPROTEASE; PROLIFERATION; INVASIVENESS; CHANNELS
AB The epithelial to mesenchymal transition (EMT) is a developmental program in which epithelial cells downregulate their cell-cell junctions, acquire spindle cell morphology and exhibit cellular motility. In breast cancer, EMT facilitates invasion of surrounding tissues and correlates closely with cancer metastasis and relapse. We found previously that the candidate tumor suppressor CLCA2 is expressed in differentiated, growth-arrested mammary epithelial cells but is downregulated during tumor progression and EMT. We further demonstrated that CLCA2 is a p53-inducible proliferation-inhibitor whose loss indicates an increased risk of metastasis. We show here that another member of the CLCA gene family, CLCA4, is expressed in mammary epithelial cells and is similarly downregulated in breast tumors and in breast cancer cell lines. Like CLCA2, the gene is stress-inducible, and ectopic expression inhibits colony formation. Transcriptional profiling studies revealed that CLCA4 and CLCA2 together are markers for mammary epithelial differentiation, and both are downregulated by TGF beta. Moreover, knockdown of CLCA4 in immortalized cells by shRNAs caused downregulation of epithelial marker E-cadherin and CLCA2, while mesenchymal markers N-cadherin, vimentin, and fibronectin were upregulated. Double knockdown of CLCA2 and CLCA4 enhanced the mesenchymal profile. These findings suggest that CLCA4 and CLCA2 play complementary but distinct roles in epithelial differentiation. Clinically, low expression of CLCA4 signaled lower relapse-free survival in basal and luminal B breast cancers.
C1 [Walia, Vijay; Elble, Randolph C.] So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62794 USA.
[Yu, Yang; Walia, Vijay; Elble, Randolph C.] So Illinois Univ, Sch Med, Simmons Canc Inst, Springfield, IL USA.
[Walia, Vijay] NCI, Lab Cell & Dev Signaling, Ctr Canc Res, Frederick, MD 21701 USA.
RP Elble, RC (reprint author), So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62794 USA.
EM relble2@siumed.edu
FU NIH [R15CA151094]; Department of Defense [W81XWH-10-1-0402]
FX This work was supported by NIH grant R15CA151094 and Department of
Defense grant number W81XWH-10-1-0402 to RCE. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 38
TC 10
Z9 10
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 26
PY 2013
VL 8
IS 12
AR e83943
DI 10.1371/journal.pone.0083943
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 281QS
UT WOS:000329116700090
PM 24386311
ER
PT J
AU Parkman, HP
Van Natta, ML
Abell, TL
McCallum, RW
Sarosiek, I
Nguyen, L
Snape, WJ
Koch, KL
Hasler, WL
Farrugia, G
Lee, L
Unalp-Arida, A
Tonascia, J
Hamilton, F
Pasricha, PJ
AF Parkman, Henry P.
Van Natta, Mark L.
Abell, Thomas L.
McCallum, Richard W.
Sarosiek, Irene
Nguyen, Linda
Snape, William J.
Koch, Kenneth L.
Hasler, William L.
Farrugia, Gianrico
Lee, Linda
Unalp-Arida, Aynur
Tonascia, James
Hamilton, Frank
Pasricha, Pankaj J.
TI Effect of Nortriptyline on Symptoms of Idiopathic Gastroparesis The
NORIG Randomized Clinical Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID DOUBLE-BLIND; GASTROINTESTINAL DISORDERS; TRICYCLIC ANTIDEPRESSANTS;
FUNCTIONAL DYSPEPSIA; MOTILIN AGONIST; SEVERITY; MULTICENTER;
VALIDATION; MANAGEMENT; SATIATION
AB IMPORTANCE Gastroparesis remains a challenging syndrome to manage, with few effective treatments and a lack of rigorously controlled trials. Tricyclic antidepressants are often used to treat refractory symptoms of nausea, vomiting, and abdominal pain. Evidence from well-designed studies for this use is lacking.
OBJECTIVE To determine whether treatment with nortriptyline results in symptomatic improvement in patients with idiopathic gastroparesis.
DESIGN, SETTING, AND PARTICIPANTS The NORIG (Nortriptyline for Idiopathic Gastroparesis) trial, a 15-week multicenter, parallel-group, placebo-controlled, double-masked, randomized clinical trial from the National Institute of Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium (GpCRC), comparing nortriptyline with placebo for symptomatic relief in idiopathic gastroparesis. One hundred thirty patients with idiopathic gastroparesis were enrolled between March 2009 and June 2012 at 7 US academic medical centers. Patient follow-up was completed in October 2012. Inclusion criteria included delayed gastric emptying and moderate to severe symptom scores using the Gastroparesis Cardinal Symptom Index (GCSI).
INTERVENTIONS Nortriptyline vs placebo. Study drug dose was increased at 3-week intervals (10, 25, 50, 75 mg) up to 75 mg at 12 weeks.
MAIN OUTCOMES AND MEASURES The primary outcome measure of symptomatic improvement was a decrease from the patient's baseline GCSI score of at least 50% on 2 consecutive 3-week GCSI assessments during 15 weeks of treatment.
RESULTS The primary symptomatic improvement outcome did not differ between 65 patients randomized to nortriptyline vs 65 patients randomized to placebo: 15 (23% [95% CI, 14%-35%]) in the nortriptyline group vs 14 (21% [95% CI, 12%-34%]) in the placebo group (P = .86). Treatment was stopped more often in the nortriptyline group (19 [29% {95% CI, 19%-42%}]) than in the placebo group (6 [9%] {95% CI, 3%-19%}]) (P = .007), but numbers of adverse events were not different (27 [95% CI, 18-39] vs 28 [95% CI, 19-40]) (P = .89).
CONCLUSIONS AND RELEVANCE Among patients with idiopathic gastroparesis, the use of nortriptyline compared with placebo for 15 weeks did not result in improvement in overall symptoms. These findings do not support the use of nortriptyline for idiopathic gastroparesis.
C1 [Parkman, Henry P.] Temple Univ, Philadelphia, PA 19140 USA.
[Van Natta, Mark L.; Lee, Linda; Unalp-Arida, Aynur; Tonascia, James] Johns Hopkins Univ, Baltimore, MD USA.
[Abell, Thomas L.] Univ Louisville, Louisville, KY 40292 USA.
[McCallum, Richard W.; Sarosiek, Irene] Texas Tech Univ, El Paso, TX USA.
[Nguyen, Linda] Stanford Univ, Palo Alto, CA 94304 USA.
[Snape, William J.] Calif Pacific Med Ctr, San Francisco, CA USA.
[Koch, Kenneth L.] Wake Forest Univ, Winston Salem, NC 27109 USA.
[Hasler, William L.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Farrugia, Gianrico] Mayo Clin, Rochester, MN USA.
[Hamilton, Frank] NIDDK, Bethesda, MD 20892 USA.
[Pasricha, Pankaj J.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
RP Parkman, HP (reprint author), Temple Univ, Sch Med, Gastroenterol Sect, Parkinson Pavil,8th Floor,3401 N Broad St, Philadelphia, PA 19140 USA.
EM henry.parkman@temple.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[U01DK073983, U01DK073975, U01DK073985, U01DK074007, U01DK073974,
U01DK074008]
FX The Gastroparesis Clinical Research Consortium (GpCRC) is supported by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
grants U01DK073983, U01DK073975, U01DK073985, U01DK074007, U01DK073974,
and U01DK074008.
NR 30
TC 28
Z9 28
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 25
PY 2013
VL 310
IS 24
BP 2640
EP 2649
DI 10.1001/jama.2013.282833
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 277KN
UT WOS:000328818000016
PM 24368464
ER
PT J
AU Noskov, SY
Rostovtseva, TK
Bezrukov, SM
AF Noskov, Sergei Yu.
Rostovtseva, Tatiana K.
Bezrukov, Sergey M.
TI ATP Transport through VDAC and the VDAC-Tubulin Complex Probed by
Equilibrium and Nonequilibrium MD Simulations
SO BIOCHEMISTRY
LA English
DT Article
ID DEPENDENT ANION CHANNEL; OUTER MITOCHONDRIAL-MEMBRANE; SCALABLE
MOLECULAR-DYNAMICS; FREE-ENERGY SIMULATIONS; ION CHANNELS; BINDING;
CONDUCTION; PERMEATION; SELECTIVITY; PROTEIN
AB Voltage-dependent anion channel (VDAC), the major channel of the mitochondrial outer membrane, serves as a principal pathway for ATP, ADP, and other respiratory substrates across this membrane. Using umbrella-sampling simulations, we established the thermodynamic and kinetic components governing ATP transport across the VDAC1 channel. We found that there are several low-affinity binding sites for ATP along the translocation pathway and that the main barrier for ATP transport is located around the center of the channel and is formed predominantly by residues in the N-terminus. The binding affinity of ATP to an open channel was found to be in the millimolar to micromolar range. However, we show that this weak binding increases the ATP translocation probability by about 10-fold compared with the VDAC pore in which attractive interactions were artificially removed. Recently, it was found that free dimeric tubulin induces a highly efficient, reversible blockage of VDAC reconstituted into planar lipid membranes. It was proposed that by blocking VDAC permeability for ATP/ADP and other mitochondrial respiratory substrates tubulin controls mitochondrial respiration. Using the Rosetta protein-protein docking algorithm, we established a tentative structure of the VDAC-tubulin complex. An extensive set of equilibrium and nonequilibrium (under applied electric field) molecular dynamics (MD) simulations was used to establish the conductance of the open and blocked channel. It was found that the presence of the unstructured C-terminal tail of tubulin in the VDAC pore decreases its conductance by more than 40% and switches its selectivity from anionic to cationic. The subsequent ID potential of mean force (PMF) computations for the VDAC-tubulin complex show that the state renders ATP transport virtually impossible. A number of residues pivotal for tubulin binding to the channel were identified that help to clarify the molecular details of VDAC-tubulin interaction and to provide new insight into the mechanism of the control of mitochondria respiration by VDAC.
C1 [Noskov, Sergei Yu.] Univ Calgary, Dept Biol Sci, Ctr Mol Simulat, Calgary, AB T2N 1N4, Canada.
[Rostovtseva, Tatiana K.; Bezrukov, Sergey M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Phys Biol, NIH, Bethesda, MD 20892 USA.
RP Noskov, SY (reprint author), Univ Calgary, Dept Biol Sci, Ctr Mol Simulat, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.
EM snoskov@ucalgary.ca
FU NICHD; National Sciences and Engineering Research Council
[RGPIN-315019]; Alberta Innovates Technology Futures New Faculty;
Canadian Foundation for Innovation
FX This work was supported with intramural funding from NICHD and the
National Sciences and Engineering Research Council (discovery grant
RGPIN-315019 to S.Y.N.). S.Y.N. is an Alberta Innovates Technology
Futures New Faculty, Canadian Institute for Health Research New
Investigator, and an Alberta Innovates Health Solutions Scholar.
Computations were performed on the West-Grid/Compute Canada facilities
and the University of Calgary TNK cluster supported by the Canadian
Foundation for Innovation.
NR 65
TC 14
Z9 14
U1 4
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD DEC 24
PY 2013
VL 52
IS 51
BP 9246
EP 9256
DI 10.1021/bi4011495
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 281YP
UT WOS:000329137200016
PM 24245503
ER
PT J
AU Lee, JE
Wang, CC
Xu, SLY
Cho, YW
Wang, LF
Feng, XS
Baldridge, A
Sartorelli, V
Zhuang, LN
Peng, WQ
Ge, K
AF Lee, Ji-Eun
Wang, Chaochen
Xu, Shiliyang
Cho, Young-Wook
Wang, Lifeng
Feng, Xuesong
Baldridge, Anne
Sartorelli, Vittorio
Zhuang, Lenan
Peng, Weiqun
Ge, Kai
TI H3K4 mono- and di-methyltransferase MLL4 is required for enhancer
activation during cell differentiation
SO ELIFE
LA English
DT Article
ID HISTONE-MODIFYING GENES; EMBRYONIC STEM-CELLS; PPAR-GAMMA; TRANSCRIPTION
FACTORS; HUMAN GENOME; LYSINE 4; ADIPOGENESIS; EXPRESSION;
IDENTIFICATION; METHYLATION
AB Enhancers play a central role in cell-type-specific gene expression and are marked by H3K4me1/2. Active enhancers are further marked by H3K27ac. However, the methyltransferases responsible for H3K4me1/2 on enhancers remain elusive. Furthermore, how these enzymes function on enhancers to regulate cell-type-specific gene expression is unclear. In this study, we identify MLL4 (KMT2D) as a major mammalian H3K4 mono- and di-methyltransferase with partial functional redundancy with MLL3 (KMT2C). Using adipogenesis and myogenesis as model systems, we show that MLL4 exhibits cell-type- and differentiation-stage-specific genomic binding and is predominantly localized on enhancers. MLL4 co-localizes with lineage-determining transcription factors (TFs) on active enhancers during differentiation. Deletion of Mll4 markedly decreases H3K4me1/2, H3K27ac, Mediator and Polymerase II levels on enhancers and leads to severe defects in cell-type-specific gene expression and cell differentiation. Together, these findings identify MLL4 as a major mammalian H3K4 mono- and di-methyltransferase essential for enhancer activation during cell differentiation.
C1 [Lee, Ji-Eun; Wang, Chaochen; Xu, Shiliyang; Cho, Young-Wook; Wang, Lifeng; Baldridge, Anne; Zhuang, Lenan; Ge, Kai] NIDDK, Adipocyte Biol & Gene Regulat Sect, Lab Endocrinol & Receptor Biol, NIH, Bethesda, MD 20892 USA.
[Xu, Shiliyang; Peng, Weiqun] George Washington Univ, Dept Phys, Washington, DC 20052 USA.
[Cho, Young-Wook] Korea Basic Sci Inst, Chuncheon Ctr, Chunchon, South Korea.
[Feng, Xuesong; Sartorelli, Vittorio] NIAMSD, Lab Muscle Stem Cells & Gene Regulat, NIH, Bethesda, MD 20892 USA.
[Peng, Weiqun] George Washington Univ, Dept Anat & Regenerat Biol, Washington, DC USA.
RP Ge, K (reprint author), NIDDK, Adipocyte Biol & Gene Regulat Sect, Lab Endocrinol & Receptor Biol, NIH, Bethesda, MD 20892 USA.
EM wpeng@gwu.edu; kaig@niddk.nih.gov
RI Wang, Lifeng/I-4888-2012; Lee, Ji-Eun/F-7891-2011;
OI Wang, Lifeng/0000-0003-4752-6547; Lee, Ji-Eun/0000-0002-3768-7016; Ge,
Kai/0000-0002-7442-5138
FU National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health [1ZIADK075003]; National Institute of
Arthritis, Musculoskeletal, and Skin Diseases, National Institutes of
Health [1ZIAAR041126]
FX National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health 1ZIADK075003 Ji-Eun Lee, Chaochen Wang,
Shiliyang Xu, Lifeng Wang, Anne Baldridge, Lenan Zhuang, Weiqun Peng,
Kai Ge; National Institute of Arthritis, Musculoskeletal, and Skin
Diseases, National Institutes of Health 1ZIAAR041126 Xuesong Feng,
Vittorio Sartorelli
NR 62
TC 78
Z9 79
U1 3
U2 19
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD DEC 24
PY 2013
VL 2
AR e01503
DI 10.7554/eLife.01503
PG 25
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 280MC
UT WOS:000329033300006
PM 24368734
ER
PT J
AU Jenkinson, SR
Williams, JA
Jeon, H
Zhang, JJ
Nitta, T
Ohigashi, I
Kruhlak, M
Zuklys, S
Sharrow, S
Adams, A
Granger, L
Choi, Y
Siebenlist, U
Bishop, GA
Hollander, GA
Takahama, Y
Hodes, RJ
AF Jenkinson, S. Rhiannon
Williams, Joy A.
Jeon, Hyein
Zhang, Jingjing
Nitta, Takeshi
Ohigashi, Izumi
Kruhlak, Michael
Zuklys, Saulius
Sharrow, Susan
Adams, Anthony
Granger, Larry
Choi, Yongwon
Siebenlist, Ulrich
Bishop, Gail A.
Hollander, Georg A.
Takahama, Yousuke
Hodes, Richard J.
TI TRAF3 enforces the requirement for T cell cross-talk in thymic medullary
epithelial development
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID SELF-TOLERANCE; NF-KAPPA-B2 P100; GENE-EXPRESSION; RECEPTOR; MICE;
ALPHA; AIRE; RANK; MICROENVIRONMENT; ORGANOGENESIS
AB Induction of self-tolerance in developing T cells depends on medullary thymic epithelial cells (mTECs), whose development, in turn, requires signals from single-positive (SP) thymocytes. Thus, the absence of SP thymocytes in Tcra(-/-) mice results in a profound deficiency in mTECs. Here, we have probed the mechanism that underlies this requirement for cross-talk with thymocytes in medullary development. Previous studies have implicated nonclassical NF-kappa B as a pathway important in the development of mTECs, because mice lacking RelB, NIK, or IKK alpha, critical components of this pathway, have an almost complete absence of mTECs, with resulting autoimmune pathology. We therefore assessed the effect of selective deletion in TEC of TNF receptor-associated factor 3 (TRAF3), an inhibitor of nonclassical NF-kappa B signaling. Deletion of TRAF3 in thymic epithelial cells allowed RelB-dependent development of normal numbers of AIRE-expressing mTECs in the complete absence of SP thymocytes. Thus, mTEC development can occur in the absence of cross-talk with SP thymocytes, and signals provided by SP T cells are needed to overcome TRAF3-imposed arrest in mTEC development mediated by inhibition of nonclassical NF-kappa B. We further observed that TRAF3 deletion is also capable of overcoming all requirements for LT beta R and CD40, which are otherwise necessary for mTEC development, but is not sufficient to overcome the requirement for RANKL, indicating a role for RANKL that is distinct from the signals provided by SP thymocytes. We conclude that TRAF3 plays a central role in regulation of mTEC development by imposing requirements for SP T cells and costimulation-mediated cross-talk in generation of the medullary compartment.
C1 [Jenkinson, S. Rhiannon; Williams, Joy A.; Jeon, Hyein; Zhang, Jingjing; Kruhlak, Michael; Sharrow, Susan; Adams, Anthony; Granger, Larry; Hodes, Richard J.] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.
[Nitta, Takeshi; Ohigashi, Izumi; Takahama, Yousuke] Univ Tokushima, Inst Genome Res, Div Expt Immunol, Tokushima 7708503, Japan.
[Zuklys, Saulius; Hollander, Georg A.] Univ Basel, Dept Med, CH-4058 Basel, Switzerland.
[Choi, Yongwon] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Siebenlist, Ulrich] NIAID, Lab Immunoregulat, Bethesda, MD 20892 USA.
[Bishop, Gail A.] Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA.
[Bishop, Gail A.] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.
[Bishop, Gail A.] Univ Iowa, Vet Affairs Med Ctr, Iowa City, IA 52242 USA.
[Hollander, Georg A.] Univ Oxford, Dept Pediat, Oxford OX1 3DW, England.
RP Hodes, RJ (reprint author), NCI, Expt Immunol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM richard_hodes@nih.gov
RI Takahama, Yousuke/A-5863-2010
FU NIAID NIH HHS [R01 AI064909]
NR 41
TC 10
Z9 11
U1 0
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 24
PY 2013
VL 110
IS 52
BP 21107
EP 21112
DI 10.1073/pnas.1314859111
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 277ZW
UT WOS:000328858800062
PM 24324158
ER
PT J
AU Sumner, AE
Furtado, JD
Courville, AB
Ricks, M
Younger-Coleman, N
Tulloch-Reid, MK
Sacks, FM
AF Sumner, Anne E.
Furtado, Jeremy D.
Courville, Amber B.
Ricks, Madia
Younger-Coleman, Novie
Tulloch-Reid, Marshall K.
Sacks, Frank M.
TI ApoC-III and visceral adipose tissue contribute to paradoxically normal
triglyceride levels in insulin-resistant African-American women
SO NUTRITION & METABOLISM
LA English
DT Article
DE ApoC-III; Visceral adipose tissue; Triglyceride; Apoliprotein C-III;
Visceral adiposity; Insulin resistance; African-Americans; Health
disparities
ID APOLIPOPROTEIN-C-III; LOW-DENSITY LIPOPROTEINS; METABOLIC SYNDROME;
ETHNIC-DIFFERENCES; CORONARY EVENTS; RISK; CIII; LDL;
HYPERTRIGLYCERIDEMIA; MEN
AB Background: African-Americans are more insulin-resistant than whites but have lower triglyceride (TG) concentrations. The metabolic basis for this is unknown. Our goal was to determine in a cross-sectional study the effect of insulin resistance, visceral adipose tissue (VAT) and the apolipoproteins, B, C-III and E, on race differences in TG content of very low density lipoproteins (VLDL).
Methods: The participants were 31 women (16 African-American, 15 white) of similar age (37 +/- 9 vs. 38 +/- 11y (mean +/- SD), P = 0.72) and BMI (32.4 +/- 7.2 vs. 29.3 +/- 6.0 kg/m(2), P = 0.21). A standard diet (33% fat, 52% carbohydrate, 15% protein) was given for 7 days followed by a test meal (40% fat, 40% carbohydrate, 20% protein) on Day 8. Insulin sensitivity index (SI) was calculated from the minimal model. VAT was measured at L2-3. The influence of race, S-1, VAT and apolipoproteins on the TG content of VLDL was determined by random effects models (REM).
Results: African-Americans were more insulin-resistant (SI: 3.6 +/- 1.3 vs. 5.6 +/- 2.6 mU/L-1. min(-1), P < 0.01) with less VAT (75 +/- 59 vs. 102 +/- 71 cm(2), P < 0.01). TG, apoB and apoC-III content of light and dense VLDL were lower in African-Americans (all P < 0.05 except for apoC-III in light VLDL, P = 0.11). ApoE content did not vary by race. In REM, VAT but not SI influenced the TG concentration of VLDL. In models with race, SI, VAT and all apolipoproteins entered, race was not significant but apoC-III and VAT remained significant determinants of TG concentration in light and dense VLDL.
Conclusions: Low concentrations of apoC-III and VAT in African-Americans contribute to race differences in TG concentrations.
C1 [Sumner, Anne E.; Ricks, Madia] Natl Inst Diabet Digest & Kidney Dis, Diabet Endocrinol & Obes Branch, NIH, Bethesda, MD USA.
[Furtado, Jeremy D.; Sacks, Frank M.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Courville, Amber B.] NIH, Ctr Clin, Dept Nutr, Bethesda, MD 20892 USA.
[Younger-Coleman, Novie; Tulloch-Reid, Marshall K.] Univ W Indies, Res Inst Trop Med, Kingston 7, Jamaica.
RP Sumner, AE (reprint author), Natl Inst Diabet Digest & Kidney Dis, Diabet Endocrinol & Obes Branch, NIH, Bethesda, MD USA.
EM AnneS@intra.niddk.nih.gov
FU Intramural Program of NIDDK; NIH Clinical Center; NIH [HL073286]
FX Anne E. Sumner and Madia Ricks are supported by the Intramural Program
of NIDDK. Amber B. Courville is supported by the NIH Clinical Center.
The grant was also funded by the NIH Bench to Bedside Program with a
supplement to HL073286 (Frank M. Sacks).
NR 33
TC 4
Z9 4
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-7075
J9 NUTR METAB
JI Nutr. Metab.
PD DEC 23
PY 2013
VL 10
AR 73
DI 10.1186/1743-7075-10-73
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 285NA
UT WOS:000329399500001
PM 24365086
ER
PT J
AU Huang, P
Lin, J
Li, WW
Rong, PF
Wang, Z
Wang, SJ
Wang, XP
Sun, XL
Aronova, M
Niu, G
Leapman, RD
Nie, ZH
Chen, XY
AF Huang, Peng
Lin, Jing
Li, Wanwan
Rong, Pengfei
Wang, Zhe
Wang, Shouju
Wang, Xiaoping
Sun, Xiaolian
Aronova, Maria
Niu, Gang
Leapman, Richard D.
Nie, Zhihong
Chen, Xiaoyuan
TI Biodegradable Gold Nanovesicles with an Ultrastrong Plasmonic Coupling
Effect for Photoacoustic Imaging and Photothermal Therapy
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article
DE biodegradable block copolymers; gold nanovesicles; photoacoustic
imaging; photothermal therapy; plasmonic coupling
ID IN-VIVO; PHOTODYNAMIC THERAPY; CANCER-CELLS; NANOPARTICLES;
NANOCRYSTALS; GRAPHENE; NANORODS; AGENT; NANOCOMPOSITES; THERANOSTICS
AB The hierarchical assembly of gold nanoparticles (GNPs) allows the localized surface plasmon resonance peaks to be engineered to the near-infrared (NIR) region for enhanced photothermal therapy (PTT). Herein we report a novel theranostic platform based on biodegradable plasmonic gold nanovesicles for photoacoustic (PA) imaging and PTT. The disulfide bond at the terminus of a PEG-b-PCL block-copolymer graft enables dense packing of GNPs during the assembly process and induces ultrastrong plasmonic coupling between adjacent GNPs. The strong NIR absorption induced by plasmon coupling and very high photothermal conversion efficiency (=37%) enable simultaneous thermal/PA imaging and enhanced PTT efficacy with improved clearance of the dissociated particles after the completion of PTT. The assembly of various nanocrystals with tailored optical, magnetic, and electronic properties into vesicle architectures opens new possibilities for the construction of multifunctional biodegradable platforms for biomedical applications.
C1 [Huang, Peng; Li, Wanwan; Rong, Pengfei; Wang, Zhe; Wang, Shouju; Wang, Xiaoping; Sun, Xiaolian; Niu, Gang; Chen, Xiaoyuan] NIBIB, Lab Mol Imaging & Nanomed LOMIN, NIH, Bethesda, MD USA.
[Lin, Jing; Nie, Zhihong] Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.
[Aronova, Maria; Leapman, Richard D.] NIBIB, Lab Cellular Imaging & Macromol Biophys, NIH, Bethesda, MD USA.
[Wang, Zhe] Xiamen Univ, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, Xiamen 361005, Peoples R China.
RP Nie, ZH (reprint author), Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.
EM znie@umd.edu; shawn.chen@nih.gov
RI Huang, Peng/H-9985-2013; Nie, Zhihong/D-7495-2011; Huang,
Peng/R-2480-2016
OI Nie, Zhihong/0000-0001-9639-905X; Huang, Peng/0000-0003-3651-7813
FU University of Maryland; NIBIB; NIH; National Key Basic Research Program
(973 Project) [2010CB933901, 2013CB733802, 2014CB744503]; National
Science Foundation of China [81272987, 31170961, 51102258, 81371596];
Chinese Academy of Sciences [2011T2J06]
FX This research was supported by the startup funds of the University of
Maryland, the Intramural Research Program (IRP) of the NIBIB, the NIH,
the National Key Basic Research Program (973 Project; 2010CB933901,
2013CB733802, 2014CB744503), the National Science Foundation of China
(81272987, 31170961, 51102258, 81371596), and a Chinese Academy of
Sciences Professorship for Senior International Scientists (2011T2J06).
NR 41
TC 138
Z9 140
U1 39
U2 342
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PD DEC 23
PY 2013
VL 52
IS 52
BP 13958
EP 13964
DI 10.1002/anie.201308986
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA 273JM
UT WOS:000328531100010
PM 24318645
ER
PT J
AU Liu, DB
Wang, ZT
Jin, A
Huang, XL
Sun, XL
Wang, F
Yan, Q
Ge, SX
Xia, NS
Niu, G
Liu, G
Walker, ARH
Chen, XY
AF Liu, Dingbin
Wang, Zhantong
Jin, Albert
Huang, Xinglu
Sun, Xiaolian
Wang, Fu
Yan, Qiang
Ge, Shengxiang
Xia, Ningshao
Niu, Gang
Liu, Gang
Walker, A. R. Hight
Chen, Xiaoyuan
TI Acetylcholinesterase-Catalyzed Hydrolysis Allows Ultrasensitive
Detection of Pathogens with the Naked Eye
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article
DE acetylcholinesterase; analytical methods; gold; hydrolysis;
nanoparticles
ID GOLD NANOPARTICLES; COLORIMETRIC DETECTION; ENTEROVIRUS 71; RAPID
DETECTION; DNA; GLUCOSE; POINT; CARE
C1 [Liu, Dingbin; Huang, Xinglu; Sun, Xiaolian; Wang, Fu; Niu, Gang; Chen, Xiaoyuan] NIBIB, Lab Mol Imaging & Nanomed LOMIN, NIH, Bethesda, MD 20892 USA.
[Wang, Zhantong; Yan, Qiang; Ge, Shengxiang; Xia, Ningshao] Xiamen Univ, Sch Publ Hlth, Natl Inst Diagnost & Vaccine Dev Infect Dis, Xiamen 361102, Peoples R China.
[Wang, Zhantong; Liu, Gang] Xiamen Univ, Sch Publ Hlth, Ctr Mol Imaging & Translat Med, Xiamen 361005, Peoples R China.
[Jin, Albert] NIBIB, Lab Cellular Imaging & Macromol Biophys, NIH, Bethesda, MD 20892 USA.
[Walker, A. R. Hight] NIST, Opt Technol Div, Phys Lab, Gaithersburg, MD 20899 USA.
RP Chen, XY (reprint author), NIBIB, Lab Mol Imaging & Nanomed LOMIN, NIH, Bethesda, MD 20892 USA.
EM shawn.chen@nih.gov
RI Hight Walker, Angela/C-3373-2009;
OI Hight Walker, Angela/0000-0003-1385-0672; Jin,
Albert/0000-0003-3826-1081; Wang, Fu/0000-0001-9222-0833
FU Major State Basic Research Development Program of China (973 Program)
[2013CB733802, 2014CB744503]; National Science Foundation of China
(NSFC) [81101101, 51273165, 81201086, 81201190, 81371596]; Key Project
of the Chinese Ministry of Education [212149]; Intramural Research
Program (IRP) of the National Institute of Biomedical Imaging and
Bioengineering (NIBIB); National Institutes of Health (NIH);
NIH-NIBIB/NIST NRC
FX This work was supported in part the Major State Basic Research
Development Program of China (973 Program; 2013CB733802 and
2014CB744503), the National Science Foundation of China (NSFC; 81101101,
51273165, 81201086, 81201190, and 81371596), a Key Project of the
Chinese Ministry of Education (212149), the Intramural Research Program
(IRP) of the National Institute of Biomedical Imaging and Bioengineering
(NIBIB), and the National Institutes of Health (NIH). D. L. was
supported by a postdoctoral fellowship from NIH-NIBIB/NIST NRC.
NR 36
TC 46
Z9 47
U1 20
U2 163
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1433-7851
EI 1521-3773
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PD DEC 23
PY 2013
VL 52
IS 52
BP 14065
EP 14069
DI 10.1002/anie.201307952
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA 273JM
UT WOS:000328531100031
PM 24155243
ER
PT J
AU Nogueira, LM
Sampson, JN
Chu, LW
Yu, K
Andriole, G
Church, T
Stanczyk, FZ
Koshiol, J
Hsing, AW
AF Nogueira, Leticia M.
Sampson, Joshua N.
Chu, Lisa W.
Yu, Kai
Andriole, Gerald
Church, Timothy
Stanczyk, Frank Z.
Koshiol, Jill
Hsing, Ann W.
TI Individual Variations in Serum Melatonin Levels through Time:
Implications for Epidemiologic Studies
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER RISK; NIGHT-SHIFT WORK; URINARY 6-SULFATOXYMELATONIN
LEVELS; LIFE-STYLE FACTORS; LIGHT-AT-NIGHT; SLEEP DURATION; CIRCADIAN
DISRUPTION; PROSTATE-CANCER; NURSES HEALTH; POSTMENOPAUSAL WOMEN
AB Melatonin, a marker for the circadian rhythm with serum levels peaking between 2AM and 5AM, is hypothesized to possess anti-cancer properties, making it a mechanistic candidate for the probable carcinogenic effect of circadian rhythm disruption. In order to weigh epidemiologic evidence on the association of melatonin with cancer, we must first understand the laboratory and biological sources of variability in melatonin levels measured in samples. Participants for this methodological study were men enrolled in the Prostate Lung Colorectal and Ovarian Cancer Screening Trial (PLCO). We measured serum melatonin levels over a five year period in 97 individuals to test if melatonin levels are steady over time. The Pearson correlation coefficient between two measures separated by 1 year was 0.87, while the correlation between two measures separated by 5 years was to 0.70. In an additional cross-sectional study of 292 individuals, we used Analysis of Variance to identify differences in melatonin levels between different lifestyle and environmental characteristics. Serum melatonin levels were slightly higher in samples collected from 130 individuals during the winter, (6.36 +/- 0.59 pg/ml) than in samples collected from 119 individuals during the summer (4.83 +/- 0.62 pg/ml). Serum melatonin levels were lowest in current smokers (3.02 +/- 1.25 pg/ml, p = 0.007) compared to never (6.66 +/- 0.66 pg/ml) and former (5.59 +/- 0.50 pg/ml) smokers whereas BMI did not significantly affect serum melatonin levels in this study. In conclusion, the high 5 year correlation of melatonin levels implies that single measurements may be used to detect population level associations between melatonin and risk of cancer. Furthermore, our results reiterate the need to record season of sample collection, and individual characteristics in order to maximize study power and prevent confounding.
C1 [Nogueira, Leticia M.; Sampson, Joshua N.; Yu, Kai; Koshiol, Jill] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Chu, Lisa W.; Hsing, Ann W.] Canc Prevent Inst Calif, Fremont, CA USA.
[Andriole, Gerald] Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA.
[Church, Timothy] Univ Minnesota, Sch Publ Hlth, Dept Environm Hlth Sci, Minneapolis, MN USA.
[Stanczyk, Frank Z.] Univ So Calif, Keck Sch Med, Dept Obstet Gynecol & Prevent Med, Los Angeles, CA 90033 USA.
RP Nogueira, LM (reprint author), NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
EM leticia.nogueira@nih.gov
OI Church, Timothy R./0000-0003-3292-5035
FU Division of Cancer Epidemiology and Genetics; Division of Cancer
Prevention, National Cancer Institute, National Institutes of Health,
Department of Health and Human Services
FX This research was supported by the Intramural Research Program of the
Division of Cancer Epidemiology and Genetics and contracts from the
Division of Cancer Prevention, National Cancer Institute, National
Institutes of Health, Department of Health and Human Services. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 98
TC 4
Z9 4
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 23
PY 2013
VL 8
IS 12
AR e83208
DI 10.1371/journal.pone.0083208
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 278IG
UT WOS:000328882000069
PM 24376664
ER
PT J
AU Nonoguchi, H
Izumi, Y
Nakayama, Y
Matsuzaki, T
Yasuoka, Y
Inoue, T
Inoue, H
Mouri, T
Kawahara, K
Saito, H
Tomita, K
AF Nonoguchi, Hiroshi
Izumi, Yuichiro
Nakayama, Yushi
Matsuzaki, Takanobu
Yasuoka, Yukiko
Inoue, Takeaki
Inoue, Hideki
Mouri, Tomohiko
Kawahara, Katsumasa
Saito, Hideyuki
Tomita, Kimio
TI Effects of Atrial Natriuretic Peptide on Bicarbonate Transport in Long-
and Short-Looped Medullary Thick Ascending Limbs of Rats
SO PLOS ONE
LA English
DT Article
ID CYCLIC ADENOSINE-MONOPHOSPHATE; CORTICAL COLLECTING DUCT; V2 VASOPRESSIN
RECEPTOR; DOWN-REGULATION; CHLORIDE REABSORPTION; ANTIDIURETIC-HORMONE;
NA+/H+ EXCHANGER; HCO3-ABSORPTION; BRATTLEBORO RAT; KIDNEY
AB Atrial natriuretic peptide (ANP) is known to influence NaCl transport in the medullary thick ascending limbs (MAL), where the largest NaCl reabsorption occurs among distal nephron segments in response to arginine vasopressin (AVP). In the present study, we investigated the effect of ANP on bicarbonate (HCO3-) transport in the MAL using an isolated tubule perfusion technique. The HCO3- concentration was measured using free-flow ultramicro-fluorometer. We first observed basal HCO3- reabsorption in both long-and short-looped MALs (lMALs, and sMALs, respectively). AVP inhibited HCO3- reabsorption in both lMALs and sMALs, whereas ANP did not change HCO3- transport. However, in the presence of AVP, ANP restored the HCO3- reabsorption inhibited by AVP both in lMAL and sMAL. The effects of ANP on HCO3- transport was mimicked by cyclic GMP. The mRNA expression level of the vasopressin V2 receptor in lMALs was significantly higher than in sMALs, whereas expression of the V1a receptor was unchanged. In summary, AVP inhibits HCO3- transport, and ANP counteracts the action of AVP on HCO3- transport both in lMALs and sMALs.
C1 [Nonoguchi, Hiroshi] Kitasato Univ, Med Ctr, Dept Internal Med, Kitamoto, Saitama, Japan.
[Nonoguchi, Hiroshi] Kitasato Univ, Med Ctr, Educ & Res Ctr, Kitamoto, Saitama, Japan.
[Izumi, Yuichiro] NHLBI, Syst Biol Ctr, NIH, Bethesda, MD 20892 USA.
[Nakayama, Yushi; Inoue, Takeaki; Inoue, Hideki; Mouri, Tomohiko; Tomita, Kimio] Kumamoto Univ, Grad Sch Med Sci, Dept Nephrol, Kumamoto, Japan.
[Matsuzaki, Takanobu; Saito, Hideyuki] Kumamoto Univ Hosp, Dept Pharm, Kumamoto, Japan.
[Yasuoka, Yukiko; Kawahara, Katsumasa] Kitasato Univ, Sch Med, Dept Physiol, Sagamihara, Kanagawa 228, Japan.
RP Nonoguchi, H (reprint author), Kitasato Univ, Med Ctr, Dept Internal Med, Kitamoto, Saitama, Japan.
EM nono@insti.kitasato-u.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
[21591034, 21591064, 24591244]; Science Research Promotion Fund from the
promotion and Mutual Aid Corporation for Private Schools of Japan
FX This study was supported by Grants-in-Aid for Scientific Research from
the Ministry of Education, Culture, Sports, Science and Technology of
Japan (21591034, 21591064, 24591244) and by the Science Research
Promotion Fund from the promotion and Mutual Aid Corporation for Private
Schools of Japan. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 42
TC 1
Z9 1
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 23
PY 2013
VL 8
IS 12
AR e83146
DI 10.1371/journal.pone.0083146
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 278IG
UT WOS:000328882000066
PM 24376658
ER
PT J
AU Su, WH
Shugart, YY
Chang, KP
Tsang, NM
Tse, KP
Chang, YS
AF Su, Wen-Hui
Shugart, Yin Yao
Chang, Kai-Ping
Tsang, Ngan-Ming
Tse, Ka-Po
Chang, Yu-Sun
TI How Genome-Wide SNP-SNP Interactions Relate to Nasopharyngeal Carcinoma
Susceptibility
SO PLOS ONE
LA English
DT Article
ID GENE-GENE INTERACTION; MISSING HERITABILITY; COMPLEX DISEASES; CLASS-I;
ASSOCIATION; PROSTATE; LOCI; STRATEGIES; EPISTASIS; RISK
AB This study is the first to use genome-wide association study (GWAS) data to evaluate the multidimensional genetic architecture underlying nasopharyngeal cancer. Since analysis of data from GWAS confirms a close and consistent association between elevated risk for nasopharyngeal carcinoma (NPC) and major histocompatibility complex class 1 genes, our goal here was to explore lesser effects of gene-gene interactions. We conducted an exhaustive genome-wide analysis of GWAS data of NPC, revealing two-locus interactions occurring between single nucleotide polymorphisms (SNPs), and identified a number of suggestive interaction loci which were missed by traditional GWAS analyses. Although none of the interaction pairs we identified passed the genome-wide Bonferroni-adjusted threshold for significance, using independent GWAS data from the same population (Stage 2), we selected 66 SNP pairs in 39 clusters with P < 0.01. We identified that in several chromosome regions, multiple suggestive interactions group to form a block-like signal, effectively reducing the rate of false discovery. The strongest cluster of interactions involved the CREB5 gene and a SNP rs1607979 on chromosome 17q22 (P = 9.86 x 10(-11)) which also show trans-expression quantitative loci (eQTL) association in Chinese population. We then detected a complicated cis-interaction pattern around the NPC-associated HLA-B locus, which is immediately adjacent to copy-number variations implicated in male susceptibility for NPC. While it remains to be seen exactly how and to what degree SNP-SNP interactions such as these affect susceptibility for nasopharyngeal cancer, future research on these questions holds great promise for increasing our understanding of this disease's genetic etiology, and possibly also that of other gene-related cancers.
C1 [Su, Wen-Hui] Chang Gung Univ, Dept Biomed Sci, Tao Yuan, Taiwan.
[Su, Wen-Hui] Chang Gung Univ, Coll Med, Grad Inst Biomed Sci, Tao Yuan, Taiwan.
[Su, Wen-Hui; Tse, Ka-Po; Chang, Yu-Sun] Chang Gung Univ, Chang Gung Mol Med Res Ctr, Tao Yuan, Taiwan.
[Shugart, Yin Yao] NIMH, Genom Res Branch, Div Neurosci & Behav Sci, NIH, Bethesda, MD 20892 USA.
[Shugart, Yin Yao] Johns Hopkins Med Sch, Dept Gastroenterol, Baltimore, MD USA.
[Chang, Kai-Ping] Chang Gung Mem Hosp Lin Kou, Dept Otolaryngol Head & Neck Surg, Tao Yuan, Taiwan.
[Tsang, Ngan-Ming] Chang Gung Mem Hosp Lin Kou, Dept Radiat Oncol, Tao Yuan, Taiwan.
RP Su, WH (reprint author), Chang Gung Univ, Dept Biomed Sci, Tao Yuan, Taiwan.
EM whsu@mail.cgu.edu.tw; kay1yao@mail.nih.gov
FU Ministry of Education (Chang Gung University); National Science Council
[NSC 101-2314-B-182-051-MY3]; Chang Gung Memorial Hospital, Taiwan
[CMRPD1A0381, CMRPD1A0382, CMRPD1A0383]; NIMH
FX This work was supported by the Ministry of Education (Chang Gung
University), the National Science Council (NSC 101-2314-B-182-051-MY3),
and Chang Gung Memorial Hospital (CMRPD1A0381, CMRPD1A0382 and
CMRPD1A0383), Taiwan. The funders had no role in the study design, data
collection and analysis, decision to publish, or preparation of the
manuscript. Dr. Yin Yao Shugart was supported by the Intramural Research
Program at NIMH.
NR 43
TC 5
Z9 5
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 23
PY 2013
VL 8
IS 12
AR e83034
DI 10.1371/journal.pone.0083034
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 278IG
UT WOS:000328882000052
PM 24376627
ER
PT J
AU Prochazkova, M
Terse, A
Amin, ND
Hall, B
Utreras, E
Pant, HC
Kulkarni, AB
AF Prochazkova, Michaela
Terse, Anita
Amin, Niranjana D.
Hall, Bradford
Utreras, Elias
Pant, Harish C.
Kulkarni, Ashok B.
TI Activation of cyclin-dependent kinase 5 mediates orofacial mechanical
hyperalgesia
SO MOLECULAR PAIN
LA English
DT Article
DE Cdk5; p35; Trigeminal ganglia; Orofacial pain; Mouse model
ID DORSAL-ROOT GANGLION; CAPSAICIN RECEPTOR; FORMALIN TEST;
NEUROTRANSMITTER RELEASE; NEUROPATHIC PAIN; TRIGEMINAL PAIN; SENSORY
NEURONS; NMDA RECEPTORS; MICE LACKING; CDK5
AB Background: Cyclin-dependent kinase 5 (Cdk5) is a unique member of the serine/threonine kinase family. This kinase plays an important role in neuronal development, and deregulation of its activity leads to neurodegenerative disorders. Cdk5 also serves an important function in the regulation of nociceptive signaling. Our previous studies revealed that the expression of Cdk5 and its activator, p35, is upregulated in nociceptive neurons during peripheral inflammation. The aim of the present study was to characterize the involvement of Cdk5 in orofacial pain. Since mechanical hyperalgesia is the distinctive sign of many orofacial pain conditions, we adapted an existing orofacial stimulation test to assess the behavioral responses to mechanical stimulation in the trigeminal region of the transgenic mice with either reduced or increased Cdk5 activity.
Results: Mice overexpressing or lacking p35, an activator of Cdk5, showed altered phenotype in response to noxious mechanical stimulation in the trigeminal area. Mice with increased Cdk5 activity displayed aversive behavior to mechanical stimulation as indicated by a significant decrease in reward licking events and licking time. The number of reward licking/facial contact events was significantly decreased in these mice as the mechanical intensity increased. By contrast, mice deficient in Cdk5 activity displayed mechanical hypoalgesia.
Conclusions: Collectively, our findings demonstrate for the first time the important role of Cdk5 in orofacial mechanical nociception. Modulation of Cdk5 activity in primary sensory neurons makes it an attractive potential target for the development of novel analgesics that could be used to treat multiple orofacial pain conditions.
C1 [Prochazkova, Michaela; Terse, Anita; Hall, Bradford; Utreras, Elias; Kulkarni, Ashok B.] Natl Inst Dent & Craniofacial Res, Funct Genom Sect, Lab Cell & Dev Biol, NIH, Bethesda, MD 20892 USA.
[Amin, Niranjana D.; Pant, Harish C.] Natl Inst Neurol Disorders & Stroke, Neurochem Lab, NIH, Bethesda, MD 20892 USA.
[Utreras, Elias] Univ Chile, Fac Sci, Lab Cellular & Neuronal Dynam, Santiago, Chile.
RP Kulkarni, AB (reprint author), Natl Inst Dent & Craniofacial Res, Funct Genom Sect, Lab Cell & Dev Biol, NIH, Bethesda, MD 20892 USA.
EM ak40m@nih.gov
FU Divisions of Intramural Research, National Institute of Dental and
Craniofacial Research; National Institute of Neurological Disorders and
Stroke, National Institutes of Health
FX This work was supported by the Divisions of Intramural Research,
National Institute of Dental and Craniofacial Research and the National
Institute of Neurological Disorders and Stroke, National Institutes of
Health. We would like to thank Drs. Michael Iadarola, Jason Keller,
Santosh Mishra, and Varsha Shukla for their helpful discussions during
the course of these studies, and Mr. Larry Jones for his expert
editorial assistance.
NR 66
TC 5
Z9 6
U1 1
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1744-8069
J9 MOL PAIN
JI Mol. Pain
PD DEC 21
PY 2013
VL 9
AR 66
DI 10.1186/1744-8069-9-66
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 294MS
UT WOS:000330051400001
PM 24359609
ER
PT J
AU Suryadevara, M
Bonville, CA
Rosenberg, HF
Domachowske, JB
AF Suryadevara, Manika
Bonville, Cynthia A.
Rosenberg, Helene F.
Domachowske, Joseph B.
TI Local production of CCL3, CCL11, and IFN-gamma correlates with disease
severity in murine parainfluenza virus infection
SO VIROLOGY JOURNAL
LA English
DT Article
DE Sendai virus; Parainfluenza virus; CCL3; MIP-1a; CCL11; Eotaxin;
Interferon-gamma
ID RESPIRATORY SYNCYTIAL VIRUS; SENDAI-VIRUS; PNEUMOVIRUS INFECTION; LUNG
PATHOLOGY; IN-VIVO; MICE; EXPRESSION; CHEMOKINES; DEXAMETHASONE;
BRONCHIOLITIS
AB Background: Using a murine model of parainfluenza virus infection (mPIV1 or Sendai virus; SeV), we compared the inflammatory responses to lethal and sub-lethal infections in inbred DBA/2 mice.
Methods: Mice were intranasally inoculated with either 1.6x10(3) or 1.6x10(5) infectious units (IU) of SeV or diluent control. Clinical data including daily weights, oxygen saturation, and lung function via whole body plethysmography were collected on days 0, 3-7, and 9-14. Clarified whole lung homogenates were evaluated for inflammatory markers by enzyme-linked immunoassay (ELISA). Data were analyzed using ANOVA or Student t-tests, as appropriate.
Results: Mice inoculated with 1.6x10(5) IU of SeV developed a lethal infection with 100% mortality by day 7, while mice inoculated with 1.6x10(3) IU developed a clinically significant infection, with universal weight loss but only 32% mortality. Interestingly, peak virus recovery from the lungs of mice inoculated with 1.6x10(5) IU of SeV did not differ substantially from that detected in mice that received the 100-fold lower inoculum. In contrast, concentrations of CCL5 (RANTES), CCL11 (eotaxin), interferon-gamma, CXCL10 (IP-10), and CCL3 (MIP-1a) were significantly higher in lung tissue homogenates from mice inoculated with 1.6x10(5) IU (p < 0.05). In the lethal infection, levels of CCL11, interferon-. and CCL3 all correlated strongly with disease severity.
Conclusion: We observed that severity of SeV-infection in DBA/2 mice was not associated with virus recovery but rather with the levels of proinflammatory cytokines, specifically CCL11, interferon-. and CCL3, detected in lung tissue in response to SeV infection.
C1 [Suryadevara, Manika; Bonville, Cynthia A.; Domachowske, Joseph B.] SUNY Upstate Med Univ, Dept Pediat, Syracuse, NY 13210 USA.
[Rosenberg, Helene F.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA.
RP Suryadevara, M (reprint author), SUNY Upstate Med Univ, Dept Pediat, 750 E Adams St, Syracuse, NY 13210 USA.
EM suryadem@upstate.edu
NR 29
TC 2
Z9 2
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PD DEC 21
PY 2013
VL 10
AR 357
DI 10.1186/1743-422X-10-357
PG 9
WC Virology
SC Virology
GA 294MX
UT WOS:000330051900001
PM 24359540
ER
PT J
AU Lamart, S
Imran, R
Simon, SL
Doi, K
Morton, LM
Curtis, RE
Lee, C
Drozdovitch, V
Maass-Moreno, R
Chen, CC
Whatley, M
Miller, DL
Pacak, K
Lee, C
AF Lamart, Stephanie
Imran, Rebecca
Simon, Steven L.
Doi, Kazutaka
Morton, Lindsay M.
Curtis, Rochelle E.
Lee, Choonik
Drozdovitch, Vladimir
Maass-Moreno, Roberto
Chen, Clara C.
Whatley, Millie
Miller, Donald L.
Pacak, Karel
Lee, Choonsik
TI Prediction of the location and size of the stomach using patient
characteristics for retrospective radiation dose estimation following
radiotherapy
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID POSITION; THERAPY; CANCER
AB Following cancer radiotherapy, reconstruction of doses to organs, other than the target organ, is of interest for retrospective health risk studies. Reliable estimation of doses to organs that may be partially within or fully outside the treatment field requires reliable knowledge of the location and size of the organs, e.g., the stomach, which is at risk from abdominal irradiation. The stomach location and size are known to be highly variable between individuals, but have been little studied. Moreover, for treatments conducted years ago, medical images of patients are usually not available in medical records to locate the stomach. In light of the poor information available to locate the stomach in historical dose reconstructions, the purpose of this work was to investigate the variability of stomach location and size among adult male patients and to develop prediction models for the stomach location and size using predictor variables generally available in medical records of radiotherapy patients treated in the past. To collect data on stomach size and position, we segmented the contours of the stomach and of the skeleton on contemporary computed tomography (CT) images for 30 male patients in supine position. The location and size of the stomach was found to depend on body mass index (BMI), ponderal index (PI), and age. For example, the anteroposterior dimension of the stomach was found to increase with increasing BMI (approximate to 0.25 cm kg(-1) m(2)) whereas its craniocaudal dimension decreased with increasing PI (approximate to-3.3 cm kg(-1) m(3)) and its transverse dimension increased with increasing PI (approximate to 2.5 cm kg(-1) m(3)). Using the prediction models, we generated three-dimensional computational stomach models from a deformable hybrid phantom for three patients of different BMI. Based on a typical radiotherapy treatment, we simulated radiotherapy treatments on the predicted stomach models and on the CT images of the corresponding patients. Those dose calculations demonstrated good agreement between predicted and actual stomachs compared with doses derived from a reference model of the body that might be used in the absence of individual CT scan data.
C1 [Lamart, Stephanie; Imran, Rebecca; Simon, Steven L.; Doi, Kazutaka; Morton, Lindsay M.; Curtis, Rochelle E.; Drozdovitch, Vladimir; Lee, Choonsik] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Lee, Choonik] Univ Michigan Hosp, Dept Radiat Oncol, Ann Arbor, MI 48109 USA.
[Maass-Moreno, Roberto; Chen, Clara C.; Miller, Donald L.] NIH, Dept Radiol & Imaging Sci, Ctr Clin, Bethesda, MD 20892 USA.
[Whatley, Millie] US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA.
[Pacak, Karel] Eunice Kennedy Shriver Natl Inst Child Hlth & Dev, NIH, Bethesda, MD USA.
RP Lamart, S (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
EM leechoonsik@mail.nih.gov
RI Morton, Lindsay/B-5234-2015; Lee, Choonsik/C-9023-2015
OI Morton, Lindsay/0000-0001-9767-2310; Lee, Choonsik/0000-0003-4289-9870
FU National Cancer Institute
FX This study utilized the high-performance computational capabilities of
the Biowulf Linux cluster at the National Institutes of Health,
Bethesda, MD (http://biowulf.nih.gov). This work was supported by the
National Cancer Institute's intramural research program.
NR 16
TC 4
Z9 4
U1 0
U2 1
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD DEC 21
PY 2013
VL 58
IS 24
BP 8739
EP 8753
DI 10.1088/0031-9155/58/24/8739
PG 15
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 266SG
UT WOS:000328043400011
PM 24301086
ER
PT J
AU Huang, X
Meng, B
Iqbal, J
Ding, BB
Perry, AM
Cao, WF
Smith, LM
Bi, CF
Jiang, CS
Greiner, TC
Weisenburger, DD
Rimsza, L
Rosenwald, A
Ott, G
Delabie, J
Campo, E
Braziel, RM
Gascoyne, RD
Cook, JR
Tubbs, RR
Jaffe, ES
Armitage, JO
Vose, JM
Staudt, LM
McKeithan, TW
Chan, WC
Ye, BH
Fu, K
AF Huang, Xin
Meng, Bin
Iqbal, Javeed
Ding, B. Belinda
Perry, Anamarija M.
Cao, Wenfeng
Smith, Lynette M.
Bi, Chengfeng
Jiang, Chunsun
Greiner, Timothy C.
Weisenburger, Dennis D.
Rimsza, Lisa
Rosenwald, Andreas
Ott, German
Delabie, Jan
Campo, Elias
Braziel, Rita M.
Gascoyne, Randy D.
Cook, James R.
Tubbs, Raymond R.
Jaffe, Elaine S.
Armitage, James O.
Vose, Julie M.
Staudt, Louis M.
McKeithan, Timothy W.
Chan, Wing C.
Ye, B. Hilda
Fu, Kai
TI Activation of the STAT3 Signaling Pathway Is Associated With Poor
Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID MOLECULAR SUBTYPES; GASTRIC-CANCER; EXPRESSION; RITUXIMAB; PROGNOSIS;
CHEMOTHERAPY; THERAPY; GENE; METALLOTHIONEIN; TRANSCRIPTION-3
AB Purpose We previously reported that constitutive STAT3 activation is a prominent feature of the activated B-cell subtype of diffuse large B-cell lymphomas (ABC-DLBCL). In this study, we investigated whether STAT3 activation can risk stratify patients with DLBCL.
Patients and Methods By an immunohistochemical method, we investigated phosphotyrosine STAT3 (PY-STAT3) expression from 185 patients with DLBCL treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). Cell line-based siRNA experiments were also performed to generate an 11-gene, PY-STAT3 activation signature, which was used to study a previously published cohort of 222 patients with DLBCL. The STAT3 activation status determined by these two methods and by STAT3 mRNA levels were then correlated with survival.
Results PY-STAT3 was detected in 37% of DLBCL and enriched in ABC-DLBCL cases (P = .03). PY-STAT3 positivity significantly correlated with poor overall survival (OS; P = .01) and event-free survival (EFS; P = .006). Similar observations were made for high levels of STAT3 mRNA. In multivariable analysis, PY-STAT3 status (P = .02), International Prognostic Index (P = .02), and BCL2 expression (P = .046) were independent prognosticators of OS in this cohort. Among the cell-of-origin subgroups, PY-STAT3 was associated with poor EFS among non-germinal center B-cell DLBCL cases only (P = .027). Similarly, the 11-gene STAT3 activation signature correlated with poor survival in the entire DLBCL cohort (OS, P < .001; EFS, P < .001) as well as the ABC-DLBCL subgroup (OS, P = .029; EFS, P = .025).
Conclusion STAT3 activation correlated with poor survival in patients with DLBCL treated with R-CHOP, especially those with tumors of the ABC-DLBCL subtype.
C1 [Huang, Xin; Meng, Bin; Cao, Wenfeng; Fu, Kai] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin, Peoples R China.
[Bi, Chengfeng] Sichuan Univ, West China Sch Med, West China Hosp, Chengdu 610064, Peoples R China.
[Huang, Xin; Meng, Bin; Iqbal, Javeed; Perry, Anamarija M.; Cao, Wenfeng; Smith, Lynette M.; Bi, Chengfeng; Jiang, Chunsun; Greiner, Timothy C.; Weisenburger, Dennis D.; Armitage, James O.; Vose, Julie M.; McKeithan, Timothy W.; Chan, Wing C.; Fu, Kai] Univ Nebraska Med Ctr, Omaha, NE 68198 USA.
[Ding, B. Belinda; Ye, B. Hilda] Albert Einstein Coll Med, Bronx, NY 10467 USA.
[Rimsza, Lisa] Univ Arizona, Tucson, AZ USA.
[Rosenwald, Andreas] Univ Wurzburg, D-97070 Wurzburg, Germany.
[Ott, German; Delabie, Jan] Univ Oslo, Rikshosp, Radiumhosp, Med Ctr, N-0027 Oslo, Norway.
[Campo, Elias] Univ Barcelona, Hosp Clin, Barcelona, Spain.
[Braziel, Rita M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Gascoyne, Randy D.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
[Cook, James R.; Tubbs, Raymond R.] Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44106 USA.
[Jaffe, Elaine S.; Staudt, Louis M.] NCI, Ctr Canc Res, Bethesda, MD 20892 USA.
RP Fu, K (reprint author), Univ Nebraska Med Ctr, Dept Pathol & Microbiol, 983135 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM kfu@unmc.edu
RI Huang, Xin/P-8103-2014;
OI Huang, Xin/0000-0001-6778-8849; McKeithan, Timothy/0000-0003-2242-3074;
Delabie, Jan/0000-0001-5023-0689; Jaffe, Elaine/0000-0003-4632-0301;
Campo, elias/0000-0001-9850-9793
FU Lymphoma Research Foundation Career Development Award; National
Institutes of Health Grant [R01 CA85573, U01 CA114778]; Leukemia &
Lymphoma Society Translational Research Grant [62550]; Chinese
Scholarship Council; National Institutes of Health Fogarty Grant [D43
TW0014290]; Lauri Strauss Leukemia Foundation
FX Supported in part by a Lymphoma Research Foundation Career Development
Award (K.F.); National Institutes of Health Grant No. R01 CA85573
(B.H.Y.) and U01 CA114778 (W.C.C.); Leukemia & Lymphoma Society
Translational Research Grant No. 62550 (B.H.Y.); scholarship awards from
the Chinese Scholarship Council (X. H. and C.B.); National Institutes of
Health Fogarty Grant No. D43 TW0014290; and a fellowship grant from the
Lauri Strauss Leukemia Foundation (B.B.D.).
NR 45
TC 38
Z9 41
U1 1
U2 16
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD DEC 20
PY 2013
VL 31
IS 36
BP 4520
EP 4528
DI 10.1200/JCO.2012.45.6004
PG 9
WC Oncology
SC Oncology
GA 282QG
UT WOS:000329186700008
PM 24220563
ER
PT J
AU Chaturvedi, AK
Anderson, WF
Lortet-Tieulent, J
Curado, MP
Ferlay, J
Franceschi, S
Rosenberg, PS
Bray, F
Gillison, ML
AF Chaturvedi, Anil K.
Anderson, William F.
Lortet-Tieulent, Joannie
Curado, Maria Paula
Ferlay, Jacques
Franceschi, Silvia
Rosenberg, Philip S.
Bray, Freddie
Gillison, Maura L.
TI Worldwide Trends in Incidence Rates for Oral Cavity and Oropharyngeal
Cancers
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMAS; PERIOD-COHORT MODELS; HUMAN-PAPILLOMAVIRUS;
NECK-CANCER; UNITED-STATES; PHARYNGEAL CANCER; HEAD; RISK; EPIDEMIOLOGY;
POPULATION
AB Purpose Human papillomavirus (HPV) has been identified as the cause of the increasing oropharyngeal cancer (OPC) incidence in some countries. To investigate whether this represents a global phenomenon, we evaluated incidence trends for OPCs and oral cavity cancers (OCCs) in 23 countries across four continents.
Methods We used data from the Cancer Incidence in Five Continents database Volumes VI to IX (years 1983 to 2002). Using age-period-cohort modeling, incidence trends for OPCs were compared with those of OCCs and lung cancers to delineate the potential role of HPV vis-a-vis smoking on incidence trends. Analyses were country specific and sex specific.
Results OPC incidence significantly increased during 1983 to 2002 predominantly in economically developed countries. Among men, OPC incidence significantly increased in the United States, Australia, Canada, Japan, and Slovakia, despite nonsignificant or significantly decreasing incidence of OCCs. In contrast, among women, in all countries with increasing OPC incidence (Denmark, Estonia, France, the Netherlands, Poland, Slovakia, Switzerland, and United Kingdom), there was a concomitant increase in incidence of OCCs. Although increasing OPC incidence among men was accompanied by decreasing lung cancer incidence, increasing incidence among women was generally accompanied by increasing lung cancer incidence. The magnitude of increase in OPC incidence among men was significantly higher at younger ages (< 60 years) than older ages in the United States, Australia, Canada, Slovakia, Denmark, and United Kingdom.
Conclusion OPC incidence significantly increased during 1983 to 2002 predominantly in developed countries and at younger ages. These results underscore a potential role for HPV infection on increasing OPC incidence, particularly among men.
C1 [Chaturvedi, Anil K.; Anderson, William F.; Rosenberg, Philip S.] NCI, Rockville, MD 20852 USA.
[Gillison, Maura L.] Ohio State Univ, Columbus, OH 43210 USA.
[Curado, Maria Paula] Int Prevent Res Inst, Lyon, France.
RP Chaturvedi, AK (reprint author), NCI, Infect & Immunoepidemiol Branch, Div Canc Epidemiol & Genet, NIH, 9609 Med Ctr Dr, Rockville, MD 20852 USA.
EM chaturva@mail.nih.gov
RI Chaturvedi, Anil/J-2024-2015; Curado, Maria Paula/M-6200-2013
OI Chaturvedi, Anil/0000-0003-2696-8899; Curado, Maria
Paula/0000-0001-8172-2483
FU Intramural Research Program of the US National Cancer Institute;
Institut National du Cancer (SPLIT project Grant) [2011/196]
FX Supported in part by the Intramural Research Program of the US National
Cancer Institute and by a grant from the Institut National du Cancer
(SPLIT project Grant No. 2011/196).
NR 37
TC 184
Z9 188
U1 6
U2 35
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD DEC 20
PY 2013
VL 31
IS 36
BP 4550
EP 4559
DI 10.1200/JCO.2013.50.3870
PG 10
WC Oncology
SC Oncology
GA 282QG
UT WOS:000329186700012
PM 24248688
ER
PT J
AU Landrigan, PJ
Wright, RO
Birnbaum, LS
AF Landrigan, Philip J.
Wright, Robert O.
Birnbaum, Linda S.
TI Mercury Toxicity in Children
SO SCIENCE
LA English
DT Letter
ID FISH CONSUMPTION; PRENATAL EXPOSURE; HAIR MERCURY; METHYLMERCURY
C1 [Landrigan, Philip J.; Wright, Robert O.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Birnbaum, Linda S.] NIEHS, Res Triangle Pk, NC 27709 USA.
RP Landrigan, PJ (reprint author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
EM phil.landrigan@mssm.edu
NR 10
TC 4
Z9 4
U1 4
U2 30
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD DEC 20
PY 2013
VL 342
IS 6165
BP 1447
EP 1447
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 274ZI
UT WOS:000328644300032
PM 24357301
ER
PT J
AU Kumar, V
Kim, K
Joseph, C
Kourrich, S
Yoo, SH
Huang, HC
Vitaterna, MH
de Villena, FPM
Churchill, G
Bonci, A
Takahashi, JS
AF Kumar, Vivek
Kim, Kyungin
Joseph, Chryshanthi
Kourrich, Said
Yoo, Seung-Hee
Huang, Hung Chung
Vitaterna, Martha H.
de Villena, Fernando Pardo-Manuel
Churchill, Gary
Bonci, Antonello
Takahashi, Joseph S.
TI C57BL/6N Mutation in Cytoplasmic FMRP interacting protein 2 Regulates
Cocaine Response
SO SCIENCE
LA English
DT Article
ID NEURONAL CONNECTIVITY; SYNAPTIC PLASTICITY; LABORATORY MOUSE; ADDICTION;
COMPLEX; SUBSTRAINS; KNOCKOUT; MEMORY; WAVE-1; GENOME
AB The inbred mouse C57BL/6J is the reference strain for genome sequence and for most behavioral and physiological phenotypes. However, the International Knockout Mouse Consortium uses an embryonic stem cell line derived from a related C57BL/6N substrain. We found that C57BL/6N has a lower acute and sensitized response to cocaine and methamphetamine. We mapped a single causative locus and identified a nonsynonymous mutation of serine to phenylalanine (S968F) in Cytoplasmic FMRP interacting protein 2 (Cyfip2) as the causative variant. The S968F mutation destabilizes CYFIP2, and deletion of the C57BL/6N mutant allele leads to acute and sensitized cocaine-response phenotypes. We propose that CYFIP2 is a key regulator of cocaine response in mammals and present a framework to use mouse substrains to identify previously unknown genes and alleles regulating behavior.
C1 [Kumar, Vivek; Kim, Kyungin; Joseph, Chryshanthi; Yoo, Seung-Hee; Huang, Hung Chung; Takahashi, Joseph S.] Univ Texas SW Med Ctr Dallas, Dept Neurosci, Dallas, TX 75390 USA.
[Kumar, Vivek; Takahashi, Joseph S.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA.
[Kourrich, Said; Bonci, Antonello] NIDA, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
[Vitaterna, Martha H.] Northwestern Univ, Dept Neurobiol, Evanston, IL 60208 USA.
[de Villena, Fernando Pardo-Manuel] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
[Churchill, Gary] Jackson Lab, Bar Harbor, ME 04609 USA.
RP Takahashi, JS (reprint author), Univ Texas SW Med Ctr Dallas, Dept Neurosci, Dallas, TX 75390 USA.
EM joseph.takahashi@utsouthwestern.edu
RI kourrich, said/M-3916-2014; Takahashi, Joseph/E-8482-2012
OI Takahashi, Joseph/0000-0003-0384-8878
FU National Research Service Award from NIDA [F32DA024556]; NIH
[U01MH61915]
FX We thank A. Khan and W. Khan for genotyping help; A. M. Wissman, J.
Gibson, and K. Huber for help with diolistics; C. Olker for behavioral
testing; C. Cowan for advice on sensitization; M. Strobel for C57BL/6
substrain DNA; S. Padrick, B. Chen, and M. Rosen for WRC reagents and
advice; T. Keane (Sanger Centre) for access to sequencing data; N. Kumar
and I. Kornblum for technical help; and O. Hermanson and P. Lowrey for
advice on manuscript. V. K. was funded through National Research Service
Award F32DA024556 from NIDA. NIH grant U01MH61915 funded J. S. T. J. S.
T. is an Investigator and S.H.Y. and V. K. were associates in the Howard
Hughes Medical Institute.
NR 23
TC 36
Z9 36
U1 1
U2 6
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD DEC 20
PY 2013
VL 342
IS 6165
BP 1508
EP 1512
DI 10.1126/science.1245503
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 274ZI
UT WOS:000328644300058
PM 24357318
ER
PT J
AU Sutherland, ML
Fabre, KM
Tagle, DA
AF Sutherland, Margaret L.
Fabre, Kristin M.
Tagle, Danilo A.
TI The National Institutes of Health Microphysiological Systems Program
focuses on a critical challenge in the drug discovery pipeline
INTRODUCTION
SO STEM CELL RESEARCH & THERAPY
LA English
DT Editorial Material
ID SPECIES-DIFFERENCES; COUMARIN; INHIBITION; METABOLISM
AB The National Institutes of Health has partnered with the US Food and Drug Administration and the Defense Advanced Research Projects Agency to accelerate the development of human microphysiological systems (MPS) that address challenges faced in predictive toxicity assessment and efficacy analysis of new molecular entities during the preclinical phase of drug development. Use of human MPS could provide better models for predicting the efficacy of new molecular entities in clinical trials. It is also anticipated that improvements in predicting drug toxicities early in the drug development process through the use of MPS or human organs-on-a-chip will decrease the need to withdraw new therapies from the market and minimize or eliminate deaths due to unidentified drug toxicities.
C1 [Sutherland, Margaret L.] NINDS, NIH, Bethesda, MD 20892 USA.
[Fabre, Kristin M.; Tagle, Danilo A.] Natl Ctr Advancing Translat Sci, NIH, Bethesda, MD 20892 USA.
RP Sutherland, ML (reprint author), NINDS, NIH, 6001 Execut Blvd, Bethesda, MD 20892 USA.
EM sutherlandm@ninds.nih.gov; fabrek@mail.nih.gov
NR 13
TC 19
Z9 19
U1 2
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD DEC 20
PY 2013
VL 4
SU 1
AR I1
DI 10.1186/scrt361
PG 5
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 286DG
UT WOS:000329444700001
PM 24565163
ER
PT J
AU Tang, WK
Xia, D
AF Tang, Wai Kwan
Xia, Di
TI Altered Intersubunit Communication Is the Molecular Basis for Functional
Defects of Pathogenic p97 Mutants
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE ATPases; Crystal Structure; Genetic Diseases; Molecular Chaperone;
Mutant; ATPase Activity; IBMPFD; Communication; p97; VCP; Prebound ADP
ID VALOSIN-CONTAINING PROTEIN; DISEASE-RELATED MUTANTS; ATPASE ACTIVITY;
AAA ATPASE; FRONTOTEMPORAL DEMENTIA; PAGET-DISEASE;
P97/VALOSIN-CONTAINING PROTEIN; CONFORMATIONAL-CHANGES;
NUCLEOTIDE-BINDING; VCP DISEASE
AB Background: Single-point mutations in AAA chaperone p97 cause multiple disorders, but the molecular basis remains unknown. Results: Significant differences in structural and biochemical properties between wild type and pathogenic p97 were revealed. Conclusion: Mutations altered the communication among subunits within a hexameric p97, resulting in p97 molecules with defective function. Significance: Mechanistic insights into the function of p97 are provided.
The human AAA ATPase p97 is a molecular chaperone essential in cellular proteostasis. Single amino acid substitutions in p97 have been linked to a clinical multiple-disorder condition known as inclusion body myopathy associated with Paget's disease of the bone and frontotemporal dementia. How the mutations affect the molecular mechanism that governs the function of p97 remains unclear. Here, we show that within the hexameric ring of a mutant p97, D1 domains fail to regulate their respective nucleotide-binding states, as evidenced by the lower amount of prebound ADP, weaker ADP binding affinity, full occupancy of adenosine-5-O-(3-thiotriphosphate) binding, and elevated overall ATPase activity, indicating a loss of communication among subunits. Defective communication between subunits is further illustrated by altered conformation in the side chain of residue Phe-360 that probes into the nucleotide-binding pocket from a neighboring subunit. Consequently, conformations of N domains in a hexameric ring of a mutant p97 become uncoordinated, thus impacting its ability to process substrate.
C1 [Tang, Wai Kwan; Xia, Di] NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Xia, D (reprint author), NCI, Cell Biol Lab, NIH, 37 Convent Dr,Bldg 37,Rm 2122C, Bethesda, MD 20892 USA.
EM xiad@mail.nih.gov
FU National Institutes of Health Intramural Research Program (NCI, Center
for Cancer Research)
FX This work was supported, in whole or in part, by the National Institutes
of Health Intramural Research Program (NCI, Center for Cancer Research).
NR 45
TC 25
Z9 25
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 20
PY 2013
VL 288
IS 51
BP 36624
EP 36635
DI 10.1074/jbc.M113.488924
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 278IQ
UT WOS:000328883400042
PM 24196964
ER
PT J
AU Kuo, CL
Zaykin, D
AF Kuo, Chia-Ling
Zaykin, Dmitri
TI The Ranking Probability Approach and Its Usage in Design and Analysis of
Large-Scale Studies
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; POSITIVE REPORT; FALSE; DISCOVERY
AB In experiments with many statistical tests there is need to balance type I and type II error rates while taking multiplicity into account. In the traditional approach, the nominal a-level such as 0.05 is adjusted by the number of tests, K, i.e., as 0.05/K. Assuming that some proportion of tests represent "true signals'', that is, originate from a scenario where the null hypothesis is false, power depends on the number of true signals and the respective distribution of effect sizes. One way to define power is for it to be the probability of making at least one correct rejection at the assumed a-level. We advocate an alternative way of establishing how "well-powered'' a study is. In our approach, useful for studies with multiple tests, the ranking probability P-x,P-u is controlled, defined as the probability of making at least x correct rejections while rejecting hypotheses with u smallest P-values. The two approaches are statistically related. Probability that the smallest P-value is a true signal (i.e., P-1,P-1) is equal to the power at the level 0.5/K, to an very good excellent approximation. Ranking probabilities are also related to the false discovery rate and to the Bayesian posterior probability of the null hypothesis. We study properties of our approach when the effect size distribution is replaced for convenience by a single "typical'' value taken to be the mean of the underlying distribution. We conclude that its performance is often satisfactory under this simplification; however, substantial imprecision is to be expected when K is very large and u is small. Precision is largely restored when three values with the respective abundances are used instead of a single typical effect size value.
C1 [Kuo, Chia-Ling] Univ Connecticut, Ctr Hlth, Ctr Quantitat Med, Farmington, CT USA.
[Zaykin, Dmitri] NIEHS, Biostat Branch, Res Triangle Pk, NC 27709 USA.
RP Zaykin, D (reprint author), NIEHS, Biostat Branch, POB 12233, Res Triangle Pk, NC 27709 USA.
EM dmitri.zaykin@nih.gov
FU Intramural Research Program of the NIH, National Institute of
Environmental Health Sciences
FX This research was supported by the Intramural Research Program of the
NIH, National Institute of Environmental Health Sciences. The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 11
TC 1
Z9 1
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2013
VL 8
IS 12
AR e83079
DI 10.1371/journal.pone.0083079
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276IX
UT WOS:000328745100086
PM 24376639
ER
PT J
AU Okamoto, KW
Robert, MA
Lloyd, AL
Gould, F
AF Okamoto, Kenichi W.
Robert, Michael A.
Lloyd, Alun L.
Gould, Fred
TI A Reduce and Replace Strategy for Suppressing Vector-Borne Diseases:
Insights from a Stochastic, Spatial Model
SO PLOS ONE
LA English
DT Article
ID AEDES-AEGYPTI DIPTERA; LIFE TABLE MODEL; GENETIC-CONTROL; CULICIDAE
PRODUCTION; MOSQUITO-CONTROL; DENGUE VECTOR; POPULATION; DISPERSAL;
WOLBACHIA; IQUITOS
AB Two basic strategies have been proposed for using transgenic Aedes aegypti mosquitoes to decrease dengue virus transmission: population reduction and population replacement. Here we model releases of a strain of Ae. aegypti carrying both a gene causing conditional adult female mortality and a gene blocking virus transmission into a wild population to assess whether such releases could reduce the number of competent vectors. We find this "reduce and replace" strategy can decrease the frequency of competent vectors below 50% two years after releases end. Therefore, this combined approach appears preferable to releasing a strain carrying only a female-killing gene, which is likely to merely result in temporary population suppression. However, the fixation of anti-pathogen genes in the population is unlikely. Genetic drift at small population sizes and the spatially heterogeneous nature of the population recovery after releases end prevent complete replacement of the competent vector population. Furthermore, releasing more individuals can be counterproductive in the face of immigration by wild-type mosquitoes, as greater population reduction amplifies the impact wildtype migrants have on the long-term frequency of the anti-pathogen gene. We expect the results presented here to give pause to expectations for driving an anti-pathogen construct to fixation by relying on releasing individuals carrying this two-gene construct. Nevertheless, in some dengue-endemic environments, a spatially heterogeneous decrease in competent vectors may still facilitate decreasing disease incidence.
C1 [Okamoto, Kenichi W.; Gould, Fred] N Carolina State Univ, Dept Entomol, Raleigh, NC 27695 USA.
[Robert, Michael A.; Lloyd, Alun L.] N Carolina State Univ, Dept Math, Raleigh, NC 27695 USA.
[Robert, Michael A.; Lloyd, Alun L.] N Carolina State Univ, Biomath Grad Program, Raleigh, NC 27695 USA.
[Lloyd, Alun L.; Gould, Fred] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
RP Okamoto, KW (reprint author), N Carolina State Univ, Dept Entomol, Raleigh, NC 27695 USA.
EM kenichi_okamoto@ncsu.edu
FU National Institutes of Health (NIH) [R01AI091980-01A1]; Foundation for
the NIH through the Bill and Melinda Gates Foundation Grand Challenges
in Global Health initiative; University of Pretoria North Carolina State
University Strategic Collaboration Seed Grant
FX This work is funded in part by National Institutes of Health (NIH) grant
R01AI091980-01A1, a grant to the Regents of the University of California
from the Foundation for the NIH through the Bill and Melinda Gates
Foundation Grand Challenges in Global Health initiative, and in part by
a University of Pretoria North Carolina State University Strategic
Collaboration Seed Grant (to A. L. Lloyd). The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 39
TC 12
Z9 12
U1 9
U2 22
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2013
VL 8
IS 12
AR e81860
DI 10.1371/journal.pone.0081860
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276IX
UT WOS:000328745100010
PM 24376506
ER
PT J
AU Polizzotto, MN
Uldrick, TS
Wang, V
Aleman, K
Wyvill, KM
Marshall, V
Pittaluga, S
O'Mahony, D
Whitby, D
Tosato, G
Steinberg, SM
Little, RF
Yarchoan, R
AF Polizzotto, Mark N.
Uldrick, Thomas S.
Wang, Victoria
Aleman, Karen
Wyvill, Kathleen M.
Marshall, Vickie
Pittaluga, Stefania
O'Mahony, Deirdre
Whitby, Denise
Tosato, Giovanna
Steinberg, Seth M.
Little, Richard F.
Yarchoan, Robert
TI Human and viral interleukin-6 and other cytokines in Kaposi sarcoma
herpesvirus-associated multicentric Castleman disease
SO BLOOD
LA English
DT Article
ID PRIMARY EFFUSION LYMPHOMA; DNA-SEQUENCES; NODE HYPERPLASIA;
GENE-EXPRESSION; HUMAN IL-6; B-CELLS; RECEPTOR; KSHV; RITUXIMAB;
ANTIBODY
AB Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a polyclonal B-cell lymphoproliferative disorder. Human (h) IL-6 and a KSHV-encoded homolog, viral IL-6, have been hypothesized to contribute to its pathogenesis, but their relative contributions to disease activity is not well understood. We prospectively characterized KSHV viral load (VL), viral (v) and hIL-6, and other cytokines during KSHV-MCD flare and remission in 21 patients with 34 flares and 20 remissions. KSHV-VL, vIL-6, hIL-6, IL-10, and to a lesser extent TNF-alpha, and IL-1 beta were each elevated during initial flares compared with remission. Flares fell into 3 distinct IL-6 profiles: those associated with elevations of vIL6-only (2 flares, 6%), hIL-6 elevations only (17 flares, 50%), and elevations in both hIL-6 and vIL-6 (13 flares, 38%). Compared with hIL-6-only flares, flares with elevated hIL-6 plus vIL-6 exhibited higher C-reactive protein (CRP) (P = .0009); worse hyponatremia (P = .02); higher KSHV VL (P = .016), and higher IL-10 (P = .012). This analysis shows vIL-6 and hIL-6 can independently or together lead to KSHV-MCD flares, and suggests that vIL-6 and hIL-6 may jointly contribute to disease severity. These findings have implications for the development of novel KSHV-MCD therapies targeting IL-6 and its downstream signaling. This trial was registered at clinicaltrials.gov as #NCT099073.
C1 [Polizzotto, Mark N.; Uldrick, Thomas S.; Wang, Victoria; Aleman, Karen; Wyvill, Kathleen M.; O'Mahony, Deirdre; Little, Richard F.; Yarchoan, Robert] NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
[Marshall, Vickie; Whitby, Denise] Frederick Natl Lab Canc Res, Viral Oncol Sect, AIDS & Canc Virus Program, Frederick, MD USA.
[Pittaluga, Stefania] NCI, Pathol Lab, Ctr Canc Res, Bethesda, MD 20892 USA.
[Tosato, Giovanna] NCI, Cellular Oncol Lab, Ctr Canc Res, Bethesda, MD 20892 USA.
[Steinberg, Seth M.] NCI, Biostat & Data Management Sect, Ctr Canc Res, Bethesda, MD 20892 USA.
RP Yarchoan, R (reprint author), NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Room 6N106,Bldg 10, Bethesda, MD 20892 USA.
EM mark.polizzotto@nih.gov; robert.yarchoan@nih.gov
FU Intramural Research Program of the National Institutes of Health,
National Cancer Institute
FX This work was supported in part by the Intramural Research Program of
the National Institutes of Health, National Cancer Institute.
NR 54
TC 37
Z9 38
U1 0
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 19
PY 2013
VL 122
IS 26
BP 4189
EP 4198
DI 10.1182/blood-2013-08-519959
PG 10
WC Hematology
SC Hematology
GA 290FX
UT WOS:000329741000013
PM 24174627
ER
PT J
AU Sheu, HL
Kim, S
Laane, J
AF Sheu, Hong-Li
Kim, Sunghwan
Laane, Jaan
TI Infrared, Raman, and Ultraviolet Absorption Spectra and Theoretical
Calculations and Structure of 2,6-Difluoropyridine in Its Ground and
Excited Electronic States
SO JOURNAL OF PHYSICAL CHEMISTRY A
LA English
DT Article
ID AB-INITIO CALCULATIONS; POTENTIAL-ENERGY FUNCTION; LASER-INDUCED
FLUORESCENCE; VIBRATIONAL-SPECTRA; DFT CALCULATIONS; SPECTROSCOPIC
DETERMINATION; 1,4-BENZODIOXAN; PYRIDINE; MODES; 1,4-DIHYDRONAPHTHALENE
AB The infrared and Raman spectra of 2,6-difluoropyridine (26DFPy) along with ab initio and DFT computations have been used to assign the vibrations of the molecule in its S-0 electronic ground state and to calculate its structure. The ultraviolet absorption spectrum showed the electronic transition to the S-1(pi pi*) state to be at 37 820.2 cm(-1). With the aid of ab initio computations the vibrational frequencies for this excited state were also determined. TD-B3LYP and CASSCF computations for the excited states were carried out to calculate the structures for the S-1(pi pi*) and S-2(pi pi*) excited states. The CASSCF results predict that the S-1(pi pi*) state is planar and that the S-2(pi pi*) state has a barrier to planarity of 256 cm(-1). The TD-B3LYP computations predict a barrier of 124 cm-1 for the S-1(pi pi*) state, but the experimental results support the planar structure. Hypothetical models for the ring-puckering potential energy function were calculated for both electronic excited states to show the predicted quantum states. The changes in the vibrational frequencies in the two excited states reflect the weaker pi bonding within the pyridine ring.
C1 [Sheu, Hong-Li; Laane, Jaan] Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA.
[Kim, Sunghwan] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, US Dept HHS, Bethesda, MD 20894 USA.
RP Laane, J (reprint author), Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA.
EM laane@chem.tamu.edu
RI Kim, Sunghwan/A-6738-2008; Laane, Jaan/O-4379-2014; Sheu,
Hong-Li/B-4889-2016
OI Kim, Sunghwan/0000-0001-9828-2074; Laane, Jaan/0000-0003-4423-6122;
FU Robert A. Welch Foundation [A-0396]; Intramural Research Program of the
NIH, National Library of Medicine; National Science Foundation
[CHE-0541587]; Biowulf Linux cluster at the National Institutes of
Health, Bethesda, MD
FX This article is dedicated to Terry A. Miller and his contributions to
the field of molecular spectroscopy. The authors wish to thank the
Robert A. Welch Foundation (Grant A-0396) for financial support. This
research was also supported in part by the Intramural Research Program
of the NIH, National Library of Medicine. Calculations were carried out
on the Texas A&M Department of Chemistry Medusa computer system funded
by the National Science Foundation, Grant No. CHE-0541587, and the
Biowulf Linux cluster at the National Institutes of Health, Bethesda, MD
(http://biowulf.nih.gov).
NR 33
TC 3
Z9 3
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1089-5639
J9 J PHYS CHEM A
JI J. Phys. Chem. A
PD DEC 19
PY 2013
VL 117
IS 50
BP 13596
EP 13604
DI 10.1021/jp407592r
PG 9
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 278WI
UT WOS:000328920200044
PM 24070189
ER
PT J
AU Weinrich, M
Worcester, DL
AF Weinrich, Michael
Worcester, David L.
TI Xenon and Other Volatile Anesthetics Change Domain Structure in Model
Lipid Raft Membranes
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID X-RAY; GENERAL-ANESTHESIA; PHASE-DIAGRAM; BILAYERS; ISOFLURANE;
CHOLESTEROL; DIFFRACTION; HALOTHANE; MECHANISM; PRESSURE
AB Inhalation anesthetics have been in clinical use for over 160 years, but the molecular mechanisms of action continue to be investigated. Direct interactions with ion channels received much attention after it was found that anesthetics do not change the structure of homogeneous model membranes. However, it was recently found that halothane, a prototypical anesthetic, changes domain structure of a binary lipid membrane. The noble gas xenon is an excellent anesthetic and provides a pivotal test of the generality of this finding, extended to ternary lipid raft mixtures. We report that xenon and conventional anesthetics change the domain equilibrium in two canonical ternary lipid raft mixtures. These findings demonstrate a membrane-mediated mechanism whereby inhalation anesthetics can affect the lipid environment of transmembrane proteins.
C1 [Weinrich, Michael] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD 20892 USA.
[Weinrich, Michael; Worcester, David L.] NIST, Ctr Neutron Res, Gaithersburg, MD 20899 USA.
[Worcester, David L.] Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.
[Worcester, David L.] Univ Missouri, Div Biol, Columbia, MO 65211 USA.
RP Weinrich, M (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD 20892 USA.
EM mw287k@nih.gov
FU US National Institute of Health [GM86685]
FX We thank Drs. Sergey Bezrukov and Hirsh Nanda for their comments, Dr.
David Sandstrom for the use of his gas chromatograph, and Dr. Jason
Simmons for his assistance with the X-ray diffractometer. D.W. was
supported by US National Institute of Health Grant GM86685 (to Stephen
H. White). The Center for Neutron Research provided facilities for
neutron and X-ray diffraction.. The identification of any commercial
product or trade name does not imply any endorsement or recommendation
by the National Institute of Standards and Technology.
NR 42
TC 12
Z9 12
U1 0
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD DEC 19
PY 2013
VL 117
IS 50
BP 16141
EP 16147
DI 10.1021/jp411261g
PG 7
WC Chemistry, Physical
SC Chemistry
GA 278WM
UT WOS:000328920600023
PM 24299622
ER
PT J
AU Cook, MB
Matthews, CE
Gunja, MZ
Abid, Z
Freedman, ND
Abnet, CC
AF Cook, Michael B.
Matthews, Charles E.
Gunja, Munira Z.
Abid, Zaynah
Freedman, Neal D.
Abnet, Christian C.
TI Physical Activity and Sedentary Behavior in Relation to Esophageal and
Gastric Cancers in the NIH-AARP Cohort
SO PLOS ONE
LA English
DT Article
ID BODY-MASS INDEX; SQUAMOUS-CELL CARCINOMA; POPULATION-BASED COHORT;
NATIONAL DEATH INDEX; SOCIOECONOMIC-STATUS; BARRETTS-ESOPHAGUS; MASTER
FILE; LIFE-STYLE; RISK; OBESITY
AB Introduction: Body mass index is known to be positively associated with an increased risk of adenocarcinomas of the esophagus, yet there is there limited evidence on whether physical activity or sedentary behavior affects risk of histology- and site-specific upper gastrointestinal cancers. We used the NIH-AARP Diet and Health Study to assess these exposures in relation to esophageal adenocarcinoma (EA), esophageal squamous cell carcinoma (ESCC), gastric cardia adenocarcinoma (GCA), and gastric non-cardia adenocarcinoma (GNCA).
Methods: Self-administered questionnaires were used to elicit physical activity and sedentary behavior exposures at various age periods. Cohort members were followed via linkage to the US Postal Service National Change of Address database, the Social Security Administration Death Master File, and the National Death Index. Cox proportional hazards regression models were used to estimate hazard ratios (HR) and 95 percent confidence intervals (95% CI)
Results: During 4.8 million person years, there were a total of 215 incident ESCCs, 631 EAs, 453 GCAs, and 501 GNCAs for analysis. Strenuous physical activity in the last 12 months (HR>(5times/week vs.never)=0.58, 95% CI: 0.39, 0.88) and typical physical activity and sports during ages 15-18 years (p for trend=0.01) were each inversely associated with GNCA risk. Increased sedentary behavior was inversely associated with EA (HR5-6 hrs/day vs. <1 hr=0.57, 95% CI: 0.36, 0.92). There was no evidence that BMI was a confounder or effect modifier of any relationship. After adjustment for multiple testing, none of these results were deemed to be statistically significant at p<0.05.
Conclusions: We find evidence for an inverse association between physical activity and GNCA risk. Associations between body mass index and adenocarcinomas of the esophagus do not appear to be related to physical activity and sedentary behavior.
C1 [Cook, Michael B.; Matthews, Charles E.; Gunja, Munira Z.; Abid, Zaynah; Freedman, Neal D.; Abnet, Christian C.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
RP Cook, MB (reprint author), NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
EM michael.cook@nih.gov
RI Cook, Michael/A-5641-2009; Abnet, Christian/C-4111-2015; matthews,
Charles/E-8073-2015; Freedman, Neal/B-9741-2015
OI Cook, Michael/0000-0002-0533-7302; Abnet, Christian/0000-0002-3008-7843;
matthews, Charles/0000-0001-8037-3103; Freedman,
Neal/0000-0003-0074-1098
NR 46
TC 1
Z9 1
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 19
PY 2013
VL 8
IS 12
AR UNSP e84805
DI 10.1371/journal.pone.0084805
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276HY
UT WOS:000328741900068
PM 24367697
ER
PT J
AU Kieffer-Kwon, KR
Tang, ZH
Mathe, E
Qian, JS
Sung, MH
Li, GL
Resch, W
Baek, S
Pruett, N
Grontved, L
Vian, L
Nelson, S
Zare, H
Hakim, O
Reyon, D
Yamane, A
Nakahashi, H
Kovalchuk, AL
Zou, JZ
Joung, JK
Sartorelli, V
Wei, CL
Ruan, XA
Hager, GL
Ruan, YJ
Casellas, R
AF Kieffer-Kwon, Kyong-Rim
Tang, Zhonghui
Mathe, Ewy
Qian, Jason
Sung, Myong-Hee
Li, Guoliang
Resch, Wolfgang
Baek, Songjoon
Pruett, Nathanael
Grontved, Lars
Vian, Laura
Nelson, Steevenson
Zare, Hossein
Hakim, Ofir
Reyon, Deepak
Yamane, Arito
Nakahashi, Hirotaka
Kovalchuk, Alexander L.
Zou, Jizhong
Joung, J. Keith
Sartorelli, Vittorio
Wei, Chia-Lin
Ruan, Xiaoan
Hager, Gordon L.
Ruan, Yijun
Casellas, Rafael
TI Interactome Maps of Mouse Gene Regulatory Domains Reveal Basic
Principles of Transcriptional Regulation
SO CELL
LA English
DT Article
ID ACTIVATION-INDUCED DEAMINASE; EMBRYONIC STEM-CELLS; LONG NONCODING RNAS;
HUMAN GENOME; CHROMATIN INTERACTIONS; AID EXPRESSION; ENHANCERS;
LYMPHOCYTES; ELEMENTS; RECOMBINATION
AB A key finding of the ENCODE project is that the enhancer landscape of mammalian cells undergoes marked alterations during ontogeny. However, the nature and extent of these changes are unclear. As part of the NIH Mouse Regulome Project, we here combined DNaseI hypersensitivity, ChIP-seq, and ChIA-PET technologies to map the promoter-enhancer interactomes of pluripotent ES cells and differentiated B lymphocytes. We confirm that enhancer usage varies widely across tissues. Unexpectedly, we find that this feature extends to broadly transcribed genes, including Myc and Pim1 cell-cycle regulators, which associate with an entirely different set of enhancers in ES and B cells. By means of high-resolution CpG methylomes, genome editing, and digital footprinting, we show that these enhancers recruit lineage-determining factors. Furthermore, we demonstrate that the turning on and off of enhancers during development correlates with promoter activity. We propose that organisms rely on a dynamic enhancer landscape to control basic cellular functions in a tissue-specific manner.
C1 [Kieffer-Kwon, Kyong-Rim; Mathe, Ewy; Qian, Jason; Resch, Wolfgang; Pruett, Nathanael; Vian, Laura; Nelson, Steevenson; Yamane, Arito; Nakahashi, Hirotaka; Casellas, Rafael] NIAMS, NIH, Bethesda, MD 20892 USA.
[Tang, Zhonghui; Li, Guoliang; Ruan, Xiaoan; Ruan, Yijun] Univ Connecticut, Jackson Lab Genom Med, Farmington, CT 06030 USA.
[Tang, Zhonghui; Li, Guoliang; Ruan, Xiaoan; Ruan, Yijun] Univ Connecticut, Dept Genet & Dev Biol, Farmington, CT 06030 USA.
[Sung, Myong-Hee; Baek, Songjoon; Grontved, Lars; Hager, Gordon L.] NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA.
[Zare, Hossein; Sartorelli, Vittorio] NIAMS, Lab Muscle Stem Cells & Gene Regulat, NIH, Bethesda, MD 20892 USA.
[Hakim, Ofir] Bar Ilan Univ, IL-5290002 Ramat Gan, Israel.
[Reyon, Deepak; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Mol Pathol Unit, Charlestown, MA 02129 USA.
[Reyon, Deepak; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA.
[Reyon, Deepak; Joung, J. Keith] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Kovalchuk, Alexander L.] NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA.
[Zou, Jizhong] NIAMS, Lab Stem Cell Biol, NIH, Bethesda, MD 20892 USA.
[Wei, Chia-Lin] DOE Joint Genome Inst, Walnut Creek, CA 94598 USA.
[Casellas, Rafael] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Casellas, R (reprint author), NIAMS, NIH, Bethesda, MD 20892 USA.
EM rafael.casellas@nih.gov
RI Li, Guoliang/I-1494-2015;
OI Li, Guoliang/0000-0003-1601-6640; Grontved, Lars/0000-0002-6735-8483
FU Intramural Research Program of NIAMS; NCI; internal Jackson Laboratory
fund [JAX19020120]; NIH [DP1 GM105378, P50 HG005550]; Defense Advanced
Research Projects Agency [W911NF-11-2-0056]; Jim and Ann Orr
Massachusetts General Hospital Research Scholar Award; NIH UGSP program
FX We thank Kefei Yu for CH12 cells and protocols; J. Simone and J. Lay for
cell sorting; G. Gutierrez for technical assistance with Illumina
analyzer. This work was supported by the Intramural Research Program of
NIAMS and NCI, and internal Jackson Laboratory fund JAX19020120 to Y.R.
J.K.J. was supported by NIH grants DP1 GM105378 and P50 HG005550, the
Defense Advanced Research Projects Agency grant W911NF-11-2-0056 and The
Jim and Ann Orr Massachusetts General Hospital Research Scholar Award.
J. Q. was supported by the NIH UGSP program. All animal experiments were
performed according to NIH guidelines. High-performance computation was
performed using NIH Helix Systems (http://helix.nih.gov). J. K. J. has a
financial interest in Transposagen Biopharmaceuticals. J.K.J.'s
interests were reviewed and are managed by Massachusetts General
Hospital and Partners HealthCare in accordance with their conflict of
interest policies.
NR 49
TC 116
Z9 120
U1 3
U2 44
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD DEC 19
PY 2013
VL 155
IS 7
BP 1507
EP 1520
DI 10.1016/j.cell.2013.11.039
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 275QW
UT WOS:000328693300008
PM 24360274
ER
PT J
AU Gomes, AP
Price, NL
Ling, AJY
Moslehi, JJ
Montgomery, MK
Rajman, L
White, JP
Teodor, JS
Wrann, CD
Hubbard, BP
Mercken, EM
Palmeira, CM
de Cabo, R
Rolo, AP
Turner, N
Bell, EL
Sinclair, DA
AF Gomes, Ana P.
Price, Nathan L.
Ling, Alvin J. Y.
Moslehi, Javid J.
Montgomery, Magdalene K.
Rajman, Luis
White, James P.
Teodor, Joao S.
Wrann, Christiane D.
Hubbard, Basil P.
Mercken, Evi M.
Palmeira, Carlos M.
de Cabo, Rafael
Rolo, Anabela P.
Turner, Nigel
Bell, Eric L.
Sinclair, David A.
TI Declining NAD(+) Induces a Pseudohypoxic State Disrupting
Nuclear-Mitochondrial Communication during Aging
SO CELL
LA English
DT Article
ID INDUCIBLE FACTOR 1-ALPHA; CANCER-CELL METABOLISM; FATTY-ACID OXIDATION;
GLUCOSE-HOMEOSTASIS; LIFE-SPAN; C-MYC; NICOTINAMIDE MONONUCLEOTIDE;
CALORIE RESTRICTION; ENERGY-EXPENDITURE; SIRT1 DEACETYLASE
AB Ever since eukaryotes subsumed the bacterial ancestor of mitochondria, the nuclear and mitochondrial genomes have had to closely coordinate their activities, as each encode different subunits of the oxidative phosphorylation (OXPHOS) system. Mitochondrial dysfunction is a hallmark of aging, but its causes are debated. We show that, during aging, there is a specific loss of mitochondrial, but not nuclear, encoded OXPHOS subunits. We trace the cause to an alternate PGC-1 alpha/beta-independent pathway of nuclear-mitochondrial communication that is induced by a decline in nuclear NAD(+) and the accumulation of HIF-1 alpha under normoxic conditions, with parallels to Warburg reprogramming. Deleting SIRT1 accelerates this process, whereas raising NAD(+) levels in old mice restores mitochondrial function to that of a young mouse in a SIRT1-dependent manner. Thus, a pseudohypoxic state that disrupts PGC-1 alpha/beta-independent nuclear-mitochondrial communication contributes to the decline in mitochondrial function with age, a process that is apparently reversible.
C1 [Gomes, Ana P.; Price, Nathan L.; Ling, Alvin J. Y.; Rajman, Luis; Hubbard, Basil P.; Sinclair, David A.] Harvard Univ, Sch Med, Dept Genet, Glenn Labs Biol Mech Aging, Boston, MA 02115 USA.
[Gomes, Ana P.; Teodor, Joao S.; Palmeira, Carlos M.; Rolo, Anabela P.] Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal.
[Gomes, Ana P.; Teodor, Joao S.; Palmeira, Carlos M.] Univ Coimbra, Fac Sci & Technol, Dept Life Sci, P-3004517 Coimbra, Portugal.
[Moslehi, Javid J.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med Oncol, Boston, MA 02115 USA.
[Moslehi, Javid J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Moslehi, Javid J.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc Med,Dept Med, Boston, MA 02115 USA.
[Montgomery, Magdalene K.; Turner, Nigel; Sinclair, David A.] Univ New S Wales, Sch Med Sci, Dept Pharmacol, Sydney, NSW 2052, Australia.
[White, James P.; Wrann, Christiane D.] Harvard Univ, Sch Med, Dept Cell Biol, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mercken, Evi M.; de Cabo, Rafael] NIA, Lab Expt Gerontol, NIH, Baltimore, MD 21224 USA.
[Rolo, Anabela P.] Univ Aveiro, Dept Biol, P-3810193 Aveiro, Portugal.
[Bell, Eric L.] MIT, Dept Biol, Paul F Glenn Lab Sci Aging, Cambridge, MA 02139 USA.
RP Sinclair, DA (reprint author), Harvard Univ, Sch Med, Dept Genet, Glenn Labs Biol Mech Aging, Boston, MA 02115 USA.
EM david_sinclair@hms.harvard.edu
RI Teodoro, Joao/F-5432-2011; de Cabo, Rafael/J-5230-2016; Turner,
Nigel/H-7176-2013;
OI Teodoro, Joao/0000-0002-1244-275X; de Cabo, Rafael/0000-0002-3354-2442;
Turner, Nigel/0000-0002-0119-9328; Sinclair, David/0000-0002-9936-436X;
, rafael/0000-0003-2830-5693
FU NIH/NIA; Glenn Foundation for Medical Research; United Mitochondrial
Disease Foundation; Juvenile Diabetes Research Foundation; Portuguese
Foundation for Science and Technology [SFRH/BD/44674/2008]; NSERC PGS-D
fellowship; Australian Research Council Future Fellowship
FX The Sinclair lab is supported by the NIH/NIA, the Glenn Foundation for
Medical Research, the United Mitochondrial Disease Foundation, the
Juvenile Diabetes Research Foundation, and a gift from the Schulak
family. A. P. G. was supported by the Portuguese Foundation for Science
and Technology (SFRH/BD/44674/2008) and B. P. H. by an NSERC PGS-D
fellowship. N.T. is supported by an Australian Research Council Future
Fellowship. We are grateful to Michael Bonkowski, Carlos Daniel de
Magalhaes Filho, Meghan Rego, Nikolina Dioufa, and David Zhang for
technical advice and experimental assistance; William Kaelin Jr. for
kindly providing the EglN1 KO mice; Daniel Kelly, John Rumsay, and
Teresa Leone for unpublished PGC-1 alpha/beta KO myoblasts and advice;
Bruce Spiegelman for PGC-1 alpha null myoblasts and advice; and Pere
Puigserver and Zachary Gerhart-Hines for a SIRT1 adenovirus. D. A. S. is
a consultant to Cohbar, OvaScience, HorizonScience, Segterra,
MetroBiotech, and GlaxoSmithKline. Cohbar, MetroBiotech, and
GlaxoSmithKline work on mitochondrially derived peptides,
NAD+, and sirtuin modulation, respectively.
NR 55
TC 253
Z9 258
U1 11
U2 97
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD DEC 19
PY 2013
VL 155
IS 7
BP 1624
EP 1638
DI 10.1016/j.cell.2013.11.037
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 275QW
UT WOS:000328693300017
PM 24360282
ER
PT J
AU Collins, FS
Hamburg, MA
AF Collins, Francis S.
Hamburg, Margaret A.
TI First FDA Authorization for Next-Generation Sequencer
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
AB The FDA has granted marketing authorization for a high-throughput genomic sequencer, Illumina's MiSeqDx, which will allow the development of innumerable new genome-based tests. Access to genomic data may transform research, clinical care, and patient engagement. This year marks 60 years since James Watson and Francis Crick described the structure of DNA and 10 years since the complete sequencing of the human genome. Fittingly, today the Food and Drug Administration (FDA) has granted marketing authorization for the first high-throughput (next-generation) genomic sequencer, Illumina's MiSeqDx, which will allow the development and use of innumerable new genome-based tests. When a global team of researchers sequenced that first human genome, it took more than a decade and cost hundreds of millions of dollars. Today, because of federal and private investment, sequencing technologies have advanced dramatically, and a human genome ...
C1 [Collins, Francis S.] NIH, Off Director, Bethesda, MD 20892 USA.
[Hamburg, Margaret A.] US Dept HHS, US FDA, Off Commissioner, Silver Spring, MD USA.
RP Collins, FS (reprint author), NIH, Off Director, Bldg 10, Bethesda, MD 20892 USA.
NR 5
TC 86
Z9 91
U1 2
U2 6
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 19
PY 2013
VL 369
IS 25
BP 2369
EP 2371
DI 10.1056/NEJMp1314561
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 274DQ
UT WOS:000328586000003
PM 24251383
ER
PT J
AU Yaffe, K
Falvey, C
Harris, TB
Newman, A
Satterfield, S
Koster, A
Ayonayon, H
Simonsick, E
AF Yaffe, Kristine
Falvey, Cherie
Harris, Tamara B.
Newman, Anne
Satterfield, Suzanne
Koster, Annemarie
Ayonayon, Hilsa
Simonsick, Eleanor
CA Hlth ABC Study
TI Effect of socioeconomic disparities on incidence of dementia among
biracial older adults: prospective study
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article
ID MILD COGNITIVE IMPAIRMENT; AFRICAN-AMERICANS; RACIAL-DIFFERENCES;
ALZHEIMER-DISEASE; WHITE DIFFERENCES; LIMITED LITERACY;
BODY-COMPOSITION; TEST-PERFORMANCE; TEST-SCORES; LIFE-COURSE
AB Objective To examine whether observed differences in dementia rates between black and white older people living in the community could be explained by measures of socioeconomic status (income, financial adequacy, education, and literacy) and health related factors.
Design Prospective cohort study.
Setting General community from two clinic sites in the United States (Pittsburgh, Pennsylvania and Memphis, Tennessee).
Participants 2457 older people (mean age 73.6 years; 1019 (41.5%) black; 1233 (50.2%) women), dementia-free at baseline, in the Health, Aging, and Body Composition study.
Main outcome measure Dementia was determined over 12 years (ending January 2011) by prescribed dementia drugs, hospital records, and decline in global cognitive scores. The influence of socioeconomic status and health related factors on dementia rates was examined in a series of Cox proportional hazard models in which these variables were added sequentially in covariate blocks.
Results Over follow-up, 449 (18.3%) participants developed dementia. Black participants were more likely than white participants to develop dementia (211 (20.7%) v 238 (16.6%), P<0.001; unadjusted hazard ratio 1.44, 95% confidence interval 1.20 to 1.74). The hazard ratio lessened somewhat after adjustment for demographics, apolipoprotein E e4, comorbidities, and lifestyle factors (1.37, 1.12 to 1.67) but was greatly reduced and no longer statistically significant when socioeconomic status was added (1.09, 0.87 to 1.37).
Conclusion These findings suggest that differences in the burden of risk factors, especially socioeconomic status, may contribute to the higher rates of dementia seen among black compared with white older people. Strategies aimed at reducing these disparities may favorably affect the incidence of dementia.
C1 [Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94121 USA.
[Falvey, Cherie] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA.
[Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Bethesda, MD 20892 USA.
[Newman, Anne] Univ Pittsburgh, Grad Sch Publ Hlth, Ctr Aging & Populat Hlth, Pittsburgh, PA 15261 USA.
[Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA.
[Koster, Annemarie] Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Maastricht, Netherlands.
[Simonsick, Eleanor] NIA, Clin Res Branch, Harbor Hosp, Baltimore, MD 21225 USA.
RP Yaffe, K (reprint author), Univ Calif San Francisco, 4150 Clement St,Box 181, San Francisco, CA 94121 USA.
EM kristine.yaffe@ucsf.edu
RI Koster, Annemarie/E-7438-2010; Newman, Anne/C-6408-2013
OI Newman, Anne/0000-0002-0106-1150
FU National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103,
N01-AG-6-2106, R01-AG028050]; NINR [R01-NR012459]; NIH, National
Institute on Aging; American Health Assistance Foundation [A201-0029]
FX National Institute on Aging (NIA) contract Nos N01-AG-6-2101,
N01-AG-6-2103, and N01-AG-6-2106; NIA grant No R01-AG028050; NINR grant
No R01-NR012459. This research was supported in part by the Intramural
Research Program of the NIH, National Institute on Aging, and a grant
from the American Health Assistance Foundation, grant number A201-0029.
The Intramural Research Program of the NIA participated in the design
and conduct of the study.
NR 47
TC 20
Z9 20
U1 3
U2 22
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD DEC 19
PY 2013
VL 347
AR f7051
DI 10.1136/bmj.f7051
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 277MS
UT WOS:000328824300003
PM 24355614
ER
PT J
AU Kline, C
Ndjomou, J
Franks, T
Kiser, R
Coalter, V
Smedley, J
Piatak, M
Mellors, JW
Lifson, JD
Ambrose, Z
AF Kline, Christopher
Ndjomou, Jean
Franks, Tamera
Kiser, Rebecca
Coalter, Vicky
Smedley, Jeremy
Piatak, Michael, Jr.
Mellors, John W.
Lifson, Jeffrey D.
Ambrose, Zandrea
TI Persistence of Viral Reservoirs in Multiple Tissues after Antiretroviral
Therapy Suppression in a Macaque RT-SHIV Model
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE INHIBITORS;
HIV-POSITIVE PATIENTS; CD4(+) T-LYMPHOCYTES; RALTEGRAVIR
INTENSIFICATION; LIFELONG PERSISTENCE; CONTROLLED-TRIAL;
DRUG-RESISTANCE; RHESUS MACAQUES; GENITAL-TRACT
AB Although antiretroviral therapy (ART) can suppress HIV-1 replication sufficiently to eliminate measurable plasma viremia, infected cells remain and ensure viral recrudescence after discontinuation of ART. We used a macaque model of HIV-1/AIDS to evaluate the location of infected cells during ART. Twelve macaques were infected with RT-SHIVmne, a SIV containing HIV-1 reverse transcriptase, conferring sensitivity to non-nucleoside reverse transcriptase inhibitors (NNRTIs). Ten to fourteen weeks post-infection, 6 animals were treated with 3 or 4 antiretroviral drugs for 17-20 weeks; 6 control animals remained untreated. Viral DNA (vDNA) and RNA (vRNA) were measured in peripheral blood mononuclear cells (PBMC) and at necropsy in multiple tissues by quantitative PCR and RT-PCR. The majority of virally infected cells were located in lymphoid tissues with variable levels in the gastrointestinal tract of both treated and untreated animals. Tissue viral DNA levels correlated with week 1 plasma viremia, suggesting that tissues that harbor proviral DNA are established within the first week of infection. PBMC vDNA levels did not correlate with plasma viremia or tissue levels of vDNA. vRNA levels were high in lymphoid and gastrointestinal tissues of the untreated animals; animals on ART had little vRNA expressed in tissues and virus could not be cultured from lymph node resting CD4+ cells after 17-20 weeks on ART, indicating little or no ongoing viral replication. Strategies for eradication of HIV-1 will need to target residual virus in ART suppressed individuals, which may not be accurately reflected by frequencies of infected cells in blood.
C1 [Kline, Christopher; Ndjomou, Jean; Franks, Tamera; Mellors, John W.; Ambrose, Zandrea] Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15213 USA.
[Kiser, Rebecca; Coalter, Vicky; Piatak, Michael, Jr.; Lifson, Jeffrey D.] Leidos Biomed Res Inc, AIDS & Canc Virus Program, Frederick Natl Lab Canc Res, Frederick, MD USA.
[Smedley, Jeremy] Leidos Biomed Res Inc, Lab Anim Sci Program, Frederick Natl Lab Canc Res, Frederick, MD USA.
RP Ambrose, Z (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, Pittsburgh, PA 15213 USA.
EM zaa4@pitt.edu
OI Smedley, Jeremy/0000-0003-3369-4662
FU American Foundation for AIDS Research (amfAR) [107149-44-RGRL]; Merck
Co., Inc. [33665]; National Cancer Institute, National Institutes of
Health (NIH) [HHSN261200800001E]
FX This work was supported by grants 107149-44-RGRL from the American
Foundation for AIDS Research (amfAR) and 33665 from Merck & Co., Inc.
(Z.A.) and with federal funds from the National Cancer Institute,
National Institutes of Health (NIH), under contract HHSN261200800001E
(J.D.L.). The funders had no role in the study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 62
TC 15
Z9 15
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 18
PY 2013
VL 8
IS 12
AR e84275
DI 10.1371/journal.pone.0084275
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276HL
UT WOS:000328740300135
PM 24367650
ER
PT J
AU Samji, H
Cescon, A
Hogg, RS
Modur, SP
Althoff, KN
Buchacz, K
Burchell, AN
Cohen, M
Gebo, KA
Gill, MJ
Justice, A
Kirk, G
Klein, MB
Korthuis, PT
Martin, J
Napravnik, S
Rourke, SB
Sterling, TR
Silverberg, MJ
Deeks, S
Jacobson, LP
Bosch, RJ
Kitahata, MM
Goedert, JJ
Moore, R
Gange, SJ
AF Samji, Hasina
Cescon, Angela
Hogg, Robert S.
Modur, Sharada P.
Althoff, Keri N.
Buchacz, Kate
Burchell, Ann N.
Cohen, Mardge
Gebo, Kelly A.
Gill, M. John
Justice, Amy
Kirk, Gregory
Klein, Marina B.
Korthuis, P. Todd
Martin, Jeff
Napravnik, Sonia
Rourke, Sean B.
Sterling, Timothy R.
Silverberg, Michael J.
Deeks, Stephen
Jacobson, Lisa P.
Bosch, Ronald J.
Kitahata, Mari M.
Goedert, James J.
Moore, Richard
Gange, Stephen J.
CA North Amer AIDS Cohort
TI Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive
Individuals in the United States and Canada
SO PLOS ONE
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; INJECTING DRUG-USERS; INFECTED PERSONS;
INCOME COUNTRIES; COHORT; INEQUALITIES; MORTALITY; SURVIVAL; TIME
AB Background: Combination antiretroviral therapy (ART) has significantly increased survival among HIV-positive adults in the United States (U. S.) and Canada, but gains in life expectancy for this region have not been well characterized. We aim to estimate temporal changes in life expectancy among HIV-positive adults on ART from 2000-2007 in the U. S. and Canada.
Methods: Participants were from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), aged >= 20 years and on ART. Mortality rates were calculated using participants' person-time from January 1, 2000 or ART initiation until death, loss to follow-up, or administrative censoring December 31, 2007. Life expectancy at age 20, defined as the average number of additional years that a person of a specific age will live, provided the current age-specific mortality rates remain constant, was estimated using abridged life tables.
Results: The crude mortality rate was 19.8/1,000 person-years, among 22,937 individuals contributing 82,022 person-years and 1,622 deaths. Life expectancy increased from 36.1 [standard error (SE) 0.5] to 51.4 [SE 0.5] years from 2000-2002 to 2006-2007. Men and women had comparable life expectancies in all periods except the last (2006-2007). Life expectancy was lower for individuals with a history of injection drug use, non-whites, and in patients with baseline CD4 counts <350 cells/mm(3).
Conclusions: A 20-year-old HIV-positive adult on ART in the U. S. or Canada is expected to live into their early 70 s, a life expectancy approaching that of the general population. Differences by sex, race, HIV transmission risk group, and CD4 count remain.
C1 [Samji, Hasina; Cescon, Angela; Hogg, Robert S.] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada.
[Hogg, Robert S.] Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada.
[Modur, Sharada P.; Althoff, Keri N.; Gebo, Kelly A.; Kirk, Gregory; Jacobson, Lisa P.; Moore, Richard; Gange, Stephen J.] Johns Hopkins Univ, Baltimore, MD USA.
[Buchacz, Kate] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Burchell, Ann N.; Rourke, Sean B.] Ontario HIV Treatment Network, Toronto, ON, Canada.
[Cohen, Mardge] Bur Hlth Serv Cook Cty, Core Ctr, Chicago, IL USA.
[Gill, M. John] Univ Calgary, Calgary, AB, Canada.
[Justice, Amy] Vet Adm Connecticut Healthcare Syst, West Haven, CT USA.
[Justice, Amy] Yale Univ, West Haven, CT USA.
[Klein, Marina B.] McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
[Korthuis, P. Todd] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Martin, Jeff] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Napravnik, Sonia] Univ N Carolina, Chapel Hill, NC USA.
[Sterling, Timothy R.] Vanderbilt Univ, Nashville, TN 37235 USA.
[Silverberg, Michael J.] Kaiser Permanente No Calif, Oakland, CA USA.
[Deeks, Stephen] Univ Calif San Francisco, San Francisco Gen Hosp, San Francisco, CA USA.
[Bosch, Ronald J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Kitahata, Mari M.] Univ Washington, Seattle, WA 98195 USA.
[Goedert, James J.] NCI, Rockville, MD USA.
RP Hogg, RS (reprint author), British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada.
EM rhogg@sfu.ca
RI Gill, John/G-7083-2016;
OI Gill, John/0000-0002-8546-8790; Gange, Stephen/0000-0001-7842-512X;
Hogg, Robert/0000-0003-3463-5488
FU National Institutes of Health [U01-AI069918, U10-AA13566, U01-AI31834,
U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039,
U01-AI35040, U01-AI35041, U01-AI35042, U01-AI35043, U01-AI37613,
U01-AI37984, U01-AI38855, U01-AI38858, U01-AI42590, U01-AI68634,
U01-AI68636, U01-HD32632, U10-EY08057, U10-EY08052, U10-EY08067,
UL1-RR024131, M01-RR-00052, M01-RR00071, M01-RR00079, M01-RR00083,
M01-RR00722, M01-RR025747, P30-AI27757, P30-AI27767, P30-AI27763,
P30-AI50410, P30-AI54999, R01-DA04334, R01-DA12568, R01-DA11602,
R01-AA16893, R24-AI067039, Z01-CP010176, AHQ290-01-0012, N02-CP55504,
AI-69432, AI-69434, K01-AI071725, K23-AI610320, K23-EY013707,
K24-DA00432, K24 AI65298, K01-AI093197]; Agency for Healthcare Research
and Quality [290-01-0012]; CDC [CDC200-2006-18797]; Canadian Institutes
of Health Research [TGF-96118, HCP-97105, CBR-86906, CBR-94036,
KRS-86251, 169621]; Canadian HIV Trials Network [24]; government of
British Columbia
FX This work was supported by grants U01-AI069918, U10-AA13566,
U01-AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004,
U01-AI35039, U01-AI35040, U01-AI35041, U01-AI35042, U01-AI35043,
U01-AI37613, U01-AI37984, U01-AI38855, U01-AI38858, U01-AI42590,
U01-AI68634, U01-AI68636, U01-HD32632, U10-EY08057, U10-EY08052,
U10-EY08067, UL1-RR024131, UL1-RR024131, M01-RR-00052, M01-RR00071,
M01-RR00079, M01-RR00083, M01-RR00722, M01-RR025747, P30-AI27757,
P30-AI27767, P30-AI27763, P30-AI50410, P30-AI54999, R01-DA04334,
R01-DA12568, R01-DA11602, R01-AA16893, R24-AI067039, Z01-CP010176,
AHQ290-01-0012, N02-CP55504, AI-69432, AI-69434, K01-AI071725,
K23-AI610320, K23-EY013707, K24-DA00432, K24 AI65298 and K01-AI093197
from the National Institutes of Health; contract 290-01-0012 from the
Agency for Healthcare Research and Quality; contract CDC200-2006-18797
from the CDC; grants TGF-96118, HCP-97105, CBR-86906, CBR-94036,
KRS-86251, and 169621 from the Canadian Institutes of Health Research;
the Canadian HIV Trials Network, project 24; and the government of
British Columbia. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 31
TC 240
Z9 241
U1 2
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 18
PY 2013
VL 8
IS 12
AR e81355
DI 10.1371/journal.pone.0081355
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276HL
UT WOS:000328740300004
PM 24367482
ER
PT J
AU Simpson, EA
Paukner, A
Sclafani, V
Suomi, SJ
Ferrari, PF
AF Simpson, Elizabeth A.
Paukner, Annika
Sclafani, Valentina
Suomi, Stephen J.
Ferrari, Pier F.
TI Lipsmacking Imitation Skill in Newborn Macaques Is Predictive of Social
Partner Discrimination
SO PLOS ONE
LA English
DT Article
ID NEONATAL IMITATION; MEMORY
AB Newborn rhesus macaques imitate facial gestures even after a delay, revealing the flexible nature of their early communicative exchanges. In the present study we examined whether newborn macaques are also sensitive to the identities of the social partners with whom they are interacting. We measured infant monkeys' (n = 90) lipsmacking and tongue protrusion gestures in a face-to-face interaction task with a human experimenter in the first week of life. After a one-minute delay, the same person who previously presented gestures or a different person returned and presented a still face to infants. We had two primary predictions: (1) infants would demonstrate higher rates of overall gesturing, and especially lipsmacking-an affiliative gesture-to a familiar person, compared to a novel person, and (2) infants' imitative skills would positively correlate with gestures to familiar, but not unfamiliar, social partners, as both abilities may reflect a strong general social interest. We found that overall infants did not produce more gestures or more lipsmacking when approached by a familiar person compared to a novel person; however, we did find individual differences in infants' social responsiveness: lipsmacking imitation was positively correlated with lipsmacking during the return period when the person was the same (p =.025), but not when the person was novel (p =.44). These findings are consistent with the notion that imitative skill is reflective of infants' more general interest in social interactions.
C1 [Simpson, Elizabeth A.; Paukner, Annika; Suomi, Stephen J.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Comparat Ethol Lab, Poolesville, MD USA.
[Simpson, Elizabeth A.; Sclafani, Valentina; Ferrari, Pier F.] Univ Parma, Dipartimento Neurosci, I-43100 Parma, Italy.
RP Simpson, EA (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Comparat Ethol Lab, Poolesville, MD USA.
EM simpsonea@mail.nih.gov
OI Simpson, Elizabeth/0000-0003-2715-2533
FU Division of Intramural Research; Eunice Kennedy Shriver National
Institute of Child Health and Human Development; Eunice Kennedy Shriver
National Institute of Child Health and Human Development [P01 HD064653]
FX This research was supported by the Division of Intramural Research,
Eunice Kennedy Shriver National Institute of Child Health and Human
Development. EAS, VS, and PFF were supported by Eunice Kennedy Shriver
National Institute of Child Health and Human Development P01 HD064653.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 16
TC 5
Z9 5
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 18
PY 2013
VL 8
IS 12
AR e82921
DI 10.1371/journal.pone.0082921
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276HL
UT WOS:000328740300080
PM 24367569
ER
PT J
AU Chen, HH
Anstrom, KJ
Givertz, MM
Stevenson, LW
Semigran, MJ
Goldsmith, SR
Bart, BA
Bull, DA
Stehlik, J
LeWinter, MM
Konstam, MA
Huggins, GS
Rouleau, JL
O'Meara, E
Tang, WHW
Starling, RC
Butler, J
Deswal, A
Felker, GM
O'Connor, CM
Bonita, RE
Margulies, KB
Cappola, TP
Ofili, EO
Mann, DL
Davila-Roman, VG
McNulty, SE
Borlaug, BA
Velazquez, EJ
Lee, KL
Shah, MR
Hernandez, AF
Braunwald, E
Redfield, MM
AF Chen, Horng H.
Anstrom, Kevin J.
Givertz, Michael M.
Stevenson, Lynne W.
Semigran, Marc J.
Goldsmith, Steven R.
Bart, Bradley A.
Bull, David A.
Stehlik, Josef
LeWinter, Martin M.
Konstam, Marvin A.
Huggins, Gordon S.
Rouleau, Jean L.
O'Meara, Eileen
Tang, W. H. Wilson
Starling, Randall C.
Butler, Javed
Deswal, Anita
Felker, G. Michael
O'Connor, Christopher M.
Bonita, Raphael E.
Margulies, Kenneth B.
Cappola, Thomas P.
Ofili, Elizabeth O.
Mann, Douglas L.
Davila-Roman, Victor G.
McNulty, Steven E.
Borlaug, Barry A.
Velazquez, Eric J.
Lee, Kerry L.
Shah, Monica R.
Hernandez, Adrian F.
Braunwald, Eugene
Redfield, Margaret M.
CA NHLBI Heart Failure Clin Res Netwo
TI Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With
Renal Dysfunction The ROSE Acute Heart Failure Randomized Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID RELAX-AHF; SERELAXIN
AB IMPORTANCE Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction; however, neither strategy has been rigorously tested.
OBJECTIVE To test the 2 independent hypotheses that, compared with placebo, addition of low-dose dopamine (2 mu g/kg/min) or low-dose nesiritide (0.005 mu g/kg/min without bolus) to diuretic therapy will enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction.
DESIGN, SETTING, AND PARTICIPANTS Multicenter, double-blind, placebo-controlled clinical trial (Renal Optimization Strategies Evaluation [ROSE]) of 360 hospitalized patients with acute heart failure and renal dysfunction (estimated glomerular filtration rate of 15-60 mL/min/1.73 m(2)), randomized within 24 hours of admission. Enrollment occurred from September 2010 to March 2013 across 26 sites in North America.
INTERVENTIONS Participants were randomized in an open, 1:1 allocation ratio to the dopamine or nesiritide strategy. Within each strategy, participants were randomized in a double-blind, 2:1 ratio to active treatment or placebo. The dopamine (n = 122) and nesiritide (n = 119) groups were independently compared with the pooled placebo group (n = 119).
MAIN OUTCOMES AND MEASURES Coprimary end points included 72-hour cumulative urine volume (decongestion end point) and the change in serum cystatin C from enrollment to 72 hours (renal function end point).
RESULTS Compared with placebo, low-dose dopamine had no significant effect on 72-hour cumulative urine volume (dopamine, 8524 mL; 95% CI, 7917-9131 vs placebo, 8296 mL; 95% CI, 7762-8830; difference, 229 mL; 95% CI, -714 to 1171 mL; P = .59) or on the change in cystatin C level (dopamine, 0.12 mg/L; 95% CI, 0.06-0.18 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, 0.01; 95% CI, -0.08 to 0.10; P = .72). Similarly, low-dose nesiritide had no significant effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95% CI, 8014-9134 vs placebo, 8296 mL; 95% CI, 7762-8830; difference, 279 mL; 95% CI, -618 to 1176 mL; P = .49) or on the change in cystatin C level (nesiritide, 0.07 mg/L; 95% CI, 0.01-0.13 vs placebo, 0.11 mg/L; 95% CI, 0.06-0.16; difference, -0.04; 95% CI, -0.13 to 0.05; P = .36). Compared with placebo, there was no effect of low-dose dopamine or nesiritide on secondary end points reflective of decongestion, renal function, or clinical outcomes.
CONCLUSION AND RELEVANCE In participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal function when added to diuretic therapy.
C1 [Chen, Horng H.; Borlaug, Barry A.; Redfield, Margaret M.] Mayo Clin, Rochester, MN 55905 USA.
[Anstrom, Kevin J.; McNulty, Steven E.; Lee, Kerry L.; Hernandez, Adrian F.] Duke Clin Res Inst, Durham, NC USA.
[Givertz, Michael M.; Stevenson, Lynne W.; Braunwald, Eugene] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Semigran, Marc J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Goldsmith, Steven R.; Bart, Bradley A.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA.
[Bull, David A.; Stehlik, Josef] Univ Utah, Salt Lake City, UT USA.
[LeWinter, Martin M.] Univ Vermont, Burlington, VT 05405 USA.
[Konstam, Marvin A.; Huggins, Gordon S.] Tufts Med Ctr, Boston, MA USA.
[Rouleau, Jean L.; O'Meara, Eileen] Univ Montreal, Montreal, PQ, Canada.
[Rouleau, Jean L.; O'Meara, Eileen] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada.
[Tang, W. H. Wilson; Starling, Randall C.] Cleveland Clin, Cleveland, OH 44106 USA.
[Butler, Javed] Emory Univ, Atlanta, GA 30322 USA.
[Deswal, Anita] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Deswal, Anita] Baylor Coll Med, Houston, TX USA.
[Felker, G. Michael; O'Connor, Christopher M.; Velazquez, Eric J.] Duke Univ, Med Ctr, Durham, NC USA.
[Felker, G. Michael; O'Connor, Christopher M.; Velazquez, Eric J.] Duke Heart Ctr, Durham, NC USA.
[Bonita, Raphael E.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
[Margulies, Kenneth B.; Cappola, Thomas P.] Univ Penn, Philadelphia, PA 19104 USA.
[Ofili, Elizabeth O.] Morehouse Sch Med, Atlanta, GA 30310 USA.
[Mann, Douglas L.; Davila-Roman, Victor G.] Washington Univ, Sch Med, St Louis, MO USA.
[Shah, Monica R.] NHLBI, Bethesda, MD 20892 USA.
RP Chen, HH (reprint author), Mayo Clin Cardiovasc Res, Guggenheim 9,Mayo Clin,200 1st St SW, Rochester, MN 55905 USA.
EM chen.horng@mayo.edu
RI Hernandez, Adrian F./A-7818-2016;
OI Patel, Ayan/0000-0003-1984-1400; Hernandez, Adrian
F./0000-0003-3387-9616; Mann, Douglas /0000-0002-2516-0145
FU National Heart, Lung, and Blood Institute (NHLBI) [U10 HL084904, U01
HL084861, U10 HL110312, U109 HL110337, U01 HL084889, U01 HL084890, U01
HL084891, U10 HL110342, U10 HL110262, U01 HL084931, U10 HL110297, U10
HL110302, U10 HL110309, U10 HL110336, U10 HL110338]; National Center for
Advancing Translational Sciences [UL1TR000454, UL1TR000135, UL1RR025008,
UL1TR000439]; National Institute on Minority Health and Health
Disparities [8 U54 MD007588]
FX This work was supported by grants from the National Heart, Lung, and
Blood Institute (NHLBI) (coordinating center: U10 HL084904; regional
clinical centers: U01 HL084861, U10 HL110312, U109 HL110337, U01
HL084889, U01 HL084890, U01 HL084891, U10 HL110342, U10 HL110262, U01
HL084931, U10 HL110297, U10 HL110302, U10 HL110309, U10 HL110336, U10
HL110338). This work is also supported by the National Center for
Advancing Translational Sciences (UL1TR000454, UL1TR000135, UL1RR025008,
UL1TR000439) and the National Institute on Minority Health and Health
Disparities (8 U54 MD007588).
NR 26
TC 117
Z9 121
U1 2
U2 14
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 18
PY 2013
VL 310
IS 23
BP 2533
EP 2543
DI 10.1001/jama.2013.282190
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 272ZZ
UT WOS:000328503600023
PM 24247300
ER
PT J
AU Gerfen, CR
Paletzki, R
Heintz, N
AF Gerfen, Charles R.
Paletzki, Ronald
Heintz, Nathaniel
TI GENSAT BAG Cre-Recombinase Driver Lines to Study the Functional
Organization of Cerebral Cortical and Basal Ganglia Circuits
SO NEURON
LA English
DT Article
ID MOTOR CORTEX; CORTICOSTRIATAL NEURONS; PROJECTION NEURONS; PYRAMIDAL
NEURONS; GENE-EXPRESSION; TRANSGENIC MICE; NEURAL CIRCUITS; RAT;
CONNECTIVITY; PATHWAY
AB Recent development of molecular genetic techniques are rapidly advancing understanding of the functional role of brain circuits in behavior. Critical to this approach is the ability to target specific neuron populations and circuits. The collection of over 250 BAC Cre-recombinase driver lines produced by the GENSAT project provides a resource for such studies. Here we provide characterization of GENSAT BAG-Cre driver lines with expression in specific neuroanatomical pathways within the cerebral cortex and basal ganglia.
C1 [Gerfen, Charles R.; Paletzki, Ronald] NIMH, Lab Syst Neurosci, Bethesda, MD 20892 USA.
[Heintz, Nathaniel] Rockefeller Univ, Howard Hughes Med Inst, Mol Biol Lab, New York, NY 10021 USA.
RP Gerfen, CR (reprint author), NIMH, Lab Syst Neurosci, Bethesda, MD 20892 USA.
EM gerfenc@mail.nih.gov
FU NIMH IRP [MH002497-24]; GENSAT [NIH/NINDS N271200723701C]; NIH/NINDS
MMRRC [201224636]; NIH/NIDA [1P30 DA035756-01]; NIH/NIMH [P50 MH090963
P2]; Howard Hughes Medical Institute
FX We acknowledge the excellent technical support and expertise of Michelle
Tenace, Scott Stavrou, Laura Kus, Shiaoching Gong, and Nicholas
Didkovsky. We also thank the NINDS GENSAT staff, Laura Mamounas, Coryse
St. Hillaire-Clarke, and Amelia Gubitz for their assistance. This study
was supported by grants to C.R.G: (NIMH IRP project MH002497-24) and
N.H. (GENSAT contract NIH/NINDS N271200723701C, NIH/NINDS MMRRC subaward
201224636, NIH/NIDA 1P30 DA035756-01, NIH/NIMH P50 MH090963 P2, and
Howard Hughes Medical Institute Investigator Award).
NR 37
TC 81
Z9 81
U1 2
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD DEC 18
PY 2013
VL 80
IS 6
BP 1368
EP 1383
DI 10.1016/j.neuron.2013.10.016
PG 16
WC Neurosciences
SC Neurosciences & Neurology
GA 278VY
UT WOS:000328919200007
PM 24360541
ER
PT J
AU Rudebeck, PH
Mitz, AR
Chacko, RV
Murray, EA
AF Rudebeck, Peter H.
Mitz, Andrew R.
Chacko, Ravi V.
Murray, Elisabeth A.
TI Effects of Amygdala Lesions on Reward-Value Coding in Orbital and Medial
Prefrontal Cortex
SO NEURON
LA English
DT Article
ID ANTERIOR CINGULATE CORTEX; PRIMATE ORBITOFRONTAL CORTEX; MAJOR
DEPRESSIVE DISORDER; DECISION-MAKING; BASOLATERAL AMYGDALA;
NEURONAL-ACTIVITY; FRONTAL-CORTEX; SINGLE NEURONS; ECONOMIC VALUE;
BEHAVIOR
AB We examined the contribution of the amygdala to value signals within orbital prefrontal cortex (OFC) and medial prefrontal cortex (MFC). On each trial, monkeys chose between two stimuli that were associated with different quantities of reward. In intact monkeys, as expected, neurons in both OFC and MFC signaled the reward quantity associated with stimuli. Contrasted with MFC, OFC contained a larger proportion of neurons encoding reward quantity and did so with faster response latencies. Removing the amygdala eliminated these differences, mainly by decreasing value coding in OFC. Similar decreases occurred in OFC immediately before and after reward delivery. Although the amygdala projects to both OFC and MFC, we found that it has its greatest influence over reward-value coding in OFC. Notably, amygdala lesions did not abolish value coding in OFC, which shows that OFC's representations of the value of objects, choices, and outcomes depends, in large part, on other sources.
C1 [Rudebeck, Peter H.; Mitz, Andrew R.; Chacko, Ravi V.; Murray, Elisabeth A.] NIMH, Neuropsychol Lab, Sect Neurobiol Learning & Memory, Bethesda, MD 20892 USA.
RP Rudebeck, PH (reprint author), NIMH, Neuropsychol Lab, Sect Neurobiol Learning & Memory, Bldg 49,Suite 1B80,49 Convent Dr, Bethesda, MD 20892 USA.
EM rudebeckp@mail.nih.gov
OI Rudebeck, Peter/0000-0002-1411-7555; Murray,
Elisabeth/0000-0003-1450-1642
FU National Institute of Mental Health
FX This work was supported by the Intramural Research Program of the
National Institute of Mental Health. We thank Kevin Blomstrom, Kevin
Fomalont, and Joshua Ripple for assistance with data collection and
James Fellows, Ping Yu Chen, and David Yu for help with surgery and
histology. We are indebted to Steven Wise and Bruno Averbeck for
comments on analyses and an earlier version of the manuscript.
NR 50
TC 31
Z9 32
U1 1
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
EI 1097-4199
J9 NEURON
JI Neuron
PD DEC 18
PY 2013
VL 80
IS 6
BP 1519
EP 1531
DI 10.1016/j.neuron.2013.09.036
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA 278VY
UT WOS:000328919200018
PM 24360550
ER
PT J
AU Sheliga, BM
Quaia, C
FitzGibbon, EJ
Cumming, BG
AF Sheliga, B. M.
Quaia, C.
FitzGibbon, E. J.
Cumming, B. G.
TI Retinal visual processing constrains human ocular following response
SO VISION RESEARCH
LA English
DT Article
DE Visual motion; Retinal ganglion cells; Contrast gain control; Surround
inhibition
ID LATERAL GENICULATE-NUCLEUS; MACAQUE V1 NEURONS; RECEPTIVE-FIELD
PROPERTIES; VERGENCE EYE-MOVEMENTS; GANGLION-CELLS; CONTRAST
SENSITIVITY; PRIMATE RETINA; CAT RETINA; SPATIAL SUMMATION; ORIENTATION
BIAS
AB Ocular following responses (OFRs) are the initial tracking eye movements elicited at ultra-short latency by sudden motion of a textured pattern. We wished to evaluate quantitatively the impact that subcortical stages of visual processing might have on the OFRs. In three experiments we recorded the OFRs of human subjects to brief horizontal motion of 1D vertical sine-wave gratings restricted to an elongated horizontal aperture. Gratings were composed of a variable number of abutting horizontal strips where alternate strips were in counterphase. In one of the experiments we also utilized gratings occupying a variable number of horizontal strips separated vertically by mean-luminance gaps. We modeled retinal center/surround receptive fields as a difference of two 2-D Gaussian functions. When the characteristics of such local filters were selected in accord with the known properties of primate retinal ganglion cells, a single-layer model was capable to quantitatively account for the observed changes in the OFR amplitude for stimuli composed of counterphase strips of different heights (Experiment 1), for a wide range of stimulus contrasts (Experiment 2) and spatial frequencies (Experiment 3). A similar model using oriented filters that resemble cortical simple cells was also able to account for these data. Since similar filters can be constructed from the linear summation of retinal filters, and these filters alone can explain the data, we conclude that retinal processing determines the response to these stimuli. Thus, with appropriately chosen stimuli, OFRs can be used to study visual spatial integration processes as early as in the retina. Published by Elsevier Ltd.
C1 [Sheliga, B. M.; Quaia, C.; FitzGibbon, E. J.; Cumming, B. G.] NEI, Sensorimotor Res Lab, NIH, Bethesda, MD 20892 USA.
RP Sheliga, BM (reprint author), NIH, Sensorimotor Res Lab, Bldg 49,Room 2A50,49 Convent Dr, Bethesda, MD 20892 USA.
EM bms@lsr.nei.nih.gov
FU Intramural Research Program of the National Eye Institute at the
National Institutes of Health
FX This research was supported by the Intramural Research Program of the
National Eye Institute at the National Institutes of Health.
NR 50
TC 4
Z9 4
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0042-6989
EI 1878-5646
J9 VISION RES
JI Vision Res.
PD DEC 18
PY 2013
VL 93
BP 29
EP 42
DI 10.1016/j.visres.2013.10.002
PG 14
WC Neurosciences; Ophthalmology
SC Neurosciences & Neurology; Ophthalmology
GA 261SY
UT WOS:000327686100004
PM 24125703
ER
PT J
AU Yamamizu, K
Piao, YL
Sharov, AA
Zsiros, V
Yu, H
Nakazawa, K
Schlessinger, D
Ko, MSH
AF Yamamizu, Kohei
Piao, Yulan
Sharov, Alexei A.
Zsiros, Veronika
Yu, Hong
Nakazawa, Kazu
Schlessinger, David
Ko, Minoru S. H.
TI Identification of Transcription Factors for Lineage-Specific ESC
Differentiation
SO STEM CELL REPORTS
LA English
DT Article
ID EMBRYONIC STEM-CELLS; COUP-TFI; DIRECT CONVERSION; HUMAN FIBROBLASTS;
DEFINED FACTORS; MOUSE EMBRYOS; GENE; EXPRESSION; RECEPTOR; NEURONS
AB A network of transcription factors (TFs) determines cell identity, but identity can be altered by overexpressing a combination of TFs. However, choosing and verifying combinations of TFs for specific cell differentiation have been daunting due to the large number of possible combinations of similar to 2,000 TFs. Here, we report the identification of individual TFs for lineage-specific cell differentiation based on the correlation matrix of global gene expression profiles. The overexpression of identified TFs-Myod1, Mef2c, Esx1, Foxa1, Hnf4a, Gata2, Gata3, Myc, Elf5, Irf2, Elf1, Sfpi1, Ets1, Smad7, Nr2f1, Sox11, Dmrt1, Sox9, Foxg1, Sox2, or Ascl1-can direct efficient, specific, and rapid differentiation into myocytes, hepatocytes, blood cells, and neurons. Furthermore, transfection of synthetic mRNAs of TFs generates their appropriate target cells. These results demonstrate both the utility of this approach to identify potent TFs for cell differentiation, and the unanticipated capacity of single TFs directly guides differentiation to specific lineage fates.
C1 [Yamamizu, Kohei; Piao, Yulan; Sharov, Alexei A.; Yu, Hong; Schlessinger, David; Ko, Minoru S. H.] NIA, Genet Lab, NIH, Baltimore, MD 21224 USA.
[Zsiros, Veronika; Nakazawa, Kazu] NIMH, Unit Genet Cognit & Behav, NIH, Bethesda, MD 20892 USA.
[Ko, Minoru S. H.] Keio Univ, Dept Syst Med, Sch Med, Sakaguchi Lab, Tokyo 1608582, Japan.
[Ko, Minoru S. H.] Japan Sci & Technol Agcy, CREST, Tokyo 1608528, Japan.
RP Ko, MSH (reprint author), NIA, Genet Lab, NIH, Baltimore, MD 21224 USA.
EM kom@z7.keio.jp
RI Nakazawa, Kazutoshi/J-6195-2015;
OI Nakazawa, Kazutoshi/0000-0001-5699-9093; Ko, Minoru/0000-0002-3530-3015
FU Intramural Research Program of the NIH, National Institute on Aging;
Japan Science and Technology Agency, CREST program; Kanae Foundation,
Japan; Uehara Memorial Foundation, Japan; Naito Foundation, Japan; Japan
Society for Promotion of Science
FX This research was supported in part by the Intramural Research Program
of the NIH, National Institute on Aging. This research was also
supported in part by the Japan Science and Technology Agency, CREST
program. K.Y. was supported by the postdoctoral fellowships from the
Kanae Foundation, Japan, Uehara Memorial Foundation, Japan, Naito
Foundation, Japan, and the Japan Society for Promotion of Science.
NR 58
TC 16
Z9 16
U1 0
U2 4
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD DEC 17
PY 2013
VL 1
IS 6
BP 545
EP 559
DI 10.1016/j.stemcr.2013.10.006
PG 15
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA AI1WY
UT WOS:000336647100008
PM 24371809
ER
PT J
AU Lombaert, IMA
Abrams, SR
Li, L
Eswarakumar, VP
Sethi, AJ
Witt, RL
Hoffman, MP
AF Lombaert, Isabelle M. A.
Abrams, Shaun R.
Li, Li
Eswarakumar, Veraragavan P.
Sethi, Aditya J.
Witt, Robert L.
Hoffman, Matthew P.
TI Combined KIT and FGFR2b Signaling Regulates Epithelial Progenitor
Expansion during Organogenesis
SO STEM CELL REPORTS
LA English
DT Article
ID RECEPTOR TYROSINE KINASES; STEM-CELL; C-KIT; PARASYMPATHETIC
INNERVATION; EMBRYONIC LUNG; MAMMARY-GLAND; SELF-RENEWAL; MOUSE;
EXPRESSION; MORPHOGENESIS
AB Organ formation and regeneration require epithelial progenitor expansion to engineer, maintain, and repair the branched tissue architecture. Identifying the mechanisms that control progenitor expansion will inform therapeutic organ (re) generation. Here, we discover that combined KIT and fibroblast growth factor receptor 2b (FGFR2b) signaling specifically increases distal progenitor expansion during salivary gland organogenesis. FGFR2b signaling upregulates the epithelial KIT pathway so that combined KIT/FGFR2b signaling, via separate AKT and mitogen-activated protein kinase (MAPK) pathways, amplifies FGFR2b-dependent transcription. Combined KIT/FGFR2b signaling selectively expands the number of KIT+K14+SOX10+ distal progenitors, and a genetic loss of KIT signaling depletes the distal progenitors but also unexpectedly depletes the K5+ proximal progenitors. This occurs because the distal progenitors produce neurotrophic factors that support gland innervation, which maintains the proximal progenitors. Furthermore, a rare population of KIT+FGFR2b+ cells is present in adult glands, in which KIT signaling also regulates epithelial-neuronal communication during homeostasis. Our findings provide a framework to direct regeneration of branched epithelial organs.
C1 [Lombaert, Isabelle M. A.; Abrams, Shaun R.; Hoffman, Matthew P.] Natl Inst Dent & Craniofacial Res, Matrix & Morphogenesis Sect, Lab Cell & Dev Biol, NIH, Bethesda, MD 20892 USA.
[Sethi, Aditya J.] Natl Inst Dent & Craniofacial Res, Dev Mech Sect, NIH, Bethesda, MD 20892 USA.
[Li, Li; Eswarakumar, Veraragavan P.] Yale Univ, Sch Med, Dept Orthoped & Rehabil, New Haven, CT 06520 USA.
[Witt, Robert L.] Helen F Graham Canc Ctr Christiana Care, Head & Neck Multidisciplinary Clin, Newark, DE 19713 USA.
RP Hoffman, MP (reprint author), Natl Inst Dent & Craniofacial Res, Matrix & Morphogenesis Sect, Lab Cell & Dev Biol, NIH, Bethesda, MD 20892 USA.
EM mhoffman@mail.nih.gov
OI Eswarakumar, Jacob/0000-0003-0784-0507
FU Dutch Niels Stensen Stichting Award for young Dutch academics to gain
experience abroad; Intramural Research Program of the National Institute
of Dental and Craniofacial Research, NIH, DHHS
FX We thank Dr. P. McCoy and Dr. A. Williams from the NHLBI Flow Cytometry
Core for technical support, Dr H. Ye (YU) for technical assistance with
the L6 cells, Dr. S. Pradhan Bhatt (UD) for assistance with human
samples, and Dr. S. Gutkind (NIDCR) and Dr. G. Martin (UCSF) for
providing the K14Cre and RosamTmG reporter mice. I.M.A.L.
received a Dutch Niels Stensen Stichting Award for young Dutch academics
to gain experience abroad. This study was supported by the Intramural
Research Program of the National Institute of Dental and Craniofacial
Research, NIH, DHHS.
NR 46
TC 22
Z9 22
U1 2
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2213-6711
J9 STEM CELL REP
JI Stem Cell Rep.
PD DEC 17
PY 2013
VL 1
IS 6
BP 604
EP 619
DI 10.1016/j.stemcr.2013.10.013
PG 16
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA AI1WY
UT WOS:000336647100012
PM 24371813
ER
PT J
AU Lamas, GA
Boineau, R
Goertz, C
Mark, DB
Rosenberg, Y
Stylianou, M
Rozema, T
Nahin, RL
Lindblad, L
Lewis, EF
Drisko, J
Lee, KL
AF Lamas, Gervasio A.
Boineau, Robin
Goertz, Christine
Mark, Daniel B.
Rosenberg, Yves
Stylianou, Mario
Rozema, Theodore
Nahin, Richard L.
Lindblad, Lauren
Lewis, Eldrin F.
Drisko, Jeanne
Lee, Kerry L.
CA TACT Trial Assess Chelation
TI Oral High-Dose Multivitamins and Minerals After Myocardial Infarction A
Randomized Trial
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID CARDIOVASCULAR-DISEASE; BETA-CAROTENE; ANTIOXIDANT VITAMINS;
CLINICAL-TRIALS; LUNG-CANCER; PREVENTION; METAANALYSIS; COMBINATION;
MORTALITY; RISK
AB Background: Whether high-dose multivitamins are effective for secondary prevention of atherosclerotic disease is unknown.
Objective: To assess whether oral multivitamins reduce cardiovascular events and are safe.
Design: Double-blind, placebo-controlled, 2 x 2 factorial, multi-center, randomized trial. (ClinicalTrials.gov: NCT00044213)
Setting: 134 U.S. and Canadian academic and clinical sites.
Patients: 1708 patients aged 50 years or older who had myocardial infarction (MI) at least 6 weeks earlier and had serum creatinine levels of 176.8 mu mol/L (2.0 mg/dL) or less.
Intervention: Patients were randomly assigned to an oral, 28-component, high-dose multivitamin and multimineral mixture or placebo.
Measurements: The primary end point was time to total death, recurrent MI, stroke, coronary revascularization, or hospitalization for angina.
Results: The median age was 65 years, and 18% of patients were women. The qualifying MI occurred a median of 4.6 years (inter-quartile range [IQR], 1.6 to 9.2 years) before enrollment. Median follow-up was 55 months (IQR, 26 to 60 months). Patients received vitamins for a median of 31 months (IQR, 13 to 59 months) in the vitamin group and 35 months (IQR, 13 to 60 months) in the placebo group (P = 0.65). Totals of 645 (76%) and 646 (76%) patients in the vitamin and placebo groups, respectively, completed at least 1 year of oral therapy (P = 0.98), and 400 (47%) and 426 (50%) patients, respectively, completed at least 3 years (P = 0.23). Totals of 394 (46%) and 390 (46%) patients in the vitamin and placebo groups, respectively, discontinued the vitamin regimen (P = 0.67), and 17% of patients withdrew from the study. The primary end point occurred in 230 (27%) patients in the vitamin group and 253 (30%) in the placebo group (hazard ratio, 0.89 [95% CI, 0.75 to 1.07]; P = 0.21). No evidence suggested harm from vitamin therapy in any category of adverse events.
Limitation: There was considerable nonadherence and withdrawal, limiting the ability to draw firm conclusions (particularly about safety).
Conclusion: High-dose oral multivitamins and multiminerals did not statistically significantly reduce cardiovascular events in patients after MI who received standard medications. However, this conclusion is tempered by the nonadherence rate.
C1 Mt Sinai Med Ctr, Miami Beach, FL 33140 USA.
NHLBI, Bethesda, MD 20892 USA.
Natl Ctr Complementary & Alternat Med, Bethesda, MD USA.
Palmer Ctr Chiropract Res, Davenport, IA USA.
Duke Clin Res Inst, Durham, NC USA.
Biogenesis Med Ctr, Landrum, SC USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Univ Kansas, Med Ctr, Kansas City, KS 66103 USA.
RP Lamas, GA (reprint author), Columbia Univ, Div Cardiol, Mt Sinai Med Ctr, 4300 Alton Rd, Miami Beach, FL 33140 USA.
EM gervasio.lamas@msmc.com
OI Mark, Daniel/0000-0001-6340-8087
FU National Institutes of Health
FX Primary Funding Source: National Institutes of Health.
NR 25
TC 19
Z9 19
U1 0
U2 6
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD DEC 17
PY 2013
VL 159
IS 12
BP 797
EP +
DI 10.7326/0003-4819-159-12-201312170-00004
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 290ED
UT WOS:000329735300012
PM 24490264
ER
PT J
AU Krause, PR
Bialek, SR
Boppana, SB
Griffiths, PD
Laughlin, CA
Ljungman, P
Mocarski, ES
Pass, RF
Read, JS
Schleiss, MR
Plotkin, SA
AF Krause, Philip R.
Bialek, Stephanie R.
Boppana, Suresh B.
Griffiths, Paul D.
Laughlin, Catherine A.
Ljungman, Per
Mocarski, Edward S.
Pass, Robert F.
Read, Jennifer S.
Schleiss, Mark R.
Plotkin, Stanley A.
TI Priorities for CMV vaccine development
SO VACCINE
LA English
DT Review
DE Cytomegalovirus; Congenital CMV; Viruses; Clinical trial endpoints;
Meeting report
ID CONGENITAL CYTOMEGALOVIRUS-INFECTION; ORGAN TRANSPLANT RECIPIENTS;
BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; GLYCOPROTEIN-B
VACCINE; DOUBLE-BLIND; ADVISORY-COMMITTEE; HEARING-LOSS; DISEASE;
IMMUNIZATION
AB A multidisciplinary meeting addressed priorities related to development of vaccines against cytomegalovirus (CMV), the cause of congenital CMV (cCMV) disease and of serious disease in the immunocompromised. Participants discussed optimal uses of a CMV vaccine, aspects of clinical study design, and the value of additional research. A universal childhood CMV vaccine could potentially rapidly reduce cCMV disease, as infected children are sources of viral transmission to seronegative and seropositive mothers. A vaccine administered to adolescents or adult women could also reduce cCMV disease by making them immune prior to pregnancy. Clinical trials of CMV vaccines in women should evaluate protection against cCMV infection, an essential precursor of cCMV disease, which is a more practical and acceptable endpoint for assessing vaccine effects on maternal-fetal transmission. Clinical trials of vaccines to evaluate prevention of CMV disease in stem cell transplant recipients could use CMV viremia at a level triggering pre-emptive antiviral therapy as an endpoint, because widespread use of pre-emptive and prophylactic antivirals has rendered CMV-induced disease too rare to be a practical endpoint for clinical trials. In solid organ transplant patients, CMV-associated disease is sufficiently common for use as a primary endpoint. Additional research to advance CMV vaccine development should include identifying factors that predict fetal loss due to CMV, determining age-specific incidence and transmission rates, defining the mechanism and relative contributions of maternal reactivation and reinfection to cCMV disease, developing assays that can distinguish between reactivation and re-infection in seropositive vaccinees, further defining predictors of sequelae from cCMV infection, and identifying clinically relevant immune response parameters to CMV (including developing validated assays that could assess CMV antibody avidity) that could lead to the establishment of immune correlates of protection. Published by Elsevier Ltd.
C1 [Krause, Philip R.] US FDA, Off Vaccines Res & Review, CBER, Bethesda, MD 20014 USA.
[Bialek, Stephanie R.] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Boppana, Suresh B.; Pass, Robert F.] Univ Alabama Birmingham, Birmingham, AL USA.
[Griffiths, Paul D.] UCL, London WC1E 6BT, England.
[Laughlin, Catherine A.] NIAID, NIH, Bethesda, MD USA.
[Ljungman, Per] Karolinska Inst, Stockholm, Sweden.
[Mocarski, Edward S.] Emory Univ, Atlanta, GA 30322 USA.
[Read, Jennifer S.] Natl Vaccine Program Off, Washington, DC USA.
[Schleiss, Mark R.] Univ Minnesota, Minneapolis, MN USA.
[Plotkin, Stanley A.] Univ Penn, Philadelphia, PA 19104 USA.
RP Krause, PR (reprint author), US FDA, Off Vaccines Res & Review, CBER, 29 Lincoln Dr, Bethesda, MD 20014 USA.
EM philip.krause@fda.hhs.gov; zqg7@cdc.gov; sboppana@peds.uab.edu;
p.griffiths@ucl.ac.uk; CLaughlin@niaid.nih.gov; Per.Ljungman@ki.se;
mocarski@emory.edu; RPass@peds.uab.edu; Jennifer.Read@fda.hhs.gov;
schleiss@umn.edu; stanley.plotkin@vaxconsult.com
OI Krause, Philip/0000-0002-1045-7536
FU Food and Drug Administration; National Institutes of Health; Centers for
Disease Control and Prevention; National Vaccine Program Office
FX We acknowledge the Food and Drug Administration, the National Institutes
of Health, the Centers for Disease Control and Prevention, and the
National Vaccine Program Office for sponsorship of the CMV Vaccine
Workshop, held in Bethesda, MD on the NIH Campus on January 11-12, 2012.
We also thank the presenters and participants at the meeting for
excellent discussions that enabled a highly productive meeting.
NR 55
TC 36
Z9 37
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD DEC 17
PY 2013
VL 32
IS 1
BP 4
EP 10
DI 10.1016/j.vaccine.2013.09.042
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 289LT
UT WOS:000329684700003
PM 24129123
ER
PT J
AU Yorkin, M
Spaccarotella, K
Martin-Biggers, J
Quick, V
Byrd-Bredbenner, C
AF Yorkin, Meredith
Spaccarotella, Kim
Martin-Biggers, Jennifer
Quick, Virginia
Byrd-Bredbenner, Carol
TI Accuracy and consistency of weights provided by home bathroom scales
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Body weight; Body mass index; Validity
ID PRESCHOOL-CHILDREN; BODY-WEIGHT; OVERWEIGHT; HEIGHT; POPULATION;
OBESITY; PREVALENCE; BMI
AB Background: Self-reported body weight is often used for calculation of Body Mass Index because it is easy to collect. Little is known about sources of error introduced by using bathroom scales to measure weight at home. The objective of this study was to evaluate the accuracy and consistency of digital versus dial-type bathroom scales commonly used for self-reported weight.
Methods: Participants brought functioning bathroom scales (n = 18 dial-type, n = 43 digital-type) to a central location. Trained researchers assessed accuracy and consistency using certified calibration weights at 10 kg, 25 kg, 50 kg, 75 kg, 100 kg, and 110 kg. Data also were collected on frequency of calibration, age and floor surface beneath the scale.
Results: All participants reported using their scale on hard surface flooring. Before calibration, all digital scales displayed 0, but dial scales displayed a mean absolute initial weight of 0.95 (1.9 SD) kg. Digital scales accurately weighed test loads whereas dial-type scale weights differed significantly (p < 0.05). Imprecision of dial scales was significantly greater than that of digital scales at all weights (p < 0.05). Accuracy and precision did not vary by scale age.
Conclusions: Digital home bathroom scales provide sufficiently accurate and consistent weights for public health research. Reminders to zero scales before each use may further improve accuracy of self-reported weight.
C1 [Yorkin, Meredith; Spaccarotella, Kim; Martin-Biggers, Jennifer; Byrd-Bredbenner, Carol] Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA.
[Quick, Virginia] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, NIH, Bethesda, MD 20892 USA.
RP Martin-Biggers, J (reprint author), Rutgers State Univ, Dept Nutr Sci, 26 Nichol Ave,Davison Hall, New Brunswick, NJ 08901 USA.
EM jmartin@njaes.rutgers.edu
RI Byrd-Bredbenner, Carol/F-8064-2015;
OI Byrd-Bredbenner, Carol/0000-0002-8010-3987; Martin-Biggers,
Jennifer/0000-0001-8857-6386; Quick, Virginia/0000-0002-4338-963X
FU United States Department of Agriculture, National Institute of Food and
Agriculture [2011-68001-30170]; Eunice Kennedy Shriver National
Institute of Child Health and Human Development Intramural Research
Training Award
FX MY, KS, JMB, VQ and CBB received funding from the United States
Department of Agriculture, National Institute of Food and Agriculture,
Grant Number 2011-68001-30170. VQ also received funding from the Eunice
Kennedy Shriver National Institute of Child Health and Human Development
Intramural Research Training Award.
NR 23
TC 3
Z9 3
U1 2
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD DEC 17
PY 2013
VL 13
AR UNSP 1194
DI 10.1186/1471-2458-13-1194
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 286XL
UT WOS:000329502500001
PM 24341761
ER
PT J
AU Li, FH
Tan, H
Singh, J
Yang, J
Xia, XF
Bao, JG
Ma, JW
Zhan, M
Wong, STC
AF Li, Fuhai
Tan, Hua
Singh, Jaykrishna
Yang, Jian
Xia, Xiaofeng
Bao, Jiguang
Ma, Jinwen
Zhan, Ming
Wong, Stephen T. C.
TI A 3D multiscale model of cancer stem cell in tumor development
SO BMC SYSTEMS BIOLOGY
LA English
DT Article; Proceedings Paper
CT 6th International Conference on Computational Systems Biology (ISB)
CY AUG 18-20, 2012
CL Xian, PEOPLES R CHINA
ID NONLINEAR SIMULATION; MATHEMATICAL-MODEL; WNT ACTIVITY; GROWTH;
INVASION; ANGIOGENESIS; METASTASIS; MORPHOLOGY; BIOLOGY
AB Background: Recent reports indicate that a subgroup of tumor cells named cancer stem cells (CSCs) or tumor initiating cells (TICs) are responsible for tumor initiation, growth and drug resistance. This subgroup of tumor cells has self-renewal capacity and could differentiate into heterogeneous tumor cell populations through asymmetric proliferation. The idea of CSC provides informative insights into tumor initiation, metastasis and treatment. However, the underlying mechanisms of CSCs regulating tumor behaviors are unclear due to the complex cancer system. To study the functions of CSCs in the complex tumor system, a few mathematical modeling studies have been proposed. Whereas, the effect of microenvironment (mE) factors, the behaviors of CSCs, progenitor tumor cells (PCs) and differentiated tumor cells (TCs), and the impact of CSC fraction and signaling heterogeneity, are not adequately explored yet.
Methods: In this study, a novel 3D multi-scale mathematical modeling is proposed to investigate the behaviors of CSCsin tumor progressions. The model integrates CSCs, PCs, and TCs together with a few essential mE factors. With this model, we simulated and investigated the tumor development and drug response under different CSC content and heterogeneity.
Results: The simulation results shown that the fraction of CSCs plays a critical role in driving the tumor progression and drug resistance. It is also showed that the pure chemo-drug treatment was not a successful treatment, as it resulted in a significant increase of the CSC fraction. It further shown that the self-renew heterogeneity of the initial CSC population is a cause of the heterogeneity of the derived tumors in terms of the CSC fraction and response to drug treatments.
Conclusions: The proposed 3D multi-scale model provides a new tool for investigating the behaviors of CSC in CSC-initiated tumors, which enables scientists to investigate and generate testable hypotheses about CSCs in tumor development and drug response under different microenvironments and drug perturbations.
C1 [Li, Fuhai; Tan, Hua; Singh, Jaykrishna; Yang, Jian; Xia, Xiaofeng; Ma, Jinwen; Zhan, Ming; Wong, Stephen T. C.] Cornell Univ, Weill Med Coll, Dept Syst Med & Bioengn, Methodist Hosp,Res Inst,NCI Ctr Modeling Canc Dev, Houston, TX 77030 USA.
[Tan, Hua; Bao, Jiguang] Beijing Normal Univ, Lab Math & Complex Syst, Minist Educ, Sch Math Sci, Beijing 100875, Peoples R China.
[Ma, Jinwen] Peking Univ, Sch Math Sci, Dept Informat Sci, Beijing 100871, Peoples R China.
[Ma, Jinwen] Peking Univ, LMAM, Beijing 100871, Peoples R China.
RP Zhan, M (reprint author), Cornell Univ, Weill Med Coll, Dept Syst Med & Bioengn, Methodist Hosp,Res Inst,NCI Ctr Modeling Canc Dev, Houston, TX 77030 USA.
EM mzhan@tmhs.org
FU NCI NIH HHS [NIH U54CA149169]
NR 33
TC 6
Z9 6
U1 1
U2 25
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1752-0509
J9 BMC SYST BIOL
JI BMC Syst. Biol.
PD DEC 17
PY 2013
VL 7
SU 2
AR S12
DI 10.1186/1752-0509-7-S2-S12
PG 12
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA 286BR
UT WOS:000329440000004
PM 24564919
ER
PT J
AU Kiggundu, VL
O'Meara, WP
Musoke, R
Nalugoda, FK
Kigozi, G
Baghendaghe, E
Lutalo, T
Achienge, MK
Reynolds, SJ
Makumbi, F
Serwadda, D
Gray, RH
Wools-Kaloustian, KK
AF Kiggundu, Valerian L.
O'Meara, Wendy P.
Musoke, Richard
Nalugoda, Fred K.
Kigozi, Godfrey
Baghendaghe, Enos
Lutalo, Tom
Achienge, Marion K.
Reynolds, Steven J.
Makumbi, Fred
Serwadda, David
Gray, Ronald H.
Wools-Kaloustian, Kara K.
TI High Prevalence of Malaria Parasitemia and Anemia among Hospitalized
Children in Rakai, Uganda
SO PLOS ONE
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MALARIA; TRANSMISSION INTENSITY; MORTALITY;
MORBIDITY; MISDIAGNOSIS; VACCINES; SITES; KENYA
AB Background: There is a paucity of data on malaria among hospitalized children in malaria endemic areas. We determined the prevalence, presentation and treatment outcomes of malaria and anemia among children in two hospitals in Rakai, Uganda.
Methods: Children under five years hospitalized in Kalisizo hospital or Bikira health center in Rakai district, Uganda between May 2011 and May 2012 were enrolled and followed-up until discharge, death or referral. Data were collected on social-demographic characteristics, current and past illnesses and clinical signs and symptoms. Blood smears, hemoglobin (Hgb) levels and HIV testing were performed from finger/heel prick blood. The associations between malaria infection and other factors were estimated using log-binomial regression to estimate adjusted prevalence risk ratios (aPRR) and 95% confidence intervals (CIs), controlling for clustering at health facilities.
Results: 2471 children were enrolled. The most common medical presentations were fever (96.2%), cough (61.7%), vomiting (44.2%), diarrhea (20.8%), and seizures (16.0%). The prevalence of malaria parasitemia was 54.6%. Children with malaria were more likely to present with a history of fever (aPRR 2.23; CI 1.18-4.24) and seizures (aPRR 1.12; CI 1.09-1.16). Confirmed malaria was significantly lower among girls than boys (aPRR 0.92; CI 0.91-0.93), HIV infected children (aPRR 0.60 CI 0.52-0.71), and children with diarrhea (aPRR 0.76; CI 0.65-0.90). The overall prevalence of anemia (Hgb, 10 g/dl) was 56.3% and severe anemia (Hgb, 6 g/dL) was 17.8%. Among children with severe anemia 76.8% had malaria parasitemia, of whom 93.1% received blood transfusion. Malaria associated mortality was 0.6%.
Conclusion: There was a high prevalence of malaria parasitemia and anemia among inpatient children under five years. Malaria prevention is a priority in this population.
C1 [Kiggundu, Valerian L.; Musoke, Richard; Nalugoda, Fred K.; Kigozi, Godfrey; Baghendaghe, Enos; Lutalo, Tom; Reynolds, Steven J.; Makumbi, Fred; Serwadda, David] Kalisizo Stn, Rakai Hlth Sci Program, Kalisizo, Rakai, Uganda.
[O'Meara, Wendy P.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA.
[O'Meara, Wendy P.] Duke Global Hlth Inst, Durham, NC USA.
[Achienge, Marion K.] Makerere Univ, Coll Hlth Sci, East African IeDEA Int Epidemiol Data Bases Evalu, Kampala, Uganda.
[Achienge, Marion K.] Makerere Univ, Coll Hlth Sci, Infect Dis Inst, Kampala, Uganda.
[Reynolds, Steven J.] NIAID, Div Intramural Res, NIH, Bethesda, MD 20892 USA.
[Makumbi, Fred; Serwadda, David] Makerere Univ, Sch Publ Hlth, Kampala, Uganda.
[Gray, Ronald H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Wools-Kaloustian, Kara K.] Indiana Univ Sch Med, Dept Med, Div Infect Dis, Indianapolis, IN 46202 USA.
RP Kiggundu, VL (reprint author), Kalisizo Stn, Rakai Hlth Sci Program, Kalisizo, Rakai, Uganda.
EM valerian@rhsp.org
FU National Institute of Allergy and Infectious Diseases (NIAID) [U01
A1069911]; National Institute of Child Health and Human Development
(NICHD); National Cancer Institute (NCI) and National Institute of
Health (NIH) through Indiana University and East Africa IeDEA
FX The project described was supported by grant No. U01 A1069911 from the
National Institute of Allergy and Infectious Diseases (NIAID); National
Institute of Child Health and Human Development (NICHD); National Cancer
Institute (NCI) and National Institute of Health (NIH) through Indiana
University and East Africa IeDEA (international epidemiological data
bases to evaluate AIDs). The contents of this project are solely the
responsibility of the authors and do not necessarily represent the
official view of the National Institute of Allergy and Infectious
Disease (NIAID); National Institute of Child Health and Human
Development (NICHD); National Cancer Institute (NCI) or National
Institute of Health (NIH). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 28
TC 4
Z9 4
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 17
PY 2013
VL 8
IS 12
AR e82455
DI 10.1371/journal.pone.0082455
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276GT
UT WOS:000328737700017
PM 24358185
ER
PT J
AU Thameem, F
Igo, RP
Freedman, BI
Langefeld, C
Hanson, RL
Schelling, JR
Elston, RC
Duggirala, R
Nicholas, SB
Goddard, KAB
Divers, J
Guo, XQ
Ipp, E
Kimmel, PL
Meoni, LA
Shah, VO
Smith, MW
Winkler, CA
Zager, PG
Knowler, WC
Nelson, RG
Pahl, MV
Parekh, RS
Kao, WHL
Rasooly, RS
Adler, SG
Abboud, HE
Iyengar, SK
Sedor, JR
AF Thameem, Farook
Igo, Robert P., Jr.
Freedman, Barry I.
Langefeld, Carl
Hanson, Robert L.
Schelling, Jeffrey R.
Elston, Robert C.
Duggirala, Ravindranath
Nicholas, Susanne B.
Goddard, Katrina A. B.
Divers, Jasmin
Guo, Xiuqing
Ipp, Eli
Kimmel, Paul L.
Meoni, Lucy A.
Shah, Vallabh O.
Smith, Michael W.
Winkler, Cheryl A.
Zager, Philip G.
Knowler, William C.
Nelson, Robert G.
Pahl, Madeline V.
Parekh, Rulan S.
Kao, W. H. Linda
Rasooly, Rebekah S.
Adler, Sharon G.
Abboud, Hanna E.
Iyengar, Sudha K.
Sedor, John R.
CA Family Invest Nephropathy & Diabet
TI A Genome-Wide Search for Linkage of Estimated Glomerular Filtration Rate
(eGFR) in the Family Investigation of Nephropathy and Diabetes (FIND)
SO PLOS ONE
LA English
DT Article
ID CHRONIC KIDNEY-DISEASE; RENAL-FUNCTION; MEXICAN-AMERICANS;
GENETIC-VARIANTS; SERUM CREATININE; IDENTIFIES 6; ASSOCIATION; LOCI;
ALBUMINURIA; TRAITS
AB Objective: Estimated glomerular filtration rate (eGFR), a measure of kidney function, is heritable, suggesting that genes influence renal function. Genes that influence eGFR have been identified through genome-wide association studies. However, family-based linkage approaches may identify loci that explain a larger proportion of the heritability. This study used genome-wide linkage and association scans to identify quantitative trait loci (QTL) that influence eGFR.
Methods: Genome-wide linkage and sparse association scans of eGFR were performed in families ascertained by probands with advanced diabetic nephropathy (DN) from the multi-ethnic Family Investigation of Nephropathy and Diabetes (FIND) study. This study included 954 African Americans (AA), 781 American Indians (AI), 614 European Americans (EA) and 1,611 Mexican Americans (MA). A total of 3,960 FIND participants were genotyped for 6,000 single nucleotide polymorphisms (SNPs) using the Illumina Linkage IVb panel. GFR was estimated by the Modification of Diet in Renal Disease (MDRD) formula.
Results: The non-parametric linkage analysis, accounting for the effects of diabetes duration and BMI, identified the strongest evidence for linkage of eGFR on chromosome 20q11 (log of the odds [LOD] = 3.34; P = 4.4x10(-5)) in MA and chromosome 15q12 (LOD = 2.84; P = 1.5x10(-4)) in EA. In all subjects, the strongest linkage signal for eGFR was detected on chromosome 10p12 (P = 5.5x10(-4)) at 44 cM near marker rs1339048. A subsequent association scan in both ancestry-specific groups and the entire population identified several SNPs significantly associated with eGFR across the genome.
Conclusion: The present study describes the localization of QTL influencing eGFR on 20q11 in MA, 15q21 in EA and 10p12 in the combined ethnic groups participating in the FIND study. Identification of causal genes/variants influencing eGFR, within these linkage and association loci, will open new avenues for functional analyses and development of novel diagnostic markers for DN.
C1 [Thameem, Farook; Abboud, Hanna E.] Univ Texas San Antonio, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA.
[Igo, Robert P., Jr.; Elston, Robert C.; Iyengar, Sudha K.; Sedor, John R.] Case Western Reserve Univ, Dept Biostat & Epidemiol, Cleveland, OH 44106 USA.
[Freedman, Barry I.; Langefeld, Carl; Divers, Jasmin] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA.
[Hanson, Robert L.; Knowler, William C.; Nelson, Robert G.] Natl Inst Diabet & Digest & Kidney Dis, Phoenix Epidemiol & Clin Res Branch, NIH, Phoenix, AZ USA.
[Schelling, Jeffrey R.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA.
[Duggirala, Ravindranath] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA.
[Nicholas, Susanne B.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Goddard, Katrina A. B.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA.
[Guo, Xiuqing] Harbor Univ Calif Los Angeles, Med Ctr, Dept Pediat, Torrance, CA USA.
[Ipp, Eli; Adler, Sharon G.] Harbor Univ Calif Los Angeles, Med Ctr, Dept Med, Torrance, CA USA.
[Kimmel, Paul L.; Rasooly, Rebekah S.] Natl Inst Diabet Digest & Kidney Dis, NIH, Bethesda, MD USA.
[Meoni, Lucy A.; Parekh, Rulan S.; Kao, W. H. Linda] Johns Hopkins Univ, Dept Epidemiol & Med, Baltimore, MD USA.
[Shah, Vallabh O.; Zager, Philip G.] Univ New Mexico, Albuquerque, NM 87131 USA.
[Smith, Michael W.] NHGRI, NIH, Bethesda, MD 20892 USA.
[Winkler, Cheryl A.] NCI, Ctr Canc Res, NIH, Frederick, MD 21701 USA.
[Pahl, Madeline V.] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA.
[Parekh, Rulan S.] Univ Toronto, Dept Pediat, Toronto, ON, Canada.
RP Iyengar, SK (reprint author), Case Western Reserve Univ, Dept Biostat & Epidemiol, Cleveland, OH 44106 USA.
EM ski@case.edu
RI Hanson, Robert/O-3238-2015;
OI Hanson, Robert/0000-0002-4252-7068; Rasooly, Rebekah/0000-0002-6357-5528
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[U01DK57292-05]; Intramural Research Program of the NIDDK; National
Cancer Institute, National Institutes of Health [HHSN26120080001E];
Intramural Research Program of the NIH, National Cancer Institute,
Center for Cancer Research
FX The authors thank all the FIND participants. This study was supported by
the research grant U01DK57292-05 from the National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK). The study was also supported
in part by the Intramural Research Program of the NIDDK. This project
has been funded in whole or in part with federal funds from the National
Cancer Institute, National Institutes of Health, under contract
HHSN26120080001E. The content of this publication does not necessarily
reflect the views or policies of the Department of Health and Human
Services, nor does mention of trade names, commercial products, or
organizations imply endorsement by the U.S. Government. This Research
was supported [in part] by the Intramural Research Program of the NIH,
National Cancer Institute, Center for Cancer Research. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 40
TC 15
Z9 15
U1 2
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 17
PY 2013
VL 8
IS 12
AR e81888
DI 10.1371/journal.pone.0081888
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276GT
UT WOS:000328737700002
PM 24358131
ER
PT J
AU Zhao, HY
Lomash, S
Glasser, C
Mayer, ML
Schuckl, P
AF Zhao, Huaying
Lomash, Suvendu
Glasser, Carla
Mayer, Mark L.
Schuckl, Peter
TI Analysis of High Affinity Self-Association by Fluorescence Optical
Sedimentation Velocity Analytical Ultracentrifugation of Labeled
Proteins: Opportunities and Limitations
SO PLOS ONE
LA English
DT Article
ID N-TERMINAL DOMAIN; DETECTED SEDIMENTATION; MACROMOLECULES; BINDING;
ACCURACY
AB Sedimentation velocity analytical ultracentrifugation (SV) is a powerful first-principle technique for the study of protein interactions, and allows a rigorous characterization of binding stoichiometry and affinities. A recently introduced commercial fluorescence optical detection system (FDS) permits analysis of high-affinity interactions by SV. However, for most proteins the attachment of an extrinsic fluorophore is an essential prerequisite for analysis by FDS-SV. Using the glutamate receptor GluA2 amino terminal domain as a model system for high-affinity homo-dimerization, we demonstrate how the experimental design and choice of fluorescent label can impact both the observed binding constants as well as the derived hydrodynamic parameter estimates for the monomer and dimer species. Specifically, FAM (5,6-carboxyfluorescein) was found to create different populations of artificially high-affinity and low-affinity dimers, as indicated by both FDS-SV and the kinetics of dimer dissociation studied using a bench-top fluorescence spectrometer and Forster Resonance Energy Transfer. By contrast, Dylight488 labeled GluA2, as well as GluA2 expressed as an EGFP fusion protein, yielded results consistent with estimates for unlabeled GluA2. Our study suggests considerations for the choice of labeling strategies, and highlights experimental designs that exploit specific opportunities of FDS-SV for improving the reliability of the binding isotherm analysis of interacting systems.
C1 [Zhao, Huaying; Schuckl, Peter] Natl Inst Biomed Imaging & Bioengn, NIH, Lab Cellular Imaging & Macromol Biophys, Dynam Macromol Assembly Sect, Bethesda, MD USA.
[Lomash, Suvendu; Glasser, Carla; Mayer, Mark L.] NICHHD, Lab Cellular & Mol Neurophysiol, Porter Neurosci Res Ctr, NIH, Bethesda, MD 20892 USA.
RP Mayer, ML (reprint author), NICHHD, Lab Cellular & Mol Neurophysiol, Porter Neurosci Res Ctr, NIH, Bethesda, MD 20892 USA.
EM mayerm@mail.nih.gov; schuckp@mail.nih.gov
OI Schuck, Peter/0000-0002-8859-6966
FU Intramural Research Programs of the National Institute of Biomedical
Imaging and Bioengineering; National Institute of Child Health and Human
Development, National Institutes of Health
FX This work was supported by the Intramural Research Programs of the
National Institute of Biomedical Imaging and Bioengineering and the
National Institute of Child Health and Human Development, National
Institutes of Health. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 32
TC 12
Z9 12
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 17
PY 2013
VL 8
IS 12
AR e83439
DI 10.1371/journal.pone.0083439
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276GT
UT WOS:000328737700057
PM 24358283
ER
PT J
AU Simon-Manso, Y
Lowenthal, MS
Kilpatrick, LE
Sampson, ML
Telu, KH
Rudnick, PA
Mallard, WG
Bearden, DW
Schock, TB
Tchekhovskoi, DV
Blonder, N
Yan, XJ
Liang, YX
Zheng, YF
Wallace, WE
Neta, P
Phinney, KW
Remaley, AT
Stein, SE
AF Simon-Manso, Yamil
Lowenthal, Mark S.
Kilpatrick, Lisa E.
Sampson, Maureen L.
Telu, Kelly H.
Rudnick, Paul A.
Mallard, W. Gary
Bearden, Daniel W.
Schock, Tracey B.
Tchekhovskoi, Dmitrii V.
Blonder, Niksa
Yan, Xinjian
Liang, Yuxue
Zheng, Yufang
Wallace, William E.
Neta, Pedatsur
Phinney, Karen W.
Remaley, Alan T.
Stein, Stephen E.
TI Metabolite Profiling of a NIST Standard Reference Material for Human
Plasma (SRM 1950): GC-MS, LC-MS, NMR, and Clinical Laboratory Analyses,
Libraries, and Web-Based Resources
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID HUMAN BLOOD-PLASMA; MASS-SPECTROMETRY; ELECTROSPRAY-IONIZATION;
CHROMATOGRAPHY/MASS SPECTROMETRY; COMPOUND IDENTIFICATION; SAMPLE
PREPARATION; SERUM; SPECTROSCOPY; METABOLOMICS; SUPPRESSION
AB Recent progress in metabolomics and the development of increasingly sensitive analytical techniques have renewed interest in global profiling, i.e., semiquantitative monitoring of all chemical constituents of biological fluids. In this work, we have performed global profiling of NIST SRM 1950, "Metabolites in Human Plasma", using GC-MS, LC-MS, and NMR Metabolome coverage, difficulties, and reproducibility of the experiments on each platform are discussed. A total of 353 metabolites have been identified in this material. GC-MS provides 65 unique identifications, and most of the identifications from NMR overlap with the LC-MS identifications, except for some small sugars that are not directly found by LC-MS. Also, repeatability and intermediate precision analyses show that the SRM 1950 profiling is reproducible enough to consider this material as a good choice to distinguish between analytical and biological variability. Clinical laboratory data shows that most results are within the reference ranges for each assay. In-house computational tools have been developed or modified for MS data processing and interactive web display: All data and programs are freely available online at http://peptide.nist.gov/ and http://srmd.nist.gov/.
C1 [Simon-Manso, Yamil; Lowenthal, Mark S.; Kilpatrick, Lisa E.; Rudnick, Paul A.; Mallard, W. Gary; Tchekhovskoi, Dmitrii V.; Blonder, Niksa; Yan, Xinjian; Liang, Yuxue; Zheng, Yufang; Neta, Pedatsur; Phinney, Karen W.; Stein, Stephen E.] NIST, Biomol Measurement Div, Gaithersburg, MD 20899 USA.
[Sampson, Maureen L.; Remaley, Alan T.] NIH, Dept Lab Med, Bethesda, MD 20892 USA.
[Telu, Kelly H.; Wallace, William E.] NIST, Div Chem Sci, Gaithersburg, MD 20899 USA.
[Bearden, Daniel W.; Schock, Tracey B.] NIST, Hollings Marine Lab, Div Chem Sci, Charleston, SC 29412 USA.
RP Simon-Manso, Y (reprint author), 100 Bur Dr,M-S 8362, Gaithersburg, MD 20899 USA.
EM ysimon@nist.gov
RI Tchekhovskoi, Dmitrii/J-2319-2014;
OI Mallard, Wm. Gary/0000-0003-2158-5098
NR 32
TC 28
Z9 28
U1 6
U2 70
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD DEC 17
PY 2013
VL 85
IS 24
BP 11725
EP 11731
DI 10.1021/ac402503m
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 277CV
UT WOS:000328797200011
PM 24147600
ER
PT J
AU Phinney, KW
Ballihaut, G
Bedner, M
Benford, BS
Camara, JE
Christopher, SJ
Davis, WC
Dodder, NG
Eppe, G
Lang, BE
Long, SE
Lowenthal, MS
McGaw, EA
Murphy, KE
Nelson, BC
Prendergast, JL
Reiner, JL
Rimmer, CA
Sander, LC
Schantz, MM
Sharpless, KE
Sniegoski, LT
Tai, SSC
Thomas, JB
Vetter, TW
Welch, MJ
Wise, SA
Wood, LJ
Guthrie, WF
Hagwood, CR
Leigh, SD
Yen, JH
Zhang, NF
Chaudhary-Webb, M
Chen, HP
Fazili, Z
LaVoie, DJ
McCoy, LF
Momin, SS
Paladugula, N
Pendergrast, EC
Pfeiffer, CM
Powers, CD
Rabinowitz, D
Rybak, ME
Schleicher, RL
Toombs, BMH
Xu, M
Zhang, M
Castle, AL
AF Phinney, Karen W.
Ballihaut, Guillaume
Bedner, Mary
Benford, Brandi S.
Camara, Johanna E.
Christopher, Steven J.
Davis, W. Clay
Dodder, Nathan G.
Eppe, Gauthier
Lang, Brian E.
Long, Stephen E.
Lowenthal, Mark S.
McGaw, Elizabeth A.
Murphy, Karen E.
Nelson, Bryant C.
Prendergast, Jocelyn L.
Reiner, Jessica L.
Rimmer, Catherine A.
Sander, Lane C.
Schantz, Michele M.
Sharpless, Katherine E.
Sniegoski, Lorna T.
Tai, Susan S. -C.
Thomas, Jeanice B.
Vetter, Thomas W.
Welch, Michael J.
Wise, Stephen A.
Wood, Laura J.
Guthrie, William F.
Hagwood, Charles R.
Leigh, Stefan D.
Yen, James H.
Zhang, Nien-Fan
Chaudhary-Webb, Madhu
Chen, Huiping
Fazili, Zia
LaVoie, Donna J.
McCoy, Leslie F.
Momin, Shahzad S.
Paladugula, Neelima
Pendergrast, Elizabeth C.
Pfeiffer, Christine M.
Powers, Carissa D.
Rabinowitz, Daniel
Rybak, Michael E.
Schleicher, Rosemary L.
Toombs, Bridgette M. H.
Xu, Mary
Zhang, Mindy
Castle, Arthur L.
TI Development of a Standard Reference Material for Metabolomics Research
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID HUMAN PLASMA; MASS-SPECTROMETRY; HUMAN URINE; METABONOMIC ANALYSIS;
DIABETES-MELLITUS; ACID-METABOLISM; HPLC-MS; DISEASE; SPECTROSCOPY;
PERFORMANCE
AB The National Institute of Standards and Technology (NIST), in collaboration with the National Institutes of Health (NTH), has developed a Standard Reference Material (SRM) to support technology development in metabolomics research. SRM 1950 Metabolites in Human Plasma is intended to have metabolite concentrations that are representative of those found in adult human plasma. The plasma used in the preparation of SRM 1950 was collected from both male and female donors, and donor ethnicity targets were selected based upon the ethnic makeup of the U.S. population. Metabolomics research is diverse in terms of both instrumentation and scientific goals. This SRM was designed to apply broadly to the field, not toward specific applications. Therefore, concentrations of approximately 100 analytes, including amino acids, fatty acids, trace elements, vitamins, hormones, selenoproteins, clinical markers, and perfluorinated compounds (PFCs), were determined. Value assignment measurements were performed by NIST and the Centers for Disease Control and Prevention (CDC). SRM 1950 is the first reference material developed specifically for metabolomics research.
C1 [Phinney, Karen W.; Lowenthal, Mark S.] NIST, Biomol Measurement Div, Gaithersburg, MD 20899 USA.
[Ballihaut, Guillaume; Bedner, Mary; Benford, Brandi S.; Camara, Johanna E.; Christopher, Steven J.; Davis, W. Clay; Dodder, Nathan G.; Eppe, Gauthier; Long, Stephen E.; McGaw, Elizabeth A.; Murphy, Karen E.; Prendergast, Jocelyn L.; Reiner, Jessica L.; Rimmer, Catherine A.; Sander, Lane C.; Schantz, Michele M.; Sharpless, Katherine E.; Sniegoski, Lorna T.; Tai, Susan S. -C.; Thomas, Jeanice B.; Vetter, Thomas W.; Welch, Michael J.; Wise, Stephen A.; Wood, Laura J.] NIST, Div Chem Sci, Gaithersburg, MD 20899 USA.
[Lang, Brian E.; Nelson, Bryant C.] NIST, Biosyst & Biomat Div, Gaithersburg, MD 20899 USA.
[Guthrie, William F.; Hagwood, Charles R.; Leigh, Stefan D.; Yen, James H.; Zhang, Nien-Fan] NIST, Stat Engn Div, Gaithersburg, MD 20899 USA.
[Chaudhary-Webb, Madhu; Chen, Huiping; Fazili, Zia; LaVoie, Donna J.; McCoy, Leslie F.; Momin, Shahzad S.; Paladugula, Neelima; Pendergrast, Elizabeth C.; Pfeiffer, Christine M.; Powers, Carissa D.; Rabinowitz, Daniel; Rybak, Michael E.; Schleicher, Rosemary L.; Toombs, Bridgette M. H.; Xu, Mary; Zhang, Mindy] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA.
[Castle, Arthur L.] NIDDK, NIH, Bethesda, MD 20892 USA.
RP Phinney, KW (reprint author), NIST, Biomol Measurement Div, Gaithersburg, MD 20899 USA.
EM karen.phinney@nist.gov
RI Dodder, Nathan/C-7971-2015;
OI Dodder, Nathan/0000-0001-5913-1767; Rybak, Michael/0000-0003-1650-8581
FU Intramural CDC HHS [CC999999]
NR 62
TC 21
Z9 21
U1 7
U2 54
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
EI 1520-6882
J9 ANAL CHEM
JI Anal. Chem.
PD DEC 17
PY 2013
VL 85
IS 24
BP 11732
EP 11738
DI 10.1021/ac402689t
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 277CV
UT WOS:000328797200012
PM 24187941
ER
PT J
AU Best, RB
AF Best, Robert B.
TI Folding and Binding: When the Force is Against You
SO BIOPHYSICAL JOURNAL
LA English
DT News Item
ID PROTEIN; CALMODULIN; LANDSCAPE; KINETICS
C1 NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
RP Best, RB (reprint author), NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
EM robertbe@helix.nih.gov
RI Best, Robert/H-7588-2016
OI Best, Robert/0000-0002-7893-3543
NR 11
TC 0
Z9 0
U1 1
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0006-3495
EI 1542-0086
J9 BIOPHYS J
JI Biophys. J.
PD DEC 17
PY 2013
VL 105
IS 12
BP 2611
EP 2612
DI 10.1016/j.bpj.2013.10.035
PG 2
WC Biophysics
SC Biophysics
GA 274HM
UT WOS:000328597400002
PM 24359729
ER
PT J
AU Chen, HH
Borlaug, BA
Anstrom, KJ
Felker, GM
Givertz, MM
Deswal, A
Bart, BA
Stevenson, LW
Rouleau, JL
O'Meara, E
LeWinter, MM
Bull, DA
Stehlik, J
Semigran, MJ
Goldsmith, SR
Ofili, EO
O'Connor, CM
Tang, WHW
Starling, RC
Butler, J
Whellan, DJ
Margulies, KB
Cappola, TP
Konstam, MA
Mann, DL
Davila-Roman, V
McNulty, SE
Velazquez, EJ
Lee, KL
Shah, MR
Hernandez, AF
Braunwald, E
Redfield, MM
AF Chen, Horng H.
Borlaug, Barry A.
Anstrom, Kevin J.
Felker, G. M.
Givertz, Michael M.
Deswal, Anita
Bart, Bradley A.
Stevenson, Lynne W.
Rouleau, Jean L.
O'Meara, Eileen
LeWinter, Martin M.
Bull, David A.
Stehlik, Josef
Semigran, Marc J.
Goldsmith, Steven R.
Ofili, Elizabeth O.
O'Connor, Christopher M.
Tang, W. H. Wilson
Starling, Randall C.
Butler, Javed
Whellan, David J.
Margulies, Kenneth B.
Cappola, Thomas P.
Konstam, Marvin A.
Mann, Douglas L.
Davila-Roman, Victor
McNulty, Steven E.
Velazquez, Eric J.
Lee, Kerry L.
Shah, Monica R.
Hernandez, Adrian F.
Braunwald, Eugene
Redfield, Magaret M.
TI Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE
AHF) Trial
SO CIRCULATION
LA English
DT Meeting Abstract
DE Acute heart failure; Renal function; Cardiovascular therapeutics;
Catecholamines; Natriuretic peptide
C1 [Chen, Horng H.; Borlaug, Barry A.; Redfield, Magaret M.] Mayo Clin, Rochester, MN USA.
[Anstrom, Kevin J.; McNulty, Steven E.; Lee, Kerry L.; Hernandez, Adrian F.] Duke Clin Rsch Inst, Durham, NC USA.
[Felker, G. M.] Duke Univ, Sch Med, Duke Heart Cntr, Durham, NC USA.
[Givertz, Michael M.; Stevenson, Lynne W.; Braunwald, Eugene] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Deswal, Anita] Baylor Coll Med, Houston, TX 77030 USA.
[Deswal, Anita] Baylor Clin, Houston, TX 77030 USA.
[Bart, Bradley A.; Goldsmith, Steven R.] Univ Minnesota, Minneapolis, MN USA.
[Rouleau, Jean L.; O'Meara, Eileen] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada.
[LeWinter, Martin M.] Univ Vermont, Burlington, VT USA.
[Bull, David A.; Stehlik, Josef] Univ Utah, Hlth Sci Cntr, Salt Lake City, UT USA.
[Semigran, Marc J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ofili, Elizabeth O.] Morehouse Sch Med, Atlanta, GA 30310 USA.
[O'Connor, Christopher M.; Velazquez, Eric J.] Duke Univ, Sch Med, Durham, NC USA.
[O'Connor, Christopher M.; Velazquez, Eric J.] Duke Heart Cntr, Durham, NC USA.
[Tang, W. H. Wilson; Starling, Randall C.] Cleveland Clin, Cleveland, OH 44106 USA.
[Butler, Javed] Emory Univ, Atlanta, GA 30322 USA.
[Whellan, David J.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
[Margulies, Kenneth B.; Cappola, Thomas P.] Univ Penn, Philadelphia, PA 19104 USA.
[Konstam, Marvin A.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Mann, Douglas L.; Davila-Roman, Victor] Washington Univ, St Louis, MO USA.
[Shah, Monica R.] NHLBI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD DEC 17
PY 2013
VL 128
IS 24
BP 2707
EP 2708
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 271SB
UT WOS:000328410800031
ER
PT J
AU Acker, MA
Parides, MK
Perrault, LP
Moskowitz, AJ
Voisine, P
Smith, PK
Gelijns, AC
Hung, JW
Blackstone, E
Puskas, J
Argenziano, M
Gammie, JS
Mack, M
Ascheim, DD
Bagiella, E
Ferguson, TB
Horvath, K
Geller, NL
Miller, MA
Woo, JY
D'Alessandro, DA
Ailawadi, G
Dagenais, F
Gardner, TJ
O'Gara, PT
Michler, R
Kron, IL
AF Acker, Michael A.
Parides, Michael K.
Perrault, Louis P.
Moskowitz, Alan J.
Voisine, Pierre
Smith, Peter K.
Gelijns, Annetine C.
Hung, Judy W.
Blackstone, Eugene
Puskas, John
Argenziano, Michael
Gammie, James S.
Mack, Michael
Ascheim, Deborah D.
Bagiella, Emilia
Ferguson, T. Bruce
Horvath, Keith
Geller, Nancy L.
Miller, Marissa A.
Woo, Joseph Y.
D'Alessandro, David A.
Ailawadi, Gorav
Dagenais, Franois
Gardner, Timothy J.
O'Gara, Patrick T.
Michler, Robert
Kron, Irving L.
TI Severe Ischemic Mitral Regurgitation: Is it Better to Repair or Replace
the Valve?
SO CIRCULATION
LA English
DT Meeting Abstract
C1 [Acker, Michael A.] Hosp Univ Penn, Div Cardiovasc Surg, Philadelphia, PA 19104 USA.
[Parides, Michael K.; Moskowitz, Alan J.; Gelijns, Annetine C.; Ascheim, Deborah D.; Bagiella, Emilia] Icahn Sch Med Mt Sinai, New York, NY USA.
[Perrault, Louis P.] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada.
[Voisine, Pierre] Inst Univ Cardiol Quebec, Div Cardiac Surg, Quebec City, PQ, Canada.
[Smith, Peter K.] Duke Univ, Durham, NC USA.
[Hung, Judy W.] Massachusetts Gen Hosp, Echocardiog Core Lab, Boston, MA 02114 USA.
[Blackstone, Eugene; Ailawadi, Gorav] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Puskas, John] Emory Univ Hosp Midtown, Atlanta, GA USA.
[Argenziano, Michael] Columbia Univ, Med Cntr, New York, NY USA.
[Gammie, James S.] Univ Maryland, Div Cardiac Surg, Baltimore, MD 21201 USA.
[Mack, Michael] Baylor Res Inst, Plano, TX USA.
[Ferguson, T. Bruce] ECU, East Carolina Heart Inst, Greenville, NC USA.
[Horvath, Keith] NIH, Heart Cntr, Suburban Hosp, Bethesda, MD 20892 USA.
[Geller, Nancy L.; Miller, Marissa A.] NHLBI, NIH, Bethesda, MD 20892 USA.
[Woo, Joseph Y.] Hosp Univ Penn, Div Cardiothorac Surg, Philadelphia, PA 19104 USA.
[D'Alessandro, David A.; Michler, Robert] Montefiore Einstein Heart Cntr, Bronx, NY USA.
[Ailawadi, Gorav; Kron, Irving L.] Univ Virginia Hlth Syst, Charlottesville, VA USA.
[Dagenais, Franois] Inst Univ Cardiol Quebec, Dept Cardiol, Quebec City, PQ, Canada.
[Gardner, Timothy J.] Christiana Care Hlth Syst, Cardiovasc Med, Newark, DE USA.
[O'Gara, Patrick T.] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD DEC 17
PY 2013
VL 128
IS 24
BP 2708
EP 2708
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 271SB
UT WOS:000328410800032
ER
PT J
AU Cooper, CJ
Murphy, TP
Cutlip, DE
D'Agostino, R
Jamerson, K
Matsumoto, AH
Jaff, MR
Michael, S
Solomon, S
Cohen, D
Tuttle, KR
Rundback, JH
Shapiro, JI
Reid, D
Henrich, W
Dworklin, L
AF Cooper, Christopher J.
Murphy, Timothy P.
Cutlip, Donald E.
D'Agostino, Ralph
Jamerson, Kenneth
Matsumoto, Alan H.
Jaff, Michael R.
Michael, Steffes
Solomon, Scott
Cohen, David
Tuttle, Katherine R.
Rundback, John H.
Shapiro, Joseph I.
Reid, Diane
Henrich, William
Dworklin, Lance
TI A Randomized Multicenter Clinical Trial of Renal Artery Stenting in
Preventing Cardiovascular and Renal Events: Results of the CORAL Study
SO CIRCULATION
LA English
DT Meeting Abstract
DE Renal circulation; Stent; Clinical trials
C1 [Cooper, Christopher J.] Univ Toledo, Toledo, OH 43606 USA.
[Murphy, Timothy P.; Dworklin, Lance] Brown Univ, Rhode Isl Hosp, Sch Med, Providence, RI 02903 USA.
[Cutlip, Donald E.] Harvard Univ, Sch Med, Beth Israel Deaconess Hosp, Boston, MA 02215 USA.
[D'Agostino, Ralph] Boston Univ, Boston, MA 02215 USA.
[Jamerson, Kenneth] Univ Michigan, Med Cntr, Ann Arbor, MI 48109 USA.
[Matsumoto, Alan H.] Univ Virginia, Charlottesville, VA USA.
[Jaff, Michael R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Michael, Steffes] Univ Minnesota, Minneapolis, MN USA.
[Solomon, Scott] Brigham & Womens Hosp, Noninvas Cardiac Lab, Boston, MA 02115 USA.
[Cohen, David] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA.
[Tuttle, Katherine R.] Providence Med Rsch Cntr, Spokane, WA USA.
[Rundback, John H.] Inst Clin Rsch, Intervent Inst, Teaneck, NJ USA.
[Shapiro, Joseph I.] Marshall Univ, Huntington, WV USA.
[Reid, Diane] NHLBI, Div Heart & Vasc Dis, Bethesda, MD 20892 USA.
[Henrich, William] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD DEC 17
PY 2013
VL 128
IS 24
BP 2710
EP 2710
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 271SB
UT WOS:000328410800037
ER
PT J
AU Kimmel, SE
French, B
Kasner, SE
Johnson, JA
Anderson, JL
Gage, BF
Rosenberg, YD
Geller, NL
Eby, CS
Madigan, R
Goldberg, S
McBane, RD
Abdel-Rahman, S
Stevens, SM
Yale, S
Mohler, ER
Fang, MC
Shah, V
Horenstein, RB
Limdi, NA
Muldowney, JS
Delafontaine, P
Gujral, JS
Desnick, RJ
Halperin, JL
Ortel, TL
Billett, HH
Pendleton, RC
Goldhaber, SZ
Caldwell, MD
Califf, RM
Ellenberg, J
AF Kimmel, Stephen E.
French, Benjamin
Kasner, Scott E.
Johnson, Julie A.
Anderson, Jeffrey L.
Gage, Brian F.
Rosenberg, Yves D.
Geller, Nancy L.
Eby, Charles S.
Madigan, Rosemary
Goldberg, Suzanne
McBane, Robert D.
Abdel-Rahman, Sherif
Stevens, Scott M.
Yale, Steven
Mohler, Emile R., III
Fang, Margaret C.
Shah, Vinay
Horenstein, Richard B.
Limdi, Nita A.
Muldowney, James S., III
Delafontaine, Patrice
Gujral, Jaspal S.
Desnick, Robert J.
Halperin, Jonathan L.
Ortel, Thomas L.
Billett, Henny H.
Pendleton, Robert C.
Goldhaber, Samuel Z.
Caldwell, Michael D.
Califf, Robert M.
Ellenberg, Jonas
TI The Clarification of Optimal Anticoagulation through Genetics (COAG)
Trial
SO CIRCULATION
LA English
DT Meeting Abstract
DE Anticoagulants; Pharmacogenetics; Anticoagulation; Genetics
C1 [Kimmel, Stephen E.; French, Benjamin; Ellenberg, Jonas] Univ PA Sch Med, Cntr Clin Epidemiol & Biostat, Philadelphia, PA USA.
[Kasner, Scott E.] Univ PA Sch Med, Hosp Univ Penn, Philadelphia, PA USA.
[Johnson, Julie A.] Univ Florida, Dept Pharmacotherapy & Translat Rsch, Gainesville, FL USA.
[Anderson, Jeffrey L.] Univ Utah, Sch Med, Salt Lake City, UT USA.
[Gage, Brian F.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
[Rosenberg, Yves D.; Goldberg, Suzanne] NHLBI, NIH, Bethesda, MD 20892 USA.
[Geller, Nancy L.] NIH, Cntr Clin Epidemiol & Biostat, Bethesda, MD 20892 USA.
[Eby, Charles S.] Washington Univ, Sch Med, Dept Med Hematol Div, St Louis, MO USA.
[Madigan, Rosemary] Univ PA Sch Med, CRCU, Philadelphia, PA USA.
[McBane, Robert D.] Mayo Clin, Coll Med, Div Internal Medciine & Cardiovasc Dis, Rochester, MN USA.
[Abdel-Rahman, Sherif] Univ Texas, Dept Prevent Med & Community Hlth, Galveston, TX USA.
[Stevens, Scott M.] Intermt Med Cntr, Murray, UT USA.
[Yale, Steven] Marshfield Clin Rsch Fdn, Clin Rsch Cntr, Marshfiled, WI USA.
[Mohler, Emile R., III] Hosp Univ Penn, Philadelphia, PA 19104 USA.
[Fang, Margaret C.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Shah, Vinay] Henry Ford Hosp, Detroit, MI 48202 USA.
[Horenstein, Richard B.] Univ Maryland, Sch Med, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA.
[Limdi, Nita A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Muldowney, James S., III] Vanderbilt Univ, Div Cardiovasc Med, Nashville, TN 37235 USA.
[Delafontaine, Patrice] Tulane Univ, Hlth Sci Cetner, Heart & Vasc Inst, New Orleans, LA 70118 USA.
[Gujral, Jaspal S.] Georgia Regents Univ, Anticoagulat Cln, Augusta, GA USA.
[Desnick, Robert J.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA.
[Halperin, Jonathan L.] Mt Sinai Sch Med, Dept Med Cardiol, New York, NY USA.
[Ortel, Thomas L.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA.
[Billett, Henny H.] Montefiore Med Cntr, Bronx, NY USA.
[Pendleton, Robert C.] Univ Utah Hlth Care, Div Gen Internal Med, Salt Lake City, UT USA.
[Goldhaber, Samuel Z.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA.
[Caldwell, Michael D.] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA.
[Califf, Robert M.] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD DEC 17
PY 2013
VL 128
IS 24
BP 2711
EP 2711
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 271SB
UT WOS:000328410800040
ER
PT J
AU Ascheim, DD
Naka, Y
Smidera, NG
Moye, LA
Lee, S
Klodell, CT
Szady, A
Parides, MK
Jeffries, N
Skerret, D
Taylor, DA
Margulies, K
Milano, C
Rogers, JG
Dewey, T
Eichorn, E
Sun, B
Feldman, D
Goldstein, D
O'Gara, PT
Simari, RD
Skarlatos, S
Taddei-Peters, W
Miller, M
Bagiella, E
Gelijns, AC
Woo, JY
AF Ascheim, Deborah D.
Naka, Yoshifumi
Smidera, Nicholas G.
Moye, Lemuel A.
Lee, Sangjin
Klodell, Charles T.
Szady, Anita
Parides, Michael K.
Jeffries, Neal
Skerret, Donna
Taylor, Doris A.
Margulies, Kenneth
Milano, Carmelo
Rogers, Joseph G.
Dewey, Todd
Eichorn, Eric
Sun, Benjamin
Feldman, David
Goldstein, Daniel
O'Gara, Patrick T.
Simari, Robert D.
Skarlatos, Sonia
Taddei-Peters, Wendy
Miller, Marissa
Bagiella, Emilia
Gelijns, Annetine C.
Woo, Joseph Y.
TI Intramyocardial Injection of Allogeneic Mesenchymal Precursor Cells in
Left Ventricular Assist Device Patients
SO CIRCULATION
LA English
DT Meeting Abstract
DE Stem cell therapy; Heart failure; Ventricular assist devices; NHLBI
C1 [Ascheim, Deborah D.; Parides, Michael K.; Bagiella, Emilia; Gelijns, Annetine C.] Icahn Sch Med Mt Sinai, New York, NY USA.
[Naka, Yoshifumi] Columbia Univ, Med Cntr, New York, NY USA.
[Smidera, Nicholas G.; Lee, Sangjin] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Moye, Lemuel A.] Univ Texas Sch Publ Hlth, Houston, TX USA.
[Klodell, Charles T.; Szady, Anita] Univ Florida, Gainesville, FL USA.
[Jeffries, Neal; Skarlatos, Sonia; Taddei-Peters, Wendy; Miller, Marissa] NHLBI, NIH, Bethesda, MD 20892 USA.
[Skerret, Donna] Mesoblast Ltd, New York, NY USA.
[Taylor, Doris A.] Texas Heart Insititute, Houston, TX USA.
[Margulies, Kenneth; Woo, Joseph Y.] Hosp Univ Penn, Philadelphia, PA 19104 USA.
[Milano, Carmelo; Rogers, Joseph G.] Duke Univ, Durham, NC USA.
[Dewey, Todd; Eichorn, Eric] Baylor Healthcare Syst, Dallas, TX USA.
[Sun, Benjamin; Feldman, David] Minneapolis Heart Inst, Minneapolis, MN USA.
[Goldstein, Daniel] Montefiore Einstein Med Cntr, Bronx, NY USA.
[O'Gara, Patrick T.] Brigham & Womens Hosp, Dept Cardiol, Boston, MA 02115 USA.
[Simari, Robert D.] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD DEC 17
PY 2013
VL 128
IS 24
BP 2713
EP 2714
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 271SB
UT WOS:000328410800044
ER
PT J
AU Traverse, JH
Henry, TD
Pepine, CJ
Willerson, JT
Zhao, DX
Ellis, SG
Lai, D
Perin, EC
Penn, MS
Hatzopoulos, AK
Chambers, J
Baran, KW
Raveendran, G
Lambert, C
Lerman, A
Simon, DI
Gee, AP
Forder, JR
Taylor, DA
Cogle, CR
Olson, RE
Skarlatos, SI
Skarlatos, SI
Ebert, RF
Moye, LA
Simari, RD
AF Traverse, Jay H.
Henry, Timothy D.
Pepine, Carl J.
Willerson, James T.
Zhao, David X.
Ellis, Stephen G.
Lai, Dejian
Perin, Emerson C.
Penn, Marc S.
Hatzopoulos, Antonis K.
Chambers, Jeffrey
Baran, Kenneth W.
Raveendran, Ganesh
Lambert, Charles
Lerman, Amir
Simon, Daniel I.
Gee, Adrian P.
Forder, John R.
Taylor, Doris A.
Cogle, Christopher R.
Olson, Rachel E.
Skarlatos, Sonia I.
Skarlatos, Sonia I.
Ebert, Ray F.
Moye, Lemuel A.
Simari, Robert D.
TI The NHLBI TIME Trial: One-Year Results
SO CIRCULATION
LA English
DT Meeting Abstract
DE Stem cell therapy; STEMI; Cardiac MRI; Infarct size
C1 [Traverse, Jay H.; Henry, Timothy D.; Olson, Rachel E.] Abbott NW Hosp, Minneapolis Heart Inst Fdn, Minneapolis, MN 55407 USA.
[Pepine, Carl J.; Forder, John R.; Cogle, Christopher R.] Univ Florida, Coll Med, Gainesville, FL USA.
[Willerson, James T.; Perin, Emerson C.; Taylor, Doris A.] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA.
[Zhao, David X.; Hatzopoulos, Antonis K.] Vanderbilt Univ, Sch Med, Minneapolis, MN USA.
[Ellis, Stephen G.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Lai, Dejian; Moye, Lemuel A.] Univ Texas Sch Publ Hlth, Houston, TX USA.
[Penn, Marc S.] Summa Cardiovasc Inst, Rootstown, OH USA.
[Chambers, Jeffrey] Mercy Hosp, Coon Rapids, MN USA.
[Baran, Kenneth W.] United Hosp, St Paul Heart Clin, St Paul, MN USA.
[Raveendran, Ganesh] Univ Minnesota, Lillehei Heart Inst, Minneapolis, MN USA.
[Lambert, Charles] Pepin Heart Hosp, Patel Rsch Inst, Tampa, FL USA.
[Lerman, Amir; Simari, Robert D.] Mayo Clin, Coll Med, Rochester, MN USA.
[Simon, Daniel I.] Univ Hosp Case Med Cntr, Cleveland, OH USA.
[Gee, Adrian P.] Baylor Coll Med, Houston, TX 77030 USA.
[Skarlatos, Sonia I.; Skarlatos, Sonia I.; Ebert, Ray F.] NHLBI, Bethesda, MD 20892 USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD DEC 17
PY 2013
VL 128
IS 24
BP 2714
EP 2714
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 271SB
UT WOS:000328410800045
ER
PT J
AU Huang, SYN
Pommier, Y
AF Huang, Shar-yin Naomi
Pommier, Yves
TI Cross-over of RNA 3'-phosphate ligase into the DNA world
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Editorial Material
ID SEQUENTIAL 2',3'-CYCLIC PHOSPHODIESTERASE; TOPOISOMERASE-I; RTCB;
REPAIR; GUANYLYLATION; 3'-PHOSPHATE; MECHANISM; HSPC117; 5'-OH
C1 [Pommier, Yves] NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Pommier, Y (reprint author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM pommier@nih.gov
NR 17
TC 2
Z9 2
U1 1
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 17
PY 2013
VL 110
IS 51
BP 20354
EP 20355
DI 10.1073/pnas.1320033110
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 273PR
UT WOS:000328548600017
PM 24282304
ER
PT J
AU Vonk, FJ
Casewell, NR
Henkel, CV
Heimberg, AM
Jansen, HJ
McCleary, RJR
Kerkkamp, HME
Vos, RA
Guerreiro, I
Calvete, JJ
Wuster, W
Woods, AE
Logan, JM
Harrison, RA
Castoe, TA
de Koning, APJ
Pollock, DD
Yandell, M
Calderon, D
Renjifo, C
Currier, RB
Salgado, D
Pla, D
Sanz, L
Hyder, AS
Ribeiro, JMC
Arntzen, JW
van den Thillart, GEEJM
Boetzer, M
Pirovano, W
Dirks, RP
Spaink, HP
Duboule, D
McGlinn, E
Kini, RM
Richardson, MK
AF Vonk, Freek J.
Casewell, Nicholas R.
Henkel, Christiaan V.
Heimberg, Alysha M.
Jansen, Hans J.
McCleary, Ryan J. R.
Kerkkamp, Harald M. E.
Vos, Rutger A.
Guerreiro, Isabel
Calvete, Juan J.
Wuester, Wolfgang
Woods, Anthony E.
Logan, Jessica M.
Harrison, Robert A.
Castoe, Todd A.
de Koning, A. P. Jason
Pollock, David D.
Yandell, Mark
Calderon, Diego
Renjifo, Camila
Currier, Rachel B.
Salgado, David
Pla, Davinia
Sanz, Libia
Hyder, Asad S.
Ribeiro, Jose M. C.
Arntzen, Jan W.
van den Thillart, Guido E. E. J. M.
Boetzer, Marten
Pirovano, Walter
Dirks, Ron P.
Spaink, Herman P.
Duboule, Denis
McGlinn, Edwina
Kini, R. Manjunatha
Richardson, Michael K.
TI The king cobra genome reveals dynamic gene evolution and adaptation in
the snake venom system
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE genomics; phylogenetics; serpentes
ID SENSING ION CHANNELS; ACCELERATED EVOLUTION; MOLECULAR EVOLUTION;
ANNOTATION PIPELINE; MICRORNA EXPRESSION; 3-FINGER TOXINS; HOX GENES;
PROTEINS; MODEL; ALIGNMENT
AB Snakes are limbless predators, and many species use venom to help overpower relatively large, agile prey. Snake venoms are complex protein mixtures encoded by several multilocus gene families that function synergistically to cause incapacitation. To examine venom evolution, we sequenced and interrogated the genome of a venomous snake, the king cobra (Ophiophagus hannah), and compared it, together with our unique transcriptome, microRNA, and proteome datasets from this species, with data from other vertebrates. In contrast to the platypus, the only other venomous vertebrate with a sequenced genome, we find that snake toxin genes evolve through several distinct co-option mechanisms and exhibit surprisingly variable levels of gene duplication and directional selection that correlate with their functional importance in prey capture. The enigmatic accessory venom gland shows a very different pattern of toxin gene expression from the main venom gland and seems to have recruited toxin-like lectin genes repeatedly for new nontoxic functions. In addition, tissue-specific microRNA analyses suggested the co-option of core genetic regulatory components of the venom secretory system from a pancreatic origin. Although the king cobra is limbless, we recovered coding sequences for all Hox genes involved in amniote limb development, with the exception of Hoxd12. Our results provide a unique view of the origin and evolution of snake venom and reveal multiple genome-level adaptive responses to natural selection in this complex biological weapon system. More generally, they provide insight into mechanisms of protein evolution under strong selection.
C1 [Vonk, Freek J.; Vos, Rutger A.; Arntzen, Jan W.] Naturalis Biodivers Ctr, NL-2333 CR Leiden, Netherlands.
[Vonk, Freek J.; Henkel, Christiaan V.; Kerkkamp, Harald M. E.; Hyder, Asad S.; Spaink, Herman P.; Richardson, Michael K.] Leiden Univ, Sylvius Lab, Inst Biol Leiden, NL-2300 RA Leiden, Netherlands.
[Vonk, Freek J.; Casewell, Nicholas R.; Wuester, Wolfgang] Bangor Univ, Sch Biol Sci, Mol Ecol & Evolut Grp, Bangor LL57 2UW, Gwynedd, Wales.
[Casewell, Nicholas R.; Harrison, Robert A.; Renjifo, Camila; Currier, Rachel B.] Univ Liverpool, Liverpool Sch Trop Med, Alistair Reid Venom Res Unit, Liverpool L3 5QA, Merseyside, England.
[Henkel, Christiaan V.; Jansen, Hans J.; van den Thillart, Guido E. E. J. M.; Dirks, Ron P.; Spaink, Herman P.] ZF Screens BV, Bio Partner Ctr, NL-2333 CH Leiden, Netherlands.
[Heimberg, Alysha M.; Salgado, David; McGlinn, Edwina] Monash Univ, Australian Regenerat Med Inst, European Mol Biol Lab Australia, Clayton, Vic 3800, Australia.
[McCleary, Ryan J. R.; Kini, R. Manjunatha] Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore.
[Guerreiro, Isabel; Duboule, Denis] Univ Geneva, Dept Genet & Evolut, CH-1211 Geneva 4, Switzerland.
[Calvete, Juan J.; Pla, Davinia; Sanz, Libia] Consejo Super Invest Cient Spain, Inst Biomed Valencia, Valencia 46010, Spain.
[Woods, Anthony E.; Logan, Jessica M.] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5000, Australia.
[Castoe, Todd A.; de Koning, A. P. Jason; Pollock, David D.] Univ Colorado, Sch Med, Dept Biochem & Mol Genet, Aurora, CO 80045 USA.
[Castoe, Todd A.] Univ Texas, Dept Biol, Arlington, TX 76010 USA.
[de Koning, A. P. Jason] Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.
[de Koning, A. P. Jason] Alberta Childrens Prov Gen Hosp, Res Inst Child & Maternal Hlth, Calgary, AB T2N 4N1, Canada.
[Yandell, Mark; Calderon, Diego] Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84132 USA.
[Salgado, David] Aix Marseille Univ, INSERM, GMGF UMR S910, F-13385 Marseille, France.
[Ribeiro, Jose M. C.] NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA.
[Boetzer, Marten; Pirovano, Walter] BaseClear BV, NL-2333 CC Leiden, Netherlands.
RP Richardson, MK (reprint author), Leiden Univ, Sylvius Lab, Inst Biol Leiden, Sylviusweg 72, NL-2300 RA Leiden, Netherlands.
EM M.K.Richardson@biology.leidenuniv.nl
RI Casewell, Nicholas/C-3187-2014; Ribeiro, Jose/J-7011-2015; Vos,
Rutger/H-9032-2012; Arntzen, Jan/E-7108-2016; Calvete, Juan/K-9619-2014;
Pollock, David/M-4740-2016; SALGADO, David/A-1417-2014;
OI Henkel, Christiaan/0000-0001-9838-8215; Pla,
Davinia/0000-0002-9810-7556; Sanz, Libia/0000-0003-4991-9598; Casewell,
Nicholas/0000-0002-8035-4719; McGlinn, Edwina/0000-0002-1829-986X;
Ribeiro, Jose/0000-0002-9107-0818; Guerreiro,
Isabel/0000-0003-1390-3535; Vos, Rutger/0000-0001-9254-7318; Arntzen,
Jan/0000-0003-3229-5993; Calvete, Juan/0000-0001-5026-3122; Pollock,
David/0000-0002-7627-4214; McCleary, Ryan/0000-0001-8232-9296
FU Naturalis Biodiversity Center; Netherlands Organization for Scientific
Research; United Kingdom Natural Environment Research Council;
Nederlandse Organisatie voor Wetenschappelijk Onderzoek; United Kingdom
Biotechnology and Biological Sciences Research Council; Dutch Government
FX We thank the following persons who helped us or contributed material
used in this study: Austin Hughes, Nathan Dunstan, Danielle de Wijze,
and Youri Lammers. We thank Bas Blankevoort for constructing Fig. 1.
This work received funding from the following sources: internal funding
from the Naturalis Biodiversity Center (F.J.V., J.W.A., and M. K. R.), a
Rubicon Grant from the Netherlands Organization for Scientific Research
(to F.J.V.), a research fellowship from the United Kingdom Natural
Environment Research Council (to N.R.C.), an Netherlands Organization
for Scientific Research Visitor's Travel Grant from Nederlandse
Organisatie voor Wetenschappelijk Onderzoek (to R.J.R.M., R. M. K., and
M. K. R.), a studentship from the United Kingdom Biotechnology and
Biological Sciences Research Council (to R. B. C.), and a Smart Mix
Grant from the Dutch Government (to M.K.R.).
NR 57
TC 130
Z9 168
U1 20
U2 116
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 17
PY 2013
VL 110
IS 51
BP 20651
EP 20656
DI 10.1073/pnas.1314702110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 273PR
UT WOS:000328548600069
PM 24297900
ER
PT J
AU Kulkarni, S
Qi, Y
O'hUigin, C
Pereyra, F
Ramsuran, V
McLaren, P
Fellay, J
Nelson, G
Chen, HY
Liao, W
Bass, S
Apps, R
Gao, XJ
Yuki, Y
Lied, A
Ganesan, A
Hunt, PW
Deeks, SG
Wolinsky, S
Walker, BD
Carrington, M
AF Kulkarni, Smita
Qi, Ying
O'hUigin, Colm
Pereyra, Florencia
Ramsuran, Veron
McLaren, Paul
Fellay, Jacques
Nelson, George
Chen, Haoyan
Liao, Wilson
Bass, Sara
Apps, Richard
Gao, Xiaojiang
Yuki, Yuko
Lied, Alexandra
Ganesan, Anuradha
Hunt, Peter W.
Deeks, Steven G.
Wolinsky, Steven
Walker, Bruce D.
Carrington, Mary
TI Genetic interplay between HLA-C and MIR148A in HIV control and Crohn
disease
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; CELL-SURFACE EXPRESSION; HEAVY-CHAIN;
DETERMINANTS; RNA; POLYMORPHISM; INFECTION; COHORT; NEF
AB Variation in the 3' untranslated region (3'UTR) of the HLA-C locus determines binding of the microRNA Hsa-miR-148a, resulting in lower cell surface expression of alleles that bind miR-148a relative to those alleles that escape its binding. The HLA-C 3'UTR variant was shown to associate with HIV control, but like the vast majority of disease associations in a region dense with causal candidates, a direct effect of HLA-C expression level on HIV control was not proven. We demonstrate that a MIR148A insertion/deletion polymorphism associates with its own expression levels, affecting the extent to which HLA-C is down-regulated, the level of HIV control, and the risk of Crohn disease only among those carrying an intact miR-148a binding site in the HLA-C 3'UTR. These data illustrate a direct effect of HLA-C expression level on HIV control that cannot be attributed to other HLA loci in linkage disequilibrium with HLA-C and highlight the rich complexity of genetic interactions in human disease.
C1 [Kulkarni, Smita; Qi, Ying; O'hUigin, Colm; Bass, Sara; Apps, Richard; Gao, Xiaojiang; Yuki, Yuko; Carrington, Mary] Frederick Natl Lab Canc Res, Sci Applicat Int Corp Frederick Inc, Ctr Canc Res Genet Core, Canc & Inflammat Program,Lab Expt Immunol, Frederick, MD 21702 USA.
[Nelson, George] Frederick Natl Lab Canc Res, Sci Applicat Int Corp Frederick Inc, Ctr Canc Res Genet Core, Basic Res Program, Frederick, MD 21702 USA.
[Kulkarni, Smita; Qi, Ying; Pereyra, Florencia; Ramsuran, Veron; Apps, Richard; Gao, Xiaojiang; Yuki, Yuko; Lied, Alexandra; Walker, Bruce D.; Carrington, Mary] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Cambridge, MA 02139 USA.
[McLaren, Paul; Fellay, Jacques] Univ Lausanne, Ecole Polytech Fed Lausanne, Sch Life Sci, CH-1011 Lausanne, Switzerland.
[McLaren, Paul; Fellay, Jacques] Univ Lausanne, Inst Microbiol, CH-1011 Lausanne, Switzerland.
[Chen, Haoyan; Liao, Wilson] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94115 USA.
[Chen, Haoyan] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Digest Dis, Dept Gastroenterol,Ren Ji Hosp, Shanghai 200001, Peoples R China.
[Ganesan, Anuradha] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20817 USA.
[Hunt, Peter W.; Deeks, Steven G.] Univ Calif San Francisco, San Francisco Gen Hosp, AIDS Div, San Francisco, CA 94110 USA.
[Wolinsky, Steven] Northwestern Univ, Feinberg Sch Med, Div Infect Dis, Chicago, IL 60611 USA.
RP Carrington, M (reprint author), Frederick Natl Lab Canc Res, Sci Applicat Int Corp Frederick Inc, Ctr Canc Res Genet Core, Canc & Inflammat Program,Lab Expt Immunol, Frederick, MD 21702 USA.
EM carringm@mail.nih.gov
RI SHCS, int. coll. A/G-4083-2011; Fellay, Jacques/A-6681-2009; SHCS,
all/G-4072-2011;
OI Fellay, Jacques/0000-0002-8240-939X; Wolinsky,
Steven/0000-0002-9625-6697
FU Swiss National Science Foundation [33CSC0-108787]; National Institute of
Allergy and Infectious Diseases (NIAID); National Cancer Institute
(NCI); National Heart, Lung and Blood Institute (NHLBI) [UO1-AI-35042,
5-MO1-RR-00722]; National Heart, Lung and Blood Institute (NHLBI)
([General Clinical Research Center]) [UO1-AI-35043, UO1-AI-37984,
UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, UO1-AI-35041]; IHCS; Bill and
Melinda Gates Foundation; AIDS Healthcare Foundation; Harvard University
Center for AIDS Research; National Institutes of Health (NIH) [P30
AI060354]; NIH, NIAID; NIH, NCI; NIH, National Institute of Child Health
and Human Development; NIH, NHLBI; NIH, National Institute on Drug
Abuse; NIH, National Institute of Mental Health; NIH, National Institute
on Aging; NIH, Fogarty International Center; NIH, Office of AIDS
Research; NCI, NIH [HHSN261200800001E, N02-CP-55504, R01-DA04334,
R01-DA12568]; Mark and Lisa Schwartz Foundation; Ragon Institute; NIH
NIAID Center for HIV/AIDS Vaccine Immunology [U01-AI-067854]; [RO1
AI087145]; [K24AI069994]; [P30 AI027763]; [UL1 RR024131]; [P30
MH62246]; [R24 AI067039]
FX We thank Drs. David Goldstein and Paul de Bakker for helpful discussions
and review of the manuscript. We also thank the patients and
investigators contributing to samples studied in the Study of the
Consequences of the Protease Inhibitor Era (SCOPE), International HIV
Controllers Study (IHCS), Swiss HIV Cohort Study (SHCS), and US Military
HIV Natural History Study (NHS). SHCS (supported by Swiss National
Science Foundation Grant 33CSC0-108787), SCOPE (supported by Grants RO1
AI087145, K24AI069994, P30 AI027763, UL1 RR024131, P30 MH62246, and R24
AI067039), and Multicenter AIDS Cohort Study (MACS) cohorts [funded by
the National Institute of Allergy and Infectious Diseases (NIAID), with
supplemental funding from the National Cancer Institute (NCI) and the
National Heart, Lung and Blood Institute (NHLBI) (Grants UO1-AI-35042,
5-MO1-RR-00722 [General Clinical Research Center], UO1-AI-35043,
UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613 and
UO1-AI-35041)] and the Infectious disease clinical research program HIV
Working group for the NHS samples. This publication resulted in part
from research supported by the IHCS, funded by the Bill and Melinda
Gates Foundation, the AIDS Healthcare Foundation, and the Harvard
University Center for AIDS Research, a program funded by National
Institutes of Health (NIH) Grant P30 AI060354, which is supported by the
following NIH Co-Funding and Participating Institutes and centers:
NIAID, NCI, National Institute of Child Health and Human Development,
NHLBI, National Institute on Drug Abuse, National Institute of Mental
Health, National Institute on Aging, Fogarty International Center, and
Office of AIDS Research. This project has been funded in part with
federal funds from the NCI, NIH, under Contracts HHSN261200800001E,
N02-CP-55504, R01-DA04334, and R01-DA12568. This research was supported
in part by a grant from the Bill and Melinda Gates Foundation as part of
the Collaboration for AIDS Vaccine Discovery, the Mark and Lisa Schwartz
Foundation, the Ragon Institute, and the NIH NIAID Center for HIV/AIDS
Vaccine Immunology (Grant U01-AI-067854). The content of this
publication does not necessarily reflect the views or policies of the
Department of Health and Human Services or the Department of Defense,
nor does mention of trade names, commercial products, or organizations
imply endorsement by the US Government.
NR 29
TC 27
Z9 27
U1 0
U2 8
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 17
PY 2013
VL 110
IS 51
BP 20705
EP 20710
DI 10.1073/pnas.1312237110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 273PR
UT WOS:000328548600078
PM 24248364
ER
PT J
AU Bakhsheshian, J
Wei, BR
Chang, KE
Shukla, S
Ambudkar, SV
Simpson, RM
Gottesman, MM
Hall, MD
AF Bakhsheshian, Joshua
Wei, Bih-Rong
Chang, Ki-Eun
Shukla, Suneet
Ambudkar, Suresh V.
Simpson, R. Mark
Gottesman, Michael M.
Hall, Matthew D.
TI Bioluminescent imaging of drug efflux at the blood-brain barrier
mediated by the transporter ABCG2
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID CANCER RESISTANCE PROTEIN; FIBRILLARY ACIDIC PROTEIN;
CENTRAL-NERVOUS-SYSTEM; P-GLYCOPROTEIN; IN-VIVO; ACTIVE EFFLUX;
RADIOLABELED SUBSTRATE; MULTIDRUG TRANSPORTER; TESTIS PENETRATION;
FIREFLY LUCIFERASE
AB ATP-binding cassette (ABC) transporters are a group of transmembrane proteins that maintain chemical homeostasis through efflux of compounds out of organelles and cells. Among other functions, ABC transporters play a key role in protecting the brain parenchyma by efflux of xenobiotics from capillary endothelial cells at the blood-brain barrier (BBB). They also prevent the entry of therapeutic drugs at the BBB, thereby limiting their efficacy. One of the key transporters playing this role is ABCG2. Although other ABC transporters can be studied through various imaging modalities, no specific probe exists for imaging ABCG2 function in vivo. Here we show that D-luciferin, the endogenous substrate of firefly luciferase, is a specific substrate for ABCG2. We hypothesized that ABCG2 function at the BBB could be evaluated by using bioluminescence imaging in transgenic mice expressing firefly luciferase in the brain. Bioluminescence signal in the brain of mice increased with co-administration of the ABCG2 inhibitors Ko143, gefitinib, and nilotinib, but not an ABCB1 inhibitor. This method for imaging ABCG2 function at the BBB will facilitate understanding of the function and pharmacokinetic inhibition of this transporter.
C1 [Bakhsheshian, Joshua; Chang, Ki-Eun; Shukla, Suneet; Ambudkar, Suresh V.; Gottesman, Michael M.; Hall, Matthew D.] NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Wei, Bih-Rong; Simpson, R. Mark] NCI, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA.
RP Gottesman, MM (reprint author), NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bldg 37, Bethesda, MD 20892 USA.
EM mgottesman@nih.gov
FU National Institutes of Health (NIH), National Cancer Institute; NIH
FX We thank Mr. George Leiman for editorial assistance, Dr. Jeih-San Liow
for training on tail vein injections, Dr. Michael Maurizi for
fluorescence spectral analysis assistance, Ms. Karen Wolcott for FACS
assistance, Ms. Susan Garfield for help with confocal microscopy, and
Dr. Robert B. Innis and Dr. Victor W. Pike for helpful discussions. This
research was supported by the Intramural Research Program of the
National Institutes of Health (NIH), National Cancer Institute. J.B. and
K.-E.C. are NIH Medical Research Scholars. The Medical Research Scholars
Program is a public-private partnership supported jointly by the NIH and
contributions to the Foundation for the NIH from Pfizer, the Leona M.
and Harry B. Helmsley Charitable Trust, the Howard Hughes Medical
Institute, as well as other private donors (listed at
www.fnih.org/work/programs-development/medical-research-scholars-program
).
NR 60
TC 15
Z9 17
U1 2
U2 17
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 17
PY 2013
VL 110
IS 51
BP 20801
EP 20806
DI 10.1073/pnas.1312159110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 273PR
UT WOS:000328548600094
PM 24297888
ER
PT J
AU Kerr, JP
Ziman, AP
Mueller, AL
Muriel, JM
Kleinhans-Welte, E
Gumerson, JD
Vogel, SS
Ward, CW
Roche, JA
Bloch, RJ
AF Kerr, Jaclyn P.
Ziman, Andrew P.
Mueller, Amber L.
Muriel, Joaquin M.
Kleinhans-Welte, Emily
Gumerson, Jessica D.
Vogel, Steven S.
Ward, Christopher W.
Roche, Joseph A.
Bloch, Robert J.
TI Dysferlin stabilizes stress-induced Ca2+ signaling in the transverse
tubule membrane
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE excitation-contraction coupling; dihydropyridine receptor; triad
junction; muscle injury
ID SKELETAL-MUSCLE FIBERS; MUSCULAR-DYSTROPHY; OSMOTIC-STRESS;
CELL-MEMBRANE; MDX MICE; REPAIR; MOUSE; PROTEIN; RECOVERY; ACTIVATION
AB Dysferlinopathies, most commonly limb girdle muscular dystrophy 2B and Miyoshi myopathy, are degenerative myopathies caused by mutations in the DYSF gene encoding the protein dysferlin. Studies of dysferlin have focused on its role in the repair of the sarcolemma of skeletal muscle, but dysferlin's association with calcium (Ca2+) signaling proteins in the transverse (t-) tubules suggests additional roles. Here, we reveal that dysferlin is enriched in the t-tubule membrane of mature skeletal muscle fibers. Following experimental membrane stress in vitro, dysferlin-deficient muscle fibers undergo extensive functional and structural disruption of the t-tubules that is ameliorated by reducing external [Ca2+] or blocking L-type Ca2+ channels with diltiazem. Furthermore, we demonstrate that diltiazem treatment of dysferlin-deficient mice significantly reduces eccentric contraction-induced t-tubule damage, inflammation, and necrosis, which resulted in a concomitant increase in postinjury functional recovery. Our discovery of dysferlin as a t-tubule protein that stabilizes stress-induced Ca2+ signaling offers a therapeutic avenue for limb girdle muscular dystrophy 2B and Miyoshi myopathy patients.
C1 [Kerr, Jaclyn P.; Ziman, Andrew P.; Mueller, Amber L.; Muriel, Joaquin M.; Kleinhans-Welte, Emily; Gumerson, Jessica D.; Roche, Joseph A.; Bloch, Robert J.] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA.
[Vogel, Steven S.] NIAAA, Sect Cellular Biophoton, Lab Mol Physiol, NIH, Bethesda, MD 20892 USA.
[Ward, Christopher W.] Univ Maryland, Sch Nursing, Baltimore, MD 21201 USA.
RP Bloch, RJ (reprint author), Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA.
EM rbloch@umaryland.edu
OI Vogel, Steven/0000-0002-3005-2667
FU Jain Foundation; Muscular Dystrophy Association; Division of Intramural
Clinical and Biological Research of the National Institute on Alcohol
Abuse and Alcoholism; Kirschstein-National Research Service Award
Individual Postdoctoral Fellowship [F32 AR057647]; Training Program in
Cellular and Integrative Neuroscience [T32 NS007375]; Interdisciplinary
Training Program in Muscle Biology [T32 AR07592]
FX We thank W. Jonathan Lederer and Brian M. Hagen (University of Maryland
School of Medicine, BioMET) for the use of confocal microscopy
facilities and expertise. Dr. Gero Miesenbock (University of Oxford)
provided the pHluorin construct. These studies were supported by the
Jain Foundation (R.J.B., J.A.R., and S.S.V.) and the Muscular Dystrophy
Association (R.J.B.). S.S.V. was supported by the Division of Intramural
Clinical and Biological Research of the National Institute on Alcohol
Abuse and Alcoholism. A.P.Z. was supported by a Kirschstein-National
Research Service Award Individual Postdoctoral Fellowship (F32
AR057647). J.P.K. was supported through the Training Program in Cellular
and Integrative Neuroscience (T32 NS007375) and the Interdisciplinary
Training Program in Muscle Biology (T32 AR07592).
NR 51
TC 37
Z9 37
U1 0
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 17
PY 2013
VL 110
IS 51
BP 20831
EP 20836
DI 10.1073/pnas.1307960110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 273PR
UT WOS:000328548600099
PM 24302765
ER
PT J
AU Blackwood, JC
Streicker, DG
Altizer, S
Rohani, P
AF Blackwood, Julie C.
Streicker, Daniel G.
Altizer, Sonia
Rohani, Pejman
TI Resolving the roles of immunity, pathogenesis, and immigration for
rabies persistence in vampire bats
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE Desmodus rotundus; zoonotic disease; host-pathogen dynamics; spatial
processes; wildlife culling
ID DESMODUS-ROTUNDUS; TRANSMITTED RABIES; INFECTION; EMERGENCE; CATTLE;
VIRUS; ARGENTINA; HOST
AB Bats are important reservoirs for emerging infectious diseases, yet the mechanisms that allow highly virulent pathogens to persist within bat populations remain obscure. In Latin America, vampire-bat-transmitted rabies virus represents a key example of how such uncertainty can impede efforts to prevent cross-species transmission. Despite decades of agricultural and human health losses, control efforts have had limited success. To establish persistence mechanisms of vampire-bat-transmitted rabies virus in Latin America, we use data from a spatially replicated, longitudinal field study of vampire bats in Peru to parameterize a series of mechanistic transmission models. We find that single-colony persistence cannot occur. Instead, dispersal of bats between colonies, combined with a high frequency of immunizing nonlethal infections, is necessary to maintain rabies virus at levels consistent with field observations. Simulations show that the strong spatial component to transmission dynamics could explain the failure of bat culls to eliminate rabies and suggests that geographic coordination of control efforts might reduce transmission to humans and domestic animals. These findings offer spatial dynamics as a mechanism for rabies persistence in bats that might be important for the understanding and control of other bat-borne pathogens.
C1 [Blackwood, Julie C.; Rohani, Pejman] Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA.
[Blackwood, Julie C.; Rohani, Pejman] Univ Michigan, Ctr Study Complex Syst, Ann Arbor, MI 48109 USA.
[Blackwood, Julie C.] Williams Coll, Dept Math & Stat, Williamstown, MA 01267 USA.
[Streicker, Daniel G.; Altizer, Sonia] Univ Georgia, Odum Sch Ecol, Athens, GA 30602 USA.
[Streicker, Daniel G.] Univ Glasgow, Inst Biodivers Anim Hlth & Comparat Med, Glasgow G12 8QQ, Lanark, Scotland.
[Rohani, Pejman] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
RP Blackwood, JC (reprint author), Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA.
EM jcb5@williams.edu
OI Streicker, Daniel/0000-0001-7475-2705
FU National Science Foundation (NSF) [DEB-1020966]; University of Georgia
(UGA)-CDC [FID-908]; NSF; UGA; National Geographic Committee for
Research and Exploration; Science and Technology Directorate, Department
of Homeland Security; Fogarty International Center, National Institutes
of Health
FX We thank the P.R. laboratory and two anonymous reviewers for their
feedback on earlier drafts of this manuscript. We also thank the Office
of Epidemiology of the Ministry of Health of Peru, the National Service
of Agricultural Health of the Ministry of Agriculture of Peru, and the
Centers for Disease Control (CDC) Rabies Program for logistical support
of field and lab work. This research was supported by National Science
Foundation (NSF) Grant DEB-1020966 and a University of Georgia (UGA)-CDC
Infectious Disease Seed Grant FID-908 to S.A. and P.R. In addition,
D.G.S. was supported by an NSF Graduate Research Fellowship, a UGA
Dissertation Completion Award, and a Young Explorers Grant from the
National Geographic Committee for Research and Exploration. P.R. was
supported by the Research and Policy for Infectious Disease Dynamics
(RAPIDD) program of the Science and Technology Directorate, Department
of Homeland Security, and the Fogarty International Center, National
Institutes of Health.
NR 33
TC 20
Z9 21
U1 0
U2 64
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 17
PY 2013
VL 110
IS 51
BP 20837
EP 20842
DI 10.1073/pnas.1308817110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 273PR
UT WOS:000328548600100
PM 24297874
ER
PT J
AU Josefsson, L
von Stockenstrom, S
Faria, NR
Sinclair, E
Bacchetti, P
Killian, M
Epling, L
Tan, A
Ho, T
Lemey, P
Shao, W
Hunt, PW
Somsouk, M
Wylie, W
Douek, DC
Loeb, L
Custer, J
Hoh, R
Poole, L
Deeks, SG
Hecht, F
Palmer, S
AF Josefsson, Lina
von Stockenstrom, Susanne
Faria, Nuno R.
Sinclair, Elizabeth
Bacchetti, Peter
Killian, Maudi
Epling, Lorrie
Tan, Alice
Ho, Terence
Lemey, Philippe
Shao, Wei
Hunt, Peter W.
Somsouk, Ma
Wylie, Will
Douek, Daniel C.
Loeb, Lisa
Custer, Jeff
Hoh, Rebecca
Poole, Lauren
Deeks, Steven G.
Hecht, Frederick
Palmer, Sarah
TI The HIV-1 reservoir in eight patients on long-term suppressive
antiretroviral therapy is stable with few genetic changes over time
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CD4(+) T-CELLS; LOW-LEVEL VIREMIA;
DRUG-RESISTANCE; RALTEGRAVIR INTENSIFICATION; INFECTED INDIVIDUALS;
LYMPHOID-TISSUE; IN-VIVO; TYPE-1; REPLICATION
AB The source and dynamics of persistent HIV-1 during long-term combinational antiretroviral therapy (cART) are critical to understanding the barriers to curing HIV-1 infection. To address this issue, we isolated and genetically characterized HIV-1 DNA from naive and memory T cells from peripheral blood and gut-associated lymphoid tissue (GALT) from eight patients after 4-12 y of suppressive cART. Our detailed analysis of these eight patients indicates that persistent HIV-1 in peripheral blood and GALT is found primarily in memory CD4(+) T cells [CD45RO(+)/CD27((+/-))]. The HIV-1 infection frequency of CD4(+) T cells from peripheral blood and GALT was higher in patients who initiated treatment during chronic compared with acute/early infection, indicating that early initiation of therapy results in lower HIV-1 reservoir size in blood and gut. Phylogenetic analysis revealed an HIV-1 genetic change between RNA sequences isolated before initiation of cART and intracellular HIV-1 sequences from the T-cell subsets after 4-12 y of suppressive cART in four of the eight patients. However, evolutionary rate analyses estimated no greater than three nucleotide substitutions per gene region analyzed during all of the 4-12 y of suppressive therapy. We also identified a clearly replication incompetent viral sequence in multiple memory T cells in one patient, strongly supporting asynchronous cell replication of a cell containing integrated HIV-1 DNA as the source. This study indicates that persistence of a remarkably stable population of infected memory cells will be the primary barrier to a cure, and, with little evidence of viral replication, this population could be maintained by homeostatic cell proliferation or other processes.
C1 [Josefsson, Lina; von Stockenstrom, Susanne; Palmer, Sarah] Swedish Inst Infect Dis Control, Dept Diagnost & Vaccinol, S-17182 Solna, Sweden.
[Josefsson, Lina; von Stockenstrom, Susanne; Palmer, Sarah] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, S-17182 Solna, Sweden.
[Faria, Nuno R.; Lemey, Philippe] Katholieke Univ Leuven, Rega Inst, Dept Microbiol & Immunol, B-3000 Louvain, Belgium.
[Sinclair, Elizabeth; Killian, Maudi; Epling, Lorrie; Tan, Alice; Ho, Terence; Hunt, Peter W.; Somsouk, Ma; Loeb, Lisa; Custer, Jeff; Hoh, Rebecca; Poole, Lauren; Deeks, Steven G.; Hecht, Frederick] Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA.
[Bacchetti, Peter] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Shao, Wei] NCI, Adv Biomed Comp Ctr, Sci Applicat Int Corp Frederick Inc, Frederick, MD 21702 USA.
[Douek, Daniel C.] NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
[Palmer, Sarah] Westmead Millennium Inst, Ctr Virus Res, Westmead, NSW 2145, Australia.
[Palmer, Sarah] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia.
RP Josefsson, L (reprint author), Swedish Inst Infect Dis Control, Dept Diagnost & Vaccinol, S-17182 Solna, Sweden.
EM Lina.Odevall@gmail.com
RI Faria, Nuno/I-2975-2012;
OI Faria, Nuno/0000-0001-8839-2798; Rodrigues Faria,
Nuno/0000-0002-9747-8822
FU amfAR Research Consortium on HIV Eradication (ARCHE); Foundation for
AIDS Research [amfAR 107857-48-RGRL]; Delaney AIDS Research Enterprise
[U19 AI096109]; Swedish International Development Agency [SWE-2009-046];
Swedish Research Council [K2011-56X-21749-01-6]; National Institutes of
Health (NIH) [AI071713, K24AI069994, K23 CA157929]; UCSF-Gladstone
Institute of Virology and Immunology Center for AIDS Research
[P30AI027763, P30 MH59037]; NIH/National Center for Research Resources
UCSF Clinical and Translational Science Institute [UL1RR024131];
European Union Seventh Framework Programme [FP7/2007-2013,
278433-PREDEMICS]; European Research Council [260864]; Erik and Edith
Fernstrom Foundation for Medical Research; Fundacao para a Ciencia e
Tecnologia [SFRH/BD/64530/2009]; Karolinska Institutet alumni funds
FX We thank the patients participating in this study. This work was
primarily supported by an amfAR Research Consortium on HIV Eradication
(ARCHE) Collaborative Research Grant from The Foundation for AIDS
Research (amfAR 107857-48-RGRL) and Delaney AIDS Research Enterprise
(U19 AI096109). The work was also supported by the Swedish International
Development Agency (SWE-2009-046), The Swedish Research Council
(K2011-56X-21749-01-6), the National Institutes of Health (NIH)
[(AI071713, K24AI069994, and K23 CA157929), the UCSF-Gladstone Institute
of Virology and Immunology Center for AIDS Research (P30AI027763 and P30
MH59037), the NIH/National Center for Research Resources UCSF Clinical
and Translational Science Institute (UL1RR024131), the European Union
Seventh Framework Programme [FP7/2007-2013] under Grant Agreement
278433-PREDEMICS, and European Research Council Grant Agreement 260864.
L. J. was supported by the Erik and Edith Fernstrom Foundation for
Medical Research and by Karolinska Institutet alumni funds. N. R. F. is
supported by Fundacao para a Ciencia e Tecnologia under Grant Agreement
SFRH/BD/64530/2009.
NR 57
TC 64
Z9 65
U1 1
U2 15
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 17
PY 2013
VL 110
IS 51
BP E4987
EP E4996
DI 10.1073/pnas.1308313110
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 273PR
UT WOS:000328548600010
PM 24277811
ER
PT J
AU Pepin, KM
Lloyd-Smith, JO
Webb, CT
Holcomb, K
Zhu, HC
Guan, Y
Riley, S
AF Pepin, Kim M.
Lloyd-Smith, James O.
Webb, Colleen T.
Holcomb, Karen
Zhu, Huachen
Guan, Yi
Riley, Steven
TI Minimizing the threat of pandemic emergence from avian influenza in
poultry systems
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Avian influenza; Live-bird markets; Efficacy of controls; Environmental
transmission; Wholesale markets
ID HONG-KONG; SOUTHERN CHINA; TRANSMISSION; VIRUSES; SURVEILLANCE; MARKETS;
H9N2
AB Background: Live-animal markets are a culturally important feature of meat distribution chains in many populations, yet they provide an opportunity for the maintenance and transmission of potentially emergent zoonotic pathogens. The ongoing human outbreak of avian H7N9 in China highlights the need for increased surveillance and control in these live-bird markets (LBMs).
Discussion: Closure of retail markets in affected areas rapidly decreased human cases to rare, sporadic occurrence, but little attention has been paid thus far to the role of upstream elements of the poultry distribution chain such as wholesale markets. This could partly explain why transmission in poultry populations has not been eliminated more broadly. We present surveillance data from both wholesale live-bird markets (wLBMs) and rLBMs in Shantou, China (from 2004-2006), and call on disease-dynamic theory to illustrate why closing rLBMs has only minor effects on the overall volume of transmission. We show that the length of time birds stay in rLBMs can severely limit transmission there, but that the system-wide effect may be reduced substantially by high levels of transmission upstream of retail markets.
Summary: Management plans that minimize transmission throughout the entire poultry supply chain are essential for minimizing exposure to the public. These include reducing stay-time of birds in markets to 1 day, standardizing poultry supply chains to limit transmission in pre-retail settings, and monitoring strains with epidemiological traits that pose a high risk of emergence. These actions will further limit human exposure to extant viruses and reduce the likelihood of the emergence of novel strains by decreasing the overall volume of transmission.
C1 [Pepin, Kim M.; Lloyd-Smith, James O.; Webb, Colleen T.; Riley, Steven] Fogarty Int Ctr, Res & Policy Dis Dynam Program, Bethesda, MD USA.
[Pepin, Kim M.; Webb, Colleen T.; Holcomb, Karen] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.
[Lloyd-Smith, James O.] Univ Calif Los Angeles, Dept Ecol & Evolutionary Biol, Los Angeles, CA USA.
[Zhu, Huachen; Guan, Yi] Univ Hong Kong, State Key Lab Emerging Infect Dis, Pokfulam, Hong Kong, Peoples R China.
[Riley, Steven] Univ London Imperial Coll Sci Technol & Med, MRC Ctr Outbreak Anal & Dis Modelling, Dept Infect Dis Epidemiol, Sch Publ Hlth, London, England.
RP Guan, Y (reprint author), Univ Hong Kong, State Key Lab Emerging Infect Dis, Pokfulam, Hong Kong, Peoples R China.
EM yguan@hkucc.hku.hk
RI Zhu, Huachen/A-8252-2017; Lloyd-Smith, James/K-4080-2012
OI Zhu, Huachen/0000-0003-2711-0501; Holcomb, Karen/0000-0002-9403-3756;
Lloyd-Smith, James/0000-0001-7941-502X
FU Research and Policy in Disease Dynamics (RAPIDD) program of the Science
and Technology Directorate; U.S. Department of Homeland Security;
Fogarty International Center, NIH; NIH [HSN266200700005C]; Li Ka Shing
Foundation and Shenzhen Peacock Program [KQTD201203]; Wellcome Trust
[093488/Z/10/Z]; Medical Research Council (UK) [MR/J008761/1]
FX Thanks to the Research and Policy in Disease Dynamics (RAPIDD) program
of the Science and Technology Directorate, U.S. Department of Homeland
Security, and the Fogarty International Center, NIH for funding this
work. YG and HZ were also funded by NIH (HSN266200700005C), Li Ka Shing
Foundation and Shenzhen Peacock Program (KQTD201203). SR was also funded
by the Wellcome Trust (093488/Z/10/Z) and the Medical Research Council
(UK, MR/J008761/1).
NR 17
TC 5
Z9 5
U1 1
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD DEC 16
PY 2013
VL 13
AR 592
DI 10.1186/1471-2334-13-592
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA 285DX
UT WOS:000329374500002
PM 24341669
ER
PT J
AU Turner, JE
Morrison, PJ
Wilhelm, C
Wilson, M
Ahlfors, H
Renauld, JC
Panzer, U
Helmby, H
Stockinger, B
AF Turner, Jan-Eric
Morrison, Peter J.
Wilhelm, Christoph
Wilson, Mark
Ahlfors, Helena
Renauld, Jean-Christophe
Panzer, Ulf
Helmby, Helena
Stockinger, Brigitta
TI IL-9-mediated survival of type 2 innate lymphoid cells promotes damage
control in helminth-induced lung inflammation
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID TRANSCRIPTION FACTOR GATA3; T-CELLS; GROWTH-FACTOR; IN-VIVO; AIRWAY
HYPERREACTIVITY; EPITHELIAL-CELLS; TGF-BETA; EXPRESSION; IL-9; IMMUNITY
AB IL-9 fate reporter mice established type 2 innate lymphoid cells (ILC2s) as major producers of this cytokine in vivo. Here we focus on the role of IL-9 and ILC2s during the lung stage of infection with Nippostrongylus brasiliensis, which results in substantial tissue damage. IL-9 receptor (IL-9R)-deficient mice displayed reduced numbers of ILC2s in the lung after infection, resulting in impaired IL-5, IL-13, and amphiregulin levels, despite undiminished numbers of Th2 cells. As a consequence, the restoration of tissue integrity and lung function was strongly impaired in the absence of IL-9 signaling. ILC2s, in contrast to Th2 cells, expressed high levels of the IL-9R, and IL-9 signaling was crucial for the survival of activated ILC2s in vitro. Furthermore, ILC2s in the lungs of infected mice required the IL-9R to up-regulate the antiapoptotic protein BCL-3 in vivo. This highlights a unique role for IL-9 as an autocrine amplifier of ILC2 function, promoting tissue repair in the recovery phase after helminth-induced lung inflammation.
C1 [Turner, Jan-Eric; Morrison, Peter J.; Wilhelm, Christoph; Wilson, Mark; Ahlfors, Helena; Stockinger, Brigitta] Natl Inst Med Res, MRC, Divis Mol Immunol, London NW7 1AA, England.
[Turner, Jan-Eric; Panzer, Ulf] Univ Klinikum Hamburg Eppendorf, Med Klin & Poliklin 3, D-20246 Hamburg, Germany.
[Wilhelm, Christoph] NIAID, Mucosal Immunol Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA.
[Renauld, Jean-Christophe] Catholic Univ Louvain, de Duve Inst, B-1200 Brussels, Belgium.
[Renauld, Jean-Christophe] Ludwig Inst Canc Res, Brussels Branch, B-1200 Brussels, Belgium.
[Helmby, Helena] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP Stockinger, B (reprint author), Natl Inst Med Res, MRC, Divis Mol Immunol, London NW7 1AA, England.
EM bstocki@nimr.mrc.ac.uk
OI Helmby, Helena/0000-0003-0761-7348
FU Medical Research Council UK [117512792, MC_UP_A253_1028]; Deutsche
Forschungsgemeinschaft (DFG) [TU 316/1-1]; DGF (Klinische Forschergruppe
228 TP1) [PA 754/7]
FX This work was supported by the Medical Research Council UK (grants U.
117512792 and MC_UP_A253_1028), a Research Fellowship from the Deutsche
Forschungsgemeinschaft (DFG) to J.-E. Turner (TU 316/1-1), and a DGF
grant to U. Panzer (Klinische Forschergruppe 228 TP1, PA 754/7).
NR 58
TC 93
Z9 98
U1 1
U2 18
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD DEC 16
PY 2013
VL 210
IS 13
BP 2951
EP 2965
DI 10.1084/jem.20130071
PG 15
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 276ID
UT WOS:000328742600013
PM 24249111
ER
PT J
AU Chopin, M
Seillet, C
Chevrier, S
Wu, L
Wang, HS
Morse, HC
Belz, GT
Nutt, SL
AF Chopin, Michael
Seillet, Cyril
Chevrier, Stephane
Wu, Li
Wang, Hongsheng
Morse, Herbert C., III
Belz, Gabrielle T.
Nutt, Stephen L.
TI Langerhans cells are generated by two distinct PU.1-dependent
transcriptional networks
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID DENDRITIC-CELL; IN-VIVO; HEMATOPOIETIC PROGENITORS; MYELOGENOUS
LEUKEMIA; BLOOD MONOCYTES; STEADY-STATE; NULL MICE; EXPRESSION; PU.1;
CD8-ALPHA(+)
AB Langerhans cells (LCs) are the unique dendritic cells found in the epidermis. While a great deal of attention has focused on defining the developmental origins of LCs, reports addressing the transcriptional network ruling their differentiation remain sparse. We addressed the function of a group of key DC transcription factors-PU.1, ID2, IRF4, and IRF8-in the establishment of the LC network. We show that although steady-state LC homeostasis depends on PU.1 and ID2, the latter is dispensable for bone marrow-derived LCs. PU.1 controls LC differentiation by regulating the expression of the critical TGF-beta responsive transcription factor RUNX3. PU.1 directly binds to the Runx3 regulatory elements in a TGF-beta-dependent manner, whereas ectopic expression of RUNX3 rescued LC differentiation in the absence of PU.1 and promoted LC differentiation from PU.1-sufficient progenitors. These findings highlight the dual molecular network underlying LC differentiation, and show the central role of PU.1 in these processes.
C1 [Chopin, Michael; Seillet, Cyril; Chevrier, Stephane; Wu, Li; Belz, Gabrielle T.; Nutt, Stephen L.] Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia.
[Chopin, Michael; Seillet, Cyril; Chevrier, Stephane; Wu, Li; Belz, Gabrielle T.; Nutt, Stephen L.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia.
[Wu, Li] Tsinghua Univ, Tsinghua Peking Univ Joint Ctr Life Sci, Sch Med, Beijing 100084, Peoples R China.
[Wang, Hongsheng; Morse, Herbert C., III] NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA.
RP Nutt, SL (reprint author), Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia.
EM nutt@wehi.edu.au
OI Morse, Herbert/0000-0002-9331-3705; Nutt, Stephen/0000-0002-0020-6637
FU National Health and Medical Research Council (NHRMC) of Australia
[APP1048278, APP1023266]; Intramural Research Program of the National
Institutes of Health; National Institute of Allergy and Infectious
Diseases; Australian Research Council
FX This work was supported by project grants (APP1048278 and APP1023266)
and fellowships from the National Health and Medical Research Council
(NHRMC) of Australia (to L. Wu, G. T. Belz, and S. L. Nutt), and the
Intramural Research Program of the National Institutes of Health,
National Institute of Allergy and Infectious Diseases (to H. C. Morse
III). S. L. Nutt and G. T. Belz are supported by an Australian Research
Council Future Fellowship. This work was made possible through Victorian
State Government Operational Infrastructure Support and Australian
Government NHMRC IRIIS.
NR 60
TC 23
Z9 23
U1 1
U2 9
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD DEC 16
PY 2013
VL 210
IS 13
BP 2967
EP 2980
DI 10.1084/jem.20130930
PG 14
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 276ID
UT WOS:000328742600014
PM 24249112
ER
PT J
AU Hannas, BR
Howdeshell, KL
Furr, J
Gray, LE
AF Hannas, Bethany R.
Howdeshell, Kembra L.
Furr, Johnathan
Gray, L. Earl, Jr.
TI In utero phthalate effects in the female rat: A model for MRKH syndrome
SO TOXICOLOGY LETTERS
LA English
DT Article
DE Reproductive malformations; Uterine; Critical period
ID MALE REPRODUCTIVE DEVELOPMENT; N-BUTYL PHTHALATE; DI(N-BUTYL) PHTHALATE;
2,4-DICHLOROPHENYL-PARA-NITROPHENYL ETHER; SEXUAL-DIFFERENTIATION;
DIBUTYL PHTHALATE; PRENATAL EXPOSURE; LATE-GESTATION; MALFORMATIONS;
TOXICITY
AB Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome is characterized by uterine and vaginal canal aplasia in normal karyotype human females and is a syndrome with poorly defined etiology. Reproductive toxicity of phthalate esters (PEs) occurs in rat offspring exposed in utero, a phenomenon that is better studied in male offspring than females. The current study reports female reproductive tract malformations in the Sprague-Dawley rat similar to those characteristic of MRKH syndrome, following in utero exposure to a mixture of 5 PEs. We determined that females are similar to 2-fold less sensitive to the effects of the 5-PE mixture than males for reproductive tract malformations. We were not fully successful in defining the critical exposure period for females; however, incidence of malformations was 88% following dosing from GD8 to 19 versus 22% and 0% for GD8-13 and GD14-19, respectively. Overall, this study provides valuable information regarding female vulnerability to in utero phthalate exposure and further characterizes a potential model for the human MRKH syndrome. Published by Elsevier Ireland Ltd.
C1 [Hannas, Bethany R.; Furr, Johnathan; Gray, L. Earl, Jr.] US EPA, NHEERL, Toxicol Assessment Div, Reprod Toxicol Branch,Off Res & Dev, Res Triangle Pk, NC 27711 USA.
[Howdeshell, Kembra L.] NIEHS, Natl Toxicol Program, Off Hlth Assessment & Translat, Res Triangle Pk, NC 27709 USA.
RP Gray, LE (reprint author), US EPA, NHEERL, RTD, MD 72, Res Triangle Pk, NC 27711 USA.
EM Hannas.bethany@epa.gov; kembra.howdeshell@nih.gov;
furr.johnathan@epa.gov; gray.earl@epa.gov
FU National Toxicology Program at the National Institute of Environmental
Health Sciences Interagency Agreement; U.S. Environmental Protection
Agency [RW-75-92285501-1]
FX National Toxicology Program at the National Institute of Environmental
Health Sciences Interagency Agreement with the U.S. Environmental
Protection Agency, Cooperative Agreement #RW-75-92285501-1.
NR 25
TC 8
Z9 8
U1 0
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0378-4274
EI 1879-3169
J9 TOXICOL LETT
JI Toxicol. Lett.
PD DEC 16
PY 2013
VL 223
IS 3
BP 315
EP 321
DI 10.1016/j.toxlet.2013.03.021
PG 7
WC Toxicology
SC Toxicology
GA 258XV
UT WOS:000327492900009
PM 23542816
ER
PT J
AU Cleeland, CS
Zhao, FM
Chang, VT
Sloan, JA
O'Mara, AM
Gilman, PB
Weiss, M
Mendoza, TR
Lee, JW
Fisch, MJ
AF Cleeland, Charles S.
Zhao, Fengmin
Chang, Victor T.
Sloan, Jeff A.
O'Mara, Ann M.
Gilman, Paul B.
Weiss, Matthias
Mendoza, Tito R.
Lee, Ju-Whei
Fisch, Michael J.
TI The Symptom Burden of Cancer: Evidence for a Core Set of Cancer-Related
and Treatment-Related Symptoms From the Eastern Cooperative Oncology
Group Symptom Outcomes and Practice Patterns Study
SO CANCER
LA English
DT Article
DE symptoms; symptom assessment; cancer; symptom management; M. D. Anderson
Symptom Inventory; MDASI
ID MULTIPLE SYMPTOMS; METASTATIC CANCER; PAIN; SEVERITY; MODERATE; MILD;
RECOMMENDATIONS; INTERFERENCE; OUTPATIENTS; PREVALENCE
AB BACKGROUND: A set of common cancer-related and treatment-related symptoms has been proposed for quality of care assessment and clinical research. Using data from a large, multicenter, prospective study, the authors assessed the effects of disease site and stage on the percentages of patients rating these proposed symptoms as moderate to severe.
METHODSThe severity of 13 symptoms proposed to represent core oncology symptoms was rated by 3106 ambulatory patients with cancer of the breast, prostate, colon/rectum, or lung, regardless of disease stage or phase of care; 2801 patients (90%) repeated the assessment 4 to 5 weeks later.
RESULTSAt the time of the initial assessment, approximately 33% of the patients reported3 symptoms in the moderate-to-severe range; 11 of the 13 symptoms were rated as moderate to severe by at least 10% of all patients and 6 were rated as moderate to severe by at least 20% of those receiving active treatment. Fatigue/tiredness was the most severe symptom, followed by disturbed sleep, pain, dry mouth, and numbness/tingling. More patients with lung cancer and patients receiving active treatment reported moderate to severe symptoms. Percentages of symptomatic patients increased by disease stage, less adequate response to therapy, and declining Eastern Cooperative Oncology Group performance status. The percentages of patients reporting moderate to severe symptoms were stable across both assessments.
CONCLUSIONSThe results of the current study support a core set of moderate to severe symptoms that are common across outpatients with solid tumors, that can guide consideration of progression-free survival as a trial outcome, and that should be considered in clinical care and in assessments of quality of care and treatment benefit. Cancer 2013;119:4333-4340. (c) 2013 American Cancer Society.
C1 [Cleeland, Charles S.] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA.
[Zhao, Fengmin] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Chang, Victor T.] Rutgers Univ Med & Dent New Jersey, Vet Affairs New Jersey Hlth Care Syst, E Orange, NJ USA.
[Sloan, Jeff A.] Mayo Clin, Coll Med, Dept Hlth Sci Res, Rochester, MN USA.
[O'Mara, Ann M.] NCI, Community Oncol & Prevent Trials Res Grp, Canc Prevent Div, Bethesda, MD 20892 USA.
[Gilman, Paul B.] Main Line Hematol Oncol Associates, Lankenau Canc Ctr, Wynnewood, PA USA.
[Weiss, Matthias] Marshfield Clin Fdn Med Res & Educ, Dept Hematol Oncol Northern Div, Marshfield, WI USA.
[Fisch, Michael J.] Univ Texas MD Anderson Canc Ctr, Dept Gen Oncol, Houston, TX 77030 USA.
RP Cleeland, CS (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, 1515 Holcombe Blvd,Unit 1450, Houston, TX 77030 USA.
EM ccleeland@mdanderson.org
FU National Cancer Institute/National Institutes of Health [CA37403,
CA15488, CA13650, CA35412, CA063847]; MD Anderson Cancer Center Support
Grant [P30 CA016672]; [R01 CA026582]
FX Supported by grants from the National Cancer Institute/National
Institutes of Health, including U10 grants CA37403, CA15488, CA13650,
CA35412, and CA063847 to the Eastern Cooperative Oncology Group; R01
CA026582 to Dr. Cleeland; and MD Anderson Cancer Center Support Grant
P30 CA016672. Neither the National Cancer Institute nor the National
Institutes of Health had any role in the study design, data collection,
analysis, interpretation, or preparation of this article.
NR 20
TC 39
Z9 39
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD DEC 15
PY 2013
VL 119
IS 24
BP 4333
EP 4340
DI 10.1002/cncr.28376
PG 8
WC Oncology
SC Oncology
GA 295BP
UT WOS:000330091900018
PM 24114037
ER
PT J
AU Winhusen, TM
Adinoff, B
Lewis, DF
Brigham, GS
Gardin, JG
Sonne, SC
Theobald, J
Ghitza, U
AF Winhusen, Theresa M.
Adinoff, Bryon
Lewis, Daniel F.
Brigham, Gregory S.
Gardin, John G., II
Sonne, Susan C.
Theobald, Jeff
Ghitza, Udi
TI A tale of two stimulants: Mentholated cigarettes may play a role in
cocaine, but not methamphetamine, dependence
SO DRUG AND ALCOHOL DEPENDENCE
LA English
DT Article
DE Menthol; Cigarettes; Cocaine dependence; Methamphetamine dependence
ID SMOKING-CESSATION; POTENTIAL IMPACT; CARBON-MONOXIDE; SUBSTANCE USE;
DRUG-USE; SMOKERS; NONSMOKERS; ADDICTION; OUTCOMES; TRIAL
AB Background: Research suggests that mentholated cigarettes may play a role in cocaine dependence. The purpose of the present study was to expand upon the research on mentholated cigarettes and cocaine dependence and to evaluate the role of mentholated cigarettes in methamphetamine dependence.
Methods: Secondary analysis of a multisite, randomized trial evaluating the impact of smoking-cessation treatment in stimulant-dependent outpatients (N = 538). Participants' reasons for concurrent use of cigarettes and illicit stimulants were assessed via self-report. Stimulant-abstinence was measured by self-report and urine drug screens. Smoking cessation was assessed via self-report and carbon monoxide levels.
Results: Of the 301 cocaine-dependent participants, 201 (67%) were menthol and 100 (33%) were non-menthol cigarette smokers. Cocaine-dependent participants who smoked menthol, compared to non-menthol, cigarettes were significantly more likely to report that cigarettes prolong their cocaine high (X-2(1) = 16.3, p < .0001, OR = 3.58 [95% CI: 1.88-6.79]) and were less likely to be stimulant abstinent during active treatment (W=3.6,p < 0.001, d=.39 [95% CI: 0.16-0.62]), at 3-month follow-up (X-2(1) = 14.4, p < 0.001, OR = .32 [95% CI: 0.17-0.581), and at 6-month follow-up (X-2(1) = 4.6, p = 0.03, OR = .53 [95% CI: 0.29-0.95]). No parallel differences were found between menthol and non-menthol methamphetamine-dependent smokers. The prevalence of Caucasian menthol smokers was significantly greater in the cocaine-dependent participants (37.2%) than in the methamphetamine-dependent participants (17.61%), (X-2(1) = 14.4, p < .001, OR = 2.77 [95% CI:1.62-4.731). Smoking cessation was not significantly associated with cigarette type for either cocaine- or methamphetamine-dependent participants.
Conclusions: The present results suggest that mentholated cigarettes play a role in cocaine, but not methamphetamine, dependence. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Winhusen, Theresa M.; Lewis, Daniel F.; Brigham, Gregory S.; Theobald, Jeff] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati Addict Res Treatment & Educ Ctr CinART, Cincinnati, OH 45220 USA.
[Adinoff, Bryon] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.
[Adinoff, Bryon] Dallas VAMC, VA North Texas Hlth Care Syst, Dallas, TX 75216 USA.
[Brigham, Gregory S.] Maryhaven, Columbus, OH 43207 USA.
[Gardin, John G., II] ADAPT Inc, Roseburg, OR 97470 USA.
[Sonne, Susan C.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Ghitza, Udi] NIDA, Ctr Clin Trials Network, Bethesda, MD 20892 USA.
RP Winhusen, TM (reprint author), Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati Addict Res Treatment & Educ Ctr CinART, 3210 Jefferson Ave, Cincinnati, OH 45220 USA.
EM winhusen@carc.uc.edu
OI Winhusen, Theresa/0000-0002-3364-0739; Brigham,
Gregory/0000-0003-1150-4493
FU National Institute on Drug Abuse (NIDA) Clinical Trials Network
[U10-DA013732, U10-DA020036, U10-DA013720, U10-DA013045, U10-DA013727,
U10-DA020024, U10-DA015815]
FX Funding for this study was provided by the National Institute on Drug
Abuse (NIDA) Clinical Trials Network: U10-DA013732 to University of
Cincinnati (Dr. Winhusen); U10-DA020036 to University of Pittsburgh (Dr.
Daley), U10-DA013720 to University of Miami School of Medicine (Drs.
Szapocznik and Metsch); U10-DA013045 to University of California Los
Angeles (Dr. Ling); U10-DA013727 to Medical University of South Carolina
(Dr. Brady); U10-DA020024 to University of Texas Southwestern Medical
Center (Dr. Trivedi);U10-DA015815 to University of California San
Francisco (Drs. Sorensen and McCarty). The publications committee of the
Clinical Trials Network (CTN) gave final approval of the analysis and
interpretation of the data and approved the manuscript.
NR 36
TC 5
Z9 5
U1 1
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0376-8716
EI 1879-0046
J9 DRUG ALCOHOL DEPEN
JI Drug Alcohol Depend.
PD DEC 15
PY 2013
VL 133
IS 3
BP 845
EP 851
DI 10.1016/j.drugalcdep.2013.09.002
PG 7
WC Substance Abuse; Psychiatry
SC Substance Abuse; Psychiatry
GA 283VH
UT WOS:000329274600007
PM 24075226
ER
PT J
AU Lavi, O
Greene, JM
Levy, D
Gottesman, MM
AF Lavi, Orit
Greene, James M.
Levy, Doron
Gottesman, Michael M.
TI The Role of Cell Density and Intratumoral Heterogeneity in Multidrug
Resistance
SO CANCER RESEARCH
LA English
DT Article
ID INDUCED APOPTOSIS; DRUG-RESISTANCE; MUTATION-RATE; CANCER-CELLS;
CHEMOTHERAPY; EVOLUTION; DYNAMICS; STATE
AB Recent data have demonstrated that cancer drug resistance reflects complex biologic factors, including tumor heterogeneity, varying growth, differentiation, apoptosis pathways, and cell density. As a result, there is a need to find new ways to incorporate these complexities in the mathematical modeling of multidrug resistance. Here, we derive a novel structured population model that describes the behavior of cancer cells under selection with cytotoxic drugs. Our model is designed to estimate intratumoral heterogeneity as a function of the resistance level and time. This updated model of the multidrug resistance problem integrates both genetic and epigenetic changes, density dependence, and intratumoral heterogeneity. Our results suggest that treatment acts as a selection process, whereas genetic/epigenetic alteration rates act as a diffusion process. Application of our model to cancer treatment suggests that reducing alteration rates as a first step in treatment causes a reduction in tumor heterogeneity and may improve targeted therapy. The new insight provided by this model could help to dramatically change the ability of clinical oncologists to design new treatment protocols and analyze the response of patients to therapy. (C) 2013 AACR.
C1 [Lavi, Orit; Gottesman, Michael M.] NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA.
[Greene, James M.; Levy, Doron] Univ Maryland, Dept Math, College Pk, MD 20742 USA.
[Greene, James M.; Levy, Doron] Univ Maryland, Ctr Sci Computat & Math Modeling CSCAMM, College Pk, MD 20742 USA.
RP Lavi, O (reprint author), NCI, Cell Biol Lab, NIH, 37 Convent Dr,Room 2112, Bethesda, MD 20892 USA.
EM orit.lavi@nih.gov
FU Intramural Research Program of the NIH, Center for Cancer Research,
National Cancer Institute; UMD-NCI Partnership for Cancer Technology;
NSF/NIGMS program [DMS-0758374]; National Cancer Institute [R01CA130817]
FX The work was supported by the Intramural Research Program of the NIH,
Center for Cancer Research, National Cancer Institute and was supported
in part by a seed grant from the UMD-NCI Partnership for Cancer
Technology. The work of D. Levy was supported in part by the joint
NSF/NIGMS program under grant number DMS-0758374 and by grant number
R01CA130817 from the National Cancer Institute.
NR 24
TC 15
Z9 15
U1 2
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
IS 24
BP 7168
EP 7175
DI 10.1158/0008-5472.CAN-13-1768
PG 8
WC Oncology
SC Oncology
GA 279DB
UT WOS:000328939200006
PM 24163380
ER
PT J
AU Pikor, LA
Lockwood, WW
Thu, KL
Vucic, EA
Chari, R
Gazdar, AF
Lam, S
Lam, WL
AF Pikor, Larissa A.
Lockwood, William W.
Thu, Kelsie L.
Vucic, Emily A.
Chari, Raj
Gazdar, Adi F.
Lam, Stephen
Lam, Wan L.
TI YEATS4 Is a Novel Oncogene Amplified in Non-Small Cell Lung Cancer That
Regulates the p53 Pathway
SO CANCER RESEARCH
LA English
DT Article
ID PUTATIVE TRANSCRIPTION FACTOR; ARRAY CGH DATA; GENE AMPLIFICATION;
HISTONE ACETYLTRANSFERASE; TUMOR-SUPPRESSOR; PROTEIN; GAS41;
ADENOCARCINOMA; EXPRESSION; CARCINOMAS
AB Genetic analyses of lung cancer have helped found new treatments in this disease. Weconducted an integrative analysis of gene expression and copy number in 261 non-small cell lung cancers (NSCLC) relative to matched normal tissues to define novel candidate oncogenes, identifying 12q13-15 and more specifically the YEATS4 gene as amplified and overexpressed in similar to 20% of the NSCLC cases examined. Overexpression of YEATS4 abrogated senescence in human bronchial epithelial cells. Conversely, RNAi-mediated attenuation of YEATS4 in human lung cancer cells reduced their proliferation and tumor growth, impairing colony formation and inducing cellular senescence. These effects were associated with increased levels of p21WAF1 and p53 and cleavage of PARP, implicating YEATS4 as a negative regulator of the p21-p53 pathway. We also found that YEATS4 expression affected cellular responses to cisplastin, with increased levels associated with resistance and decreased levels with sensitivity. Taken together, our findings reveal YEATS4 as a candidate oncogene amplified in NSCLC, and a novel mechanism contributing to NSCLC pathogenesis. (C) 2013 AACR.
C1 [Pikor, Larissa A.; Thu, Kelsie L.; Vucic, Emily A.; Lam, Stephen; Lam, Wan L.] BC Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada.
[Lockwood, William W.] NIH, Bethesda, MD 20892 USA.
[Chari, Raj] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Gazdar, Adi F.] Univ Texas South Western, Hamon Ctr Therapeut, Dallas, TX USA.
RP Pikor, LA (reprint author), BC Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada.
EM lpikor@bccrc.ca
OI Vucic, Emily/0000-0002-2728-8708
FU Canadian Institutes for Health Research [MOP 86731, 94867]; Canadian
Cancer Society [CCS20485]; NCI Early Detection Research Network
[U01CA0864021]; Canary Foundation; Vanier Canada Graduate Scholarship;
CIHR Jean-Francois Saint Denis Fellowship in Cancer Research; CIHR
Frederick Banting & Charles Best Canada Graduate Scholarship; Banting
Postdoctoral Fellowship
FX Funding for this work is provided by the Canadian Institutes for Health
Research (MOP 86731, 94867), Canadian Cancer Society (CCS20485), NCI
Early Detection Research Network (U01CA0864021), and the Canary
Foundation. L. A. Pikor and K. L. Thu are supported by Vanier Canada
Graduate Scholarship, W. W. Lockwood by CIHR Jean-Francois Saint Denis
Fellowship in Cancer Research, E. A. Vucic by CIHR Frederick Banting &
Charles Best Canada Graduate Scholarship, and R. Chari by Banting
Postdoctoral Fellowship.
NR 49
TC 9
Z9 9
U1 0
U2 5
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
IS 24
BP 7301
EP 7312
DI 10.1158/0008-5472.CAN-13-1897
PG 12
WC Oncology
SC Oncology
GA 279DB
UT WOS:000328939200018
PM 24170126
ER
PT J
AU Greten, TF
Duffy, AG
Korangy, F
AF Greten, Tim F.
Duffy, Austin G.
Korangy, Firouzeh
TI Hepatocellular Carcinoma from an Immunologic Perspective
SO CLINICAL CANCER RESEARCH
LA English
DT Review
ID T-CELL RESPONSES; RADIOFREQUENCY THERMAL ABLATION; TARGETED ONCOLYTIC
POXVIRUS; PHASE-I TRIAL; ANTITUMOR IMMUNITY; SUPPRESSOR-CELLS;
CLINICAL-TRIAL; LIVER-CANCER; GLYPICAN-3; INFLAMMATION
AB Hepatocellular carcinoma is the third most common cancer worldwide. It is an inflammation-associated cancer. Multiple investigators have demonstrated that analysis of the tumor microenvironment may be used to predict patient outcome, indicating the importance of local immune responses in this disease. In contrast with other types of cancer, in which surgery, radiation, and systemic cytotoxic chemotherapies dominate the treatment options, in hepatocellular carcinoma locoregional treatments are widely applied. Such treatments induce rapid tumor cell death and antitumor immune responses, which may favor or impair the patients' outcome. Recent immunotherapeutic studies demonstrating promising results include trials evaluating intratumoral injection of an oncolytic virus expressing granulocyte macrophage colony-stimulating factor, glypican-3 targeting treatments, and anti-CTLA4 treatment. Although some of these novel approaches may provide benefit as single agents, there is a clear opportunity in hepatocellular carcinoma to evaluate these in combination with the standard modalities to more effectively harness the immune response. (C)2013 AACR.
C1 [Greten, Tim F.; Duffy, Austin G.; Korangy, Firouzeh] NCI, GI Malignancy Sect, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Greten, TF (reprint author), NCI, Bldg 10 Rm 12N226,9000 Rockville Pike, Bethesda, MD 20892 USA.
EM tim.greten@nih.gov
RI Greten, Tim/B-3127-2015
OI Greten, Tim/0000-0002-0806-2535
FU Intramural Research Program of the NIH, National Cancer Institute,
Center for Cancer Research
FX This work was financially supported by grants from the Intramural
Research Program of the NIH, National Cancer Institute, Center for
Cancer Research (to T. F. Greten).
NR 54
TC 17
Z9 18
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD DEC 15
PY 2013
VL 19
IS 24
BP 6678
EP 6685
DI 10.1158/1078-0432.CCR-13-1721
PG 8
WC Oncology
SC Oncology
GA 279CY
UT WOS:000328938700006
PM 24030702
ER
PT J
AU Lee, JH
Park, KS
Alberobello, AT
Kallakury, B
Weng, MT
Wang, Y
Giaccone, G
AF Lee, Jih-Hsiang
Park, Kang-Seo
Alberobello, Anna Teresa
Kallakury, Bhaskar
Weng, Meng-Tzu
Wang, Yisong
Giaccone, Giuseppe
TI The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung
Cancers In Vitro and In Vivo
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID PHASE-II; MYELOPROLIFERATIVE DISORDERS; SOLID TUMORS; DOUBLE-BLIND;
JAK2; MUTATIONS; CYTOKINE; TRIAL; MYELOFIBROSIS; RUXOLITINIB
AB Purpose: The prognosis of small cell lung cancer (SCLC) is poor, and there has been very little progress in the medical treatment of SCLC in the past two decades. We investigated the potential of Janus-activated kinases (JAK) inhibitor, AZD1480, for treatment of SCLC in vitro and in vivo.
Experimental Design: JAK1 and JAK2 were inhibited by AZD1480 or siRNAs, and the effect of inhibition of JAK gene family on SCLC cell viability was evaluated. The effect of AZD1480 on cell-cycle distribution and apoptosis induction was studied. Antitumor effects of AZD1480 in tumor xenografts were assessed.
Results: AZD1480 significantly inhibited growth of six out of 13 SCLC cells with IC(50)s ranging from 0.73 to 3.08 mu mol/L. Knocking down of JAK2 and JAK1 inhibited proliferation of Jak2-positive/Jak1-negative H82 cells and Jak1-positive/Jak2-negative GLC4 cells, respectively. Treatment of SCLC cells with AZD1480 for 24 hours resulted in an increase of 4N DNA content and histone 3 serine 10 phosphorylation, indicative of G(2)-M phase arrest. Moreover, SCLCs underwent apoptosis after AZD1480 treatment as exemplified by the downregulation of MCL1, the accumulation of cleaved caspase 3, cleaved PARP, and increase of annexin-V-positive cells. Finally, xenograft experiments showed that AZD1480 attenuated the growth of H82 and GLC4 tumors in mice, and we observed stronger apoptosis as well as decreased CD31-positive endothelial cells in H82 and GLC4 xenografts upon AZD1480 treatment.
Conclusions: JAK inhibitor AZD1480 attenuated growth of SCLC cells in vitro and in vivo. Clinical development of anti-JAKs therapies in SCLC warrants further investigation. (C)2013 AACR.
C1 [Lee, Jih-Hsiang; Park, Kang-Seo; Weng, Meng-Tzu; Wang, Yisong; Giaccone, Giuseppe] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA.
[Park, Kang-Seo; Alberobello, Anna Teresa; Kallakury, Bhaskar; Weng, Meng-Tzu; Wang, Yisong; Giaccone, Giuseppe] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
RP Giaccone, G (reprint author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Res Bldg,Rm W503, Washington, DC 20007 USA.
EM gg496@georgetown.edu
RI Giaccone, Giuseppe/E-8297-2017
OI Giaccone, Giuseppe/0000-0002-5023-7562
FU NIH
FX The study was sponsored by the intramural grant of the NIH.
NR 42
TC 13
Z9 13
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD DEC 15
PY 2013
VL 19
IS 24
BP 6777
EP 6786
DI 10.1158/1078-0432.CCR-13-1110
PG 10
WC Oncology
SC Oncology
GA 279CY
UT WOS:000328938700015
PM 24158701
ER
PT J
AU Kreitman, RJ
Wilson, W
Calvo, KR
Arons, E
Roth, L
Sapolsky, J
Zhou, H
Raffeld, M
Stetler-Stevenson, M
AF Kreitman, Robert J.
Wilson, Wyndham
Calvo, Katherine R.
Arons, Evgeny
Roth, Laura
Sapolsky, Jeffrey
Zhou, Hong
Raffeld, Mark
Stetler-Stevenson, Maryalice
TI Cladribine with Immediate Rituximab for the Treatment of Patients with
Variant Hairy Cell Leukemia
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID MINIMAL RESIDUAL DISEASE; TERM-FOLLOW-UP; MARGINAL ZONE LYMPHOMA;
VILLOUS LYMPHOCYTES; 2-CHLORODEOXYADENOSINE; DIAGNOSIS; FEATURES;
IMMUNOGLOBULIN; PENTOSTATIN; DISORDERS
AB Purpose: In contrast with the classic form, variant hairy cell leukemia (HCLv) responds poorly to single-agent purine analogs, expresses unmutated BRAF, has shorter overall survival, and lacks effective standard therapy. No treatment has achieved a high complete remission (CR) rate even in small series, and of 39 reported cases from six studies, overall response rate after cladribine was 44% with 8% CRs. Rituximab has been found to increase the sensitivity of malignant cells to cladribine, suggesting that combination with cladribine might improve response in HCLv. To test this hypothesis, patients with HCLv were treated with simultaneous cladribine and rituximab.
Experimental Design: Patients with HCLv with 0 to 1 prior courses of cladribine received cladribine 0.15 mg/kg for days 1 to 5, with eight weekly doses of rituximab 375 mg/m(2) beginning day 1. Restaging was performed, and minimal residual disease (MRD) in blood and marrow was quantified using PCR, immunohistochemistry, and flow cytometry.
Results: By 6 months, 9 (90%) of 10 patients achieved CR, compared with 3 (8%) of 39 reported cases treated with cladribine alone (P < 0.0001). Of the 9 CRs, 8 remain free of MRD at 12 to 48 (median 27) months of follow-up. No dose-limiting toxicities were observed when beginning cladribine and rituximab on the same day, although most patients required short-term steroids to prevent and treat rituximab infusion reactions. Cytopenias in CRs resolved in 7 to 211 (median 34) days without major infections.
Conclusion: Although cladribine alone lacks effectiveness for early or relapsed HCLv, cladribine with immediate rituximab achieves CRs without MRD and is feasible to administer. (C)2013 AACR.
C1 [Raffeld, Mark; Stetler-Stevenson, Maryalice] NCI, Pathol Lab, Bethesda, MD 20892 USA.
[Wilson, Wyndham] NCI, Metab Branch, Bethesda, MD 20892 USA.
[Calvo, Katherine R.] NIH, Ctr Clin, Dept Lab Med, Bethesda, MD 20892 USA.
RP Kreitman, RJ (reprint author), 37-5124b,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.
EM kreitmar@mail.nih.gov
OI Calvo, Katherine/0000-0002-0771-4191
FU Intramural Research Program; NCI; NIH; Hairy Cell Leukemia Foundation;
Genentech
FX This work was supported by the Intramural Research Program, NCI, NIH,
and the Hairy Cell Leukemia Foundation. The rituximab for the trial was
sponsored by Genentech.
NR 47
TC 12
Z9 12
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD DEC 15
PY 2013
VL 19
IS 24
BP 6873
EP 6881
DI 10.1158/1078-0432.CCR-13-1752
PG 9
WC Oncology
SC Oncology
GA 279CY
UT WOS:000328938700024
PM 24277451
ER
PT J
AU Guo, TL
Germolec, DR
Zhang, LX
Auttachoat, W
Smith, MJ
White, KL
AF Guo, T. L.
Germolec, D. R.
Zhang, Ling X.
Auttachoat, W.
Smith, M. J.
White, K. L., Jr.
TI Contact sensitizing potential of pyrogallol and 5-amino-o-cresol in
female BALB/c mice
SO TOXICOLOGY
LA English
DT Article
DE Hair dyes; Pyrogallol; 5-Amino-o-cresol; Chemical hypersensitivity;
Lymph node subpopulations
ID LOCAL LYMPH-NODE; RISK-ASSESSMENT; CUMULATIVE IRRITATION; HELA-CELLS;
ASSAY; ALLERGENS; SKIN; IRRITANTS; APOPTOSIS; CHEMICALS
AB Hair dye components such as pyrogallol and cresol have been shown previously to promote allergic reactions such as rashes, dermal inflammation, irritation and dermatitis. The objective of this study was to determine the contact sensitization potential of pyrogallol (PYR) and 5-amino-o-cresol (AOC) when applied dermally to female BALB/c mice. Measurement of the contact hypersensitivity response was initially accomplished using the local lymph node assay. For PYR, significant increases in the proliferation of lymph node cells were observed at concentrations of 0.5% (w/v) and higher. For AOC, borderline increases, albeit significant, in auricular lymph node cell proliferation were observed at 5% and 10%. Results from the irritancy assay suggested that PYR, but not AOC, was an irritant. To further delineate whether PYR was primarily an irritant or a contact sensitizer, the mouse ear swelling test (MEST) was conducted. A significant increase in mouse ear thickness was observed at 72 h following challenge with 0.5% PYR in mice that had been sensitized with 5% PYR In contrast, no effects were observed in the MEST in mice sensitized and challenged with the highest achievable concentration of AOC (10%). Additional studies examining lymph node subpopulations and CD86 (B7.2) expression by B cells further support the indication that PYR was a sensitizer in BALB/c mice. The results demonstrate that PYR is both a sensitizer and an irritant in female BALB/c mice. However, the contact sensitization potential of AOC is minimal in this strain of mouse. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Guo, T. L.; Zhang, Ling X.; Auttachoat, W.; Smith, M. J.; White, K. L., Jr.] Univ Georgia, Coll Vet Med, Dept Vet Biosci & Diagnost Imaging, Athens, GA 30602 USA.
[Germolec, D. R.] NIEHS, Div Natl Toxicol Program, RTP, Res Triangle Pk, NC 27709 USA.
RP Guo, TL (reprint author), Univ Georgia, Coll Vet Med, Dept Vet Biosci & Diagnost Imaging, Athens, GA 30602 USA.
EM tlguo1@uga.edu
FU NIEHS [N01-ES-55538]
FX This study was supported by the NIEHS contract N01-ES-55538. The authors
would like to thank Dr. Steven D. Holladay at University of Georgia for
his critical and editorial review, and D.L. Musgrove and R.D. Brown at
Virginia Commonwealth University for their technical assistance. This
article may be the work product of an employee or group of employees of
the National Institute of Environmental Health Sciences (NIEHS),
National Institutes of Health (NIH), however, the statements, opinions
or conclusions contained therein do not necessarily represent the
statements, opinions or conclusions of NIEHS, NIH or the United States
government.
NR 51
TC 2
Z9 2
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0300-483X
J9 TOXICOLOGY
JI Toxicology
PD DEC 15
PY 2013
VL 314
IS 2-3
BP 202
EP 208
DI 10.1016/j.tox.2013.10.006
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA 280DH
UT WOS:000329008400002
PM 24172597
ER
PT J
AU Ruhl, CE
Everhart, JE
AF Ruhl, Constance E.
Everhart, James E.
TI The Association of Low Serum Alanine Aminotransferase Activity With
Mortality in the US Population
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE alanine aminotransferase; body composition; mortality; National Health
and Nutrition Examination Survey
ID ALL-CAUSE MORTALITY; BODY-MASS INDEX; PHYSICAL PERFORMANCE BATTERY;
LOWER-EXTREMITY FUNCTION; UNITED-STATES; CAFFEINE CONSUMPTION; PREDICT
MORTALITY; SARCOPENIA; DISABILITY; RISK
AB Elevated alanine aminotransferase (ALT) activity, an important marker of liver injury, has been associated inconsistently with higher mortality. We evaluated whether persons with nonelevated ALT levels are the most appropriate comparison group by examining the relationships of low ALT with mortality and body composition in the US National Health and Nutrition Examination Survey (NHANES). In NHANES 19881994, the mortality risk of persons in ALT deciles 1, 2, 3, and 10 was compared with that of persons in deciles 49 (mortality was relatively flat across these deciles) over an 18-year period (through 2006) among 14,950 viral-hepatitis-negative adults. In NHANES 19992006, low ALT was evaluated in association with dual-energy x-ray absorptiometry body composition measures among 15,028 adults. Multivariate-adjusted mortality was higher for decile 1 (hazard ratio (HR) 1.42, 95 confidence interval (CI): 1.24, 1.63), decile 2 (HR 1.27, 95 CI: 1.06, 1.53), and decile 3 (HR 1.25, 95 CI: 1.04, 1.50) and nonsignificantly higher for decile 10 (HR 1.21, 95 CI: 0.91, 1.61) than for deciles 49. Adjusted appendicular lean mass was decreased among the lowest ALT deciles. In the US population, low ALT was associated with higher mortality risk, possibly attributable to decreased appendicular lean mass. For mortality studies of elevated ALT levels, the most appropriate comparison group is persons in the middle range of ALT rather than all persons with nonelevated ALT.
C1 [Ruhl, Constance E.] Social & Sci Syst Inc, Silver Spring, MD 20910 USA.
[Everhart, James E.] NIDDK, NIH, Bethesda, MD 20892 USA.
RP Ruhl, CE (reprint author), Social & Sci Syst Inc, 8757 Georgia Ave,12th Floor, Silver Spring, MD 20910 USA.
EM cruhl@s-3.com
FU National Institute of Diabetes and Digestive and Kidney Diseases
[HHSN2762012 00161U]
FX This work was supported by a contract (HHSN2762012 00161U) from the
National Institute of Diabetes and Digestive and Kidney Diseases.
NR 40
TC 10
Z9 11
U1 2
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD DEC 15
PY 2013
VL 178
IS 12
BP 1702
EP 1711
DI 10.1093/aje/kwt209
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 271IZ
UT WOS:000328386500005
PM 24071009
ER
PT J
AU Lin, SW
Abnet, CC
AF Lin, Shih-Wen
Abnet, Christian C.
TI RE: "PROSPECTIVE STUDY OF ULTRAVIOLET RADIATION EXPOSURE AND MORTALITY
RISK IN THE UNITED STATES" Reply
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Letter
ID NONMELANOMA SKIN-CANCER; SUNLIGHT; TRENDS
C1 [Lin, Shih-Wen; Abnet, Christian C.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
RP Lin, SW (reprint author), NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
EM lins4@mail.nih.gov
RI Abnet, Christian/C-4111-2015
OI Abnet, Christian/0000-0002-3008-7843
FU Intramural NIH HHS
NR 11
TC 0
Z9 0
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD DEC 15
PY 2013
VL 178
IS 12
BP 1762
EP 1763
DI 10.1093/aje/kwt266
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 271IZ
UT WOS:000328386500013
PM 24471178
ER
PT J
AU Taguchi, A
Maruyama, H
Nameta, M
Yamamoto, T
Matsuda, J
Kulkarni, AB
Yoshioka, H
Ishii, S
AF Taguchi, Atsumi
Maruyama, Hiroki
Nameta, Masaaki
Yamamoto, Tadashi
Matsuda, Junichiro
Kulkarni, Ashok B.
Yoshioka, Hidekatsu
Ishii, Satoshi
TI A symptomatic Fabry disease mouse model generated by inducing
globotriaosylceramide synthesis
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE enzyme replacement therapy; Fabry disease; globotriaosylceramide
synthesis; symptomatic mouse model
ID ALPHA-GALACTOSIDASE-A; ENZYME REPLACEMENT THERAPY; NATURAL-HISTORY;
DEFICIENT MICE; CHAPERONE THERAPY; AGALSIDASE-ALPHA; GAUCHER-DISEASE;
KNOCKOUT MICE; ANIMAL-MODEL; CELL
AB Fabry disease is a lysosomal storage disorder in which neutral glycosphingolipids, predominantly Gb3 (globotriaosylceramide), accumulate due to deficient alpha-Gal A (alpha-galactosidase A) activity. The GLAko (alpha-Gal A-knockout) mouse has been used as a model for Fabry disease, but it does not have any symptomatic abnormalities. In the present study, we generated a symptomatic mouse model (G3Stg/GLAko) by cross-breeding GLAko mice with transgenic mice expressing human Gb3 synthase. G3Stg/GLAko mice had high Gb3 levels in major organs, and their serum Gb3 level at 5-25 weeks of age was 6-10-fold higher than that in GLAko mice of the same age. G3Stg/GLAko mice showed progressive renal impairment, with albuminuria at 3 weeks of age, decreased urine osmolality at 5 weeks, polyuria at 10 weeks and increased blood urea nitrogen at 15 weeks. The urine volume and urinary albumin concentration were significantly reduced in the G3Stg/GLAko mice when human recombinant alpha-Gal A was administered intravenously. These data suggest that Gb3 accumulation is a primary pathogenic factor in the symptomatic phenotype of G3Stg/GLAko mice, and that this mouse line is suitable for studying the pathogenesis of Fabry disease and for preclinical studies of candidate therapies.
C1 [Taguchi, Atsumi; Yoshioka, Hidekatsu; Ishii, Satoshi] Oita Univ, Fac Med, Dept Matrix Med, Oita 8795593, Japan.
[Maruyama, Hiroki] Niigata Univ, Grad Sch Med & Dent Sci, Dept Clin Nephrosci, Niigata 9518120, Japan.
[Nameta, Masaaki; Yamamoto, Tadashi] Niigata Univ, Electron Microscope Core Facil, Niigata 9518120, Japan.
[Matsuda, Junichiro] Natl Inst Biomed Innovat, Lab Anim Models Human Dis, Osaka 5670085, Japan.
[Kulkarni, Ashok B.] Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD 20892 USA.
[Ishii, Satoshi] GlycoPharma Corp, Biochem Lab, Oita 8700822, Japan.
RP Ishii, S (reprint author), Oita Univ, Fac Med, Dept Matrix Med, Oita 8795593, Japan.
EM ishiis01@oita-u.ac.jp
FU Ministry of Education, Science and Culture of Japan [KM23390223]
FX This work was supported by a Grant-in-Aid for Scientific Research (B)
from the Ministry of Education, Science and Culture of Japan [grant
number KM23390223 (to H.M. and S.I.)].
NR 45
TC 9
Z9 9
U1 0
U2 3
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264-6021
J9 BIOCHEM J
JI Biochem. J.
PD DEC 15
PY 2013
VL 456
BP 373
EP 383
DI 10.1042/BJ20130825
PN 3
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 278GB
UT WOS:000328876100006
PM 24094090
ER
PT J
AU Vang, AG
Housley, W
Dong, HL
Basole, C
Ben-Sasson, SZ
Kream, BE
Epstein, PM
Clark, RB
Brocke, S
AF Vang, Amanda G.
Housley, William
Dong, Hongli
Basole, Chaitali
Ben-Sasson, Shlomo Z.
Kream, Barbara E.
Epstein, Paul M.
Clark, Robert B.
Brocke, Stefan
TI Regulatory T-cells and cAMP suppress effector T-cells independently of
PKA-CREM/ICER: a potential role for Epac
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE cyclic nucleotide phosphodiesterase; immune tolerance;
immunosuppression; inducible cAMP early repressor (ICER); T-cell
proliferation
ID PROTEIN-KINASE-A; EARLY REPRESSOR ICER; CYCLIC-AMP; GENE-EXPRESSION;
LEUKEMIC-CELLS; MESSENGER-RNA; LIPID RAFTS; TGF-BETA; IL-2; ACTIVATION
AB cAMP signalling is both a major pathway as well as a key therapeutic target for inducing immune tolerance and is involved in Treg cell (regulatory T-cell) function. To achieve potent immunoregulation, cAMP can act through several downstream effectors. One proposed mechanism is that cAMP-mediated suppression, including immunosuppression by Treg cells, results from activation of PKA (protein kinase A) leading to the induction of the transcription factor ICER (inducible cAMP early repressor). In the present study, we examined CD4(+)CD25(-) Teff cell (effector T-cell) and CD4(+)CD25(+) Treg cell immune responses in Crem (cAMP-response-element modulator) gene-deficient mice which lack ICER (Crem(-/-)/ICER-deficient mice). ICER deficiency did not significantly alter the frequency or number of Treg cells and Teff cells. Treg cells or a pharmacological increase in cAMP suppressed Teff cells from Crem(+/+) and Crem(-/-) /ICER-deficient mice to an equivalent degree, demonstrating that ICER is dispensable in these functions. Additionally, activating the cAMP effector Epac (exchange protein directly activated by cAMP) suppressed Teff cells. Treg cells expressed low levels of all cyclic nucleotide Pde (phosphodiesterase) genes tested, but high levels of Epac. These data identify ICER as a redundant mediator of Treg cells and cAMP action on Teff cells and suggest that Epac may function as an alternative effector to promote cAMP-dependent Teff cell suppression.
C1 [Vang, Amanda G.; Housley, William; Basole, Chaitali; Clark, Robert B.; Brocke, Stefan] Univ Connecticut, Ctr Hlth, Dept Immunol, Farmington, CT 06030 USA.
[Vang, Amanda G.; Dong, Hongli; Epstein, Paul M.; Brocke, Stefan] Univ Connecticut, Ctr Hlth, Dept Pharmacol, Farmington, CT 06030 USA.
[Dong, Hongli; Kream, Barbara E.; Epstein, Paul M.] Univ Connecticut, Ctr Hlth, Dept Cell Biol, Farmington, CT 06030 USA.
[Ben-Sasson, Shlomo Z.] NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA.
[Kream, Barbara E.; Clark, Robert B.] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA.
[Kream, Barbara E.] Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA.
RP Epstein, PM (reprint author), Univ Connecticut, Ctr Hlth, Dept Pharmacol, 263 Farmington Ave, Farmington, CT 06030 USA.
EM epstein@nso1.uchc.edu; sbrocke@uchc.edu
OI Basole, Chaitali/0000-0003-0644-7324
FU National Multiple Sclerosis Society [RG 4544A1/1, RG 4070A6];
institutional start-up funds; Connecticut Breast Health Initiative; CT
Department of Public Health; Smart Family Foundation; Lea's Foundation
for Leukemia Research; National Institutes of Health [1R56 A1072533-01
Al, R01 AR046542]
FX This work was supported by the National Multiple Sclerosis Society
[grant numbers RG 4544A1/1 (to S.B.) and RG 4070A6 (R.C.)],
institutional start-up funds (to S.B.), the Connecticut Breast Health
Initiative (to P.M.E. and S.B.), the CT Department of Public Health (to
P.M.E. and S.B.), the Smart Family Foundation (to P.M.E. and S.B.), the
Lea's Foundation for Leukemia Research (to P.M.E.) and the National
Institutes of Health [grant numbers 1R56 A1072533-01 Al (to R.B.C.) and
R01 AR046542 (to B.E.K.)].
NR 50
TC 10
Z9 10
U1 0
U2 5
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264-6021
J9 BIOCHEM J
JI Biochem. J.
PD DEC 15
PY 2013
VL 456
BP 463
EP 473
DI 10.1042/BJ20130064
PN 3
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 278GB
UT WOS:000328876100014
PM 24007532
ER
PT J
AU Battesti, A
Hoskins, JR
Tong, S
Milanesio, P
Mann, JM
Kravats, A
Tsegaye, YM
Bougdour, A
Wickner, S
Gottesman, S
AF Battesti, Aurelia
Hoskins, Joel R.
Tong, Song
Milanesio, Paola
Mann, Jessica M.
Kravats, Andrea
Tsegaye, Yodit M.
Bougdour, Alexandre
Wickner, Sue
Gottesman, Susan
TI Anti-adaptors provide multiple modes for regulation of the RssB adaptor
protein
SO GENES & DEVELOPMENT
LA English
DT Article
DE RpoS; ClpX; IraP; response regulator; RsbP
ID ESCHERICHIA-COLI; SIGMA(S) PROTEOLYSIS; PHOSPHORYLATION; RPOS;
RECOGNITION; STABILITY; PHOSPHATE; PATHWAY; SITE; OMPR
AB RpoS, an RNA polymerase sigma factor, controls the response of Escherichia coli and related bacteria to multiple stress responses. During nonstress conditions, RpoS is rapidly degraded by ClpXP, mediated by the adaptor protein RssB, a member of the response regulator family. In response to stress, RpoS degradation ceases. Small anti-adaptor proteins-IraP, IraM, and IraD, each made under a different stress condition-block RpoS degradation. RssB mutants resistant to either IraP or IraM were isolated and analyzed in vivo and in vitro. Each of the anti-adaptors is unique in its interaction with RssB and sensitivity to RssB mutants. One class of mutants defined an RssB N-terminal region close to the phosphorylation site and critical for interaction with IraP but unnecessary for IraM and IraD function. A second class, in the RssB C-terminal PP2C-like domain, led to activation of RssB function. These mutants allowed the response regulator to act in the absence of phosphorylation but did not abolish interaction with anti-adaptors. This class of mutants is broadly resistant to the anti-adaptors and bears similarity to constitutively activated mutants found in a very different PP2C protein. The mutants provide insight into how the anti-adaptors perturb RssB response regulator function and activation.
C1 [Battesti, Aurelia; Hoskins, Joel R.; Tong, Song; Milanesio, Paola; Mann, Jessica M.; Kravats, Andrea; Tsegaye, Yodit M.; Bougdour, Alexandre; Wickner, Sue; Gottesman, Susan] NCI, Mol Biol Lab, Bethesda, MD 20892 USA.
RP Gottesman, S (reprint author), NCI, Mol Biol Lab, Bldg 37, Bethesda, MD 20892 USA.
EM gottesms@helix.nih.gov
RI Bougdour, Alexandre/K-3795-2014
OI Bougdour, Alexandre/0000-0002-5895-0020
FU Intramural Research Program of the National Institutes of Health (NIH),
National Cancer Institute, Center for Cancer Research; NIH undergraduate
scholarship program
FX We thank members of the laboratory, M. Galperin, M. Maurizi, and D.
Dougan, for their comments on the manuscript. We thank A. Boulanger for
discussions on using the Phos-tag method. This research was supported by
the Intramural Research Program of the National Institutes of Health
(NIH), National Cancer Institute, Center for Cancer Research. J.M.M. was
supported by the NIH undergraduate scholarship program.
NR 32
TC 14
Z9 16
U1 0
U2 8
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD DEC 15
PY 2013
VL 27
IS 24
BP 2722
EP 2735
DI 10.1101/gad.229617.113
PG 14
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 278LW
UT WOS:000328892800009
PM 24352426
ER
PT J
AU Chattopadhyay, G
Shevach, EM
AF Chattopadhyay, Gouri
Shevach, Ethan M.
TI Antigen-Specific Induced T Regulatory Cells Impair Dendritic Cell
Function via an IL-10/MARCH1-Dependent Mechanism
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID MHC CLASS-II; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CUTTING EDGE;
IN-VITRO; FOXP3(+); INTERLEUKIN-10; EXPRESSION; MATURATION; INDUCTION;
CTLA-4
AB Foxp3(+) T regulatory cells (Tregs) are critically important for the maintenance of immunological tolerance, immune homeostasis, and prevention of autoimmunity. Dendritic cells (DCs) are one of the major targets of Treg-mediated suppression. Some studies have suggested that Treg-mediated suppression of DC function is mediated by the interaction of CTLA-4 on Tregs with CD80/CD86 on the DCs resulting in downregulation of CD80/CD86 expression and a decrease in costimulation. We have re-examined the effects of Tregs on mouse DC function in a model in which Ag-specific, induced Tregs (iTregs) are cocultured with DCs in the absence of T effector cells. iTreg-treated DCs are markedly defective in their capacity to activate naive T cells. iTregs from CTLA4-deficient mice failed to induce downregulation of CD80/CD86, but DCs treated with CTLA-4-deficient iTregs still exhibited impaired capacity to activate naive T cells. The iTreg-induced defect in DC function could be completely reversed by anti-IL-10, and IL-10-deficient iTregs failed to downregulate DC function. iTreg-treated DCs expressed high levels of MARCH1, an E3 ubiquitin ligase, recently found to degrade CD86 and MHC class II on the DCs and expressed lower levels of CD83, a molecule involved in neutralizing the function of MARCH1. Both the enhanced expression of MARCH1 and the decreased expression of CD83 were mediated by IL-10 produced by the iTregs. Taken together, these studies demonstrate that a major suppressive mechanism of DC function by iTregs is secondary to the effects of IL-10 on MARCH1 and CD83 expression.
C1 [Chattopadhyay, Gouri; Shevach, Ethan M.] NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA.
RP Shevach, EM (reprint author), NIAID, NIH, Bldg 10,Room 11N315,10 Ctr Dr,MSC 1892, Bethesda, MD 20892 USA.
EM eshevach@niaid.nih.gov
FU Division of Intramural Research, National Institute of Allergy and
Infectious Diseases
FX This work was supported by the Division of Intramural Research, National
Institute of Allergy and Infectious Diseases.
NR 38
TC 26
Z9 28
U1 0
U2 7
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 2013
VL 191
IS 12
BP 5875
EP 5884
DI 10.4049/jimmunol.1301693
PG 10
WC Immunology
SC Immunology
GA 272TM
UT WOS:000328483900014
PM 24218453
ER
PT J
AU Zhang, XR
Paun, A
Claudio, E
Wang, HS
Siebenlist, U
AF Zhang, Xiaoren
Paun, Andrea
Claudio, Estefania
Wang, Hongshan
Siebenlist, Ulrich
TI The Tumor Promoter and NF-kappa B Modulator Bcl-3 Regulates Splenic B
Cell Development
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID MARGINAL-ZONE; CYCLIN D1; T-CELLS; LYMPHOMA; GENE; TRANSCRIPTION;
EXPRESSION; PROLIFERATION; DEGRADATION; MACROPHAGES
AB Bcl-3 is an atypical member of the family of I kappa B proteins. Unlike the classic members, Bcl-3 functions as a nuclear transcriptional cofactor that may, depending on context, promote or suppress genes via association with p50/NF-kappa B1 or p52/NF-kappa B2 homodimers. Bcl-3 is also an oncogene, because it is a partner in recurrent translocations in B cell tumors, resulting in deregulated expression. Bcl-3 functions, however, remain poorly understood. We have investigated the role of Bcl-3 in B cells and discovered a previously unknown involvement in the splenic development of these cells. Loss of Bcl-3 in B cells resulted in significantly more marginal zone (MZ) and fewer follicular (FO) B cells. Conversely, transgenic expression of Bcl-3 in B cells generated fewer MZ and more FO B cells. Both Bcl-3(-/-) FO and MZ B cells were more responsive to LPS stimulation compared with their wild-type counterparts, including increased proliferation. By contrast, Bcl-3(-/-) FO B cells were more prone to apoptosis upon BCR stimulation, also limiting their expansion. The data reveal Bcl-3 as a regulator of B cell fate determination, restricting the MZ path and favoring the FO pathway, at least in part, via increased signal-specific survival of the latter, a finding of relevance to its tumorigenic activity.
C1 [Zhang, Xiaoren; Paun, Andrea; Claudio, Estefania; Wang, Hongshan; Siebenlist, Ulrich] NIAID, Lab Mol Immunol, NIH, Bethesda, MD 20892 USA.
[Zhang, Xiaoren] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Lab Stem Cell Biol, Shanghai 200031, Peoples R China.
[Zhang, Xiaoren] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200031, Peoples R China.
RP Siebenlist, U (reprint author), NIH, Bldg 10,Room 11B15A, Bethesda, MD 20892 USA.
EM xrzhang@sibs.ac.cn; usiebenlist@niaid.nih.gov
FU Intramural Research Program of the National Institute of Allergy and
Infectious Diseases, National Institutes of Health; National Basic
Research program [2014CB541904]; National Natural Science Foundation of
China [31370881]
FX This work was supported by the Intramural Research Program of the
National Institute of Allergy and Infectious Diseases, National
Institutes of Health; the National Basic Research program
(2014CB541904); and the National Natural Science Foundation of China
(31370881).
NR 49
TC 11
Z9 11
U1 0
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 2013
VL 191
IS 12
BP 5984
EP 5992
DI 10.4049/jimmunol.1300611
PG 9
WC Immunology
SC Immunology
GA 272TM
UT WOS:000328483900025
PM 24244019
ER
PT J
AU Jaiswal, H
Kaushik, M
Sougrat, R
Gupta, M
Dey, A
Verma, R
Ozato, K
Tailor, P
AF Jaiswal, Hemant
Kaushik, Monika
Sougrat, Rachid
Gupta, Monica
Dey, Anup
Verma, Rohit
Ozato, Keiko
Tailor, Prafullakumar
TI Batf3 and Id2 Have a Synergistic Effect on Irf8-Directed Classical CD8
alpha(+) Dendritic Cell Development
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID INTERFERON-PRODUCING CELLS; MYELOID PROGENITOR CELLS; SEQUENCE
BINDING-PROTEIN; TRANSCRIPTION FACTOR; REGULATORY FACTOR-8; IN-VIVO;
SUBSET DEVELOPMENT; M-CSF; MOUSE; EXPRESSION
AB Dendritic cells (DCs) are heterogeneous cell populations represented by different subtypes, each varying in terms of gene expression patterns and specific functions. Recent studies identified transcription factors essential for the development of different DC subtypes, yet molecular mechanisms for the developmental program and functions remain poorly understood. In this study, we developed and characterized a mouse DC progenitor-like cell line, designated DC9, from Irf8(-/-) bone marrow cells as a model for DC development and function. Expression of Irf8 in DC9 cells led to plasmacytoid DCs and CD8 alpha(+) DC-like cells, with a concomitant increase in plasmacytoid DC-and CD8 alpha(+) DC-specific gene transcripts and induction of type I IFNs and IL12p40 following TLR ligand stimulation. Irf8 expression in DC9 cells led to an increase in Id2 and Batf3 transcript levels, transcription factors shown to be important for the development of CD8 alpha(+) DCs. We show that, without Irf8, expression of Id2 and Batf3 was not sufficient for directing classical CD8 alpha(+) DC development. When coexpressed with Irf8, Batf3 and Id2 had a synergistic effect on classical CD8 alpha(+) DC development. We demonstrate that Irf8 is upstream of Batf3 and Id2 in the classical CD8 alpha(+) DC developmental program and define the hierarchical relationship of transcription factors important for classical CD8 alpha(+) DC development.
C1 [Jaiswal, Hemant; Kaushik, Monika; Verma, Rohit; Tailor, Prafullakumar] Natl Inst Immunol, Lab Innate Immun, New Delhi 110067, India.
[Sougrat, Rachid] King Abdullah Univ Sci & Technol, Nanobiol Lab, Thuwal 239556900, Saudi Arabia.
[Gupta, Monica; Dey, Anup; Ozato, Keiko] NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA.
RP Tailor, P (reprint author), Natl Inst Immunol, Lab Innate Immun, Aruna Asaf Ali Marg, New Delhi 110067, India.
EM tailorp@nii.ac.in
OI Sougrat, Rachid/0000-0001-6476-1886
FU National Institute of Immunology Core Fund; Council for Scientific and
Industrial Research, Government of India; Ramalingaswami Fellowship
FX This work was supported by the National Institute of Immunology Core
Fund. P.T. is a Ramalingaswami fellow, Department of Biotechnology,
"Government of India" at National Institute of Immunology. H.J. and R.V.
are supported by a fellowship from the Council for Scientific and
Industrial Research, Government of India. M.K. is supported by a
contingency grant of the Ramalingaswami Fellowship awarded to P.T.
NR 57
TC 11
Z9 11
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 2013
VL 191
IS 12
BP 5993
EP 6001
DI 10.4049/jimmunol.1203541
PG 9
WC Immunology
SC Immunology
GA 272TM
UT WOS:000328483900026
PM 24227775
ER
PT J
AU Malachowa, N
Kobayashi, SD
Freedman, B
Dorward, DW
DeLeo, FR
AF Malachowa, Natalia
Kobayashi, Scott D.
Freedman, Brett
Dorward, David W.
DeLeo, Frank R.
TI Staphylococcus aureus Leukotoxin GH Promotes Formation of Neutrophil
Extracellular Traps
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID PANTON-VALENTINE LEUKOCIDIN; HUMAN POLYMORPHONUCLEAR LEUKOCYTES;
IN-VIVO; GENE-EXPRESSION; INFECTION; LIPOPOLYSACCHARIDE; CONTRIBUTES;
ACTIVATION; GENERATION; LEUCOCIDIN
AB Staphylococcus aureus secretes numerous virulence factors that facilitate evasion of the host immune system. Among these molecules are pore-forming cytolytic toxins, including Panton-Valentine leukocidin (PVL), leukotoxin GH (LukGH; also known as LukAB), leukotoxin DE, and g-hemolysin. PVL and LukGH have potent cytolytic activity in vitro, and both toxins are proinflammatory in vivo. Although progress has been made toward elucidating the role of these toxins in S. aureus virulence, our understanding of the mechanisms that underlie the proinflammatory capacity of these toxins, as well as the associated host response toward them, is incomplete. To address this deficiency in knowledge, we assessed the ability of LukGH to prime human PMNs for enhanced bactericidal activity and further investigated the impact of the toxin on neutrophil function. We found that, unlike PVL, LukGH did not prime human neutrophils for increased production of reactive oxygen species nor did it enhance binding and/or uptake of S. aureus. Unexpectedly, LukGH promoted the release of neutrophil extracellular traps (NETs), which, in turn, ensnared but did not kill S. aureus. Furthermore, we found that electropermeabilization of human neutrophils, used as a separate means to create pores in the neutrophil plasma membrane, similarly induced formation of NETs, a finding consistent with the notion that NETs can form during nonspecific cytolysis. We propose that the ability of LukGH to promote formation of NETs contributes to the inflammatory response and host defense against S. aureus infection.
C1 [Malachowa, Natalia; Kobayashi, Scott D.; Freedman, Brett; DeLeo, Frank R.] NIAID, Lab Bacterial Pathogenesis, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.
[Dorward, David W.] NIAID, Microscopy Unit, Res Technol Branch, Rocky Mt Labs,NIH, Hamilton, MT 59840 USA.
RP DeLeo, FR (reprint author), NIAID, Lab Human Bacterial Pathogenesis, Rocky Mt Labs, NIH, 903 South 4th St, Hamilton, MT 59840 USA.
EM fdeleo@niaid.nih.gov
OI DeLeo, Frank/0000-0003-3150-2516
FU Intramural Research Program of the National Institute of Allergy and
Infectious Diseases, National Institutes of Health
FX This work was supported by the Intramural Research Program of the
National Institute of Allergy and Infectious Diseases, National
Institutes of Health.
NR 42
TC 27
Z9 27
U1 1
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 2013
VL 191
IS 12
BP 6022
EP 6029
DI 10.4049/jimmunol.1301821
PG 8
WC Immunology
SC Immunology
GA 272TM
UT WOS:000328483900029
PM 24190656
ER
PT J
AU Munitic, I
Torchia, MLG
Meena, NP
Zhu, GZ
Li, CC
Ashwell, JD
AF Munitic, Ivana
Torchia, Maria Letizia Giardino
Meena, Netra Pal
Zhu, Guozhi
Li, Caiyi C.
Ashwell, Jonathan D.
TI Optineurin Insufficiency Impairs IRF3 but Not NF-kappa B Activation in
Immune Cells
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID SEVERE LIVER DEGENERATION; OPEN-ANGLE GLAUCOMA; GENE-EXPRESSION;
POLYUBIQUITIN BINDING; SIGNALING PATHWAY; VIRAL-INFECTION; MICE LACKING;
NEURAL-TUBE; IKK-EPSILON; MYOSIN-VI
AB Optineurin is a widely expressed polyubiquitin-binding protein that has been implicated in regulating cell signaling via its NF-kappa B essential modulator-homologous C-terminal ubiquitin (Ub)-binding region. Its functions are controversial, with in vitro studies finding that optineurin suppressed TNF-mediated NF-kappa B activation and virus-induced activation of IFN regulatory factor 3 (IRF3), whereas bone marrow-derived macrophages (BMDMs) from mice carrying an optineurin Ub-binding point mutation had normal TLR-mediated NF-kappa B activation and diminished IRF3 activation. We have generated a mouse model in which the entire Ub-binding C-terminal region is deleted (Optn(470T)). Akin to C-terminal optineurin mutations found in patients with certain neurodegenerative diseases, Optn(470T) was expressed at substantially lower levels than the native protein, allowing assessment not only of the lack of Ub binding, but also of protein insufficiency. Embryonic lethality with incomplete penetrance was observed for 129 x C57BL/6 Optn(470T)/(470T) mice, but after further backcrossing to C57BL/6, offspring viability was restored. Moreover, the mice that survived were indistinguishable from wild type littermates and had normal immune cell distributions. Activation of NF-kappa B in Optn(470T) BMDM and BM-derived dendritic cells with TNF or via TLR4, T cells via the TCR, and B cells with LPS or anti-CD40 was normal. In contrast, optineurin and/or its Ub-binding function was necessary for optimal TANK binding kinase 1 and IRF3 activation, and both Optn(470T) BMDMs and bone marrow-derived dendritic cells had diminished IFN-beta production upon LPS stimulation. Importantly, Optn(470T) mice produced less IFN-beta upon LPS challenge. Therefore, endogenous optineurin is dispensable for NF-kappa B activation but necessary for optimal IRF3 activation in immune cells.
C1 [Munitic, Ivana; Torchia, Maria Letizia Giardino; Meena, Netra Pal; Zhu, Guozhi; Li, Caiyi C.; Ashwell, Jonathan D.] NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA.
RP Ashwell, JD (reprint author), NCI, Lab Immune Cell Biol, NIH, Bethesda, MD 20892 USA.
EM ivana.munitic@biotech.uniri.hr; jda@pop.nci.nih.gov
FU Intramural Research Program of the Center for Cancer Research, National
Cancer Institute, National Institutes of Health
FX This work was supported by the Intramural Research Program of the Center
for Cancer Research, National Cancer Institute, National Institutes of
Health.
NR 68
TC 20
Z9 21
U1 0
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 2013
VL 191
IS 12
BP 6231
EP 6240
DI 10.4049/jimmunol.1301696
PG 10
WC Immunology
SC Immunology
GA 272TM
UT WOS:000328483900050
PM 24244017
ER
PT J
AU Lundqvist, A
Smith, AL
Takahashi, Y
Wong, S
Bahceci, E
Cook, L
Ramos, C
Tawab, A
McCoy, JP
Read, EJ
Khuu, HM
Bolan, CD
Joo, J
Geller, N
Leitman, SF
Calandra, G
Dunbar, C
Kurlander, R
Childs, RW
AF Lundqvist, Andreas
Smith, Aleah L.
Takahashi, Yoshiyuki
Wong, Susan
Bahceci, Erkut
Cook, Lisa
Ramos, Catalina
Tawab, Abdul
McCoy, J. Philip, Jr.
Read, Elizabeth J.
Khuu, Hanh M.
Bolan, Charles D.
Joo, Jungnam
Geller, Nancy
Leitman, Susan F.
Calandra, Gary
Dunbar, Cynthia
Kurlander, Roger
Childs, Richard W.
TI Differences in the Phenotype, Cytokine Gene Expression Profiles, and In
Vivo Alloreactivity of T Cells Mobilized with Plerixafor Compared with
G-CSF
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID VERSUS-HOST-DISEASE; BLOOD STEM-CELLS; HEMATOPOIETIC PROGENITOR CELLS;
PERIPHERAL-BLOOD; BONE-MARROW; ALLOGENEIC TRANSPLANTATION; HEMATOLOGICAL
MALIGNANCIES; HEALTHY-VOLUNTEERS; CXCR4 ANTAGONIST; RANDOMIZED-TRIAL
AB Plerixafor (Mozobil) is a CXCR4 antagonist that rapidly mobilizes CD34(+) cells into circulation. Recently, plerixafor has been used as a single agent to mobilize peripheral blood stem cells for allogeneic hematopoietic cell transplantation. Although G-CSF mobilization is known to alter the phenotype and cytokine polarization of transplanted T cells, the effects of plerixafor mobilization on T cells have not been well characterized. In this study, we show that alterations in the T cell phenotype and cytokine gene expression profiles characteristic of G-CSF mobilization do not occur after mobilization with plerixafor. Compared with non-mobilized T cells, plerixafor-mobilized T cells had similar phenotype, mixed lymphocyte reactivity, and Foxp3 gene expression levels in CD4(+) T cells, and did not undergo a change in expression levels of 84 genes associated with Th1/Th2/Th3 pathways. In contrast with plerixafor, G-CSF mobilization decreased CD62L expression on both CD4 and CD8(+) T cells and altered expression levels of 16 cytokine-associated genes in CD3(+) T cells. To assess the clinical relevance of these findings, we explored a murine model of graft-versus-host disease in which transplant recipients received plerixafor or G-CSF mobilized allograft from MHC-matched, minor histocompatibility-mismatched donors; recipients of plerixafor mobilized peripheral blood stem cells had a significantly higher incidence of skin graft-versus-host disease compared with mice receiving G-CSF mobilized transplants (100 versus 50%, respectively, p = 0.02). These preclinical data show plerixafor, in contrast with G-CSF, does not alter the phenotype and cytokine polarization of T cells, which raises the possibility that T cell-mediated immune sequelae of allogeneic transplantation in humans may differ when donor allografts are mobilized with plerixafor compared with G-CSF.
C1 [Lundqvist, Andreas; Smith, Aleah L.; Wong, Susan; Cook, Lisa; Ramos, Catalina; McCoy, J. Philip, Jr.; Dunbar, Cynthia; Childs, Richard W.] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.
[Lundqvist, Andreas] Karolinska Inst, Dept Oncol Pathol, S-17176 Stockholm, Sweden.
[Takahashi, Yoshiyuki] Nagoya Univ, Grad Sch Med, Nagoya, Aichi 4668550, Japan.
[Bahceci, Erkut] Yale Univ, Sch Med, Sect Med Oncol, New Haven, CT 06520 USA.
[Tawab, Abdul; Kurlander, Roger] NIH, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA.
[Read, Elizabeth J.; Khuu, Hanh M.; Bolan, Charles D.; Joo, Jungnam; Geller, Nancy; Leitman, Susan F.] NIH, Dept Transfus Med, Ctr Clin, Bethesda, MD 20892 USA.
[Calandra, Gary] Sanofi Oncol, Cambridge, MA 02139 USA.
RP Childs, RW (reprint author), NHLBI, Hematol Branch, NIH, 10CRC,3-5330, Bethesda, MD 20892 USA.
EM childsr@nhlbi.nih.gov
OI Lundqvist, Andreas/0000-0002-9709-2970
FU National Institutes of Health, National Heart, Lung, and Blood
Institute, Hematology Branch; Swedish and European Research Councils
FX This work was supported by the intramural research program of the
National Institutes of Health, National Heart, Lung, and Blood
Institute, Hematology Branch and the Swedish and European Research
Councils (A.L.).
NR 45
TC 10
Z9 10
U1 0
U2 3
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 2013
VL 191
IS 12
BP 6241
EP 6249
DI 10.4049/jimmunol.1301148
PG 9
WC Immunology
SC Immunology
GA 272TM
UT WOS:000328483900051
PM 24244025
ER
PT J
AU Yaniv, Y
AF Yaniv, Yael
TI Cardiac troponin I phosphorylation and the force-length relationship
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Editorial Material
ID GENERATION; DEPENDENCE
C1 Natl Inst Aging, Program, Biomed Res Ctr, Lab Cardiovascular Sci, Baltimore, MD USA.
RP Yaniv, Y (reprint author), Natl Inst Aging, Program, Biomed Res Ctr, Lab Cardiovascular Sci, Baltimore, MD USA.
EM yanivyael@gmail.com
RI Yaniv, Yael/B-3311-2015
OI Yaniv, Yael/0000-0002-5183-6284
FU Intramural NIH HHS
NR 9
TC 0
Z9 0
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
EI 1469-7793
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD DEC 15
PY 2013
VL 591
IS 24
BP 6135
EP 6136
DI 10.1113/jphysiol.2013.265090
PG 2
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA 274BI
UT WOS:000328579700007
PM 24339151
ER
PT J
AU Seo, YJ
Muench, L
Reid, A
Chen, JZ
Kang, YN
Hooker, JM
Volkow, ND
Fowler, JS
Kim, SW
AF Seo, Young Jun
Muench, Lisa
Reid, Alicia
Chen, Jinzhu
Kang, Yeona
Hooker, Jacob M.
Volkow, Nora D.
Fowler, Joanna S.
Kim, Sung Won
TI Radionuclide labeling and evaluation of candidate radioligands for PET
imaging of histone deacetylase in the brain
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Carbon-11; Positron emission tomography; SAHA; Brain; Epigenetics; Brain
permeability
ID TRICHOSTATIN-A; INHIBITORS; POTENT; RADIOSYNTHESIS; MECHANISMS;
DISORDERS; EFFICIENT; ESTERS; MS-275
AB Histone deacetylases (HDACs) regulate gene expression by inducing conformational changes in chromatin. Ever since the discovery of a naturally occurring HDAC inhibitor, trichostatin A (TSA) stimulated the recent development of suberoylanilide (SAHA, Zolinza (R)), HDAC has become an important molecular target for drug development. This has created the need to develop specific in vivo radioligands to study epigenetic regulation and HDAC engagement for drug development for diseases including cancer and disorders. 6-([F-18]Fluoroacetamido)-1-hexanoicanilide ([F-18]FAHA) was recently developed as a HDAC substrate and shows moderate blood-brain barrier (BBB) permeability and specific signal (by metabolic trapping/or deacetylation) but rapid metabolism. Here, we report the radiosynthesis of two carbon-11 labeled candidate radiotracers (substrate-and inhibitor-based radioligand) for HDAC and their evaluation in non-human primate brain. PET studies showed very low brain uptake and rapid metabolism of both labeled compounds but revealed a surprising enhancement of brain penetration by F for H substitution when comparing one of these to [F-18]FAHA. Further structural refinement is needed for the development of brain-penetrant, metabolically stable HDAC radiotracers and to understand the role of fluorine substitution on brain penetration. Published by Elsevier Ltd.
C1 [Seo, Young Jun; Chen, Jinzhu; Kang, Yeona; Fowler, Joanna S.] Brookhaven Natl Lab, Dept Biosci, Upton, NY 11973 USA.
[Seo, Young Jun] Chonbuk Natl Univ, Dept Chem, Jeonju 561756, South Korea.
[Muench, Lisa; Volkow, Nora D.; Kim, Sung Won] NIAAA, Lab Neuroimaging, Bethesda, MD 20892 USA.
[Reid, Alicia] CUNY Medgar Evers Coll, Dept Phys Environm & Comp Sci, Brooklyn, NY 11225 USA.
[Hooker, Jacob M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Charlestown, MA 02129 USA.
[Volkow, Nora D.] NIDA, Rockville, MD 20852 USA.
RP Hooker, JM (reprint author), NIAAA, 10 Ctr Dr,Rm B2L304, Bethesda, MD 20892 USA.
EM hooker@nmr.mgh.harvard.edu; sunny.kim@nih.gov
OI Hooker, Jacob/0000-0002-9394-7708
FU DOE [BR KP1503010]; NIH [1R01DA030321]; U.S. Department of Energy
[DEAC02-98CH10886]; National Institute on Alcohol Abuse and Alcoholism
FX This work was supported by DOE grant B&R KP1503010 and NIH grant
1R01DA030321. In addition, the work at Brookhaven National Laboratory
was performed under contract DEAC02-98CH10886 with the U.S. Department
of Energy, and with infrastructure support from its Office of Biological
and Environmental Research. Salary support for SWK and LM was provided
by the intramural program of the National Institute on Alcohol Abuse and
Alcoholism. We are grateful to the PET radiotracer and imaging team at
BNL (Dr. Michael Schueller, David Alexoff, Colleen Shea, Youwen Xu,
Pauline Carter, Payton King, Barbara Hubbard and Don Warner) for
carrying out primate imaging experiments. We used two computational
chemistry programs available in the Center for Molecular Modeling
(http://cmm.cit.nih.gov) and the Helix Systems (http://helix.nih.gov) at
the National Institutes of Health, Bethesda, MD.
NR 30
TC 10
Z9 10
U1 3
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD DEC 15
PY 2013
VL 23
IS 24
BP 6700
EP 6705
DI 10.1016/j.bmcl.2013.10.038
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 263DU
UT WOS:000327787700033
PM 24210501
ER
PT J
AU Magill, SS
Klompas, M
Balk, R
Burns, SM
Deutschman, CS
Diekema, D
Fridkin, S
Greene, L
Guh, A
Gutterman, D
Hammer, B
Henderson, D
Hess, D
Hill, NS
Horan, T
Kollef, M
Levy, M
Septimus, E
VanAntwerpen, C
Wright, D
Lipsett, P
AF Magill, Shelley S.
Klompas, Michael
Balk, Robert
Burns, Suzanne M.
Deutschman, Clifford S.
Diekema, Daniel
Fridkin, Scott
Greene, Linda
Guh, Alice
Gutterman, David
Hammer, Beth
Henderson, David
Hess, Dean
Hill, Nicholas S.
Horan, Teresa
Kollef, Marin
Levy, Mitchell
Septimus, Edward
VanAntwerpen, Carole
Wright, Don
Lipsett, Pamela
TI Developing a New, National Approach to Surveillance for
Ventilator-Associated Events: Executive Summary
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
DE ventilator-associated pneumonia; intensive care unit; epidemiology;
public health; critical care; mechanical ventilation
C1 [Magill, Shelley S.; Fridkin, Scott; Guh, Alice; Horan, Teresa] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA.
[Klompas, Michael] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA.
[Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
[Klompas, Michael] Brigham & Womens Hosp, Infect Control Dept, Boston, MA 02115 USA.
[Klompas, Michael] Soc Healthcare Epidemiol Amer, Arlington, VA USA.
[Balk, Robert] Rush Univ, Sch Med, Div Pulm & Crit Care Med, Chicago, IL 60612 USA.
[Balk, Robert; Burns, Suzanne M.; Deutschman, Clifford S.; Gutterman, David; Hammer, Beth; Hill, Nicholas S.; Kollef, Marin; Levy, Mitchell; Lipsett, Pamela] Crit Care Soc Collaborat Amer Assoc Crit Care Nur, Charlottesville, VA USA.
[Burns, Suzanne M.] Univ Virginia, Sch Nursing Crit & Acute Care, Charlottesville, VA USA.
[Deutschman, Clifford S.] Univ Penn, Perelman Sch Med, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA.
[Diekema, Daniel] Univ Iowa, Carver Coll Med, Div Infect Dis, Iowa City, IA USA.
[Diekema, Daniel] Healthcare Infect Control Practices Advisory Comm, Atlanta, GA USA.
[Greene, Linda] Rochester Gen Hlth Syst, Infect Prevent & Control Dept, Rochester, NY USA.
[Greene, Linda] Assoc Profess Infect Control & Epidemiol, Washington, DC USA.
[Gutterman, David] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA.
[Hammer, Beth] Zablocki VA Med Ctr, Dept Cardiol, Milwaukee, WI USA.
[Henderson, David] NIH, Hosp Epidemiol & Qual Improvement, Ctr Clin, Bethesda, MD 20892 USA.
[Hess, Dean] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA.
[Hess, Dean] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA.
[Hess, Dean] Amer Assoc Resp Care, Irving, TX USA.
[Hill, Nicholas S.] Tufts Med Ctr, Div Pulm & Crit Care Med, Boston, MA USA.
[Kollef, Marin] Washington Univ, Div Pulm & Crit Care Med, St Louis, MO USA.
[Levy, Mitchell] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Div Pulm Crit Care & Sleep, Providence, RI 02903 USA.
[Septimus, Edward] Texas A&M Hlth Sci Ctr, Dept Internal Med, College Stn, TX USA.
[Septimus, Edward] Infect Dis Soc Amer, Arlington, VA USA.
[VanAntwerpen, Carole] New York State Dept Hlth, Bur Healthcare Associated Infect, Albany, NY USA.
[VanAntwerpen, Carole] Council State & Terr Epidemiologists, Atlanta, GA USA.
[Wright, Don] US Dept HHS, Off Dis Prevent & Hlth Promot, Washington, DC 20201 USA.
[Lipsett, Pamela] Johns Hopkins Univ, Sch Med, Dept Surg Anesthesiol & Crit Care Med, Baltimore, MD USA.
RP Magill, SS (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-24, Atlanta, GA 30329 USA.
EM smagill@cdc.gov
NR 2
TC 12
Z9 13
U1 1
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD DEC 15
PY 2013
VL 57
IS 12
BP 1742
EP 1746
DI 10.1093/cid/cit577
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 262FT
UT WOS:000327720400013
PM 24280662
ER
PT J
AU Mullis, CE
Laeyendecker, O
Reynolds, SJ
Ocama, P
Quinn, J
Boaz, I
Gray, RH
Kirk, GD
Thomas, DL
Quinn, TC
Stabinski, L
AF Mullis, Caroline E.
Laeyendecker, Oliver
Reynolds, Steven J.
Ocama, Ponsiano
Quinn, Jeffrey
Boaz, Iga
Gray, Ronald H.
Kirk, Gregory D.
Thomas, David L.
Quinn, Thomas C.
Stabinski, Lara
TI High Frequency of False-Positive Hepatitis C Virus Enzyme-Linked
Immunosorbent Assay in Rakai, Uganda
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE hepatitis C virus; ELISA; Africa
ID HIV; EPIDEMIOLOGY; PREVALENCE; INFECTION; PERFORMANCE; ANTIBODIES;
AFRICA
AB The prevalence of hepatitis C virus (HCV) infection in sub-Saharan Africa remains unclear. We tested 1000 individuals from Rakai, Uganda, with the Ortho version 3.0 HCV enzyme-linked immunosorbent assay. All serologically positive samples were tested for HCV RNA. Seventy-six of the 1000 (7.6%) participants were HCV antibody positive; none were confirmed by detection of HCV RNA.
C1 [Mullis, Caroline E.; Laeyendecker, Oliver; Reynolds, Steven J.; Quinn, Jeffrey; Thomas, David L.; Quinn, Thomas C.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Laeyendecker, Oliver; Reynolds, Steven J.; Quinn, Thomas C.; Stabinski, Lara] NIAID, Div Intramural Res, NIH, Baltimore, MD USA.
[Ocama, Ponsiano] Makerere Univ, Dept Med, Kampala, Uganda.
[Boaz, Iga] Rakai Hlth Sci Program, Entebbe, Uganda.
[Gray, Ronald H.; Kirk, Gregory D.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
RP Laeyendecker, O (reprint author), NIAID, LIR, NIH, 855 N Wolfe St,Rm 538A, Baltimore, MD USA.
EM olaeyen1@jhmi.edu
OI Laeyendecker, Oliver/0000-0002-6429-4760
FU Division of Intramural Research, National Institute of Allergy and
Infectious Diseases (NIAID), National Institutes of Health (NIH); HIV
Prevention Trials Network; NIAID; Eunice Kennedy Shriver National
Institute of Child Health and Human Development; National Institute on
Drug Abuse; National Institute of Mental Health; Office of AIDS
Research, of the NIH; Department of Health and Human Services
[UM1-AI068613, R37 DA 13806]
FX This work was supported by the Division of Intramural Research, National
Institute of Allergy and Infectious Diseases (NIAID), National
Institutes of Health (NIH). Additional support was provided by the HIV
Prevention Trials Network sponsored by the NIAID, the Eunice Kennedy
Shriver National Institute of Child Health and Human Development, the
National Institute on Drug Abuse, the National Institute of Mental
Health, and the Office of AIDS Research, of the NIH, Department of
Health and Human Services (UM1-AI068613 and R37 DA 13806).
NR 11
TC 16
Z9 16
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
EI 1537-6591
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD DEC 15
PY 2013
VL 57
IS 12
BP 1747
EP 1750
DI 10.1093/cid/cit602
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 262FT
UT WOS:000327720400014
PM 24051866
ER
PT J
AU Platt, JL
Rogers, BJ
Rogers, KC
Harwood, AJ
Kimmel, AR
AF Platt, James L.
Rogers, Benjamin J.
Rogers, Kelley C.
Harwood, Adrian J.
Kimmel, Alan R.
TI Different CHD chromatin remodelers are required for expression of
distinct gene sets and specific stages during development of
Dictyostelium discoideum
SO DEVELOPMENT
LA English
DT Article
DE SNF2; Transcriptome profiling; RNA-seq; Chemotaxis; Growth;
Differentiation
ID CHARGE SYNDROME; SACCHAROMYCES-CEREVISIAE; SNF2 FAMILY; GROUP-SIZE;
PROTEIN; CHEMOTAXIS; MUTATIONS; DOMAIN; CHROMODOMAINS; TRANSCRIPTION
AB Control of chromatin structure is crucial for multicellular development and regulation of cell differentiation. The CHD (chromodomain-helicase-DNA binding) protein family is one of the major ATP-dependent, chromatin remodeling factors that regulate nucleosome positioning and access of transcription factors and RNA polymerase to the eukaryotic genome. There are three mammalian CHD subfamilies and their impaired functions are associated with several human diseases. Here, we identify three CHD orthologs (ChdA, ChdB and ChdC) in Dictyostelium discoideum. These CHDs are expressed throughout development, but with unique patterns. Null mutants lacking each CHD have distinct phenotypes that reflect their expression patterns and suggest functional specificity. Accordingly, using genome-wide (RNA-seq) transcriptome profiling for each null strain, we show that the different CHDs regulate distinct gene sets during both growth and development. ChdC is an apparent ortholog of the mammalian Class III CHD group that is associated with the human CHARGE syndrome, and GO analyses of aberrant gene expression in chdC nulls suggest defects in both cell-autonomous and non-autonomous signaling, which have been confirmed through analyses of chdC nulls developed in pure populations or with low levels of wild-type cells. This study provides novel insight into the broad function of CHDs in the regulation development and disease, through chromatin-mediated changes in directed gene expression.
C1 [Platt, James L.; Rogers, Kelley C.; Kimmel, Alan R.] NIDDK, Lab Cellular & Dev Biol, NIH, Bethesda, MD 20892 USA.
[Platt, James L.; Rogers, Benjamin J.; Harwood, Adrian J.] Cardiff Univ, Sch Biosci, Cardiff CF10 3AX, S Glam, Wales.
RP Harwood, AJ (reprint author), Cardiff Univ, Sch Biosci, Museum Ave, Cardiff CF10 3AX, S Glam, Wales.
EM harwoodaj@cf.ac.uk; alank@helix.nih.gov
OI Harwood, Adrian/0000-0003-3124-5169
FU National Institutes of Health (NIH); National Institute of Diabetes and
Digestive and Kidney Diseases; Wellcome Trust/NIH
FX This research was supported by the Intramural Research Program of the
National Institutes of Health (NIH), the National Institute of Diabetes
and Digestive and Kidney Diseases, and a Wellcome Trust/NIH Programme
Studentship to J.L.P. Deposited in PMC for immediate release.
NR 74
TC 3
Z9 3
U1 0
U2 7
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 0950-1991
EI 1477-9129
J9 DEVELOPMENT
JI Development
PD DEC 15
PY 2013
VL 140
IS 24
BP 4926
EP 4936
DI 10.1242/dev.099879
PG 11
WC Developmental Biology
SC Developmental Biology
GA 264PR
UT WOS:000327892200011
PM 24301467
ER
PT J
AU Sanders, AR
Goring, HHH
Duan, JB
Drigalenko, EI
Moy, W
Freda, J
He, DL
Shi, JX
Gejman, PV
AF Sanders, Alan R.
Goering, Harald H. H.
Duan, Jubao
Drigalenko, Eugene I.
Moy, Winton
Freda, Jessica
He, Deli
Shi, Jianxin
Gejman, Pablo V.
CA MGS
TI Transcriptome study of differential expression in schizophrenia
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; FUNCTIONAL PROMOTER POLYMORPHISM; GLOBAL
GENE-EXPRESSION; HISTONE MESSENGER-RNAS; OF-THE-LITERATURE;
AUTOIMMUNE-DISEASES; BIPOLAR DISORDER; CELL-CYCLE; RHEUMATOID-ARTHRITIS;
MULTIPLE-SCLEROSIS
AB Schizophrenia genome-wide association studies (GWAS) have identified common SNPs, rare copy number variants (CNVs) and a large polygenic contribution to illness risk, but biological mechanisms remain unclear. Bioinformatic analyses of significantly associated genetic variants point to a large role for regulatory variants. To identify gene expression abnormalities in schizophrenia, we generated whole-genome gene expression profiles using microarrays on lymphoblastoid cell lines (LCLs) from 413 cases and 446 controls. Regression analysis identified 95 transcripts differentially expressed by affection status at a genome-wide false discovery rate (FDR) of 0.05, while simultaneously controlling for confounding effects. These transcripts represented 89 genes with functions such as neurotransmission, gene regulation, cell cycle progression, differentiation, apoptosis, microRNA (miRNA) processing and immunity. This functional diversity is consistent with schizophrenia's likely significant pathophysiological heterogeneity. The overall enrichment of immune-related genes among those differentially expressed by affection status is consistent with hypothesized immune contributions to schizophrenia risk. The observed differential expression of extended major histocompatibility complex (xMHC) region histones (HIST1H2BD, HIST1H2BC, HIST1H2BH, HIST1H2BG and HIST1H4K) converges with the genetic evidence from GWAS, which find the xMHC to be the most significant susceptibility locus. Among the differentially expressed immune-related genes, B3GNT2 is implicated in autoimmune disorders previously tied to schizophrenia risk (rheumatoid arthritis and Graves' disease), and DICER1 is pivotal in miRNA processing potentially linking to miRNA alterations in schizophrenia (e. g. MIR137, the second strongest GWAS finding). Our analysis provides novel candidate genes for further study to assess their potential contribution to schizophrenia.
C1 [Sanders, Alan R.; Duan, Jubao; Moy, Winton; Freda, Jessica; He, Deli; Gejman, Pablo V.] NorthShore Univ HealthSyst, Dept Psychiat & Behav Sci, Evanston, IL 60201 USA.
[Sanders, Alan R.; Duan, Jubao; Gejman, Pablo V.] Univ Chicago, Dept Psychiat & Behav Sci, Chicago, IL 60637 USA.
[Goering, Harald H. H.; Drigalenko, Eugene I.] Texas Biomed Res Inst, Dept Genet, San Antonio, TX 78227 USA.
[Shi, Jianxin] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[MGS] Mol Genet Schizophrenia MGS Collaborat, Evanston, IL 60201 USA.
RP Sanders, AR (reprint author), 1001 Univ Pl, Evanston, IL 60201 USA.
EM alan.sanders.md@gmail.com
FU National Institutes of Health (NIH) [RC2MH090030, R01MH067257, R01MH
059588, R01MH059571, R01MH059565, R01MH059587, R01MH060870, R01M
H059566, R01MH059586, R01MH061675, R01MH060879, R01MH081800,
U01MH046276, U01MH046289, U01MH046318, U01MH079469, U01MH079470, U54RR
020278, RR017515]; Genetic Association Information Network (GAIN); Paul
Michael Donovan Charitable Foundation
FX This work was supported primarily by the National Institutes of Health
(NIH grant RC2MH090030 to A. R. S.); as well as for MGS by NIH grants
(R01MH067257 to N.G.B., R01MH 059588 to B.J.M., R01MH059571 to P. V. G.,
R01MH059565 to R. F., R01MH059587 to F. A., R01MH060870 to W. F. B.,
R01M H059566 to D. W. B., R01MH059586 to J.M.S., R01MH061675 to D. F.
L., R01MH060879 to C. R. C., R01MH081800 to P. V. G., U01MH046276 to C.
R. C., U01MH046289 to C. Kaufmann, U01MH046318 to M. T. Tsuang,
U01MH079469 to P. V. G. and U01MH079470 to D. F. L.), the Genetic
Association Information Network (GAIN, for genotyping of half of the EA
sample and almost all the AA sample), and The Paul Michael Donovan
Charitable Foundation. Genotyping was carried out by the Center for
Genotyping and Analysis at the Broad Institute of Harvard and MIT (S. G.
and D. B. M.), supported by NIH grant U54RR 020278. Analyses done in San
Antonio (E. I. D., H. H. H. G.) were conducted in facilities constructed
with support from NIH grant RR017515, and a gift from the AT&T
Foundation. The funders had no role in study design, data collection and
analysis, decision to publish or preparation of the manuscript.
NR 173
TC 27
Z9 27
U1 5
U2 25
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 15
PY 2013
VL 22
IS 24
BP 5001
EP 5014
DI 10.1093/hmg/ddt350
PG 14
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 259QY
UT WOS:000327542600011
PM 23904455
ER
PT J
AU Wang, HS
Haiman, CA
Burnett, T
Fortini, BK
Kolonel, LN
Henderson, BE
Signorello, LB
Blot, WJ
Keku, TO
Berndt, SI
Newcomb, PA
Pande, M
Amos, CI
West, DW
Casey, G
Sandler, RS
Haile, R
Stram, DO
Le Marchand, L
AF Wang, Hansong
Haiman, Christopher A.
Burnett, Terrilea
Fortini, Barbara K.
Kolonel, Laurence N.
Henderson, Brian E.
Signorello, Lisa B.
Blot, William J.
Keku, Temitope O.
Berndt, Sonja I.
Newcomb, Polly A.
Pande, Mala
Amos, Christopher I.
West, Dee W.
Casey, Graham
Sandler, Robert S.
Haile, Robert
Stram, Daniel O.
Le Marchand, Loic
TI Fine-mapping of genome-wide association study-identified risk loci for
colorectal cancer in African Americans
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID SUSCEPTIBILITY LOCI; GENETIC ASSOCIATION; CHINESE POPULATION; WINNERS
CURSE; VARIANTS; METAANALYSIS; SCAN; 8Q24; PARAMETERS; ALLELES
AB Genome-wide association studies of colorectal cancer (CRC) in Europeans and Asians have identified 21 risk susceptibility regions [ 29 index single-nucleotide polymorphisms (SNPs)]. Characterizing these risk regions in diverse racial groups with different linkage disequilibrium (LD) structure can help localize causal variants. We examined associations between CRC and all 29 index SNPs in 6597 African Americans (1894 cases and 4703 controls). Nine SNPs in eight regions(5q31.1, 6q26-q27, 8q23.3, 8q24.21, 11q13.4, 15q13.3, 18q21.1 and 20p12.3) formally replicated in our data with one-sided P-values <0.05 and the same risk directions as reported previously. We performed fine-mapping of the 21 risk regions(including 250 kb on both sides of the index SNPs) using genotyped and imputed markers at the density of the 1000 Genomes Project to search for additional or more predictive risk markers. Among the SNPs correlated with the index variants, two markers, rs12759486 (or rs7547751, a putative functional variant in perfect LD with it) in 1q41 and rs7252505 in 19q13.1, were more strongly and statistically significantly associated with CRC (P < 0.0006). The average per allele risk was improved using the replicated index variants and the two new markers (odds ratio 5 1.14, P = 6.5 x 10(-16)) in African Americans, compared with using all index SNPs (odds ratio = 1.07, P = 3.4 x 10(-10)). The contribution of the two new risk SNPs to CRC heritability was estimated to be 1.5% in African Americans. This study highlights the importance of fine-mapping in diverse populations.
C1 [Wang, Hansong; Burnett, Terrilea; Kolonel, Laurence N.; Le Marchand, Loic] Univ Hawaii, Ctr Canc, Program Epidemiol, Honolulu, HI 96813 USA.
[Haiman, Christopher A.; Fortini, Barbara K.; Henderson, Brian E.; Casey, Graham; Stram, Daniel O.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Haiman, Christopher A.; Fortini, Barbara K.; Henderson, Brian E.; Casey, Graham; Stram, Daniel O.] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
[Signorello, Lisa B.; Blot, William J.] Int Epidemiol Inst, Rockville, MD USA.
[Signorello, Lisa B.; Blot, William J.] Vanderbilt Univ, Dept Med, Div Epidemiol, Vanderbilt Epidemiol Ctr, Nashville, TN USA.
[Signorello, Lisa B.; Blot, William J.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Keku, Temitope O.; Sandler, Robert S.] Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC USA.
[Berndt, Sonja I.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Newcomb, Polly A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Pande, Mala] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
[Amos, Christopher I.] Dartmouth Coll, Geisel Sch Med, Dept Community & Family Med, Lebanon, NH 03756 USA.
[West, Dee W.] Canc Prevent Inst Calif, Fremont, CA USA.
[Haile, Robert] Stanford Canc Inst, Stanford, CA USA.
RP Wang, HS (reprint author), Univ Hawaii, Ctr Canc, 701 Ilalo St, Honolulu, HI 96813 USA.
EM hansongw@hawaii.edu
FU National Cancer Institute (NCI) [R01CA126895, R01CA126895-S1,
R01CA104132]; California Breast Cancer Research Program grant
[15UB-8402]; NCI [UM1CA164973, R37CA54281, P01CA33619, R01CA 63464,
U01CA074799, U01CA074794, U01CA074806, R01CA092447, U01CA93326,
R01CA66635, K07CA160753]; MD Anderson University Cancer Fund; MD
Anderson Cancer Center Duncan Family Institute for Cancer Prevention and
Risk Assessment; Center for Clinical and Translational Sciences of the
University of Texas Health Science Center at Houston; NCI Cancer Center
Support Grant [CA16672]
FX This work was supported by National Cancer Institute (NCI) grants
(R01CA126895, R01CA126895-S1 and R01CA104132) and California Breast
Cancer Research Program grant (15UB-8402). The MEC study is funded by
NCI grants (UM1CA164973, R37CA54281, P01CA33619 and R01CA 63464). The
CCFR studies included were funded by NCI grants (U01CA074799 to Familial
Colorectal Neoplasia Collaborative Group at University of Southern
California, U01CA074794 to Seattle Colorectal Cancer Family Registry and
U01CA074806 to University of Hawaii Colorectal Cancer Family Registry).
The SCCS was funded by NCI grant (R01CA092447). UNC-CanCORS was funded
by NCI grant (U01CA93326). The North Carolina Rectal Cancer study was
funded by NCI grant (R01CA66635). The MD Anderson data collection was
supported in part by the MD Anderson University Cancer Fund, the MD
Anderson Cancer Center Duncan Family Institute for Cancer Prevention and
Risk Assessment, the Center for Clinical and Translational Sciences of
the University of Texas Health Science Center at Houston, NCI Cancer
Center Support Grant (CA16672) and NCI grant (K07CA160753).
NR 33
TC 15
Z9 16
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 15
PY 2013
VL 22
IS 24
BP 5048
EP 5055
DI 10.1093/hmg/ddt337
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 259QY
UT WOS:000327542600015
PM 23851122
ER
PT J
AU Amiri-Kordestani, L
Mena, E
Lindenberg, ML
Kurdziel, K
Choyke, P
Patronas, N
Frye, R
Lin, N
Bala, S
Fojo, T
Bates, S
AF Amiri-Kordestani, L.
Mena, E.
Lindenberg, M. L.
Kurdziel, K.
Choyke, P.
Patronas, N.
Frye, R.
Lin, N.
Bala, S.
Fojo, T.
Bates, S.
TI 18F-FLT-PET/CT for the prediction of response to ANG-1005 therapy in
patients with brain metastases from breast cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 NCI, Bethesda, MD 20892 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
SU 24
MA P4-01-09
DI 10.1158/0008-5472.SABCS13-P4-01-09
PG 1
WC Oncology
SC Oncology
GA V40RY
UT WOS:000209496901265
ER
PT J
AU Anderson, WF
AF Anderson, W. F.
TI Divergent trends in breast cancer subtypes, a manifestation of cancer
heterogeneity
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Anderson, W. F.] NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
SU 24
MA ES05-2
DI 10.1158/0008-5472.SABCS13-ES05-2
PG 2
WC Oncology
SC Oncology
GA V40RY
UT WOS:000209496900020
ER
PT J
AU Berg, P
Kirolikar, S
Ginsburg, E
Schwartz, A
Simmens, S
AF Berg, P.
Kirolikar, S.
Ginsburg, E.
Schwartz, A.
Simmens, S.
TI BP1, a homeoprotein, regulates estrogen receptor alpha and induces
estrogen independence
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 George Washington Univ, Washington, DC USA.
NCI, Mammary Biol & Tumorigenesis Lab, NIH, Bethesda, MD 20892 USA.
George Washington Univ, Med Ctr, Washington, DC 20037 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
SU 24
MA P5-09-11
DI 10.1158/0008-5472.SABCS13-P5-09-11
PG 2
WC Oncology
SC Oncology
GA V40RY
UT WOS:000209496902158
ER
PT J
AU Cortazar, P
Zhang, L
Untch, M
Mehta, K
Constantino, J
Wolmark, N
Bonnefoi, H
Piccart, M
Gianni, L
Valagussa, P
Zujewski, JA
Justice, R
Loibl, S
Swain, SM
Bogaerts, J
Baselga, J
Prowell, TM
Rastogi, P
Sridhara, R
Tang, S
Pazdur, R
Mamounas, E
von Minckwitz, G
AF Cortazar, P.
Zhang, L.
Untch, M.
Mehta, K.
Constantino, J.
Wolmark, N.
Bonnefoi, H.
Piccart, M.
Gianni, L.
Valagussa, P.
Zujewski, J. A.
Justice, R.
Loibl, S.
Swain, S. M.
Bogaerts, J.
Baselga, J.
Prowell, T. M.
Rastogi, P.
Sridhara, R.
Tang, S.
Pazdur, R.
Mamounas, E.
von Minckwitz, G.
TI A definition of a high-risk early-breast cancer population based on data
from the collaborative trials in neoadjuvant breast cancer (CTNeoBC)
meta-analysis
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 HELIOS Klinikum Berlin Buch, D-13125 Berlin, Germany.
GBG Forsch GmbH, Neu Isenburg, Germany.
NSABP, Pittsburgh, PA USA.
INSERM, U916, Inst Bergonie, F-75654 Paris 13, France.
Inst Jules Bordet, B-1000 Brussels, Belgium.
San Raffaele Sci Insitute, Milan, Italy.
Fdn Michelangelo, Milan, Italy.
NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA.
Medstar Washington Hosp Ctr, Washington, DC USA.
EORTC Headquarters, Brussels, Belgium.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Orlando Hlth MD Anderson Canc Ctr, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
SU 24
MA P5-17-01
DI 10.1158/0008-5472.SABCS13-P5-17-01
PG 2
WC Oncology
SC Oncology
GA V40RY
UT WOS:000209496902235
ER
PT J
AU Goetz, MP
Suman, VA
Reid, JR
Northfelt, DW
Mahr, MA
Dockter, T
Haluska, PJ
Kuffel, M
Burhow, S
Safgren, S
McGovern, R
Collins, J
Streicher, H
Hawse, JR
Erlichman, C
Ingle, JN
Ames, MM
AF Goetz, M. P.
Suman, V. A.
Reid, J. R.
Northfelt, D. W.
Mahr, M. A.
Dockter, T.
Haluska, P. J.
Kuffel, M.
Burhow, S.
Safgren, S.
McGovern, R.
Collins, J.
Streicher, H.
Hawse, J. R.
Erlichman, C.
Ingle, J. N.
Ames, M. M.
TI A first-in-human phase I study of the tamoxifen (TAM) metabolite,
Z-endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor
(AI) refractory metastatic breast cancer (MBC) (NCT01327781)
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 Mayo Clin, Rochester, MN USA.
Mayo Clin, Scottsdale, AZ USA.
NCI, Bethesda, MD 20892 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
SU 24
MA PD3-4
DI 10.1158/0008-5472.SABCS13-PD3-4
PG 1
WC Oncology
SC Oncology
GA V40RY
UT WOS:000209496903069
ER
PT J
AU Gucalp, A
Morris, PG
Zhou, XK
Giri, DD
Lyengar, NM
Heckman-Stoddard, BM
Dunn, B
Garber, JE
Crew, KD
Hershman, DL
Nangia, JR
Cook, ED
Brown, PH
Dannenberg, AJ
Hudis, CA
AF Gucalp, A.
Morris, P. G.
Zhou, X. K.
Giri, D. D.
Lyengar, N. M.
Heckman-Stoddard, B. M.
Dunn, B.
Garber, J. E.
Crew, K. D.
Hershman, D. L.
Nangia, J. R.
Cook, E. D.
Brown, P. H.
Dannenberg, A. J.
Hudis, C. A.
TI A multicenter phase II study of docosahexaenoic acid (DHA) in triple
negative breast cancer (TNBC) survivors
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Columbia Univ, Med Ctr, New York, NY USA.
Baylor Coll Med, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Weill Cornell Med Coll, New York, NY USA.
NCI, Div Canc Prevent, Bethesda, MD 20892 USA.
EM gucalpa@mskcc.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
SU 24
MA OT3-3-01
DI 10.1158/0008-5472.SABCS13-OT3-3-01
PG 2
WC Oncology
SC Oncology
GA V40RY
UT WOS:000209496900100
ER
PT J
AU Janosky, M
Demaria, S
Novik, Y
Oratz, R
Tiersten, A
Goldberg, J
Wang, E
Marincola, F
Fenton-Kerimian, M
Maisonet, O
Axelrod, D
Sacris, E
Levine, P
Formenti, S
Adams, S
AF Janosky, M.
Demaria, S.
Novik, Y.
Oratz, R.
Tiersten, A.
Goldberg, J.
Wang, E.
Marincola, F.
Fenton-Kerimian, M.
Maisonet, O.
Axelrod, D.
Sacris, E.
Levine, P.
Formenti, S.
Adams, S.
TI Novel combination of toll-like receptor (TLR)-7 agonist imiquimod and
local radiotherapy in the treatment of breast cancer chest wall
recurrences or skin metastases
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 NYU, New York, NY 10003 USA.
NIH, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
SU 24
MA OT2-1-02
DI 10.1158/0008-5472.SABCS13-OT2-1-02
PG 2
WC Oncology
SC Oncology
GA V40RY
UT WOS:000209496900057
ER
PT J
AU Jassem, J
Duchnowska, R
Hua, E
Qian, Y
Biernat, W
Sosinska-Mielcarek, K
Gril, B
Stark, A
Hewitt, S
Liewehr, DJ
Steinberg, SM
Palmieri, D
Steeg, PS
AF Jassem, J.
Duchnowska, R.
Hua, E.
Qian, Y.
Biernat, W.
Sosinska-Mielcarek, K.
Gril, B.
Stark, A.
Hewitt, S.
Liewehr, D. J.
Steinberg, S. M.
Palmieri, D.
Steeg, P. S.
TI Profound prevention of experimental brain metastases of breast cancer by
temozolomide in a MGMT-dependent manner
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 Med Univ Gdansk, Gdansk, Poland.
NCI, Womens Canc Sect, Mol Pharmacol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.
NHLBI, NIH, Bthesda, MD USA.
Mil Inst Med, Warsaw, Poland.
Reg Canc Ctr, Gdansk, Poland.
NCI, Lab Anim Sci Program, SAIC Frederick, NIH, Frederick, MD 21701 USA.
UKSH Campus Kiel, Klin Neurochirurg, Kiel, Germany.
NCI, Pathol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
NCI, NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
SU 24
MA P6-11-04
DI 10.1158/0008-5472.SABCS13-P6-11-04
PG 1
WC Oncology
SC Oncology
GA V40RY
UT WOS:000209496903026
ER
PT J
AU Julian, TB
Anderson, SJ
Krag, DN
Weaver, DL
Costantino, JP
Ashikaga, T
Harlow, SP
Mamounas, EP
Wolmark, N
AF Julian, T. B.
Anderson, S. J.
Krag, D. N.
Weaver, D. L.
Costantino, J. P.
Ashikaga, T.
Harlow, S. P.
Mamounas, E. P.
Wolmark, N.
TI 10-yr follow-up results of occult detected sentinel node disease: NSABP
B-32, a randomized phase III clinical trial to compare sentinel node
resection (SNR) to conventional axillary dissection (AD) in clinically
node-negative breast cancer patients
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA USA.
Allegheny Gen Hosp West Penn Allegheny Hlth Syst, Pittsburgh, PA USA.
Natl Surg Adjuvant Breast & Bowel Project Biostat, Pittsburgh, PA USA.
Univ Vermont, Burlington, VT USA.
MD Anderson Canc Ctr, Orlando, FL USA.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
SU 24
MA S2-05
DI 10.1158/0008-5472.SABCS13-S2-05
PG 1
WC Oncology
SC Oncology
GA V40RY
UT WOS:000209496903112
ER
PT J
AU Nielsen, TO
Polley, MYC
AF Nielsen, T. O.
Polley, M-Y C.
CA Int Ki67 Breast Canc Working Grp
TI An international Ki67 reproducibility study: Harmonizing scoring
methodology
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
NCI, Bethesda, MD 20892 USA.
BIG NABCG Collaborat, Brussels, Belgium.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
SU 24
MA S2-07
DI 10.1158/0008-5472.SABCS13-S2-07
PG 2
WC Oncology
SC Oncology
GA V40RY
UT WOS:000209496903114
ER
PT J
AU Nussenzweig, A
Callen, E
AF Nussenzweig, A.
Callen, E.
TI 53BP1 mediates productive and mutagenic DNA repair through distinct
phosphoprotein interactions
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 [Nussenzweig, A.; Callen, E.] NIH, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
SU 24
MA ES01-2
DI 10.1158/0008-5472.SABCS13-ES01-2
PG 2
WC Oncology
SC Oncology
GA V40RY
UT WOS:000209496900012
ER
PT J
AU O'Sullivan, CC
Holmes, E
Spielmann, M
Perez, EA
Joensuu, H
Costantino, JP
Delaloge, S
Rastogi, P
Zardavas, D
Ballman, KV
de Azambuja, E
Piccart-Gebhart, M
Zujewski, JA
Gelber, RD
AF O'Sullivan, C. C.
Holmes, E.
Spielmann, M.
Perez, E. A.
Joensuu, H.
Costantino, J. P.
Delaloge, S.
Rastogi, P.
Zardavas, D.
Ballman, K. V.
de Azambuja, E.
Piccart-Gebhart, M.
Zujewski, J. A.
Gelber, R. D.
TI The prognosis of small HER2+breast cancers: A meta-analysis of the
randomized trastuzumab trials
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 NCI, NIH, Bethesda, MD 20892 USA.
Frontier Sci Scotland, Kincraig, Inverness, Scotland.
Inst Gustave Roussy, Villejuif, France.
Inst Jules Bordet, B-1000 Brussels, Belgium.
Mayo Clin, Jacksonville, FL 32224 USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
SU 24
MA S6-03
DI 10.1158/0008-5472.SABCS13-S6-03
PG 1
WC Oncology
SC Oncology
GA V40RY
UT WOS:000209496903138
ER
PT J
AU Park, IH
Kong, SY
Ro, JY
Kwon, Y
Kang, JH
Mo, HJ
Jung, SY
Lee, S
Lee, KS
Kang, HS
Lee, E
Ro, J
AF Park, I. H.
Kong, S-Y
Ro, J. Y.
Kwon, Y.
Kang, J. H.
Mo, H. J.
Jung, S-Y
Lee, S.
Lee, K. S.
Kang, H-S
Lee, E.
Ro, J.
TI Prognostic implications of tumor-infiltrating lymphocytes (TIL) in
association with PD-L1 expression, and serum cytokine levels in early
breast cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 Natl Canc Ctr, Ctr Breast Canc, Bethesda, MD USA.
Natl Canc Ctr, Breast & Endocrine Canc Branch, Res Inst, Bethesda, MD USA.
Natl Canc Ctr, Bethesda, MD USA.
Cornell Univ, Methodist Hosp, Houston, TX USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
SU 24
MA P5-01-12
DI 10.1158/0008-5472.SABCS13-P5-01-12
PG 2
WC Oncology
SC Oncology
GA V40RY
UT WOS:000209496902086
ER
PT J
AU Slamon, DJ
Swain, SM
Buyse, M
Martin, M
Geyer, CE
Im, YH
Pienkowski, T
Kim, SB
Robert, NJ
Steger, G
Crown, J
Verma, S
Eiermann, W
Costantino, JP
Im, SA
Mamounas, EP
Schwartzberg, L
Paterson, A
Mackey, JR
Provencher, L
Press, MF
Thirlwell, M
Bee-Munteanu, V
Henschel, V
Crepelle-Flechais, A
Wolmark, N
AF Slamon, D. J.
Swain, S. M.
Buyse, M.
Martin, M.
Geyer, C. E.
Im, Y-H
Pienkowski, T.
Kim, S-B
Robert, N. J.
Steger, G.
Crown, J.
Verma, S.
Eiermann, W.
Costantino, J. P.
Im, S-A
Mamounas, E. P.
Schwartzberg, L.
Paterson, A.
Mackey, J. R.
Provencher, L.
Press, M. F.
Thirlwell, M.
Bee-Munteanu, V.
Henschel, V.
Crepelle-Flechais, A.
Wolmark, N.
TI Primary results from BETH, a phase 3 controlled study of adjuvant
chemotherapy and trastuzumab +/- bevacizumab in patients with
HER2-positive, node-positive or high risk node-negative breast cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 Univ Calif Los Angeles, Los Angeles, CA USA.
MedStar Washington Hosp Ctr, Washington, MD USA.
IDDI, Louvain, Belgium.
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland.
Inst Oncol, Warsaw, Poland.
Virginia Commonwealth Univ, Richmond, VA USA.
Asan Med Ctr, Seoul, South Korea.
US Oncol Res, Fairfax, VA USA.
ABCSG, Vienna, Austria.
ICORG, Dublin, Ireland.
RotKreuzKlinikum, Munich, Germany.
GEICAM, Madrid, Spain.
Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
USC Norris Comprehens Canc Ctr, Los Angeles, CA USA.
F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland.
NSABP, Pittsburgh, PA USA.
Seoul Natl Univ, Coll Med, Seoul, South Korea.
Ottawa Hosp Reg Canc Ctr, Ottawa, ON, Canada.
ACORN Res, Memphis, TN USA.
Tom Baker Canc Clin, Calgary, AB, Canada.
CHA Univ Quebec, Hop St Sacrement, Quebec City, PQ, Canada.
TRIO, Edmonton, AB, Canada.
Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada.
MD Anderson Canc Ctr Orlando, Orlando, FL USA.
Allegheny Canc Ctr, Pittsburgh, PA USA.
Univ Pittsburgh, Pittsburgh, PA USA.
NR 0
TC 8
Z9 8
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
SU 24
MA S1-03
DI 10.1158/0008-5472.SABCS13-S1-03
PG 2
WC Oncology
SC Oncology
GA V40RY
UT WOS:000209496903102
ER
PT J
AU Somlo, G
Frankel, P
Luu, T
Ma, C
Arun, B
Garcia, A
Cigler, T
Fleming, G
Harvey, H
Sparano, J
Nanda, R
Chew, H
Moynihan, T
Vahdat, L
Goetz, M
Hurria, A
Mortimer, J
Gandara, D
Chen, A
Weitzel, J
AF Somlo, G.
Frankel, P.
Luu, T.
Ma, C.
Arun, B.
Garcia, A.
Cigler, T.
Fleming, G.
Harvey, H.
Sparano, J.
Nanda, R.
Chew, H.
Moynihan, T.
Vahdat, L.
Goetz, M.
Hurria, A.
Mortimer, J.
Gandara, D.
Chen, A.
Weitzel, J.
TI Efficacy of ABT-888 (veliparib) in patients with BRCA-associated breast
cancer
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 City Hope Canc Ctr, Duarte, CA USA.
Washington Univ, Sch Med, St Louis, MO USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
USC Norris Comprehens Canc Ctr, Los Angeles, CA USA.
Weill Cornell Med Coll, New York, NY USA.
Alliance Clin Trials Oncol, Chicago, IL USA.
Milton S Hershey Med Ctr, Hershey, PA USA.
Montefiore Med Ctr, Bronx, NY 10467 USA.
Univ Chicago, Chicago, IL 60637 USA.
Univ Calif, Davis Canc Ctr, Sacramento, CA USA.
Mayo Clin, Rochester, MN USA.
NCI, Bethesda, MD 20892 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2013
VL 73
SU 24
MA P2-16-05
DI 10.1158/0008-5472.SABCS13-P2-16-05
PG 1
WC Oncology
SC Oncology
GA V40RY
UT WOS:000209496901054
ER
PT J
AU Lesniak, WG
Jyoti, A
Mishra, MK
Louissaint, N
Romero, R
Chugani, DC
Kannan, S
Kannan, RM
AF Lesniak, Wojciech G.
Jyoti, Amar
Mishra, Manoj K.
Louissaint, Nicolette
Romero, Roberto
Chugani, Diane C.
Kannan, Sujatha
Kannan, Rangaramanujam M.
TI Concurrent quantification of tryptophan and its major metabolites
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
DE Kynurenine pathway; Serotonin; Kynurenic acid; Tryptophan metabolites;
HPLC
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; KYNURENIC ACID; HUMAN SERUM;
GASTROINTESTINAL-TRACT; FLUORESCENCE DETECTION; MASS-SPECTROMETRY;
AMNIOTIC-FLUID; RABBIT BRAIN; AMINO-ACIDS; RAT PLASMA
AB An imbalance in tryptophan (TRP) metabolites is associated with several neurological and inflammatory disorders. Therefore, analytical methods allowing for simultaneous quantification of TRP and its major metabolites would be highly desirable, and may be valuable as potential biomarkers. We have developed a HPLC method for concurrent quantitative determination of tryptophan, serotonin, 5-hydroxyindoleacetic acid, kynurenine, and kynurenic acid in tissue and fluids. The method utilizes the intrinsic spectroscopic properties of TRP and its metabolites that enable UV absorbance and fluorescence detection by HPLC, without additional labeling. The origin of the peaks related to analytes of interest was confirmed by UV-Vis spectral patterns using a PDA detector and mass spectrometry. The developed methods were validated in rabbit fetal brain and amniotic fluid at gestational day 29. Results are in excellent agreement with those reported in the literature for the same regions. This method allows for rapid quantification of tryptophan and four of its major metabolites concurrently. A change in the relative ratios of these metabolites can provide important insights in predicting the presence and progression of neuroinflammation in disorders such as cerebral palsy, autism, multiple sclerosis, Alzheimer disease, and schizophrenia. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Lesniak, Wojciech G.; Mishra, Manoj K.; Kannan, Rangaramanujam M.] Wayne State Univ, Childrens Hosp Michigan, Dept Chem Engn & Mat Sci, Detroit, MI 48202 USA.
[Lesniak, Wojciech G.; Mishra, Manoj K.; Louissaint, Nicolette; Kannan, Rangaramanujam M.] Johns Hopkins Univ, Dept Ophthalmol, Ctr Nanomed, Sch Med, Baltimore, MD 21287 USA.
[Lesniak, Wojciech G.; Jyoti, Amar; Mishra, Manoj K.; Romero, Roberto; Kannan, Rangaramanujam M.] NICHHD, Perinatol Res Branch, NIH, DHHS, Detroit, MI 48201 USA.
[Lesniak, Wojciech G.; Jyoti, Amar; Mishra, Manoj K.; Romero, Roberto; Kannan, Rangaramanujam M.] NICHHD, Perinatol Res Branch, NIH, DHHS, Bethesda, MD 20892 USA.
[Jyoti, Amar; Kannan, Sujatha] Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Sch Med, Baltimore, MD 21287 USA.
[Chugani, Diane C.] Wayne State Univ, Childrens Hosp Michigan, Carman & Ann Adams Dept Pediat, Detroit, MI 48202 USA.
RP Kannan, RM (reprint author), Johns Hopkins Sch Med, Dept Ophthalmol, Ctr Nanomed, Baltimore, MD 21218 USA.
EM krangar1@jhmi.edu
FU Perinatology Research Branch, Division of Intramural Research, Eunice
Kennedy Shriver National Institute of Child Health and Human Development
(NICHD), NIH; NICHD [R01HD069562]
FX This research was supported in part by the Perinatology Research Branch,
Division of Intramural Research, Eunice Kennedy Shriver National
Institute of Child Health and Human Development (NICHD), NIH, and by
R01HD069562, NICHD (S.K.).
NR 36
TC 7
Z9 7
U1 8
U2 81
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
EI 1096-0309
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD DEC 15
PY 2013
VL 443
IS 2
BP 222
EP 231
DI 10.1016/j.ab.2013.09.001
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 255ZQ
UT WOS:000327279700017
PM 24036037
ER
PT J
AU Leibenluft, E
Pine, DS
AF Leibenluft, Ellen
Pine, Daniel S.
TI Resting State Functional Connectivity and Depression: In Search of a
Bottom Line
SO BIOLOGICAL PSYCHIATRY
LA English
DT Editorial Material
ID CINGULATE CORTEX; MAJOR DEPRESSION; DISORDER; NETWORKS; MRI
C1 [Leibenluft, Ellen; Pine, Daniel S.] NIMH, Emot & Dev Branch, Div Intramural Res Programs, Natl Inst Hlth,Dept Hlth & Human Serv, Bethesda, MD 20892 USA.
RP Leibenluft, E (reprint author), Bldg 15K Room 210,MSC 2670,15K North Dr, Bethesda, MD 20892 USA.
EM leibs@mail.nih.gov
NR 10
TC 3
Z9 3
U1 2
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD DEC 15
PY 2013
VL 74
IS 12
BP 868
EP 869
DI 10.1016/j.biopsych.2013.10.001
PG 2
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 252DC
UT WOS:000326983900007
PM 24246362
ER
PT J
AU Enjuanes, A
Albero, R
Clot, G
Navarro, A
Bea, S
Pinyol, M
Martin-Subero, JI
Klapper, W
Staudt, LM
Jaffe, ES
Rimsza, L
Braziel, RM
Delabie, J
Cook, JR
Tubbs, RR
Gascoyne, R
Connors, JM
Weisenburger, DD
Greiner, TC
Chan, WC
Lopez-Guillermo, A
Rosenwald, A
Ott, G
Campo, E
Jares, P
AF Enjuanes, Anna
Albero, Robert
Clot, Guillem
Navarro, Alba
Bea, Silvia
Pinyol, Magda
Martin-Subero, Jose I.
Klapper, Wolfram
Staudt, Louis M.
Jaffe, Elaine S.
Rimsza, Lisa
Braziel, Rita M.
Delabie, Jan
Cook, James R.
Tubbs, Raymond R.
Gascoyne, Randy
Connors, Joseph M.
Weisenburger, Dennis D.
Greiner, Timothy C.
Chan, Wing-Chung
Lopez-Guillermo, Armando
Rosenwald, Andreas
Ott, German
Campo, Elias
Jares, Pedro
TI Genome-wide methylation analyses identify a subset of mantle cell
lymphoma with a high number of methylated CpGs and aggressive
clinicopathological features
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE mantle cell lymphoma; genome-wide; hypermethylation; hypomethylation;
pathogenesis
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; TUMOR-SUPPRESSOR GENES; DNA METHYLATION;
FOLLICULAR LYMPHOMA; HYPERMETHYLATION; CANCER; EXPRESSION;
PROLIFERATION; P16(INK4A); MICROARRAY
AB Mantle cell lymphoma (MCL) is a B-cell neoplasm with an aggressive clinical behavior characterized by the t(11;14)(q13;q32) and cyclin D1 overexpression. To clarify the potential contribution of altered DNA methylation in the development and/or progression of MCL, we performed genome-wide methylation profiling of a large cohort of primary MCL tumors (n = 132), MCL cell lines (n = 6) and normal lymphoid tissue samples (n = 31), using the Infinium HumanMethylation27 BeadChip. DNA methylation was compared to gene expression, chromosomal alterations and clinicopathological parameters. Primary MCL displayed a heterogeneous methylation pattern dominated by DNA hypomethylation when compared to normal lymphoid samples. A total of 454 hypermethylated and 875 hypomethylated genes were identified as differentially methylated in at least 10% of primary MCL. Annotation analysis of hypermethylated genes recognized WNT pathway inhibitors and several tumor suppressor genes as frequently methylated, and a substantial fraction of these genes (22%) showed a significant downregulation of their transcriptional levels. Furthermore, we identified a subset of tumors with extensive CpG methylation that had an increased proliferation signature, higher number of chromosomal alterations and poor prognosis. Our results suggest that a subset of MCL displays a dysregulation of DNA methylation characterized by the accumulation of CpG hypermethylation highly associated with increased proliferation that may influence the clinical behavior of the tumors.
C1 [Enjuanes, Anna] Univ Barcelona, Genom Unit, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain.
[Albero, Robert; Clot, Guillem; Navarro, Alba; Bea, Silvia; Pinyol, Magda; Campo, Elias; Jares, Pedro] Univ Barcelona, Dept Anat Pathol, Inst Invest Biomed August Pi & Sunyer, Hematopathol Sect,Hosp Clin, Barcelona, Spain.
[Martin-Subero, Jose I.] Univ Barcelona, Dept Anat Pathol Pharmacol & Microbiol, Barcelona, Spain.
[Klapper, Wolfram] Univ Hosp Schleswig Holstein, Hematopathol Sect, Kiel, Germany.
[Klapper, Wolfram] Univ Hosp Schleswig Holstein, Lymph Node Registry, Dept Pathol, Kiel, Germany.
[Staudt, Louis M.] NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Jaffe, Elaine S.] NCI, Hematopathol Dept, Pathol Lab, Ctr Canc Res, Bethesda, MD 20892 USA.
[Rimsza, Lisa] Univ Arizona, Coll Med, Dept Pathol, Tucson, AZ 85721 USA.
[Braziel, Rita M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Delabie, Jan] Aker Univ Hosp, Rikshosp, Dept Pathol, Oslo, Norway.
[Cook, James R.; Tubbs, Raymond R.] Dept Mol & Anat Pathol, Cleveland, OH USA.
[Cook, James R.; Tubbs, Raymond R.] Dept Pathol, Cleveland, OH USA.
[Cook, James R.; Tubbs, Raymond R.] Dept Lab Med Inst, Cleveland, OH USA.
[Gascoyne, Randy; Connors, Joseph M.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
[Weisenburger, Dennis D.; Greiner, Timothy C.; Chan, Wing-Chung] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA.
[Lopez-Guillermo, Armando] Univ Barcelona, Hosp Clin, Dept Hematol, Barcelona, Spain.
[Rosenwald, Andreas] Univ Wurzburg, Inst Pathol, Wurzburg, Germany.
[Ott, German] Robert Bosch Krankenhaus, Dept Clin Pathol, Stuttgart, Germany.
[Ott, German] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany.
RP Jares, P (reprint author), Hosp Cln, Dept Anat Pathol, Villarroel 170, Barcelona 08036, Spain.
EM pjares@clinic.ub.es
RI Navarro, Alba/H-2611-2015; ENJUANES, Anna/H-3245-2015; Klapper,
Wolfram/S-6314-2016; Bea, Silvia/K-7699-2014
OI Navarro, Alba/0000-0002-4041-0974; ENJUANES, Anna/0000-0002-4679-6687;
Jaffe, Elaine/0000-0003-4632-0301; Martin-Subero, Jose
Ignacio/0000-0001-8809-5195; Campo, elias/0000-0001-9850-9793; Delabie,
Jan/0000-0001-5023-0689; Bea, Silvia/0000-0001-7192-2385
FU Lymphoma Research Foundation [LRF07168]; Asociacion Espanola Contra el
Cancer (AECC) of Barcelona; Spanish Ministry of Science and Innovation
[CICYT SAF 2008/03630]; Tematica de Investigacion Cooperativa en Cancer
(RTICC) [RD06/0020/0039]; Instituto de Salud Carlos III (ISCIII);
Spanish Ministry of Science and Innovation & European Regional
Development Fund (ERDF) "Una manera de hacer Europa"; Generalitat de
Catalunya [2009-SGR-992]; Formacion de personal de Investigacion
[FPU11-3997]; Instituto de Salud Carlos III, Fondo Investigaciones
Sanitarias [PI11/01177]; Formacion de Personal Investigador
[BES-2007-16330]; Interdisciplinary Center for Clinical Research (IZKF);
University of Wurzburg, Germany; Robert-Bosch-Stiftung
FX Grant sponsor: Lymphoma Research Foundation; Grant number: LRF07168;
Grant sponsor: The Asociacion Espanola Contra el Cancer (AECC) of
Barcelona 2008; Grant sponsor: The CICYT SAF 2008/03630 from the Spanish
Ministry of Science and Innovation; Grant sponsor: Red Tematica de
Investigacion Cooperativa en Cancer (RTICC); Grant number:
RD06/0020/0039; Grant sponsors Instituto de Salud Carlos III (ISCIII),
Spanish Ministry of Science and Innovation & European Regional
Development Fund (ERDF) "Una manera de hacer Europa", Generalitat de
Catalunya (2009-SGR-992); Grant sponsor: "Formacion de personal de
Investigacion"; Grant number: FPU11-3997; Grant sponsor: "Instituto de
Salud Carlos III, Fondo Investigaciones Sanitarias"; Grant number:
PI11/01177; Grant sponsor: "Formacion de Personal Investigador"; Grant
number: BES-2007-16330; Grant sponsors The Interdisciplinary Center for
Clinical Research (IZKF), University of Wurzburg, Germany, The
Robert-Bosch-Stiftung
NR 50
TC 8
Z9 8
U1 2
U2 37
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD DEC 15
PY 2013
VL 133
IS 12
BP 2852
EP 2863
DI 10.1002/ijc.28321
PG 12
WC Oncology
SC Oncology
GA 233JW
UT WOS:000325565600010
PM 23754783
ER
PT J
AU Koutros, S
Baris, D
Fischer, A
Tang, W
Garcia-Closas, M
Karagas, MR
Schwenn, M
Johnson, A
Figueroa, J
Waddell, R
Prokunina-Olsson, L
Rothman, N
Silverman, DT
AF Koutros, Stella
Baris, Dalsu
Fischer, Alexander
Tang, Wei
Garcia-Closas, Montserrat
Karagas, Margaret R.
Schwenn, Molly
Johnson, Alison
Figueroa, Jonine
Waddell, Richard
Prokunina-Olsson, Ludmila
Rothman, Nathaniel
Silverman, Debra T.
TI Differential urinary specific gravity as a molecular phenotype of the
bladder cancer genetic association in the urea transporter gene, SLC14A1
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE bladder cancer; urinary specific gravity; genome-wide association study;
epidemiology
ID GENOME-WIDE ASSOCIATION; FLUID INTAKE; RISK; CONSUMPTION; EXPRESSION;
COHORT
AB Genome-wide association studies (GWAS) identified associations between markers within the solute carrier family 14 (urea transporter), member 1 (SLC14A1) gene and risk of bladder cancer. SLC14A1 defines the Kidd blood groups in erythrocytes and is also involved in concentration of the urine in the kidney. We evaluated the association between a representative genetic variant (rs10775480) of SLC14A1 and urine concentration, as measured by urinary specific gravity (USG), in a subset of 275 population-based controls enrolled in the New England Bladder Cancer Study. Overnight urine samples were collected, and USG was measured using refractometry. Analysis of covariance was used to estimate adjusted least square means for USG in relation to rs10775480. We also examined the mRNA expression of both urea transporters, SLC14A1 and SLC14A2, in a panel of human tissues. USG was decreased with each copy of the rs10775480 risk T allele (p-trend=0.011) with a significant difference observed for CC vs. TT genotypes (p-value(tukey)=0.024). RNA-sequencing in the bladder tissue showed high expression of SLC14A1 and the absence of SLC14A2, while both transporters were expressed in the kidney. We suggest that the molecular phenotype of this GWAS finding is the genotype-specific biological activity of SLC14A1 in the bladder tissue. Our data suggest that SLC14A1 could be a unique urea transporter in the bladder that has the ability to influence urine concentration and that this mechanism might explain the increased bladder cancer susceptibility associated with rs10775480.
C1 [Koutros, Stella; Baris, Dalsu; Fischer, Alexander; Tang, Wei; Garcia-Closas, Montserrat; Figueroa, Jonine; Prokunina-Olsson, Ludmila; Rothman, Nathaniel; Silverman, Debra T.] NCI, Div Canc Epidemiol & Genet, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA.
[Garcia-Closas, Montserrat] Inst Canc Res, Epidemiol Sect, London SW3 6JB, England.
[Garcia-Closas, Montserrat] Inst Canc Res, Genet Sect, London SW3 6JB, England.
[Garcia-Closas, Montserrat] Breakthrough Breast Canc Res Ctr, London, England.
[Karagas, Margaret R.; Waddell, Richard] Dartmouth Med Sch, Sect Biostat & Epidemiol, Dept Community & Family Med, Hanover, NH USA.
[Schwenn, Molly] Maine Canc Registry, Augusta, ME USA.
[Johnson, Alison] Vermont Canc Registry, Burlington, VT USA.
RP Koutros, S (reprint author), NCI, Div Canc Epidemiol & Genet, Occupat & Environm Epidemiol Branch, 9609 Med Ctr Dr,Room 6-E116,MSC 9771, Bethesda, MD 20892 USA.
EM koutross@mail.nih.gov
RI Garcia-Closas, Montserrat /F-3871-2015;
OI Garcia-Closas, Montserrat /0000-0003-1033-2650; Prokunina-Olsson,
Ludmila/0000-0002-9622-2091
FU Intramural Research Program of the National Institutes of Health,
National Cancer Institute, Division of Cancer Epidemiology and Genetics
FX Grant sponsor: Intramural Research Program of the National Institutes of
Health, National Cancer Institute, Division of Cancer Epidemiology and
Genetics
NR 29
TC 5
Z9 5
U1 2
U2 33
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD DEC 15
PY 2013
VL 133
IS 12
BP 3008
EP 3013
DI 10.1002/ijc.28325
PG 6
WC Oncology
SC Oncology
GA 233JW
UT WOS:000325565600026
PM 23754249
ER
PT J
AU Cotten, M
Watson, SJ
Kellam, P
Al-Rabeeah, AA
Makhdoom, HQ
Assiri, A
Al-Tawfiq, JA
Alhakeem, RF
Madani, H
AlRabiah, FA
Al Hajjar, S
Al-Nassir, WN
Albarrak, A
Flemban, H
Balkhy, HH
Alsubaie, S
Palser, AL
Gall, A
Bashford-Rogers, R
Rambaut, A
Zumla, AI
Memish, ZA
AF Cotten, Matthew
Watson, Simon J.
Kellam, Paul
Al-Rabeeah, Abdullah A.
Makhdoom, Hatem Q.
Assiri, Abdullah
Al-Tawfiq, Jaffar A.
Alhakeem, Rafat F.
Madani, Hossam
AlRabiah, Fahad A.
Al Hajjar, Sami
Al-Nassir, Wafa N.
Albarrak, Ali
Flemban, Hesham
Balkhy, Hanan H.
Alsubaie, Sarah
Palser, Anne L.
Gall, Astrid
Bashford-Rogers, Rachael
Rambaut, Andrew
Zumla, Alimuddin I.
Memish, Ziad A.
TI Transmission and evolution of the Middle East respiratory syndrome
coronavirus in Saudi Arabia: a descriptive genomic study
SO LANCET
LA English
DT Article
ID HUMAN AIRWAY EPITHELIUM; PHYLOGENETIC ANALYSIS; SPIKE PROTEIN;
ACTIVATION; RECEPTOR; INFECTIONS; INFERENCE; CLEAVAGE; TMPRSS2; SITES
AB Background Since June, 2012, Middle East respiratory syndrome coronavirus (MERS-CoV) has, worldwide, caused 104 infections in people including 49 deaths, with 82 cases and 41 deaths reported from Saudi Arabia. In addition to confirming diagnosis, we generated the MERS-CoV genomic sequences obtained directly from patient samples to provide important information on MERS-CoV transmission, evolution, and origin.
Methods Full genome deep sequencing was done on nucleic acid extracted directly from PCR-confirmed clinical samples. Viral genomes were obtained from 21 MERS cases of which 13 had 100%, four 85-95%, and four 30-50% genome coverage. Phylogenetic analysis of the 21 sequences, combined with nine published MERS-CoV genomes, was done.
Findings Three distinct MERS-CoV genotypes were identified in Riyadh. Phylogeographic analyses suggest the MERS-CoV zoonotic reservoir is geographically disperse. Selection analysis of the MERS-CoV genomes reveals the expected accumulation of genetic diversity including changes in the S protein. The genetic diversity in the Al-Hasa cluster suggests that the hospital outbreak might have had more than one virus introduction.
Interpretation We present the largest number of MERS-CoV genomes (21) described so far. MERS-CoV full genome sequences provide greater detail in tracking transmission. Multiple introductions of MERS-CoV are identified and suggest lower R 0 values. Transmission within Saudi Arabia is consistent with either movement of an animal reservoir, animal products, or movement of infected people. Further definition of the exposures responsible for the sporadic introductions of MERS-CoV into human populations is urgently needed.
C1 [Al-Rabeeah, Abdullah A.; Assiri, Abdullah; Alhakeem, Rafat F.; Zumla, Alimuddin I.; Memish, Ziad A.] Minist Hlth, Global Ctr Mass Gatherings Med, Riyadh 11176, Saudi Arabia.
[Cotten, Matthew; Watson, Simon J.; Kellam, Paul; Palser, Anne L.; Gall, Astrid; Bashford-Rogers, Rachael] Wellcome Trust Sanger Inst, Hinxton, England.
[Makhdoom, Hatem Q.; Madani, Hossam] Minist Hlth, Jeddah Reg Lab, Jeddah, Saudi Arabia.
[Al-Tawfiq, Jaffar A.] Saudi Aramco Med Serv Org, Dhahran, Saudi Arabia.
[Rambaut, Andrew] Ashworth Labs, Inst Evolutionary Biol, Edinburgh, Midlothian, Scotland.
[Rambaut, Andrew] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
[AlRabiah, Fahad A.; Al Hajjar, Sami] King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia.
[Al-Nassir, Wafa N.] Natl Guard Hlth Affairs Dammam, Imam Abdulrahman Bin Mohamed Hosp, Dammam, Saudi Arabia.
[Albarrak, Ali] Prince Sultan Mil Med City, Riyadh, Saudi Arabia.
[Flemban, Hesham] Alhada Mil Hosp, Riyadh, Saudi Arabia.
[Balkhy, Hanan H.] King Abdul Aziz Med City, Riyadh, Saudi Arabia.
[Alsubaie, Sarah] King Saud Univ, Riyadh 11451, Saudi Arabia.
[Kellam, Paul; Zumla, Alimuddin I.] UCL, Div Infect & Immun, London, England.
[Zumla, Alimuddin I.] UCL Hosp NHS Fdn Trust, London, England.
RP Memish, ZA (reprint author), Minist Hlth, Global Ctr Mass Gatherings Med, Riyadh 11176, Saudi Arabia.
EM zmemish@yahoo.com
OI Assiri, Abdullah/0000-0002-5605-2876; Zumla,
Alimuddin/0000-0002-5111-5735; Rambaut, Andrew/0000-0003-4337-3707
FU Saudi Arabian Ministry of Health; Wellcome Trust; European Community;
National Institute of Health Research University College London
Hospitals Biomedical Research Centre
FX Funding Saudi Arabian Ministry of Health, Wellcome Trust, European
Community, and National Institute of Health Research University College
London Hospitals Biomedical Research Centre.
NR 32
TC 94
Z9 107
U1 3
U2 37
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD DEC 14
PY 2013
VL 382
IS 9909
BP 1993
EP 2002
DI 10.1016/S0140-6736(13)61887-5
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 269EI
UT WOS:000328223700026
PM 24055451
ER
PT J
AU Hsu, DC
Sereti, I
Ananworanich, J
AF Hsu, Denise C.
Sereti, Irini
Ananworanich, Jintanat
TI Serious Non-AIDS events: Immunopathogenesis and interventional
strategies
SO AIDS RESEARCH AND THERAPY
LA English
DT Review
DE Serious non-AIDS events; Immune activation; HIV infection
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; HEPATITIS-C VIRUS;
COMBINATION ANTIRETROVIRAL THERAPY; T-CELL-ACTIVATION;
CORONARY-HEART-DISEASE; CARDIOVASCULAR RISK-FACTORS; REACTIVE
PROTEIN-LEVELS; LIVER-RELATED MORTALITY; INDIVIDUAL PARTICIPANT
METAANALYSIS
AB Despite the major advances in the management of HIV infection, HIV-infected patients still have greater morbidity and mortality than the general population. Serious non-AIDS events (SNAEs), including non-AIDS malignancies, cardiovascular events, renal and hepatic disease, bone disorders and neurocognitive impairment, have become the major causes of morbidity and mortality in the antiretroviral therapy (ART) era. SNAEs occur at the rate of 1 to 2 per 100 person-years of follow-up. The pathogenesis of SNAEs is multifactorial and includes the direct effect of HIV and associated immunodeficiency, underlying co-infections and co-morbidities, immune activation with associated inflammation and coagulopathy as well as ART toxicities. A number of novel strategies such as ART intensification, treatment of co-infection, the use of anti-inflammatory drugs and agents that reduce microbial translocation are currently being examined for their potential effects in reducing immune activation and SNAEs. However, currently, initiation of ART before advanced immunodeficiency, smoking cessation, optimisation of cardiovascular risk factors and treatment of HCV infection are most strongly linked with reduced risk of SNAEs or mortality. Clinicians should therefore focus their attention on addressing these issues prior to the availability of further data.
C1 [Hsu, Denise C.] Univ New S Wales, Kirby Inst Infect & Immun Soc, Sydney, NSW, Australia.
[Sereti, Irini] NIAID, HIV Pathogenesis Unit, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA.
[Ananworanich, Jintanat] Red Cross AIDS Res Ctr, HIV Netherlands Australia Thailand Res Collaborat, Bangkok, Thailand.
[Ananworanich, Jintanat] Red Cross AIDS Res Ctr, SEARCH, Bangkok, Thailand.
RP Hsu, DC (reprint author), Univ New S Wales, Kirby Inst Infect & Immun Soc, Sydney, NSW, Australia.
EM d.hsu@amr.org.au
NR 224
TC 22
Z9 22
U1 1
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-6405
J9 AIDS RES THER
JI Aids Res. Ther.
PD DEC 13
PY 2013
VL 10
AR 29
DI 10.1186/1742-6405-10-29
PG 15
WC Infectious Diseases
SC Infectious Diseases
GA AB8FP
UT WOS:000332025900002
PM 24330529
ER
PT J
AU Youn, A
Simon, R
AF Youn, Ahrim
Simon, Richard
TI Using passenger mutations to estimate the timing of driver mutations and
identify mutator alterations
SO BMC BIOINFORMATICS
LA English
DT Article
DE Probabilistic modeling of tumor development; Estimating the order of
mutations during tumorigenesis; Identifying mutator genes
ID SOMATIC MUTATIONS; HUMAN CANCERS; DNA-REPAIR; TUMOR; TUMORIGENESIS;
PPP2R2A; GENE
AB Background: Recent developments in high-throughput genomic technologies make it possible to have a comprehensive view of genomic alterations in tumors on a whole genome scale. Only a small number of somatic alterations detected in tumor genomes are driver alterations which drive tumorigenesis. Most of the somatic alterations are passengers that are neutral to tumor cell selection. Although most research efforts are focused on analyzing driver alterations, the passenger alterations also provide valuable information about the history of tumor development.
Results: In this paper, we develop a method for estimating the age of the tumor lineage and the timing of the driver alterations based on the number of passenger alterations. This method also identifies mutator genes which increase genomic instability when they are altered and provides estimates of the increased rate of alterations caused by each mutator gene. We applied this method to copy number data and DNA sequencing data for ovarian and lung tumors. We identified well known mutators such as TP53, PRKDC, BRCA1/2 as well as new mutator candidates PPP2R2A and the chromosomal region 22q13.33. We found that most mutator genes alter early during tumorigenesis and were able to estimate the age of individual tumor lineage in cell generations.
Conclusions: This is the first computational method to identify mutator genes and to take into account the increase of the alteration rate by mutator genes, providing more accurate estimates of the tumor age and the timing of driver alterations.
C1 [Youn, Ahrim; Simon, Richard] NCI, Biometr Res Branch, Bethesda, MD 20892 USA.
RP Simon, R (reprint author), NCI, Biometr Res Branch, Bethesda, MD 20892 USA.
EM rsimon@mail.nih.gov
NR 32
TC 5
Z9 5
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD DEC 13
PY 2013
VL 14
AR 363
DI 10.1186/1471-2105-14-363
PG 11
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Mathematical & Computational Biology
GA AC0QY
UT WOS:000332201000001
PM 24330428
ER
PT J
AU Wang, Y
Tjandra, N
AF Wang, Yu
Tjandra, Nico
TI Structural Insights of tBid, the Caspase-8-activated Bid, and Its BH3
Domain
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Apoptosis; Bcl-2; NMR; Protein Dynamics; Protein Structure; LPPG
Micelles; tBid
ID CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBER; OUTER MITOCHONDRIAL-MEMBRANE;
TRIPLE-RESONANCE NMR; CELL-DEATH; CONFORMATIONAL-CHANGES; BACKBONE
DYNAMICS; INDUCE APOPTOSIS; PROTEIN FAMILY; BAX ACTIVATION
AB Background: The membrane-associated tBid promotes Bax membrane insertion and activation. Results: tBid adopts an extended structure in 1-palmitoyl-2-hydroxy-sn-glycero-3-[phospho-RAC-(1-glycerol)] (LPPG) micelles with its six helices including the BH3 domain interacting with the micelles. Conclusion: An on the membrane binding mode was suggested for tBid interaction with Bax. Significance: Revealing tBid structure on the membrane is key to the understanding of tBid-mediated Bax activation.
The Bcl-2 family proteins regulate mitochondria-mediated apoptosis through intricate molecular mechanisms. One of the pro-apoptotic proteins, tBid, can induce apoptosis by promoting Bax activation, Bax homo-oligomerization, and mitochondrial outer membrane permeabilization. Association of tBid on the mitochondrial outer membrane is key to its biological function. Therefore knowing the conformation of tBid on the membrane will be the first step toward understanding its crucial role in triggering apoptosis. Here, we present NMR characterization of the structure and dynamics of human tBid in 1-palmitoyl-2-hydroxy-sn-glycero-3-[phospho-RAC-(1-glycerol)] micelles. Our data showed that tBid is monomeric with six well defined -helices in the micelles. Compared with the full-length Bid structure, a longer flexible loop between tBid helix (4) and (5) was observed. Helices in tBid do not pack into a compact-fold but form an extended structure with a C-shape configuration in the micelles. All six tBid helices were shown to interact with LPPG micelles, with helix (6) and (7) being more embedded. Of note, the BH3-containing helix (3), which was previously believed to be exposed above the membrane surface, is also membrane associated, suggesting an on the membrane binding mode for tBid interaction with Bax. Our data provided structural details on the membrane-associated state of tBid and the functional implications of its membrane-associated BH3 domain.
C1 [Wang, Yu; Tjandra, Nico] NHLBI, Lab Mol Biophys, Biochem & Biophys Ctr, NIH, Bethesda, MD 20892 USA.
RP Tjandra, N (reprint author), NHLBI, Lab Mol Biophys, Biochem & Biophys Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM tjandran@nhlbi.nih.gov
FU National Institutes of Health grant from the Intramural Research Program
of the NHLBI
FX This work was supported, in whole or in part, by a National Institutes
of Health grant from the Intramural Research Program of the NHLBI (to N.
T.).
NR 79
TC 20
Z9 20
U1 3
U2 17
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 13
PY 2013
VL 288
IS 50
BP 35840
EP 35851
DI 10.1074/jbc.M113.503680
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 291FZ
UT WOS:000329814700021
PM 24158446
ER
PT J
AU Chagas, AC
Calvo, E
Rios-Velasquez, CM
Pessoa, FAC
Medeiros, JF
Ribeiro, JMC
AF Chagas, Andrezza C.
Calvo, Eric
Rios-Velasquez, Claudia M.
Pessoa, Felipe A. C.
Medeiros, Jansen F.
Ribeiro, Jose M. C.
TI A deep insight into the sialotranscriptome of the mosquito, Psorophora
albipes
SO BMC GENOMICS
LA English
DT Article
ID SALIVARY-GLAND TRANSCRIPTOME; FLY LUTZOMYIA-LONGIPALPIS; WEST NILE
VIRUS; RNA-SEQ DATA; AEDES-AEGYPTI; YELLOW-FEVER; SEQUENCE ALIGNMENT;
VECTOR COMPETENCE; IXODES-SCAPULARIS; ENZOOTIC STRAINS
AB Background: Psorophora mosquitoes are exclusively found in the Americas and have been associated with transmission of encephalitis and West Nile fever viruses, among other arboviruses. Mosquito salivary glands represent the final route of differentiation and transmission of many parasites. They also secrete molecules with powerful pharmacologic actions that modulate host hemostasis, inflammation, and immune response. Here, we employed next generation sequencing and proteome approaches to investigate for the first time the salivary composition of a mosquito member of the Psorophora genus. We additionally discuss the evolutionary position of this mosquito genus into the Culicidae family by comparing the identity of its secreted salivary compounds to other mosquito salivary proteins identified so far.
Results: Illumina sequencing resulted in 13,535,229 sequence reads, which were assembled into 3,247 contigs. All families were classified according to their in silico-predicted function/activity. Annotation of these sequences allowed classification of their products into 83 salivary protein families, twenty (24.39%) of which were confirmed by our subsequent proteome analysis. Two protein families were deorphanized from Aedes and one from Ochlerotatus, while four protein families were described as novel to Psorophora genus because they had no match with any other known mosquito salivary sequence. Several protein families described as exclusive to Culicines were present in Psorophora mosquitoes, while we did not identify any member of the protein families already known as unique to Anophelines. Also, the Psorophora salivary proteins had better identity to homologs in Aedes (69.23%), followed by Ochlerotatus (8.15%), Culex (6.52%), and Anopheles (4.66%), respectively.
Conclusions: This is the first sialome (from the Greek sialo = saliva) catalog of salivary proteins from a Psorophora mosquito, which may be useful for better understanding the lifecycle of this mosquito and the role of its salivary secretion in arboviral transmission.
C1 [Chagas, Andrezza C.; Calvo, Eric; Ribeiro, Jose M. C.] NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD USA.
[Rios-Velasquez, Claudia M.; Pessoa, Felipe A. C.] Fiocruz MS, Inst Leonidas & Maria Deane, Biodivers Lab, Manaus, Amazonas, Brazil.
[Medeiros, Jansen F.] Fiocruz Rondonia, Entomol Lab, Porto Velho, Rondonia, Brazil.
RP Ribeiro, JMC (reprint author), NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD USA.
EM jribeiro@nih.gov
RI Ribeiro, Jose/J-7011-2015; Rios Velasquez, Claudia Maria/K-2901-2015;
OI Calvo, Eric/0000-0001-7880-2730; Ribeiro, Jose/0000-0002-9107-0818
FU Intramural Research Program of the Division of Intramural Research,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health; Fundacao Oswaldo Cruz (Fiocruz) represented by
Instituto Leonidas e Maria Deane (ILMD); FIOCRUZ/CNPq
FX This work was supported by the Intramural Research Program of the
Division of Intramural Research, National Institute of Allergy and
Infectious Diseases, National Institutes of Health and by Fundacao
Oswaldo Cruz (Fiocruz) represented by Instituto Leonidas e Maria Deane
(ILMD). We also thank the PAPES V program support FIOCRUZ/CNPq. We are
grateful to Dr. Michalis Kotsyfakis for the critical reading of the
manuscript and to Brenda Rae Marshall, DPSS, NIAID, for editing
assistance. In addition, we thank Dr. Roberto Rocha
(Fiocruz/Amazonia/Brazil) for his support. Because JMCR, EC, and ACC are
government employees and this is a government work, the work is in the
public domain in the United States. Notwithstanding any other
agreements, the NIH reserves the right to provide the work to
PubMedCentral for display and use by the public, and PubMedCentral may
tag or modify the work consistent with its customary practices. You can
establish rights outside of the U.S. subject to a government use
license.
NR 73
TC 11
Z9 11
U1 0
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD DEC 13
PY 2013
VL 14
AR 875
DI 10.1186/1471-2164-14-875
PG 19
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 285AE
UT WOS:000329363900001
PM 24330624
ER
PT J
AU Akazawa, Y
Isomoto, H
Matsushima, K
Kanda, T
Minami, H
Yamaghchi, N
Taura, N
Shiozawa, K
Ohnita, K
Takeshima, F
Nakano, M
Moss, J
Hirayama, T
Nakao, K
AF Akazawa, Yuko
Isomoto, Hajime
Matsushima, Kayoko
Kanda, Tsutomu
Minami, Hitomi
Yamaghchi, Naoyuki
Taura, Naota
Shiozawa, Ken
Ohnita, Ken
Takeshima, Fuminao
Nakano, Masayuki
Moss, Joel
Hirayama, Toshiya
Nakao, Kazuhiko
TI Endoplasmic Reticulum Stress Contributes to Helicobacter Pylori
VacA-Induced Apoptosis
SO PLOS ONE
LA English
DT Article
ID CYTOCHROME-C RELEASE; UNFOLDED PROTEIN RESPONSE; GASTRIC
EPITHELIAL-CELLS; FATTY LIVER-DISEASE; VACUOLATING CYTOTOXIN; ER STRESS;
MOLECULAR-MECHANISMS; UP-REGULATION; TOXIN VACA; DEATH
AB Vacuolating cytotoxin A (VacA) is one of the important virulence factors produced by H. pylori. VacA induces apoptotic cell death, which is potentiated by ammonia. VacA also causes cell death by mitochondrial damage, via signaling pathways that are not fully defined. Our aim was to determine whether endoplasmic reticulum (ER) stress is associated with VacA-induced mitochondrial dysfunction and apoptosis. We found that C/EBP homologous protein (CHOP), a key signaling protein of ER stress-induced apoptosis, was transcriptionally up-regulated following incubation of gastric epithelial cells with VacA. The effect of VacA on CHOP induction was significantly enhanced by co-incubation with ammonium chloride. Phosphorylation of eukaryotic initiation factor 2 (eIF2)-alpha, which is known to occur downstream of the ER stress sensor PKR-like ER-localized eIF2-alpha kinase (PERK) and to regulate CHOP expression, was also observed following incubation with VacA in the presence of ammonium chloride. Knockdown of CHOP by siRNA resulted in inhibition of VacA-induced apoptosis. Further studies showed that silencing of the PERK gene with siRNA attenuated VacA-mediated phosphorylation of eIF2-alpha, CHOP induction, expression of BH3-only protein Bim and Bax activation, and cell death induced by VacA with ammonium chloride, indicating that ER stress may lead to mitochondrial dysfunction during VacA-induced toxicity. Activation of ER stress and up-regulation of BH3-only proteins were also observed in human H. pylori-infected gastric mucosa. Collectively, this study reveals a possible association between VacA-induced apoptosis in gastric epithelial cells, and activation of ER stress in H. pylori-positive gastric mucosa.
C1 [Akazawa, Yuko; Isomoto, Hajime; Matsushima, Kayoko; Kanda, Tsutomu; Minami, Hitomi; Yamaghchi, Naoyuki; Taura, Naota; Shiozawa, Ken; Ohnita, Ken; Takeshima, Fuminao; Nakao, Kazuhiko] Nagasaki Univ Hosp, Dept Gastroenterol & Hepatol, Nagasaki, Japan.
[Nakano, Masayuki; Hirayama, Toshiya] Nagasaki Univ, Dept Bacteriol, Inst Trop Med, Nagasaki 852, Japan.
[Moss, Joel] NHLBI, Cardiovasc & Pulm Branch, NIH, Bethesda, MD 20892 USA.
RP Akazawa, Y (reprint author), Nagasaki Univ Hosp, Dept Gastroenterol & Hepatol, Nagasaki, Japan.
EM akazaway@nagassaki-u.ac.jp
FU MEXT/JSPS KAKENHI [22890138]
FX This study was supported by MEXT/JSPS KAKENHI Grant Number 22890138.
http://www.mext.go.jp/english/. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 50
TC 10
Z9 11
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 13
PY 2013
VL 8
IS 12
AR e82322
DI 10.1371/journal.pone.0082322
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276FP
UT WOS:000328734200037
PM 24349255
ER
PT J
AU Varchetta, S
Lusso, P
Hudspeth, K
Mikulak, J
Mele, D
Paolucci, S
Cimbro, R
Malnati, M
Riva, A
Maserati, R
Mondelli, MU
Mavilio, D
AF Varchetta, Stefania
Lusso, Paolo
Hudspeth, Kelly
Mikulak, Joanna
Mele, Dalila
Paolucci, Stefania
Cimbro, Raffaello
Malnati, Mauro
Riva, Agostino
Maserati, Renato
Mondelli, Mario U.
Mavilio, Domenico
TI Sialic acid-binding Ig-like lectin-7 interacts with HIV-1 gp120 and
facilitates infection of CD4(pos) T cells and macrophages
SO RETROVIROLOGY
LA English
DT Article
DE HIV-1 infection; Siglec-7; CD4+T cells; Macrophages; AIDS patients
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NATURAL-KILLER-CELLS;
PSEUDOMONAS-AERUGINOSA; ALVEOLAR MACROPHAGES; TRANS-INFECTION;
HUMAN-MONOCYTES; IMMUNE-SYSTEM; TROPIC HIV-1; TYPE-1 HIV-1; SIGLECS
AB Background: Sialic acid-binding Ig-like lectin-7 (Siglec-7) expression is strongly reduced on natural killer (NK) cells from HIV-1 infected viremic patients. To investigate the mechanism(s) underlying this phenomenon, we hypothesized that Siglec-7 could contribute to the infection of CD4(pos) target cells following its interaction with HIV-1 envelope (Env) glycoprotein 120 (gp120).
Results: The ability of Siglec-7 to bind gp120 Env in a sialic acid-dependent manner facilitates the infection of both T cells and monocyte-derived macrophages (MDMs). Indeed, pre-incubation of HIV-1 with soluble Siglec-7 (sSiglec-7) increases the infection rate of CD4(pos) T cells, which do not constitutively express Siglec-7. Conversely, selective blockade of Siglec-7 markedly reduces the degree of HIV-1 infection in Siglec-7(pos) MDMs. Finally, the sSiglec-7 amount is increased in the serum of AIDS patients with high levels of HIV-1 viremia and inversely correlates with CD4(pos) T cell counts.
Conclusions: Our results show that Siglec-7 binds HIV-1 and contributes to enhance the susceptibility to infection of CD4(pos) T cells and MDMs. This phenomenon plays a role in HIV-1 pathogenesis and in disease progression, as suggested by the inverse correlation between high serum level of sSiglec-7 and the low CD4(pos) T cell count observed in AIDS patients in the presence of chronic viral replication.
C1 [Varchetta, Stefania; Mele, Dalila; Mondelli, Mario U.] Policlin San Matteo, Res Labs, Dept Infect Dis, Fdn IRCCS, I-27100 Pavia, Italy.
[Lusso, Paolo; Cimbro, Raffaello] NIAID, Lab Immunoregulat, NIH, Bethesda, MD 20892 USA.
[Hudspeth, Kelly; Mikulak, Joanna; Mavilio, Domenico] Humanitas Clin & Res Ctr, Unit Clin & Expt Immunol, Milan, Italy.
[Paolucci, Stefania] Fdn IRCCS Policlin San Matteo, SS Virol Mol, SC Virol & Microbiol, Pavia, Italy.
[Malnati, Mauro] Ist Sci San Raffaele, Unit Human Virol, Div Immunol Transplantat & Infect Dis, I-20132 Milan, Italy.
[Riva, Agostino] Univ Milan, Dipartimento Sci Clin DISC, L Sacco Hosp, Infect Dis & Immunopathol Sect, Milan, Italy.
[Maserati, Renato] Fdn IRCCS Policlin San Matteo, HIV Outpatient Clin, Dept Infect Dis, Pavia, Italy.
[Mondelli, Mario U.] Univ Pavia, Dept Internal Med, I-27100 Pavia, Italy.
[Mavilio, Domenico] Univ Milan, Dept Med Biotechnol & Translat Med, Milan, Italy.
RP Mavilio, D (reprint author), Humanitas Clin & Res Ctr, Unit Clin & Expt Immunol, Milan, Italy.
EM domenico.mavilio@humanitas.it
OI Varchetta, Stefania/0000-0002-0289-2896; Mavilio,
Domenico/0000-0001-6147-0952; Cimbro, Raffaello/0000-0002-6251-5160
FU Italian Ministry of Health, Ricerca Finalizzata, Bando ISS
[RF-ICH-2009-1299677]
FX This work was supported by the Italian Ministry of Health, Ricerca
Finalizzata, Bando ISS, [Grant number RF-ICH-2009-1299677] to D. M.,
Ministero della Salute, by Ricerca Corrente Fondazione IRCCS Policlinico
San Matteo: "Role of Innate Immune Response during Hepatitis C virus
infection", and by the intramural research program of National Institute
of Allergy and Infectious Diseases, National Institutes of Health, USA.
NR 62
TC 8
Z9 8
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD DEC 13
PY 2013
VL 10
AR 154
DI 10.1186/1742-4690-10-154
PG 13
WC Virology
SC Virology
GA 280SE
UT WOS:000329050300002
PM 24330394
ER
PT J
AU Ryan, JF
Pang, K
Schnitzler, CE
Nguyen, AD
Moreland, RT
Simmons, DK
Koch, BJ
Francis, WR
Havlak, P
Smith, SA
Putnam, NH
Haddock, SHD
Dunn, CW
Wolfsberg, TG
Mullikin, JC
Martindale, MQ
Baxevanis, AD
AF Ryan, Joseph F.
Pang, Kevin
Schnitzler, Christine E.
Anh-Dao Nguyen
Moreland, R. Travis
Simmons, David K.
Koch, Bernard J.
Francis, Warren R.
Havlak, Paul
Smith, Stephen A.
Putnam, Nicholas H.
Haddock, Steven H. D.
Dunn, Casey W.
Wolfsberg, Tyra G.
Mullikin, James C.
Martindale, Mark Q.
Baxevanis, Andreas D.
CA NISC Comparative Sequencing Progra
TI The Genome of the Ctenophore Mnemiopsis leidyi and Its Implications for
Cell Type Evolution
SO SCIENCE
LA English
DT Article
ID NERVOUS-SYSTEM; HOMEOBOX GENES; METAZOAN; ORIGIN; EXPRESSION; REVEALS;
TREE; ULTRASTRUCTURE; ORGANIZATION; INSIGHTS
AB An understanding of ctenophore biology is critical for reconstructing events that occurred early in animal evolution. Toward this goal, we have sequenced, assembled, and annotated the genome of the ctenophore Mnemiopsis leidyi. Our phylogenomic analyses of both amino acid positions and gene content suggest that ctenophores rather than sponges are the sister lineage to all other animals. Mnemiopsis lacks many of the genes found in bilaterian mesodermal cell types, suggesting that these cell types evolved independently. The set of neural genes in Mnemiopsis is similar to that of sponges, indicating that sponges may have lost a nervous system. These results present a newly supported view of early animal evolution that accounts for major losses and/or gains of sophisticated cell types, including nerve and muscle cells.
C1 [Ryan, Joseph F.; Schnitzler, Christine E.; Anh-Dao Nguyen; Moreland, R. Travis; Koch, Bernard J.; Wolfsberg, Tyra G.; Mullikin, James C.; Baxevanis, Andreas D.] NHGRI, Genome Technol Branch, Div Intramural Res, NIH, Bethesda, MD 20892 USA.
[Ryan, Joseph F.; Pang, Kevin] Univ Bergen, Sars Int Ctr Marine Mol Biol, N-5008 Bergen, Norway.
[Simmons, David K.; Martindale, Mark Q.] Univ Florida, Whitney Lab Marine Biosci, St Augustine, FL 32080 USA.
[Francis, Warren R.; Haddock, Steven H. D.] Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA.
[Havlak, Paul; Putnam, Nicholas H.] Rice Univ, Dept Ecol & Evolutionary Biol, Houston, TX 77098 USA.
[Mullikin, James C.; NISC Comparative Sequencing Progra] NHGRI, NIH Intramural Sequencing Ctr, NIH, Rockville, MD 20852 USA.
[Smith, Stephen A.; Dunn, Casey W.] Brown Univ, Dept Ecol & Evolutionary Biol, Providence, RI 02912 USA.
[Smith, Stephen A.] Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA.
RP Baxevanis, AD (reprint author), NHGRI, Genome Technol Branch, Div Intramural Res, NIH, Bethesda, MD 20892 USA.
EM andy@mail.nih.gov
RI Putnam, Nicholas/B-9968-2008;
OI Putnam, Nicholas/0000-0002-1315-782X; Dunn, Casey/0000-0003-0628-5150
FU National Human Genome Research Institute (NHGRI), NIH; NASA; NSF; Sars
International Centre for Marine Molecular Biology; University of Bergen
FX This research was supported by the Intramural Research Program of the
National Human Genome Research Institute (NHGRI), NIH. This work was
also supported in part by NASA and NSF grants to M. Q. M. J.F.R.
received additional support from the Sars International Centre for
Marine Molecular Biology and the University of Bergen. We thank A.
Young, B. Schmidt, N. Gurson, R. Legaspi, B. Novotny, and R. Blakesley,
who were responsible for the sequencing performed at the NIH Intramural
Sequencing Center (NISC); A. Prasad, D. Gildea, N. Trivedi, A. Yun, K.
Siewert, D. Leja, S. Bond, and G. Bouffard at NHGRI; A. Hejnol, D.
Chourrout, L. Leclere, G. Richards, F. Rentzsch, C. Martin, H. Hausen,
S. Henriet, S. Church, and S9 at Sars; B. Vellutini for the photo of M.
leidyi used in Fig. 1A; W. Browne for access to additional RNA-seq data
from early developmental stages of M. leidyi; J. Lehmann for supplying
an updated near intron pair matrix; C. Trapnell for help with the Bowtie
short-read aligner and Cufflinks transcript assembly program; M.
Srivastava for phylogenetic data sets and advice; I. Ruiz-Trillo and the
Origins of Multicellularity Sequencing Project, Broad Institute of
Harvard and MIT for use of their genomic data; D. Rokhsar and the Joint
Genome Institute for use of their genomic data; and other researchers
whose publicly available sequence data were used in this study. The
views expressed in this paper do not necessarily reflect the views of
those acknowledged. We dedicate this manuscript to the pioneering work
of the late Sebastian Beroe of the Stazione Zoologica in Naples. The
authors declare no competing financial interests. The genome sequence
data can be accessed from GenBank as project accession AGCP00000000 and
from http://research.nhgri.nih.gov/mnemiopsis/. Contributions are as
follows: genome and RNA-seq sequencing and assembly: NISC and J. C. M.;
annotation: J. F. R., K. P., C. E. S., P. H., N. H. P., A.-D.N., R. T.
M., B. J. K., and T. G. W.; analysis: J. F. R., K. P., C. E. S., D. K.
S., B. J. K., P. H., N. H. P., M. Q. M., and A. D. B.; additional
ctenophore data: S. H. D. H. and W. R. F.; phylogenetics: J. F. R., S.
A. S., and C. W. D.; writing: J. F. R., K. P., C. E. S., D. K. S., R. T.
M., C. W. D., M. Q. M., and A. D. B.; project design and coordination:
J. F. R., M. Q. M., and A.D.B.
NR 53
TC 212
Z9 214
U1 12
U2 115
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD DEC 13
PY 2013
VL 342
IS 6164
BP 1336
EP +
DI 10.1126/science.1242592
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 268UL
UT WOS:000328196000040
ER
PT J
AU Hardy, RR
Roederer, M
AF Hardy, Richard R.
Roederer, Mario
TI Leonard Herzenberg (1931-2013): The Life of FACS Obituary
SO IMMUNITY
LA English
DT Biographical-Item
C1 [Hardy, Richard R.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Roederer, Mario] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
RP Roederer, M (reprint author), NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
EM roederer@nih.gov
NR 1
TC 0
Z9 0
U1 0
U2 0
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD DEC 12
PY 2013
VL 39
IS 6
BP 989
EP 991
DI 10.1016/j.immuni.2013.11.008
PG 3
WC Immunology
SC Immunology
GA AA2UZ
UT WOS:000330951000002
PM 24479158
ER
PT J
AU Lavender, KJ
Pang, WW
Messer, RJ
Duley, AK
Race, B
Phillips, K
Scott, D
Peterson, KE
Chan, CK
Dittmer, U
Dudek, T
Allen, TM
Weissman, IL
Hasenkrug, KJ
AF Lavender, Kerry J.
Pang, Wendy W.
Messer, Ronald J.
Duley, Amanda K.
Race, Brent
Phillips, Katie
Scott, Dana
Peterson, Karin E.
Chan, Charles K.
Dittmer, Ulf
Dudek, Timothy
Allen, Todd M.
Weissman, Irving L.
Hasenkrug, Kim J.
TI BLT-humanized C57BL/6 Rag2(-/-)gamma(-/-)(c)CD47(-/-) mice are resistant
to GVHD and develop B- and T-cell immunity to HIV infection
SO BLOOD
LA English
DT Article
ID HEMATOPOIETIC STEM-CELLS; SCID-HU MOUSE; REGULATORY PROTEIN ALPHA;
RECEPTOR-GAMMA CHAIN; IN-VIVO; CORD BLOOD; ENGRAFTMENT; MODEL;
IMMUNODEFICIENCY; RESPONSES
AB The use of C57BL/6 Rag2(-/-)gamma(-/-)(c) mice as recipients for xenotransplantation with human immune systems (humanization) has been problematic because C57BL/6 SIRP alpha does not recognize human CD47, and such recognition is required to suppress macrophage-mediated phagocytosis of transplanted human hematopoietic stem cells (HSCs). We show that genetic inactivation of CD47 on the C57BL/6 Rag2(-/-)gamma(-/-)(c) background negates the requirement for CD47-signal recognition protein alpha (SIRP alpha) signaling and induces tolerance to transplanted human HSCs. These triple-knockout, bone marrow, liver, thymus (TKO-BLT) humanized mice develop organized lymphoid tissues including mesenteric lymph nodes, splenic follicles and gut-associated lymphoid tissue that demonstrate high levels of multilineage hematopoiesis. Importantly, these mice have an intact complement system and showed no signs of graft-versus-host disease (GVHD) out to 29 weeks after transplantation. Sustained, high-level HIV-1 infection was observed via either intrarectal or intraperitoneal inoculation. TKO-BLT mice exhibited hallmarks of human HIV infection including CD4(+) T-cell depletion, immune activation, and development of HIV-specific B-and T-cell responses. The lack of GVHD makes the TKO-BLT mouse a significantly improved model for long-term studies of pathogenesis, immune responses, therapeutics, and vaccines to human pathogens.
C1 [Lavender, Kerry J.; Messer, Ronald J.; Duley, Amanda K.; Race, Brent; Phillips, Katie; Peterson, Karin E.; Hasenkrug, Kim J.] NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, Hamilton, MT USA.
[Pang, Wendy W.; Chan, Charles K.; Weissman, Irving L.] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA.
[Pang, Wendy W.; Chan, Charles K.; Weissman, Irving L.] Stanford Univ, Sch Med, Ludwig Ctr Canc Cell Res, Stanford, CA 94305 USA.
[Scott, Dana] NIAID, Rocky Mt Vet Branch, Rocky Mt Labs, NIH, Hamilton, MT USA.
[Dittmer, Ulf] Univ Duisburg Essen, Univ Hosp Essen, Inst Virol, Essen, Germany.
[Dudek, Timothy; Allen, Todd M.] Ragon Inst Massachusetts Gen Hosp MIT & Harvard, Cambridge, MA USA.
RP Hasenkrug, KJ (reprint author), Rocky Mt Labs, 903 S 4th St, Hamilton, MT 59875 USA.
EM kerry.lavender@nih.gov; khasenkrug@nih.gov
RI Allen, Todd/F-5473-2011
FU Intramural Research Program of the National Institute of Allergy and
Infectious Diseases, National Institutes of Health HIVRAD grant [P01
AI104715]; Intramural Research Program of the Medical Faculty of the
University Duisburg-Essen; Ludwig Foundation
FX This work was supported by the Intramural Research Program of the
National Institute of Allergy and Infectious Diseases, National
Institutes of Health HIVRAD grant P01 AI104715 (to T. M. A.), the
Intramural Research Program of the Medical Faculty of the University
Duisburg-Essen, and funding from the Ludwig Foundation.
NR 38
TC 26
Z9 28
U1 0
U2 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 12
PY 2013
VL 122
IS 25
BP 4013
EP 4020
DI 10.1182/blood-2013-06-506949
PG 8
WC Hematology
SC Hematology
GA 290FH
UT WOS:000329739100009
PM 24021673
ER
PT J
AU Ma, DY
Mizurini, DM
Assumpcao, TCF
Li, Y
Qi, YW
Kotsyfakis, M
Ribeiro, JMC
Monteiro, RQ
Francischetti, IMB
AF Ma, Dongying
Mizurini, Daniella M.
Assumpcao, Teresa C. F.
Li, Yuan
Qi, Yanwei
Kotsyfakis, Michail
Ribeiro, Jose M. C.
Monteiro, Robson Q.
Francischetti, Ivo M. B.
TI Desmolaris, a novel factor XIa anticoagulant from the salivary gland of
the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis
in vivo
SO BLOOD
LA English
DT Article
ID FACTOR PATHWAY INHIBITOR; TISSUE FACTOR PATHWAY; FACTOR-XA; ARTERIAL
THROMBOSIS; CAROTID-ARTERY; COAGULATION; PROTEIN; ACTIVATION; DOMAIN;
PROTEASES
AB The identity of vampire bat saliva anticoagulant remained elusive for almost a century. Sequencing the salivary gland genes from the vampire bat Desmodus rotundus identified Desmolaris as a novel 21.5-kDa naturally deleted (Kunitz 1-domainless) form of tissue factor pathway inhibitor. Recombinant Desmolaris was expressed in HEK293 cells and characterized as a slow, tight, and noncompetitive inhibitor of factor (F) XIa by a mechanism modulated by heparin. Desmolaris also inhibits FXa with lower affinity, independently of protein S. In addition, Desmolaris binds kallikrein and reduces bradykinin generation in plasma activated with kaolin. Truncated and mutated forms of Desmolaris determined that Arg32 in the Kunitz-1 domain is critical for protease inhibition. Moreover, Kunitz-2 and the carboxyl-terminus domains mediate interaction of Desmolaris with heparin and are required for optimal inhibition of FXIa and FXa. Notably, Desmolaris (100 mu g/kg) inhibited FeCl3-induced carotid artery thrombus without impairing hemostasis. These results imply that FXIa is the primary in vivo target for Desmolaris at antithrombotic concentrations. Desmolaris also reduces the polyphosphate-induced increase in vascular permeability and collagen-and epinephrine-mediated thromboembolism in mice. Desmolaris emerges as a novel anticoagulant targeting FXIa under conditions in which the coagulation activation, particularly the contact pathway, plays a major pathological role.
C1 [Ma, Dongying; Assumpcao, Teresa C. F.; Li, Yuan; Ribeiro, Jose M. C.; Francischetti, Ivo M. B.] NIAID, Sect Vector Biol, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.
[Mizurini, Daniella M.; Monteiro, Robson Q.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Rio De Janeiro, Brazil.
[Qi, Yanwei] NIAID, Malaria Funct Genom Sect, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.
[Kotsyfakis, Michail] Acad Sci Czech Republic, Inst Parasitol, Ctr Biol, CR-37005 Ceske Budejovice, Czech Republic.
RP Francischetti, IMB (reprint author), NIAID, Sect Vector Biol, Lab Malaria & Vector Res, NIH, 12735 Twinbrook Pkwy,Twinbrook 3 Bldg,Room 2E-32C, Rockville, MD 20852 USA.
EM ifrancischetti@niaid.nih.gov
RI Kotsyfakis, Michail/G-9525-2014; ma, dongying/D-8623-2012; Monteiro,
Robson/B-8007-2014; Ribeiro, Jose/J-7011-2015;
OI Kotsyfakis, Michail/0000-0002-7526-1876; Ribeiro,
Jose/0000-0002-9107-0818
FU Division of Intramural Research, NIAID, National Institutes of Health;
Grant Agency of the Czech Republic [P502/12/2409]
FX This work was supported by the Intramural Research Program of the
Division of Intramural Research, NIAID, National Institutes of Health,
and the Grant Agency of the Czech Republic (grant P502/12/2409) (M.K.).
NR 50
TC 13
Z9 14
U1 0
U2 20
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 12
PY 2013
VL 122
IS 25
BP 4094
EP 4106
DI 10.1182/blood-2013-08-517474
PG 13
WC Hematology
SC Hematology
GA 290FH
UT WOS:000329739100018
PM 24159172
ER
PT J
AU Kochenderfer, JN
Dudley, ME
Carpenter, RO
Kassim, SH
Rose, JJ
Telford, WG
Hakim, FT
Halverson, DC
Fowler, DH
Hardy, NM
Mato, AR
Hickstein, DD
Gea-Banacloche, JC
Pavletic, SZ
Sportes, C
Maric, I
Feldman, SA
Hansen, BG
Wilder, JS
Blacklock-Schuver, B
Jena, B
Bishop, MR
Gress, RE
Rosenberg, SA
AF Kochenderfer, James N.
Dudley, Mark E.
Carpenter, Robert O.
Kassim, Sadik H.
Rose, Jeremy J.
Telford, William G.
Hakim, Frances T.
Halverson, David C.
Fowler, Daniel H.
Hardy, Nancy M.
Mato, Anthony R.
Hickstein, Dennis D.
Gea-Banacloche, Juan C.
Pavletic, Steven Z.
Sportes, Claude
Maric, Irina
Feldman, Steven A.
Hansen, Brenna G.
Wilder, Jennifer S.
Blacklock-Schuver, Bazetta
Jena, Bipulendu
Bishop, Michael R.
Gress, Ronald E.
Rosenberg, Steven A.
TI Donor-derived CD19-targeted T cells cause regression of malignancy
persisting after allogeneic hematopoietic stem cell transplantation
SO BLOOD
LA English
DT Article
ID CHIMERIC-ANTIGEN-RECEPTOR; CHRONIC LYMPHOCYTIC-LEUKEMIA;
GRAFT-VERSUS-LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; INTERNATIONAL WORKSHOP;
REDUCED-INTENSITY; CLINICAL-TRIAL; HOST-DISEASE; LYMPHOMA; THERAPY
AB New treatments are needed for B-cell malignancies persisting after allogeneic hematopoietic stem cell transplantation (alloHSCT). We conducted a clinical trial of allogeneic T cells genetically modified to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19. T cells for genetic modification were obtained from each patient's alloHSCT donor. All patients had malignancy that persisted after alloHSCT and standard donor lymphocyte infusions (DLIs). Patients did not receive chemotherapy prior to the CAR T-cell infusions and were not lymphocyte depleted at the time of the infusions. The 10 treated patients received a single infusion of allogeneic anti-CD19-CAR T cells. Three patients had regressions of their malignancies. One patient with chronic lymphocytic leukemia (CLL) obtained an ongoing complete remission after treatment with allogeneic anti-CD19-CAR T cells, another CLL patient had tumor lysis syndrome as his leukemia dramatically regressed, and a patient with mantle cell lymphoma obtained an ongoing partial remission. None of the 10 patients developed graft-versus-host disease (GVHD). Toxicities included transient hypotension and fever. We detected cells containing the anti-CD19-CAR gene in the blood of 8 of 10 patients. These results show for the first time that donor-derived allogeneic anti-CD19-CAR T cells can cause regression of B-cell malignancies resistant to standard DLIs without causing GVHD. This trial was registered at www.clinicaltrials.gov as #NCT01087294.
C1 [Kochenderfer, James N.; Carpenter, Robert O.; Rose, Jeremy J.; Telford, William G.; Hakim, Frances T.; Halverson, David C.; Fowler, Daniel H.; Hardy, Nancy M.; Hickstein, Dennis D.; Gea-Banacloche, Juan C.; Pavletic, Steven Z.; Sportes, Claude; Hansen, Brenna G.; Blacklock-Schuver, Bazetta; Gress, Ronald E.] NCI, Expt Transplantat & Immunol Branch, Bethesda, MD 20892 USA.
[Dudley, Mark E.; Kassim, Sadik H.; Feldman, Steven A.; Rosenberg, Steven A.] NCI, Surg Branch, Bethesda, MD 20892 USA.
[Mato, Anthony R.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA.
[Maric, Irina] NIH, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA.
[Wilder, Jennifer S.] NCI, Clin Res Directorate Sci Applicat Int Corp Freder, Frederick, MD 21701 USA.
[Jena, Bipulendu] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Bishop, Michael R.] Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA.
RP Kochenderfer, JN (reprint author), NIH, 10 Ctr Dr,CRC Room 3-3330, Bethesda, MD 20892 USA.
EM kochendj@mail.nih.gov
RI Jena, Bipulendu/G-8206-2014
FU National Institutes of Health National Cancer Institute, Center for
Cancer Research; National Institutes of Health National Cancer Institute
[HHSN261200800001E]
FX This work was supported by intramural funding of the National Institutes
of Health National Cancer Institute, Center for Cancer Research. This
project has been funded in part with federal funds from the National
Institutes of Health National Cancer Institute (contract no.
HHSN261200800001E).
NR 45
TC 161
Z9 170
U1 5
U2 39
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 12
PY 2013
VL 122
IS 25
BP 4129
EP 4139
DI 10.1182/blood-2013-08-519413
PG 11
WC Hematology
SC Hematology
GA 290FH
UT WOS:000329739100022
PM 24055823
ER
PT J
AU Brady, OJ
Johansson, MA
Guerra, CA
Bhatt, S
Golding, N
Pigott, DM
Delatte, H
Grech, MG
Leisnham, PT
Maciel-de-Freitas, R
Styer, LM
Smith, DL
Scott, TW
Gething, PW
Hay, SI
AF Brady, Oliver J.
Johansson, Michael A.
Guerra, Carlos A.
Bhatt, Samir
Golding, Nick
Pigott, David M.
Delatte, Helene
Grech, Marta G.
Leisnham, Paul T.
Maciel-de-Freitas, Rafael
Styer, Linda M.
Smith, David L.
Scott, Thomas W.
Gething, Peter W.
Hay, Simon I.
TI Modelling adult Aedes aegypti and Aedes albopictus survival at different
temperatures in laboratory and field settings
SO PARASITES & VECTORS
LA English
DT Article
DE Aedes; Survival; Temperature; Mortality; Longevity; Modelling;
Mark-release-recapture; Dengue; Transmission; Generalised additive
models
ID DENGUE VIRUS TRANSMISSION; BLOOD PLUS SUGAR; RIO-DE-JANEIRO;
DIPTERA-CULICIDAE; RELEASE-RECAPTURE; PUERTO-RICO; CONTAINER
PRODUCTIVITY; LIFE TABLE; MORTALITY; MOSQUITOS
AB Background: The survival of adult female Aedes mosquitoes is a critical component of their ability to transmit pathogens such as dengue viruses. One of the principal determinants of Aedes survival is temperature, which has been associated with seasonal changes in Aedes populations and limits their geographical distribution. The effects of temperature and other sources of mortality have been studied in the field, often via mark-release-recapture experiments, and under controlled conditions in the laboratory. Survival results differ and reconciling predictions between the two settings has been hindered by variable measurements from different experimental protocols, lack of precision in measuring survival of free-ranging mosquitoes, and uncertainty about the role of age-dependent mortality in the field.
Methods: Here we apply generalised additive models to data from 351 published adult Ae. aegypti and Ae. albopictus survival experiments in the laboratory to create survival models for each species across their range of viable temperatures. These models are then adjusted to estimate survival at different temperatures in the field using data from 59 Ae. aegypti and Ae. albopictus field survivorship experiments. The uncertainty at each stage of the modelling process is propagated through to provide confidence intervals around our predictions.
Results: Our results indicate that adult Ae. albopictus has higher survival than Ae. aegypti in the laboratory and field, however, Ae. aegypti can tolerate a wider range of temperatures. A full breakdown of survival by age and temperature is given for both species. The differences between laboratory and field models also give insight into the relative contributions to mortality from temperature, other environmental factors, and senescence and over what ranges these factors can be important.
Conclusions: Our results support the importance of producing site-specific mosquito survival estimates. By including fluctuating temperature regimes, our models provide insight into seasonal patterns of Ae. aegypti and Ae. albopictus population dynamics that may be relevant to seasonal changes in dengue virus transmission. Our models can be integrated with Aedes and dengue modelling efforts to guide and evaluate vector control, better map the distribution of disease and produce early warning systems for dengue epidemics.
C1 [Brady, Oliver J.; Guerra, Carlos A.; Bhatt, Samir; Golding, Nick; Pigott, David M.; Gething, Peter W.; Hay, Simon I.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Tinbergen Bldg,South Parks Rd, Oxford, England.
[Johansson, Michael A.] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR USA.
[Delatte, Helene] CIRAD, UMR PVBMT, St Piarre 97410, Reunion.
[Grech, Marta G.] Univ Nacl Patagonia San Juan Bosco, FCN Sede, Lab Invest Ecol & Sistemat Anim, Esquel, Chubut, Argentina.
[Leisnham, Paul T.] Univ Maryland, Dept Environm Sci & Technol, College Pk, MD 20742 USA.
[Maciel-de-Freitas, Rafael] Fiocruz MS, Inst Oswaldo Cruz, Lab Transmissores Hematozoarios, BR-21045900 Rio De Janeiro, RJ, Brazil.
[Styer, Linda M.] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12208 USA.
[Smith, David L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Scott, Thomas W.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA.
[Smith, David L.; Scott, Thomas W.; Hay, Simon I.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
RP Brady, OJ (reprint author), Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Tinbergen Bldg,South Parks Rd, Oxford, England.
EM oliver.brady@zoo.ox.ac.uk
RI Hay, Simon/F-8967-2015;
OI Golding, Nick/0000-0001-8916-5570; Hay, Simon/0000-0002-0611-7272;
Gething, Peter/0000-0001-6759-5449; Brady, Oliver/0000-0002-3235-2129;
Pigott, David/0000-0002-6731-4034
FU BBSRC studentship; Department of Zoology at the University of Oxford;
Medical Research Council (UK) Career Development Fellow [K00669X]; Bill
and Melinda Gates Foundation [OPP1068048]; Bill AMP; Melinda Gates
Foundation [OPP1053338]; Wellcome Trust [095066]; EU [21803]; RAPIDD
program of the Science AMP; Technology Directorate; Department of
Homeland Security; Fogarty International Center, National Institutes of
Health
FX O.J.B. is funded by a BBSRC studentship. DMP is funded by a Sir Richard
Southwood Graduate Scholarship from the Department of Zoology at the
University of Oxford. P.W.G is a Medical Research Council (UK) Career
Development Fellow (#K00669X) and receives support from the Bill and
Melinda Gates Foundation (#OPP1068048) which also supports S.B. N.G. is
funded by a grant from the Bill & Melinda Gates Foundation (OPP1053338).
S. I. H. is funded by a Senior Research Fellowship from the Wellcome
Trust (095066). This study was partially funded by EU grant 21803 IDAMS
(http://www.idams.eu). The contents of this publication are the sole
responsibility of the authors and don't necessarily reflect the views of
the European Commission. S.I.H. C.A.G. and T.W.S. also acknowledge
funding support from the RAPIDD program of the Science & Technology
Directorate, Department of Homeland Security, and the Fogarty
International Center, National Institutes of Health.
NR 79
TC 56
Z9 56
U1 5
U2 58
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-3305
J9 PARASITE VECTOR
JI Parasites Vectors
PD DEC 12
PY 2013
VL 6
AR 351
DI 10.1186/1756-3305-6-351
PG 12
WC Parasitology
SC Parasitology
GA 277RW
UT WOS:000328838000002
PM 24330720
ER
PT J
AU Biancotto, A
Wank, A
Perl, S
Cook, W
Olnes, MJ
Dagur, PK
Fuchs, JC
Langweiler, M
Wang, E
McCoy, JP
AF Biancotto, Angelique
Wank, Abigail
Perl, Shira
Cook, Wendell
Olnes, Matthew J.
Dagur, Pradeep K.
Fuchs, J. Christopher
Langweiler, Marc
Wang, Ena
McCoy, J. Philip
TI Baseline Levels and Temporal Stability of 27 Multiplexed Serum Cytokine
Concentrations in Healthy Subjects
SO PLOS ONE
LA English
DT Article
ID BEAD ARRAY ASSAYS; ATHEROSCLEROSIS; ASSOCIATION; SENSITIVITY; EOTAXIN;
PLASMA; RANTES; ALPHA
AB Background: Cytokines are humoral molecules that elicit regulatory function in immunologic pathways. The level and type of cytokine production has become critical in distinguishing physiologic from pathologic immune conditions. Cytokine profiling has become an important biomarker discovery tool in monitoring of the immune system. However, the variations in cytokine levels in individual subjects over time in healthy individuals have not been extensively studied. In this study, we use multiplex bead arrays to evaluate 27 analytes in paired serum samples taken seven days apart from 144 healthy individuals in order to assess variations over a short time period.
Methods: Fluorescent bead-based immunoassay (Luminex) was used to measure 27 analytes in serum samples. Measurements were performed on matched samples from 144 healthy donors. To assess inter-plate variability, one arbitrarily selected serum sample was analyzed on each of the first ten plates as bridge sample.
Results: Using the bridge sample, we showed minimal inter-plate variations in the measurement of most analytes. In measurement of cytokines from the 144 patients at two time points, we found that three cytokines (IL-2, IL-15 and GM-CSF) were undetectable and five analytes (RANTES, MCP-1, VEGF, MIP-1 beta and PDGF-BB) showed significant difference in concentrations at Day 0 compared to Day 7.
Conclusions: The current study demonstrated higher variations in cytokine levels among individuals than were observed for samples obtained one week apart from identical donors. These data suggest that a serum sample from each subject for use as a baseline measurement is a better control for clinical trials rather than sera from a paired cohort.
C1 [Biancotto, Angelique; Wank, Abigail; Perl, Shira; Cook, Wendell; Olnes, Matthew J.; Dagur, Pradeep K.; Fuchs, J. Christopher; Langweiler, Marc; Wang, Ena; McCoy, J. Philip] NIH, Ctr Human Immunol Autoimmun & Inflammat, Bethesda, MD 20892 USA.
RP McCoy, JP (reprint author), NIH, Ctr Human Immunol Autoimmun & Inflammat, Bldg 10, Bethesda, MD 20892 USA.
EM Mccoyj@nhlbi.nih.gov
FU NIH CHI
FX This work was supported by the NIH CHI intramural research program. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 23
TC 23
Z9 24
U1 2
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 12
PY 2013
VL 8
IS 12
AR UNSP e76091
DI 10.1371/journal.pone.0076091
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276EU
UT WOS:000328731800001
PM 24348989
ER
PT J
AU Kimmel, SE
French, B
Kasner, SE
Johnson, JA
Anderson, JL
Gage, BF
Rosenberg, YD
Eby, CS
Madigan, RA
McBane, RB
Abdel-Rahman, SZ
Stevens, SM
Yale, S
Mohler, ER
Fang, MC
Shah, V
Horenstein, RB
Limdi, NA
Muldowney, JAS
Gujral, J
Delafontaine, P
Desnick, RJ
Ortel, TL
Billett, HH
Pendleton, RC
Geller, NL
Halperin, JL
Goldhaber, SZ
Caldwell, MD
Califf, RM
Ellenberg, JH
AF Kimmel, Stephen E.
French, Benjamin
Kasner, Scott E.
Johnson, Julie A.
Anderson, Jeffrey L.
Gage, Brian F.
Rosenberg, Yves D.
Eby, Charles S.
Madigan, Rosemary A.
McBane, Robert B.
Abdel-Rahman, Sherif Z.
Stevens, Scott M.
Yale, Steven
Mohler, Emile R., III
Fang, Margaret C.
Shah, Vinay
Horenstein, Richard B.
Limdi, Nita A.
Muldowney, James A. S., III
Gujral, Jaspal
Delafontaine, Patrice
Desnick, Robert J.
Ortel, Thomas L.
Billett, Henny H.
Pendleton, Robert C.
Geller, Nancy L.
Halperin, Jonathan L.
Goldhaber, Samuel Z.
Caldwell, Michael D.
Califf, Robert M.
Ellenberg, Jonas H.
CA COAG Investigators
TI A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID GENETICS COAG TRIAL; OPTIMAL ANTICOAGULATION; ATRIAL-FIBRILLATION;
THERAPY; CLARIFICATION; DISEASE; PREDICT
AB BackgroundThe clinical utility of genotype-guided (pharmacogenetically based) dosing of warfarin has been tested only in small clinical trials or observational studies, with equivocal results.
MethodsWe randomly assigned 1015 patients to receive doses of warfarin during the first 5 days of therapy that were determined according to a dosing algorithm that included both clinical variables and genotype data or to one that included clinical variables only. All patients and clinicians were unaware of the dose of warfarin during the first 4 weeks of therapy. The primary outcome was the percentage of time that the international normalized ratio (INR) was in the therapeutic range from day 4 or 5 through day 28 of therapy.
ResultsAt 4 weeks, the mean percentage of time in the therapeutic range was 45.2% in the genotype-guided group and 45.4% in the clinically guided group (adjusted mean difference, [genotype-guided group minus clinically guided group], -0.2; 95% confidence interval, -3.4 to 3.1; P=0.91). There also was no significant between-group difference among patients with a predicted dose difference between the two algorithms of 1 mg per day or more. There was, however, a significant interaction between dosing strategy and race (P=0.003). Among black patients, the mean percentage of time in the therapeutic range was less in the genotype-guided group than in the clinically guided group. The rates of the combined outcome of any INR of 4 or more, major bleeding, or thromboembolism did not differ significantly according to dosing strategy.
ConclusionsGenotype-guided dosing of warfarin did not improve anticoagulation control during the first 4 weeks of therapy. (Funded by the National Heart, Lung, and Blood Institute and others; COAG ClinicalTrials.gov number, NCT00839657.)
In this trial, 1015 patients were assigned to the use of either a genotype-guided algorithm or a clinically guided algorithm for warfarin dosing during the first 5 days. At 4 weeks, there was no significant difference in the percentage of time in the therapeutic INR range. The need for clinical trials before widespread adoption of genotype-guided drug dosing and selection remains widely debated.(1)-(4) Warfarin therapy has served as a model for the potential for pharmacogenetics to improve patient care.(1) Observational studies have identified two genes, CYP2C9 and VKORC1, that are associated with variation in warfarin maintenance doses. However, the clinical utility of starting warfarin at the maintenance dose predicted by genotype-guided algorithms has been tested only in small trials, none of which were definitive.(5)-(8) In contrast, observational studies have suggested potential benefits from genotype-guided dosing.(9),(10) In addition, previous clinical trials could not determine ...
C1 [Kimmel, Stephen E.; French, Benjamin; Kasner, Scott E.; Madigan, Rosemary A.; Mohler, Emile R., III; Ellenberg, Jonas H.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Johnson, Julie A.] Univ Florida, Gainesville, FL USA.
[Anderson, Jeffrey L.; Stevens, Scott M.] Intermt Med Ctr, Murray, UT USA.
[Gage, Brian F.; Eby, Charles S.] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Rosenberg, Yves D.; Geller, Nancy L.] NHLBI, NIH, Bethesda, MD 20892 USA.
[McBane, Robert B.] Mayo Clin, Coll Med, Rochester, MN USA.
[Abdel-Rahman, Sherif Z.] Univ Texas Med Branch, Galveston, TX 77555 USA.
[Yale, Steven; Caldwell, Michael D.] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA.
[Fang, Margaret C.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Shah, Vinay] Henry Ford Hosp, Detroit, MI 48202 USA.
[Horenstein, Richard B.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Limdi, Nita A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Muldowney, James A. S., III] Vanderbilt Univ, Nashville, TN 37235 USA.
[Gujral, Jaspal] Georgia Regents Med Ctr, Augusta, GA USA.
[Delafontaine, Patrice] Tulane Univ, New Orleans, LA 70118 USA.
[Desnick, Robert J.; Halperin, Jonathan L.] Mt Sinai Sch Med, New York, NY USA.
[Billett, Henny H.] Montefiore Med Ctr, New York, NY USA.
[Ortel, Thomas L.; Califf, Robert M.] Duke Univ, Med Ctr, Durham, NC USA.
[Pendleton, Robert C.] Univ Utah Hlth Care, Provo, UT USA.
[Goldhaber, Samuel Z.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Kimmel, SE (reprint author), Ctr Therapeut Effectiveness Res, 923 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM stevek@mail.med.upenn.edu
OI Delafontaine, Patrice/0000-0003-3744-3617
FU National Heart, Lung, and Blood Institute [HHSN-268200800003C]; Pfizer;
Janssen; Novartis; Merck; Medtronic; Photothera; AstraZeneca; Cardionet;
W.L. Gore; Acorda; Daiichi Asubio; Boehringer Ingelheim; Siemens;
serving on an advisory board for Instrumentation Laboratory; Iverson
Genetics; MCG; Bristol-Myers Squibb; Theravasc; Bayer; Instrumentation
Laboratory; Eisai; GlaxoSmithKline; Daiichi Sankyo; Daiichi SanIcyo;
Baxter; Portola; Sanofi-Aventis; Daiichi Sanlcyo; EKOS; Johnson Johnson;
Roche; Bristol-Myers Squibb Foundation; Regeneron; CV Sight; Eli Lilly;
Gambro; Kowa; Genentech; Laboratoires Servier; Amylin; Merck/Schering
Plough
FX Supported under a contract (HHSN-268200800003C) with the National Heart,
Lung, and Blood Institute. Bristol-Myers Squibb donated Coumadin
(warfarin). GenMark Diagnostics and AutoGenomics loaned genotyping
platforms to the clinical centers.; Dr. Kimmel reports receiving
consulting fees from Pfizer and Janssen; Dr. Kasner, receiving personal
fees from Novartis, Pfizer, Merck, Medtronic, Photothera, AstraZeneca,
and Cardionet and grant support from W.L. Gore, Acorda, and Daiichi
Asubio; Dr. Gage, receiving consulting fees from Boehringer Ingelheim;
Dr. Eby, receiving grant support from Siemens and serving on an advisory
board for Instrumentation Laboratory; Dr. Stevens, receiving grant
support from Iverson Genetics; Dr. Muldowney, receiving consulting fees
from MCG (formerly Milliman Care Guidelines), lecture fees from
Bristol-Myers Squibb, Pfizer, and Boehringer Ingelheim, and grant
support from Novartis and Theravasc; Dr. Ortel, receiving consulting
fees from Boehringer Ingelheim, Bayer, and Instrumentation Laboratory
and grant support from Eisai, GlaxoSmithKline, Pfizer, Daiichi Sankyo,
and Instrumentation Laboratory; Dr. Goldhaber, receiving consulting fees
from Bristol-Myers Squibb, Daiichi SanIcyo, Baxter, Boehringer
Ingelheim, Eisai, Merck, Pfizer, Portola, and Sanofi-Aventis and grant
support from Bristol-Myers Squibb, Daiichi Sanlcyo, EKOS, and Johnson &
Johnson; Dr. Caldwell, holding a patent, issued to the Marshfield
Clinic, on the use of CYP4F2 for warfarin dosing; Dr. Califf, serving as
a board member at Portola, receiving consulting fees from Novartis,
Johnson & Johnson, Bayer, Roche, Pfizer, Bristol-Myers Squibb
Foundation, Regeneron, CV Sight, Daiichi Sankyo, Eli Lilly, Gambro,
Kowa, Genentech, GlaxoSmithKline, Laboratoires Servier, and Portola,
receiving grant support from Amylin, Johnson & Johnson, Merck/Schering
Plough, Novartis, Bristol-Myers Squibb Foundation, and Eli Lilly, and
having an equity interest in N30 Pharma; and Dr. Ellenberg, receiving
consulting fees from Bristol-Myers Squibb. No other potential conflict
of interest relevant to this article was reported.
NR 30
TC 273
Z9 289
U1 1
U2 14
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 12
PY 2013
VL 369
IS 24
BP 2283
EP 2293
DI 10.1056/NEJMoa1310669
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 268FV
UT WOS:000328156300006
PM 24251361
ER
PT J
AU Schiffman, M
Solomon, D
AF Schiffman, Mark
Solomon, Diane
TI Cervical-Cancer Screening with Human Papillomavirus and Cytologic
Cotesting
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID LIQUID-BASED CYTOLOGY; NEOPLASIA GRADE 2/3; COLLABORATIVE REANALYSIS;
INDIVIDUAL DATA; CLINICAL-PRACTICE; AMERICAN SOCIETY; 5-YEAR RISKS;
WOMEN; HPV; TESTS
C1 [Schiffman, Mark] NCI, Div Canc Epidemiol & Genet, NIH, Rockville, MD 20850 USA.
[Solomon, Diane] NCI, Canc Prevent Div, NIH, Rockville, MD 20850 USA.
RP Schiffman, M (reprint author), NCI, Div Canc Epidemiol & Genet, 9609 Med Ctr Dr, Rockville, MD 20850 USA.
EM schiffmm@exchange.nih.gov
NR 54
TC 23
Z9 24
U1 1
U2 10
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 12
PY 2013
VL 369
IS 24
BP 2324
EP 2331
DI 10.1056/NEJMcp1210379
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 268FV
UT WOS:000328156300010
PM 24328466
ER
PT J
AU Banala, AK
Zhang, P
Plenge, P
Cyriac, G
Kopajtic, T
Katz, JL
Loland, CJ
Newman, AH
AF Banala, Ashwini K.
Zhang, Peng
Plenge, Per
Cyriac, George
Kopajtic, Theresa
Katz, Jonathan L.
Loland, Claus Juul
Newman, Amy Hauck
TI Design and Synthesis of
1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-
5-carbonitrile (Citalopram) Analogues as Novel Probes for the Serotonin
Transporter S1 and S2 Binding Sites
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HIGH-AFFINITY; NEUROTRANSMITTER TRANSPORTERS; NOREPINEPHRINE
TRANSPORTERS; H-3 IMIPRAMINE; ALLOSTERIC MECHANISM; BACTERIAL HOMOLOG;
5-HT TRANSPORTER; ANTIDEPRESSANTS; LEUT; RECOGNITION
AB The serotonin transporter (SERT) is the primary target for antidepressant drugs. The existence of a high affinity primary orthosteric binding site (S1) and a low affinity secondary site (S2) has been described, and their relation to antidepressant pharmacology has been debated. Herein, structural modifications to the N, 4, 5, and 4' positions of (+/-)citalopram (1) are reported. All of the analogues were SERT-selective and demonstrated that steric bulk was tolerated at the SERT Si site, including two dimeric ligands (15 and 51). In addition, eight analogues were identified with similar potencies to S-1 for decreasing the dissociation of [H-3]S-1 from the S1 site via allosteric modulation at S2. Both dimeric compounds had similar affinities for the SERT Si site (K-i = 19.7 and 30.2 nM, respectively), whereas only the N-substituted analogue, 51, was as effective as S-1 in allosterically modulating the binding of [H-3]S-1 via S2.
C1 [Banala, Ashwini K.; Zhang, Peng; Cyriac, George; Newman, Amy Hauck] NIDA, Med Chem Sect, Mol Targets & Medicat Discovery Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA.
[Kopajtic, Theresa; Katz, Jonathan L.] NIDA, Psychobiol Sect, Mol Targets & Medicat Discovery Branch, Intramural Res Program,NIH, Baltimore, MD 21224 USA.
[Plenge, Per; Loland, Claus Juul] Univ Copenhagen, Mol Neuropharmacol Lab, Dept Neurosci & Pharmacol, Fac Hlth & Med Sci, DK-2200 Copenhagen N, Denmark.
RP Newman, AH (reprint author), NIDA, Med Chem Sect, Mol Targets & Medicat Discovery Branch, Intramural Res Program,NIH, 333 Cassell Dr, Baltimore, MD 21224 USA.
EM cllo@sund.ku.dk; anewman@intra.nida.nih.gov
RI Loland, Claus/E-5975-2014;
OI Loland, Claus/0000-0002-1773-1446; Katz, Jonathan/0000-0002-1068-1159
FU NIDA Intramural Research Program; Danish Independent Research Council -
Sapere Aude; Lundbeck Foundation; NIH visiting postdoctoral fellowship;
NIH Intramural Research Training Award (IRTA) postdoctoral fellowship;
postbaccalaureate IRTA fellowship
FX This work was supported by the NIDA Intramural Research Program (A.H.N.
and J.L.K.), Danish Independent Research Council - Sapere Aude (C.J.L.),
and the Lundbeck Foundation (C.J.L.). B.A.K. was supported by an NIH
visiting postdoctoral fellowship, P.Z. was supported by an NIH
Intramural Research Training Award (IRTA) postdoctoral fellowship, and
G.C.C. was supported by a postbaccalaureate IRTA fellowship. The authors
would like to thank Dr. Lei Shi, Weill Medical School of Cornell
University, for advising us on the Si docking models in the design of
Figure 1, Dr. Vivek Kumar (NIDA-IRP) for his critical reading of an
earlier version of this manuscript, Dr. Dwight Williams (NIDA-IRP summer
student) for his contributions to the synthesis of several intermediates
described herein, and Bente Bennike (UC) for excellent technical
assistance.
NR 39
TC 11
Z9 11
U1 6
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD DEC 12
PY 2013
VL 56
IS 23
BP 9709
EP 9724
DI 10.1021/jm4014136
PG 16
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 273IY
UT WOS:000328529700029
PM 24237160
ER
PT J
AU Cho, HS
Schotte, F
Dashdorj, N
Kyndt, J
Anfinrud, PA
AF Cho, Hyun Sun
Schotte, Friedrich
Dashdorj, Naranbaatar
Kyndt, John
Anfinrud, Philip A.
TI Probing Anisotropic Structure Changes in Proteins with Picosecond
Time-Resolved Small-Angle X-ray Scattering
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID PHOTOACTIVE YELLOW PROTEIN; HALOPHILIC PHOTOTROPHIC BACTERIUM;
ECTOTHIORHODOSPIRA-HALOPHILA; INFRARED-SPECTROSCOPY; QUANTUM YIELD;
DYNAMICS; CRYSTALLOGRAPHY; PHOTOCYCLE; MYOGLOBIN; KINETICS
AB We have exploited the principle of photoselection and the method of time-resolved small-angle X-ray scattering (SAXS) to investigate protein size and shape changes following photoactivation of photoactive yellow protein (PYP) in solution with similar to 150 ps time resolution. This study partially overcomes the orientational average intrinsic to solution scattering methods and provides structural information at a higher level of detail. Photoactivation of the p-coumaric acid (pCA) chromophore in PYP produces a highly contorted, short-lived, red-shifted intermediate (pR(0)), and triggers prompt, protein compaction of approximately 0.3% along the direction defined by the electronic transition dipole moment of the chromophore. Contraction along this dimension is accompanied by expansion along the orthogonal directions, with the net protein volume change being approximately -0.25%. More than half the strain arising from formation of pR(0) is relieved by the pR(0) to pR(1) structure transition (1.8 +/- 0.2 ns), with the persistent strain presumably contributing to the driving force needed to generate the spectroscopically blue-shifted pB signaling state. The results reported here are consistent with the near-atomic resolution structural dynamics reported in a recent time-resolved Laue crystallography study of PYP crystals and suggest that the early time structural dynamics in the crystalline state carry over to proteins in solution.
C1 [Cho, Hyun Sun; Schotte, Friedrich; Dashdorj, Naranbaatar; Anfinrud, Philip A.] NIDDK, Lab Chem Phys, NIH, Bethesda, MD 20892 USA.
[Kyndt, John] Bellevue Univ, Coll Sci & Technol, Bellevue, NE 68005 USA.
RP Anfinrud, PA (reprint author), NIDDK, Lab Chem Phys, NIH, Bethesda, MD 20892 USA.
EM anfinrud@nih.gov
FU National Center for Research Resources [5P41RR007707]; National
Institute of General Medical Sciences from NIH [8P41GM103543]; U.S. DOE
[DE-AC02-06CH11357]; National Institute of Diabetes and Digestive and
Kidney Diseases, NIH
FX We thank Dr. Rob Henning and Dr. Irina Kosheleva for assistance
preparing the 14-ID-B beamline for our studies and Bernard Howder, Jr.
for machining many of the components required to pursue time-resolved
x-ray studies on this beamline. We are grateful to the late Prof.
Cusanovich for his early participation in this collaborative effort. Use
of the BioCARS Sector 14 was supported by National Center for Research
Resources Grant 5P41RR007707 and National Institute of General Medical
Sciences Grant 8P41GM103543 from NIH. Use of the Advanced Photon Source,
an Office of Science User Facility operated for the U.S. Department of
Energy (DOE) Office of Science by Argonne National Laboratory, was
supported by U.S. DOE Contract DE-AC02-06CH11357. The time-resolved
setup at Sector 14 was funded in part through collaboration with P.A.A.
This research was supported by the Intramural Research Program of the
National Institute of Diabetes and Digestive and Kidney Diseases, NIH.
VMD was developed by the Theoretical and Computational Biophysics Group
in the Beckman Institute for Advanced Science and Technology at the
University of Illinois at Urbana-Champaign.
NR 40
TC 10
Z9 10
U1 1
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD DEC 12
PY 2013
VL 117
IS 49
SI SI
BP 15825
EP 15832
DI 10.1021/jp407593j
PG 8
WC Chemistry, Physical
SC Chemistry
GA 273IR
UT WOS:000328529000060
PM 24125473
ER
PT J
AU Markovski, M
Wickner, S
AF Markovski, Monica
Wickner, Sue
TI Preventing Bacterial Suicide: A Novel Toxin-Antitoxin Strategy
SO MOLECULAR CELL
LA English
DT Editorial Material
ID REPLICATION; SYSTEMS
AB In this issue of Molecular Cell, Aarke et al. (2013) identify a toxin-antitoxin system in Caulobacter crescentus that acts by a unique mechanism. The toxin, which blocks DNA replication, is constitutively degraded by CIpXP, and this degradation requires the antitoxin, a CIpXP adaptor.
C1 [Markovski, Monica; Wickner, Sue] NCI, Mol Biol Lab, Bethesda, MD 20892 USA.
RP Wickner, S (reprint author), NCI, Mol Biol Lab, Bldg 37, Bethesda, MD 20892 USA.
EM wickners@mail.nih.gov
FU Intramural NIH HHS [ZIA BC008710-36]
NR 10
TC 7
Z9 7
U1 2
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1097-2765
J9 MOL CELL
JI Mol. Cell
PD DEC 12
PY 2013
VL 52
IS 5
BP 611
EP 612
DI 10.1016/j.molcel.2013.11.018
PG 2
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 274FI
UT WOS:000328591800001
PM 24332174
ER
PT J
AU Hasson, SA
Kane, LA
Yamano, K
Huang, CH
Sliter, DA
Buehler, E
Wang, CX
Heman-Ackah, SM
Hessa, T
Guha, R
Martin, SE
Youle, RJ
AF Hasson, Samuel A.
Kane, Lesley A.
Yamano, Koji
Huang, Chiu-Hui
Sliter, Danielle A.
Buehler, Eugen
Wang, Chunxin
Heman-Ackah, Sabrina M.
Hessa, Tara
Guha, Rajarshi
Martin, Scott E.
Youle, Richard J.
TI High-content genome-wide RNAi screens identify regulators of parkin
upstream of mitophagy
SO NATURE
LA English
DT Article
ID PINK1; PATHWAY; MITOCHONDRIA; RECRUITMENT; SENSITIVITY; ACTIVATION;
MUTATIONS; MEMBRANE; PROMOTES; COMPLEX
AB An increasing body of evidence points to mitochondrial dysfunction as a contributor to the molecular pathogenesis of neurodegenerative diseases such as Parkinson's disease(1). Recent studies of the Parkinson's disease associated genes PINK1 (ref. 2) and parkin (PARK2, ref. 3) indicate that they may act in a quality control pathway preventing the accumulation of dysfunctional mitochondria(4-8). Here we elucidate regulators that have an impact on parkin translocation to damaged mitochondria with genome-wide small interfering RNA (siRNA) screens coupled to high-content microscopy. Screening yielded gene candidates involved in diverse cellular processes that were subsequently validated in low-throughput assays. This led to characterization of TOMM7 as essential for stabilizing PINK1 on the outer mitochondrial membrane following mitochondrial damage. We also discovered that HSPA1L (HSP70 family member) and BAG4 have mutually opposing roles in the regulation of parkin translocation. The screens revealed that SIAH3, found to localize to mitochondria, inhibits PINK1 accumulation after mitochondrial insult, reducing parkin translocation. Overall, our screens provide a rich resource to understand mitochondrial quality control.
C1 [Hasson, Samuel A.; Kane, Lesley A.; Yamano, Koji; Huang, Chiu-Hui; Sliter, Danielle A.; Wang, Chunxin; Hessa, Tara; Youle, Richard J.] NINDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA.
[Hasson, Samuel A.; Buehler, Eugen; Guha, Rajarshi; Martin, Scott E.] NIH, Div Preclin Innovat, Natl Ctr Adv Translat Sci, Rockville, MD 20850 USA.
[Heman-Ackah, Sabrina M.] NIH, Ctr Regenerat Med, Bethesda, MD 20892 USA.
RP Youle, RJ (reprint author), NINDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA.
EM youler@ninds.nih.gov
RI Wang, Chunxin/B-9312-2016
OI Wang, Chunxin/0000-0001-6015-6806
FU Japan Society for Promotion of Science; NIGMS Research Associate
Program; NIH, NINDS; Trans-NIH RNAi initiative
FX We thank P. Tuzmen for qRT-PCR assistance; C. Klumpp for automation; D.
Maric for FACS sorting; C. Smith for microscopy assistance; H. Jaffe for
mass spectrometry analyses; R. Fields (NINDS) for lentivirus assistance;
N. Malik for iPS-derived neurons; the NINDS DNA Sequencing Facility; K.
Mihara for the TOMM7 antibody and A. Koretsky and N. Caplen for support.
Research was supported by the Japan Society for Promotion of Science
Postdoctoral Fellowship for Research Abroad (K.Y.), the NIGMS Research
Associate Program, the Intramural Research Program of the NIH, NINDS and
the Trans-NIH RNAi initiative.
NR 30
TC 93
Z9 101
U1 4
U2 50
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD DEC 12
PY 2013
VL 504
IS 7479
BP 291
EP +
DI 10.1038/nature12748
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 267TQ
UT WOS:000328121500039
PM 24270810
ER
PT J
AU Courcoulas, AP
Christian, NJ
Belle, SH
Berk, PD
Flum, DR
Garcia, L
Horlick, M
Kalarchian, MA
King, WC
Mitchell, JE
Patterson, EJ
Pender, JR
Pomp, A
Pories, WJ
Thirlby, RC
Yanovski, SZ
Wolfe, BM
AF Courcoulas, Anita P.
Christian, Nicholas J.
Belle, Steven H.
Berk, Paul D.
Flum, David R.
Garcia, Luis
Horlick, Mary
Kalarchian, Melissa A.
King, Wendy C.
Mitchell, James E.
Patterson, Emma J.
Pender, John R.
Pomp, Alfons
Pories, Walter J.
Thirlby, Richard C.
Yanovski, Susan Z.
Wolfe, Bruce M.
CA Labs Consortium
TI Weight Change and Health Outcomes at 3 Years After Bariatric Surgery
Among Individuals With Severe Obesity
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID ROUX-EN-Y; TYPE-2 DIABETES-MELLITUS; GASTRIC BYPASS; LONGITUDINAL
ASSESSMENT; REPORTING WEIGHT; MEDICAL THERAPY; BLOOD-PRESSURE;
RISK-FACTORS; HYPERTENSION; SAFETY
AB IMPORTANCE Severe obesity (body mass index [BMI] >= 35) is associated with a broad range of health risks. Bariatric surgery induces weight loss and short-term health improvements, but little is known about long-term outcomes of these operations.
OBJECTIVE To report 3-year change in weight and select health parameters after common bariatric surgical procedures.
DESIGN AND SETTING The Longitudinal Assessment of Bariatric Surgery (LABS) Consortium is a multicenter observational cohort study at 10 US hospitals in 6 geographically diverse clinical centers.
PARTICIPANTS AND EXPOSURE Adults undergoing first-time bariatric surgical procedures as part of routine clinical care by participating surgeons were recruited between 2006 and 2009 and followed up until September 2012. Participants completed research assessments prior to surgery and 6 months, 12 months, and then annually after surgery.
MAIN OUTCOMES AND MEASURES Three years after Roux-en-Y gastric bypass (RYGB) or laparoscopic adjustable gastric banding (LAGB), we assessed percent weight change from baseline and the percentage of participants with diabetes achieving hemoglobin A(1c) levels less than 6.5% or fasting plasma glucose values less than 126 mg/dL without pharmacologic therapy. Dyslipidemia and hypertension resolution at 3 years was also assessed.
RESULTS At baseline, participants (N = 2458) were 18 to 78 years old, 79% were women, median BMI was 45.9 (IQR, 41.7-51.5), and median weight was 129 kg (IQR, 115-147). For their first bariatric surgical procedure, 1738 participants underwent RYGB, 610 LAGB, and 110 other procedures. At baseline, 774 (33%) had diabetes, 1252 (63%) dyslipidemia, and 1601 (68%) hypertension. Three years after surgery, median actual weight loss for RYGB participants was 41 kg (IQR, 31-52), corresponding to a percentage of baseline weight lost of 31.5% (IQR, 24.6%-38.4%). For LAGB participants, actual weight loss was 20 kg (IQR, 10-29), corresponding to 15.9% (IQR, 7.9%-23.0%). The majority of weight loss was evident 1 year after surgery for both procedures. Five distinct weight change trajectory groups were identified for each procedure. Among participants who had diabetes at baseline, 216 RYGB participants (67.5%) and 28 LAGB participants (28.6%) experienced partial remission at 3 years. The incidence of diabetes was 0.9% after RYGB and 3.2% after LAGB. Dyslipidemia resolved in 237 RYGB participants (61.9%) and 39 LAGB participants (27.1%); remission of hypertension occurred in 269 RYGB participants (38.2%) and 43 LAGB participants (17.4%).
CONCLUSIONS AND RELEVANCE Among participants with severe obesity, there was substantial weight loss 3 years after bariatric surgery, with the majority experiencing maximum weight change during the first year. However, there was variability in the amount and trajectories of weight loss and in diabetes, blood pressure, and lipid outcomes.
C1 [Courcoulas, Anita P.] Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA 15213 USA.
[Christian, Nicholas J.; Belle, Steven H.; King, Wendy C.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA.
[Berk, Paul D.] Columbia Univ, Med Ctr, Dept Med, New York, NY USA.
[Flum, David R.] Univ Washington, Dept Surg, Seattle, WA 98195 USA.
[Garcia, Luis] Univ N Dakota, Sch Hlth Sci, Dept Surg, Grand Forks, ND 58201 USA.
[Horlick, Mary; Yanovski, Susan Z.] NIDDK, Div Digest Dis & Nutr, Bethesda, MD 20892 USA.
[Kalarchian, Melissa A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Mitchell, James E.] Univ N Dakota, Sch Med & Hlth Sci, Dept Neurosci, Neuropsychiatr Res Inst, Grand Forks, ND 58201 USA.
[Patterson, Emma J.] Legacy Good Samaritan Med Ctr, Dept Surg, Portland, OR USA.
[Pender, John R.; Pories, Walter J.] E Carolina Univ, Brody Sch Med, Dept Surg, Greenville, NC USA.
[Pomp, Alfons] Weill Cornell Med Coll, Dept Surg, New York, NY USA.
[Thirlby, Richard C.] Virginia Mason Med Ctr, Dept Surg, Seattle, WA 98101 USA.
[Wolfe, Bruce M.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA.
RP Courcoulas, AP (reprint author), Univ Pittsburgh, Med Ctr, Dept Surg, 3380 Blvd Allies,Ste 390, Pittsburgh, PA 15213 USA.
EM courcoulasap@upmc.edu
OI King, Wendy/0000-0002-0740-0029; Kalarchian, Melissa/0000-0003-2099-9299
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[U01 DK066557, U01-DK66667, UL1-RR024996, U01-DK66568, M01RR-00037,
U01-DK66471, U01-DK66526, U01-DK66585, UL1-RR024153, U01-DK66555]
FX LABS-2 was a cooperative agreement funded by the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) with grants for the
data coordinating center (U01 DK066557), Columbia University Medical
Center (U01-DK66667) (in collaboration with Cornell University Medical
Center Clinical and Translational Research Center [CTRC], grant
UL1-RR024996), University of Washington (U01-DK66568) (in collaboration
with CTRC, grant M01RR-00037), Neuropsychiatric Research Institute
(U01-DK66471), East Carolina University (U01-DK66526), University of
Pittsburgh Medical Center (U01-DK66585) (in collaboration with CTRC,
grant UL1-RR024153), and Oregon Health and Science University
(U01-DK66555).
NR 36
TC 198
Z9 201
U1 6
U2 29
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 11
PY 2013
VL 310
IS 22
BP 2416
EP 2425
DI 10.1001/jama.2013.280928
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 266NN
UT WOS:000328030900022
PM 24189773
ER
PT J
AU Christian, NJ
King, WC
Yanovski, SZ
Courcoulas, AP
Belle, SH
AF Christian, Nicholas J.
King, Wendy C.
Yanovski, Susan Z.
Courcoulas, Anita P.
Belle, Steven H.
TI Validity of Self-reported Weights Following Bariatric Surgery
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID BODY-MASS INDEX; HEIGHT
C1 [Christian, Nicholas J.; King, Wendy C.; Belle, Steven H.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
[Yanovski, Susan Z.] NIDDKD, Bethesda, MD USA.
[Courcoulas, Anita P.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
RP Christian, NJ (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, 130 DeSoto St,127 Parran Hall, Pittsburgh, PA 15261 USA.
EM christiann@edc.pitt.edu
OI King, Wendy/0000-0002-0740-0029
FU NCATS NIH HHS [UL1 TR000005, UL1 TR000457]; NCRR NIH HHS [M01 RR000037,
M01RR-00037, UL1 RR024153, UL1 RR024996, UL1-RR024153, UL1-RR024996];
NIDDK NIH HHS [U01-DK66585, U01 DK066471, U01 DK066526, U01 DK066555,
U01 DK066557, U01 DK066568, U01 DK066585, U01 DK066667, U01-DK66471,
U01-DK66526, U01-DK66555, U01-DK66568, U01-DK66667]
NR 6
TC 21
Z9 21
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 11
PY 2013
VL 310
IS 22
BP 2454
EP 2456
DI 10.1001/jama.2013.281043
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 266NN
UT WOS:000328030900027
PM 24189698
ER
PT J
AU Forni, PE
Bharti, K
Flannery, EM
Shimogori, T
Wray, S
AF Forni, Paolo Emanuele
Bharti, Kapil
Flannery, Ellen M.
Shimogori, Tomomi
Wray, Susan
TI The Indirect Role of Fibroblast Growth Factor-8 in Defining Neurogenic
Niches of the Olfactory/GnRH Systems
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID GONADOTROPIN-RELEASING-HORMONE; EPITHELIAL-MESENCHYMAL INTERACTIONS;
NEURAL INDUCTION; CLEFT-LIP; KALLMANN-SYNDROME; FACIAL PRIMORDIA;
PROGENITOR CELLS; BMP INHIBITION; GNRH-1 NEURONS; CHICK-EMBRYO
AB Bone morphogenic protein-4 (BMP4) and fibroblast growth factor-8 (FGF8) are thought to have opposite roles in defining epithelial versus neurogenic fate in the developing olfactory/vomeronasal system. In particular, FGF8 has been implicated in specification of olfactory and gonadotropin releasing hormone-1 (GnRH) neurons, as well as in controlling olfactory stem cell survival. Using different knock-in mouse lines and Cre-lox-mediated lineage tracing, Fgf8 expression and cell lineage was analyzed in the developing nose in relation to the expression of Bmp4 and its antagonist Noggin (Nog). FGF8 is expressed by cells that acquire an epidermal, respiratory cell fate and not by stem cells that acquire neuronal olfactory or vomeronasal cell fate. Ectodermal and mesenchymal sources of BMP4 control the expression of BMP/TGF beta antagonist Nog, whereas mesenchymal sources of Nog define the neurogenic borders of the olfactory pit. Fgf8 hypomorph mouse models, Fgf8(neo/neo) and Fgf8(neo/null), displayed severe craniofacial defects together with overlapping defects in the olfactory pit including (1) lack of neuronal formation ventrally, where GnRH neurons normally form, and (2) altered expression of Bmp4 and Nog, with Nog ectopically expressed in the nasal mesenchyme and no longer defining the GnRH and vomeronasal neurogenic border. Together our data show that (1) FGF8 is not sufficient to induce ectodermal progenitors of the olfactory pit to acquire neural fate and (2) altered neurogenesis and lack of GnRH neuron specification after chronically reduced Fgf8 expression reflected dysgenesis of the nasal region and loss of a specific neurogenic permissive milieu that was defined by mesenchymal signals.
C1 [Forni, Paolo Emanuele; Flannery, Ellen M.; Wray, Susan] Natl Inst Neurol Disorders & Stroke, Cellular & Dev Neurobiol Sect, Bethesda, MD 20892 USA.
[Bharti, Kapil] NEI, Unit Ocular & Stem Cell Translat Res, NIH, Bethesda, MD 20892 USA.
[Shimogori, Tomomi] RIKEN, Brain Sci Inst, Lab Mol Mech Thalamus Dev, Wako, Saitama 3510198, Japan.
RP Wray, S (reprint author), NINDS, NIH, Bldg 35,Rm 3A-1012, Bethesda, MD 20892 USA.
EM wrays@ninds.nih.gov
RI Flannery, Ellen/D-3941-2014;
OI wray, susan/0000-0001-7670-3915
FU Intramural Research Program of the National Institutes of Health,
National Institute of Neurological Disorders and Stroke [NS002824-13]
FX This work was supported by the Intramural Research Program of the
National Institutes of Health, National Institute of Neurological
Disorders and Stroke (NS002824-13). Several monoclonal antibodies used
in these studies were obtained from the Developmental Studies Hybridoma
Bank developed under National Institute of Child Health and Human
Development and maintained by the University of Iowa, Department of
Biology, Iowa City, Iowa.
NR 70
TC 5
Z9 5
U1 0
U2 4
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD DEC 11
PY 2013
VL 33
IS 50
BP 19620
EP 19634
DI 10.1523/JNEUROSCI.3238-13.2013
PG 15
WC Neurosciences
SC Neurosciences & Neurology
GA 274SP
UT WOS:000328626800022
PM 24336726
ER
PT J
AU Sekerkova, G
Kim, JA
Nigro, MJ
Becker, EBE
Hartmann, J
Birnbaumer, L
Mugnaini, E
Martina, M
AF Sekerkova, Gabriella
Kim, Jin-Ah
Nigro, Maximiliano J.
Becker, Esther B. E.
Hartmann, Jana
Birnbaumer, Lutz
Mugnaini, Enrico
Martina, Marco
TI Early Onset of Ataxia in Moonwalker Mice Is Accompanied by Complete
Ablation of Type II Unipolar Brush Cells and Purkinje Cell Dysfunction
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID TRPC3 CHANNELS; CEREBELLUM; TRANSMISSION
AB Transient receptor potential "canonical" cation channels (TRPC) are involved in many cellular activities, including neuronal synaptic transmission. These channels couple lipid metabolism, calcium homeostasis, and electrophysiological properties as they are calcium permeable and activated through the phospholipase C pathway and by diacylglycerol. The TRPC3 subunit is abundantly expressed in Purkinje cells (PCs), where it mediates slow metabotropic glutamate receptor-mediated synaptic responses. Recently, it has been shown that heterozygous moonwalker mice, which are a model of cerebellar ataxia, carry a dominant gain-of-function mutation (T635A) in the TRPC3 gene. This mutation leads to PC loss and dysmorphism, which have been suggested to cause the ataxia. However, the ataxic phenotype is present from a very early stage (before weaning), whereas PC loss does not appear until several months of age. Here we show that another class of cerebellar neurons, the type II unipolar brush cells (UBCs), express functional TRPC3 channels; intriguingly, these cells are ablated in moonwalker mice by 1 month of age. Additionally, we show that in moonwalker mice, intrinsic excitability of PCs is altered as early as 3 weeks after birth. We suggest that this altered excitability and the TRPC3-mediated loss of type II UBCs may both contribute to the ataxic phenotype of these mice and that different calcium handling in PCs and type II UBCs may account for the dramatic differences in sensitivity to the moonwalker mutation between these cell types.
C1 [Sekerkova, Gabriella; Kim, Jin-Ah; Nigro, Maximiliano J.; Mugnaini, Enrico; Martina, Marco] Northwestern Univ, Dept Physiol, Feinberg Sch Med, Chicago, IL 60611 USA.
[Sekerkova, Gabriella; Mugnaini, Enrico] Northwestern Univ, Dept Cell & Mol Biol, Feinberg Sch Med, Chicago, IL 60611 USA.
[Becker, Esther B. E.] Univ Oxford, Dept Physiol Anat & Genet, MRC, Funct Genom Unit, Oxford OX1 3PT, England.
[Hartmann, Jana] Tech Univ Munich, Inst Neurosci, D-80802 Munich, Germany.
[Birnbaumer, Lutz] NIEHS, Neurobiol Lab, NIH, Dept Hlth & Human Serv, Durham, NC 27709 USA.
RP Martina, M (reprint author), Northwestern Univ, Dept Physiol, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.
EM m-martina@northwestern.edu
RI Hartmann, Jana/C-1024-2008
FU NIH [NS 09904]; DFG Grant [SFB 870]; Intramural Research Program of the
NIH [Z01-ES-101864]; Royal Society, London
FX This work was supported by NIH Grant NS 09904 (M.M.), DFG Grant SFB 870
(J.H.), and the Intramural Research Program of the NIH (project
Z01-ES-101864, L.B.). E.B.E.B. is the recipient of a Research Fellowship
from the Royal Society, London. E.B.E.B. thanks Kay E. Davies for
generous support.
NR 18
TC 13
Z9 13
U1 0
U2 7
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD DEC 11
PY 2013
VL 33
IS 50
BP 19689
EP 19694
DI 10.1523/JNEUROSCI.2294-13.2013
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 274SP
UT WOS:000328626800028
PM 24336732
ER
PT J
AU Rajendran, A
Endo, M
Hidaka, K
Tran, PLT
Mergny, JL
Gorelick, RJ
Sugiyama, H
AF Rajendran, Arivazhagan
Endo, Masayuki
Hidaka, Kumi
Phong Lan Thao Tran
Mergny, Jean-Louis
Gorelick, Robert J.
Sugiyama, Hiroshi
TI HIV-1 Nucleocapsid Proteins as Molecular Chaperones for Tetramolecular
Antiparallel G-Quadruplex Formation
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID TELOMERE-BINDING-PROTEIN; ATOMIC-FORCE MICROSCOPY; ZINC-FINGER
STRUCTURES; DNA ORIGAMI; REVERSE TRANSCRIPTION; STRANDED-DNA;
G-QUARTETS; IN-VITRO; HELICASE; TYPE-1
AB HIV-1 nucleocapsid proteins (NCps) facilitate remodeling of nucleic acids to fold thermodynamically stable conformations, and thus called nucleic acid chaperones. To date only little is known on the stoichiometry, NCp-NCp interactions, chaperone activity on G-quadruplex formation, and so on. We report here the direct and real-time analysis on such properties of proteolytic intermediate NCp15 and mature NCp7 using DNA origami. The protein particles were found to predominantly exist in monomeric form, while dimeric and multimeric forms were also observed both in free solution and bound to the quadruplex structure. The formation and the dissociation events of the G-quadruplexes were well documented in real-time and the intermediate-like states were also visualized. We anticipate that this pioneering study will strengthen our understanding on the chaperone activity of HIV-1 proteins which in turn will be helpful for the drug design based on G-quadruplex and also for the development of drugs against AIDS.
C1 [Rajendran, Arivazhagan; Hidaka, Kumi; Sugiyama, Hiroshi] Kyoto Univ, Dept Chem, Grad Sch Sci, Kyoto 6068502, Japan.
[Endo, Masayuki; Sugiyama, Hiroshi] Kyoto Univ, Inst Integrated Cell Mat Sci WPI iCeMS, Sakyo Ku, Kyoto 6068501, Japan.
[Endo, Masayuki; Sugiyama, Hiroshi] Japan Sci & Technol Corp JST, CREST, Chiyoda Ku, Tokyo 1020075, Japan.
[Phong Lan Thao Tran; Mergny, Jean-Louis] Univ Bordeaux, INSERM, U869, ARNA Lab, F-33607 Pessac, France.
[Gorelick, Robert J.] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.
RP Endo, M (reprint author), Kyoto Univ, Inst Integrated Cell Mat Sci WPI iCeMS, Sakyo Ku, Kyoto 6068501, Japan.
EM endo@kuchem.kyoto-u.ac.jp; hs@kuchem.kyoto-u.ac.jp
RI Sugiyama, Hiroshi/C-7687-2011; Endo, Masayuki/J-5874-2014; Rajendran,
Arivazhagan/D-6736-2012; Mergny, Jean-Louis/E-2860-2013
OI Rajendran, Arivazhagan/0000-0002-9319-6107; Mergny,
Jean-Louis/0000-0003-3043-8401
FU CREST grant from the Japan Science and Technology Corporation (JST); WPI
program (WPI-iCeMS, Kyoto University); JSPS KAKENHI [24310097, 24225005,
24104002]; Mitsubishi Foundation; Asahi Glass Foundation; Japan Society
for the Promotion of Science (JSPS); Aquitaine Regional Council; ANR
[G4-Toolbox, Quarpdiem, Oligoswitch]; National Cancer Institute,
National Institutes of Health [HHSN261200800001E]; Leidos Biomedical
Research, Inc.
FX We thank Sebastien Lyonnais and Gilles Mirambeau for their kind
assistance with the proteins used in this study. We express our sincere
thanks for the CREST grant from the Japan Science and Technology
Corporation (JST), grants from the WPI program (WPI-iCeMS, Kyoto
University), and JSPS KAKENHI (Grant numbers 24310097, 24225005 and
24104002). Financial supports from The Mitsubishi Foundation and The
Asahi Glass Foundation to M.E. are also acknowledged. A.R. expresses
sincere thanks to the Japan Society for the Promotion of Science (JSPS)
for the Postdoctoral fellowship. P.L.T.T. and J.-L.M. sincerely thank
the Aquitaine Regional Council and the ANR program G4-Toolbox, Quarpdiem
and Oligoswitch for financial support. For R.J.G., this project has been
funded in whole or in part with federal funds from the National Cancer
Institute, National Institutes of Health, under contract
HHSN261200800001E with Leidos Biomedical Research, Inc.
NR 50
TC 17
Z9 17
U1 1
U2 48
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD DEC 11
PY 2013
VL 135
IS 49
BP 18575
EP 18585
DI 10.1021/ja409085j
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA 272CU
UT WOS:000328438700053
PM 24224650
ER
PT J
AU Platig, J
Ott, E
Girvan, M
AF Platig, J.
Ott, E.
Girvan, M.
TI Robustness of network measures to link errors
SO PHYSICAL REVIEW E
LA English
DT Article
ID COMPLEX NETWORKS; REGULATORY NETWORKS; RECONSTRUCTION; EMERGENCE
AB In various applications involving complex networks, network measures are employed to assess the relative importance of network nodes. However, the robustness of such measures in the presence of link inaccuracies has not been well characterized. Here we present two simple stochastic models of false and missing links and study the effect of link errors on three commonly used node centrality measures: degree centrality, betweenness centrality, and dynamical importance. We perform numerical simulations to assess robustness of these three centrality measures. We also develop an analytical theory, which we compare with our simulations, obtaining very good agreement.
C1 [Platig, J.; Ott, E.; Girvan, M.] Univ Maryland, Inst Res Elect & Appl Phys, College Pk, MD 20742 USA.
[Platig, J.] NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Platig, J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
RP Platig, J (reprint author), Univ Maryland, Inst Res Elect & Appl Phys, College Pk, MD 20742 USA.
EM jplatig@jimmy.harvard.edu
RI O, E/F-1630-2015
FU Army Research Office [W911NF-12-1-0101]; University of Maryland/National
Cancer Institute (NIH) Partnership for Cancer Technology
FX We thank Shane Squires for his helpful input. This work was supported by
the Army Research Office under Grant No. W911NF-12-1-0101 and by the
University of Maryland/National Cancer Institute (NIH) Partnership for
Cancer Technology.
NR 23
TC 8
Z9 8
U1 0
U2 15
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 1539-3755
EI 1550-2376
J9 PHYS REV E
JI Phys. Rev. E
PD DEC 11
PY 2013
VL 88
IS 6
AR 062812
DI 10.1103/PhysRevE.88.062812
PG 8
WC Physics, Fluids & Plasmas; Physics, Mathematical
SC Physics
GA 275RM
UT WOS:000328695100006
PM 24483516
ER
PT J
AU Legros, M
Xu, CG
Morrison, A
Scott, TW
Lloyd, AL
Gould, F
AF Legros, Mathieu
Xu, Chonggang
Morrison, Amy
Scott, Thomas W.
Lloyd, Alun L.
Gould, Fred
TI Modeling the Dynamics of a Non- Limited and a Self-Limited Gene Drive
System in Structured Aedes aegypti Populations
SO PLOS ONE
LA English
DT Article
ID MOSQUITO-BORNE DISEASES; ENGINEERED UNDERDOMINANCE; CULICIDAE
PRODUCTION; INSECT POPULATIONS; RNA INTERFERENCE; PEST POPULATIONS;
VIRUS-RESISTANCE; MEIOTIC DRIVE; TRANSGENES; DIPTERA
AB Recently there have been significant advances in research on genetic strategies to control populations of disease-vectoring insects. Some of these strategies use the gene drive properties of selfish genetic elements to spread physically linked anti-pathogen genes into local vector populations. Because of the potential of these selfish elements to spread through populations, control approaches based on these strategies must be carefully evaluated to ensure a balance between the desirable spread of the refractoriness-conferring genetic cargo and the avoidance of potentially unwanted outcomes such as spread to non-target populations. There is also a need to develop better estimates of the economics of such releases. We present here an evaluation of two such strategies using a biologically realistic mathematical model that simulates the resident Aedes aegypti mosquito population of Iquitos, Peru. One strategy uses the selfish element Medea, a non-limited element that could permanently spread over a large geographic area; the other strategy relies on Killer-Rescue genetic constructs, and has been predicted to have limited spatial and temporal spread. We simulate various operational approaches for deploying these genetic strategies, and quantify the optimal number of released transgenic mosquitoes needed to achieve definitive spread of Medea-linked genes and/or high frequencies of Killer-Rescue-associated elements. We show that for both strategies the most efficient approach for achieving spread of anti-pathogen genes within three years is generally to release adults of both sexes in multiple releases over time. Even though females in these releases should not transmit disease, there could be public concern over such releases, making the less efficient male-only release more practical. This study provides guidelines for operational approaches to population replacement genetic strategies, as well as illustrates the use of detailed spatial models to assist in safe and efficient implementation of such novel genetic strategies.
C1 [Legros, Mathieu; Xu, Chonggang; Gould, Fred] N Carolina State Univ, Dept Entomol, Raleigh, NC 27695 USA.
[Legros, Mathieu; Morrison, Amy; Scott, Thomas W.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA.
[Legros, Mathieu] ETH, Inst Integrat Biol, Zurich, Switzerland.
[Xu, Chonggang] Los Alamos Natl Lab, Div Earth & Environm Sci, Los Alamos, NM 87545 USA.
[Morrison, Amy; Scott, Thomas W.; Lloyd, Alun L.; Gould, Fred] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
[Lloyd, Alun L.] N Carolina State Univ, Dept Math, Raleigh, NC 27695 USA.
[Lloyd, Alun L.] N Carolina State Univ, Biomath Grad Program, Raleigh, NC 27695 USA.
RP Legros, M (reprint author), N Carolina State Univ, Dept Entomol, Raleigh, NC 27695 USA.
EM legros.mathieu@gmail.com
RI Legros, Mathieu/E-6767-2011;
OI Legros, Mathieu/0000-0003-3807-8594; Xu, Chonggang/0000-0002-0937-5744
FU National Institutes of Health [R01-AI54954-0IA2]; Regents of the
University of California from the Foundation for the National Institutes
of Health Grand Challenges in Global Health initiative
FX This work was funded by National Institutes of Health grant
R01-AI54954-0IA2, and through the Regents of the University of
California from the Foundation for the National Institutes of Health
Grand Challenges in Global Health initiative. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 36
TC 5
Z9 5
U1 3
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 10
PY 2013
VL 8
IS 12
AR UNSP e83354
DI 10.1371/journal.pone.0083354
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 275VW
UT WOS:000328707400130
PM 24340097
ER
PT J
AU Parrow, NL
Leshin, JA
Levine, M
AF Parrow, Nermi L.
Leshin, Jonathan A.
Levine, Mark
TI Parenteral Ascorbate As a Cancer Therapeutic: A Reassessment Based on
Pharmacokinetics
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Review
ID DOSE VITAMIN-C; RECOMMENDED DIETARY ALLOWANCE; TERMINAL HUMAN CANCER;
CELLS IN-VITRO; PHARMACOLOGICAL ASCORBATE; ORTHOMOLECULAR TREATMENT;
TUMOR-GROWTH; SUPPLEMENTAL ASCORBATE; MALIGNANT MESOTHELIOMA; SUPPORTIVE
TREATMENT
AB Significance: Ewan Cameron reported that ascorbate, given orally and intravenously at doses of up to 10g/day, was effective in the treatment of cancer. Double-blind placebo-controlled clinical trials showed no survival advantage when the same doses of ascorbate were given orally, leading the medical and scientific communities to dismiss the use of ascorbate as a potential cancer treatment. However, the route of administration results in major differences in ascorbate bioavailability. Tissue and plasma concentrations are tightly controlled in response to oral administration, but this can be bypassed by intravenous administration. These data provide a plausible scientific rationale for the absence of a response to orally administered ascorbate in the Mayo clinic trials and indicate the need to reassess ascorbate as a cancer therapeutic. Recent Advances: High dose ascorbate is selectively cytotoxic to cancer cell lines through the generation of extracellular hydrogen peroxide (H2O2). Murine xenograft models confirm a growth inhibitory effect of pharmacological concentrations. The safety of intravenous ascorbate has been verified in encouraging pilot clinical studies. Critical Issues: Neither the selective toxicity of pharmacologic ascorbate against cancer cells nor the mechanism of H2O2-mediated cytotoxicity is fully understood. Despite promising preclinical data, the question of clinical efficacy remains. Future Directions: A full delineation of mechanism is of interest because it may indicate susceptible cancer types. Effects of pharmacologic ascorbate used in combination with standard treatments need to be defined. Most importantly, the clinical efficacy of ascorbate needs to be reassessed using proper dosing, route of administration, and controls. Antioxid. Redox Signal. 19, 2141-2156.
C1 [Parrow, Nermi L.; Leshin, Jonathan A.; Levine, Mark] NIDDK, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bethesda, MD 20892 USA.
RP Levine, M (reprint author), NIDDK, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bldg 10,Room 4D52,10 Ctr Dr, Bethesda, MD 20892 USA.
EM markl@intra.niddk.nih.gov
FU Intramural Research Program of the National Institute of Diabetes and
Digestive and Kidney Diseases, National Institutes of Health (NIH) [ZIA
DK053212]
FX We are indebted to the patients and healthy volunteers who agreed to
participate in the clinical studies reviewed in this article. This work
was supported by the Intramural Research Program of the National
Institute of Diabetes and Digestive and Kidney Diseases, National
Institutes of Health (NIH) (ZIA DK053212). The opinions are those of the
authors and do not represent official NIH policy.
NR 82
TC 21
Z9 23
U1 0
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523-0864
EI 1557-7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD DEC 10
PY 2013
VL 19
IS 17
BP 2141
EP 2156
DI 10.1089/ars.2013.5372
PG 16
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 273SQ
UT WOS:000328557000012
PM 23621620
ER
PT J
AU Li, WQ
Qureshi, AA
Ma, J
Goldstein, AM
Giovannucci, EL
Stampfer, MJ
Han, JL
AF Li, Wen-Qing
Qureshi, Abrar A.
Ma, Jing
Goldstein, Alisa M.
Giovannucci, Edward L.
Stampfer, Meir J.
Han, Jiali
TI Personal History of Prostate Cancer and Increased Risk of Incident
Melanoma in the United States
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID PROSPECTIVE COHORT; ANDROGEN RECEPTOR; ASSOCIATION; SUBSEQUENT;
TELOMERES; BLOCKADE; HEALTH; CELLS; ACNE; SKIN
AB Purpose Steroid hormones, particularly androgens, play a major role in prostatic carcinogenesis. Personal history of severe acne, a surrogate for higher androgen activity, has been associated with an increased risk of prostate cancer (PCa), and one recent study indicated that severe teenage acne was a novel risk factor for melanoma. These findings suggest a possible relationship between PCa and risk of melanoma. We prospectively evaluated this association among US men.
Methods A total of 42,372 participants in the Health Professionals' Follow-Up Study (HPFS; 1986 to 2010) were included. Biennially self-reported PCa diagnosis was confirmed using pathology reports. Diagnosis of melanoma and nonmelanoma skin cancer (NMSC) was self-reported biennially, and diagnosis of melanoma was pathologically confirmed. We sought to confirm the association in 18,603 participants from the Physicians' Health Study (PHS; 1982 to 1998).
Results We identified 539 melanomas in the HPFS. Personal history of PCa was associated with an increased risk of melanoma (multivariate-adjusted hazard ratio [HR], 1.83; 95% CI, 1.32 to 2.54). Although we also detected a marginally increased risk of NMSC associated with PCa (HR, 1.08; 95% CI, 0.995 to 1.16), the difference in the magnitude of the association between melanoma and NMSC was significant (P for heterogeneity = .002). We did not find an altered risk of melanoma associated with personal history of other cancers. The association between PCa and risk of incident melanoma was confirmed in the PHS (HR, 2.17; 95% CI, 1.12 to 4.21).
Conclusion Personal history of PCa is associated with an increased risk of melanoma, which may not be entirely a result of greater medical scrutiny.
C1 [Li, Wen-Qing; Goldstein, Alisa M.] NCI, NIH, Rockville, MD USA.
[Li, Wen-Qing; Qureshi, Abrar A.; Ma, Jing; Giovannucci, Edward L.; Stampfer, Meir J.; Han, Jiali] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Giovannucci, Edward L.; Stampfer, Meir J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Han, Jiali] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Simon Canc Ctr, Indianapolis, IN 46204 USA.
[Han, Jiali] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China.
RP Han, JL (reprint author), 181 Longwood Ave, Boston, MA 02115 USA.
EM jiali.han@channing.harvard.edu
RI Li, Wenqing/N-2293-2014
OI Li, Wenqing/0000-0002-1283-4091
FU National Institutes of Health (NIH) [P01 CA055075]; National Cancer
Institute [CA-34944, CA-40360, CA-097193]; National Heart, Lung, and
Blood Institute, Bethesda, MD [HL-26490, HL-34595]; Intramural Research
Program of the NIH; National Cancer Institute; Division of Cancer
Epidemiology and Genetics
FX The Health Professionals' Follow-Up Study is partly supported by
National Institutes of Health (NIH) Grant No. P01 CA055075. The
Physicians' Health Study is supported by Grants No, CA-34944, CA-40360,
and CA-097193 from the National Cancer Institute and Grants No. HL-26490
and HL-34595 from the National Heart, Lung, and Blood Institute,
Bethesda, MD. The current analysis was supported by the Intramural
Research Program of the NIH, National Cancer Institute, and the Division
of Cancer Epidemiology and Genetics.
NR 33
TC 12
Z9 12
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD DEC 10
PY 2013
VL 31
IS 35
BP 4394
EP +
DI 10.1200/JCO.2013.51.1915
PG 11
WC Oncology
SC Oncology
GA 277KJ
UT WOS:000328817400004
PM 24190118
ER
PT J
AU Gao, Y
Kuang, Y
Du, XW
Zhou, J
Chandran, P
Horkay, F
Xu, B
AF Gao, Yuan
Kuang, Yi
Du, Xuewen
Zhou, Jie
Chandran, Preethi
Horkay, Ferenc
Xu, Bing
TI Imaging Self-Assembly Dependent Spatial Distribution of Small Molecules
in a Cellular Environment
SO LANGMUIR
LA English
DT Article
ID GREEN FLUORESCENT PROTEIN; SUPRAMOLECULAR HYDROGELS; ENZYMATIC
FORMATION; LIVING CELLS; ACTIN CYTOSKELETON; DESIGNED PEPTIDE;
NANOFIBERS; NANOSTRUCTURES; DERIVATIVES; INHIBITION
AB Self-assembly of small molecules, as a more common phenomenon than one previously thought, can be either beneficial or detrimental to cells. Despite its profound biological implications, how the self-assembly of small molecules behave in a cellular environment is largely unknown and barely explored. This work studies four fluorescent molecules that consist of the same peptidic backbone (e.g., Phe-Phe-Lys) and enzyme trigger (e.g., a phosphotyrosine residue), but bear different fluorophores on the side chain of the lysine residue of the peptidic motif. These molecules, however, exhibit a different ability of self-assembly before and after enzymatic transformation (e.g., dephosphorylation). Fluorescent imaging reveals that self-assembly directly affects the distribution of these small molecules in a cellular environment. Moreover, cell viability tests suggest that the states and the locations of the molecular assemblies in the cellular environment control the phenotypes of the cells. For example, the molecular nanofibers of one of the small molecules apparently stabilize actin filaments and alleviate the insult of an F-actin toxin (e.g., latrunculin A). Combining fluorescent imaging and enzyme-instructed self-assembly of small peptidic molecules, this work demonstrates self-assembly as a key factor for dictating the spatial distribution of small molecules in a cellular environment. In addition, it illustrates a useful approach, based on enzyme-instructed self-assembly of small molecules, to modulate spatiotemporal profiles of small molecules in a cellular environment, which allows the use of the emergent properties of small molecules to control the fate of cells.
C1 [Gao, Yuan; Kuang, Yi; Du, Xuewen; Zhou, Jie; Xu, Bing] Brandeis Univ, Dept Chem, Waltham, MA 02454 USA.
[Gao, Yuan; Horkay, Ferenc] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Tissue Biophys & Biomimet, Program Pediat Imaging & Tissue Sci, NIH, Bethesda, MD 20892 USA.
[Chandran, Preethi] Howard Univ, Dept Chem Engn, Washington, DC 20059 USA.
RP Xu, B (reprint author), Brandeis Univ, Dept Chem, 415 South St, Waltham, MA 02454 USA.
EM bxu@brandeis.edu
RI Gao, Yuan/D-7441-2012; XU, Bing/A-7828-2008
OI Gao, Yuan/0000-0001-9509-4924; XU, Bing/0000-0002-4639-387X
FU National Institutes of Health (NIH) [R01CA142746]; Human Frontiers
Science Program (HFSP); MRSEC; National Research Council Research
Associateship Award at NICHD; Intramural Research Program of the
NICHD/NIH; Brandeis
FX The authors acknowledge the National Institutes of Health (NIH
R01CA142746), Human Frontiers Science Program (HFSP), MRSEC, start-up
fund of Brandeis for funding to B.X. and National Research Council
Research Associateship Award to Y.G. at NICHD. Y.G., P.C., and F.H.
acknowledge the support of the Intramural Research Program of the
NICHD/NIH.
NR 48
TC 12
Z9 12
U1 2
U2 32
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD DEC 10
PY 2013
VL 29
IS 49
BP 15191
EP 15200
DI 10.1021/la403457c
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
Multidisciplinary
SC Chemistry; Materials Science
GA 272CD
UT WOS:000328437000008
PM 24266765
ER
PT J
AU Liu, T
Ren, D
Zhu, XP
Yin, Z
Jin, GX
Zhao, Z
Robinson, D
Li, XP
Wong, K
Cui, KM
Zhao, H
Wong, STC
AF Liu, Timothy
Ren, Ding
Zhu, Xiaoping
Yin, Zheng
Jin, Guangxu
Zhao, Zhen
Robinson, Daniel
Li, Xuping
Wong, Kelvin
Cui, Kemi
Zhao, Hong
Wong, Stephen T. C.
TI Transcriptional signaling pathways inversely regulated in Alzheimer's
disease and glioblastoma multiform
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CELL-CYCLE PROGRESSION; IN-VIVO; PARKINSONS-DISEASE; BREAST-CANCER;
PIN1; TAU; PROTEIN; KINASE; ACTIVATION; DIAGNOSIS
AB Convincing epidemiological data suggest an inverse association between cancer and neurodegeneration, including Alzheimer's disease (AD). Since both AD and cancer are characterized by abnormal, but opposing cellular behavior, i.e., increased cell death in AD while excessive cell growth occurs in cancer, this motivates us to initiate the study into unraveling the shared genes and cell signaling pathways linking AD and glioblastoma multiform (GBM). In this study, a comprehensive bioinformatics analysis on clinical microarray datasets of 1,091 GBM and 524 AD cohorts was performed. Significant genes and pathways were identified from the bioinformatics analyses - in particular ERK/MAPK signaling, up-regulated in GBM and Angiopoietin Signaling pathway, reciprocally up-regulated in AD - connecting GBM and AD (P < 0.001), were investigated in details for their roles in GBM growth in an AD environment. Our results showed that suppression of GBM growth in an AD background was mediated by the ERK-AKT-p21-cell cycle pathway and anti-angiogenesis pathway.
C1 [Liu, Timothy; Ren, Ding; Zhu, Xiaoping; Yin, Zheng; Jin, Guangxu; Zhao, Zhen; Robinson, Daniel; Li, Xuping; Wong, Kelvin; Cui, Kemi; Zhao, Hong; Wong, Stephen T. C.] Weill Cornell Med Coll, Houston Methodist Res Inst, Dept Syst Med & Bioengn, Houston, TX 77030 USA.
[Jin, Guangxu; Zhao, Hong; Wong, Stephen T. C.] NCI, Ctr Modeling Canc Dev, Houston Methodist Res Inst, Houston, TX 77030 USA.
[Yin, Zheng; Zhao, Zhen; Li, Xuping; Wong, Kelvin; Wong, Stephen T. C.] Houston Methodist Res Inst, Dept Syst Med & Bioengn, TT & WF Chao Ctr BRAIN, Houston, TX 77030 USA.
[Ren, Ding] PLA 85 Hosp, Dept Oncol, Shanghai 200030, Peoples R China.
RP Zhao, H (reprint author), Weill Cornell Med Coll, Houston Methodist Res Inst, Dept Syst Med & Bioengn, Houston, TX 77030 USA.
EM hzhao@tmhs.org; stwong@tmhs.org
RI Yin, Zheng/J-9307-2015
OI Yin, Zheng/0000-0002-3547-0606
FU NIH [U54 CA149196, R01 CA121225]; TT & WF Chao Foundation; John S. Dunn
Research Foundation; Texas Advanced Computing Center (TACC)
[TG-MCB110130]
FX This research is funded by NIH U54 CA149196, NIH R01 CA121225, TT & WF
Chao Foundation grant and John S. Dunn Research Foundation grant to
STCW. We thank Dr. Neal Copeland for providing comments on the
manuscript, and Drs. James Mancuso and Rebecca Danforth for
proofreading, Drs. Dennis Selkoe (Harvard Medical School) and Santosh
Kesari (UC San Diego School of Medicine) for providing the 7PA2,
U87VIII, and GL261 cell lines. All the microscopic imaging and
ImageStream analysis were performed at Houston Methodist Research
Institute's Advanced Cellular and Tissue Microscope Core Facility. We
also acknowledge the computational time funding support from the Texas
Advanced Computing Center (TACC; Project ID: TG-MCB110130) at the
University of Texas in Austin and BlueBioU (IBM POWER 7 Bioscience
Computing Core at Rice University) to access super-computing resources.
NR 53
TC 6
Z9 6
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 10
PY 2013
VL 3
AR 3467
DI 10.1038/srep03467
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 267VF
UT WOS:000328125700006
PM 24322672
ER
PT J
AU Pickl-Herk, A
Luque, D
Vives-Adrian, L
Querol-Audi, J
Garriga, D
Trus, BL
Verdaguer, N
Blaas, D
Caston, JR
AF Pickl-Herk, Angela
Luque, Daniel
Vives-Adrian, Laia
Querol-Audi, Jordi
Garriga, Damia
Trus, Benes L.
Verdaguer, Nuria
Blaas, Dieter
Caston, Jose R.
TI Uncoating of common cold virus is preceded by RNA switching as
determined by X-ray and cryo-EM analyses of the subviral A-particle
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE genome uncoating; X-ray analysis; 3D cryo-EM; picornavirus
ID RECEPTOR-MEMBRANE COMPLEX; HUMAN RHINOVIRUS; ELECTRON-MICROSCOPY;
POLIOVIRUS-RECEPTOR; MATURATION CLEAVAGE; DISEASE VIRUS; CELL ENTRY;
RESOLUTION; MECHANISM; INTERMEDIATE
AB During infection, viruses undergo conformational changes that lead to delivery of their genome into host cytosol. In human rhinovirus A2, this conversion is triggered by exposure to acid pH in the endosome. The first subviral intermediate, the A-particle, is expanded and has lost the internal viral protein 4 (VP4), but retains its RNA genome. The nucleic acid is subsequently released, presumably through one of the large pores that open at the icosahedral twofold axes, and is transferred along a conduit in the endosomal membrane; the remaining empty capsids, termed B-particles, are shuttled to lysosomes for degradation. Previous structural analyses revealed important differences between the native protein shell and the empty capsid. Nonetheless, little is known of A-particle architecture or conformation of the RNA core. Using 3D cryo-electron microscopy and X-ray crystallography, we found notable changes in RNA-protein contacts during conversion of native virus into the A-particle uncoating intermediate. In the native virion, we confirmed interaction of nucleotide(s) with Trp(38) of VP2 and identified additional contacts with the VP1 N terminus. Study of A-particle structure showed that the VP2 contact is maintained, that VP1 interactions are lost after exit of the VP1 N-terminal extension, and that the RNA also interacts with residues of the VP3 N terminus at the fivefold axis. These associations lead to formation of a well-ordered RNA layer beneath the protein shell, suggesting that these interactions guide ordered RNA egress.
C1 [Pickl-Herk, Angela; Blaas, Dieter] Med Univ Vienna, Dept Med Biochem, Max F Perutz Labs, A-1030 Vienna, Austria.
[Luque, Daniel; Caston, Jose R.] CSIC, Ctr Nacl Biotecnol, Dept Struct Macromol, E-28049 Madrid, Spain.
[Luque, Daniel; Caston, Jose R.] CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, E-28049 Madrid, Spain.
[Luque, Daniel] Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid 28220, Spain.
[Vives-Adrian, Laia; Querol-Audi, Jordi; Verdaguer, Nuria] CSIC, Inst Biol Mol Barcelona, E-08028 Barcelona, Spain.
[Trus, Benes L.] NIH, Imaging Sci Lab, Ctr Informat Technol, Bethesda, MD 20892 USA.
RP Caston, JR (reprint author), CSIC, Ctr Nacl Biotecnol, Dept Struct Macromol, Plaza Murillo 2, E-28049 Madrid, Spain.
EM nvmcri@ibmb.csic.es; dieter.blaas@medunivie.ac.at; jrcaston@cnb.csic.es
RI Caston, Jose/L-5896-2014; Luque, Daniel/I-6467-2015;
OI Caston, Jose/0000-0003-2350-9048; Luque, Daniel/0000-0002-0151-6020;
Garriga, Damia/0000-0003-0410-538X
FU Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR); Spanish
Ministry of Economy and Competitivity [BIO2011-24333, BFU2011-25902];
National Institutes of Health Intramural Research Program; Center for
Information Technology; Austrian Science Foundation [18693-B09];
Austrian Exchange Service [Ostereichischer Austauschdienst (OEAD)] [ES
03/2010, AT2009-0041]; [70172]; [2669]
FX We thank I. Gosler for preparing the virus, T. Marlovits for advice, G.
Resch for help with the Polara microscope, H. Kowalski for critical
reading of the manuscript and helpful comments, and C. Mark for
editorial assistance. D.B. and A.P.-H. are particularly thankful to S.
Hafenstein and R. S. Sinkovic for help and advice in the early phase of
the project, and K. Djinovic-Carugo in the initial crystallization
trials. Part of the data processing was performed on the Vienna
Scientific Cluster (Project 70172 to D.B.), and X-ray data were obtained
at the SLS (beamline PX1) Villigen, Switzerland (BioStruct Project
2669). L.V.-A. is the recipient of a Formacio de Investigadors (FI)
fellowship from the Agencia de Gestio d'Ajuts Universitaris i de Recerca
(AGAUR). This work was supported by grants from the Spanish Ministry of
Economy and Competitivity (BIO2011-24333 to N.V. and BFU2011-25902 to
J.R.C.), the National Institutes of Health Intramural Research Program
and the Center for Information Technology (to B.L.T.), and the Austrian
Science Foundation Project 18693-B09. Short stays in Madrid were made
possible by funding through "Acciones Integradas" (ES 03/2010 to D.B.
and AT2009-0041 to N.V.) awarded by the Austrian Exchange Service
[Ostereichischer Austauschdienst (OEAD)].
NR 43
TC 18
Z9 18
U1 1
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 10
PY 2013
VL 110
IS 50
BP 20063
EP 20068
DI 10.1073/pnas.1312128110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 266YY
UT WOS:000328061700036
PM 24277846
ER
PT J
AU Furuta, K
Walseng, E
Roche, PA
AF Furuta, Kazuyuki
Walseng, Even
Roche, Paul A.
TI Internalizing MHC class II-peptide complexes are ubiquitinated in early
endosomes and targeted for lysosomal degradation
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID INVARIANT CHAIN CONTAINS; DENDRITIC CELLS; RAPID INTERNALIZATION;
SURFACE EXPRESSION; CYTOPLASMIC TAIL; DOWN-REGULATION; CLATHRIN;
COMPARTMENTS; MOLECULES; PATHWAY
AB As sentinels of the immune system, dendritic cells (DCs) continuously generate and turnover antigenic peptide-MHC class II complexes (pMHC-II). pMHC-II generation is a complex process that involves many well-characterized MHC-II biosynthetic intermediates; however, the mechanisms leading to MHC-II turnover/degradation are poorly understood. We now show that pMHC-II complexes undergoing clathrin-independent endocytosis from the DC surface are efficiently ubiquitinated by the E3 ubiquitin ligase March-I in early endosomes, whereas biosynthetically immature MHC-II-Invariant chain (Ii) complexes are not. The inability of MHC-II-Ii to serve as a March-I substrate is a consequence of Ii sorting motifs that divert the MHC-II-Ii complex away from March-I+ early endosomes. When these sorting motifs are mutated, or when clathrin-mediated endocytosis is inhibited, MHC-II-Ii complexes internalize by using a clathrin-independent endocytosis pathway and are now ubiquitinated as efficiently as pMHC-II complexes. These data show that the selective ubiquitination of internalizing surface pMHC-II in March-I+ early endosomes promotes degradation of "old" pMHC-II and spares forms of MHC-II that have not yet loaded antigenic peptides or have not yet reached the DC surface.
C1 [Furuta, Kazuyuki; Walseng, Even; Roche, Paul A.] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA.
[Furuta, Kazuyuki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Deptartment Immunobiol, Okayama 7008530, Japan.
[Walseng, Even] Scripps Florida, Scripps Res Inst, Dept Canc Biol, Jupiter, FL 33458 USA.
RP Roche, PA (reprint author), NCI, Expt Immunol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM paul.roche@nih.gov
FU Japan Society for the Promotion of Science; National Institutes of
Health
FX We thank Peter Cresswell, Satoshi Ishido, and Juan Bonifacino for the
gift of reagents used in this study; Mike Kruhlak and the Experimental
Immunology Branch microscopy facility for expert technical advice; and
Richard Hodes for critical reading of this manuscript. This work was
supported by the Japan Society for the Promotion of Science (K. F.) and
the Intramural Research Program of the National Institutes of Health
(P.A.R.).
NR 34
TC 9
Z9 9
U1 2
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 10
PY 2013
VL 110
IS 50
BP 20188
EP 20193
DI 10.1073/pnas.1312994110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 266YY
UT WOS:000328061700057
PM 24277838
ER
PT J
AU Chen, ZC
Fischer, ER
Kouiavskaia, D
Hansen, BT
Ludtke, SJ
Bidzhieva, B
Makiya, M
Agulto, L
Purcell, RH
Chumakov, K
AF Chen, Zhaochun
Fischer, Elizabeth R.
Kouiavskaia, Diana
Hansen, Bryan T.
Ludtke, Steven J.
Bidzhieva, Bella
Makiya, Michelle
Agulto, Liane
Purcell, Robert H.
Chumakov, Konstantin
TI Cross-neutralizing human anti-poliovirus antibodies bind the recognition
site for cellular receptor
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE phage display; passive immunization; antiviral therapy; broadly reactive
antibodies
ID ELECTRON-MICROSCOPY; ANTIGENIC STRUCTURE; MONOCLONAL-ANTIBODIES;
COMPLEXES; ERADICATION; MUTANTS; VIRUS; CD155; RNA
AB Most structural information about poliovirus interaction with neutralizing antibodies was obtained in the 1980s in studies of mouse monoclonal antibodies. Recently we have isolated a number of human/chimpanzee anti-poliovirus antibodies and demonstrated that one of them, MAb A12, could neutralize polioviruses of both serotypes 1 and 2. This communication presents data on isolation of an additional cross-neutralizing antibody (F12) and identification of a previously unknown epitope on the surface of poliovirus virions. Epitope mapping was performed by sequencing of antibody-resistant mutants and by cryo-EM of complexes of virions with Fab fragments. The results have demonstrated that both cross-neutralizing antibodies bind the site located at the bottom of the canyon surrounding the fivefold axis of symmetry that was previously shown to interact with cellular poliovirus receptor CD155. However, the same antibody binds to serotypes 1 and 2 through different specific interactions. It was also shown to interact with type 3 poliovirus, albeit with about 10-fold lower affinity, insufficient for effective neutralization. Antibody interaction with the binding site of the cellular receptor may explain its broad reactivity and suggest that further screening or antibody engineering could lead to a universal antibody capable of neutralizing all three serotypes of poliovirus.
C1 [Chen, Zhaochun; Makiya, Michelle; Agulto, Liane; Purcell, Robert H.] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
[Fischer, Elizabeth R.; Hansen, Bryan T.] NIAID, Electron Microscopy Unit, Res Technol Branch, Rocky Mt Labs, Hamilton, MT 59840 USA.
[Kouiavskaia, Diana; Bidzhieva, Bella; Chumakov, Konstantin] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20852 USA.
[Ludtke, Steven J.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Natl Ctr Macromol Imaging, Houston, TX 77030 USA.
RP Purcell, RH (reprint author), NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
EM robert.purcell@nih.gov; konstantin.chumakov@fda.hhs.gov
FU National Institute of Allergy and Infectious Diseases, National
Institutes of Health; Food and Drug Administration Center for Biologics
Evaluation and Research; NIH [R01-GM080139]
FX This work was supported in part by the Intramural Research Program of
the National Institute of Allergy and Infectious Diseases, National
Institutes of Health, the Food and Drug Administration Center for
Biologics Evaluation and Research, and NIH Grant R01-GM080139 (to S.L.).
NR 31
TC 16
Z9 16
U1 1
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 10
PY 2013
VL 110
IS 50
BP 20242
EP 20247
DI 10.1073/pnas.1320041110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 266YY
UT WOS:000328061700066
PM 24277851
ER
PT J
AU Kim, TS
Park, JE
Shukla, A
Choi, S
Murugan, RN
Lee, JH
Ahn, M
Rhee, K
Bang, JK
Kim, BY
Loncarek, J
Erikson, RL
Lee, KS
AF Kim, Tae-Sung
Park, Jung-Eun
Shukla, Anil
Choi, Sunho
Murugan, Ravichandran N.
Lee, Jin H.
Ahn, Mija
Rhee, Kunsoo
Bang, Jeong K.
Kim, Bo Y.
Loncarek, Jadranka
Erikson, Raymond L.
Lee, Kyung S.
TI Hierarchical recruitment of Plk4 and regulation of centriole biogenesis
by two centrosomal scaffolds, Cep192 and Cep152
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID DUPLICATION; ELEGANS; PROTEIN; REVEALS; CELLS; SAS-6; INTERACTS;
SUGGEST; KINASE; ZYG-1
AB Centrosomes play an important role in various cellular processes, including spindle formation and chromosome segregation. They are composed of two orthogonally arranged centrioles, whose duplication occurs only once per cell cycle. Accurate control of centriole numbers is essential for the maintenance of genomic integrity. Although it is well appreciated that polo-like kinase 4 (Plk4) plays a central role in centriole biogenesis, how it is recruited to centrosomes and whether this step is necessary for centriole biogenesis remain largely elusive. Here we showed that Plk4 localizes to distinct subcentrosomal regions in a temporally and spatially regulated manner, and that Cep192 and Cep152 serve as two distinct scaffolds that recruit Plk4 to centrosomes in a hierarchical order. Interestingly, Cep192 and Cep152 competitively interacted with the cryptic polo box of Plk4 through their homologous N-terminal sequences containing acidic-alpha-helix and N/Q-rich motifs. Consistent with these observations, the expression of either one of these N-terminal fragments was sufficient to delocalize Plk4 from centrosomes. Furthermore, loss of the Cep192- or Cep152-dependent interaction with Plk4 resulted in impaired centriole duplication that led to delayed cell proliferation. Thus, the spatiotemporal regulation of Plk4 localization by two hierarchical scaffolds, Cep192 and Cep152, is critical for centriole biogenesis.
C1 [Kim, Tae-Sung; Park, Jung-Eun; Choi, Sunho; Lee, Jin H.; Lee, Kyung S.] NCI, Lab Metab, Ctr Canc Res, Bethesda, MD 20892 USA.
[Shukla, Anil; Loncarek, Jadranka] NCI, Lab Prot Dynam & Signaling, Ctr Canc Res, Ft Detrick, MD 21702 USA.
[Choi, Sunho] Dong A ST, Res Labs, Yongin 449905, Gyeonggi Do, South Korea.
[Murugan, Ravichandran N.; Ahn, Mija; Bang, Jeong K.] Korean Basic Sci Inst, Div Magnet Resonance, Ochang 363883, Chungbuk Do, South Korea.
[Rhee, Kunsoo] Seoul Natl Univ, Dept Biol Sci, Seoul 151742, South Korea.
[Kim, Bo Y.] Korea Res Inst Biosci & Biotechnol, World Class Inst, Ochang 363883, Chungbuk Do, South Korea.
[Erikson, Raymond L.] Harvard Univ, Biol Labs, Cambridge, MA 02138 USA.
RP Erikson, RL (reprint author), Harvard Univ, Biol Labs, Cambridge, MA 02138 USA.
EM erikson@mcb.harvard.edu; kyunglee@mail.nih.gov
OI Shukla, Anil/0000-0001-7797-7299
FU National Cancer Institute; Korea Basic Science Institute Research Grant
[T33418]; World Class Institute Program [WCI 2009002]; Ministry of
Science, ICT, and Future Planning of Korea
FX This work was supported in part by National Cancer Institute Intramural
Grants (to K. S. L. and J.L.), Korea Basic Science Institute Research
Grant T33418 (to J.K.B.), and the World Class Institute (WCI 2009002)
Program funded by Ministry of Science, ICT, and Future Planning of Korea
(to B.Y.K.).
NR 34
TC 39
Z9 39
U1 3
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 10
PY 2013
VL 110
IS 50
BP E4849
EP E4857
DI 10.1073/pnas.1319656110
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 266YY
UT WOS:000328061700007
PM 24277814
ER
PT J
AU Vargesson, N
Mahony, C
Erskine, L
Niven, J
Greig, NH
Figg, WD
AF Vargesson, Neil
Mahony, Chris
Erskine, Lynda
Niven, Jennifer
Greig, Nigel H.
Figg, William Douglas
TI Reply to D'Amato et al. and Zeldis et al.: Screening of thalidomide
derivatives in chicken and zebrafish embryos
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Letter
ID INHIBITS ANGIOGENESIS
C1 [Vargesson, Neil; Mahony, Chris; Erskine, Lynda] Univ Aberdeen, Sch Med Sci, Aberdeen AB25 2ZD, Scotland.
[Niven, Jennifer] Univ Aberdeen, Sch Med, Inst Med Sci, Aberdeen AB25 2ZD, Scotland.
[Greig, Nigel H.] NIA, Drug Design & Dev Sect, Translat Gerontol Branch, Intramural Res Program,NIH,Biomed Res Ctr, Baltimore, MD 21224 USA.
[Figg, William Douglas] NCI, Mol Pharmacol Sect, Genitourinary Malignancies Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA.
RP Vargesson, N (reprint author), Univ Aberdeen, Sch Med Sci, Aberdeen AB25 2ZD, Scotland.
EM n.vargesson@abdn.ac.uk
RI Figg Sr, William/M-2411-2016;
OI Vargesson, Neil/0000-0001-8027-114X
NR 7
TC 1
Z9 1
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 10
PY 2013
VL 110
IS 50
BP E4820
EP E4820
DI 10.1073/pnas.1318475110
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 266YY
UT WOS:000328061700003
PM 24471177
ER
PT J
AU Dobrovolskaia, MA
McNeil, SE
AF Dobrovolskaia, Marina A.
McNeil, Scott E.
TI Understanding the correlation between in vitro and in vivo
immunotoxicity tests for nanomedicines
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Nanoparticles; Thrombosis; Disseminated intravascular coagulation;
Procoagulant activity; Coagulopathy; Hemolysis; Complement activation;
Cytokines; Anaphylaxis; Phagocytosis
ID CFU-GM ASSAY; HUMAN WHOLE-BLOOD; COMPLEMENT ACTIVATION; IMMUNE-SYSTEM;
PROCOAGULANT ACTIVITY; RISK-ASSESSMENT; EXTENDED HISTOPATHOLOGY;
PLATELET-AGGREGATION; SCAVENGER RECEPTOR; THROMBUS FORMATION
AB Preclinical characterization of novel nanotechnology-based formulations is often challenged by physicochemical characteristics, sterility/sterilization issues, safety and efficacy. Such challenges are not unique to nanomedicine, as they are common in the development of small and macromolecular drugs. However, due to the lack of a general consensus on critical characterization parameters, a shortage of harmonized protocols to support testing, and the vast variety of engineered nanomaterials, the translation of nanomedicines into clinic is particularly complex. Understanding the immune compatibility of nanoformulations has been identified as one of the important factors in (pre) clinical development and requires reliable in vitro and in vivo immunotoxicity tests. The generally low sensitivity of standard in vivo toxicity tests to immunotoxicities, inter-species variability in the structure and function of the immune system, high costs and relatively low throughput of in vivo tests, and ethical concerns about animal use underscore the need for trustworthy in vitro assays. Here, we consider the correlation (or lack thereof) between in vitro and in vivo immunotoxicity tests as a mean to identify useful in vitro assays. We review literature examples and case studies from the experience of the NCI Nanotechnology Characterization Lab, and highlight assays where predictability has been demonstrated for a variety of nanomaterials and assays with high potential for predictability in vivo. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Dobrovolskaia, Marina A.; McNeil, Scott E.] NCI, Nanotechnol Characterizat Lab, Adv Technol Program, SAIC Frederick Inc, Frederick, MD 21702 USA.
RP McNeil, SE (reprint author), NCI, Nanotechnol Characterizat Lab, SAIC Frederick Inc, 1050 Boyles St,Bldg 469, Frederick, MD 21702 USA.
EM ncl@mail.nih.gov
RI Nanotechnology Characterization Lab, NCL/K-8454-2012
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]
FX This project has been funded in whole or in part with federal funds from
the National Cancer Institute, National Institutes of Health, under
contract HHSN261200800001E. The content of this publication does not
necessarily reflect the views or policies of the Department of Health
and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the U. S. Government. We
are grateful to Allen Kane for the help with preparation of
illustrations, to the NCL technical staff Barry Neun, Timothy Potter,
Christopher McLeland, Jamie Rodrigues and Sarah Skoczen for generating
the data using various in vitro immunoassays and to the NCL's
toxicologist Dr. Stephan Stern for sharing his expertise and help with
establishing in vitro-in vivo correlation for immunoassays.
NR 114
TC 40
Z9 40
U1 4
U2 53
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD DEC 10
PY 2013
VL 172
IS 2
BP 456
EP 466
DI 10.1016/j.jconrel.2013.05.025
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 260NN
UT WOS:000327601700009
PM 23742883
ER
PT J
AU Stern, ST
Zou, P
Skoczen, S
Xie, SW
Liboiron, B
Harasym, T
Tardi, P
Mayer, LD
McNeil, SE
AF Stern, Stephan T.
Zou, Peng
Skoczen, Sarah
Xie, Sherwin
Liboiron, Barry
Harasym, Troy
Tardi, Paul
Mayer, Lawrence D.
McNeil, Scott E.
TI Prediction of nanoparticle prodrug metabolism by pharmacokinetic
modeling of biliary excretion
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Biliary clearance; Pharmacokinetic modeling and simulation; Nanomicellar
prodrug
ID IN-VIVO; UNBOUND PACLITAXEL; CANCER-PATIENTS; PHASE-I; DOCETAXEL; RATS;
FORMULATION; EFFICACY; PLASMA
AB Pharmacokinetic modeling and simulation is a powerful tool for the prediction of drug concentrations in the absence of analytical techniques that allow for direct quantification. The present study applied this modeling approach to determine active drug release from a nanoparticle prodrug formulation. A comparative pharmacokinetic study of a nanoscale micellar docetaxel (DTX) prodrug, Procet 8, and commercial DTX formulation, Taxotere, was conducted in bile duct cannulated rats. The nanoscale (similar to 40 nm) size of the Procet 8 formulation resulted in confinement within the plasma space and high prodrug plasma concentrations. Ex vivo prodrug hydrolysis during plasma sample preparation resulted in unacceptable error that precluded direct measurement of DTX concentrations. Pharmacokinetic modeling of Taxotere and Procet 8 plasma concentrations, and their associated biliary metabolites, allowed for prediction of the DTX concentration profile and DTX bioavailability, and thereby evaluation of Procet 8 metabolism.
Procet 8 plasma decay and in vitro plasma hydrolytic rates were identical, suggesting that systemic clearance of the prodrug was primarily metabolic. The Procet 8 and Taxotere plasma profiles, and associated docetaxel hydroxy-tert-butyl carbamate (HDTX) metabolite biliary excretion, were best fit by a two compartment model, with both linear and non-linear DTX clearance, and first order Procet 8 hydrolysis. The model estimated HDTX clearance rate agreed with in vitro literature values, supporting the predictability of the proposed model. Model simulation at the 10 mg DTX equivalent/kg dose level predicted DTX formation rate-limited kinetics and a peak plasma DTX concentration of 39 ng/mL at 4 h for Procet 8, in comparison to 2826 ng/mL for Taxotere. As a result of non-linear DTX clearance, the DTX AUCinf for the Procet 8 formulation was predicted to be 2.6 times lower than Taxotere (775 vs. 2017 h x ng/mL, respectively), resulting in an absolute bioavailability estimate of 38%. As DTX clearance in man is considered linear, this low bioavailability is likely species-dependent. These data support the use of pharmacokinetic modeling and simulation in cases of complex formulations, where analytical methods for direct measurement of free (released) drug concentrations are unavailable. Uses of such models may include interpretation of preclinical toxicology studies, selection of first in man dosing regimens, and PK/PD model development. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Stern, Stephan T.; Zou, Peng; Skoczen, Sarah; McNeil, Scott E.] SAIC Frederick Inc, Frederick Natl Lab Canc Res, Adv Technol Program, Nanotechnol Characterizat Lab, Frederick, MD 21702 USA.
[Xie, Sherwin; Liboiron, Barry; Harasym, Troy; Tardi, Paul; Mayer, Lawrence D.] Celator Pharmaceut Corp, Vancouver, BC V6P 6P2, Canada.
RP Stern, ST (reprint author), SAIC Frederick Inc, Frederick Natl Lab Canc Res, Adv Technol Program, Nanotechnol Characterizat Lab, Frederick, MD 21702 USA.
EM sternstephan@mail.nih.gov
RI Nanotechnology Characterization Lab, NCL/K-8454-2012; Zou,
Peng/J-9300-2015
FU National Cancer Institute, the National Institutes of Health
[HHSN261200800001E]
FX This project has been funded in whole or in part with federal funds from
the National Cancer Institute, the National Institutes of Health, under
contract HHSN261200800001E. The content of this publication does not
necessarily reflect the views or policies of the Department of Health
and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the U.S. Government. The
authors thank Drs. Rachael M. Crist and Jennifer Hall Grossman for
assistance with the preparation of the manuscript.
NR 26
TC 3
Z9 3
U1 2
U2 38
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD DEC 10
PY 2013
VL 172
IS 2
BP 558
EP 567
DI 10.1016/j.jconrel.2013.04.025
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 260NN
UT WOS:000327601700019
PM 23664969
ER
PT J
AU Kovalchik, SA
Varadhan, R
Weiss, CO
AF Kovalchik, Stephanie A.
Varadhan, Ravi
Weiss, Carlos O.
TI Assessing heterogeneity of treatment effect in a clinical trial with the
proportional interactions model
SO STATISTICS IN MEDICINE
LA English
DT Article
DE effect modification; heterogeneity of treatment effect; interaction;
risk stratification; subgroup analysis
ID GENERALIZED LINEAR-MODELS; SAMPLE-SIZE CALCULATIONS; SUBGROUP ANALYSES;
TESTS; POWER
AB Understanding how individuals vary in their response to treatment is an important task of clinical research. For standard regression models, a proportional interactions model first described by Follmann and Proschan (1999) offers a powerful approach for identifying effect modification in a randomized clinical trial when multiple variables influence treatment response. In this paper, we present a framework for using the proportional interactions model in the context of a parallel-arm clinical trial with multiple prespecified candidate effect modifiers. To protect against model misspecification, we propose a selection strategy that considers all possible proportional interactions models. We develop a modified Bonferroni correction for multiple testing that accounts for the positive correlation among candidate models. We describe methods for constructing a confidence interval for the proportionality parameter. In simulation studies, we show that our modified Bonferroni adjustment controls familywise error and has greater power to detect proportional interactions compared with multiplcity-corrected subgroup analyses. We demonstrate our methodology by using the Studies of Left Ventricular Dysfunction Treatment trial, a placebo-controlled randomized clinical trial of the efficacy of enalapril to reduce the risk of death or hospitalization in chronic heart failure patients. An R package called anoint is available for implementing the proportional interactions methodology. Copyright (c) 2013 John Wiley & Sons, Ltd.
C1 [Kovalchik, Stephanie A.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA.
[Varadhan, Ravi] Johns Hopkins Univ, Ctr Aging & Hlth, Baltimore, MD 21205 USA.
[Varadhan, Ravi] Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21205 USA.
[Weiss, Carlos O.] Johns Hopkins Univ, Div Geriatr Med & Gerontol, Baltimore, MD 21205 USA.
RP Varadhan, R (reprint author), Johns Hopkins Univ, Ctr Aging & Hlth, 2024 E Monument St,Suite 2-700, Baltimore, MD 21205 USA.
EM rvaradhan@jhmi.edu
FU Food and Drug Administration, Department of Health and Human Services
[HHSF2232010000072C]; RSR [08-48]; Center for Drug Evaluation and
Research, U.S. Food and Drug Administration; National Cancer Institute
FX We are grateful to Dr. Nilanjan Chatterjee, Dr. Hormuzd Katki, Dr.
Sue-Jane Wang, and Dr. Estelle Russek-Cohen for the useful comments they
provided to us during the writing of this manuscript. Our study used
research materials from the SOLVD-T obtained from the National Heart
Lung and Blood Institute Biologic Specimen and Data Repository
Information Coordinating Center and does not necessarily reflect the
opinions or views of the SOLVD-T or the National Heart Lung and Blood
Institute. The analyses upon which this publication is based were
performed under contract number HHSF2232010000072C, entitled,
"Partnership in Applied Comparative Effectiveness Science", sponsored by
the Food and Drug Administration, Department of Health and Human
Services. This research was also supported by the RSR grant no.08-48 and
awarded by the Center for Drug Evaluation and Research, U.S. Food and
Drug Administration. Dr. Kovalchik's work was supported by the
intramural research program of the National Cancer Institute. Dr.
Varadhan is a Brookdale Leadership in Aging Fellow at the Johns Hopkins
University.
NR 17
TC 4
Z9 4
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-6715
EI 1097-0258
J9 STAT MED
JI Stat. Med.
PD DEC 10
PY 2013
VL 32
IS 28
BP 4906
EP 4923
DI 10.1002/sim.5881
PG 18
WC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Medicine, Research &
Experimental; Statistics & Probability
SC Mathematical & Computational Biology; Public, Environmental &
Occupational Health; Medical Informatics; Research & Experimental
Medicine; Mathematics
GA 248UH
UT WOS:000326729100004
PM 23788362
ER
PT J
AU Puetz, TW
Morley, CA
Herring, MP
AF Puetz, Timothy W.
Morley, Christopher A.
Herring, Matthew P.
TI The Challenge of Definition and Moving Creative Arts Therapy Research
Forward
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Puetz, Timothy W.] NIH, Off Director, Bethesda, MD 20802 USA.
[Morley, Christopher A.] ArtReach Fdn Inc, Atlanta, GA USA.
[Herring, Matthew P.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA.
RP Puetz, TW (reprint author), NIH, Off Director, 9000 Rockville Pike, Bethesda, MD 20802 USA.
EM timothy.puetz@nih.gov
RI Herring, Matthew/O-2265-2014
OI Herring, Matthew/0000-0002-6835-5321
NR 5
TC 0
Z9 0
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD DEC 9
PY 2013
VL 173
IS 22
BP 2094
EP 2095
DI 10.1001/jamainternmed.2013.10494
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA AA2WL
UT WOS:000330954800027
PM 24322467
ER
PT J
AU Jacobs, AC
Calkins, MJ
Jadhav, A
Dorjsuren, D
Maloney, D
Simeonov, A
Jaruga, P
Dizdaroglu, M
McCullough, AK
Lloyd, RS
AF Jacobs, Aaron C.
Calkins, Marcus J.
Jadhav, Ajit
Dorjsuren, Dorjbal
Maloney, David
Simeonov, Anton
Jaruga, Pawel
Dizdaroglu, Miral
McCullough, Amanda K.
Lloyd, R. Stephen
TI Inhibition of DNA Glycosylases via Small Molecule Purine Analogs
SO PLOS ONE
LA English
DT Article
ID OXIDATIVELY DAMAGED DNA; T4 ENDONUCLEASE-V; REPAIR ENZYME; NEIL1 DNA;
THYMIDYLATE SYNTHASE; PARP INHIBITORS; EXCISION-REPAIR; MODIFIED BASES;
IN-VITRO; PROTEIN
AB Following the formation of oxidatively-induced DNA damage, several DNA glycosylases are required to initiate repair of the base lesions that are formed. Recently, NEIL1 and other DNA glycosylases, including OGG1 and NTH1 were identified as potential targets in combination chemotherapeutic strategies. The potential therapeutic benefit for the inhibition of DNA glycosylases was validated by demonstrating synthetic lethality with drugs that are commonly used to limit DNA replication through dNTP pool depletion via inhibition of thymidylate synthetase and dihydrofolate reductase. Additionally, NEIL1-associated synthetic lethality has been achieved in combination with Fanconi anemia, group G. As a prelude to the development of strategies to exploit the potential benefits of DNA glycosylase inhibition, it was necessary to develop a reliable high-throughput screening protocol for this class of enzymes. Using NEIL1 as the proof-of-principle glycosylase, a fluorescence-based assay was developed that utilizes incision of site-specifically modified oligodeoxynucleotides to detect enzymatic activity. This assay was miniaturized to a 1536-well format and used to screen small molecule libraries for inhibitors of the combined glycosylase/AP lyase activities. Among the top hits of these screens were several purine analogs, whose postulated presence in the active site of NEIL1 was consistent with the paradigm of NEIL1 recognition and excision of damaged purines. Although a subset of these small molecules could inhibit other DNA glycosylases that excise oxidatively-induced DNA adducts, they could not inhibit a pyrimidine dimer-specific glycosylase.
C1 [Jacobs, Aaron C.; Calkins, Marcus J.; McCullough, Amanda K.; Lloyd, R. Stephen] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA.
[Jadhav, Ajit; Dorjsuren, Dorjbal; Maloney, David; Simeonov, Anton] NIH, Natl Ctr Adv Translat Sci, Rockville, MD USA.
[Jaruga, Pawel; Dizdaroglu, Miral] NIST, Biomol Measurement Div, Gaithersburg, MD 20899 USA.
[McCullough, Amanda K.; Lloyd, R. Stephen] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA.
RP Lloyd, RS (reprint author), Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA.
EM lloydst@ohsu.edu
RI Jaruga, Pawel/M-4378-2015
FU National Institutes of Health [R01 DK75974, P01 CA160032, T32 ES007060];
National Cancer Institute of the National Institutes of Health
[T32CA106195]; National Center for Advancing Translational Sciences;
Molecular Libraries Initiative of the National Institutes of Health
Roadmap for Medical Research [U54MH084681]
FX This work was supported in part by National Institutes of Health (R01
DK75974, P01 CA160032) to RSL. ACJ was supported by National Institutes
of Health (T32 ES007060). Research reported in this publication was also
partially supported by the National Cancer Institute of the National
Institutes of Health under award number T32CA106195 for MC. Support by
the intramural research program of the National Center for Advancing
Translational Sciences and the Molecular Libraries Initiative of the
National Institutes of Health Roadmap for Medical Research (U54MH084681)
is gratefully acknowledged. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 40
TC 10
Z9 10
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 9
PY 2013
VL 8
IS 12
AR e81667
DI 10.1371/journal.pone.0081667
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 275VD
UT WOS:000328705200041
PM 24349107
ER
PT J
AU Cooper, A
Garcia, M
Petrovas, C
Yamamoto, T
Koup, RA
Nabel, GJ
AF Cooper, Arik
Garcia, Mayra
Petrovas, Constantinos
Yamamoto, Takuya
Koup, Richard A.
Nabel, Gary J.
TI HIV integration and T cell death: additional commentary
SO RETROVIROLOGY
LA English
DT Editorial Material
ID DEPENDENT PROTEIN-KINASE; VIRUS TYPE-1 INFECTION; SIV INFECTION;
GASTROINTESTINAL-TRACT; LYMPHOID-TISSUE; IN-VIVO; DEPLETION;
LYMPHOCYTES; APOPTOSIS; REPLICATION
AB Estaquier et al. provide commentary on our paper that elucidated the mechanism by which HIV-1 causes cell death in activated CD4 T lymphocytes. We showed that proviral DNA integration triggers DNA-PK dependent death signaling, leading to p53 phosphorylation and cell demise (Cooper A et al. Nature 498:376-379, 2013). They have raised several hypothetical points that we further clarify here.
C1 [Cooper, Arik; Garcia, Mayra; Nabel, Gary J.] NIAID, Virol Lab, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
[Petrovas, Constantinos; Yamamoto, Takuya; Koup, Richard A.] NIAID, Immunol Lab, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
RP Nabel, GJ (reprint author), Sanofi, 640 Mem Dr, Cambridge, MA 02139 USA.
EM Gary.Nabel@sanofi.com
RI Yamamoto, Takuya/L-2642-2013
OI Yamamoto, Takuya/0000-0003-3753-1211
NR 27
TC 2
Z9 2
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD DEC 9
PY 2013
VL 10
AR 150
DI 10.1186/1742-4690-10-150
PG 3
WC Virology
SC Virology
GA 280RZ
UT WOS:000329049800002
PM 24321564
ER
PT J
AU Anchoori, RK
Karanam, B
Peng, SW
Wang, JW
Jiang, R
Tanno, T
Orlowski, RZ
Matsui, W
Zhao, M
Rudek, MA
Hung, CF
Chen, X
Walters, KJ
Roden, RBS
AF Anchoori, Ravi K.
Karanam, Balasubramanyam
Peng, Shiwen
Wang, Joshua W.
Jiang, Rosie
Tanno, Toshihiko
Orlowski, Robert Z.
Matsui, William
Zhao, Ming
Rudek, Michelle A.
Hung, Chien-fu
Chen, Xiang
Walters, Kylie J.
Roden, Richard B. S.
TI A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor
RPN13/ADRM1 as a Therapy for Cancer
SO CANCER CELL
LA English
DT Article
ID OVERCOME BORTEZOMIB RESISTANCE; DEUBIQUITINATING ENZYME;
MULTIPLE-MYELOMA; OVARIAN-CANCER; PROTEIN INTERACTOME; 26S PROTEASOME;
SYSTEM; SUBUNIT; CELLS; INHIBITOR
AB The bis-benzylidine piperidone RA190 covalently binds to cysteine 88 of ubiquitin receptor RPN13 in the 19S regulatory particle and inhibits proteasome function, triggering rapid accumulation of polyubiquitinated proteins. Multiple myeloma (MM) lines, even those resistant to bortezomib, were sensitive to RA190 via endoplasmic reticulum stress-related apoptosis. RA190 stabilized targets of human papillonnavirus (HPV) E6 oncoprotein, and preferentially killed HPV-transformed cells. After oral or intraperitoneal dosing of mice, RA190 distributed to plasma and major organs except the brain and inhibited proteasome function in skin and muscle. RA190 administration profoundly reduced growth of MM and ovarian cancer xenografts, and oral RA190 treatment retarded HPV16(+) syngeneic mouse tumor growth, without affecting spontaneous HPV-specific CD8(+) T cell responses, suggesting its therapeutic potential.
C1 [Anchoori, Ravi K.; Tanno, Toshihiko; Matsui, William; Zhao, Ming; Rudek, Michelle A.; Roden, Richard B. S.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21231 USA.
[Karanam, Balasubramanyam; Peng, Shiwen; Wang, Joshua W.; Jiang, Rosie; Hung, Chien-fu; Roden, Richard B. S.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21231 USA.
[Roden, Richard B. S.] Johns Hopkins Univ, Dept Gynecol & Obstet, Baltimore, MD 21231 USA.
[Orlowski, Robert Z.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Div Canc Med, Houston, TX 77030 USA.
[Chen, Xiang; Walters, Kylie J.] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
[Chen, Xiang; Walters, Kylie J.] NCI, Prot Proc Sect, Struct Biophys Lab, Ctr Canc Res, Frederick, MD 21702 USA.
RP Roden, RBS (reprint author), Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21231 USA.
EM roden@jhmi.edu
OI Matsui, William/0000-0002-3088-0964
FU National Institutes of Health ATIP Program [P50 CA098252, CA136472];
M.D. Anderson Cancer Center Specialized Program of Research Excellence
in Multiple Myeloma [P50 CA142509]; Sidney Kimmel Comprehensive Cancer
Center Analytical Pharmacology Core at Johns Hopkins [P30 CA006973, UL1
RR 025005]; HERA Foundation; Ephraim and Wilma Shaw Roseman Foundation
FX We thank B. Vogelstein (Johns Hopkins University) for the HCT116 lines
and D. Piwnica-Worms (Washington University, St. Louis, MO) for the
4UbFL and FL plasmids. Grant support was provided by National Institutes
of Health ATIP Program grants P50 CA098252 and CA136472 and the M.D.
Anderson Cancer Center Specialized Program of Research Excellence in
Multiple Myeloma (P50 CA142509). The project was supported in part by
the Sidney Kimmel Comprehensive Cancer Center Analytical Pharmacology
Core at Johns Hopkins (P30 CA006973 and UL1 RR 025005). We also thank
the HERA Foundation and the Ephraim and Wilma Shaw Roseman Foundation
for support. NMR data were acquired in the NMR facility at the
University of Minnesota, and data processing and depiction occurred in
the Minnesota Supercomputing Institute Basic Sciences Computing Lab. We
also thank P. Villalta (University of Minnesota) for his help with the
LC-MS and E. Arriaga (University of Minnesota) for allowing us to use
his spectrofluorometer.
NR 38
TC 34
Z9 34
U1 1
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
EI 1878-3686
J9 CANCER CELL
JI Cancer Cell
PD DEC 9
PY 2013
VL 24
IS 6
BP 791
EP 805
DI 10.1016/j.ccr.2013.11.001
PG 15
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 272EN
UT WOS:000328443200012
PM 24332045
ER
PT J
AU Yasuda, K
Zhang, HY
Loiselle, D
Haystead, T
Macara, IG
Mili, S
AF Yasuda, Kyota
Zhang, Huaye
Loiselle, David
Haystead, Timothy
Macara, Ian G.
Mili, Stavroula
TI The RNA-binding protein Fus directs translation of localized mRNAs in
APC-RNP granules
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID AMYOTROPHIC-LATERAL-SCLEROSIS; POLYPOSIS-COLI PROTEIN; STRESS GRANULES;
SACCHAROMYCES-CEREVISIAE; CELL-MIGRATION; P BODIES; IN-VIVO; POLARITY;
TDP-43; ROLES
AB RNA localization pathways direct numerous mRNAs to distinct subcellular regions and affect many physiological processes. In one such pathway the tumor-suppressor protein adenomatous polyposis coli (APC) targets RNAs to cell protrusions, forming APC-containing ribonucleoprotein complexes (APC-RNPs). Here, we show that APC-RNPs associate with the RNA-binding protein Fus/TLS (fused in sarcoma/translocated in liposarcoma). Fus is not required for APC-RNP localization but is required for efficient translation of associated transcripts. Labeling of newly synthesized proteins revealed that Fus promotes translation preferentially within protrusions. Mutations in Fus cause amyotrophic lateral sclerosis (ALS) and the mutant protein forms inclusions that appear to correspond to stress granules. We show that overexpression or mutation of Fus results in formation of granules, which preferentially recruit APC-RNPs. Remarkably, these granules are not translationally silent. Instead, APC-RNP transcripts are translated within cytoplasmic Fus granules. These results unexpectedly show that translation can occur within stress-like granules. Importantly, they identify a new local function for cytoplasmic Fus with implications for ALS pathology.
C1 [Yasuda, Kyota; Mili, Stavroula] NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
[Zhang, Huaye] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, Piscataway, NJ 08854 USA.
[Loiselle, David; Haystead, Timothy] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.
[Macara, Ian G.] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA.
RP Mili, S (reprint author), NCI, Cellular & Mol Biol Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.
EM voula.mili@nih.gov
FU NIH [CA138905]; Human Frontier Science Program [HFSP-RGP0031]
FX This work was supported by grant CA138905 from the NIH to S. Mill and
grant HFSP-RGP0031 from the Human Frontier Science Program to I.G.
Macara.
NR 39
TC 32
Z9 32
U1 0
U2 12
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0021-9525
EI 1540-8140
J9 J CELL BIOL
JI J. Cell Biol.
PD DEC 9
PY 2013
VL 203
IS 5
BP 737
EP 746
DI 10.1083/jcb.201306058
PG 10
WC Cell Biology
SC Cell Biology
GA 270HQ
UT WOS:000328309900005
PM 24297750
ER
PT J
AU Bouvier, A
Deleaval, F
Doyley, MM
Yazdani, SK
Finet, G
Le Floc'h, S
Cloutier, G
Pettigrew, RI
Ohayon, J
AF Bouvier, Adeline
Deleaval, Flavien
Doyley, Marvin M.
Yazdani, Saami K.
Finet, Gerard
Le Floc'h, Simon
Cloutier, Guy
Pettigrew, Roderic I.
Ohayon, Jacques
TI A direct vulnerable atherosclerotic plaque elasticity reconstruction
method based on an original material-finite element formulation:
theoretical framework
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID INTRAVASCULAR ULTRASOUND; IN-VIVO; CORONARY-ARTERY; CIRCUMFERENTIAL
STRESS; RADIOFREQUENCY DATA; CAP THICKNESS; WORKING GROUP; ELASTOGRAPHY;
MODEL; RUPTURE
AB The peak cap stress (PCS) amplitude is recognized as a biomechanical predictor of vulnerable plaque (VP) rupture. However, quantifying PCS in vivo remains a challenge since the stress depends on the plaque mechanical properties. In response, an iterative material finite element (FE) elasticity reconstruction method using strain measurements has been implemented for the solution of these inverse problems. Although this approach could resolve the mechanical characterization of VPs, it suffers from major limitations since (i) it is not adapted to characterize VPs exhibiting high material discontinuities between inclusions, and (ii) does not permit real time elasticity reconstruction for clinical use. The present theoretical study was therefore designed to develop a direct material-FE algorithm for elasticity reconstruction problems which accounts for material heterogeneities. We originally modified and adapted the extended FE method (Xfem), used mainly in crack analysis, to model material heterogeneities. This new algorithm was successfully applied to six coronary lesions of patients imaged in vivo with intravascular ultrasound. The results demonstrated that the mean relative absolute errors of the reconstructed Young's moduli obtained for the arterial wall, fibrosis, necrotic core, and calcified regions of the VPs decreased from 95.3 +/- 15.56%, 98.85 +/- 72.42%, 103.29 +/- 111.86% and 95.3 +/- 10.49%, respectively, to values smaller than 2.6 x 10(-8)+/- 5.7 x 10(-8)% (i.e. close to the exact solutions) when including modified-Xfem method into our direct elasticity reconstruction method.
C1 [Bouvier, Adeline; Deleaval, Flavien; Ohayon, Jacques] UJF, CNRS, Lab TIMC IMAG DyCTiM, UMR 5525,In3S, Grenoble, France.
[Doyley, Marvin M.] Univ Rochester, Dept Elect & Comp Engn, Rochester, NY USA.
[Yazdani, Saami K.] Univ S Alabama, Dept Mech Engn, Mobile, AL 36688 USA.
[Finet, Gerard] Hosp Civils Lyon, Dept Hemodynam & Intervent Cardiol, Lyon, France.
[Finet, Gerard] Univ Lyon 1, INSERM, U886, F-69365 Lyon, France.
[Le Floc'h, Simon] Univ Montpellier 2, CNRS, UMR 5508, Lab LMGC, Montpellier, France.
[Cloutier, Guy] Univ Montreal Hosp Res Ctr CRCHUM, Lab Biorheol & Med Ultrason, Montreal, PQ, Canada.
[Pettigrew, Roderic I.] NIDDK, Lab Integrat Cardiovasc Imaging Sci, NIH, Bethesda, MD 20892 USA.
[Ohayon, Jacques] Univ Savoie, Polytech Annecy Chambery, Le Bourget Du Lac, France.
RP Pettigrew, RI (reprint author), NIDDK, Lab Integrat Cardiovasc Imaging Sci, NIH, Bethesda, MD 20892 USA.
EM jacques.ohayon@imag.fr
RI Doyley, Marvin/N-3765-2013; Ohayon, Jacques/M-6576-2014
FU ANR (MELANII) [09-BLANC-0423]; NSERC [STPGP-381136-09]; la Region
Rhone-Alpes, France; French Ministry for Higher Education and Research
(MENRT)
FX This research was supported by a joint international program of the ANR
(MELANII project # 09-BLANC-0423) and NSERC strategic grant
#STPGP-381136-09. Flavien Deleaval held a doctoral fellowship from la
Region Rhone-Alpes, France (2010-13). Adeline Bouvier held a doctoral
fellowship from the French Ministry for Higher Education and Research
(MENRT 2010-13).
NR 55
TC 4
Z9 4
U1 1
U2 14
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD DEC 7
PY 2013
VL 58
IS 23
BP 8457
EP 8476
DI 10.1088/0031-9155/58/23/8457
PG 20
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 266SA
UT WOS:000328042800012
PM 24240392
ER
PT J
AU Kang'ethe, W
Bernstein, HD
AF Kang'ethe, Wanyoike
Bernstein, Harris D.
TI Stepwise Folding of an Autotransporter Passenger Domain Is Not Essential
for Its Secretion
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Escherichia coli; Membrane Proteins; Protein Folding; Protein
Translocation; Virulence Factors; Autotransporter
ID OUTER-MEMBRANE TRANSLOCATION; PARALLEL BETA-HELIX; ESCHERICHIA-COLI;
BACTERIAL AUTOTRANSPORTER; CRYSTAL-STRUCTURE; RECOMBINANT PROTEINS;
VIRULENCE FACTOR; SERINE-PROTEASE; P22 TAILSPIKE; BIOGENESIS
AB Background: It has been proposed that stepwise folding of the extracellular (passenger) domains of bacterial autotransporter proteins drives their secretion. Results: Mutations in N-terminal or medial segments of a passenger domain that severely impair folding only moderately reduce secretion efficiency. Conclusion: Stepwise folding only partially accounts for the energetics of autotransporter secretion. Significance: Autotransporter secretion may involve the use of a novel energy source.
Autotransporters are a superfamily of virulence proteins produced by Gram-negative bacteria. They consist of an N-terminal -helical domain (passenger domain) that is secreted into the extracellular space and a C-terminal -barrel domain (-domain) that anchors the protein to the outer membrane. Because the periplasm lacks ATP, vectorial folding of the passenger domain in a C-to-N-terminal direction has been proposed to drive the secretion reaction. Consistent with this hypothesis, mutations that disrupt the folding of the C terminus of the passenger domain of the Escherichia coli O157:H7 autotransporter EspP have been shown to cause strong secretion defects. Here, we show that point mutations introduced at specific locations near the middle or N terminus of the EspP -helix that perturb folding also impair secretion, but to a lesser degree. Surprisingly, we found that even multiple mutations that potentially abolish the stability of several consecutive rungs of the -helix only moderately reduce secretion efficiency. Although these results provide evidence that the free energy derived from passenger domain folding contributes to secretion efficiency, they also suggest that a significant fraction of the energy required for secretion is derived from another source.
C1 [Kang'ethe, Wanyoike; Bernstein, Harris D.] NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA.
RP Bernstein, HD (reprint author), NIDDK, Genet & Biochem Branch, Bldg 5,Rm 201, Bethesda, MD 20892 USA.
EM harris_bernstein@nih.gov
FU NIDDK Intramural Research Program of the National Institutes of Health
FX This work was supported, in whole or in part, by the NIDDK Intramural
Research Program of the National Institutes of Health.
NR 44
TC 10
Z9 10
U1 4
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 6
PY 2013
VL 288
IS 49
BP 35028
EP 35038
DI 10.1074/jbc.M113.515635
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 291YA
UT WOS:000329867600005
PM 24165126
ER
PT J
AU Mulligan, C
Mindell, JA
AF Mulligan, Christopher
Mindell, Joseph A.
TI Mechanism of Transport Modulation by an Extracellular Loop in an
Archaeal Excitatory Amino Acid Transporter (EAAT) Homolog
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Amino Acid Transport; Chemical Modification; Glutamate; Membrane
Transport; Reconstitution of Membrane Transporters; Transporters;
Protein Cross-linking
ID DEPENDENT ASPARTATE TRANSPORTER; GLUTAMATE TRANSPORTER;
PYROCOCCUS-HORIKOSHII; CRYSTAL-STRUCTURE; TRANSLOCATION; BINDING;
SODIUM; STOICHIOMETRY; SUBSTRATE; EXCHANGE
AB Background: The extracellular loop, 3L4, plays an important, unknown role in the transport cycle of the glutamate transporter homolog, Glt(Ph). Results: Cleaving 3L4 differentially affects transport cycle steps. Conclusion: 3L4 discriminates between substrate-loaded and empty states of the transporter. Significance: Empty and loaded forms of the transport domain have structurally distinguishable forms, reflecting essential features of the transport mechanism.
Secondary transporters in the excitatory amino acid transporter family terminate glutamatergic synaptic transmission by catalyzing Na+-dependent removal of glutamate from the synaptic cleft. Recent structural studies of the aspartate-specific archaeal homolog, Glt(Ph), suggest that transport is achieved by a rigid body, piston-like movement of the transport domain, which houses the substrate-binding site, between the extracellular and cytoplasmic sides of the membrane. This transport domain is connected to an immobile scaffold by three loops, one of which, the 3-4 loop (3L4), undergoes substrate-sensitive conformational change. Proteolytic cleavage of the 3L4 was found to abolish transport activity indicating an essential function for this loop in the transport mechanism. Here, we demonstrate that despite the presence of fully cleaved 3L4, Glt(Ph) is still able to sample conformations relevant for transport. Optimized reconstitution conditions reveal that fully cleaved Glt(Ph) retains some transport activity. Analysis of the kinetics and temperature dependence of transport accompanied by direct measurements of substrate binding reveal that this decreased transport activity is not due to alteration of the substrate binding characteristics but is caused by the significantly reduced turnover rate. By measuring solute counterflow activity and cross-link formation rates, we demonstrate that cleaving 3L4 severely and specifically compromises one or more steps contributing to the movement of the substrate-loaded transport domain between the outward- and inward-facing conformational states, sparing the equivalent step(s) during the movement of the empty transport domain. These results reveal a hitherto unknown role for the 3L4 in modulating an essential step in the transport process.
C1 [Mulligan, Christopher; Mindell, Joseph A.] NINDS, Membrane Transport Biophys Sect, Porter Neurosci Res Ctr, NIH, Bethesda, MD 20892 USA.
RP Mindell, JA (reprint author), NINDS, Membrane Transport Biophys Sect, Porter Neurosci Res Ctr, NIH, Bethesda, MD 20892 USA.
EM mindellj@ninds.nih.gov
OI Mindell, Joseph/0000-0002-6952-8247
FU Intramural Research Program of the National Institutes of Health, NINDS
FX This work was supported by the Intramural Research Program of the
National Institutes of Health, NINDS.
NR 27
TC 9
Z9 9
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 6
PY 2013
VL 288
IS 49
BP 35266
EP 35276
DI 10.1074/jbc.M113.508408
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 291YA
UT WOS:000329867600025
PM 24155238
ER
PT J
AU Lam, MPY
Lau, E
Liem, DA
Ping, PP
AF Lam, Maggie P. Y.
Lau, Edward
Liem, David A.
Ping, Peipei
TI Cyclophilin D and Acetylation A New Link in Cardiac Signaling
SO CIRCULATION RESEARCH
LA English
DT Editorial Material
DE Editorials; acetylation; cyclophilin D; metabolism; mitochondria;
proteomics
ID MITOCHONDRIAL PROTEIN-PHOSPHORYLATION; PERMEABILITY TRANSITION;
HEART-FAILURE; DEACETYLATION; PROTECTION; SIRTUIN-3; BIOLOGY
C1 [Ping, Peipei] Univ Calif Los Angeles, David Geffen Sch Med, NHLBI, Dept Physiol,Prote Ctr, Los Angeles, CA 90095 USA.
[Ping, Peipei] Univ Calif Los Angeles, David Geffen Sch Med, NHLBI, Dept Med,Prote Ctr, Los Angeles, CA 90095 USA.
RP Ping, PP (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, NHLBI, Dept Physiol,Prote Ctr, Los Angeles, CA 90095 USA.
EM pping@mednet.ucla.edu
OI Lau, Edward/0000-0001-9083-5922; Ping, Peipei/0000-0003-3583-3881
FU NHLBI NIH HHS [R37 HL063901, HL-R37-63901]; PHS HHS [HHSN268201000035C]
NR 16
TC 3
Z9 3
U1 1
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD DEC 6
PY 2013
VL 113
IS 12
BP 1268
EP 1269
DI 10.1161/CIRCRESAHA.113.302687
PG 2
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Hematology
GA 298VY
UT WOS:000330353800037
PM 24311610
ER
PT J
AU Nguyen, TTM
Wong, R
Menazza, S
Sun, JH
Chen, Y
Wang, GH
Gucek, M
Steenbergen, C
Sack, MN
Murphy, E
AF Nguyen, Tiffany Tuyen M.
Wong, Renee
Menazza, Sara
Sun, Junhui
Chen, Yong
Wang, Guanghui
Gucek, Marjan
Steenbergen, Charles
Sack, Michael N.
Murphy, Elizabeth
TI Cyclophilin D Modulates Mitochondrial Acetylome
SO CIRCULATION RESEARCH
LA English
DT Article
DE acetylation; cyclophilin D; mitochondria; proteomics; sirtuin 3
ID PERMEABILITY TRANSITION PORE; LYSINE ACETYLATION; CELL-DEATH; EMERGING
CHARACTERIZATION; CALORIE RESTRICTION; S-NITROSYLATION; HEART-FAILURE;
SIRT3; DEACETYLATION; PROTEINS
AB Rationale: Mice lacking cyclophilin D (CypD(-/-)), a mitochondrial chaperone protein, have altered cardiac metabolism. As acetylation has been shown to regulate metabolism, we tested whether changes in protein acetylation might play a role in these metabolic changes in CypD(-/-) hearts.
Objective: Our aim was to test the hypothesis that loss of CypD alters the cardiac mitochondrial acetylome.
Methods and Results: To identify changes in lysine-acetylated proteins and to map acetylation sites after ablation of CypD, we subjected tryptic digests of isolated cardiac mitochondria from wild-type and CypD(-/-) mice to immunoprecipitation using agarose beads coupled to antiacetyl lysine antibodies followed by mass spectrometry. We used label-free analysis for the relative quantification of the 875 common peptides that were acetylated in wildtype and CypD(-/-) samples and found 11 peptides (10 proteins) decreased and 96 peptides (48 proteins) increased in CypD(-/-) samples. We found increased acetylation of proteins in fatty acid oxidation and branched-chain amino acid metabolism. To evaluate whether this increase in acetylation might play a role in the inhibition of fatty acid oxidation that was previously reported in CypD(-/-) hearts, we measured the activity of L-3-hydroxyacyl-CoA dehydrogenase, which was acetylated in the CypD(-/-) hearts. Consistent with the hypothesis, L-3-hydroxyacyl-CoA dehydrogenase activity was inhibited by approximate to 50% compared with the wild-type mitochondria.
Conclusions: These results implicate a role for CypD in modulating protein acetylation. Taken together, these results suggest that ablation of CypD leads to changes in the mitochondrial acetylome, which may contribute to altered mitochondrial metabolism in CypD(-/-) mice.
C1 [Nguyen, Tiffany Tuyen M.; Menazza, Sara; Sun, Junhui; Murphy, Elizabeth] NHLBI, Syst Biol Ctr, NIH, Bethesda, MD 20892 USA.
[Wong, Renee] NHLBI, Div Cardiovasc Sci, NIH, Bethesda, MD 20892 USA.
[Chen, Yong; Wang, Guanghui; Gucek, Marjan] NHLBI, Prote Core Facil, NIH, Bethesda, MD 20892 USA.
[Sack, Michael N.] NHLBI, Ctr Mol Med, NIH, Bethesda, MD 20892 USA.
[Steenbergen, Charles] Johns Hopkins Med Ctr, Dept Pathol, Baltimore, MD USA.
RP Murphy, E (reprint author), NHLBI, NIH, Bldg 10,Rm 8N202,10 Ctr Dr, Bethesda, MD 20892 USA.
EM murphy1@mail.nih.gov
RI chen, yong/E-2432-2011
FU National Institutes of Health's National Heart, Lung, and Blood
Institute intramural program
FX This work was supported by the National Institutes of Health's National
Heart, Lung, and Blood Institute intramural program.
NR 38
TC 22
Z9 23
U1 4
U2 22
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD DEC 6
PY 2013
VL 113
IS 12
BP 1308
EP +
DI 10.1161/CIRCRESAHA.113.301867
PG 19
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Hematology
GA 298VY
UT WOS:000330353800047
PM 24062335
ER
PT J
AU Pollitt, LC
Mackinnon, MJ
Mideo, N
Read, AF
AF Pollitt, Laura C.
Mackinnon, Margaret J.
Mideo, Nicole
Read, Andrew F.
TI Mosquito transmission, growth phenotypes and the virulence of malaria
parasites
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Transmission; Virulence; Mosquitoes; Within-host dynamics;
Plasmodium chabaudi
ID RODENT MALARIA; EVOLUTION
AB Background: A series of elegant experiments was recently published which demonstrated that transmission of malaria parasites through mosquitoes elicited an attenuated growth phenotype, whereby infections grew more slowly and reached peak parasitaemia at least five-fold lower than parasites which had not been mosquito transmitted. To assess the implications of these results it is essential to understand whether the attenuated infection phenotype is a general phenomenon across parasites genotypes and conditions.
Methods: Using previously published data, the impact of mosquito transmission on parasite growth rates and virulence of six Plasmodium chabaudi lines was analysed.
Results: The effect of mosquito transmission varied among strains, but did not lead to pronounced or consistent reductions in parasite growth rate.
Conclusions: Mosquito-induced attenuated growth phenotype is sensitive to experimental conditions.
C1 [Pollitt, Laura C.; Read, Andrew F.] Penn State Univ, Ctr Infect Dis Dynam, State Coll, PA 16801 USA.
[Mackinnon, Margaret J.] Kenya Govt Med Res Ctr, Wellcome Trust Res Programme, Kilifi, Kenya.
[Mackinnon, Margaret J.] Univ Oxford, Nuffield Dept Med, Oxford, England.
[Mideo, Nicole] Univ Toronto, Dept Ecol & Evolut Biol, Toronto, ON, Canada.
[Read, Andrew F.] Penn State Univ, Dept Entomol, University Pk, PA 16802 USA.
[Read, Andrew F.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
RP Pollitt, LC (reprint author), Penn State Univ, Ctr Infect Dis Dynam, Millennium Sci Complex, State Coll, PA 16801 USA.
EM laura.pollitt@googlemail.com
RI Mackinnon, Margaret/L-3155-2013
OI Mackinnon, Margaret/0000-0003-1279-9625
FU National Institutes of Health [R01 GM089932, R01AI089819]; NSERC;
Leverhulme Trust
FX Authors are funded by the National Institutes of Health (LCP and AFR;
R01 GM089932 and R01AI089819), and an NSERC Discovery Grant (NM). The
original experiments were funded by The Leverhulme Trust. The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript. We thank members of the
Read-Thomas lab group, the Center for Infectious Disease Dynamics, and
the Research and Policy in Infectious Disease Dynamics program of the
Science and Technology Directorate, Department of Homeland Security, and
the Fogarty International Center for discussion.
NR 8
TC 5
Z9 5
U1 1
U2 16
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD DEC 6
PY 2013
VL 12
AR 440
DI 10.1186/1475-2875-12-440
PG 4
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 281OD
UT WOS:000329110000001
PM 24314024
ER
PT J
AU Griffin, AJ
Crane, DD
Wehrly, TD
Scott, DP
Bosio, CM
AF Griffin, Amanda J.
Crane, Deborah D.
Wehrly, Tara D.
Scott, Dana P.
Bosio, Catharine M.
TI Alternative Activation of Macrophages and Induction of Arginase Are Not
Components of Pathogenesis Mediated by Francisella Species
SO PLOS ONE
LA English
DT Article
ID EARLY IL-4 PRODUCTION; TULARENSIS SCHU S4; SCHISTOSOMA-MANSONI;
IMMUNE-RESPONSE; TULAREMIA; INFECTION; PULMONARY; VACCINE; CELLS;
REPLICATION
AB Virulent Francisella tularensis ssp tularensis is an intracellular, Gram negative bacterium that causes acute lethal disease following inhalation of fewer than 15 organisms. Pathogenicity of Francisella infections is tied to its unique ability to evade and suppress inflammatory responses in host cells. It has been proposed that induction of alternative activation of infected macrophages is a mechanism by which attenuated Francisella species modulate host responses. In this report we reveal that neither attenuated F. tularensis Live Vaccine Strain (LVS) nor virulent F. tularensis strain SchuS4 induce alternative activation of macrophages in vitro or in vivo. LVS, but not SchuS4, provoked production of arginase1 independent of alternative activation in vitro and in vivo. However, absence of arginase1 did not significantly impact intracellular replication of LVS or SchuS4. Together our data establish that neither induction of alternative activation nor expression of arginase1 are critical features of disease mediated by attenuated or virulent Francisella species.
C1 [Griffin, Amanda J.; Crane, Deborah D.; Wehrly, Tara D.; Bosio, Catharine M.] NIAID, Immun Pulm Pathogens Sect, Intracellular Parasites Lab, Rocky Mt Vet Branch,Rocky Mt Labs,NIH, Hamilton, MT USA.
[Scott, Dana P.] NIAID, Vet Pathol Sect, Rocky Mt Vet Branch, Rocky Mt Labs,NIH, Hamilton, MT USA.
RP Bosio, CM (reprint author), NIAID, Immun Pulm Pathogens Sect, Intracellular Parasites Lab, Rocky Mt Vet Branch,Rocky Mt Labs,NIH, Hamilton, MT USA.
EM bosioc@niaid.nih.gov
RI Bosio, Catharine/D-7456-2015
NR 33
TC 5
Z9 5
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 6
PY 2013
VL 8
IS 12
AR e82096
DI 10.1371/journal.pone.0082096
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 273WJ
UT WOS:000328566700058
PM 24324751
ER
PT J
AU Roll-Mecak, A
AF Roll-Mecak, Antonina
TI Shining Light at Microtubule Crossroads
SO SCIENCE
LA English
DT Editorial Material
ID KATANIN; ARRAYS; ORGANIZATION; SITES
C1 NIH, Cell Biol & Biophys Unit, Porter Neurosci Res Ctr, Bethesda, MD 20892 USA.
RP Roll-Mecak, A (reprint author), NIH, Cell Biol & Biophys Unit, Porter Neurosci Res Ctr, 35 Convent Dr,MSC 3700, Bethesda, MD 20892 USA.
EM antonina@mail.nih.gov
FU Intramural NIH HHS
NR 13
TC 0
Z9 0
U1 0
U2 12
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD DEC 6
PY 2013
VL 342
IS 6163
BP 1180
EP 1181
DI 10.1126/science.1248235
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 264DT
UT WOS:000327857900027
PM 24311672
ER
PT J
AU de la Roche, M
Ritter, AT
Angus, KL
Dinsmore, C
Earnshaw, CH
Reiter, JF
Griffiths, GM
AF de la Roche, Maike
Ritter, Alex T.
Angus, Karen L.
Dinsmore, Colin
Earnshaw, Charles H.
Reiter, Jeremy F.
Griffiths, Gillian M.
TI Hedgehog Signaling Controls T Cell Killing at the Immunological Synapse
SO SCIENCE
LA English
DT Article
ID PRIMARY CILIUM; INDIAN HEDGEHOG; ACTIVATION; DIFFERENTIATION;
POLARIZATION; INHIBITION; TRANSPORT
AB The centrosome is essential for cytotoxic T lymphocyte (CTL) function, contacting the plasma membrane and directing cytotoxic granules for secretion at the immunological synapse. Centrosome docking at the plasma membrane also occurs during cilia formation. The primary cilium, formed in nonhematopoietic cells, is essential for vertebrate Hedgehog (Hh) signaling. Lymphocytes do not form primary cilia, but we found and describe here that Hh signaling played an important role in CTL killing. T cell receptor activation, which "prearms" CTLs with cytotoxic granules, also initiated Hh signaling. Hh pathway activation occurred intracellularly and triggered Rac1 synthesis. These events "prearmed" CTLs for action by promoting the actin remodeling required for centrosome polarization and granule release. Thus, Hh signaling plays a role in CTL function, and the immunological synapse may represent a modified cilium.
C1 [de la Roche, Maike; Ritter, Alex T.; Angus, Karen L.; Earnshaw, Charles H.; Griffiths, Gillian M.] Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 0XY, England.
[Dinsmore, Colin; Reiter, Jeremy F.] Univ Calif San Francisco, Cardiovasc Res Inst, Dept Biochem & Biophys, San Francisco, CA 94158 USA.
[Ritter, Alex T.] NICHD, NIH, Bethesda, MD 20892 USA.
RP Griffiths, GM (reprint author), Univ Cambridge, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 0XY, England.
EM gg305@cam.ac.uk
OI Earnshaw, Charles/0000-0002-7926-8506; Griffiths,
Gillian/0000-0003-0434-5842
FU Wellcome Trust [075880]; Wellcome Trust Strategic Award for core
facilities at the CIMR [100140]; NIH [R01AR05439, R01GM095941];
Burroughs Wellcome Fund; David and Lucile F. Packard Foundation; Sandler
Family Supporting Foundation
FX We thank R. Rohatgi for the MSCV-Ptch1-EYFP construct and the Smo
antibodies; S. Munro (Cambridge) for PACT (pericentrin)-RFP; M. Davidson
(University of Florida) for Farnesyl-5-TagBFP2; R. Zamoyska for
Lck-depleted spleens; D. Fearon, T. Crompton, J. Kaufman, M. A. de la
Roche, and A. Schuldt for helpful discussions and critical reading of
the manuscript; and R. Rohatgi and J. Stinchcombe for helpful
discussions. We also thank the flow cytometry core facility at the
Cambridge Institute for Medical Research (CIMR) for cell sorting and
assistance with the calcium assay. This work was supported by a Wellcome
Trust Principal Research Fellowship to G. M. G. (075880), a Wellcome
Trust Strategic Award for core facilities at the CIMR (100140), NIH
(R01AR05439 and R01GM095941), the Burroughs Wellcome Fund, the David and
Lucile F. Packard Foundation, and the Sandler Family Supporting
Foundation to J. R. The data presented in this paper are provided in the
main paper and supplementary materials.
NR 30
TC 40
Z9 40
U1 3
U2 19
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD DEC 6
PY 2013
VL 342
IS 6163
BP 1247
EP 1250
DI 10.1126/science.1244689
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 264DT
UT WOS:000327857900051
PM 24311692
ER
PT J
AU Behl, M
Elmore, SA
Malarkey, DE
Hejtmancik, MR
Gerken, DK
Chhabra, RS
AF Behl, Mamta
Elmore, Susan A.
Malarkey, David E.
Hejtmancik, Milton R.
Gerken, Diane K.
Chhabra, Rajendra S.
TI Perinatal toxicity and carcinogenicity studies of styrene-acrylonitrile
trimer, a ground water contaminant
SO TOXICOLOGY
LA English
DT Article
DE Styrene acrylonitrile trimer; Cancer; Toxicity; Rats; Developmental
AB Styrene acrylonitrile (SAN) trimer is a by-product in the production of acrylonitrile styrene plastics. Following a report of a childhood cancer cluster in the Toms River section of Dover Township, New Jersey, SAN Trimer was identified as one of the groundwater contaminants at Reich Farm Superfund site in the township. The contaminants from the Reich Farm site's ground water plume impacted two wells at the Parkway well field. The National Toxicology Program (NTP) studied the toxicity and carcinogenicity of SAN Trimer in rats exposed during their perinatal developmental period and adulthood. The chronic toxicity and carcinogenicity studies in F344/N rats were preceded by 7- and 18-week perinatal toxicity studies to determine the exposure concentrations for the 2-year studies. Subsequently, Fisher 344 pregnant dams were exposed to SAN Trimer containing diet at 400, 800, or 1600 ppm concentrations during gestation, nursing and weaning periods of offspring followed by two year of adult exposures to both male and female pups. There was no statistically significant evidence of carcinogenic activity following SAN-Trimer exposure; however, rare neoplasms in the brain and spinal cord were observed in males and to lesser extent in female rats. These incidences were considered within the range of historical background in the animal model used in the current studies. Therefore, the presence of a few rarely occurring CNS tumors in the treated groups were not judged to be associated with the SAN Trimer exposure. The major finding was a dose-related peripheral neuropathy associated with the sciatic nerves in females and spinal nerve roots in males and females thereby suggesting that SAN Trimer is potentially a nervous system toxicant. Published by Elsevier Ireland Ltd.
C1 [Behl, Mamta] Kelly Govt Solut, Res Triangle Pk, NC USA.
[Behl, Mamta; Elmore, Susan A.; Malarkey, David E.; Chhabra, Rajendra S.] NIEHS, Div Natl Toxicol Program, Res Triangle Pk, NC 27709 USA.
[Hejtmancik, Milton R.; Gerken, Diane K.] Battelle Mem Inst, Columbus, OH 43201 USA.
RP Behl, M (reprint author), NIEHS, Div Natl Toxicol Program, POB 12233, Res Triangle Pk, NC 27709 USA.
EM behlmv@niehs.nih.gov
FU Intramural NIH HHS [Z99 ES999999]
NR 21
TC 0
Z9 1
U1 1
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0300-483X
J9 TOXICOLOGY
JI Toxicology
PD DEC 6
PY 2013
VL 314
IS 1
BP 84
EP 94
DI 10.1016/j.cox.2013.09.006
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA V39SC
UT WOS:000209429700010
PM 24060431
ER
PT J
AU Thakur, SA
Flake, GP
Travlos, GS
Dill, JA
Grumbein, SL
Harbo, SJ
Hooth, MJ
AF Thakur, Sheetal A.
Flake, Gordon P.
Travlos, Greg S.
Dill, Jeffrey A.
Grumbein, Sondra L.
Harbo, Sam J.
Hooth, Michelle J.
TI Evaluation of propargyl alcohol toxicity and carcinogenicity in F344/N
rats and B6C3F1/N mice following whole-body inhalation exposure
SO TOXICOLOGY
LA English
DT Article
DE Propargyl alcohol; Toxicity; Carcinogenicity; Chronic; Occupational;
Respiratory
AB Propargyl alcohol (PA) is a high production volume chemical used in synthesis of many industrial chemicals and agricultural products. Despite the potential for prolonged or accidental exposure to PA in industrial settings, the toxicity potential of PA was not well characterized. To address the knowledge gaps relevant to the toxicity profile of PA, the National Toxicology Program (NTP) conducted 2-week, 14-week and 2-year studies in male and female F344/N rats and B6C3F1/N mice. For the 2-week inhalation study, the rats and mice were exposed to 0, 31.3, 62.5, 125, 250 or 500 ppm. Significant mortality was observed in both rats and mice exposed to >= 125 ppm of PA. The major target organ of toxicity in both mice and rats was the liver with exposure-related histopathological changes (250 and 500 ppm). Based on the decreased survival in the 2-week study, the rats and mice were exposed to 0, 4, 8, 16, 32 or 64 ppm of PA in the 14-week study. No treatment-related mortality was observed. Mean body weights of male (>= 8 ppm) and female mice (32 and 64 ppm) were significantly decreased (7-16%). Histopathological changes were noted in the nasal cavity, and included suppurative inflammation, squamous metaplasia, hyaline droplet accumulation, olfactory epithelium atrophy, and necrosis. In the 2-year inhalation studies, the rats were exposed to 0, 16, 32 and 64 ppm of PA and the mice were exposed to 0, 8, 16 and 32 ppm of PA. Survival of male rats was significantly reduced (32 and 64 ppm). Mean body weights of 64 ppm male rats were significantly decreased relative to the controls. Both mice and rats showed a spectrum of non-neoplastic changes in the nose. Increased neoplastic incidences of nasal respiratory/transitional epithelial adenoma were observed in both rats and mice. The incidence of mononuclear cell leukemia was significantly increased in male rats and was considered to be treatment-related. In conclusion, the key findings from this study indicated that the nose was the primary target organ of toxicity for PA. Long term inhalation exposure to PA led to nonneoplastic changes in the nose, and increased incidences of respiratory/transitional epithelial adenomas in both mice and rats. Increased incidences of harderian gland adenoma may also have been related to exposure to PA in male mice. (C) 2013 Published by Elsevier Ireland Ltd.
C1 [Thakur, Sheetal A.; Flake, Gordon P.; Travlos, Greg S.; Hooth, Michelle J.] NIEHS, Div Natl Toxicol Program, NIH, NTP, Res Triangle Pk, NC 27709 USA.
[Dill, Jeffrey A.; Grumbein, Sondra L.; Harbo, Sam J.] Battelle Toxicol Northwest, Richland, WA 99352 USA.
RP Hooth, MJ (reprint author), NIEHS, Div Natl Toxicol Program, NIH, NTP, 111 TW Alexander Dr,POB 12233,MD K2-07, Res Triangle Pk, NC 27709 USA.
EM thakursa@niehs.nih.gov
FU NIH, National Institute of Environmental Health Sciences
FX This research was supported by the NIH, National Institute of
Environmental Health Sciences. We thank Dr. Mathew Stout (DNTP/NIEHS)
and Dr. Deepa Rao (Contractor, DNTP/NIEHS) for their helpful review of
the manuscript.
NR 42
TC 1
Z9 2
U1 1
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0300-483X
J9 TOXICOLOGY
JI Toxicology
PD DEC 6
PY 2013
VL 314
IS 1
BP 100
EP 111
DI 10.1016/j.tox.2013.09.002
PG 12
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA V39SC
UT WOS:000209429700012
PM 24035744
ER
PT J
AU Wang, HY
Dittmer, TA
Richards, EJ
AF Wang, Haiyi
Dittmer, Travis A.
Richards, Eric J.
TI Arabidopsis CROWDED NUCLEI (CRWN) proteins are required for nuclear size
control and heterochromatin organization
SO BMC PLANT BIOLOGY
LA English
DT Article
DE Nuclear organization; Nuclear morphology; Nuclear DNA density;
Heterochromatin
ID SUN-KASH BRIDGES; INTERPHASE NUCLEI; PORE COMPLEX; CELL-SIZE; THALIANA;
ENVELOPE; MORPHOLOGY; PLANTS; CHROMATIN; DOMAIN
AB Background: Plant nuclei superficially resemble animal and fungal nuclei, but the machinery and processes that underlie nuclear organization in these eukaryotic lineages appear to be evolutionarily distinct. Among the candidates for nuclear architectural elements in plants are coiled-coil proteins in the NMCP (Nuclear Matrix Constituent Protein) family. Using genetic and cytological approaches, we dissect the function of the four NMCP family proteins in Arabidopsis encoded by the CRWN genes, which were originally named LINC (LITTLE NUCLEI).
Results: CRWN proteins are essential for viability as evidenced by the inability to recover mutants that have disruptions in all four CRWN genes. Mutants deficient in different combinations of the four CRWN paralogs exhibit altered nuclear organization, including reduced nuclear size, aberrant nuclear shape and abnormal spatial organization of constitutive heterochromatin. Our results demonstrate functional diversification among CRWN paralogs; CRWN1 plays the predominant role in control of nuclear size and shape followed by CRWN4. Proper chromocenter organization is most sensitive to the deficiency of CRWN4. The reduction in nuclear volume in crwn mutants in the absence of a commensurate reduction in endoreduplication levels leads to an increase in average nuclear DNA density.
Conclusions: Our findings indicate that CRWN proteins are important architectural components of plant nuclei that play diverse roles in both heterochromatin organization and the control of nuclear morphology.
C1 [Wang, Haiyi; Richards, Eric J.] Cornell Univ, Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA.
[Dittmer, Travis A.] NCI, NIH, Bethesda, MD 20892 USA.
RP Richards, EJ (reprint author), Cornell Univ, Boyce Thompson Inst Plant Res, 533 Tower Rd, Ithaca, NY 14853 USA.
EM ejr77@cornell.edu
RI Richards, Eric/E-6866-2012
FU National Science Foundation [MCB-0956820]; Boyce Thompson Institute
FX We are grateful for the guidance and facilities provided by Wojtek
Pawlowski, Choon-lin Tiang, Mamta Srivastava and Boyce Thompson
Institute's Plant Cell Imaging Center. We thank Natalie Henkhaus, Erika
Hughes, and Molly Shook for helpful comments and discussion. The T-DNA
mutant lines used in this study were obtained from the Arabidopsis
Biological Resource Center at The Ohio State University. This work was
supported by a grant from the National Science Foundation to EJR
(MCB-0956820) and from funds provided by the Boyce Thompson Institute.
NR 38
TC 21
Z9 22
U1 4
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2229
J9 BMC PLANT BIOL
JI BMC Plant Biol.
PD DEC 5
PY 2013
VL 13
AR UNSP 200
DI 10.1186/1471-2229-13-200
PG 13
WC Plant Sciences
SC Plant Sciences
GA AC1GC
UT WOS:000332241200001
PM 24308514
ER
PT J
AU Berglund, LJ
Avery, DT
Ma, CS
Moens, L
Deenick, EK
Bustamante, J
Boisson-Dupuis, S
Wong, M
Adelstein, S
Arkwright, PD
Bacchetta, R
Bezrodnik, L
Dadi, H
Roifman, CM
Fulcher, DA
Ziegler, JB
Smart, JM
Kobayashi, M
Picard, C
Durandy, A
Cook, MC
Casanova, JL
Uzel, G
Tangye, SG
AF Berglund, Lucinda J.
Avery, Danielle T.
Ma, Cindy S.
Moens, Leen
Deenick, Elissa K.
Bustamante, Jacinta
Boisson-Dupuis, Stephanie
Wong, Melanie
Adelstein, Stephen
Arkwright, Peter D.
Bacchetta, Rosa
Bezrodnik, Liliana
Dadi, Harjit
Roifman, Chaim M.
Fulcher, David A.
Ziegler, John B.
Smart, Joanne M.
Kobayashi, Masao
Picard, Capucine
Durandy, Anne
Cook, Matthew C.
Casanova, Jean-Laurent
Uzel, Gulbu
Tangye, Stuart G.
TI IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2
to enhance their differentiation into plasmablasts
SO BLOOD
LA English
DT Article
ID HYPER-IGE SYNDROME; FOLLICULAR-HELPER-CELLS; ANTIBODY-RESPONSES;
T-CELLS; TERMINAL DIFFERENTIATION; HYPERIMMUNOGLOBULIN-E;
IMMUNE-RESPONSES; IMMUNOGLOBULIN-A; SECRETING CELLS; EXPRESSION
AB B-cell responses are guided by the integration of signals through the B-cell receptor (BCR), CD40, and cytokine receptors. The common gamma chain (gamma c)-binding cytokine interleukin (IL)-21 drives humoral immune responses via STAT3-dependent induction of transcription factors required for plasma cell generation. We investigated additional mechanisms by which IL-21/STAT3 signaling modulates human B-cell responses by studying patients with STAT3 mutations. IL-21 strongly induced CD25 (IL-2R alpha) in normal, but not STAT3-deficient, CD40L-stimulated naive B cells. Chromatin immunoprecipitation confirmed IL2RA as a direct target of STAT3. IL-21-induced CD25 expression was also impaired on B cells from patients with IL2RG or IL21R mutations, confirming a requirement for intact IL-21R signaling in this process. IL-2 increased plasmablast generation and immunoglobulin secretion from normal, but not CD25-deficient, naive B cells stimulated with CD40L/IL-21. IL-2 and IL-21 were produced by T follicular helper cells, and neutralizing both cytokines abolished the B-cell helper capacity of these cells. Our results demonstrate that IL-21, via STAT3, sensitizes B cells to the stimulatory effects of IL-2. Thus, IL-2 may play an adjunctive role in IL-21-induced B-cell differentiation. Lack of this secondary effect of IL-21 may amplify the humoral immunodeficiency in patients with mutations in STAT3, IL2RG, or IL21R due to impaired responsiveness to IL-21. (Blood. 2013;122(24):3940-3950)
C1 [Berglund, Lucinda J.; Avery, Danielle T.; Ma, Cindy S.; Moens, Leen; Deenick, Elissa K.; Tangye, Stuart G.] St Vincents Hosp, Garvan Inst Med Res, Immunol Res Program, Darlinghurst, NSW 2010, Australia.
[Berglund, Lucinda J.; Ma, Cindy S.; Deenick, Elissa K.; Tangye, Stuart G.] Univ New S Wales, St Vincents Clin Sch, Sydney, NSW 2052, Australia.
[Berglund, Lucinda J.; Fulcher, David A.] Westmead Hosp, Dept Immunol, Inst Clin Pathol & Med Res, Westmead, NSW 2145, Australia.
[Bustamante, Jacinta; Boisson-Dupuis, Stephanie; Picard, Capucine; Casanova, Jean-Laurent] Univ Paris 05, Necker Med Sch, Lab Human Genet Infect Dis, Necker Branch,INSERM,U980, Paris, France.
[Bustamante, Jacinta; Picard, Capucine; Durandy, Anne] Hop Necker Enfants Malad, AP HP, Study Ctr Primary Immunodeficiencies, Paris, France.
[Bustamante, Jacinta; Picard, Capucine; Durandy, Anne; Casanova, Jean-Laurent] Univ Paris 05, Inst Imagine, Paris, France.
[Boisson-Dupuis, Stephanie; Casanova, Jean-Laurent] Rockefeller Univ, Rockefeller Branch, Lab Human Genet Infect Dis, New York, NY 10021 USA.
[Wong, Melanie] Childrens Hosp Westmead, Dept Immunol, Westmead, NSW, Australia.
[Adelstein, Stephen] Royal Prince Alfred Hosp, Sydney, NSW, Australia.
[Arkwright, Peter D.] Univ Manchester, Royal Manchester Childrens Hosp, Manchester, Lancs, England.
[Bacchetta, Rosa] Ist Sci San Raffaele, San Raffaele Telethon Inst Gene Therapy HSR TIGET, I-20132 Milan, Italy.
[Bezrodnik, Liliana] Ricardo Gutierrez Children Hosp, Immunol Unit, Buenos Aires, DF, Argentina.
[Dadi, Harjit; Roifman, Chaim M.] Hosp Sick Children, Canadian Ctr Primary Immunodeficiency, Toronto, ON M5G 1X8, Canada.
[Dadi, Harjit; Roifman, Chaim M.] Univ Toronto, Toronto, ON, Canada.
[Ziegler, John B.] Sydney Childrens Hosp, Dept Immunol, Randwick, NSW, Australia.
[Ziegler, John B.] Univ NSW, Sch Womens & Childrens Hlth, Randwick, NSW, Australia.
[Smart, Joanne M.] Royal Childrens Hosp Melbourne, Dept Allergy & Immunol, Melbourne, Vic, Australia.
[Kobayashi, Masao] Hiroshima Univ, Dept Pediat, Grad Sch Biomed Sci, Hiroshima, Japan.
[Durandy, Anne] Hop Necker Enfants Malad, INSERM, U768, Paris, France.
[Cook, Matthew C.] Australian Natl Univ, Sch Med, Canberra, ACT, Australia.
[Cook, Matthew C.] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia.
[Cook, Matthew C.] Canberra Hosp, Dept Immunol, Canberra, ACT, Australia.
[Uzel, Gulbu] NIAID, Immunopathogenesis Sect, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA.
RP Tangye, SG (reprint author), Garvan Inst Med Res, 384 Victoria St, Darlinghurst, NSW 2010, Australia.
EM s.tangye@garvan.org.au
RI Tangye, Stuart/H-4023-2014; Adelstein, Stephen/I-7936-2016;
OI Adelstein, Stephen/0000-0001-7221-6298; Deenick,
Elissa/0000-0002-9271-0004; Picard, Capucine/0000-0001-8788-5056;
Arkwright, Peter/0000-0002-7411-5375
FU National Health and Medical Research Council of Australia; Research
Foundation-Flanders (FWO), Belgium
FX This work was supported by research grants and fellowships awarded by
the National Health and Medical Research Council of Australia (L.J.B.,
C. S. M., E. K. D., M. C. C., S. G. T.) and a Postdoctoral Fellowship
from Research Foundation-Flanders (FWO), Belgium (L.M).
NR 50
TC 28
Z9 29
U1 1
U2 11
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 5
PY 2013
VL 122
IS 24
BP 3940
EP 3950
DI 10.1182/blood-2013-06-506865
PG 11
WC Hematology
SC Hematology
GA 290EV
UT WOS:000329737600018
PM 24159173
ER
PT J
AU Wang, L
Miao, YL
Zheng, XF
Lackford, B
Zhou, BY
Han, L
Yao, CG
Ward, JM
Burkholder, A
Lipchina, I
Fargo, DC
Hochedlinger, K
Shi, YS
Williams, CJ
Hu, G
AF Wang, Li
Miao, Yi-Liang
Zheng, Xiaofeng
Lackford, Brad
Zhou, Bingying
Han, Leng
Yao, Chengguo
Ward, James M.
Burkholder, Adam
Lipchina, Inna
Fargo, David C.
Hochedlinger, Konrad
Shi, Yongsheng
Williams, Carmen J.
Hu, Guang
TI The THO Complex Regulates Pluripotency Gene mRNA Export and Controls
Embryonic Stem Cell Self-Renewal and Somatic Cell Reprogramming
SO CELL STEM CELL
LA English
DT Article
ID GENOME-WIDE ANALYSIS; HUMAN TREX COMPLEX; TRANSCRIPTIONAL NETWORK; MRNP
BIOGENESIS; MOUSE; DIFFERENTIATION; EXPRESSION; CIRCUITRY; PROTEIN;
NANOG
AB Embryonic stem cell (ESC) self-renewal and differentiation are governed by a broad-ranging regulatory network. Although the transcriptional regulatory mechanisms involved have been investigated extensively, posttranscriptional regulation is still poorly understood. Here we describe a critical role of the THO complex in ESC self-renewal and differentiation. We show that THO preferentially interacts with pluripotency gene transcripts through Thoc5 and is required for self-renewal at least in part by regulating their export and expression. During differentiation, THO loses its interaction with those transcripts due to reduced Thoc5 expression, leading to decreased expression of pluripotency proteins that facilitates exit from self-renewal. THO is also important for the establishment of pluripotency, because its depletion inhibits somatic cell reprogramming and blastocyst development. Together, our data indicate that THO regulates pluripotency gene mRNA export to control ESC self-renewal and differentiation, and therefore uncover a role for this aspect of posttranscriptional regulation in stem cell fate specification.
C1 [Wang, Li; Zheng, Xiaofeng; Lackford, Brad; Hu, Guang] NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA.
[Miao, Yi-Liang; Williams, Carmen J.] NIEHS, Reprod & Dev Toxicol Lab, Res Triangle Pk, NC 27709 USA.
[Zhou, Bingying] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.
[Zhou, Bingying] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Han, Leng] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
[Yao, Chengguo; Shi, Yongsheng] Univ Calif Irvine, Dept Microbiol & Mol Genet, Sch Med, Irvine, CA 92697 USA.
[Ward, James M.; Burkholder, Adam; Fargo, David C.] NIEHS, Res Triangle Pk, NC 27709 USA.
[Lipchina, Inna; Hochedlinger, Konrad] Massachusetts Gen Hosp, Dept Stem Cell & Regenerat Biol, Harvard Stem Cell Inst, Boston, MA 02114 USA.
RP Hu, G (reprint author), NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA.
EM hug4@niehs.nih.gov
RI Williams, Carmen/E-2170-2013; Hu, Guang/E-7474-2016
OI Williams, Carmen/0000-0001-6440-7086; Hu, Guang/0000-0003-0437-4723
FU NIH, National Institute of Environmental Health Sciences [1ZIAES102745,
1ZIAES102985]; NIH [R01GM090056, R01HD058013]; American Cancer Society
[RSG-12-186]
FX We thank Drs. Karen Adelman, Perry Blackshear, Traci Hall, Raja Jothi,
and Paul Wade for critically reading the manuscript. This study was
supported in part by the Intramural Research Program of the NIH,
National Institute of Environmental Health Sciences 1ZIAES102745 (to L.
W., X.Z., B. L., and G. H.) and 1ZIAES102985 (to Y.M. and C. W.), NIH
R01GM090056 and American Cancer Society Grant RSG-12-186 (to C.Y. and
Y.S.), and NIH R01HD058013 (to I. L. and K.H.).
NR 68
TC 23
Z9 24
U1 2
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1934-5909
EI 1875-9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD DEC 5
PY 2013
VL 13
IS 6
BP 676
EP 690
DI 10.1016/j.stem.2013.10.008
PG 15
WC Cell & Tissue Engineering; Cell Biology
SC Cell Biology
GA 287VZ
UT WOS:000329571700011
PM 24315442
ER
PT J
AU Meyer, KB
O'Reilly, M
Michailidou, K
Carlebur, S
Edwards, SL
French, JD
Prathalingham, R
Dennis, J
Bolla, MK
Wang, Q
de Santiago, I
Hopper, JL
Tsimiklis, H
Apicella, C
Southey, MC
Schmidt, MK
Broeks, A
Van't Veer, LJ
Hogervorst, FB
Muir, K
Lophatananon, A
Stewart-Brown, S
Siriwanarangsan, P
Fasching, PA
Lux, MP
Ekici, AB
Beckmann, MW
Peto, J
Silva, ID
Fletcher, O
Johnson, N
Sawyer, EJ
Tomlinson, I
Kerin, MJ
Miller, N
Marme, F
Schneeweiss, A
Sohn, C
Burwinkel, B
Guenel, P
Truong, T
Laurent-Puig, P
Menegaux, F
Bojesen, SE
Nordestgaard, BG
Nielsen, SF
Flyger, H
Milne, RL
Zamora, MP
Arias, JI
Benitez, J
Neuhausen, S
Anton-Culver, H
Ziogas, A
Dur, CC
Brenner, H
Muller, H
Arndt, V
Stegmaier, C
Meindl, A
Schmutzler, RK
Engel, C
Ditsch, N
Brauch, H
Bruning, T
Ko, YD
Nevanlinna, H
Muranen, TA
Aittomaki, K
Blomqvist, C
Matsuo, K
Ito, H
Iwata, H
Yatabe, Y
Dork, T
Helbig, S
Bogdanova, NV
Lindblom, A
Margolin, S
Mannermaa, A
Kataja, V
Kosma, VM
Hartikainen, JM
Chenevix-Trench, G
Wu, AH
Tseng, CC
Van Den Berg, D
Stram, DO
Lambrechts, D
Thienpont, B
Christiaens, MR
Smeets, A
Chang-Claude, J
Rudolph, A
Seibold, P
Flesch-Janys, D
Radice, P
Peterlongo, P
Bonanni, B
Bernard, L
Couch, FJ
Olson, JE
Wang, XS
Purrington, K
Giles, GG
Severi, G
Baglietto, L
McLean, C
Haiman, CA
Henderson, BE
Schumacher, F
Le Marchand, L
Simard, J
Goldberg, MS
Labreche, F
Dumont, M
Teo, SH
Yip, CH
Phuah, SY
Kristensen, V
Alnaes, GG
Borresen-Dale, AL
Zheng, W
Deming-Halverson, S
Shrubsole, M
Long, JR
Winqvist, R
Pylkas, K
Jukkola-Vuorinen, A
Kauppila, S
Andrulis, IL
Knight, JA
Glendon, G
Tchatchou, S
Devilee, P
Tollenaar, RAEM
Seynaeve, CM
Garcia-Closas, M
Figueroa, J
Chanock, SJ
Lissowska, J
Czene, K
Darabi, H
Eriksson, K
Hooning, MJ
Martens, JWM
van den Ouweland, AMW
van Deurzen, CHM
Hall, P
Li, JM
Liu, JJ
Humphreys, K
Shu, XO
Lu, W
Gao, YT
Cai, H
Cox, A
Reed, MWR
Blot, W
Signorello, LB
Cai, QY
Pharoah, PDP
Ghoussaini, M
Harrington, P
Tyrer, J
Kang, D
Choi, JY
Park, SK
Noh, DY
Hartman, M
Hui, M
Lim, WY
Buhari, SA
Hamann, U
Forsti, A
Rudiger, T
Ulmer, HU
Jakubowska, A
Lubinski, J
Jaworska, K
Durda, K
Sangrajrang, S
Gaborieau, V
Brennan, P
Mckay, J
Vachon, C
Slager, S
Fostira, F
Pilarski, R
Shen, CY
Hsiung, CN
Wu, PE
Hou, MF
Swerdlow, A
Ashworth, A
Orr, N
Schoemaker, MJ
Ponder, BAJ
Dunning, AM
Easton, DF
AF Meyer, Kerstin B.
O'Reilly, Martin
Michailidou, Kyriaki
Carlebur, Saskia
Edwards, Stacey L.
French, Juliet D.
Prathalingham, Radhika
Dennis, Joe
Bolla, Manjeet K.
Wang, Qin
de Santiago, Ines
Hopper, John L.
Tsimiklis, Helen
Apicella, Carmel
Southey, Melissa C.
Schmidt, Marjanka K.
Broeks, Annegien
Van't Veer, Laura J.
Hogervorst, Frans B.
Muir, Kenneth
Lophatananon, Artitaya
Stewart-Brown, Sarah
Siriwanarangsan, Pornthep
Fasching, Peter A.
Lux, Michael P.
Ekici, Arif B.
Beckmann, Matthias W.
Peto, Julian
Silva, Isabel dos Santos
Fletcher, Olivia
Johnson, Nichola
Sawyer, Elinor J.
Tomlinson, Ian
Kerin, Michael J.
Miller, Nicola
Marme, Federick
Schneeweiss, Andreas
Sohn, Christof
Burwinkel, Barbara
Guenel, Pascal
Truong, Therese
Laurent-Puig, Pierre
Menegaux, Florence
Bojesen, Stig E.
Nordestgaard, Borge G.
Nielsen, Sune F.
Flyger, Henrik
Milne, Roger L.
Pilar Zamora, M.
Arias, Jose I.
Benitez, Javier
Neuhausen, Susan
Anton-Culver, Hoda
Ziogas, Argyrios
Dur, Christina C.
Brenner, Hermann
Mueller, Heiko
Arndt, Volker
Stegmaier, Christa
Meindl, Alfons
Schmutzler, Rita K.
Engel, Christoph
Ditsch, Nina
Brauch, Hiltrud
Bruening, Thomas
Ko, Yon-Dschun
Nevanlinna, Heli
Muranen, Taru A.
Aittomaeki, Kristiina
Blomqvist, Carl
Matsuo, Keitaro
Ito, Hidemi
Iwata, Hiroji
Yatabe, Yasushi
Doerk, Thilo
Helbig, Sonja
Bogdanova, Natalia V.
Lindblom, Annika
Margolin, Sara
Mannermaa, Arto
Kataja, Vesa
Kosma, Veli-Matti
Hartikainen, Jaana M.
Chenevix-Trench, Georgia
Wu, Anna H.
Tseng, Chiu-chen
Van Den Berg, David
Stram, Daniel O.
Lambrechts, Diether
Thienpont, Bernard
Christiaens, Marie-Rose
Smeets, Ann
Chang-Claude, Jenny
Rudolph, Anja
Seibold, Petra
Flesch-Janys, Dieter
Radice, Paolo
Peterlongo, Paolo
Bonanni, Bernardo
Bernard, Loris
Couch, Fergus J.
Olson, Janet E.
Wang, Xianshu
Purrington, Kristen
Giles, Graham G.
Severi, Gianluca
Baglietto, Laura
McLean, Catriona
Haiman, Christopher A.
Henderson, Brian E.
Schumacher, Fredrick
Le Marchand, Loic
Simard, Jacques
Goldberg, Mark S.
Labreche, France
Dumont, Martine
Teo, Soo-Hwang
Yip, Cheng-Har
Phuah, Sze-Yee
Kristensen, Vessela
Alnaes, Grethe Grenaker
Borresen-Dale, Anne-Lise
Zheng, Wei
Deming-Halverson, Sandra
Shrubsole, Martha
Long, Jirong
Winqvist, Robert
Pylkaes, Katri
Jukkola-Vuorinen, Arja
Kauppila, Saila
Andrulis, Irene L.
Knight, Julia A.
Glendon, Gord
Tchatchou, Sandrine
Devilee, Peter
Tollenaar, Robert A. E. M.
Seynaeve, Caroline M.
Garcia-Closas, Montserrat
Figueroa, Jonine
Chanock, Stephen J.
Lissowska, Jolanta
Czene, Kamila
Darabi, Hartef
Eriksson, Kimael
Hooning, Maartje J.
Martens, John W. M.
van den Ouweland, Ans M. W.
van Deurzen, Carolien H. M.
Hall, Per
Li, Jingmei
Liu, Jianjun
Humphreys, Keith
Shu, Xiao-Ou
Lu, Wei
Gao, Yu-Tang
Cai, Hui
Cox, Angela
Reed, Malcolm W. R.
Blot, William
Signorello, Lisa B.
Cai, Qiuyin
Pharoah, Paul D. P.
Ghoussaini, Maya
Harrington, Patricia
Tyrer, Jonathan
Kang, Daehee
Choi, Ji-Yeob
Park, Sue K.
Noh, Dong-Young
Hartman, Mikael
Hui, Miao
Lim, Wei-Yen
Buhari, Shaik A.
Hamann, Ute
Foersti, Asta
Ruediger, Thomas
Ulmer, Hans-Ulrich
Jakubowska, Anna
Lubinski, Jan
Jaworska, Katarzyna
Durda, Katarzyna
Sangrajrang, Suleeporn
Gaborieau, Valerie
Brennan, Paul
Mckay, James
Vachon, Celine
Slager, Susan
Fostira, Florentia
Pilarski, Robert
Shen, Chen-Yang
Hsiung, Chia-Ni
Wu, Pei-Ei
Hou, Ming-Feng
Swerdlow, Anthony
Ashworth, Alan
Orr, Nick
Schoemaker, Minouk J.
Ponder, Bruce A. J.
Dunning, Alison M.
Easton, Douglas F.
CA Network, G
Investigators, K
Group, AOCS
TI Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative
Functional Variants Differentially Bind FOXA1 and E2F1
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; ESTROGEN-RECEPTOR BINDING; SUSCEPTIBILITY LOCI;
AFRICAN-AMERICAN; EXPRESSION; TRANSCRIPTION; DETERMINANT; CHROMATIN;
REVEALS; WOMEN
AB The 10q26 locus in the second intron of FGFR2 is the locus most strongly associated with estrogen-receptor-positive breast cancer in genome-wide association studies. We conducted fine-scale mapping in case-control studies genotyped with a custom chip (iCOGS), comprising 41 studies (n = 89,050) of European ancestry, 9 Asian ancestry studies (n = 13,983), and 2 African ancestry studies (n = 2,028) from the Breast Cancer Association Consortium. We identified three statistically independent risk signals within the locus. Within risk signals 1 and 3, genetic analysis identified five and two variants, respectively, highly correlated with the most strongly associated SNPs. By using a combination of genetic fine mapping, data on DNase hypersensitivity, and electrophoretic mobility shift assays to study protein-DNA binding, we identified rs35054928, rs2981578, and rs45631563 as putative functional SNPs. Chromatin immunoprecipitation showed that FOXA1 preferentially bound to the risk-associated allele (C) of rs2981578 and was able to recruit ER alpha to this site in an allele-specific manner, whereas E2F1 preferentially bound the risk variant of rs35054928. The risk alleles were preferentially found in open chromatin and bound by Ser5 phosphorylated RNA polymerase II, suggesting that the risk alleles are associated with changes in transcription. Chromatin conformation capture demonstrated that the risk region was able to interact with the promoter of FGFR2, the likely target gene of this risk region. A role for FOXA1 in mediating breast cancer susceptibility at this locus is consistent with the finding that the FGFR2 risk locus primarily predisposes to estrogen-receptor-positive disease.
C1 [Meyer, Kerstin B.; O'Reilly, Martin; Carlebur, Saskia; Prathalingham, Radhika; de Santiago, Ines; Ponder, Bruce A. J.] Univ Cambridge, CRUK Cambridge Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England.
[Meyer, Kerstin B.; O'Reilly, Martin; Carlebur, Saskia; Prathalingham, Radhika; de Santiago, Ines; Ponder, Bruce A. J.] Univ Cambridge, Dept Oncol, Li Ka Shing Ctr, Cambridge CB2 0RE, England.
[Michailidou, Kyriaki; Dennis, Joe; Bolla, Manjeet K.; Wang, Qin; Pharoah, Paul D. P.; Ghoussaini, Maya; Harrington, Patricia; Tyrer, Jonathan; Dunning, Alison M.; Easton, Douglas F.] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England.
[Michailidou, Kyriaki; Dennis, Joe; Bolla, Manjeet K.; Wang, Qin; Pharoah, Paul D. P.; Ghoussaini, Maya; Harrington, Patricia; Tyrer, Jonathan; Dunning, Alison M.; Easton, Douglas F.] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Oncol, Cambridge CB1 8RN, England.
[Edwards, Stacey L.; French, Juliet D.; Chenevix-Trench, Georgia] QIMR Berghofer Med Res Inst, Dept Genet, Brisbane, Qld 4029, Australia.
[Edwards, Stacey L.; French, Juliet D.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld 4072, Australia.
[Hopper, John L.; Apicella, Carmel; Giles, Graham G.; Severi, Gianluca] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic 3010, Australia.
[Tsimiklis, Helen; Southey, Melissa C.] Univ Melbourne, Dept Pathol, Melbourne, Vic 3010, Australia.
[Schmidt, Marjanka K.; Broeks, Annegien; Van't Veer, Laura J.; Hogervorst, Frans B.] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands.
[Muir, Kenneth] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England.
[Muir, Kenneth] Univ Manchester, Inst Populat Hlth, Manchester M13 9PL, Lancs, England.
[Lophatananon, Artitaya; Stewart-Brown, Sarah] Univ Warwick, Div Hlth Sci, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England.
[Siriwanarangsan, Pornthep] Minist Publ Hlth, Bangkok 10400, Thailand.
[Fasching, Peter A.; Lux, Michael P.] Univ Erlangen Nurnberg, Univ Breast Ctr Franconia, Dept Gynecol & Obstet, Univ Hosp Erlangen, D-91054 Erlangen, Germany.
[Fasching, Peter A.; Ekici, Arif B.; Beckmann, Matthias W.] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Peto, Julian; Silva, Isabel dos Santos] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
[Fletcher, Olivia; Johnson, Nichola; Garcia-Closas, Montserrat; Ashworth, Alan; Orr, Nick] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England.
[Sawyer, Elinor J.] Guys & St Thomas NHS Fdn Trust, Div Canc Studies, NIHR Comprehensive Biomed Res Ctr, London SE1 9RT, England.
[Tomlinson, Ian] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
[Tomlinson, Ian] Univ Oxford, Oxford Biomed Res Ctr, Oxford OX3 7BN, England.
[Kerin, Michael J.; Miller, Nicola] Univ Coll Hosp Galway, Inst Clin Sci, Galway, Ireland.
[Marme, Federick; Schneeweiss, Andreas; Sohn, Christof; Burwinkel, Barbara] Heidelberg Univ, Dept Obstet & Gynecol, D-69120 Heidelberg, Germany.
[Marme, Federick; Schneeweiss, Andreas] Heidelberg Univ, Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany.
[Burwinkel, Barbara] German Canc Res Ctr, Mol Epidemiol Grp, D-69120 Heidelberg, Germany.
[Guenel, Pascal; Truong, Therese; Menegaux, Florence] INSERM, CESP, UMRS 1018, F-94807 Villejuif, France.
[Guenel, Pascal; Truong, Therese; Menegaux, Florence] Univ Paris Sud, INSERM, UMRS 1018, F-94807 Villejuif, France.
[Laurent-Puig, Pierre] Univ Paris Sorbonne Cite, UMR S775 Inserm, F-75270 Paris, France.
[Bojesen, Stig E.; Nordestgaard, Borge G.; Nielsen, Sune F.] Univ Copenhagen, Herlev Hosp, Copenhagen Univ Hosp, Copenhagen Gen Populat Stud, DK-2730 Herlev, Denmark.
[Bojesen, Stig E.; Nordestgaard, Borge G.; Nielsen, Sune F.] Univ Copenhagen, Herlev Hosp, Copenhagen Univ Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark.
[Flyger, Henrik] Copenhagen Univ Hosp, Dept Breast Surg, Herlev Hosp, DK-2730 Herlev, Denmark.
[Milne, Roger L.] Spanish Natl Canc Res Ctr CNIO, Genet & Mol Epidemiol Grp, Human Canc Genet Program, Madrid 28029, Spain.
[Pilar Zamora, M.] Hosp Univ Paz, Serv Oncol Med, Madrid 28046, Spain.
[Arias, Jose I.] Hosp Monte Naranco, Serv Cirugia Gen & Especialidades, Oviedo 33012, Spain.
[Benitez, Javier] Spanish Natl Canc Res Ctr CNIO, Human Genet Grp, Human Canc Genet Program, Madrid 28029, Spain.
[Benitez, Javier] CIBERER, Valencia 46010, Spain.
[Neuhausen, Susan] Beckman Res Inst, Duarte, CA 91010 USA.
[Anton-Culver, Hoda; Ziogas, Argyrios] Univ Calif Irvine, Dept Epidemiol, Irvine, CA 92697 USA.
[Dur, Christina C.] Canc Prevent Inst Calif, Fremont, CA 94538 USA.
[Brenner, Hermann; Mueller, Heiko; Arndt, Volker] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, D-69120 Heidelberg, Germany.
[Stegmaier, Christa] Saarland Canc Registry, D-66024 Saarbrucken, Germany.
[Meindl, Alfons] Tech Univ Munich, Div Obstet & Gynecol, D-81675 Munich, Germany.
[Schmutzler, Rita K.] Univ Cologne, Div Mol Gynecooncol, Dept Obstet & Gynaecol, D-50931 Cologne, Germany.
[Engel, Christoph] Univ Leipzig, Inst Med Informat Statist & Epidemiol, D-04107 Leipzig, Germany.
[Ditsch, Nina] Univ Munich, Dept Obstet & Gynaecol, D-80539 Munich, Germany.
[Brauch, Hiltrud] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany.
[Brauch, Hiltrud] Univ Tubingen, D-72074 Tubingen, Germany.
[Bruening, Thomas] Ruhr Univ Bochum, Inst Prevent & Occupat Med German Social Accident, D-44789 Bochum, Germany.
[Ko, Yon-Dschun] Evangel Klin Bonn gGmbH, Dept Internal Med, D-53113 Bonn, Germany.
[Nevanlinna, Heli; Muranen, Taru A.] Univ Helsinki, Dept Obstet & Gynaecol, Helsinki 00029, Finland.
[Nevanlinna, Heli; Muranen, Taru A.] Helsinki Univ Cent Hosp, Helsinki 00029, Finland.
[Aittomaeki, Kristiina] Helsinki Univ Cent Hosp, Dept Clin Genet, Helsinki 00029, Finland.
[Blomqvist, Carl] Helsinki Univ Cent Hosp, Dept Oncol, Helsinki 00029, Finland.
[Matsuo, Keitaro] Kyushu Univ, Fac Med Sci, Dept Prevent Med, Fukuoka 8128582, Japan.
[Ito, Hidemi] Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Nagoya, Aichi 4648681, Japan.
[Iwata, Hiroji] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi 4648681, Japan.
[Yatabe, Yasushi] Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi 4648681, Japan.
[Doerk, Thilo; Helbig, Sonja] Hannover Med Sch, Dept Obstet & Gynaecol, D-30625 Hannover, Germany.
[Bogdanova, Natalia V.] Hannover Med Sch, Dept Radiat Oncol, D-30625 Hannover, Germany.
[Margolin, Sara] Karolinska Inst, Dept Oncol Pathol, S-17177 Stockholm, Sweden.
[Mannermaa, Arto; Kosma, Veli-Matti; Hartikainen, Jaana M.] Kuopio Univ Hosp, Sch Med, Inst Clin Med Pathol & Forens Med, Dept Clin Pathol, Kuopio 70211, Finland.
[Mannermaa, Arto; Kosma, Veli-Matti; Hartikainen, Jaana M.] Kuopio Univ Hosp, Sch Med, Canc Ctr Eastern Finland, Dept Clin Pathol, Kuopio 70211, Finland.
[Mannermaa, Arto; Kosma, Veli-Matti; Hartikainen, Jaana M.] Kuopio Univ Hosp, Sch Med, Univ Eastern Finland, Dept Clin Pathol, Kuopio 70211, Finland.
[Mannermaa, Arto; Kosma, Veli-Matti; Hartikainen, Jaana M.] Kuopio Univ Hosp, Sch Med, Imaging Ctr, Dept Clin Pathol, Kuopio 70211, Finland.
[Kataja, Vesa] Kuopio Univ Hosp, Sch Med, Inst Clin Med Oncol, Univ Eastern Finland, Kuopio 70211, Finland.
[Kataja, Vesa] Kuopio Univ Hosp, Sch Med, Inst Clin Med Oncol, Canc Ctr, Kuopio 70211, Finland.
[Wu, Anna H.; Tseng, Chiu-chen; Van Den Berg, David; Stram, Daniel O.; Haiman, Christopher A.; Henderson, Brian E.; Schumacher, Fredrick] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA.
[Lambrechts, Diether; Thienpont, Bernard] VRC, VIB, B-3000 Louvain, Belgium.
[Lambrechts, Diether; Thienpont, Bernard] Univ Leuven, B-3000 Louvain, Belgium.
[Christiaens, Marie-Rose] Univ Hosp Gasthuisberg, Dept Oncol, B-3000 Louvain, Belgium.
[Smeets, Ann] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium.
[Chang-Claude, Jenny; Rudolph, Anja; Seibold, Petra] German Canc Res Ctr, Div Canc Epidemiol, D-69120 Heidelberg, Germany.
[Flesch-Janys, Dieter] Univ Clin Hamburg Eppendorf, Dept Canc Epidemiol, Clin Canc Registry, D-20246 Hamburg, Germany.
[Flesch-Janys, Dieter] Univ Clin Hamburg Eppendorf, Dept Canc Epidemiol, Inst Med Biometr & Epidemiol, D-20246 Hamburg, Germany.
[Radice, Paolo] INT, Unit Mol Bases Genet Risk & Genet Testing, Dept Prevent Predict Med, Fdn IRCCS, I-20133 Milan, Italy.
[Peterlongo, Paolo] IFOM, Fdn Ist FIRC Oncol Mol, I-20139 Milan, Italy.
[Bonanni, Bernardo] IEO, Div Canc Prevent & Genet, I-20141 Milan, Italy.
[Bernard, Loris] IEO, Dept Expt Oncol, I-20141 Milan, Italy.
[Bernard, Loris] Cogentech Canc Genet Test Lab, I-20139 Milan, Italy.
[Couch, Fergus J.; Wang, Xianshu] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA.
[Olson, Janet E.; Vachon, Celine; Slager, Susan] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA.
[Purrington, Kristen] Karmanos Canc Ctr, Detroit, MI 48201 USA.
[Giles, Graham G.; Severi, Gianluca; Baglietto, Laura] Canc Epidemiol Ctr, Canc Council Victoria, Melbourne, Vic 3053, Australia.
[McLean, Catriona] Alfred Hosp, Melbourne, Vic 3181, Australia.
[Le Marchand, Loic] Univ Hawaii, Canc Res Ctr, Epidemiol Program, Honolulu, HI 96813 USA.
[Simard, Jacques; Dumont, Martine] Univ Quebec, Canc Genom Lab, Ctr Hosp, Quebec City, PQ QCG1V4G2, Canada.
[Simard, Jacques; Dumont, Martine] Univ Laval, Canc Genom Lab, Quebec City, PQ QCG1V4G2, Canada.
[Goldberg, Mark S.] McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada.
[Goldberg, Mark S.] McGill Univ, Royal Victoria Hosp, Div Clin Epidemiol, Hlth Ctr, Montreal, PQ H3A 1A1, Canada.
[Labreche, France] Univ Montreal, Dept Social & Prevent Med, Dept Sante Environm & Sante Travail, Montreal, PQ H3A 3C2, Canada.
[Teo, Soo-Hwang; Phuah, Sze-Yee] Canc Res Initiat Fdn, Sime Darby Med Ctr, Selangor 47500, Malaysia.
[Teo, Soo-Hwang; Yip, Cheng-Har; Phuah, Sze-Yee] Univ Malaya, Med Ctr, Breast Canc Res Unit, Univ Malaya Canc Res Inst, Kuala Lumpur 50603, Malaysia.
[Kristensen, Vessela; Alnaes, Grethe Grenaker; Borresen-Dale, Anne-Lise] Oslo Univ Hosp, Dept Genet, Inst Canc Res, N-0310 Oslo, Norway.
[Kristensen, Vessela; Borresen-Dale, Anne-Lise] Univ Oslo, Fac Med Fac Div Ahus, N-0318 Oslo, Norway.
[Zheng, Wei; Deming-Halverson, Sandra; Shrubsole, Martha; Long, Jirong; Shu, Xiao-Ou; Cai, Hui; Blot, William; Signorello, Lisa B.; Cai, Qiuyin] Vanderbilt Univ, Sch Med,Vanderbilt Ingram Canc Ctr, Div Epidemiol, Dept Med,Vanderbilt Epidemiol Ctr,, Nashville, TN 37203 USA.
[Winqvist, Robert; Pylkaes, Katri] Univ Oulu, Lab Canc Genet & Tumor Biol, Dept Clin Chem, Oulu Univ Hosp, Oulu 90014, Finland.
[Winqvist, Robert; Pylkaes, Katri] Univ Oulu, Lab Canc Genet & Tumor Biol, Bioctr Oulu, Oulu Univ Hosp, Oulu 90014, Finland.
[Jukkola-Vuorinen, Arja; Kauppila, Saila] Univ Oulu, Dept Oncol, Oulu Univ Hosp, Oulu 90014, Finland.
[Andrulis, Irene L.; Knight, Julia A.; Glendon, Gord; Tchatchou, Sandrine] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G IX5, Canada.
[Andrulis, Irene L.] Univ Toronto, Dept Mol Genet, Toronto, ON M5S IA8, Canada.
[Knight, Julia A.] Univ Toronto, Div Epidemiol, Dalla Lana Sch Publ Hlth, Toronto, ON M5S 1A8, Canada.
[Devilee, Peter] Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RC Leiden, Netherlands.
[Devilee, Peter] Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands.
[Tollenaar, Robert A. E. M.] Leiden Univ, Med Ctr, Dept Surg Oncol, NL-2300 RC Leiden, Netherlands.
[Seynaeve, Caroline M.; Hooning, Maartje J.; Martens, John W. M.] Erasmus MC Canc Inst, Dept Med Oncol, NL-3075 EA Rotterdam, Netherlands.
[Garcia-Closas, Montserrat] Inst Canc Res, Div Genet & Epidemiol, Surrey SM2 5NG, England.
[Figueroa, Jonine; Chanock, Stephen J.] NCI, Div Canc Epidemiol & Genet, Rockville, MD 20892 USA.
[Lissowska, Jolanta; Swerdlow, Anthony; Schoemaker, Minouk J.] M Sklodowska Curie Mem Canc Ctr, Dept Canc Epidemiol & Prevent, PL-02781 Warsaw, Poland.
[Lissowska, Jolanta; Swerdlow, Anthony; Schoemaker, Minouk J.] Inst Oncol, Dept Canc Epidemiol & Prevent, PL-02781 Warsaw, Poland.
[Czene, Kamila; Darabi, Hartef; Eriksson, Kimael; Hall, Per; Humphreys, Keith] Karolinska Inst, Dept Med Epidemiol & Biostat, S-17177 Stockholm, Sweden.
[van den Ouweland, Ans M. W.] Erasmus Univ, Med Ctr, Dept Clin Genet, NL-3008 AE Rotterdam, Netherlands.
[van Deurzen, Carolien H. M.] Erasmus Univ, Med Ctr, Dept Pathol, NL-3008 AE Rotterdam, Netherlands.
[Li, Jingmei; Liu, Jianjun] Genome Inst Singapore, Div Human Genet, Singapore 138672, Singapore.
[Lu, Wei] Shanghai Ctr Dis Control & Prevent, Shanghai 200336, Peoples R China.
[Gao, Yu-Tang] Shanghai Canc Inst, Dept Epidemiol, Shanghai 200032, Peoples R China.
[Cox, Angela; Reed, Malcolm W. R.; Blot, William] Univ Sheffield, CRUK, YCR Sheffield Canc Res Ctr, Sheffield S10 2RX, S Yorkshire, England.
[Signorello, Lisa B.] Int Epidemiol Inst, Rockville, MD 20850 USA.
[Kang, Daehee; Park, Sue K.] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul 110799, South Korea.
[Kang, Daehee; Choi, Ji-Yeob] Seoul Natl Univ, Dept Biomed Sci, Grad Sch, Seoul 110799, South Korea.
[Noh, Dong-Young] Seoul Natl Univ, Coll Med, Dept Surg, Seoul 110799, South Korea.
[Hartman, Mikael; Hui, Miao; Lim, Wei-Yen] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117597, Singapore.
[Hartman, Mikael; Hui, Miao; Lim, Wei-Yen] Natl Univ Hlth Syst, Singapore 119228, Singapore.
[Buhari, Shaik A.] Natl Univ Hlth Syst, Div Gen Surg, Singapore 119228, Singapore.
[Hamann, Ute] German Canc Res Ctr, D-69120 Heidelberg, Germany.
[Foersti, Asta] Skanes Univ Sjukhus, Ctr Primary Hlth Care Res, Clin Res Ctr, S-20502 Malmo, Sweden.
[Ruediger, Thomas] Stadt Klin Karlsruhe, Inst Pathol, D-76133 Karlsruhe, Germany.
[Ulmer, Hans-Ulrich] Frauenklin Stadtklin Baden Baden, D-76532 Baden Baden, Germany.
[Jakubowska, Anna; Lubinski, Jan; Jaworska, Katarzyna; Durda, Katarzyna] Pomeranian Med Univ, Dept Genet & Pathol, PL-70115 Szczecin, Poland.
[Jaworska, Katarzyna] Med Univ Warsaw, Postgrad Sch Mol Med, PL-02091 Warsaw, Poland.
[Sangrajrang, Suleeporn] Natl Canc Inst, Bangkok 10400, Thailand.
[Gaborieau, Valerie; Brennan, Paul; Mckay, James] Int Agcy Res Canc, F-69372 Lyon, France.
[Fostira, Florentia] NSCR Demokritos, INRASTES, Mol Diagnost Lab, Athens 15310, Greece.
[Pilarski, Robert] Ohio State Univ, Dept Internal Med, James Comprehens Canc Ctr, Columbus, OH 43210 USA.
[Shen, Chen-Yang; Hsiung, Chia-Ni] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.
[Shen, Chen-Yang; Wu, Pei-Ei] China Med Univ, Coll Publ Hlth, Taichung 40402, Taiwan.
[Hou, Ming-Feng] Kaohsiung Med Univ, Chung Ho Mem Hosp, Taiwan Biobank, Kaohsiung, Taiwan.
[Hou, Ming-Feng] Kaohsiung Med Univ, Chung Ho Mem Hosp, Ctr Canc, Kaohsiung, Taiwan.
[Hou, Ming-Feng] Kaohsiung Med Univ, Chung Ho Mem Hosp, Dept Surg, Kaohsiung, Taiwan.
[Swerdlow, Anthony; Ashworth, Alan; Orr, Nick] Inst Canc Res, Div Breast Canc Res, Surrey SM2 5NG, England.
RP Meyer, KB (reprint author), Univ Cambridge, CRUK Cambridge Inst, Li Ka Shing Ctr, Robinson Way, Cambridge CB2 0RE, England.
RI Jakubowska, Anna/O-8050-2014; Yip, Cheng-Har/B-1909-2010; Hartikainen,
Jaana/E-6256-2015; Garcia-Closas, Montserrat /F-3871-2015; French,
Juliet/A-4982-2011; Radice, Paolo/O-3119-2013; Li, Jingmei/I-2904-2012;
Andrulis, Irene/E-7267-2013; Ditsch, Nina/F-6267-2014; Teo,
Soo-hwang/H-2353-2014; Hartman, Mikael/B-4324-2011; Noh,
Dong-Young/G-5531-2011; Bernard, Loris/K-5953-2014; Knight,
Julia/A-6843-2012; Pilarski, Robert/E-3871-2011; Shrubsole,
Martha/K-5052-2015; Dork, Thilo/J-8620-2012; U-ID, Kyushu/C-5291-2016;
laurent-puig, pierre/B-2226-2013; Bowtell, David/H-1007-2016; Bruning,
Thomas/G-8120-2015; Edwards, Stacey/A-4980-2011; Brenner,
Hermann/B-4627-2017;
OI Garcia-Closas, Montserrat /0000-0003-1033-2650; Li,
Jingmei/0000-0001-8587-7511; Lux, Michael Patrick/0000-0002-2781-2178;
Czene, Kamila/0000-0002-3233-5695; Lissowska,
Jolanta/0000-0003-2695-5799; Dunning, Alison
Margaret/0000-0001-6651-7166; Muranen, Taru/0000-0002-5895-1808;
Nevanlinna, Heli/0000-0002-0916-2976; Cox, Angela/0000-0002-5138-1099;
Thienpont, Bernard/0000-0002-8772-6845; Giles,
Graham/0000-0003-4946-9099; Matsuo, Keitaro/0000-0003-1761-6314; Arndt,
Volker/0000-0001-9320-8684; Shrubsole, Martha/0000-0002-5591-7575;
laurent-puig, pierre/0000-0001-8475-5459; Bowtell,
David/0000-0001-9089-7525; Bruning, Thomas/0000-0001-9560-5464; Brenner,
Hermann/0000-0002-6129-1572; Devilee, Peter/0000-0002-8023-2009;
Schoemaker, Minouk/0000-0001-8403-2234
FU Cancer Research UK [10124, 10118, 10119]; NCI NIH HHS [P30 CA015083, R01
CA077398, R01 CA092447]; Wellcome Trust [090532]
NR 35
TC 39
Z9 39
U1 2
U2 40
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD DEC 5
PY 2013
VL 93
IS 6
BP 1046
EP 1060
DI 10.1016/j.ajhg.2013.10.026
PG 15
WC Genetics & Heredity
SC Genetics & Heredity
GA 273FS
UT WOS:000328521300005
PM 24290378
ER
PT J
AU Lin, SW
Abnet, CC
Freedman, ND
Murphy, G
Risques, R
Prunkard, D
Rabinovitch, P
Pan, QJ
Roth, MJ
Wang, GQ
Wei, WQ
Lu, N
Taylor, PR
Qiao, YL
Dawsey, SM
AF Lin, Shih-Wen
Abnet, Christian C.
Freedman, Neal D.
Murphy, Gwen
Risques, Rosana
Prunkard, Donna
Rabinovitch, Peter
Pan, Qin-Jing
Roth, Mark J.
Wang, Guo-Qing
Wei, Wen-Qiang
Lu, Ning
Taylor, Philip R.
Qiao, You-Lin
Dawsey, Sanford M.
TI Measuring telomere length for the early detection of precursor lesions
of esophageal squamous cell carcinoma
SO BMC CANCER
LA English
DT Article
DE Esophageal squamous cell carcinoma; Esophageal squamous dysplasia; Early
detection; Screening; Balloon cytology; Telomeres
ID GENERAL-POPULATION TRIAL; COLORECTAL-CANCER; ASYMPTOMATIC ADULTS;
CYTOLOGIC DETECTION; BARRETTS-ESOPHAGUS; CHINA; LINXIAN; RISK;
INSTABILITY; DYSPLASIA
AB Background: Esophageal cancer is the sixth leading cause of cancer death worldwide; current early detection screening tests are inadequate. Esophageal balloon cytology successfully retrieves exfoliated and scraped superficial esophageal epithelial cells, but cytologic reading of these cells has poor sensitivity and specificity for detecting esophageal squamous dysplasia (ESD), the precursor lesion of esophageal squamous cell carcinoma (ESCC). Measuring telomere length, a marker for chromosomal instability, may improve the utility of balloon cytology for detecting ESD and early ESCC.
Methods: We examined balloon cytology specimens from 89 asymptomatic cases of ESD (37 low-grade and 52 high-grade) and 92 age-and sex-matched normal controls from an esophageal cancer early detection screening study. All subjects also underwent endoscopy and biopsy, and ESD was diagnosed histopathologically. DNA was extracted from the balloon cytology cells, and telomere length was measured by quantitative PCR. A receiver operating characteristic (ROC) curve was plotted for telomere length as a diagnostic marker for high-grade dysplasia.
Results: Telomere lengths were comparable among the low-and high-grade dysplasia cases and controls, with means of 0.96, 0.96, and 0.92, respectively. The area under the ROC curve was 0.55 for telomere length as a diagnostic marker for high-grade dysplasia. Further adjustment for subject characteristics, including sex, age, smoking, drinking, hypertension, and body mass index did not improve the use of telomere length as a marker for ESD.
Conclusions: Telomere length of esophageal balloon cytology cells was not associated with ESCC precursor lesions. Therefore, telomere length shows little promise as an early detection marker for ESCC in esophageal balloon samples.
C1 [Lin, Shih-Wen; Abnet, Christian C.; Freedman, Neal D.; Murphy, Gwen; Taylor, Philip R.; Dawsey, Sanford M.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Risques, Rosana; Prunkard, Donna; Rabinovitch, Peter] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Pan, Qin-Jing; Wang, Guo-Qing; Wei, Wen-Qiang; Lu, Ning; Qiao, You-Lin] Chinese Acad Med Sci, Inst Canc, Beijing 100021, Peoples R China.
[Roth, Mark J.] NCI, Pathol Lab, Ctr Canc Res, Bethesda, MD 20892 USA.
RP Lin, SW (reprint author), NCI, Div Canc Epidemiol & Genet, 9609 Med Ctr Dr, Bethesda, MD 20892 USA.
EM lins4@mail.nih.gov; qiaoy@public.bta.net.cn
RI Qiao, You-Lin/B-4139-2012; Abnet, Christian/C-4111-2015; Murphy,
Gwen/G-7443-2015; Freedman, Neal/B-9741-2015
OI Qiao, You-Lin/0000-0001-6380-0871; Abnet, Christian/0000-0002-3008-7843;
Freedman, Neal/0000-0003-0074-1098
FU National Cancer Institute [N01-SC-91019]; Cancer Institute of the
Chinese Academy of Medical Sciences; Intramural Research Program of the
Division of Cancer Epidemiology and Genetics of the National Cancer
Institute, NIH
FX This study was supported by National Cancer Institute contract
N01-SC-91019 with the Cancer Institute of the Chinese Academy of Medical
Sciences and by the Intramural Research Program of the Division of
Cancer Epidemiology and Genetics of the National Cancer Institute, NIH.
NR 40
TC 6
Z9 6
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD DEC 5
PY 2013
VL 13
AR 578
DI 10.1186/1471-2407-13-578
PG 8
WC Oncology
SC Oncology
GA 280MN
UT WOS:000329034600002
PM 24308314
ER
PT J
AU Trost, B
Kindrachuk, J
Scruten, E
Griebel, P
Kusalik, A
Napper, S
AF Trost, Brett
Kindrachuk, Jason
Scruten, Erin
Griebel, Philip
Kusalik, Anthony
Napper, Scott
TI Kinotypes: stable species- and individual-specific profiles of cellular
kinase activity
SO BMC GENOMICS
LA English
DT Article
ID PERSONALIZED MEDICINE; PROTEIN-KINASES; CANCER; BIOMARKERS; KINOME;
PHOSPHOPROTEOME; RESPONSES; TARGETS; ANTIGEN; MODELS
AB Background: Recently, questions have been raised regarding the ability of animal models to recapitulate human disease at the molecular level. It has also been demonstrated that cellular kinases, individually or as a collective unit (the kinome), play critical roles in regulating complex biology. Despite the intimate relationship between kinases and health, little is known about the variability, consistency and stability of kinome profiles across species and individuals.
Results: As a preliminary investigation of the existence of species-and individual-specific kinotypes (kinome signatures), peptide arrays were employed for the analysis of peripheral blood mononuclear cells collected weekly from human and porcine subjects (n = 6) over a one month period. The data revealed strong evidence for species-specific signalling profiles. Both humans and pigs also exhibited evidence for individual-specific kinome profiles that were independent of natural changes in blood cell populations.
Conclusions: Species-specific kinotypes could have applications in disease research by facilitating the selection of appropriate animal models or by revealing a baseline kinomic signature to which treatment-induced profiles could be compared. Similarly, individual-specific kinotypes could have implications in personalized medicine, where the identification of molecular patterns or signatures within the kinome may depend on both the levels of kinome diversity and temporal stability across individuals.
C1 [Trost, Brett; Kusalik, Anthony] Univ Saskatchewan, Dept Comp Sci, Saskatoon, SK S7N 0W0, Canada.
[Kindrachuk, Jason] NIAID, NIH, Emerging Viral Pathogens Sect, Frederick, MD USA.
[Scruten, Erin; Griebel, Philip; Napper, Scott] Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK, Canada.
[Griebel, Philip] Univ Saskatchewan, Sch Publ Hlth, Saskatoon, SK, Canada.
[Napper, Scott] Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 0W0, Canada.
RP Napper, S (reprint author), Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK, Canada.
EM scott.napper@usask.ca
RI Trost, Brett/K-4127-2016;
OI Trost, Brett/0000-0003-4863-7273; Kindrachuk, Jason/0000-0002-3305-7084
FU Genome Canada; Natural Sciences and Engineering Research Council of
Canada (NSERC); Intramural Research Program of the NIH/NIAID
FX This work was supported in part by Genome Canada, the Natural Sciences
and Engineering Research Council of Canada (NSERC), and the Intramural
Research Program of the NIH/NIAID.
NR 35
TC 5
Z9 5
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD DEC 5
PY 2013
VL 14
AR 854
DI 10.1186/1471-2164-14-854
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 275AP
UT WOS:000328647700001
PM 24314169
ER
PT J
AU Grinholc, M
Nakonieczna, J
Negri, A
Rapacka-Zdonczyk, A
Motyka, A
Fila, G
Kurlenda, J
Leibner-Ciszak, J
Otto, M
Bielawski, KP
AF Grinholc, Mariusz
Nakonieczna, Joanna
Negri, Alessandro
Rapacka-Zdonczyk, Aleksandra
Motyka, Agata
Fila, Grzegorz
Kurlenda, Julianna
Leibner-Ciszak, Justyna
Otto, Michael
Bielawski, Krzysztof P.
TI The agr function and polymorphism: Impact on Staphylococcus aureus
susceptibility to photoinactivation
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE Accessory gene regulator; Gene polymorphism; Photoinactivation;
Staphylococcus aureus
ID METHICILLIN-RESISTANT; PHOTODYNAMIC INACTIVATION; GROWTH-PHASE;
VIRULENCE; THERAPY; EXPRESSION; BACTERIA; ALLELES; LOCUS; TIME
AB Staphylococcus aureus is an important human pathogen that causes healthcare-associated and community-acquired infections. Moreover, the growing prevalence of multiresistant strains requires the development of alternative methods to antibiotic therapy. One effective therapeutic option may be antimicrobial photodynamic inactivation (aPDI). Recently, S. aureus strain-dependent response to PDI was demonstrated, although the mechanism underlying this phenomenon remains unexplained. The aim of the current study was to investigate statistically relevant correlations between the functionality and polymorphisms of agr gene determined for 750 methicillin-susceptible and methicillin-resistant S. aureus strains and their responses to photodynamic inactivation using protoporphyrin IX. An AluI and RsaI digestion of the agr gene PCR product revealed existing correlations between the determined digestion profiles (designations used for the first time) and the PDI response. Moreover, the functionality of the agr system affected S. aureus susceptibility to PDI. Based on our results, we conclude that the agr gene may be a genetic factor affecting the strain dependent response to PDI. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Grinholc, Mariusz; Nakonieczna, Joanna; Negri, Alessandro; Rapacka-Zdonczyk, Aleksandra; Motyka, Agata; Fila, Grzegorz; Bielawski, Krzysztof P.] Univ Gdansk, Intercoll Fac Biotechnol, Dept Biotechnol, Lab Mol Diagnost, PL-80822 Gdansk, Poland.
[Grinholc, Mariusz; Nakonieczna, Joanna; Negri, Alessandro; Rapacka-Zdonczyk, Aleksandra; Motyka, Agata; Fila, Grzegorz; Bielawski, Krzysztof P.] Med Univ Gdansk, PL-80822 Gdansk, Poland.
[Kurlenda, Julianna] State Higher Vocat Sch Koszalin, PL-75582 Koszalin, Poland.
[Leibner-Ciszak, Justyna] BLIRT SA BioLab Innovat Res Technol, PL-80172 Gdansk, Poland.
[Otto, Michael] NIAID, Lab Human Bacterial Pathogenesis, NIH, Bethesda, MD 20892 USA.
RP Grinholc, M (reprint author), Univ Gdansk, Intercoll Fac Biotechnol, Dept Biotechnol, Lab Mol Diagnost, Kladki 24, PL-80822 Gdansk, Poland.
EM grinholc@biotech.ug.edu.pl
RI Motyka, Agata/D-2450-2017; Grinholc, Mariusz/F-5962-2011; Bielawski,
Krzysztof/D-8711-2011
OI Motyka, Agata/0000-0001-7717-8251; Otto, Michael/0000-0002-2222-4115;
FU NIAID/NIH [HHSN27220 0700055C]; National Science Centre (NCN)
[1651/B/P01/2010/39]; Intramural Research Program of the National
Institute of Allergy and Infectious Diseases (NIAID), U.S. National
Institutes of Health (NIH)
FX Isogenic pairs of agr mutants were obtained through the Network of
Antimicrobial Resistance in Staphylococcus aureus (NARSA) program
supported under NIAID/NIH Contract#HHSN27220 0700055C. MALDI-TOF MS
analysis were performed at LM Bruss Laboratory in Poland. This work was
supported by the Grant No. 1651/B/P01/2010/39 from the National Science
Centre (NCN). M.O. was supported by the Intramural Research Program of
the National Institute of Allergy and Infectious Diseases (NIAID), U.S.
National Institutes of Health (NIH).
NR 36
TC 1
Z9 1
U1 0
U2 6
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD DEC 5
PY 2013
VL 129
BP 100
EP 107
DI 10.1016/j.jphotobiol.2013.10.006
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 275WS
UT WOS:000328710500012
PM 24211295
ER
PT J
AU Barupal, DK
Lee, SJ
Karoly, ED
Adhya, S
AF Barupal, Dinesh Kumar
Lee, Sang Jun
Karoly, Edward D.
Adhya, Sankar
TI Inactivation of Metabolic Genes Causes Short- and Long-Range
dys-Regulation in Escherichia coli Metabolic Network
SO PLOS ONE
LA English
DT Article
ID TRANSCRIPTIONAL REGULATION; EVOLUTION; GLUCOSE; STRESS; FLUX;
EXPRESSION; MODULARITY; CONVERSION; PATHWAYS; BACTERIA
AB The metabolic network in E. coli can be severely affected by the inactivation of metabolic genes that are required to catabolize a nutrient (D-galactose). We hypothesized that the resulting accumulation of small molecules can yield local as well as systemic effects on the metabolic network. Analysis of metabolomics data in wild-type and D-galactose non-utilizing mutants, galT, galU and galE, reveal the large metabolic differences between the wild-type and the mutants when the strains were grown in D-galactose. Network mapping suggested that the enzymatic defects affected the metabolic modules located both at short-and long-ranges from the D-galactose metabolic module. These modules suggested alterations in glutathione, energy, nucleotide and lipid metabolism and disturbed carbon to nitrogen ratio in mutant strains. The altered modules are required for normal cell growth for the wild-type strain, explaining why the cell growth is inhibited in the mutants in the presence of D-galactose. Identification of these distance-based dys-regulations would enhance the systems level understanding of metabolic networks of microorganisms having importance in biomedical and biotechnological research.
C1 [Barupal, Dinesh Kumar] Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA.
[Lee, Sang Jun] KRIBB, Infect & Immun Res Ctr, Taejon, South Korea.
[Lee, Sang Jun] Univ Sci & Technol, Taejon, South Korea.
[Lee, Sang Jun; Adhya, Sankar] NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Karoly, Edward D.] Metabolon Inc, Durham, NC USA.
RP Adhya, S (reprint author), NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bldg 37, Bethesda, MD 20892 USA.
EM sadhya@helix.nih.gov
FU Intramural Research Program of the National Institutes of Health,
National Cancer Institute, Center for Cancer Research
FX This research was supported by the Intramural Research Program of the
National Institutes of Health, National Cancer Institute, Center for
Cancer Research. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 37
TC 2
Z9 2
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 5
PY 2013
VL 8
IS 12
AR e78360
DI 10.1371/journal.pone.0078360
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 273WD
UT WOS:000328566100003
PM 24363806
ER
PT J
AU Chufan, EE
Kapoor, K
Sim, HM
Singh, S
Talele, TT
Durell, SR
Ambudkar, SV
AF Chufan, Eduardo E.
Kapoor, Khyati
Sim, Hong-May
Singh, Satyakam
Talele, Tanaji T.
Durell, Stewart R.
Ambudkar, Suresh V.
TI Multiple Transport-Active Binding Sites Are Available for a Single
Substrate on Human P-Glycoprotein (ABCB1)
SO PLOS ONE
LA English
DT Article
ID DRUG-BINDING; MULTIDRUG-RESISTANCE; CATALYTIC CYCLE; ATP HYDROLYSIS;
FUNCTIONAL-CHARACTERIZATION; EXPRESSION SYSTEM; MAMMALIAN-CELLS;
MOLECULAR-BASIS; RESIDUES; REVEALS
AB P-glycoprotein (Pgp, ABCB1) is an ATP-Binding Cassette (ABC) transporter that is associated with the development of multidrug resistance in cancer cells. Pgp transports a variety of chemically dissimilar amphipathic compounds using the energy from ATP hydrolysis. In the present study, to elucidate the binding sites on Pgp for substrates and modulators, we employed site-directed mutagenesis, cell-and membrane-based assays, molecular modeling and docking. We generated single, double and triple mutants with substitutions of the Y307, F343, Q725, F728, F978 and V982 residues at the proposed drug-binding site with cys in a cysless Pgp, and expressed them in insect and mammalian cells using a baculovirus expression system. All the mutant proteins were expressed at the cell surface to the same extent as the cysless wild-type Pgp. With substitution of three residues of the pocket (Y307, Q725 and V982) with cysteine in a cysless Pgp, QZ59S-SSS, cyclosporine A, tariquidar, valinomycin and FSBA lose the ability to inhibit the labeling of Pgp with a transport substrate, [I-125]-Iodoarylazidoprazosin, indicating these drugs cannot bind at their primary binding sites. However, the drugs can modulate the ATP hydrolysis of the mutant Pgps, demonstrating that they bind at secondary sites. In addition, the transport of six fluorescent substrates in HeLa cells expressing triple mutant (Y307C/Q725C/V982C) Pgp is also not significantly altered, showing that substrates bound at secondary sites are still transported. The homology modeling of human Pgp and substrate and modulator docking studies support the biochemical and transport data. In aggregate, our results demonstrate that a large flexible pocket in the Pgp transmembrane domains is able to bind chemically diverse compounds. When residues of the primary drug-binding site are mutated, substrates and modulators bind to secondary sites on the transporter and more than one transport-active binding site is available for each substrate.
C1 [Chufan, Eduardo E.; Kapoor, Khyati; Sim, Hong-May; Durell, Stewart R.; Ambudkar, Suresh V.] NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Singh, Satyakam; Talele, Tanaji T.] St Johns Univ, Dept Pharmaceut Sci, Coll Pharm & Hlth Sci, Queens, NY USA.
RP Ambudkar, SV (reprint author), NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bldg 37, Bethesda, MD 20892 USA.
EM ambudkar@helix.nih.gov
FU National Institutes of Health, National Cancer Institute, Center for
Cancer Research
FX This research was supported by the Intramural Research Program of the
National Institutes of Health, National Cancer Institute, Center for
Cancer Research. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 57
TC 21
Z9 21
U1 1
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 5
PY 2013
VL 8
IS 12
AR e82463
DI 10.1371/journal.pone.0082463
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 273WD
UT WOS:000328566100113
PM 24349290
ER
PT J
AU Baz, M
Luke, CJ
Cheng, X
Jin, H
Subbarao, K
AF Baz, Mariana
Luke, Catherine J.
Cheng, Xing
Jin, Hong
Subbarao, Kanta
TI H5N1 vaccines in humans
SO VIRUS RESEARCH
LA English
DT Article
DE H5N1; Vaccine strategies; Pandemic; Adjuvants; Clinical trials
ID INFLUENZA-A H5N1; VIRUS-LIKE PARTICLES; PROTECTIVE IMMUNE-RESPONSES;
INACTIVATED WHOLE VIRUS; CROSS-REACTIVE IMMUNITY; MEMORY B-CELLS;
TO-PERSON TRANSMISSION; CHILDREN AGED 3; AVIAN-INFLUENZA; PANDEMIC
INFLUENZA
AB The spread of highly pathogenic avian H5N1 influenza viruses since 1997 and their virulence for poultry and humans has raised concerns about their potential to cause an influenza pandemic. Vaccines offer the most viable means to combat a pandemic threat. However, it will be a challenge to produce, distribute and implement a new vaccine if a pandemic spreads rapidly. Therefore, efforts are being undertaken to develop pandemic vaccines that use less antigen and induce cross-protective and long-lasting responses, that can be administered as soon as a pandemic is declared or possibly even before, in order to prime the population and allow for a rapid and protective antibody response. In the last few years, several vaccine manufacturers have developed candidate pandemic and pre-pandemic vaccines, based on reverse genetics and have improved the immunogenicity by formulating these vaccines with different adjuvants. Some of the important and consistent observations from clinical studies with H5N1 vaccines are as follows: two doses of inactivated vaccine are generally necessary to elicit the level of immunity required to meet licensure criteria, less antigen can be used if an oil-in-water adjuvant is included, in general antibody titers decline rapidly but can be boosted with additional doses of vaccine and if high titers of antibody are elicited, cross-reactivity against other clades is observed. Prime-boost strategies elicit a more robust immune response. In this review, we discuss data from clinical trials with a variety of H5N1 influenza vaccines. We also describe studies conducted in animal models to explore the possibility of reassortment between pandemic live attenuated vaccine candidates and seasonal influenza viruses, since this is an important consideration for the use of live vaccines in a pandemic setting. Published by Elsevier B.V.
C1 [Baz, Mariana; Luke, Catherine J.; Subbarao, Kanta] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
[Cheng, Xing; Jin, Hong] MedImmune, Mountain View, CA USA.
RP Subbarao, K (reprint author), NIAID, Emerging Resp Viruses Sect, Infect Dis Lab, NIH, Bldg 33,Room 3E13C-1,33 North Dr,MSC 3203, Bethesda, MD 20892 USA.
EM ksubbarao@niaid.nih.gov
FU Intramural Research Program of the NIAID, NIH
FX We thank Jadon Jackson and the staff of the Comparative Medicine Branch,
NIAID, for excellent technical support and animal care. All animal
experiments were done at the NIH Bethesda, MD, in compliance with the
guidelines of the NIAID/NIH Institutional Animal Care and Use Committee.
Histopathological analysis was conducted by Lily Cheng and Fernando
Torres-Velez from the Comparative Medicine Branch, NIAID. We thank
Leatrice Vogel, Weijia Wang and Winnie Chan for excellent technical
assistance. We thank George Kemble for helpful discussions on the
reassortant studies. This research was supported by the Intramural
Research Program of the NIAID, NIH, and was performed as part of a
Cooperative Research and Development Agreement (CRADA No. AI-0155)
between the Laboratory of Infectious Diseases, NIAID and MedImmune.
NR 195
TC 33
Z9 35
U1 0
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD DEC 5
PY 2013
VL 178
IS 1
BP 78
EP 98
DI 10.1016/j.virusres.2013.05.006
PG 21
WC Virology
SC Virology
GA 273GA
UT WOS:000328522100010
PM 23726847
ER
PT J
AU Kost, RG
Lee, LM
Yessis, J
Wesley, RA
Henderson, DK
Coller, BS
AF Kost, Rhonda G.
Lee, Laura M.
Yessis, Jennifer
Wesley, Robert A.
Henderson, David K.
Coller, Barry S.
TI Assessing Participant-Centered Outcomes to Improve Clinical Research
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID PERCEPTION
C1 [Kost, Rhonda G.; Coller, Barry S.] Rockefeller Univ, New York, NY 10021 USA.
[Lee, Laura M.; Wesley, Robert A.; Henderson, David K.] NIH, Ctr Clin, Bethesda, MD 20892 USA.
[Yessis, Jennifer] Univ Waterloo, Propel Ctr Populat Hlth Impact, Waterloo, ON N2L 3G1, Canada.
RP Kost, RG (reprint author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.
FU NCATS NIH HHS [UL1 TR000043]; NCRR NIH HHS [UL1 RR024143]
NR 5
TC 12
Z9 12
U1 1
U2 4
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 5
PY 2013
VL 369
IS 23
BP 2179
EP 2181
DI 10.1056/NEJMp1311461
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 263II
UT WOS:000327801100004
PM 24304050
ER
PT J
AU Parsa, A
Kao, WHL
Xie, DW
Astor, BC
Li, M
Hsu, CY
Feldman, HI
Parekh, RS
Kusek, JW
Greene, TH
Fink, JC
Anderson, AH
Choi, MJ
Wright, JT
Lash, JP
Freedman, BI
Ojo, A
Winkler, CA
Raj, DS
Kopp, JB
He, J
Jensvold, NG
Tao, KX
Lipkowitz, MS
Appel, LJ
AF Parsa, Afshin
Kao, W. H. Linda
Xie, Dawei
Astor, Brad C.
Li, Man
Hsu, Chi-yuan
Feldman, Harold I.
Parekh, Rulan S.
Kusek, John W.
Greene, Tom H.
Fink, Jeffrey C.
Anderson, Amanda H.
Choi, Michael J.
Wright, Jackson T., Jr.
Lash, James P.
Freedman, Barry I.
Ojo, Akinlolu
Winkler, Cheryl A.
Raj, Dominic S.
Kopp, Jeffrey B.
He, Jiang
Jensvold, Nancy G.
Tao, Kaixiang
Lipkowitz, Michael S.
Appel, Lawrence J.
CA AASK Study Investigators
CRIC Study Investigators
TI APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID STAGE RENAL-DISEASE; BASE-LINE CHARACTERISTICS; FOCAL SEGMENTAL
GLOMERULOSCLEROSIS; AFRICAN-AMERICANS; RACIAL-DIFFERENCES; INSUFFICIENCY
COHORT; FUNCTION DECLINE; GENE; MYH9; CKD
AB BackgroundAmong patients in the United States with chronic kidney disease, black patients are at increased risk for end-stage renal disease, as compared with white patients.
MethodsIn two studies, we examined the effects of variants in the gene encoding apolipoprotein L1 (APOL1) on the progression of chronic kidney disease. In the African American Study of Kidney Disease and Hypertension (AASK), we evaluated 693 black patients with chronic kidney disease attributed to hypertension. In the Chronic Renal Insufficiency Cohort (CRIC) study, we evaluated 2955 white patients and black patients with chronic kidney disease (46% of whom had diabetes) according to whether they had 2 copies of high-risk APOL1 variants (APOL1 high-risk group) or 0 or 1 copy (APOL1 low-risk group). In the AASK study, the primary outcome was a composite of end-stage renal disease or a doubling of the serum creatinine level. In the CRIC study, the primary outcomes were the slope in the estimated glomerular filtration rate (eGFR) and the composite of end-stage renal disease or a reduction of 50% in the eGFR from baseline.
ResultsIn the AASK study, the primary outcome occurred in 58.1% of the patients in the APOL1 high-risk group and in 36.6% of those in the APOL1 low-risk group (hazard ratio in the high-risk group, 1.88; P<0.001). There was no interaction between APOL1 status and trial interventions or the presence of baseline proteinuria. In the CRIC study, black patients in the APOL1 high-risk group had a more rapid decline in the eGFR and a higher risk of the composite renal outcome than did white patients, among those with diabetes and those without diabetes (P<0.001 for all comparisons).
ConclusionsRenal risk variants in APOL1 were associated with the higher rates of end-stage renal disease and progression of chronic kidney disease that were observed in black patients as compared with white patients, regardless of diabetes status. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others.)
C1 [Parsa, Afshin; Fink, Jeffrey C.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Kao, W. H. Linda; Li, Man; Appel, Lawrence J.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Choi, Michael J.; Appel, Lawrence J.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Kao, W. H. Linda; Appel, Lawrence J.] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA.
[Xie, Dawei; Feldman, Harold I.; Anderson, Amanda H.; Tao, Kaixiang] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Xie, Dawei; Feldman, Harold I.; Anderson, Amanda H.; Tao, Kaixiang] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Astor, Brad C.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53706 USA.
[Hsu, Chi-yuan] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Parekh, Rulan S.] Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
[Parekh, Rulan S.] Univ Hlth Network, Toronto, ON, Canada.
[Kusek, John W.; Kopp, Jeffrey B.] NIDDK, NIH, Bethesda, MD 20892 USA.
[Winkler, Cheryl A.] NCI, Ctr Canc Res, SAIC Frederick, Frederick, MD USA.
[Greene, Tom H.] Univ Utah, Sch Med, Salt Lake City, UT USA.
[Wright, Jackson T., Jr.] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA.
[Lash, James P.] Univ Illinois, Coll Med, Chicago, IL USA.
[Freedman, Barry I.] Wake Forest Sch Med, Winston Salem, NC USA.
[Ojo, Akinlolu] Univ Michigan, Sch Med, Ann Arbor, MI USA.
[Raj, Dominic S.] George Washington Univ, Sch Med, Washington, DC USA.
[Lipkowitz, Michael S.] Georgetown Univ, Sch Med, Washington, DC USA.
[He, Jiang] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA.
[Hsu, Chi-yuan; Jensvold, Nancy G.] Kaiser Permanente No Calif, Oakland, CA USA.
RP Appel, LJ (reprint author), Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-642, Baltimore, MD 21287 USA.
EM lappel@jhmi.edu
OI Kopp, Jeffrey/0000-0001-9052-186X; Fink, Jeffrey/0000-0002-5622-5052
FU National Institute of Diabetes and Digestive and Kidney Diseases
FX Funded by the National Institute of Diabetes and Digestive and Kidney
Diseases and others.
NR 42
TC 169
Z9 171
U1 4
U2 16
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 5
PY 2013
VL 369
IS 23
BP 2183
EP 2196
DI 10.1056/NEJMoa1310345
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA 263II
UT WOS:000327801100005
PM 24206458
ER
PT J
AU Elia, N
Ott, C
Lippincott-Schwartz, J
AF Elia, Natalie
Ott, Carolyn
Lippincott-Schwartz, Jennifer
TI Incisive Imaging and Computation for Cellular Mysteries: Lessons from
Abscission
SO CELL
LA English
DT Review
ID STRUCTURED ILLUMINATION MICROSCOPY; ESCRT-III; FLUORESCENCE MICROSCOPY;
PERICENTRIOLAR MATERIAL; CYTOKINETIC ABSCISSION; INTERCELLULAR BRIDGE;
MAMMALIAN-CELLS; FINAL STAGES; MIDBODY; RESOLUTION
AB The final cleavage event that terminates cell division, abscission of the small, dense intercellular bridge, has been particularly challenging to resolve. Here, we describe imaging innovations that helped answer long-standing questions about the mechanism of abscission. We further explain how computational modeling of high-resolution data was employed to test hypotheses and generate additional insights. We present the model that emerges from application of these complimentary approaches. Similar experimental strategies will undoubtedly reveal exciting details about other underresolved cellular structures.
C1 [Elia, Natalie] Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel.
[Elia, Natalie] Ben Gurion Univ Negev, NIBN, IL-84105 Beer Sheva, Israel.
[Ott, Carolyn; Lippincott-Schwartz, Jennifer] Eunice Kennedy Shriver NICHHD, Cell Biol & Metab Program, NIH, Bethesda, MD 20892 USA.
RP Elia, N (reprint author), Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel.
EM elianat@post.bgu.ac.il; jlippin@helix.nih.gov
FU Marie Curie Intergration grant (CIG); Israel Science foundadtion (ISF);
EU
FX The authors thank Erin Fincher and Nicole Jonas from the NICHD Unit on
Computer Support Services for creating the graphics used in the figures.
We also thank Christian Hellriegel (Zeiss), and members of the
Lippincott-Schwartz laboratory, Schuyler VanEngelenberg, Prabuddha
Sengupta, Angelika Rambold, and Bennet Waxse for helpful comments on the
text. N.E. is supported by the Marie Curie Intergration grant (CIG), EU
and by the Israel Science foundadtion (ISF).
NR 65
TC 13
Z9 13
U1 3
U2 22
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD DEC 5
PY 2013
VL 155
IS 6
BP 1220
EP 1231
DI 10.1016/j.cell.2013.11.011
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 269VS
UT WOS:000328271100008
PM 24315094
ER
PT J
AU Law, AY
Hebert, RL
Nasrallah, R
Langenbach, R
Wong, CKC
Wagner, GF
AF Law, Alice Y.
Hebert, Richard L.
Nasrallah, Rania
Langenbach, Robert
Wong, Chris K. C.
Wagner, Graham F.
TI Cyclooxygenase-2 mediates induction of the renal stanniocalcin-1 gene by
arginine vasopressin
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Vasopressin; Stanniocalcin-1; COX-2; Prostanoids; Kidney
ID HUMAN CANCER-CELLS; RAT-KIDNEY; MESSENGER-RNA; MOUSE KIDNEY; EXPRESSION;
PROTEIN; PHOSPHORYLATION; PHOSPHATE; EXCRETION; APOPTOSIS
AB In rats and mice, the renal stanniocalcin-1 (STC-1) gene is expressed in most nephron segments, but is differentially induced in response to dehydration. In cortical segments STC-1 mRNA levels are upregulated by the hypertonicity of dehydration, while hypovolemia causes gene induction in the inner medulla (papilla). In both cases induction is mediated by arginine vasopressin (AVP) acting via the V2 receptor (V2R). The intent of STC-1 gene upregulation during dehydration has yet to be established. Therefore, to narrow down the range of possible actions, we mapped out the pathway by which V2R occupancy upregulates the gene. V2R occupancy activates two different renal pathways in response to dehydration. The first is antidiuretic in nature and is mediated by direct V2R occupancy. The second pathway is indirect and counter-regulates AVP-mediated antidiuresis. It involves COX-2 (cyclooxygenase-2) and the prostanoids, and is activated by the V2R-mediated rise in medullary interstitial osmolality. The resulting prostanoids counter-regulate AVP-mediated antidiuresis. They also upregulate renal cytoprotective mechanisms. The present studies employed models of COX inhibition and COX gene deletion to address the possible involvement of the COX pathway. The results showed that both general and specific inhibitors of COX-2 blocked STC-1 gene induction in response to dehydration. Gene induction in response to dehydration was also abolished in COX-2 null mice (cortex and papilla), but not in COX-1 null mice. STC-1 gene induction in response to V2R occupancy was also uniquely abolished in COX-2 nulls (both regions). These findings therefore collectively suggest that AVP-mediated elevations in STC-1 gene expression are wholly dependent on functional COX-2 activity. As such, a permissive role for STC-1 in AVP-mediated antidiuresis can be ruled out, and its range of possible actions has been narrowed down to AVP counter-regulation and renal cytoprotection. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Law, Alice Y.; Wagner, Graham F.] Univ Western Ontario, Schulich Sch Med & Dent, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada.
[Law, Alice Y.; Wong, Chris K. C.] Hong Kong Baptist Univ, Dept Biol, Kowloon Tong, Hong Kong, Peoples R China.
[Langenbach, Robert] NIEHS, Lab Toxicol & Pharmacol, Res Triangle Pk, NC 27709 USA.
[Hebert, Richard L.; Nasrallah, Rania] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada.
RP Wagner, GF (reprint author), Univ Western Ontario, Schulich Sch Med & Dent, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada.
EM graham.wagner@schulich.uwo.ca
FU Kidney Foundation of Canada; Division of Intramural Research of the
National Institute of Environmental Health Sciences (NIEHS) at the
National Institutes of Health (NIH)
FX Grant support from The Kidney Foundation of Canada to G.F.W. and R.L.H.,
and from The Division of Intramural Research of the National Institute
of Environmental Health Sciences (NIEHS) at the National Institutes of
Health (NIH) to R.L. is gratefully appreciated.
NR 42
TC 0
Z9 0
U1 0
U2 15
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0303-7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD DEC 5
PY 2013
VL 381
IS 1-2
BP 210
EP 219
DI 10.1016/j.mce.2013.07.008
PG 10
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA 260AU
UT WOS:000327568200023
PM 23877023
ER
PT J
AU Roederer, M
AF Roederer, Mario
TI Leonard Herzenberg (1931-2013) OBITUARY
SO NATURE
LA English
DT Biographical-Item
C1 [Roederer, Mario] US Natl Inst Allergy & Infect Dis, ImmunoTechnol Sect, Vaccine Res Ctr, Bethesda, MD USA.
RP Roederer, M (reprint author), US Natl Inst Allergy & Infect Dis, ImmunoTechnol Sect, Vaccine Res Ctr, Bethesda, MD USA.
EM roederer@nih.gov
NR 1
TC 1
Z9 1
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD DEC 5
PY 2013
VL 504
IS 7478
BP 34
EP 34
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 264BK
UT WOS:000327851700021
PM 24305144
ER
PT J
AU Kruse, AC
Ring, AM
Manglik, A
Hu, JX
Hu, K
Eitel, K
Hubner, H
Pardon, E
Valant, C
Sexton, PM
Christopoulos, A
Felder, CC
Gmeiner, P
Steyaert, J
Weis, WI
Garcia, KC
Wess, J
Kobilka, BK
AF Kruse, Andrew C.
Ring, Aaron M.
Manglik, Aashish
Hu, Jianxin
Hu, Kelly
Eitel, Katrin
Huebner, Harald
Pardon, Els
Valant, Celine
Sexton, Patrick M.
Christopoulos, Arthur
Felder, Christian C.
Gmeiner, Peter
Steyaert, Jan
Weis, William I.
Garcia, K. Christopher
Wess, Juergen
Kobilka, Brian K.
TI Activation and allosteric modulation of a muscarinic acetylcholine
receptor
SO NATURE
LA English
DT Article
ID PROTEIN-COUPLED RECEPTOR; SITE-DIRECTED MUTAGENESIS; BINDING-SITE;
BETA(2)-ADRENERGIC RECEPTOR; CRYSTAL-STRUCTURE; STRUCTURAL BASIS;
AMINO-ACIDS; IDENTIFICATION; NANOBODY; LIGANDS
AB Despite recent advances in crystallography and the availability of G-protein-coupled receptor (GPCR) structures, little is known about the mechanism of their activation process, as only the beta(2) adrenergic receptor (beta(2)AR) and rhodopsin have been crystallized in fully active conformations. Here we report the structure of an agonist-bound, active state of the human M2 muscarinic acetylcholine receptor stabilized by a G-protein mimetic camelid antibody fragment isolated by conformational selection using yeast surface display. In addition to the expected changes in the intracellular surface, the structure reveals larger conformational changes in the extracellular region and orthosteric binding site than observed in the active states of the beta(2)AR and rhodopsin. We also report the structure of the M2 receptor simultaneously bound to the orthosteric agonist iperoxo and the positive allosteric modulator LY2119620. This structure reveals that LY2119620 recognizes a largely pre-formed binding site in the extracellular vestibule of the iperoxo-bound receptor, inducing a slight contraction of this outer binding pocket. These structures offer important insights into the activation mechanism and allosteric modulation of muscarinic receptors.
C1 [Kruse, Andrew C.; Ring, Aaron M.; Manglik, Aashish; Weis, William I.; Garcia, K. Christopher; Kobilka, Brian K.] Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA.
[Ring, Aaron M.; Weis, William I.; Garcia, K. Christopher] Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.
[Hu, Jianxin; Hu, Kelly; Wess, Juergen] NIDDKD, Mol Signaling Sect, Bioorgan Chem Lab, Bethesda, MD 20892 USA.
[Eitel, Katrin; Huebner, Harald; Gmeiner, Peter] Univ Erlangen Nurnberg, Dept Chem & Pharm, D-91052 Erlangen, Germany.
[Pardon, Els; Steyaert, Jan] Vrije Univ Brussel, Struct Biol Brussels, B-1050 Brussels, Belgium.
[Pardon, Els; Steyaert, Jan] VIB, Struct Biol Res Ctr, B-1050 Brussels, Belgium.
[Valant, Celine; Sexton, Patrick M.; Christopoulos, Arthur] Monash Inst Pharmaceut Sci, Parkville, Vic 3052, Australia.
[Valant, Celine; Sexton, Patrick M.; Christopoulos, Arthur] Monash Univ, Dept Pharmacol, Parkville, Vic 3052, Australia.
[Felder, Christian C.] Eli Lilly & Co, Neurosci, Indianapolis, IN 46285 USA.
RP Kobilka, BK (reprint author), Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, 279 Campus Dr, Stanford, CA 94305 USA.
EM kobilka@stanford.edu
RI Christopoulos, Arthur/B-6207-2013; Weis, William/G-1437-2011; Steyaert,
Jan/H-4662-2011; Gmeiner, Peter/N-5275-2015; Sexton,
Patrick/B-1319-2008;
OI Christopoulos, Arthur/0000-0003-4442-3294; Weis,
William/0000-0002-5583-6150; Steyaert, Jan/0000-0002-3825-874X; Sexton,
Patrick/0000-0001-8902-2473; Valant, Celine/0000-0002-2509-7465
FU National Science Foundation [1223785]; Stanford Medical Scientist
Training Program; American Heart Association; Ruth L. Kirschstein
National Research Service Award; National Institutes of Health
[NS02847123, GM08311806]; Mathers Foundation; Deutsche
Forschungsgemeinschaft [GM 13/10-1]; National Health and Medical
Research Council (NHMRC) of Australia [519461]; NHMRC; Howard Hughes
Medical Institute; Intramural Research Program, NIDDK; NIH; US
Department of Health and Human Services
FX We acknowledge support from the National Science Foundation (graduate
fellowship to A. C. K., and Award 1223785 to B. K. K.), the Stanford
Medical Scientist Training Program (A. M. and A. M. R.), the American
Heart Association (A. M.), the Ruth L. Kirschstein National Research
Service Award (A. M. R.), National Institutes of Health grants
NS02847123 and GM08311806 (B. K. K.), the Mathers Foundation (B. K. K.,
W. I. W. and K. C. G.), the Deutsche Forschungsgemeinschaft for the
grant GM 13/10-1 (K. E., H. H., P. G.), the National Health and Medical
Research Council (NHMRC) of Australia program grant 519461 (P. M. S. and
A. C.), NHMRC Principal Research Fellowships (P. M. S. and A. C.), and
the Howard Hughes Medical Institute (K. C. G.). This work was supported
in part by the Intramural Research Program, NIDDK, NIH, US Department of
Health and Human Services (J.H., K. H. and J.W.). We thank K. Leach for
performing ERK assays, and B. Davie and P. Scammells for synthesis of
iperoxo. We thank H. Xiao, C. H. Croy and D. A. Schober for functional
characterization of LY2119620. We thank T. S. Kobilka for preparation of
affinity chromatography reagents and F. S. Thian for help with cell
culture.
NR 48
TC 233
Z9 236
U1 16
U2 116
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD DEC 5
PY 2013
VL 504
IS 7478
BP 101
EP +
DI 10.1038/nature12735
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 264BK
UT WOS:000327851700039
PM 24256733
ER
PT J
AU Ogawa, Y
Kim, SK
Dana, R
Clayton, J
Jain, S
Rosenblatt, MI
Perez, VL
Shikari, H
Riemens, A
Tsubota, K
AF Ogawa, Yoko
Kim, Stella K.
Dana, Reza
Clayton, Janine
Jain, Sandeep
Rosenblatt, Mark I.
Perez, Victor L.
Shikari, Hasanain
Riemens, Anjo
Tsubota, Kazuo
TI International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus
Group: Proposed Diagnostic Criteria for Chronic GVHD (Part I)
SO SCIENTIFIC REPORTS
LA English
DT Article
ID STEM-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; DRY EYE DISEASE;
MANIFESTATIONS; SEVERITY; SURFACE; COMPLICATIONS; DEFINITION;
DIFFERENCE; SCALES
AB The International Chronic Ocular GVHD Consensus Group held 4 working meetings to define new diagnostic metrics for chronic ocular graft-versus-host disease (GVHD). After considering the factors currently used to diagnose chronic ocular GVHD, the Consensus Group identified 4 subjective and objective variables to measure in patients following allogeneic hematopoietic stem cell transplantation (HSCT): OSDI, Schirmer's score without anesthesia, corneal staining, and conjunctival injection. Each variable was scored 0-2 or 0-3, with a maximum composite score of 11. Consideration was also given to the presence or the absence of systemic GVHD. On the basis of their composite score and the presence or absence of systemic GVHD, patients were assigned to one of three diagnostic categories: NO, PROBABLE, or DEFINITE ocular GVHD. New diagnostic criteria for chronic ocular GVHD are presented by the Consensus Group. Validation studies are needed to identify the best combination of the proposed metrics to maximize diagnostic sensitivity and specificity.
C1 [Ogawa, Yoko; Tsubota, Kazuo] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
[Kim, Stella K.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Dana, Reza; Shikari, Hasanain] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Clayton, Janine] NIH, Bethesda, MD 20892 USA.
[Jain, Sandeep] Univ Illinois, Corneal Neurobiol Lab, Chicago, IL USA.
[Rosenblatt, Mark I.] Weill Cornell Med Coll, New York, NY USA.
[Perez, Victor L.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
[Riemens, Anjo] Univ Med Ctr Utrecht, Utrecht, Netherlands.
RP Ogawa, Y (reprint author), Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
EM yoko@z7.keio.jp
FU Global Clinical Research Center Program for Keio University from
Japanese Ministry of Health, Labor, and Welfare
FX We thank Mizuka Kamoi, Miki Uchino, Yukako Tatematsu, Yumiko Ban, Saori
Yaguchi, Isami Hayashi and Catherine Oshima from Department of
Ophthalmology, Keio University, Japan; Samantha Herretes from Bascom
Palmer Eye Institute, Miami for supporting this collaborative study.
This work was supported by the grant for Global Clinical Research Center
Program for Keio University from Japanese Ministry of Health, Labor, and
Welfare 2011.
NR 49
TC 25
Z9 25
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 5
PY 2013
VL 3
AR 3419
DI 10.1038/srep03419
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 264MB
UT WOS:000327880600001
PM 24305504
ER
PT J
AU Civini, S
Jin, P
Ren, JQ
Sabatino, M
Castiello, L
Jin, JJ
Wang, H
Zhao, YL
Marincola, F
Stroncek, D
AF Civini, Sara
Jin, Ping
Ren, Jiaqiang
Sabatino, Marianna
Castiello, Luciano
Jin, Jianjian
Wang, Huan
Zhao, Yuanlong
Marincola, Francesco
Stroncek, David
TI Leukemia cells induce changes in human bone marrow stromal cells
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Bone marrow stromal cells (BMSCs); Leukemia; Tumor microenvironment;
Hematopoietic niche
ID ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; CHRONIC
LYMPHOCYTIC-LEUKEMIA; THERAPY POSITION STATEMENT; PROGENITOR CELLS;
INTERNATIONAL-SOCIETY; KINASE INHIBITORS; UP-REGULATION; IN-VITRO; AML
AB Background: Bone marrow stromal cells (BMSCs) are multipotent cells that support angiogenesis, wound healing, and immunomodulation. In the hematopoietic niche, they nurture hematopoietic cells, leukemia, tumors and metastasis. BMSCs secrete of a wide range of cytokines, growth factors and matrix proteins which contribute to the pro-tumorigenic marrow microenvironment. The inflammatory cytokines IFN-gamma and TNF-alpha change the BMSC secretome and we hypothesized that factors produced by tumors or leukemia would also affect the BMSC secretome and investigated the interaction of leukemia cells with BMSCs.
Methods: BMSCs from healthy subjects were co-cultured with three myeloid leukemia cell lines (TF-1, TF-1 alpha and K562) using a trans-well system. Following co-culture, the BMSCs and leukemia cells were analyzed by global gene expression analysis and culture supernatants were analyzed for protein expression. As a control, CD34+ cells were also cocultured with BMSCs.
Results: Co-culture induced leukemia cell gene expression changes in stem cell pluripotency, TGF-beta signaling and carcinoma signaling pathways. BMSCs co-cultured with leukemia cells up-regulated a number of proinflammatory genes including IL-17 signaling-related genes and IL-8 and CCL2 levels were increased in co-culture supernatants. In contrast, purine metabolism, mTOR signaling and EIF2 signaling pathways genes were up-regulated in BMSCs co-cultured with CD34+ cells.
Conclusions: BMSCs react to the presence of leukemia cells undergoing changes in the cytokine and chemokine secretion profiles. Thus, BMSCs and leukemia cells both contribute to the creation of a competitive niche more favorable for leukemia stem cells.
C1 [Civini, Sara; Jin, Ping; Ren, Jiaqiang; Sabatino, Marianna; Castiello, Luciano; Jin, Jianjian; Wang, Huan; Zhao, Yuanlong; Stroncek, David] NIH, Ctr Clin, Dept Transfus Med, Cell Proc Sect, Bethesda, MD 20892 USA.
[Marincola, Francesco] NIH, Ctr Clin, Dept Transfus Med, IDIS, Bethesda, MD 20892 USA.
[Marincola, Francesco] Sidra Med & Res Ctr, Doha, Qatar.
RP Stroncek, D (reprint author), NIH, Ctr Clin, Dept Transfus Med, Cell Proc Sect, Bldg 10,Room 3C720,9000 Rockville Pike, Bethesda, MD 20892 USA.
EM DStroncek@cc.nih.gov
RI Castiello, Luciano/K-8616-2016
OI Castiello, Luciano/0000-0001-7146-3158
FU Department of Transfusion Medicine, Clinical Center, NIH
FX The authors thank the Bone Marrow Stromal Cell Transplant Center, NIH
for providing the BMSCs and Jeff Miller MD, NIDDK, NIH, Bethesda,
Maryland for supplying the CD34+ cells. These studies were
supported by research funds provided the Department of Transfusion
Medicine, Clinical Center, NIH.
NR 53
TC 18
Z9 18
U1 1
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD DEC 4
PY 2013
VL 11
AR 298
DI 10.1186/1479-5876-11-298
PG 14
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 285OF
UT WOS:000329402600001
PM 24304929
ER
PT J
AU Herskowitz, JH
Feng, YB
Mattheyses, AL
Hales, CM
Higginbotham, LA
Duong, DM
Montine, TJ
Troncoso, JC
Thambisetty, M
Seyfried, NT
Levey, AI
Lah, JJ
AF Herskowitz, Jeremy H.
Feng, Yangbo
Mattheyses, Alexa L.
Hales, Chadwick M.
Higginbotham, Lenora A.
Duong, Duc M.
Montine, Thomas J.
Troncoso, Juan C.
Thambisetty, Madhav
Seyfried, Nicholas T.
Levey, Allan I.
Lah, James J.
TI Pharmacologic Inhibition of ROCK2 Suppresses Amyloid-beta Production in
an Alzheimer's Disease Mouse Model
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID PRECURSOR PROTEIN APP; RHO-KINASE; PHOSPHORYLATION; MUTATION; CELLS;
SELECTIVITY; MICROSCOPY; PATHWAY; ENZYME; BACE1
AB Alzheimer's disease (AD) is the leading cause of dementia and has no cure. Genetic, cell biological, and biochemical studies suggest that reducing amyloid-beta (A beta) production may serve as a rational therapeutic avenue to delay or preventADprogression. Inhibition of RhoA, a Rho GTPase family member, is proposed to curb A beta production. However, a barrier to this hypothesis has been the limited understanding of how the principal downstream effectors of RhoA, Rho-associated, coiled-coil containing protein kinase (ROCK) 1 and ROCK2, modulate A beta generation. Here, we report that ROCK1 knockdown increased endogenous human A beta production, whereas ROCK2 knockdown decreased A beta levels. Inhibition of ROCK2 kinase activity, using an isoform-selective small molecule (SR3677), suppressed beta-site APP cleaving enzyme 1 (BACE1) enzymatic action and diminished production of A beta in AD mouse brain. Immunofluorescence and confocal microscopy analyses revealed that SR3677 alters BACE1 endocytic distribution and promotes amyloid precursor protein (APP) traffic to lysosomes. Moreover, SR3677 blocked ROCK2 phosphorylation of APP at threonine 654 (T654); in neurons, T654 was critical for APP processing to A beta. These observations suggest that ROCK2 inhibition reduces A beta levels through independent mechanisms. Finally, ROCK2 protein levels were increased in asymptomatic AD, mild cognitive impairment, and AD brains, demonstrating that ROCK2 levels change in the earliest stages of AD and remain elevated throughout disease progression. Collectively, these findings highlight ROCK2 as a mechanism-based therapeutic target to combat A beta production in AD.
C1 [Herskowitz, Jeremy H.; Hales, Chadwick M.; Higginbotham, Lenora A.; Seyfried, Nicholas T.; Levey, Allan I.; Lah, James J.] Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA.
[Herskowitz, Jeremy H.; Hales, Chadwick M.; Higginbotham, Lenora A.; Levey, Allan I.; Lah, James J.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
[Mattheyses, Alexa L.] Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA.
[Duong, Duc M.; Seyfried, Nicholas T.] Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.
[Feng, Yangbo] Scripps Res Inst, Translat Res Inst, Jupiter, FL 33458 USA.
[Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98104 USA.
[Troncoso, Juan C.] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
[Troncoso, Juan C.] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
[Thambisetty, Madhav] NIA, Unit Clin & Translat Neurosci, Baltimore, MD 21224 USA.
[Thambisetty, Madhav] NIA, Lab Behav Neurosci, Baltimore, MD 21224 USA.
RP Lah, JJ (reprint author), Ctr Neurodegenerat Dis, 615 Michael St,Suite 505, Atlanta, GA 30322 USA.
EM jlah@emory.edu
FU National Institutes of Health through National Institute on Aging (NIA)
[5K99AG043552-02]; National Institute of Neurological Disorders and
Stroke (NINDS) [P30NS055077]; NIA [AG025688, P01AG1449, AG05136]; NIA
Intramural Research Program of the National Institutes of Health; Johns
Hopkins University Alzheimer's Disease Research Center [NIAAG05146];
Alzheimer's Association [IIRG-09-134090, NIRG-12-242297]; Emory
University Integrated Cellular Imaging Microscopy Core of the Emory
Neuroscience NINDS Core Facilities grant
FX This work was supported by the National Institutes of Health through
National Institute on Aging (NIA) Grant 5K99AG043552-02 to J.H.H.,
National Institute of Neurological Disorders and Stroke (NINDS) Grant
P30NS055077, and NIA Grants AG025688, P01AG1449, and AG05136. This work
was supported in part by the NIA Intramural Research Program of the
National Institutes of Health. J.C.T. was supported by grants from the
Johns Hopkins University Alzheimer's Disease Research Center
(NIAAG05146) and the Alzheimer's Association (IIRG-09-134090). N.T.S. is
supported by Alzheimer's Association Grant NIRG-12-242297. We thank the
donors of ADR, a program of the BrightFocus Foundation, for support of
this research. This research project was supported in part by the Emory
University Integrated Cellular Imaging Microscopy Core of the Emory
Neuroscience NINDS Core Facilities grant. We thank Dr. Ranjita Betarbet
and Craig Heilman for technical assistance.
NR 46
TC 28
Z9 29
U1 2
U2 16
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD DEC 4
PY 2013
VL 33
IS 49
BP 19086
EP 19098
DI 10.1523/JNEUROSCI.2508-13.2013
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA 267PO
UT WOS:000328110100006
PM 24305806
ER
PT J
AU Won, YJ
Lu, VB
Puhl, HL
Ikeda, SR
AF Won, Yu-Jin
Lu, Van B.
Puhl, Henry L., III
Ikeda, Stephen R.
TI beta-Hydroxybutyrate Modulates N-Type Calcium Channels in Rat
Sympathetic Neurons by Acting as an Agonist for the G-Protein-Coupled
Receptor FFA3
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID CHAIN FATTY-ACIDS; MAJOR PELVIC GANGLION; VOLTAGE-DEPENDENT MODULATION;
NERVOUS-SYSTEM; NICOTINIC-ACID; GUT MICROBIOTA; CA2+ CHANNELS; HUMAN
COLON; PUMA-G; GPR41
AB Free fatty acids receptor 3 (FFA3, GPR41) and 2 (FFA2, GPR43), for which the short-chain fatty acids (SCFAs) acetate and propionate are agonist, have emerged as important G-protein-coupled receptors influenced by diet and gut flora composition. Arecent study (Kimura et al., 2011) demonstrated functional expression of FFA3 in the rodent sympathetic nervous system (SNS) providing a potential link between nutritional status and autonomic function. However, little is known of the source of endogenous ligands, signaling pathways, or effectors in sympathetic neurons. In this study, we found that FFA3 and FFA2 are unevenly expressed in the rat SNS with higher transcript levels in prevertebral (e. g., celiac-superior mesenteric and major pelvic) versus paravertebral (e. g., superior cervical and stellate) ganglia. FFA3, whether heterologously or natively expressed, coupled via PTX-sensitive G-proteins to produce voltage-dependent inhibition of N-type Ca2+ channels (Ca(v)2.2) in sympathetic neurons. In addition to acetate and propionate, we show that beta-hydroxybutyrate (BHB), a metabolite produced during ketogenic conditions, is also an FFA3 agonist. This contrasts with previous interpretations of BHB as an antagonist at FFA3. Together, these results indicate that endogenous BHB levels, especially when elevated under certain conditions, such as starvation, diabetic ketoacidosis, and ketogenic diets, play a potentially important role in regulating the activity of the SNS through FFA3.
C1 [Won, Yu-Jin; Lu, Van B.; Puhl, Henry L., III; Ikeda, Stephen R.] NIAAA, Sect Transmitter Signaling, Lab Mol Physiol, NIH, Bethesda, MD 20892 USA.
RP Ikeda, SR (reprint author), NIAAA, Lab Mol Physiol, NIH, 5625 Fishers Lane,Room TS 11, Rockville, MD 20852 USA.
EM sikeda@mail.nih.gov
OI Ikeda, Stephen/0000-0002-4088-9508; Lu, Van/0000-0002-4880-6455; Puhl,
Henry/0000-0003-3095-7201
FU intramural program at the National Institutes of Health, National
Institute on Alcohol Abuse and Alcoholism
FX This work was supported by the intramural program at the National
Institutes of Health, National Institute on Alcohol Abuse and
Alcoholism.
NR 46
TC 27
Z9 28
U1 4
U2 34
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD DEC 4
PY 2013
VL 33
IS 49
BP 19314
EP 19325
DI 10.1523/JNEUROSCI.3102-13.2013
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 267PO
UT WOS:000328110100027
PM 24305827
ER
PT J
AU Myerburg, RJ
Halperin, H
Egan, DA
Boineau, R
Chugh, SS
Gillis, AM
Goldhaber, JI
Lathrop, DA
Liu, P
Niemann, JT
Ornato, JP
Sopko, G
Van Eyk, JE
Walcott, GP
Weisfeldt, ML
Wright, JD
Zipes, DP
AF Myerburg, Robert J.
Halperin, Henry
Egan, Debra A.
Boineau, Robin
Chugh, Sumeet S.
Gillis, Anne M.
Goldhaber, Joshua I.
Lathrop, David A.
Liu, Peter
Niemann, James T.
Ornato, Joseph P.
Sopko, George
Van Eyk, Jennifer E.
Walcott, Gregory P.
Weisfeldt, Myron L.
Wright, Jacqueline D.
Zipes, Douglas P.
TI Pulseless Electric Activity Definition, Causes, Mechanisms, Management,
and Research Priorities for the Next Decade: Report From a National
Heart, Lung, and Blood Institute Workshop
SO CIRCULATION
LA English
DT Article
DE arrhythmias; cardiac; death; sudden; cardiac; heart arrest
ID HOSPITAL CARDIAC-ARREST; SUDDEN UNEXPECTED DEATH; IMPLANTABLE
CARDIOVERTER-DEFIBRILLATORS; EMERGENCY CARDIOVASCULAR CARE; CORONARY
PERFUSION-PRESSURE; ACUTE MYOCARDIAL-INFARCTION; CHEST COMPRESSION
DEVICE; VENTRICULAR-FIBRILLATION; CARDIOPULMONARY-RESUSCITATION;
ELECTROMECHANICAL DISSOCIATION
C1 Univ Miami Miller Sch Med, Miami, FL USA.
[Myerburg, Robert J.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
[Halperin, Henry; Van Eyk, Jennifer E.; Weisfeldt, Myron L.] Johns Hopkins Med Inst, Baltimore, MD USA.
[Egan, Debra A.; Boineau, Robin; Lathrop, David A.; Sopko, George; Wright, Jacqueline D.] NHLBI, NIH, Bethesda, MD 20892 USA.
[Chugh, Sumeet S.; Goldhaber, Joshua I.] Cedars Sinai Heart Inst, Los Angeles, CA USA.
[Gillis, Anne M.] Univ Calgary, Calgary, AB, Canada.
[Liu, Peter] Univ Toronto, Toronto, ON, Canada.
[Niemann, James T.] Univ Calif Los Angeles, Harbor Med Ctr, Torrance, CA 90509 USA.
[Ornato, Joseph P.] Virginia Commonwealth Univ, Med Ctr, Richmond, VA 23284 USA.
[Walcott, Gregory P.] Univ Alabama Birmingham, Birmingham, AL USA.
[Zipes, Douglas P.] Krannert Cardiovasc Res Inst, Indianapolis, IN USA.
RP Myerburg, RJ (reprint author), Jackson Mem Hosp, Div Cardiol, Cent Bldg,Room C-401,1611 NW 12th Ave, Miami, FL 33136 USA.
EM rmyerbur@med.miami.edu
FU Zoll Circulation, Inc.; Medtronic, Inc.; Physio-Control, Inc.
FX Dr Halperin receives consultant fees and grant support from Zoll
Circulation, Inc. Dr Gillis receives research support from Medtronic,
Inc. Dr Walcott receives research support from Physio-Control, Inc. The
remaining authors report no conflicts.
NR 80
TC 31
Z9 32
U1 1
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD DEC 3
PY 2013
VL 128
IS 23
BP 2532
EP 2541
DI 10.1161/CIRCULATIONAHA.113.004490
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 262HD
UT WOS:000327724000016
PM 24297818
ER
PT J
AU Vandeput, F
Szabo-Fresnais, N
Ahmad, F
Kho, C
Lee, A
Krall, J
Dunlop, A
Hazel, MW
Wohlschlegel, JA
Hajjar, RJ
Houslay, MD
Manganiello, VC
Movsesian, MA
AF Vandeput, Fabrice
Szabo-Fresnais, Nicolas
Ahmad, Faiyaz
Kho, Changwon
Lee, Ahyoung
Krall, Judith
Dunlop, Allan
Hazel, Mark W.
Wohlschlegel, James A.
Hajjar, Roger J.
Houslay, Miles D.
Manganiello, Vincent C.
Movsesian, Matthew A.
TI Selective regulation of cyclic nucleotide phosphodiesterase PDE3A
isoforms
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE cAMP; protein-protein interactions
ID PROTEIN-KINASE-A; CAMP EARLY REPRESSOR; MEDIATED PHOSPHORYLATION;
CARDIOMYOCYTE APOPTOSIS; HYDROLYTIC ACTIVITY; CARDIAC MYOCYTES;
HUMAN-PLATELETS; ACTIVATION; HEART; 3B
AB Inhibitors of cyclic nucleotide phosphodiesterase (PDE) PDE3A have inotropic actions in human myocardium, but their long-term use increases mortality in patients with heart failure. Two isoforms in cardiac myocytes, PDE3A1 and PDE3A2, have identical amino acid sequences except for a unique N-terminal extension in PDE3A1. We expressed FLAG-tagged PDE3A1 and PDE3A2 in HEK293 cells and examined their regulation by PKA- and PKC-mediated phosphorylation. PDE3A1, which is localized to intracellular membranes, and PDE3A2, which is cytosolic, were phosphorylated at different sites within their common sequence. Exposure to isoproterenol led to phosphorylation of PDE3A1 at the 14-3-3-binding site S312, whereas exposure to PMA led to phosphorylation of PDE3A2 at an alternative 14-3-3-binding site, S428. PDE3A2 activity was stimulated by phosphorylation at S428, whereas PDE3A1 activity was not affected by phosphorylation at either site. Phosphorylation of PDE3A1 by PKA and of PDE3A2 by PKC led to shifts in elution on gel-filtration chromatography consistent with increased interactions with other proteins, and 2D electrophoresis of coimmuno-precipitated proteins revealed that the two isoforms have distinct protein interactomes. A similar pattern of differential phosphorylation of endogenous PDE3A1 and PDE3A2 at S312 and S428 is observed in human myocardium. The selective phosphorylation of PDE3A1 and PDE3A2 at alternative sites through different signaling pathways, along with the different functional consequences of phosphorylation for each isoform, suggest they are likely to have distinct roles in cyclic nucleotide-mediated signaling in human myocardium, and raise the possibility that isoform-selective inhibition may allow inotropic responses without an increase in mortality.
C1 [Vandeput, Fabrice; Szabo-Fresnais, Nicolas; Krall, Judith; Hazel, Mark W.; Movsesian, Matthew A.] VA Salt Lake City Hlth Care Syst, Cardiol Sect, Salt Lake City, UT USA.
[Vandeput, Fabrice; Szabo-Fresnais, Nicolas; Krall, Judith; Hazel, Mark W.; Movsesian, Matthew A.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84148 USA.
[Vandeput, Fabrice; Szabo-Fresnais, Nicolas; Krall, Judith; Hazel, Mark W.; Movsesian, Matthew A.] Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT 84148 USA.
[Ahmad, Faiyaz; Manganiello, Vincent C.] NHLBI, Cardiovasc Pulm Branch, NIH, Bethesda, MD 20892 USA.
[Kho, Changwon; Lee, Ahyoung; Hajjar, Roger J.] Mt Sinai Sch Med, Cardiovasc Res Ctr, New York, NY 10029 USA.
[Dunlop, Allan] Univ Glasgow, Mol Pharmacol Grp, Inst Psychol & Neurosci, Glasgow G128QQ, Lanark, Scotland.
[Wohlschlegel, James A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.
[Houslay, Miles D.] Kings Coll London, Inst Pharmaceut Sci Biomed Sci, London SE1 9NH, England.
RP Movsesian, MA (reprint author), VA Salt Lake City Hlth Care Syst, Cardiol Sect, Salt Lake City, UT USA.
EM matthew.movsesian@hsc.utah.edu
OI Houslay, Miles/0000-0002-3826-8091
FU US Department of Veterans Affairs [CARA-029-09F, CARA-027-12S]; American
Heart Association; National Institutes of Health [R01 HL093183,
HL088434, P20 HL100396]; National Institutes of Health (National Heart,
Lung, and Blood Institute) [HHSN268201000045C, P50 HL112324, GM089778];
UK Medical Research Council; Fondation Leducq [06CVD02, 13CVD01]
FX We thank Susan Taylor for her gift of the catalytic subunit of PKA. This
work was supported by research grants from the US Department of Veterans
Affairs (Merit Review CARA-029-09F and CARA-027-12S, to M. A. M.), the
American Heart Association (M. A. M.), the National Institutes of Health
(Grants R01 HL093183, HL088434, and P20 HL100396; a National Heart,
Lung, and Blood Institute Program of Excellence in Nanotechnology Award;
Contract HHSN268201000045C; Grant P50 HL112324, to R.J.H., and Grant
GM089778, to J.A.W.), the UK Medical Research Council (M. D. H.), and
the Fondation Leducq (06CVD02, to M. A. M. and M. D. H.; 13CVD01, to
R.J.H.).
NR 32
TC 9
Z9 9
U1 1
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 3
PY 2013
VL 110
IS 49
BP 19778
EP 19783
DI 10.1073/pnas.1305427110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 262OJ
UT WOS:000327744900038
PM 24248367
ER
PT J
AU Gopich, IV
Szabo, A
AF Gopich, Irina V.
Szabo, Attila
TI Diffusion modifies the connectivity of kinetic schemes for multisite
binding and catalysis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE multisite phosphorylation; escape and capture probabilities; splitting
probability; diffusion-influenced rate constants; ultrasensitivity
ID ERK MAP KINASE; PROCESSIVE PHOSPHORYLATION; PROTEIN-KINASE; ENZYME
AB The simplest way to describe the influence of the relative diffusion of the reactants on the time course of bimolecular reactions is to modify or renormalize the phenomenological rate constants that enter into the rate equations of conventional chemical kinetics. However, for macromolecules with multiple inequivalent reactive sites, this is no longer sufficient, even in the low concentration limit. The physical reason is that an enzyme (or a ligand) that has just modified (or dissociated from) one site can bind to a neighboring site rather than diffuse away. This process is not described by the conventional chemical kinetics, which is only valid in the limit that diffusion is fast compared with reaction. Using an exactly solvable many-particle reaction-diffusion model, we show that the influence of diffusion on the kinetics of multisite binding and catalysis can be accounted for by not only scaling the rates, but also by introducing new connections into the kinetic scheme. The rate constants that describe these new transitions or reaction channels turn out to have a transparent physical interpretation: The chemical rates are scaled by the appropriate probabilities that a pair of reactants, which are initially in contact, bind rather than diffuse apart. The theory is illustrated by application to phosphorylation of a multisite substrate.
C1 [Gopich, Irina V.; Szabo, Attila] NIDDK, NIH, Chem Phys Lab, Bethesda, MD 20892 USA.
RP Gopich, IV (reprint author), NIDDK, NIH, Chem Phys Lab, Bethesda, MD 20892 USA.
EM irinag@niddk.nih.gov; attilas@nih.gov
RI Szabo, Attila/H-3867-2012
FU National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health
FX We thank A. M. Berezhkovskii, H. Qian, S. Y. Shvartsman, and P. R. ten
Wolde for their helpful comments and A. R. Panchenko for numerous
discussions and stimulating our interest in this problem. This work was
supported by the Intramural Research Program of the National Institute
of Diabetes and Digestive and Kidney Diseases, National Institutes of
Health.
NR 19
TC 9
Z9 9
U1 0
U2 23
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 3
PY 2013
VL 110
IS 49
BP 19784
EP 19789
DI 10.1073/pnas.1319943110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 262OJ
UT WOS:000327744900039
PM 24248348
ER
PT J
AU Nelson, AC
Cauceglia, JW
Merkley, SD
Youngson, NA
Oler, AJ
Nelson, RJ
Cairns, BR
Whitelaw, E
Potts, WK
AF Nelson, Adam C.
Cauceglia, Joseph W.
Merkley, Seth D.
Youngson, Neil A.
Oler, Andrew J.
Nelson, Randy J.
Cairns, Bradley R.
Whitelaw, Emma
Potts, Wayne K.
TI Reintroducing domesticated wild mice to sociality induces adaptive
transgenerational effects on MUP expression
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE social selection; sexy sons; epigenetics
ID MAJOR URINARY PROTEINS; IN-HOUSE MICE; INDIVIDUAL-RECOGNITION;
AGGRESSIVE-BEHAVIOR; MUSCULUS-DOMESTICUS; GENETIC ADAPTATION; MOUSE;
LIVER; METHYLATION; EVOLUTION
AB When brought into captivity, wild animals can adapt to domestication within 10 generations. Such adaptations may decrease fitness in natural conditions. Many selective pressures are disrupted in captivity, including social behavioral networks. Although lack of sociality in captivity appears to mediate domestication, the underlying mechanisms are not well understood. Additionally, determining the contribution of genetic inheritance vs. transgenerational effects during relaxed selection may provide insight into the flexibility of adaptation. When wild-derived mice kept under laboratory conditions for eight generations were reintroduced to sociality and promiscuity (free mate choice), they adapted within two generations. Fitness assessments between this promiscuous lineage and a monogamous laboratory lineage revealed male-specific effects. Promiscuous-line males had deficits in viability, but a striking advantage in attracting mates, and their scent marks were also more attractive to females. Here, we investigate mechanistic details underlying this olfactory signal and identify a role of major urinary protein (MUP) pheromones. Promiscuous-line males inherit higher MUP expression than monogamous-line males through transgenerational inheritance. Sociality-driven maternal and paternal effects reveal intriguing conflicts among parents and offspring over pheromone expression. MUP up-regulation is not driven by hormone-driven transduction pathways, but rather is associated with reduction in DNA methylation of a CpG dinucleotide in the promoter. This reduction in methylation could enhance transcription by promoting the binding of transcription factor USF1 (upstream stimulatory factor 1). Finally, we experimentally demonstrate that increased MUP expression is a female attractant. These results identify molecular mechanisms guiding domestication and adaptive responses to fluctuating sociality.
C1 [Nelson, Adam C.; Cauceglia, Joseph W.; Merkley, Seth D.; Potts, Wayne K.] Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.
[Youngson, Neil A.] Univ New S Wales, Sch Med Sci, Sydney, NSW 2052, Australia.
[Oler, Andrew J.] NIAID, Bioinformat & Computat Biosci Branch, Off Cyber Infrastruct & Computat Biol, NIH, Bethesda, MD 20892 USA.
[Nelson, Randy J.] Ohio State Univ, Wexner Med Ctr, Dept Neurosci, Columbus, OH 43210 USA.
[Oler, Andrew J.; Cairns, Bradley R.] Univ Utah, Sch Med, Dept Oncol Sci, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Whitelaw, Emma] La Trobe Inst Mol Sci, Dept Genet, Sch Mol Sci, Melbourne, Vic 3086, Australia.
RP Nelson, AC (reprint author), Harvard Univ, Cambridge, MA 02138 USA.
EM adamnelson@fas.harvard.edu
OI Cauceglia, Joseph/0000-0001-9384-9254; Potts, Wayne/0000-0003-4137-0326
FU National Science Foundation [0909801, 0914244, 0918969]; National
Institutes of Health [R01-GM039578, R01-GM109500]
FX We thank John Sampinos, Christine Sembrano, Linda Morrison, and Jon Gale
for help with experiments. We also thank Catherine Dulac for support.
This work was funded by National Science Foundation Grants 0909801 (to
A.C.N.), 0914244 (to A.C.N.), and 0918969 (to W. K. P.), and by National
Institutes of Health Genetics Training Grant T32 (to A.C.N.) and
R01-GM039578 and R01-GM109500 (to W.K.P.).
NR 54
TC 18
Z9 18
U1 2
U2 26
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 3
PY 2013
VL 110
IS 49
BP 19848
EP 19853
DI 10.1073/pnas.1310427110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 262OJ
UT WOS:000327744900050
PM 24248373
ER
PT J
AU Chen, AC
Oathes, DJ
Chang, C
Bradley, T
Zhou, ZW
Williams, LM
Glover, GH
Deisseroth, K
Etkin, A
AF Chen, Ashley C.
Oathes, Desmond J.
Chang, Catie
Bradley, Travis
Zhou, Zheng-Wei
Williams, Leanne M.
Glover, Gary H.
Deisseroth, Karl
Etkin, Amit
TI Causal interactions between fronto-parietal central executive and
default-mode networks in humans
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE task positive network; task negative network; fMRI; neuromodulation
ID TRANSCRANIAL MAGNETIC STIMULATION; ANTERIOR CINGULATE CORTEX; FUNCTIONAL
CONNECTIVITY; BRAIN NETWORKS; PSYCHOPHYSIOLOGICAL INTERACTIONS;
PREFRONTAL CORTEX; BOLD-FMRI; DEPRESSION; EXCITABILITY; RTMS
AB Information processing during human cognitive and emotional operations is thought to involve the dynamic interplay of several large-scale neural networks, including the fronto-parietal central executive network (CEN), cingulo-opercular salience network (SN), and the medial prefrontal-medial parietal default mode networks (DMN). It has been theorized that there is a causal neural mechanism by which the CEN/SN negatively regulate the DMN. Support for this idea has come from correlational neuroimaging studies; however, direct evidence for this neural mechanism is lacking. Here we undertook a direct test of this mechanism by combining transcranial magnetic stimulation (TMS) with functional MRI to causally excite or inhibit TMS-accessible prefrontal nodes within the CEN or SN and determine consequent effects on the DMN. Single-pulse excitatory stimulations delivered to only the CEN node induced negative DMN connectivity with the CEN and SN, consistent with the CEN/SN's hypothesized negative regulation of the DMN. Conversely, low-frequency inhibitory repetitive TMS to the CEN node resulted in a shift of DMN signal fro\m its normally low-frequency range to a higher frequency, suggesting disinhibition of DMN activity. Moreover, the CEN node exhibited this causal regulatory relationship primarily with the medial prefrontal portion of the DMN. These findings significantly advance our understanding of the causal mechanisms by which major brain networks normally coordinate information processing. Given that poorly regulated information processing is a hallmark of most neuropsychiatric disorders, these findings provide a foundation for ways to study network dysregulation and develop brain stimulation treatments for these disorders.
C1 [Chen, Ashley C.; Oathes, Desmond J.; Bradley, Travis; Williams, Leanne M.; Deisseroth, Karl; Etkin, Amit] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
[Chang, Catie; Glover, Gary H.] Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA.
[Chang, Catie; Glover, Gary H.] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA.
[Deisseroth, Karl] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.
[Chen, Ashley C.; Oathes, Desmond J.; Williams, Leanne M.; Etkin, Amit] Vet Affairs Palo Alto Hlth Care Syst, Sierra Pacific Mental Illness Res Educ & Clin Ctr, Palo Alto, CA 94304 USA.
[Chang, Catie] NINDS, Adv MRI Sect, Lab Funct & Mol Imaging, NIH, Bethesda, MD 20892 USA.
[Zhou, Zheng-Wei] Tsinghua Univ, Dept Biomed Engn, Beijing 100084, Peoples R China.
[Deisseroth, Karl] Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA.
RP Deisseroth, K (reprint author), Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
EM deissero@stanford.edu; amitetkin@stanford.edu
RI Williams, Leanne/B-4095-2012;
OI Oathes, Desmond/0000-0001-7346-2669
FU National Institutes of Health (NIH) [P30 MH089888, R01 MH091860];
Sierra-Pacific Mental Illness Research Education and Clinical Center at
the Palo Alto Department of Veterans Affairs (VA); NIH, the Wiegers
Family Fund; Snyder Foundation; NIH [P41 EB015891]; War Related Illness
and Injury Study Center Special Fellowship Program at the VA Palo Alto;
Medical Research Service of the Department of Veterans Affairs, VA Palo
Alto
FX We thank Anett Gyurak, Alan Schatzberg, and Paul Hamilton for comments
on the manuscript. A.E. was supported by National Institutes of Health
(NIH) Grants P30 MH089888 and R01 MH091860, and the Sierra-Pacific
Mental Illness Research Education and Clinical Center at the Palo Alto
Department of Veterans Affairs (VA). K.D. was supported by the NIH, the
Wiegers Family Fund, and the Snyder Foundation. G.H.G. was supported by
NIH Grant P41 EB015891. D.J.O. was supported by the War Related Illness
and Injury Study Center Special Fellowship Program at the VA Palo Alto
and the Medical Research Service of the Department of Veterans Affairs,
VA Palo Alto.
NR 55
TC 82
Z9 82
U1 3
U2 51
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 3
PY 2013
VL 110
IS 49
BP 19944
EP 19949
DI 10.1073/pnas.1311772110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 262OJ
UT WOS:000327744900066
PM 24248372
ER
PT J
AU Burdick, RC
Hu, WS
Pathak, VK
AF Burdick, Ryan C.
Hu, Wei-Shau
Pathak, Vinay K.
TI Nuclear import of APOBEC3F-labeled HIV-1 preintegration complexes
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE retrovirus; microscopy; early events
ID IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE TRANSCRIPTION; DNA INTEGRATION;
CAPSID PROTEIN; IN-VIVO; INFECTION; REPLICATION; CELLS; RNA; APOBEC3G
AB Human cytidine deaminases APOBEC3F (A3F) and APOBEC3G (A3G) are host factors that incorporate into virions and restrict virus replication. We labeled HIV-1 particles with yellow fluorescent protein (YFP)-tagged APOBEC3 proteins and examined their association with preintegration complexes (PICs) in infected cells. Labeling of PICs with A3F-YFP, and to a lesser extent A3G-YFP, could be used to visualize PICs in the nuclei, which was dependent on nuclear pore protein Nup153 but not TNPO3. We show that reverse transcription is not required for nuclear import of PICs, indicating that a viral core uncoating event associated with reverse transcription, and the central DNA flap that forms during reverse transcription, are not required for nuclear import. We also quantify association of cytoplasmic PICs with nuclear envelope (NE) and report that capsid mutations that increase or decrease core stability dramatically reduce NE association and nuclear import of PICs. In addition, we find that nuclear PICs remain close to the NE and are not distributed throughout the nuclei. These results provide tools for tracking retroviral PICs in infected cells and reveal insights into HIV-1 replication.
C1 [Burdick, Ryan C.; Pathak, Vinay K.] NCI, Viral Mutat Sect, Ctr Canc Res, Frederick, MD 21702 USA.
[Hu, Wei-Shau] NCI, Viral Recombinat Sect, HIV Drug Resistance Program, Ctr Canc Res, Frederick, MD 21702 USA.
RP Pathak, VK (reprint author), NCI, Viral Mutat Sect, Ctr Canc Res, Frederick, MD 21702 USA.
EM vinay.pathak@nih.gov
FU National Institutes of Health, Center for Cancer Research, National
Cancer Institute
FX We thank Krista Delviks-Frankenberry and Maria Hamscher for construction
of CA mutants, Stephen Lockett and De Chen (Optical Microscopy and Image
Analysis Laboratory, Leidos Biomedical Research, Inc.) for use of the
Zeiss LSM710 confocal microscope and help with data analysis, Dan Larson
for providing Localize, and Sergey Plisov for help with data analysis.
This research was supported in part by the Intramural Research Program
of the National Institutes of Health, Center for Cancer Research,
National Cancer Institute.
NR 54
TC 17
Z9 17
U1 0
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 3
PY 2013
VL 110
IS 49
BP E4780
EP E4789
DI 10.1073/pnas.1315996110
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 262OJ
UT WOS:000327744900010
PM 24248339
ER
PT J
AU Larson, CL
Beare, PA
Howe, D
Heinzen, RA
AF Larson, Charles L.
Beare, Paul A.
Howe, Dale
Heinzen, Robert A.
TI Coxiella burnetii effector protein subverts clathrin-mediated vesicular
trafficking for pathogen vacuole biogenesis
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE type IV secretion; vesicular fusion
ID TRANS-GOLGI NETWORK; MHC CLASS-II; ADAPTER COMPLEX; SORTING SIGNALS;
HIV-1 NEF; LEGIONELLA-PNEUMOPHILA; MEMBRANE-TRANSPORT; DILEUCINE MOTIF;
DOWN-REGULATION; ENDOSOMES
AB Successful macrophage colonization by Coxiella burnetii, the cause of human Q fever, requires pathogen-directed biogenesis of a large, growth-permissive parasitophorous vacuole (PV) with phagolysosomal characteristics. The vesicular trafficking pathways co-opted by C. burnetii for PV development are poorly defined; however, it is predicted that effector proteins delivered to the cytosol by a defective in organelle trafficking/intracellular multiplication (Dot/Icm) type 4B secretion system are required for membrane recruitment. Here, we describe involvement of clathrin-mediated vesicular trafficking in PV generation and the engagement of this pathway by the C. burnetii type 4B secretion system substrate Coxiella vacuolar protein A (CvpA). CvpA contains multiple dileucine [DERQ]XXXL[LI] and tyrosine (YXX Phi)-based endocytic sorting motifs like those recognized by the clathrin adaptor protein (AP) complexes AP1, AP2, and AP3. A C. burnetii Delta cvpA mutant exhibited significant defects in replication and PV development, confirming the importance of CvpA in infection. Ectopically expressed mCherry-CvpA localized to tubular and vesicular domains of pericentrosomal recycling endosomes positive for Rab11 and transferrin receptor, and CvpA membrane interactions were lost upon mutation of endocytic sorting motifs. Consistent with CvpA engagement of the endocytic recycling system, ectopic expression reduced uptake of transferrin. In pull-down assays, peptides containing CvpA-sorting motifs and full-length CvpA interacted with AP2 subunits and clathrin heavy chain. Furthermore, depletion of AP2 or clathrin by siRNA treatment significantly inhibited C. burnetii replication. Thus, our results reveal the importance of clathrin-coated vesicle trafficking in C. burnetii infection and define a role for CvpA in subverting these transport mechanisms.
C1 [Larson, Charles L.; Beare, Paul A.; Howe, Dale; Heinzen, Robert A.] NIAID, Coxiella Pathogenesis Sect, Intracellular Parasites Lab, Rocky Mt Labs,NIH, Hamilton, MT 59840 USA.
RP Heinzen, RA (reprint author), NIAID, Coxiella Pathogenesis Sect, Intracellular Parasites Lab, Rocky Mt Labs,NIH, Hamilton, MT 59840 USA.
EM rheinzen@niaid.nih.gov
FU National Institutes of Health, National Institute of Allergy and
Infectious Disease
FX We thank Daniel E. Voth for technical contributions, Olivia
Steele-Mortimer for helpful suggestions, Austin Athman for graphics
support, and Jean Celli for critical review of this manuscript. This
work was supported by the Intramural Research Program of the National
Institutes of Health, National Institute of Allergy and Infectious
Disease.
NR 68
TC 28
Z9 28
U1 0
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 3
PY 2013
VL 110
IS 49
BP E4770
EP E4779
DI 10.1073/pnas.1309195110
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 262OJ
UT WOS:000327744900009
PM 24248335
ER
PT J
AU Hartsough, EJ
Meyer, RD
Chitalia, V
Jiang, Y
Marquez, VE
Zhdanova, IV
Weinberg, J
Costello, CE
Rahimi, N
AF Hartsough, Edward J.
Meyer, Rosana D.
Chitalia, Vipul
Jiang, Yan
Marquez, Victor E.
Zhdanova, Irina V.
Weinberg, Janice
Costello, Catherine E.
Rahimi, Nader
TI Lysine Methylation Promotes VEGFR-2 Activation and Angiogenesis
SO SCIENCE SIGNALING
LA English
DT Article
ID ENDOTHELIAL-CELL PROLIFERATION; GROWTH-FACTOR RECEPTORS; ARGININE
METHYLATION; HISTONE METHYLATION; SIGNAL-TRANSDUCTION; DOWN-REGULATION;
PHOSPHORYLATION; UBIQUITINATION; CANCER; ACETYLATION
AB Activation of vascular endothelial growth factor receptor-2 (VEGFR-2), an endothelial cell receptor tyrosine kinase, promotes tumor angiogenesis and ocular neovascularization. We report the methylation of VEGFR-2 at multiple Lys and Arg residues, including Lys1041, a residue that is proximal to the activation loop of the kinase domain. Methylation of VEGFR-2 was independent of ligand binding and was not regulated by ligand stimulation. Methylation of Lys1041 enhanced tyrosine phosphorylation and kinase activity in response to ligands. Additionally, interfering with the methylation of VEGFR-2 by pharmacological inhibition or by site-directed mutagenesis revealed that methylation of Lys1041 was required for VEGFR-2-mediated angiogenesis in zebrafish and tumor growth in mice. We propose that methylation of Lys1041 promotes the activation of VEGFR-2 and that similar posttranslational modification could also regulate the activity of other receptor tyrosine kinases.
C1 [Hartsough, Edward J.; Meyer, Rosana D.; Rahimi, Nader] Boston Univ Med Campus, Sch Med, Dept Pathol, Boston, MA 02118 USA.
[Hartsough, Edward J.; Meyer, Rosana D.; Rahimi, Nader] Boston Univ Med Campus, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
[Chitalia, Vipul] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Jiang, Yan; Costello, Catherine E.] Boston Univ Med Campus, Sch Med, Dept Biochem, Boston, MA 02118 USA.
[Jiang, Yan; Costello, Catherine E.] Boston Univ Med Campus, Sch Med, Ctr Biomed Mass Spectrometry, Boston, MA 02118 USA.
[Marquez, Victor E.] NCI, Biol Chem Lab, Frederick, MD 21702 USA.
[Zhdanova, Irina V.] Boston Univ Med Campus, Dept Anat & Neurobiol, Boston, MA 02118 USA.
[Weinberg, Janice] Boston Univ Med Campus, Sch Publ Hlth, Boston, MA 02118 USA.
RP Rahimi, N (reprint author), Boston Univ Med Campus, Sch Med, Dept Pathol, Boston, MA 02118 USA.
EM nrahimi@bu.edu
OI Rahimi, Nader/0000-0002-6745-1725
FU NIH/National Eye Institute [R01EY017955, P41 RR010888/GM104603, S10
RR020946]; NIH/National Heart, Lung, and Blood Institute [N01
HHSN268201000031C]; K08 award (NIH/National Institute of Diabetes and
Digestive and Kidney Diseases) [DK080946]; K08 award (Department of
Medicine Career Investment Award); Department of Pathology, Boston
University; Massachusetts Lions Foundation; Intramural Research Program
of the NIH, National Cancer Institute, Center for Cancer Research
FX Funding: This work was supported in part through a grant from the
NIH/National Eye Institute (R01EY017955 to N.R.); P41 RR010888/GM104603,
S10 RR020946, and NIH/National Heart, Lung, and Blood Institute contract
N01 HHSN268201000031C (to C. E. C.); and K08 award (NIH/National
Institute of Diabetes and Digestive and Kidney Diseases DK080946 and
Department of Medicine Career Investment Award to V. C.). This work was
also supported by a grant from the Department of Pathology, Boston
University, and a Massachusetts Lions Foundation grant to the Department
of Ophthalmology. This research was also supported in part by the
Intramural Research Program of the NIH, National Cancer Institute,
Center for Cancer Research (V.E.M.).
NR 39
TC 13
Z9 14
U1 0
U2 10
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD DEC 3
PY 2013
VL 6
IS 304
AR ra104
DI 10.1126/scisignal.2004289
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 265HO
UT WOS:000327941400002
PM 24300896
ER
PT J
AU Revollo, JR
Oakley, RH
Lu, NZ
Kadmiel, M
Gandhavadi, M
Cidlowski, JA
AF Revollo, Javier R.
Oakley, Robert H.
Lu, Nick Z.
Kadmiel, Mahita
Gandhavadi, Maheer
Cidlowski, John A.
TI HES1 Is a Master Regulator of Glucocorticoid Receptor-Dependent Gene
Expression
SO SCIENCE SIGNALING
LA English
DT Article
ID HELIX FACTOR HES-1; NEURONAL DIFFERENTIATION; FUNCTIONAL-ANALYSIS;
TRANSGENIC MICE; LOOP; MECHANISMS; PROMOTER; INSULIN; NOTCH; RESISTANCE
AB Hairy and enhancer of split-1 (HES1) is a basic helix-loop-helix transcription factor that is a key regulator of development and organogenesis. However, little is known about the role of HES1 after birth. Glucocorticoids, primary stress hormones that are essential for life, regulate numerous homeostatic processes that permit vertebrates to cope with physiological challenges. The molecular actions of glucocorticoids are mediated by glucocorticoid receptor-dependent regulation of nearly 25% of the genome. Here, we established a genome-wide molecular link between HES1 and glucocorticoid receptors that controls the ability of cells and animals to respond to stress. Glucocorticoid signaling rapidly and robustly silenced HES1 expression. This glucocorticoid-dependent repression of HES1 was necessary for the glucocorticoid receptor to regulate many of its target genes. Mice with conditional knockout of HES1 in the liver exhibited an expanded glucocorticoid receptor signaling profile and aberrant metabolic phenotype. Our results indicate that HES1 acts as a master repressor, the silencing of which is required for proper glucocorticoid signaling.
C1 [Revollo, Javier R.; Oakley, Robert H.; Lu, Nick Z.; Kadmiel, Mahita; Gandhavadi, Maheer; Cidlowski, John A.] NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA.
[Revollo, Javier R.] US FDA, Div Genet & Mol Toxicol, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
[Lu, Nick Z.] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Allergy Immunol, Chicago, IL 60611 USA.
RP Cidlowski, JA (reprint author), NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA.
EM cidlows1@niehs.nih.gov
FU Intramural Research Program of the NIH, NIEHS
FX Funding: This research was supported by the Intramural Research Program
of the NIH, NIEHS. Author contributions: J.R.R. designed and performed
the experiments, analyzed the data, and wrote the manuscript. R.H.O.
designed the experiments, analyzed the data, and wrote the manuscript.
N.Z.L. designed and performed the experiments. M. K. designed and
performed the experiments and analyzed the data. M. G. performed the
experiments. J.A.C. designed the experiments, analyzed the data, and
wrote the manuscript.
NR 30
TC 10
Z9 10
U1 0
U2 8
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD DEC 3
PY 2013
VL 6
IS 304
AR ra103
DI 10.1126/scisignal.2004389
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 265HO
UT WOS:000327941400001
PM 24300895
ER
PT J
AU Cruz, FC
Alves, FHF
Leao, RM
Planeta, CS
Crestani, CC
AF Cruz, F. C.
Alves, F. H. F.
Leao, R. M.
Planeta, C. S.
Crestani, C. C.
TI ROLE OF THE BED NUCLEUS OF THE STRIA TERMINALIS IN CARDIOVASCULAR
CHANGES FOLLOWING CHRONIC TREATMENT WITH COCAINE AND TESTOSTERONE: A
ROLE BEYOND DRUG SEEKING IN ADDICTION?
SO NEUROSCIENCE
LA English
DT Article
DE addiction; steroids; cocaine; baroreflex; BNST; extended amygdala
ID CORTICOTROPIN-RELEASING-FACTOR; ACUTE RESTRAINT STRESS; BAROREFLEX
CARDIAC COMPONENT; ANABOLIC-ANDROGENIC STEROIDS; MODULATES BAROREFLEX;
UNANESTHETIZED RATS; HEART-RATE; FUNCTIONAL-ACTIVITY; EXTENDED AMYGDALA;
RESPONSES
AB Neural plasticity has been observed in the bed nucleus of the stria terminalis (BNST) following exposure to both cocaine and androgenic anabolic steroids. Here we investigated the involvement of the BNST on changes in cardiovascular function and baroreflex activity following either single or combined administration of cocaine and testosterone for 10 consecutive days in rats. Single administration of testosterone increased values of arterial pressure, evoked rest bradycardia and reduced baroreflex-mediated bradycardia. These effects of testosterone were not affected by BNST inactivation caused by local bilateral microinjections of the nonselective synaptic blocker CoCl2. The single administration of cocaine as well as the combined treatment with testosterone and cocaine increased both bradycardiac and tachycardiac responses of the baroreflex. Cocaine-evoked baroreflex changes were totally reversed after BNST inactivation. However, BNST inhibition in animals subjected to combined treatment with cocaine and testosterone reversed only the increase in reflex tachycardia, whereas facilitation of reflex bradycardia was not affected by local BNST treatment with CoCl2. In conclusion, the present study provides the first direct evidence that the BNST play a role in cardiovascular changes associated with drug abuse. Our findings suggest that alterations in cardiovascular function following subchronic exposure to cocaine are mediated by neural plasticity in the BNST. The single treatment with cocaine and the combined administration of testosterone and cocaine had similar effects on baroreflex activity, however the association with testosterone inhibited cocaine-induced changes in the BNST control of reflex bradycardia. Testosterone-induced cardiovascular changes seem to be independent of the BNST. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Cruz, F. C.; Leao, R. M.; Planeta, C. S.; Crestani, C. C.] Univ Estadual Paulista, UNESP, Sch Pharmaceut Sci, Lab Pharmacol,Dept Nat Act Principles & Toxicol, BR-14801902 Araraquara, SP, Brazil.
[Cruz, F. C.] NIDA, Behav Neurosci Branch, Intramural Res Program, US Natl Inst Hlth,Dept Hlth & Human Serv, Baltimore, MD USA.
[Alves, F. H. F.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Pharmacol, BR-14090090 Ribeirao Preto, SP, Brazil.
[Leao, R. M.; Planeta, C. S.; Crestani, C. C.] Joint UFSCar UNESP Grad Program Physiol Sci, Sao Paulo, Brazil.
RP Crestani, CC (reprint author), Sao Paulo State Univ, UNESP, Sch Pharmaceut Sci, Lab Pharmacol,Dept Nat Act Principles & Toxicol, Rodovia Araraquara Jau Km 01,Campus Univ,Caixa Po, BR-14801902 Araraquara, SP, Brazil.
EM crestani@fcfar.unesp.br
RI Crestani, Carlos/E-4161-2012;
OI Crestani, Carlos Cesar/0000-0002-1942-858X
FU Sao Paulo Research Foundation (FAPESP) [2010/16192-8]; National Council
for Scientific and Technological Development (CNPq) [474177/2010-6];
PADC-School of Pharmaceutical Sciences-Sao Paulo State University
FX The authors wish to thank Elisabete Z.P. Lepera, Rosana F.P. Silva and
Ivanilda Fortunato for technical assistance. This study was supported by
Sao Paulo Research Foundation (FAPESP) grant # 2010/16192-8; National
Council for Scientific and Technological Development (CNPq) grant #
474177/2010-6; and PADC-School of Pharmaceutical Sciences-Sao Paulo
State University. Cleopatra S Planeta is a CNPq research fellow.
NR 64
TC 5
Z9 5
U1 0
U2 61
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
EI 1873-7544
J9 NEUROSCIENCE
JI Neuroscience
PD DEC 3
PY 2013
VL 253
BP 29
EP 39
DI 10.1016/j.neuroscience.2013.08.034
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA 252HZ
UT WOS:000326997100004
PM 23994153
ER
PT J
AU Peay, HL
Rosenstein, DL
Biesecker, BB
AF Peay, Holly L.
Rosenstein, Donald L.
Biesecker, Barbara B.
TI Adaptation to bipolar disorder and perceived risk to children: a survey
of parents with bipolar disorder
SO BMC PSYCHIATRY
LA English
DT Article
DE Bipolar disorder; Adaptation; Quality of life; Genetic; Risk perception
ID QUALITY-OF-LIFE; MENTAL-HEALTH; DISPOSITIONAL OPTIMISM; BRIEF COPE;
ILLNESS; PERCEPTIONS; ATTITUDES; QUESTIONNAIRE; SYMPTOMS; FAMILIES
AB Background: Bipolar disorder (BPD) is a common condition associated with significant morbidity and reduced quality of life. In addition to challenges caused by their mood symptoms, parents affected with BPD harbor concerns about the mental health of their children. Among adult parents who perceive themselves to have BPD, this study aims to examine participants' coping methods; identify predictors of adaptation; assess parental perceptions of risks for mood disorders among their children; and describe the relationships among illness appraisals, coping, adaptation to one's own illness, and perceived risk to one's children.
Methods: Parents who self-identified as having BPD completed a web-based survey that assessed dispositional optimism, coping, perceived illness severity, perceived etiology of BPD, perceived risk to offspring, and adaptation to BPD. Participants had at least one unaffected child who was 30 years of age or below.
Results: 266 parents were included in the analysis. 87% of parents endorsed a "somewhat greater" or "much greater" risk for mood disorders in one's child(ren) than someone without a family history. Endorsing a genetic/familial etiology to BPD was positively correlated with perceived risk for mood disorders in children (r(s) = .3, p < 0.01) and active coping with BDP (r = .2, p < 0.01). Increased active coping (beta = 0.4, p < 0.001) and dispositional optimism (beta = 0.3, p < 0.001) were positively associated with better adaptation, while using denial coping was negatively associated with adaptation (beta = -0.3, p < 0.001). The variables explained 55.2% of the variance in adaptation (F = 73.2, p < 0.001). Coping mediated the effect of perceived illness severity on adaptation.
Conclusions: These data inform studies of interventions that extend beyond symptom management and aim to improve the psychological wellbeing of parents with BPD. Interventions targeted at illness perceptions and those aimed at enhancing coping should be studied for positive effects on adaptation. Parents with BPD may benefit from genetic counseling to promote active coping with their condition, and manage worry about perceived risk to their children.
C1 [Peay, Holly L.; Biesecker, Barbara B.] NHGRI, Social & Behav Res Branch, Bethesda, MD 20892 USA.
[Rosenstein, Donald L.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27599 USA.
[Rosenstein, Donald L.] Univ N Carolina, Comprehens Canc Support Program, Chapel Hill, NC 27599 USA.
RP Peay, HL (reprint author), NHGRI, Social & Behav Res Branch, Bldg 31 Room B1B36 31 Ctr Dr MSC 2073, Bethesda, MD 20892 USA.
EM hpeay@mail.nih.gov
FU Intramural Research Program of the National Human Genome Research
Institute, National Institutes of Health
FX This work was supported by the Intramural Research Program of the
National Human Genome Research Institute, National Institutes of Health.
The authors have no conflicts to disclose.
NR 34
TC 3
Z9 3
U1 1
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-244X
J9 BMC PSYCHIATRY
JI BMC Psychiatry
PD DEC 2
PY 2013
VL 13
AR 327
DI 10.1186/1471-244X-13-327
PG 8
WC Psychiatry
SC Psychiatry
GA 285IL
UT WOS:000329387300001
PM 24294897
ER
PT J
AU Ault, A
Tennant, SM
Gorres, JP
Eckhaus, M
Sandler, NG
Roque, A
Livio, S
Bao, S
Foulds, KE
Kao, SF
Roederer, M
Schmidlein, P
Boyd, MA
Pasetti, MF
Douek, DC
Estes, JD
Nabel, GJ
Levine, MM
Rao, SS
AF Ault, Alida
Tennant, Sharon M.
Gorres, J. Patrick
Eckhaus, Michael
Sandler, Netanya G.
Roque, Annelys
Livio, Sofie
Bao, Saran
Foulds, Kathryn E.
Kao, Shing-Fen
Roederer, Mario
Schmidlein, Patrick
Boyd, Mary Adetinuke
Pasetti, Marcela F.
Douek, Daniel C.
Estes, Jacob D.
Nabel, Gary J.
Levine, Myron M.
Rao, Srinivas S.
TI Safety and tolerability of a live oral Salmonella typhimurium vaccine
candidate in SIV-infected nonhuman primates
SO VACCINE
LA English
DT Article
DE Nontyphoidal Salmonella; Live oral vaccine; Nonhuman primates; Simian
immunodeficiency virus; Human immunodeficiency virus
ID NONTYPHOIDAL SALMONELLA; AFRICAN ADULTS; HIV-INFECTION; TYPHOID-FEVER;
BACTEREMIA; DISEASE; BLOOD; CHILDREN; TRANSMISSION; PATHOGENESIS
AB Nontyphoidal Salmonella (NTS) serovars are a common cause of acute food-borne gastroenteritis worldwide and can cause invasive systemic disease in young infants, the elderly, and immunocompromised hosts, accompanied by high case fatality. Vaccination against invasive NTS disease is warranted where the disease incidence and mortality are high and multidrug resistance is prevalent, as in sub-Saharan Africa. Live-attenuated vaccines that mimic natural infection constitute one strategy to elicit protection. However, they must particularly be shown to be adequately attenuated for consideration of immunocompromised subjects. Accordingly, we examined the safety and tolerability of an oral live attenuated Salmonella typhimurium vaccine candidate, CVD 1921, in an established chronic simian immunodeficiency virus (SIV)-infected rhesus macaque model. We evaluated clinical parameters, histopathology, and measured differences in mucosal permeability to wild-type and vaccine strains. Compared to the wild-type S. typhimurium strain 177 in both SIV-infected and SIV-uninfected nonhuman primate hosts, this live-attenuated vaccine shows reduced shedding and systemic spread, exhibits limited pathological disease manifestations in the digestive tract, and induces low levels of cellular infiltration in tissues. Furthermore, wild-types. typhimurium induces increased intestinal epithelial damage and permeability, with infiltration of neutrophils and macrophages in both Sly-infected and SIV-uninfected nonhuman primates compared to the vaccine strain. Based on shedding, systemic spread, and histopathology, the live-attenuated S. typhimurium strain CVD 1921 appears to be safe and well-tolerated in the nonhuman primate model, including chronically Sly-infected rhesus macaques. (C) 2013 Published by Elsevier Ltd.
C1 [Ault, Alida; Gorres, J. Patrick; Bao, Saran; Rao, Srinivas S.] NIAID, Lab Anim Med, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
[Tennant, Sharon M.; Livio, Sofie; Schmidlein, Patrick; Boyd, Mary Adetinuke; Pasetti, Marcela F.; Levine, Myron M.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.
[Estes, Jacob D.] SAIC Frederick Inc, Frederick Natl Lab Canc Res, AIDS & Canc Virus Program, Frederick, MD 21702 USA.
[Sandler, Netanya G.; Roque, Annelys; Douek, Daniel C.] NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
[Eckhaus, Michael; Foulds, Kathryn E.; Kao, Shing-Fen; Roederer, Mario] NIAID, Nonhuman Primate Immunogen Core Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
[Nabel, Gary J.] Sanofi Inc, Global Res & Dev, Cambridge, MA 02139 USA.
RP Rao, SS (reprint author), 40 Convent Dr, Bethesda, MD 20892 USA.
EM srao1@mail.nih.gov
OI Utay, Netanya/0000-0002-6407-8670
FU Intramural Research Program of the NIH Vaccine Research Center; Middle
Atlantic RCE Program NIAID/NIH [2 U54 AI057168]
FX This research was supported by the Intramural Research Program of the
NIH Vaccine Research Center and the Middle Atlantic RCE Program
NIAID/NIH 2 U54 AI057168 grant. To fully disclose any potential
conflicts of interest, the authors Myron M. Levine and Sharon Tennant
are listed on a patent application entitled "Broad spectrum vaccine
against non-typhoidal Salmonella", US 2011/0274714 A1. The authors would
like to thank Mr. Sunil Sen and Mr. Paul Kamate for identification of
Salmonella. We would also like to thank Dr. Raphael Simon for providing
purified LPS and flagella for use in ELISAs, Judy Stein for assistance
in coordinating material transfers and managing regulatory issues, Alan
Dodson and John-Paul Todd for supporting monkey studies, Hana Bao and
Wanxin Liu for their assistance in CD68+ quantification, Mythreyi
Shastri and Brenda Hartman for assistance in manuscript preparation, and
Linda Bessacque for administrative support.
NR 38
TC 9
Z9 10
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD DEC 2
PY 2013
VL 31
IS 49
BP 5879
EP 5888
DI 10.1016/j.vaccine.2013.09.041
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 274GW
UT WOS:000328595800014
PM 24099872
ER
PT J
AU Riolo, MA
King, AA
Rohani, P
AF Riolo, Maria A.
King, Aaron A.
Rohani, Pejman
TI Can vaccine legacy explain the British pertussis resurgence?
SO VACCINE
LA English
DT Article
DE Epidemiology; Pertussis; Age-structure; Mathematical model
ID BORDETELLA-PERTUSSIS; ACELLULAR VACCINES; TRANSMISSION; EFFICACY;
ENGLAND; DISEASE; SPREAD; WALES
AB Pertussis incidence has been rising in some countries, including the UK, despite sustained high vaccine coverage. We questioned whether it is possible to explain the resurgence without recourse to complex hypotheses about pathogen evolution, subclinical infections, or trends in surveillance efficiency. In particular, we investigated the possibility that the resurgence is a consequence of the legacy of incomplete pediatric immunization, in the context of cohort structure and age-dependent transmission. We constructed a model of pertussis transmission in England and Wales based on data on age-specific contact rates and historical vaccine coverage estimates. We evaluated the agreement between model-predicted and observed patterns of age-specific pertussis incidence under a variety of assumptions regarding the duration of immunity. Under the assumption that infection-derived immunity is complete and lifelong, and regardless of the duration of vaccine-induced immunity, the model consistently predicts a resurgence of pertussis incidence comparable to that which has been observed. Interestingly, no resurgence is predicted when infection- and vaccine-derived immunities wane at the same rate. These results were qualitatively insensitive to rates of primary vaccine failure. We conclude that the alarming resurgence of pertussis among adults and adolescents in Britain and elsewhere may simply be a legacy of historically inadequate coverage employing imperfect vaccines. Indeed, we argue that the absence of resurgence at this late date would be more surprising. Our analysis shows that careful accounting for age dependence in contact rates and susceptibility is prerequisite to the identification of which features of pertussis epidemiology want additional explanation. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Riolo, Maria A.; King, Aaron A.; Rohani, Pejman] Ctr Study Complex Syst, Ann Arbor, MI 48109 USA.
[Riolo, Maria A.; King, Aaron A.] Univ Michigan, Dept Math, Ann Arbor, MI 48109 USA.
[King, Aaron A.; Rohani, Pejman] Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA.
[King, Aaron A.; Rohani, Pejman] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
RP Riolo, MA (reprint author), Univ Michigan, Dept Math, Ann Arbor, MI 48109 USA.
EM mariolo@umich.edu
RI King, Aaron/B-8092-2012
OI King, Aaron/0000-0001-6159-3207
FU Research and Policy in Infectious Disease Dynamics program of the
Science and Technology Directorate, Department of Homeland Security, the
Fogarty International Center, National Institutes of Health; National
Institutes of Health [1R01AI101155]; Vaccine Modeling Initiative of the
Bill & Melinda Gates Foundation
FX We thank Doug Jackson and an anonymous reviewer for their helpful
comments on the paper. PR and AAK are supported by the Research and
Policy in Infectious Disease Dynamics program of the Science and
Technology Directorate, Department of Homeland Security, the Fogarty
International Center, National Institutes of Health and by a research
grant from the National Institutes of Health (1R01AI101155). PR also
received support from the Vaccine Modeling Initiative of the Bill &
Melinda Gates Foundation.
NR 34
TC 18
Z9 18
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD DEC 2
PY 2013
VL 31
IS 49
BP 5903
EP 5908
DI 10.1016/j.vaccine.2013.09.020
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 274GW
UT WOS:000328595800017
PM 24139837
ER
PT J
AU Lacerda, M
Moore, PL
Ngandu, NK
Seaman, M
Gray, ES
Murrell, B
Krishnamoorthy, M
Nonyane, M
Madiga, M
Wibmer, CK
Sheward, D
Bailer, RT
Gao, HM
Greene, KM
Karim, SSA
Mascola, JR
Korber, BTM
Montefiori, DC
Morris, L
Williamson, C
Seoighe, C
AF Lacerda, Miguel
Moore, Penny L.
Ngandu, Nobubelo K.
Seaman, Michael
Gray, Elin S.
Murrell, Ben
Krishnamoorthy, Mohan
Nonyane, Molati
Madiga, Maphuti
Wibmer, Constantinos Kurt
Sheward, Daniel
Bailer, Robert T.
Gao, Hongmei
Greene, Kelli M.
Karim, Salim S. Abdool
Mascola, John R.
Korber, Bette T. M.
Montefiori, David C.
Morris, Lynn
Williamson, Carolyn
Seoighe, Cathal
CA CAVD-NSDP Consortium
TI Identification of broadly neutralizing antibody epitopes in the HIV-1
envelope glycoprotein using evolutionary models
SO VIROLOGY JOURNAL
LA English
DT Article
DE HIV; Antibodies; Neutralization sensitivity; Epitope prediction;
Evolutionary model
ID IMMUNODEFICIENCY-VIRUS TYPE-1; B-CELL RESPONSES; INFECTION; GP120;
PHYLOGENIES; BINDING; RECOMBINATION; INDIVIDUALS; DISCOVERY; ALGORITHM
AB Background: Identification of the epitopes targeted by antibodies that can neutralize diverse HIV-1 strains can provide important clues for the design of a preventative vaccine.
Methods: We have developed a computational approach that can identify key amino acids within the HIV-1 envelope glycoprotein that influence sensitivity to broadly cross-neutralizing antibodies. Given a sequence alignment and neutralization titers for a panel of viruses, the method works by fitting a phylogenetic model that allows the amino acid frequencies at each site to depend on neutralization sensitivities. Sites at which viral evolution influences neutralization sensitivity were identified using Bayes factors (BFs) to compare the fit of this model to that of a null model in which sequences evolved independently of antibody sensitivity. Conformational epitopes were identified with a Metropolis algorithm that searched for a cluster of sites with large Bayes factors on the tertiary structure of the viral envelope.
Results: We applied our method to ID50 neutralization data generated from seven HIV-1 subtype C serum samples with neutralization breadth that had been tested against a multi-clade panel of 225 pseudoviruses for which envelope sequences were also available. For each sample, between two and four sites were identified that were strongly associated with neutralization sensitivity (2ln(BF) > 6), a subset of which were experimentally confirmed using site-directed mutagenesis.
Conclusions: Our results provide strong support for the use of evolutionary models applied to cross-sectional viral neutralization data to identify the epitopes of serum antibodies that confer neutralization breadth.
C1 [Lacerda, Miguel; Seoighe, Cathal] Natl Univ Ireland Galway, Sch Math Stat & Appl Math, Galway, Ireland.
[Lacerda, Miguel] Univ Cape Town, Fac Sci, Dept Stat Sci, ZA-7925 Cape Town, South Africa.
[Moore, Penny L.; Gray, Elin S.; Nonyane, Molati; Madiga, Maphuti; Wibmer, Constantinos Kurt; Morris, Lynn] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Ctr HIV & STIs, Johannesburg, South Africa.
[Moore, Penny L.; Morris, Lynn] Univ Witwatersrand, Sch Pathol, Johannesburg, South Africa.
[Ngandu, Nobubelo K.; Sheward, Daniel; Williamson, Carolyn] Univ Cape Town, Fac Hlth Sci, Div Med Virol, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.
[Ngandu, Nobubelo K.; Sheward, Daniel; Williamson, Carolyn] NHLS, Cape Town, South Africa.
[Seaman, Michael] Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Harvard, MA USA.
[Murrell, Ben] MRC, eHlth Res & Innovat Platform, Biomed Informat Res Div, Tygerberg, South Africa.
[Murrell, Ben] Univ Stellenbosch, Dept Math Sci, Div Comp Sci, ZA-7600 Stellenbosch, South Africa.
[Krishnamoorthy, Mohan; Korber, Bette T. M.] Los Alamos Natl Lab, Los Alamos, NM USA.
[Bailer, Robert T.; Mascola, John R.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.
[Gao, Hongmei; Greene, Kelli M.; Montefiori, David C.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.
[Karim, Salim S. Abdool] Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa, Durban, South Africa.
[Karim, Salim S. Abdool] Columbia Univ, Ctr AIDS Programme Res South Africa, Columbia, NY USA.
[Korber, Bette T. M.] Santa Fe Inst, Santa Fe, NM 87501 USA.
RP Seoighe, C (reprint author), Natl Univ Ireland Galway, Sch Math Stat & Appl Math, Galway, Ireland.
EM cathal.seoighe@nuigalway.ie
RI Abdool Karim, Salim Safurdeen/N-5947-2013;
OI Abdool Karim, Salim Safurdeen/0000-0002-4986-2133; Moore,
Penny/0000-0001-8719-4028; , Carolyn/0000-0003-0125-1226; Korber,
Bette/0000-0002-2026-5757; Wibmer, Constantinos
Kurt/0000-0003-2329-2280; Gray, Elin/0000-0002-8613-3570
NR 57
TC 6
Z9 6
U1 1
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PD DEC 2
PY 2013
VL 10
AR 347
DI 10.1186/1743-422X-10-347
PG 18
WC Virology
SC Virology
GA 276YK
UT WOS:000328785400001
PM 24295501
ER
PT J
AU Burbelo, PD
Ching, KH
Morse, CG
Alevizos, I
Bayat, A
Cohen, JI
Ali, MA
Kapoor, A
Browne, SK
Holland, SM
Kovacs, JA
Iadarola, MJ
AF Burbelo, Peter D.
Ching, Kathryn H.
Morse, Caryn G.
Alevizos, Ilias
Bayat, Ahmad
Cohen, Jeffrey I.
Ali, Mir A.
Kapoor, Amit
Browne, Sarah K.
Holland, Steven M.
Kovacs, Joseph A.
Iadarola, Michael J.
TI Altered Antibody Profiles against Common Infectious Agents in Chronic
Disease
SO PLOS ONE
LA English
DT Article
ID EPSTEIN-BARR-VIRUS; LUCIFERASE IMMUNOPRECIPITATION SYSTEMS;
SALIVARY-GLAND BIOPSIES; SJOGRENS-SYNDROME; HUMORAL RESPONSES;
HOMOSEXUAL MEN; GUT MICROBIOME; DNA; IMMUNODEFICIENCY; TYPE-2
AB Despite the important diagnostic value of evaluating antibody responses to individual human pathogens, antibody profiles against multiple infectious agents have not been used to explore health and disease mainly for technical reasons. We hypothesized that the interplay between infection and chronic disease might be revealed by profiling antibodies against multiple agents. Here, the levels of antibodies against a panel of 13 common infectious agents were evaluated with the quantitative Luciferase Immunoprecipitation Systems (LIPS) in patients from three disease cohorts including those with pathogenic anti-interferon-gamma autoantibodies (IFN-gamma AAB), HIV and Sjogren's syndrome (SjS) to determine if their antibody profiles differed from control subjects. The IFN-gamma AAB patients compared to controls demonstrated statistically higher levels of antibodies against VZV (p=0.0003), EBV (p=0.002), CMV (p=0.003), and C. albicans (p=0.03), but lower antibody levels against poliovirus (p=0.04). Comparison of HIV patients with blood donor controls revealed that the patients had higher levels of antibodies against CMV (p=0.0008), HSV-2 (p=0.0008), EBV (p=0.001), and C. albicans (p=0.01), but showed decreased levels of antibodies against coxsackievirus B4 (p=0.0008), poliovirus (p=0.0005), and HHV-6B (p=0.002). Lastly, SjS patients had higher levels of anti-EBV antibodies (p=0.03), but lower antibody levels against several enteroviruses including a newly identified picornavirus, HCoSV-A (p=0.004), coxsackievirus B4 (p=0.04), and poliovirus (p=0.02). For the IFN-gamma AAB and HIV cohorts, principal component analysis revealed unique antibody clusters that showed the potential to discriminate patients from controls. The results suggest that antibody profiles against these and likely other common infectious agents may yield insight into the interplay between exposure to infectious agents, dysbiosis, adaptive immunity and disease activity.
C1 [Burbelo, Peter D.] Natl Inst Dent & Craniofacial Res, Clin Dent Res Core, NIH, Bethesda, MD USA.
[Ching, Kathryn H.] USDA, Western Reg Res Ctr, Albany, CA 94710 USA.
[Morse, Caryn G.; Kovacs, Joseph A.] NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA.
[Alevizos, Ilias] Natl Inst Dent & Craniofacial Res, Sjogren Syndrome Clin, Mol Physiol & Therapeut Branch, NIH, Bethesda, MD USA.
[Bayat, Ahmad; Iadarola, Michael J.] NIH, Dept Perioperat Med, Ctr Clin, Bethesda, MD 20892 USA.
[Cohen, Jeffrey I.; Ali, Mir A.] NIAID, Med Virol Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
[Kapoor, Amit] Columbia Univ, Ctr Infect & Immun, New York, NY USA.
[Browne, Sarah K.; Holland, Steven M.] NIAID, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA.
RP Burbelo, PD (reprint author), Natl Inst Dent & Craniofacial Res, Clin Dent Res Core, NIH, Bethesda, MD USA.
EM burbelop@nidcr.nih.gov
OI Morse, Caryn/0000-0002-1177-4365
FU Division of Intramural Research, National Institute of Dental and
Craniofacial Research; National Institute of Allergy and Infectious
Diseases; Clinical Center, NIH; Center for Neuroscience and Regenerative
Medicine; NIH [AI090196, AI081132]
FX This work was supported by the Division of Intramural Research, National
Institute of Dental and Craniofacial Research, the National Institute of
Allergy and Infectious Diseases, the Clinical Center, NIH, the Center
for Neuroscience and Regenerative Medicine and from NIH grants AI090196
and AI081132. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 40
TC 2
Z9 2
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 2
PY 2013
VL 8
IS 12
AR e81635
DI 10.1371/journal.pone.0081635
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 265IN
UT WOS:000327944500082
PM 24312567
ER
PT J
AU Eakin, K
Li, YZ
Chiang, YH
Hoffer, BJ
Rosenheim, H
Greig, NH
Miller, JP
AF Eakin, Katharine
Li, Yazhou
Chiang, Yung-Hsiao
Hoffer, Barry J.
Rosenheim, Hilary
Greig, Nigel H.
Miller, Jonathan P.
TI Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive
Impairment in Rats
SO PLOS ONE
LA English
DT Article
ID GLUCAGON-LIKE PEPTIDE-1; CONTROLLED CORTICAL IMPACT; TYPE-2
DIABETES-MELLITUS; MORRIS WATER MAZE; ALZHEIMERS-DISEASE; SIGNALING
PATHWAY; GENE-EXPRESSION; BINDING-SITES; UNITED-STATES; AMYLOID-BETA
AB Traumatic brain injury represents a major public health issue that affects 1.7 million Americans each year and is a primary contributing factor (30.5%) of all injury-related deaths in the United States. The occurrence of traumatic brain injury is likely underestimated and thus has been termed "a silent epidemic". Exendin-4 is a long-acting glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes mellitus that not only effectively induces glucose-dependent insulin secretion to regulate blood glucose levels but also reduces apoptotic cell death of pancreatic beta-cells. Accumulating evidence also supports a neurotrophic and neuroprotective role of glucagon-like peptide-1 in an array of cellular and animal neurodegeneration models. In this study, we evaluated the neuroprotective effects of Exendin-4 using a glutamate toxicity model in vitro and fluid percussion injury in vivo. We found neuroprotective effects of Exendin-4 both in vitro, using markers of cell death, and in vivo, using markers of cognitive function, as assessed by Morris Water Maze. In combination with the reported benefits of ex-4 in other TBI models, these data support repositioning of Exendin-4 as a potential treatment for traumatic brain injury.
C1 [Eakin, Katharine; Hoffer, Barry J.; Rosenheim, Hilary; Miller, Jonathan P.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA.
[Li, Yazhou; Greig, Nigel H.] NIA, Drug Design & Dev Sect, Lab Translat Gerontol, Intramural Res Program,NIH, Baltimore, MD 21224 USA.
[Chiang, Yung-Hsiao] Taipei Med Univ, Grad Inst Neural Regenerat Med, PhD Program Neural Regenerat Med, Taipei, Taiwan.
[Chiang, Yung-Hsiao] Taipei Med Univ Hosp, Dept Neurosurg, Taipei, Taiwan.
RP Miller, JP (reprint author), Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA.
EM jonathan.p.miller@case.edu
FU Intramural Research Program of the National Institute on Aging, National
Institutes of Health; Lincoln Master Clinician in Neurosurgery Award,
USPHS [NS070825]; National Science Council of Taiwan
[NSC98-2321-B-038-002-MY3]
FX This research was supported in part by the Intramural Research Program
of the National Institute on Aging, National Institutes of Health; the
Lincoln Master Clinician in Neurosurgery Award to Jonathan Miller, USPHS
# NS070825; and the National Science Council of Taiwan to Yung-Hsiao
Chiang, #NSC98-2321-B-038-002-MY3. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 58
TC 20
Z9 21
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 2
PY 2013
VL 8
IS 12
AR e82016
DI 10.1371/journal.pone.0082016
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 265IN
UT WOS:000327944500114
PM 24312624
ER
PT J
AU Ng, KT
Ng, KY
Khong, WX
Chew, KK
Singh, PK
Yap, JK
Tan, MT
Leo, YS
Laeyendecker, O
Quinn, TC
Kamarulzaman, A
Tee, KK
Ng, OT
AF Kim Tien Ng
Kah Ying Ng
Wei Xin Khong
Kuan Kiat Chew
Singh, Palvinder Kaur
Joe Kwan Yap
Mei Ting Tan
Yee Sin Leo
Laeyendecker, Oliver
Quinn, Thomas C.
Kamarulzaman, Adeeba
Kok Keng Tee
Oon Tek Ng
TI Phylodynamic Profile of HIV-1 Subtype B, CRF01_AE and the Recently
Emerging CRF51_01B among Men Who Have Sex with Men (MSM) in Singapore
SO PLOS ONE
LA English
DT Article
ID TRANSMISSION NETWORKS; MAXIMUM-LIKELIHOOD; RECOMBINANT FORMS; INFECTION;
RISK; EPIDEMIC; POPULATION; PREVALENCE; TYPE-1; IDENTIFICATION
AB HIV-1 subtype B and CRF01_AE are the predominant infecting subtypes among men who have sex with men (MSM) in Singapore. The genetic history, population dynamics and pattern of transmission networks of these genotypes remain largely unknown. We delineated the phylodynamic profiles of HIV-1 subtype B, CRF01_AE and the recently characterized CRF51_01B strains circulating among the MSM population in Singapore. A total of 105 (49.5%) newly-diagnosed treatment-naive MSM were recruited between February 2008 and August 2009. Phylogenetic reconstructions of the protease gene (HXB2: 2239 - 2629), gp120 (HXB2: 6942 - 7577) and gp41 (HXB2: 7803 - 8276) of the env gene uncovered five monophyletic transmission networks (two each within subtype B and CRF01_AE and one within CRF51_01B lineages) of different sizes (involving 3 - 23 MSM subjects, supported by posterior probability measure of 1.0). Bayesian coalescent analysis estimated that the emergence and dissemination of multiple sub-epidemic networks occurred between 1995 and 2005, driven largely by subtype B and later followed by CRF01_AE. Exponential increase in effective population size for both subtype B and CRF01_AE occurred between 2002 to 2007 and 2005 to 2007, respectively. Genealogical estimates suggested that the novel CRF51_01B lineages were probably generated through series of recombination events involving CRF01_AE and multiple subtype B ancestors. Our study provides the first insight on the phylodynamic profiles of HIV-1 subtype B, CRF01_AE and CRF51_01B viral strains circulating among MSM in Singapore.
C1 [Kim Tien Ng; Kamarulzaman, Adeeba; Kok Keng Tee] Univ Malaya, Fac Med, Ctr Excellence Res AIDS CERiA, Dept Med, Kuala Lumpur, Malaysia.
[Kah Ying Ng; Wei Xin Khong; Kuan Kiat Chew; Singh, Palvinder Kaur; Joe Kwan Yap; Mei Ting Tan; Yee Sin Leo; Oon Tek Ng] Tan Tock Seng Hosp, Communicable Dis Ctr, Inst Infect Dis & Epidemiol, Singapore, Singapore.
[Laeyendecker, Oliver; Quinn, Thomas C.] Johns Hopkins Sch Med, Div Infect Dis, Baltimore, MD USA.
[Laeyendecker, Oliver; Quinn, Thomas C.] NIAID, Immunoregulat Lab, Div Intramural Res, NIH, Baltimore, MD USA.
RP Tee, KK (reprint author), Univ Malaya, Fac Med, Ctr Excellence Res AIDS CERiA, Dept Med, Kuala Lumpur, Malaysia.
EM k2tee@um.edu.my
RI Ng, Kim Tien/K-7667-2013; Tee, Kok Keng/A-8148-2008;
OI Ng, Kim Tien/0000-0002-4097-9984; Tee, Kok Keng/0000-0002-7923-5448;
Laeyendecker, Oliver/0000-0002-6429-4760
FU Singapore National Medical Research Training Fellowship Grant
[EDG10nov070]; Malaysia Ministry of Higher Education High Impact
Research (HIR) grants [H-500001-00-A000012-000001, E-000001-20001];
Division of Intramural Research, NIAID, NIH
FX This work was supported by the Singapore National Medical Research
Training Fellowship Grant (EDG10nov070 to OTN) and the Malaysia Ministry
of Higher Education High Impact Research (HIR) grants
(H-500001-00-A000012-000001 to KKT and E-000001-20001 to AK). Additional
support was provided by the Division of Intramural Research, NIAID, NIH.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 42
TC 4
Z9 5
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 2
PY 2013
VL 8
IS 12
AR e80884
DI 10.1371/journal.pone.0080884
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 265IN
UT WOS:000327944500044
PM 24312505
ER
PT J
AU Mudunuri, US
Khouja, M
Repetski, S
Venkataraman, G
Che, A
Luke, BT
Girard, FP
Stephens, RM
AF Mudunuri, Uma S.
Khouja, Mohamad
Repetski, Stephen
Venkataraman, Girish
Che, Anney
Luke, Brian T.
Girard, F. Pascal
Stephens, Robert M.
TI Knowledge and Theme Discovery across Very Large Biological Data Sets
Using Distributed Queries: A Prototype Combining Unstructured and
Structured Data
SO PLOS ONE
LA English
DT Article
ID GOOGLE FLU TRENDS; GENE-EXPRESSION; JOURNAL ARTICLES; NETWORK; TOOL
AB As the discipline of biomedical science continues to apply new technologies capable of producing unprecedented volumes of noisy and complex biological data, it has become evident that available methods for deriving meaningful information from such data are simply not keeping pace. In order to achieve useful results, researchers require methods that consolidate, store and query combinations of structured and unstructured data sets efficiently and effectively. As we move towards personalized medicine, the need to combine unstructured data, such as medical literature, with large amounts of highly structured and high-throughput data such as human variation or expression data from very large cohorts, is especially urgent. For our study, we investigated a likely biomedical query using the Hadoop framework. We ran queries using native MapReduce tools we developed as well as other open source and proprietary tools. Our results suggest that the available technologies within the Big Data domain can reduce the time and effort needed to utilize and apply distributed queries over large datasets in practical clinical applications in the life sciences domain. The methodologies and technologies discussed in this paper set the stage for a more detailed evaluation that investigates how various data structures and data models are best mapped to the proper computational framework.
C1 [Mudunuri, Uma S.; Che, Anney; Luke, Brian T.; Stephens, Robert M.] SAIC Frederick Inc, Frederick Natl Lab Canc Res, Adv Biomed Comp Ctr, Informat Syst Program, Frederick, MD USA.
[Khouja, Mohamad; Repetski, Stephen; Venkataraman, Girish; Girard, F. Pascal] Oracle Corp, Reston, VA USA.
RP Mudunuri, US (reprint author), SAIC Frederick Inc, Frederick Natl Lab Canc Res, Adv Biomed Comp Ctr, Informat Syst Program, Frederick, MD USA.
EM mudunuriu@mail.nih.gov
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]
FX This project has been funded in whole or in part with federal funds from
the National Cancer Institute, National Institutes of Health, under
Contract HHSN261200800001E. The content of this publication does not
necessarily reflect the views or policies of the Department of Health
and Human Services, nor does mention of trade names, commercial
products, or organizations imply endorsement by the U. S. government.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript. No additional
external funding received for this study.
NR 25
TC 9
Z9 9
U1 4
U2 31
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 2
PY 2013
VL 8
IS 12
AR e80503
DI 10.1371/journal.pone.0080503
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 265IN
UT WOS:000327944500027
PM 24312478
ER
PT J
AU Song, YR
Gilbert, D
O'Sullivan, TN
Yang, CY
Pan, WQ
Fathalizadeh, A
Lu, L
Haines, DC
Martin, PL
Van Dyke, T
AF Song, Yurong
Gilbert, Debra
O'Sullivan, T. Norene
Yang, Chunyu
Pan, Wenqi
Fathalizadeh, Alisan
Lu, Lucy
Haines, Diana C.
Martin, Philip L.
Van Dyke, Terry
TI Carcinoma Initiation via Rb Tumor Suppressor Inactivation: A Versatile
Approach to Epithelial Subtype-Dependent Cancer Initiation in Diverse
Tissues
SO PLOS ONE
LA English
DT Article
ID LARGE T-ANTIGEN; RETINOBLASTOMA GENE; CHOROID-PLEXUS; G(1) CONTROL; J
DOMAIN; IN-VIVO; KERATINS; PROGRESSION; MICE; DNA
AB Carcinomas arise in a complex microenvironment consisting of multiple distinct epithelial lineages surrounded by a variety of stromal cell types. Understanding cancer etiologies requires evaluating the relationship among cell types during disease initiation and through progression. Genetically engineered mouse (GEM) models facilitate the prospective examination of early oncogenic events, which is not possible in humans. Since most solid tumors harbor aberrations in the RB network, we developed an inducible GEM approach for the establishment and assessment of carcinoma initiation in a diverse range of epithelial tissues and subtypes upon inactivation of RB-mediated tumor suppression (RB-TS). The system allows independent assessment of epithelial subtypes that express either cytokeratins (K) 18 or 19. By Cre-dependent expression of a protein that dominantly inactivates RB and functionally redundant proteins p107 and p130, neoplasia could be initiated in either K18 or K19 expressing cells of numerous tissues. By design, because only a single pathway aberration was engineered, carcinomas developed stochastically only after long latency. Hence, this system, which allows for directed cell type-specific carcinoma initiation, facilitates further definition of events that can progress neoplasms to aggressive cancers via engineered, carcinogen-induced and/or spontaneous evolution.
C1 [Song, Yurong; Gilbert, Debra; O'Sullivan, T. Norene; Lu, Lucy; Van Dyke, Terry] NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21701 USA.
[Yang, Chunyu] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
[Pan, Wenqi] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC USA.
[Fathalizadeh, Alisan] Michigan State Univ, E Lansing, MI 48824 USA.
[Haines, Diana C.] SAIC Frederick, Frederick Natl Lab Canc Res, Pathol Histotechnol Lab, Frederick, MD USA.
[Martin, Philip L.] SAIC Frederick, Frederick Natl Lab Canc Res, Ctr Adv Preclin Res, Frederick, MD USA.
RP Van Dyke, T (reprint author), NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21701 USA.
EM vandyket@mail.nih.gov
FU National Cancer Institute, National Institutes of Health
[HHSN261200800001E]; Department of Defense [PC050306]; Prostate Cancer
Foundation; NCI [RO1-CA046283]
FX This work was supported in part by the National Cancer Institute,
National Institutes of Health, under Contract No. HHSN261200800001E, and
in part by grants RO1-CA046283 from NCI and PC040619 from the Department
of Defense, and Prostate Cancer Foundation to TVD. YS was supported by
postdoctoral training award (PC050306) from the Department of Defense.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript. The content of
this publication does not necessarily reflect the views or policies of
the Department of Health and Human Services, nor does mention of trade
names, commercial products, or organizations imply endorsement by the
U.S. Government.
NR 40
TC 2
Z9 2
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 2
PY 2013
VL 8
IS 12
AR e80459
DI 10.1371/journal.pone.0080459
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 265IN
UT WOS:000327944500026
PM 24312475
ER
PT J
AU Yu, SJ
Tseng, KY
Shen, H
Harvey, BK
Airavaara, M
Wang, Y
AF Yu, Seong-Jin
Tseng, Kuan-Yin
Shen, Hui
Harvey, Brandon K.
Airavaara, Mikko
Wang, Yun
TI Local Administration of AAV-BDNF to Subventricular Zone Induces
Functional Recovery in Stroke Rats
SO PLOS ONE
LA English
DT Article
ID ADENOASSOCIATED VIRUS VECTORS; FOCAL CEREBRAL-ISCHEMIA; REDUCES INFARCT
SIZE; NEUROTROPHIC FACTOR; MEDIATED DELIVERY; PRECURSOR CELLS; IN-VITRO;
BRAIN; NEUROGENESIS; MICE
AB Migration of new neuroprogenitor cells (NPCs) from the subventricular zone (SVZ) plays an important role in neurorepair after injury. Previous studies have shown that brain derived neurotrophic factor (BDNF) enhances the migration of NPCs from SVZ explants in neonatal mice in vitro. The purpose of this study was to identify the role of BDNF in SVZ cells using AAV-BDNF in an animal model of stroke. BDNF protein production after AAV-BDNF infection was verified in primary neuronal culture. AAV-BDNF or AAV-RFP was injected into the left SVZ region of adult rats at 14 days prior to right middle cerebral artery occlusion (MCAo). SVZ tissues were collected from the brain and placed in Metrigel cultures 1 day after MCAo. Treatment with AAV-BDNF significantly increased the migration of SVZ cells in the stroke brain in vitro. In another set of animals, AAV-GFP was co-injected with AAV-BDNF or AAV-RFP to label cells in left SVZ prior to right MCAo. Local administration of AAV-BDNF significantly enhanced recovery of locomotor function and migration of GFP-positive cells from the SVZ toward the lesioned hemisphere in stroke rats. Our data suggest that focal administration of AAV-BDNF to the SVZ increases behavioral recovery post stroke, possibly through the enhancement of migration of cells from SVZ in stroke animals. Regional manipulation of BDNF expression through AAV may be a novel approach for neurorepair in stroke brains.
C1 [Yu, Seong-Jin; Wang, Yun] Natl Hlth Res Inst, Ctr Neuropsychiat Res, Zhunan, Taiwan.
[Yu, Seong-Jin; Shen, Hui; Harvey, Brandon K.; Wang, Yun] NIDA, Neural Protect & Regenerat Sect, Intramural Res Program, Baltimore, MD USA.
[Tseng, Kuan-Yin; Airavaara, Mikko] Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Helsinki, Finland.
RP Wang, Y (reprint author), Natl Hlth Res Inst, Ctr Neuropsychiat Res, Zhunan, Taiwan.
EM ywang@nhri.org.tw
OI Airavaara, Mikko/0000-0002-2026-1609
FU National Institute on Drug Abuse, intramural research program; National
Health Research Institutes, Taiwan
FX This study was supported by the National Institute on Drug Abuse,
intramural research program and the National Health Research Institutes,
Taiwan. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 28
TC 10
Z9 10
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 2
PY 2013
VL 8
IS 12
AR UNSP e81750
DI 10.1371/journal.pone.0081750
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 265IN
UT WOS:000327944500094
PM 24312581
ER
PT J
AU Pickrell, AM
Youle, RJ
AF Pickrell, Alicia M.
Youle, Richard J.
TI Mitochondrial Disease: mtDNA and Protein Segregation Mysteries in iPSCs
SO CURRENT BIOLOGY
LA English
DT Editorial Material
ID DNA MUTATIONS; STEM-CELLS; PROMOTES; MICE
C1 [Pickrell, Alicia M.; Youle, Richard J.] NINDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA.
RP Pickrell, AM (reprint author), NINDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA.
EM youler@ninds.nih.gov
FU Intramural NIH HHS [Z99 NS999999]
NR 16
TC 5
Z9 5
U1 1
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0960-9822
EI 1879-0445
J9 CURR BIOL
JI Curr. Biol.
PD DEC 2
PY 2013
VL 23
IS 23
BP R1052
EP R1054
DI 10.1016/j.cub.2013.10.048
PG 3
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 266FH
UT WOS:000328008300016
PM 24309284
ER
PT J
AU Shimizu, K
Stopfer, M
AF Shimizu, Kazumichi
Stopfer, Mark
TI Gap junctions
SO CURRENT BIOLOGY
LA English
DT Editorial Material
C1 [Shimizu, Kazumichi; Stopfer, Mark] NICHD, NIH, Bethesda, MD 20892 USA.
RP Stopfer, M (reprint author), NICHD, NIH, 35 Lincoln Dr,Room 3A-102,Msc 3715, Bethesda, MD 20892 USA.
EM stopferm@mail.nih.gov
NR 10
TC 4
Z9 5
U1 1
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0960-9822
EI 1879-0445
J9 CURR BIOL
JI Curr. Biol.
PD DEC 2
PY 2013
VL 23
IS 23
BP R1026
EP R1031
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 266FH
UT WOS:000328008300005
PM 24309273
ER
PT J
AU Walters, AD
Cohen-Fix, O
AF Walters, Alison D.
Cohen-Fix, Orna
TI Nuclear Division: Giving Daughters Their Fair Share
SO CURRENT BIOLOGY
LA English
DT Editorial Material
ID SCHIZOSACCHAROMYCES-JAPONICUS; MEMBRANE-PROTEINS; PORE COMPLEXES;
IN-VIVO; ENVELOPE; CHROMATIN; DYNAMICS; CELLS; PERIPHERY; TETHERS
C1 [Walters, Alison D.; Cohen-Fix, Orna] NIDDK, Lab Cell & Mol Biol, NIH, Bethesda, MD 20892 USA.
RP Walters, AD (reprint author), NIDDK, Lab Cell & Mol Biol, NIH, Bethesda, MD 20892 USA.
EM alison.walters@nih.gov; ornac@helix.nih.gov
NR 16
TC 0
Z9 0
U1 0
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0960-9822
EI 1879-0445
J9 CURR BIOL
JI Curr. Biol.
PD DEC 2
PY 2013
VL 23
IS 23
BP R1045
EP R1047
DI 10.1016/j.cub.2013.10.041
PG 3
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 266FH
UT WOS:000328008300013
PM 24309281
ER
PT J
AU Stanton, ME
Higgs, ES
Koblinsky, M
AF Stanton, Mary Ellen
Higgs, Elizabeth S.
Koblinsky, Marge
TI Investigating Financial Incentives for Maternal Health: An Introduction
SO JOURNAL OF HEALTH POPULATION AND NUTRITION
LA English
DT Article
DE Health services research: Maternal health services; Maternal
welfare/economics; Pregnancy; Programme evaluation
ID CHILD SURVIVAL
AB Projection of current trends in maternal and neonatal mortality reduction shows that many countries will fall short of the UN Millennium Development Goal 4 and 5. Underutilization of maternal health services contributes to this poor progress toward reducing maternal and neonatal morbidity and mortality. Moreover, the quality of services continues to lag in many countries, with a negative effect on the health of women and their babies, including deterring women from seeking care. To enhance the use and provision of quality maternal care, countries and donors are increasingly using financial incentives. This paper introduces the JHPN Supplement, in which each paper reviews the evidence of the effectiveness of a specific financial incentive instrument with the aim of improving the use and quality of maternal healthcare and impact. The US Agency for International Development and the US National Institutes of Health convened a US Government Evidence Summit on Enhancing Provision and Use of Maternal Health Services through Financial Incentives on 24-25 April 2012 in Washington, DC. The Summit brought together leading global experts in finance, maternal health, and health systems from governments, academia, development organizations, and foundations to assess the evidence on whether financial incentives significantly and substantially increase provision, use and quality of maternal health services, and the contextual factors that impact the effectiveness of these incentives. Evidence review teams evaluated the multidisciplinary evidence of various financial mechanisms, including supply-side incentives (e.g. performance-based financing, user fees, and various insurance mechanisms) and demand-side incentives (e.g. conditional cash transfers, vouchers, user fee exemptions, and subsidies for care-seeking). At the Summit, the teams presented a synthesis of evidence and initial recommendations on practice, policy, and research for discussion. The Summit enabled structured feedback on recommendations which the teams included in their final papers appearing in this Supplement. Papers in this Supplement review the evidence for a specific financial incentive mechanism (e.g. pay for performance, conditional cash transfer) to improve the use and quality of maternal healthcare and makes recommendations for programmes and future research. While data on programmes using financial incentives for improved use and indications of the quality of maternal health services support specific conclusions and recommendations, including those for future research, data linking the use of financial incentives with improved health outcomes are minimal.
C1 [Stanton, Mary Ellen; Koblinsky, Marge] US Agcy Int Dev, Washington, DC 20523 USA.
[Higgs, Elizabeth S.] NIAID, Bethesda, MD 20892 USA.
RP Stanton, ME (reprint author), US Agcy Int Dev, 1300 Penn Ave,NW, Washington, DC 20523 USA.
EM mstanton@usaid.gov
FU federal government; United States Agency for International Development;
National Institute of Allergy and Infectious Disease; Johns Hopkins
University School of Public Health; John Snow, Inc.
FX This work was carried out by US Federal Government Employees and persons
supported through contractual mechanisms by the federal government. This
is an open-access article under the terms of the Creative Attribution
License which permits unrestricted use, distribution, and reproduction
in any medium, provided that the original authors and source are
credited. The views and opinions in this paper are those of the authors
and not necessarily of the United States Agency for International
Development nor the National Institute of Allergy and Infectious
Diseases. Among the authors, MES is paid by the United States Agency for
International Development. ESH is paid by the National Institute of
Allergy and Infectious Disease and was on assignment with the Bureau for
Global Health at the United States Agency for International Development
during the planning of the Evidence Summit. MK is currently paid by the
United States Agency for International Development through an
Intergovernmental Personnel Act Assignment Agreement with Johns Hopkins
University School of Public Health and, during the summit planning, was
paid by John Snow, Inc.
NR 12
TC 1
Z9 1
U1 1
U2 3
PU ICDDR B
PI DHAKA
PA MOHAKHALI, 1212 DHAKA, BANGLADESH
SN 1606-0997
EI 2072-1315
J9 J HEALTH POPUL NUTR
JI J. Heatlh Popul. Nutr.
PD DEC
PY 2013
VL 31
IS 4
SU 2
BP 1
EP 7
PG 7
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AR7FZ
UT WOS:000343746200001
PM 24992799
ER
PT J
AU Morgan, L
Stanton, ME
Higgs, ES
Balster, RL
Bellows, BW
Brandes, N
Comfort, AB
Eichler, R
Glassman, A
Hatt, LE
Conlon, CM
Koblinsky, M
AF Morgan, Lindsay
Stanton, Mary Ellen
Higgs, Elizabeth S.
Balster, Robert L.
Bellows, Ben W.
Brandes, Neal
Comfort, Alison B.
Eichler, Rena
Glassman, Amanda
Hatt, Laurel E.
Conlon, Claudia M.
Koblinsky, Marge
TI Financial Incentives and Maternal Health: Where Do We Go from Here?
SO JOURNAL OF HEALTH POPULATION AND NUTRITION
LA English
DT Article
DE Healthcare-seeking behaviour; Health services research; Maternal health
services; economics/utilization; Motivation; Newborn health services;
Pregnancy; Programme evaluation
ID CASH TRANSFER PROGRAM; IMPACT EVALUATION; CARE; INSURANCE; ACCESS;
MEXICO; INTERVENTIONS; SERVICES; COVERAGE; INDIA
AB Health financing strategies that incorporate financial incentives are being applied in many low- and middle-income countries, and improving maternal and neonatal health is often a central goal. As yet, there have been few reviews of such programmes and their impact on maternal health. The US Government Evidence Summit on Enhancing Provision and use of Maternal Health Services through Financial Incentives was convened on 24-25 April 2012 to address this gap. This article, the final in a series assessing the effects of financial incentives-performance-based incentives (PBIs), insurance, user fee exemption programmes, conditional cash transfers, and vouchers-summarizes the evidence and discusses issues of context, programme design and implementation, cost=effectiveness, and sustainability. We suggest key areas to consider when designing and implementing financial incentive programmes for enhancing maternal health and highlight gaps in evidence that could benefit from additional research. Although the methodological rigor of studies varies, the evidence, overall, suggests that financial incentives can enhance demand for and improve the supply of maternal health services. Definitive evidence demonstrating a link between incentives and improved health outcomes is lacking; however, the evidence suggests that financial incentives can increase the quantity and quality of maternal health services and address health systems and financial barriers that prevent women from accessing and providers from delivering quality, lifesaving maternal healthcare.
C1 [Morgan, Lindsay] Broad Branch Associates, Washington, DC 20008 USA.
[Stanton, Mary Ellen; Brandes, Neal; Conlon, Claudia M.; Koblinsky, Marge] US Agcy Int Dev, Washington, DC 20523 USA.
[Higgs, Elizabeth S.] NIAID, Div Clin Res, Bethesda, MD 20892 USA.
[Balster, Robert L.] Virginia Commonwealth Univ, Richmond, VA USA.
[Bellows, Ben W.] Populat Council, Nairobi, Kenya.
[Comfort, Alison B.; Hatt, Laurel E.] ABT Associates Inc, Bethesda, MD USA.
[Glassman, Amanda] Ctr Global Dev, Washington, DC USA.
RP Morgan, L (reprint author), Broad Branch Associates, Washington, DC 20008 USA.
EM lindsaymorgan@broadbranch.org
FU National Academy of Sciences; Maternal and Child Health Integrated
Program through John Snow, Inc.; Johns Hopkins Bloomberg School of
Public Health; Maternal and Child Health Integrated Program of USAID
FX The views and opinions expressed in this paper are those of the authors
and not necessarily of the United States Agency for International
Development (USAID), the United States National Institute of Allergy and
Infectious Diseases (NIAID), or any of the affiliations of the authors.
Among the authors, ESH is paid by the National Institute of Allergy and
Infectious Diseases and was on assignment with the Bureau for Global
Health at USAID during the planning and execution of the Evidence
Summit. RLB is paid by Virginia Commonwealth University in Richmond, VA,
USA. During the planning of the Evidence Summit, he was a Jefferson
Science Fellow assigned to the USAID and received supplemental support
from the National Academy of Sciences. Currently, he receives part of
his salary through an Intergovernmental Personnel Act arrangement with
USAID. Lindsay Morgan was funded through the Maternal and Child Health
Integrated Program of USAID for this work. At the time of the Summit,
Marge Koblinsky was funded by the Maternal and Child Health Integrated
Program through John Snow, Inc.; she is now funded by Johns Hopkins
Bloomberg School of Public Health to work with USAID.
NR 34
TC 6
Z9 6
U1 2
U2 11
PU ICDDR B
PI DHAKA
PA MOHAKHALI, 1212 DHAKA, BANGLADESH
SN 1606-0997
EI 2072-1315
J9 J HEALTH POPUL NUTR
JI J. Heatlh Popul. Nutr.
PD DEC
PY 2013
VL 31
IS 4
SU 2
BP 8
EP 22
PG 15
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AR7FZ
UT WOS:000343746200002
PM 24992800
ER
PT J
AU Higgs, ES
Stammer, E
Roth, R
Balster, RL
AF Higgs, Elizabeth S.
Stammer, Emily
Roth, Rebecca
Balster, Robert L.
TI Evidence Acquisition and Evaluation for Evidence Summit on Enhancing
Provision and Use of Maternal Health Services through Financial
Incentives
SO JOURNAL OF HEALTH POPULATION AND NUTRITION
LA English
DT Article
DE Incentive; Maternal health services; Maternal mortality; Motivation;
Perinatal mortality; Prenatal care; Reimbursement
ID PROTECTING CHILDREN; FAMILY CARE
AB Recognizing the need for evidence to inform US Government and governments of the low- and middle-income countries on efficient, effective maternal health policies, strategies, and programmes, the US Government convened the Evidence Summit on Enhancing Provision and Use of Maternal Health Services through Financial Incentives in April 2012 in Washington, DC, USA. This paper summarizes the background and methods for the acquisition and evaluation of the evidence used for achieving the goals of the Summit. The goal of the Summit was to obtain multidisciplinary expert review of literature to inform both US Government and governments of the low- and middle-income countries on evidence-informed practice, policies, and strategies for financial incentives. Several steps were undertaken to define the tasks for the Summit and identify the appropriate evidence for review. The process began by identifying focal questions intended to inform governments of the low- and middle-income countries and the US Government about the efficacy of supply-and demand-side financial incentives for enhanced provision and use of quality maternal health services. Experts were selected representing the research and programme communities, academia, relevant non=governmental organizations, and government agencies and were assembled into Evidence Review Teams. This was followed by a systematic process to gather relevant peer-reviewed literature that would inform the focal questions. Members of the Evidence Review Teams were invited to add relevant papers not identified in the initial literature review to complete the bibliography. The Evidence Review Teams were asked to comply with a specific evaluation framework for recommendations on practice and policy based on both expert opinion and the quality of the data. Details of the search processes and methods used for screening and quality reviews are described.
C1 [Higgs, Elizabeth S.] NIAID, Bethesda, MD 20892 USA.
[Higgs, Elizabeth S.; Roth, Rebecca; Balster, Robert L.] US Agcy Int Dev, Washington, DC 20523 USA.
[Stammer, Emily] Knowledge Management Serv, Washington, DC USA.
[Balster, Robert L.] Virginia Commonwealth Univ, Richmond, VA USA.
RP Higgs, ES (reprint author), NIAID, Div Clin Res, NIH, DHHS, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM ehiggs@niaid.nih.gov
FU National Institute of Allergy and Infectious Diseases; Bureau for Global
Health at USAID; USAID; National Academy of Sciences
FX This work was carried out by the United States Federal Government
Employees and persons supported through contractual mechanisms by the
federal government. This is an open-access article under the terms of
the Creative Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided that the original
authors and source are credited. Among the authors, ESH is supported by
the National Institute of Allergy and Infectious Diseases and was on
assignment with the Bureau for Global Health at USAID during the
planning and execution of the Evidence Summit. ES is paid by Knowledge
Management Services in Washington, DC. This organization received
contractual funding from USAID for their work on the Evidence Summit. RR
is currently paid by USAID. During the planning of the Evidence Summit,
she was paid by the National Institutes of Health and was on assignment
with the Bureau for Global Health at USAID. RLB is paid by Virginia
Commonwealth University in Richmond, VA, USA. During the planning of the
Evidence Summit, he was a Jefferson Science Fellow assigned to USAID and
received supplemental support from the National Academy of Sciences. He
currently receives part of his salary through an Intergovernmental
Personnel Act arrangement with USAID. Under the direction of USAID
staff, Knowledge Management Services designed the search and screening
process, and USAID facilitated the publication of the manuscripts
resulting from the Evidence Summit process. No funding bodies had any
role in the data analysis or conclusions drawn from the literature
reviews. The views and opinions expressed in this paper are those of the
authors and not necessarily of the National Institutes of Health, the
Department of Health and Human Services, or the Government of the United
States.
NR 6
TC 2
Z9 2
U1 0
U2 0
PU ICDDR B
PI DHAKA
PA MOHAKHALI, 1212 DHAKA, BANGLADESH
SN 1606-0997
EI 2072-1315
J9 J HEALTH POPUL NUTR
JI J. Heatlh Popul. Nutr.
PD DEC
PY 2013
VL 31
IS 4
SU 2
BP 23
EP 35
PG 13
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AR7FZ
UT WOS:000343746200003
PM 24992801
ER
PT J
AU Glassman, A
Duran, D
Fleisher, L
Singer, D
Sturke, R
Angeles, G
Charles, J
Emrey, B
Gleason, J
Mwebsa, W
Saldana, K
Yarrow, K
Koblinsky, M
AF Glassman, Amanda
Duran, Denizhan
Fleisher, Lisa
Singer, Daniel
Sturke, Rachel
Angeles, Gustavo
Charles, Jodi
Emrey, Bob
Gleason, Joanne
Mwebsa, Winnie
Saldana, Kelly
Yarrow, Kristina
Koblinsky, Marge
TI Impact of Conditional Cash Transfers on Maternal and Newborn Health
SO JOURNAL OF HEALTH POPULATION AND NUTRITION
LA English
DT Article
DE Conditional cash transfers; Global health; Incentives; Maternal health;
Millennium Development Goals; Newborn health; Social protection
ID CLUSTER RANDOMIZED-TRIAL; JANANI SURAKSHA YOJANA; TRANSFER PROGRAM;
RURAL-AREAS; OPORTUNIDADES; MEXICO; INTERVENTIONS; DELIVERY; CARE;
INCENTIVES
AB Maternal and newborn health (MNH) is a high priority for global health and is included among the Millennium Development Goals (MDGs). However, the slow decline in maternal and newborn mortality jeopardizes achievements of the targets of MDGs. According to UNICEF, 60 million women give birth outside of health facilities, and family planning needs are satisfied for only 50%. Further, skilled birth attendance and the use of antenatal care are most inequitably distributed in maternal and newborn health interventions in low- and middle-income countries. Conditional cash transfer (CCT) programmes have been shown to increase health service utilization among the poorest but little is written on the effects of such programmes on maternal and newborn health. We carried out a systematic review of studies on CCT that report maternal and newborn health outcomes, including studies from 8 countries. The CCT programmes have increased antenatal visits, skilled attendance at birth, delivery at a health facility, and tetanus toxoid vaccination for mothers and reduced the incidence of low birthweight. The programmes have not had a significant impact on fertility while the impact on maternal and newborn mortality has not been well-documented thus far. Given these positive effects, we make the case for further investment in CCT programmes for maternal and newborn health, noting gaps in knowledge and providing recommendations for better design and evaluation of such programmes. We recommend more rigorous impact evaluations that document impact pathways and take factors, such as cost-effectiveness, into account.
C1 [Glassman, Amanda; Duran, Denizhan] Ctr Global Dev, Washington, DC 20036 USA.
[Fleisher, Lisa; Charles, Jodi; Emrey, Bob; Saldana, Kelly; Yarrow, Kristina; Koblinsky, Marge] US Agcy Int Dev, Washington, DC 20523 USA.
[Singer, Daniel] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Rockville, MD USA.
[Sturke, Rachel] NIH, Bethesda, MD 20892 USA.
[Angeles, Gustavo] Univ N Carolina, Chapel Hill, NC USA.
[Gleason, Joanne] Populat Council, New York, NY USA.
[Mwebsa, Winnie] Save The Children, Fairfield, CT USA.
RP Glassman, A (reprint author), Ctr Global Dev, 2055 L St NW Fifth Floor, Washington, DC 20036 USA.
EM aglassman@cgdev.org
NR 37
TC 10
Z9 10
U1 3
U2 13
PU ICDDR B
PI DHAKA
PA MOHAKHALI, 1212 DHAKA, BANGLADESH
SN 1606-0997
EI 2072-1315
J9 J HEALTH POPUL NUTR
JI J. Heatlh Popul. Nutr.
PD DEC
PY 2013
VL 31
IS 4
SU 2
BP 48
EP 66
PG 19
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AR7FZ
UT WOS:000343746200005
PM 24992803
ER
PT J
AU Bellows, BW
Conlon, CM
Higgs, ES
Townsend, JW
Nahed, MG
Cavanaugh, K
Grainger, CG
Okal, J
Gorter, AC
AF Bellows, Ben W.
Conlon, Claudia M.
Higgs, Elizabeth S.
Townsend, John W.
Nahed, Matta G.
Cavanaugh, Karen
Grainger, Corinne G.
Okal, Jerry
Gorter, Anna C.
TI A Taxonomy and Results from a Comprehensive Review of 28 Maternal Health
Voucher Programmes
SO JOURNAL OF HEALTH POPULATION AND NUTRITION
LA English
DT Review
DE Demand-side financing; Maternal healthcare; Results-based financing;
Vouchers
ID MILLENNIUM DEVELOPMENT GOALS; FACILITY-BASED DELIVERIES;
PAY-FOR-PERFORMANCE; DEVELOPING-COUNTRIES; SERVICE UTILIZATION; KENYA;
EQUITY; CARE; DEMAND; IMPACT
AB It is increasingly clear that Millennium Development Goal 4 and 5 will not be achieved in many low- and middle-income countries with the weakest gains among the poor. Recognizing that there are large inequalities in reproductive health outcomes, the post-2015 agenda on universal health coverage will likely generate strategies that target resources where maternal and newborn deaths are the highest. In 2012, the United States Agency for International Development convened an Evidence Summit to review the knowledge and gaps on the utilization of financial incentives to enhance the quality and uptake of maternal healthcare. The goal was to provide donors and governments of the low-and middle-income countries with evidence-informed recommendations on practice, policy, and strategies regarding the use of financial incentives, including vouchers, to enhance the demand and supply of maternal health services. The findings in this paper are intended to guide governments interested in maternal health voucher programmes with recommendations for sustainable implementation and impact. The Evidence Summit undertook a systematic review of five financing strategies. This paper presents the methods and findings for vouchers, building on a taxonomy to catalogue knowledge about voucher programme design and functionality. More than 120 characteristics under five major categories were identified: programme principles (objectives and financing); governance and management; benefits package and beneficiary targeting; providers (contracting and service pricing); and implementation arrangements (marketing, claims processing, and monitoring and evaluation). Among the 28 identified maternal health voucher programmes, common characteristics included: a stated objective to increase the use of services among the means-tested poor; contracted-out programme management; contracting either exclusively private facilities or a mix of public and private providers; prioritizing community-based distribution of vouchers; and tracking individual claims for performance purposes. Maternal voucher programmes differed on whether contracted providers were given training on clinical or administrative issues; whether some form of service verification was undertaken at facility or community-level; and the relative size of programme management costs in the overall programme budget. Evidence suggests voucher programmes can serve populations with national-level impact. Reaching scale depends on whether the voucher programme can: (i) keep management costs low, (ii) induce a large demand-side response among the bottom two quintiles, and (iii) achieve a quality of care that translates a greater number of facility-based deliveries into a reduction in maternal morbidity and mortality.
C1 [Bellows, Ben W.; Townsend, John W.; Okal, Jerry] Populat Council, Nairobi, Kenya.
[Conlon, Claudia M.; Nahed, Matta G.; Cavanaugh, Karen] US Agcy Int Dev, Washington, DC 20523 USA.
[Higgs, Elizabeth S.] NIAID, Bethesda, MD 20892 USA.
[Grainger, Corinne G.] Opt Consultancy Serv Ltd, London, England.
[Gorter, Anna C.] Inst Ctr Americano Salud, Managua, Nicaragua.
RP Bellows, BW (reprint author), Populat Council, POB 17643-00500, Nairobi, Kenya.
EM bbellows@popcouncil.org
NR 58
TC 12
Z9 12
U1 2
U2 9
PU ICDDR B
PI DHAKA
PA MOHAKHALI, 1212 DHAKA, BANGLADESH
SN 1606-0997
EI 2072-1315
J9 J HEALTH POPUL NUTR
JI J. Heatlh Popul. Nutr.
PD DEC
PY 2013
VL 31
IS 4
SU 2
BP 106
EP 128
PG 23
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health
GA AR7FZ
UT WOS:000343746200008
PM 24992806
ER
PT J
AU Tang, E
Arany, P
AF Tang, Elieza
Arany, Praveen
TI Photobiomodulation and implants: implications for dentistry
SO JOURNAL OF PERIODONTAL AND IMPLANT SCIENCE
LA English
DT Review
DE Dental implants; Low-level laser therapy; Peri-implantitis; Phototherapy
ID LEVEL LASER THERAPY; MINI-IMPLANTS; IN-VIVO; STABILITY; DISEASES;
RABBITS; BIOLOGY; TISSUE
AB The use of dental implants has become a mainstay of rehabilitative and restorative dentistry. With an impressive clinical success rate, there remain a few minor clinical issues with the use of implants such as peri-implant mucositis and peri-implantitis. The use of laser technology with implants has a fascinating breadth of applications, beginning from their precision manufacturing to clinical uses for surgical site preparation, reducing pain and inflammation, and promoting osseointegration and tissue regeneration. This latter aspect is the focus of this review, which outlines various studies of implants and laser therapy in animal models. The use of low level light therapy or photobiomodulation has demonstrated its efficacy in these studies. Besides more research studies to understand its molecular mechanisms, significant efforts are needed to standardize the clinical dosing and deliveryprotocols for laser therapy to ensure the maximal efficacy and safety of this potent clinical tool for photobiomodulation.
C1 [Tang, Elieza; Arany, Praveen] Natl Inst Dent & Craniofacial Res, Cell Regulat & Control Unit, NIH, Bethesda, MD 20892 USA.
RP Arany, P (reprint author), Natl Inst Dent & Craniofacial Res, Cell Regulat & Control Unit, NIH, 30 Convent Dr,3A-301, Bethesda, MD 20892 USA.
EM praveen.arany@nih.gov
FU Intramural Research Program, National Institute of Dental and
Craniofacial Research, National Institutes of Health
FX This work was funded by the Intramural Research Program, National
Institute of Dental and Craniofacial Research, National Institutes of
Health.
NR 29
TC 6
Z9 6
U1 1
U2 9
PU KOREAN ACAD PERIODONTOLOGY
PI SEOUL
PA OFFICIAL B-D 2212, 163 SINMUNRO 1-GA, JONGNO-GU, SEOUL, 110-990, SOUTH
KOREA
SN 2093-2278
EI 2093-2286
J9 J PERIODONTAL IMPLAN
JI J. Periodontal Implant Sci.
PD DEC
PY 2013
VL 43
IS 6
BP 262
EP 268
DI 10.5051/jpis.2013.43.6.262
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA AP8QP
UT WOS:000342344200003
PM 24455438
ER
PT J
AU Rigby, MR
DiMeglio, LA
Rendell, MS
Felner, EI
Dostou, JM
Gitelman, SE
Patel, CM
Griffin, KJ
Tsalikian, E
Gottlieb, PA
Greenbaum, CJ
Sherry, NA
Moore, WV
Monzavi, R
Willi, SM
Raskin, P
Moran, A
Russell, WE
Pinckney, A
Keyes-Elstein, L
Howell, M
Aggarwal, S
Lim, N
Phippard, D
Nepom, GT
McNamara, J
Ehlers, MR
AF Rigby, Mark R.
DiMeglio, Linda A.
Rendell, Marc S.
Felner, Eric I.
Dostou, Jean M.
Gitelman, Stephen E.
Patel, Chetanbabu M.
Griffin, Kurt J.
Tsalikian, Eva
Gottlieb, Peter A.
Greenbaum, Carla J.
Sherry, Nicole A.
Moore, Wayne V.
Monzavi, Roshanak
Willi, Steven M.
Raskin, Philip
Moran, Antoinette
Russell, William E.
Pinckney, Ashley
Keyes-Elstein, Lynette
Howell, Michael
Aggarwal, Sudeepta
Lim, Noha
Phippard, Deborah
Nepom, Gerald T.
McNamara, James
Ehlers, Mario R.
CA T1DAL Study Team
TI Targeting of memory T cells with alefacept in new-onset type 1 diabetes
(T1DAL study): 12 month results of a randomised, double-blind,
placebo-controlled phase 2 trial
SO LANCET DIABETES & ENDOCRINOLOGY
LA English
DT Article
ID CHRONIC PLAQUE PSORIASIS; C-PEPTIDE; THERAPY; PRESERVATION; MULTICENTER;
TEPLIZUMAB; RESPONSES
AB Background Type 1 diabetes results from autoimmune targeting of the pancreatic beta cells, likely mediated by effector memory T (Tem) cells. CD2, a T cell surface protein highly expressed on Tem cells, is targeted by the fusion protein alefacept, depleting Tem cells and central memory T (Tcm) cells. We postulated that alefacept would arrest autoimmunity and preserve residual beta cells in patients newly diagnosed with type 1 diabetes.
Methods The T1DAL study is a phase 2, double-blind, placebo-controlled trial in patients with type 1 diabetes, aged 12-35 years who, within 100 days of diagnosis, were enrolled at 14 US sites. Patients were randomly assigned (2: 1) to receive alefacept (two 12-week courses of 15 mg intramuscularly per week, separated by a 12-week pause) or a placebo. Randomisation was stratified by site, and was computer-generated with permuted blocks of three patients per block. All participants and site personnel were masked to treatment assignment. The primary endpoint was the change from baseline in mean 2 h C-peptide area under the curve (AUC) at 12 months. Secondary endpoints at 12 months were the change from baseline in the 4 h C-peptide AUC, insulin use, major hypoglycaemic events, and HbA(1c) concentrations. This trial is registered with ClinicalTrials.gov, number NCT00965458.
Findings Of 73 patients assessed for eligibility, 33 were randomly assigned to receive alefacept and 16 to receive placebo. The mean 2 h C-peptide AUC at 12 months increased by 0.015 nmol/L (95% CI-0.080 to 0.110) in the alefacept group and decreased by 0 115 nmol/L (-0.278 to 0.047) in the placebo group, and the difference between groups was not significant (p=0.065). However, key secondary endpoints were met: the mean 4 h C-peptide AUC was significantly higher (mean increase of 0.015 nmol/L [95% CI-0.076 to 0.106] vs decrease of -0.156 nmol/L [-0.305 to -0.006]; p=0.019), and daily insulin use (0.48 units per kg per day for placebo vs 0.36 units per kg per day for alefacept; p= 0.02) and the rate of hypoglycaemic events (mean of 10.9 events per person per year for alefacept vs 17.3 events for placebo; p< 0.0001) was significantly lower at 12 months in the alefacept group than in the placebo group. Mean HbA(1c) concentrations at week 52 were not different between treatment groups (p=0.75). So far, no serious adverse events were reported and all patients had at least one adverse event. In the alefacept group, 29 (88%) participants had an adverse event related to study drug versus 15 (94%) participants in the placebo group. In the alefacept group, 14 (42%) participants had grade 3 or 4 adverse events compared with nine (56%) participants in the placebo group; no deaths occurred.
Interpretation Although the primary outcome was not met, at 12 months, alefacept preserved the 4 h C-peptide AUC, lowered insulin use, and reduced hypoglycaemic events, suggesting efficacy. Safety and tolerability were similar in the alefacept and placebo groups. Alefacept could be useful to preserve beta-cell function in patients with new-onset type 1 diabetes.
C1 [Rigby, Mark R.; DiMeglio, Linda A.] Indiana Univ, Indianapolis, IN 46204 USA.
[Rigby, Mark R.; DiMeglio, Linda A.] Indiana Univ Hlth, Riley Hosp Children, Indianapolis, IN USA.
[Rendell, Marc S.] Creighton Diabet Ctr, Omaha, NE USA.
[Felner, Eric I.] Emory Univ, Atlanta, GA 30322 USA.
[Dostou, Jean M.] Univ N Carolina, Durham, NC USA.
[Gitelman, Stephen E.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Patel, Chetanbabu M.; Griffin, Kurt J.] Univ Arizona, Tucson, AZ USA.
[Tsalikian, Eva] Univ Iowa, Iowa City, IA USA.
[Gottlieb, Peter A.] Univ Colorado, Barbara Davis Ctr, Aurora, CO USA.
[Greenbaum, Carla J.; Nepom, Gerald T.] Benaroya Res Inst, Seattle, WA USA.
[Sherry, Nicole A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Moore, Wayne V.] Childrens Mercy Hosp, Kansas City, MO 64108 USA.
[Monzavi, Roshanak] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
[Willi, Steven M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Raskin, Philip] Univ Texas Dallas, SW Med Ctr, Dallas, TX USA.
[Moran, Antoinette] Univ Minnesota, Minneapolis, MN USA.
[Russell, William E.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Pinckney, Ashley; Keyes-Elstein, Lynette] Fed Syst Div, Chapel Hill, NC USA.
[Howell, Michael; Aggarwal, Sudeepta; Lim, Noha; Phippard, Deborah; Ehlers, Mario R.] Immune Tolerance Network, Bethesda, MD USA.
[McNamara, James] NIAID, Bethesda, MD 20892 USA.
RP Rigby, MR (reprint author), Indiana Hosp, 705 Riley Hosp Dr,ROC 4270, Indianapolis, IN 46202 USA.
EM mrigby@iu.edu
OI DiMeglio, Linda/0000-0002-8033-6078; Nepom, Gerald/0000-0002-8063-1464
FU US National Institutes of Health; Juvenile Diabetes Research Foundation
FX US National Institutes of Health and the Juvenile Diabetes Research
Foundation
NR 29
TC 54
Z9 54
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2213-8587
J9 LANCET DIABETES ENDO
JI Lancet Diabetes Endocrinol.
PD DEC
PY 2013
VL 1
IS 4
BP 284
EP 294
DI 10.1016/S2213-8587(13)70111-6
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AP1AV
UT WOS:000341799700013
PM 24622414
ER
PT J
AU Gitelman, SE
Gottlieb, PA
Rigby, MR
Felner, EI
Willi, SM
Fisher, LK
Moran, A
Gottschalk, M
Moore, WV
Pinckney, A
Keyes-Elstein, L
Aggarwal, S
Phippard, D
Sayre, PH
Ding, LN
Bluestone, JA
Ehlers, MR
AF Gitelman, Stephen E.
Gottlieb, Peter A.
Rigby, Mark R.
Felner, Eric I.
Willi, Steven M.
Fisher, Lynda K.
Moran, Antoinette
Gottschalk, Michael
Moore, Wayne V.
Pinckney, Ashley
Keyes-Elstein, Lynette
Aggarwal, Sudeepta
Phippard, Deborah
Sayre, Peter H.
Ding, Linna
Bluestone, Jeffrey A.
Ehlers, Mario R.
CA START Study Team
TI Antithymocyte globulin treatment for patients with recent-onset type 1
diabetes: 12-month results of a randomised, placebo-controlled, phase 2
trial
SO LANCET DIABETES & ENDOCRINOLOGY
LA English
DT Article
ID BETA-CELL FUNCTION; THYMOCYTE GLOBULIN; DOUBLE-BLIND; NOD MICE;
TRANSPLANTATION; THERAPY; RECONSTITUTION; INDEPENDENCE; INDUCTION;
MELLITUS
AB Background Type 1 diabetes results from T-cell-mediated destruction of beta cells. Findings from preclinical studies and pilot clinical trials suggest that antithymocyte globulin (ATG) might be effective for reducing this autoimmune response. We assessed the safety and efficacy of rabbit ATG in preserving islet function in participants with recentonset type 1 diabetes, and report here our 12-month results.
Methods For this phase 2, randomised, placebo-controlled, clinical trial, we enrolled patients with recent-onset type 1 diabetes, aged 12-35 years, and with a peak C-peptide of 0.4 nM or greater on mixed meal tolerance test from 11 sites in the USA. We used a computer generated randomisation sequence to randomly assign patients (2:1, with permuted-blocks of size three or six and stratified by study site) to receive either 6.5 mg/kg ATG or placebo over a course of four days. All participants were masked and initially managed by an unmasked drug management team, which managed all aspects of the study until month 3. Thereafter, to maintain masking for diabetes management throughout the remainder of the study, participants received diabetes management from an independent, masked study physician and nurse educator. The primary endpoint was the baseline-adjusted change in 2-h area under the curve C-peptide response to mixed meal tolerance test from baseline to 12 months. Analyses were by intention to treat. This is a planned interim analysis of an on-going trial that will run for 24 months of follow-up. This study is registered with ClinicalTrials.gov, number NCT00515099.
Findings Between Sept 10, 2007, and June 1, 2011, we screened 154 individuals, randomly allocating 38 to ATG and 20 to placebo. We recorded no between-group difference in the primary endpoint: participants in the ATG group had a mean change in C-peptide area under the curve of -0.195 pmol/mL (95% CI -0.292 to -0.098) and those in the placebo group had a mean change of -0.239 pmol/mL (-0.361 to -0.118) in the placebo group (p=0.591). All except one participant in the ATG group had both cytokine release syndrome and serum sickness, which was associated with a transient rise in interleukin-6 and acute-phase proteins. Acute T cell depletion occurred in the ATG group, with slow reconstitution over 12 months. However, effector memory T cells were not depleted, and the ratio of regulatory to effector memory T cells declined in the first 6 months and stabilised thereafter. ATG-treated patients had 159 grade 3-4 adverse events, many associated with T-cell depletion, compared with 13 in the placebo group, but we detected no between-group difference in incidence of infectious diseases.
Interpretation Our findings suggest that a brief course of ATG does not result in preservation of beta-cell function 12 months later in patients with new-onset type 1 diabetes. Generalised T-cell depletion in the absence of specific depletion of effector memory T cells and preservation of regulatory T cells seems to be an ineffective treatment for type 1 diabetes.
C1 [Gitelman, Stephen E.; Bluestone, Jeffrey A.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Gottlieb, Peter A.] Univ Colorado, Barbara Davis Ctr, Aurora, CO USA.
[Rigby, Mark R.] Indiana Univ, Indianapolis, IN 46204 USA.
[Rigby, Mark R.] Riley Childrens Hosp, Indianapolis, IN 46204 USA.
[Felner, Eric I.] Emory Univ, Atlanta, GA 30322 USA.
[Willi, Steven M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Fisher, Lynda K.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
[Moran, Antoinette] Univ Minnesota, Minneapolis, MN USA.
[Gottschalk, Michael] Univ Calif San Diego, San Diego, CA 92103 USA.
[Moore, Wayne V.] Childrens Mercy Hosp, Kansas City, MO 64108 USA.
[Pinckney, Ashley; Keyes-Elstein, Lynette] Rho Fed Syst Div, Chapel Hill, NC USA.
[Aggarwal, Sudeepta; Phippard, Deborah] Immune Tolerance Network, Bethesda, MD USA.
[Sayre, Peter H.; Ehlers, Mario R.] Immune Tolerance Network, San Francisco, CA USA.
[Ding, Linna] NIAID, Bethesda, MD 20892 USA.
RP Gitelman, SE (reprint author), Univ Calif San Francisco, Box 0434,Rm S-679,513 Parnassus Ave, San Francisco, CA 94143 USA.
EM sgitelma@peds.ucsf.edu
FU US National Institutes of Health; Juvenile Diabetes Research Foundation
FX US National Institutes of Health and the Juvenile Diabetes Research
Foundation.
NR 28
TC 47
Z9 49
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2213-8587
J9 LANCET DIABETES ENDO
JI Lancet Diabetes Endocrinol.
PD DEC
PY 2013
VL 1
IS 4
BP 306
EP 316
DI 10.1016/S2213-8587(13)70065-2
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AP1AV
UT WOS:000341799700015
PM 24622416
ER
PT J
AU Merke, DP
Poppas, DP
AF Merke, Deborah P.
Poppas, Dix P.
TI Management of adolescents with congenital adrenal hyperplasia
SO LANCET DIABETES & ENDOCRINOLOGY
LA English
DT Review
ID STEROID 21-HYDROXYLASE DEFICIENCY; BONE-MINERAL DENSITY;
GENOTYPE-PHENOTYPE CORRELATION; CLINICAL-PRACTICE GUIDELINE;
TERM-FOLLOW-UP; REST TUMORS; UROGENITAL MOBILIZATION; CONSENSUS
STATEMENT; ENDOCRINE-SOCIETY; LUTEINIZING-HORMONE
AB The management of congenital adrenal hyperplasia involves suppression of adrenal androgen production, in addition to treatment of adrenal insufficiency. Management of adolescents with congenital adrenal hyperplasia is especially challenging because changes in the hormonal milieu during puberty can lead to inadequate suppression of adrenal androgens, psychosocial issues often affect adherence to medical therapy, and sexual function plays a major part in adolescence and young adulthood. For these reasons, treatment regimen reassessment is indicated during adolescence. Patients with non-classic congenital adrenal hyperplasia require reassessment regarding the need for glucocorticoid drug treatment. No clinical trials have compared various regimens for classic congenital adrenal hyperplasia in adults, thus therapy is individualised and based on the prevention of adverse outcomes. Extensive patient education is key during transition from paediatric care to adult care and should include education of females with classic congenital adrenal hyperplasia regarding their genital anatomy and surgical history. Common issues for these patients include urinary incontinence, vaginal stenosis, clitoral pain, and cosmetic concerns; for males with classic congenital adrenal hyperplasia, common issues include testicular adrenal rest tumours. Transition from paediatric to adult care is most successful when phased over many years. Education of health-care providers on how to successfully transition patients is greatly needed.
C1 [Merke, Deborah P.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD 20892 USA.
[Merke, Deborah P.] NIH, Ctr Clin, Bethesda, MD 20892 USA.
[Poppas, Dix P.] New York Presbyterian Hosp, Weill Cornell Med Ctr, Comprehens Ctr Congenital Adrenal Hyperplasia, Komansky Ctr Childrens Hlth,Inst Pediat Urol, New York, NY USA.
RP Merke, DP (reprint author), NIH, Ctr Clin, Bethesda, MD 20892 USA.
EM dmerke@nih.gov
FU National Institutes of Health Clinical Center; Eunice Kennedy Shriver
National Institute of Child Health and Human Development (NICHD)
FX This work was supported (in part) by the Intramural Research Programs of
the National Institutes of Health Clinical Center and of the Eunice
Kennedy Shriver National Institute of Child Health and Human Development
(NICHD).
NR 100
TC 11
Z9 12
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2213-8587
J9 LANCET DIABETES ENDO
JI Lancet Diabetes Endocrinol.
PD DEC
PY 2013
VL 1
IS 4
BP 341
EP 352
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AP1AV
UT WOS:000341799700018
PM 24622419
ER
PT J
AU Sanchez, JL
Agan, BK
Tsai, AY
Macalino, GE
Wurapa, E
Mbuchi, M
Dueger, E
Horton, KC
Montano-Torres, SM
Tilley, DH
Saylors, KE
Puplampu, N
Duplessis, CC
Harrison, DJ
Putnam, SD
Garges, EC
Espinosa, BJ
Dejli, J
Meyers, M
Yingst, SL
Jerse, AE
Maktabi, HH
Burke, RL
Jordan, NN
Nowak, G
Hsu, K
Soge, OO
Holmes, KK
McClelland, RS
MacDonald, MR
Payin, JA
Gaydos, JC
Tramont, EC
AF Sanchez, Jose L.
Agan, Brian K.
Tsai, Alice Y.
Macalino, Grace E.
Wurapa, Eyako
Mbuchi, Margaret
Dueger, Erica
Horton, Katherine C.
Montano-Torres, Silvia M.
Tilley, Drake H.
Saylors, Karen E.
Puplampu, Naiki
Duplessis, Christopher C.
Harrison, Dustin J.
Putnam, Shannon D.
Garges, Eric C.
Espinosa, Benjamin J.
Dejli, Jamal
Meyers, Mitchell
Yingst, Samuel L.
Jerse, Ann E.
Maktabi, Hala H.
Burke, Ronald L.
Jordan, Nikki N.
Nowak, Gosia
Hsu, Katherine
Soge, Olusegun O.
Holmes, King K.
McClelland, R. Scott
MacDonald, Michael R.
Payin, Julie A.
Gaydos, Joel C.
Tramont, Edmund C.
TI Expanded Sexually Transmitted Infection Surveillance Efforts in the
United States Military: A Time for Action
SO MILITARY MEDICINE
LA English
DT Editorial Material
ID RESISTANT NEISSERIA-GONORRHOEAE; DISEASES-TREATMENT-GUIDELINES;
SIMPLEX-VIRUS TYPE-2; GONOCOCCAL INFECTIONS; QUADRIVALENT VACCINE;
HUMAN-PAPILLOMAVIRUS; HIV-INFECTION; NO LONGER; CHLAMYDIA; ARMY
C1 [Sanchez, Jose L.; Tsai, Alice Y.; Maktabi, Hala H.; Burke, Ronald L.; Gaydos, Joel C.] Armed Forces Hlth Surveillance Ctr, Silver Spring, MD 20904 USA.
[Sanchez, Jose L.; Payin, Julie A.; Gaydos, Joel C.] Henry M Jackson Fdn Adv Mil Med, Silver Spring, MD 20904 USA.
[Agan, Brian K.; Macalino, Grace E.] Uniformed Serv Univ Hlth Sci USU, Bethesda, MD 20814 USA.
[Wurapa, Eyako; Mbuchi, Margaret] US Embassy, US Army Med Res Unit Kenya, Nairobi 00621, Kenya.
[Dueger, Erica; Horton, Katherine C.] US Ctr Dis Control & Prevent, US Naval Med Res Unit 3, Cairo, Egypt.
[Dueger, Erica; Horton, Katherine C.] US Ctr Dis Control & Prevent, GDDRC, Cairo, Egypt.
[Montano-Torres, Silvia M.; Tilley, Drake H.] Ctr Med Naval CMST, US Naval Med Res Unit Peru 6, Lima, Peru.
[Saylors, Karen E.] Global Viral & Metabiota, San Francisco, CA 94104 USA.
[Puplampu, Naiki; Duplessis, Christopher C.] US Naval Med Res Unit 3 Detachment, Legon, Ghana.
[Puplampu, Naiki; Duplessis, Christopher C.] Univ Ghana, Noguchi Mem Inst Med Res, Legon, Ghana.
[Harrison, Dustin J.] US Naval Med Res Unit 2, JBPHH, Honolulu, HI 96860 USA.
[Putnam, Shannon D.] US Naval Hlth Res Ctr, San Diego, CA 92106 USA.
[Garges, Eric C.] Walter Reed Army Inst Res, Prevent Med Branch, Silver Spring, MD 20910 USA.
[Espinosa, Benjamin J.] US Naval Med Res Ctr, Biol Def Res Directorate, Ft Detrick, MD 21702 USA.
[Dejli, Jamal] US Naval Environm & Prevent Med Unit 2, Norfolk, VA 23511 USA.
[Meyers, Mitchell; Yingst, Samuel L.] Armed Forces Res Inst Med Sci, Bangkok 10400, Thailand.
[Jerse, Ann E.] Uniformed Serv Univ Hlth Sci USC, Bethesda, MD 20814 USA.
[Jordan, Nikki N.] USAPHC, Dis Epidemiol Program, Aberdeen Proving Ground, MD 21010 USA.
[Jordan, Nikki N.] Army Inst Publ Hlth, Aberdeen Proving Ground, MD 21010 USA.
[Nowak, Gosia] US Navy & Marine Corps Public Hlth Ctr NMCPHC, EpiData Ctr, Portsmouth, VA 23708 USA.
[Hsu, Katherine] Massachusetts Dept Publ Hlth, Div STD Prevent & HIV AIDS Surveillance, Boston, MA 02130 USA.
[Soge, Olusegun O.; Holmes, King K.; McClelland, R. Scott] Univ Washington, Harborview Med Ctr, Dept Global Hlth, Seattle, WA 98104 USA.
[Soge, Olusegun O.; Holmes, King K.; McClelland, R. Scott] Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA.
[MacDonald, Michael R.] Navy & Marine Corps Public Hlth Ctr, Sexual Hlth & Responsibil Program, Portsmouth, VA 23708 USA.
[Tramont, Edmund C.] NIAID, Div Clin Res, NIH, Rockville, MD 20852 USA.
RP Sanchez, JL (reprint author), Armed Forces Hlth Surveillance Ctr, 11800 Tech Rd,Suite 220, Silver Spring, MD 20904 USA.
OI Agan, Brian/0000-0002-5114-1669
NR 58
TC 0
Z9 1
U1 0
U2 5
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD DEC
PY 2013
VL 178
IS 12
BP 1271
EP 1280
DI 10.7205/MILMED-D-13-00137
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA AN7UF
UT WOS:000340805800001
PM 24306007
ER
PT J
AU Talbot, LA
Metter, EJ
Fleg, JL
Weinstein, AA
Frick, KD
AF Talbot, Laura A.
Metter, E. Jeffrey
Fleg, Jerome L.
Weinstein, Ali A.
Frick, Kevin D.
TI Cost Effectiveness of Two Army Physical Fitness Programs
SO MILITARY MEDICINE
LA English
DT Article
ID HEART-DISEASE RISK; INTERVENTION; SCORES
AB Repeated failure in the Army Physical Fitness Test (APFT) is associated with lower fitness level, premature discharge, and significant career disruption, at high economic and health costs to the individual soldier and the U.S. Army. We used cost-effectiveness analysis to estimate the health and economic implications of two exercise interventions for Army National Guard (ARNG) soldiers who had failed the APFT, a traditional remediation program and a new pedometer-based program called Fitness for Life, involving individual counseling and follow-up telephone calls. Effectiveness of the interventions was analyzed in terms of APFT pass rates and calculated 10-year coronary heart disease risk. Costs were calculated based on tracking of resources used in the programs. APFT pass rates were 54.3% and 47.9%, respectively, for traditional and Fitness for Life programs, p = not significant. Neither program affected 10-year coronary heart disease risk. For assumed APFT pass rates up to 40% without any formal remediation, both the traditional remediation program and the ARNG Fitness for Life intervention had cost savings without significant group differences. Depending on the ARNG unit and personnel preference, although the Fitness for Life Program was more expensive and thus less cost-effective, either program could be cost-effective and of benefit to the military.
C1 [Talbot, Laura A.] Univ Tennessee, Hlth Sci Ctr, Coll Nursing, Memphis, TN 38163 USA.
[Metter, E. Jeffrey] NIA, Clin Res Branch, Harbor Hosp, Baltimore, MD 21225 USA.
[Fleg, Jerome L.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA.
[Weinstein, Ali A.] George Mason Univ, Ctr Study Chron Illness & Disabil, Fairfax, VA 22030 USA.
[Frick, Kevin D.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
RP Talbot, LA (reprint author), Univ Tennessee, Hlth Sci Ctr, Coll Nursing, 920 Madison Ave,Suite 1045, Memphis, TN 38163 USA.
FU TriService Nursing Research Program, Uniformed Services University of
the Health Sciences (USU); DHHS, NIH, National Center for Research
Resources [5 M01 RR0279]; Johns Hopkins Bayview General Clinical
Research Center; National Institutes of Health, National Institute on
Aging
FX We thank the Army National Guard Volunteers in the Fitness for Life
Study. This research was sponsored by the TriService Nursing Research
Program, Uniformed Services University of the Health Sciences (USU). USU
is the awarding and administering office.; We acknowledge the core
laboratory and data management support, and equipment provided by Johns
Hopkins Bayview General Clinical Research Center, (which is funded by
DHHS, NIH, National Center for Research Resources, No. 5 M01 RR0279) and
the Intramural Research Program of the National Institutes of Health,
National Institute on Aging. This research is funded by Triservice
Nursing Research Program, Johns Hopkins Bayview General Clinical
Research Center, and the Intramural Research Program of the National
Institutes of Health, National Institute on Aging.
NR 8
TC 2
Z9 2
U1 2
U2 3
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD DEC
PY 2013
VL 178
IS 12
BP 1353
EP 1357
DI 10.7205/MILMED-D-13-00118
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA AN7UF
UT WOS:000340805800013
PM 24306019
ER
PT J
AU Pun, T
Nijholt, A
AF Pun, Thierry
Nijholt, Anton
TI Report on the 2013 Affective Computing and Intelligent Interaction
Conference (ACII 2013)
SO AI MAGAZINE
LA English
DT Article
AB The 2013 Affective Computing and Intelligent Interaction Conference (ACII 2013) was held in Geneva, Switzerland, September 2-5, 2013. This report summarizes the major events of the conference.
C1 [Pun, Thierry] Univ Geneva, Dept Comp Sci, Geneva, Switzerland.
[Pun, Thierry] Univ Geneva, Comp Vis & Multimedia Lab, Geneva, Switzerland.
[Pun, Thierry] NIH, Bethesda, MD 20892 USA.
[Pun, Thierry] CERN European Lab, Meyrin, Switzerland.
[Nijholt, Anton] TNO Delft, Delft, Netherlands.
[Nijholt, Anton] Philips Reseatch Europe, Leiden, Netherlands.
RP Pun, T (reprint author), Univ Geneva, Dept Comp Sci, Geneva, Switzerland.
FU IEEE Computer Society; AAAI - the American Association for Artificial
Intelligence
FX ACII 2013 was organized by the Computer Vision and Multimedia Laboratory
and the Swiss Center for Affective Sciences of the University of Geneva,
Switzerland. The conference was technically cosponsored by the IEEE
Computer Society and by AAAI - the American Association for Artificial
Intelligence. Electronic proceedings were distributed to the
participants on an USB stick, and all papers will be available on IEEE
Xplore. Two special journal issues of selected works presented at ACII
are planned, in the IEEE Transactions on Affective Computing
(editor-in-chief, Jonathan Gratch) and in the Springer Journal on
Multimodal User Interfaces (editor-in-chief, Jean-Claude Martin).
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC ARTIFICIAL INTELL
PI MENLO PK
PA 445 BURGESS DRIVE, MENLO PK, CA 94025-3496 USA
SN 0738-4602
J9 AI MAG
JI AI Mag.
PD WIN
PY 2013
VL 34
IS 4
BP 121
EP 122
PG 2
WC Computer Science, Artificial Intelligence
SC Computer Science
GA AI5FY
UT WOS:000336892000011
ER
PT J
AU Li, KG
Jurkowski, JM
Davison, KK
AF Li, Kaigang
Jurkowski, Janine M.
Davison, Kirsten K.
TI Social Support May Buffer the Effect of Intrafamilial Stressors on
Preschool Children's Television Viewing Time in Low-Income Families
SO CHILDHOOD OBESITY
LA English
DT Article
ID PHYSICAL-ACTIVITY QUESTIONNAIRE; DEPRESSIVE SYMPTOMS; SEDENTARY
BEHAVIOR; OBESITY; INTERVENTION; ASSOCIATION; VALIDITY; ADOLESCENTS;
OVERWEIGHT; CHILDHOOD
AB Background: Excessive television (TV) viewing in preschool children has been linked to negative outcomes during childhood, including childhood obesity. In a sample of low-income families, this study examined associations between intrafamilial factors and preschool children's TV-viewing time and the moderating effect of social support from nonfamily members on this association.
Methods: In 2010, 129 mothers/female guardians of 2- to 5-year-old children enrolled at five Head Start centers in Rensselaer County, New York, completed a self-report survey. The survey assessed child TV-viewing time (including TV, DVDs, and videos) and intrafamilial risk factors, including maternal perceived stress, depressive symptoms, TV viewing, leisure-time physical activity (inactivity), and family functioning. Social support from nonfamily members (nonfamily social support) was also measured and examined as an effect modifier.
Results: Children watched TV an average of 160 minutes per day. Moderate depressive symptoms (Personal Health Questionnaire depression scale scores >= 10), higher perceived stress, poorer family functioning, and higher maternal TV-viewing were significantly and independently associated with greater minutes of child TV viewing, controlling for covariates. In all instances, nonfamily social support moderated these associations, such that negative experiences within the family environment were linked with higher child TV-viewing time under conditions of low nonfamily social support, but not high nonfamily support.
Conclusions: Social support from nonfamily members may buffer potentially negative effects of intrafamilial factors on preschool children's TV-viewing time.
C1 [Li, Kaigang; Jurkowski, Janine M.] SUNY Albany, Sch Publ Hlth, Dept Hlth Policy Management & Behav, Rensselaer, NY USA.
[Davison, Kirsten K.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
RP Li, KG (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Hlth Behav Branch, 6100 Execut Blvd,7B13C, Bethesda, MD 20892 USA.
EM lik2@mail.nih.gov
FU National Institutes of Health [5R24MD004865]
FX The authors express their sincere gratitude to the Commission on
Economic Opportunity for the Greater Capital Region, and the Head Start
families they serve, for their commitment to the project. The authors
also thank the members of their advisory board for the extensive hours
and insight the members contributed to the design, implementation, and
evaluation of the CHL program. This research was supported by the
National Institutes of Health (grant no.: 5R24MD004865).
NR 45
TC 2
Z9 2
U1 2
U2 15
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2153-2168
EI 2153-2176
J9 CHILD OBES
JI Child Obes.
PD DEC
PY 2013
VL 9
IS 6
BP 484
EP 491
DI 10.1089/chi.2013.0071
PG 8
WC Pediatrics
SC Pediatrics
GA AI5GA
UT WOS:000336892200004
PM 24168754
ER
PT J
AU Ho, N
Kim, J
Prasad, V
AF Ho, Nancy
Kim, Julie
Prasad, Vinay
TI Dense breasts and legislating medicine
SO CLEVELAND CLINIC JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID SCREENING MAMMOGRAPHY; CANCER; FREQUENCY; APPROVAL; ACT
C1 [Ho, Nancy] Univ Maryland, Dept Med, Div Gastroenterol, Baltimore, MD 21201 USA.
[Kim, Julie] Northwestern Univ, Dept Med, Chicago, IL 60611 USA.
[Prasad, Vinay] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA.
RP Prasad, V (reprint author), NCI, Med Oncol Branch, NIH, 10 Ctr Dr 10-12N226, Bethesda, MD 20892 USA.
EM vinayak.prasad@nih.gov
NR 15
TC 2
Z9 2
U1 1
U2 1
PU CLEVELAND CLINIC
PI CLEVELAND
PA 9500 EUCLID AVE, CLEVELAND, OH 44106 USA
SN 0891-1150
EI 1939-2869
J9 CLEV CLIN J MED
JI Clevel. Clin. J. Med.
PD DEC
PY 2013
VL 80
IS 12
BP 768
EP 770
DI 10.3949/ccjm.80a.13048
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA AI2ZR
UT WOS:000336728200007
PM 24307160
ER
PT J
AU Lackritz, EM
Wilson, CB
Guttmacher, AE
Howse, JL
Engmann, CM
Rubens, CE
Mason, EM
Muglia, LJ
Gravett, MG
Goldenberg, RL
Murray, JC
Spong, CY
Simpson, JL
AF Lackritz, Eve M.
Wilson, Christopher B.
Guttmacher, Alan E.
Howse, Jennifer L.
Engmann, Cyril M.
Rubens, Craig E.
Mason, Elizabeth M.
Muglia, Louis J.
Gravett, Michael G.
Goldenberg, Robert L.
Murray, Jeffrey C.
Spong, Catherine Y.
Simpson, Joe Leigh
CA Preterm Birth Res Priority Setting
TI A solution pathway for preterm birth: accelerating a priority research
agenda
SO LANCET GLOBAL HEALTH
LA English
DT Editorial Material
C1 [Lackritz, Eve M.; Rubens, Craig E.; Gravett, Michael G.] GAPPS, Seattle, WA 98101 USA.
[Wilson, Christopher B.; Engmann, Cyril M.; Murray, Jeffrey C.] Bill & Melinda Gates Fdn, Seattle, WA USA.
[Guttmacher, Alan E.; Spong, Catherine Y.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
[Howse, Jennifer L.; Simpson, Joe Leigh] March Dimes Fdn, White Plains, NY USA.
[Mason, Elizabeth M.] World Hlth Org, Dept Maternal Newborn Child & Adolescent Hlth, Geneva, Switzerland.
[Muglia, Louis J.] Univ Cincinnati, Coll Med, Dept Pediat, Perinatal Inst, Cincinnati, OH USA.
[Gravett, Michael G.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA.
[Goldenberg, Robert L.] Columbia Univ, Dept Obstet & Gynecol, Med Ctr, New York, NY USA.
[Murray, Jeffrey C.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.
RP Lackritz, EM (reprint author), GAPPS, Seattle, WA 98101 USA.
EM eve.lackritz@seattlechildrens.org
FU NICHD NIH HHS [P01 HD011149, R01 HD069819]
NR 12
TC 12
Z9 12
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2214-109X
J9 LANCET GLOB HEALTH
JI Lancet Glob. Health
PD DEC
PY 2013
VL 1
IS 6
BP E328
EP E330
DI 10.1016/S2214-109X(13)70120-7
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AH8YH
UT WOS:000336423600010
PM 25104592
ER
PT J
AU Feuermann, Y
Kang, K
Gavrilova, O
Haetscher, N
Jang, SJ
Yoo, KH
Jiang, CT
Gonzalez, FJ
Robinson, GW
Hennighausen, L
AF Feuermann, Yonatan
Kang, Keunsoo
Gavrilova, Oksana
Haetscher, Nadine
Jang, Seung Jin
Yoo, Kyung Hyun
Jiang, Changtao
Gonzalez, Frank J.
Robinson, Gertraud W.
Hennighausen, Lothar
TI MiR-193b and miR-365-1 are not required for the development and function
of brown fat in the mouse
SO RNA BIOLOGY
LA English
DT Article
DE brown fat; miR-193b; mouse; gene knock-out; RNA-seq
ID SKELETAL-MUSCLE; DIFFERENTIATION; EXPRESSION; GENE; MICE; PROLIFERATION;
MICRORNA-133; PRDM16; WHITE
AB Generating heat and maintaining body temperature is the primary function of brown adipose tissue ( BAT). Previous studies have implicated microRNAs, including miR-193b and miR-365-1, in BAT differentiation. We used mouse genetics to further understand the specific contributions of these two miRs. BAT function in mice with an inactivated miR-193b-365-1 locus, as determined by their response to the selective beta 3 adrenergic receptor agonist CL316.243 and their tolerance to cold exposure, was normal and expression of genes associated with functional BAT, including Prdm16 and Ucp1, was unaffected. In addition, genome-wide expression profiles of miRNAs and mRNAs in BAT in the presence and absence of miR-193b-365-1 were determined. In summary, these data demonstrate, in contrast to earlier work, that the development, differentiation, and function of BAT do not require the presence of miR-193b and miR-365-1.
C1 [Feuermann, Yonatan; Kang, Keunsoo; Haetscher, Nadine; Jang, Seung Jin; Yoo, Kyung Hyun; Robinson, Gertraud W.; Hennighausen, Lothar] NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA.
[Gavrilova, Oksana] NIDDK, Mouse Metab Core, NIH, Bethesda, MD 20892 USA.
[Jiang, Changtao; Gonzalez, Frank J.] NCI, Lab Metab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Haetscher, Nadine] Goethe Univ Frankfurt, Inst Tumor Biol & Expt Therapy, D-60054 Frankfurt, Germany.
[Haetscher, Nadine] Goethe Univ Frankfurt, LOEWE Ctr Cell & Gene Therapy Frankfurt, D-60054 Frankfurt, Germany.
[Haetscher, Nadine] Goethe Univ Frankfurt, Dept Hematol Oncol, D-60054 Frankfurt, Germany.
RP Hennighausen, L (reprint author), NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA.
EM lotharh@mail.nih.gov
OI Feuermann, Yonatan/0000-0002-6561-6397
FU NIDDK; NCI; German Jose Carreras Leukemia Foundation [DJCLS R11/02];
LOEWE Center for Cell and Gene Therapy Frankfurt; Hessisches Ministerium
fur Wissenschaft und Kunst [III L 4-518/17.004 (2010)];
Georg-Speyer-Haus
FX This work was supported by the NIDDK and NCI Intramural Research
Programs. We acknowledge Tatyana Chanturiya for technical support, Kai
Ge (NIDDK) and Vittorio Sartorelli (NIAMS) for reagents and advice, Marc
Reitman for scientific input and Michael Rieger for comments. N.H. was
supported by the German Jose Carreras Leukemia Foundation (DJCLS R11/02)
and by the LOEWE Center for Cell and Gene Therapy Frankfurt, Hessisches
Ministerium fur Wissenschaft und Kunst (III L 4-518/17.004 (2010) and
the Georg-Speyer-Haus.
NR 30
TC 10
Z9 12
U1 0
U2 0
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1547-6286
EI 1555-8584
J9 RNA BIOL
JI RNA Biol.
PD DEC
PY 2013
VL 10
IS 12
BP 1807
EP 1814
DI 10.4161/rna.27239
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AH6OO
UT WOS:000336250500006
PM 24356587
ER
PT J
AU Sharma, ST
Nieman, LK
AF Sharma, S. T.
Nieman, L. K.
TI Is prolactin measurement of value during inferior petrosal sinus
sampling in patients with adrenocorticotropic hormone-dependent
Cushing's Syndrome?
SO JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
LA English
DT Review
DE Cushing's syndrome; inferior petrosal sinus sampling; IPSS; prolactin
ID CORTICOTROPIN-RELEASING-HORMONE; PITUITARY VENOUS EFFLUENT;
DIFFERENTIAL-DIAGNOSIS; ENDOCRINE MARKERS; DISEASE; CATHETERIZATION; CRF
AB Inferior petrosal sinus sampling (IPSS) is considered the gold standard test to distinguish between Cushing's disease (CD) and ectopic ACTH syndrome (EAS). Anomalous venous drainage, abnormal venous anatomy, and lack of expertise can lead to false-negative IPSS results and thereby misclassification of patients with ACTH-dependent Cushing's syndrome. Prolactin measurement during IPSS can improve diagnostic accuracy and decrease false negative results. A baseline prolactin inferior petrosal sinus to peripheral (IPS/P) ratio (ipsilateral to the dominant post-CRH ACTH IPS/P ratio) of 1.8 or more suggests successful catheterization during IPSS. Prolactin-normalized ACTH IPS/P ratios can then be used to differentiate between a pituitary and ectopic source of ACTH. Values <= 0.7 are suggestive of EAS and those >= 1.3 are indicative of CD, but the implication of values between 0.7 and 1.3 remains unclear and needs further investigation. Larger prospective studies are also needed for further evaluation of the role of contralateral prolactin IPS/P ratios, postCRH prolactin values, and prolactin-adjusted ACTH inter-sinus ratios for tumor localization in CD. (C) 2013, Editrice Kurtis
C1 [Sharma, S. T.; Nieman, L. K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Program Reprod & Adult Endocrinol, NIH, Bethesda, MD USA.
RP Sharma, ST (reprint author), Bldg 10 CRC 1East Rm 3140,10 Ctr Dr, Bethesda, MD 20892 USA.
EM sharmast@mail.nih.gov
FU intramural program of the Eunice Kennedy Shriver National Institute of
Child Health and Human Development, National Institutes of Health
FX This work was supported by the intramural program of the Eunice Kennedy
Shriver National Institute of Child Health and Human Development,
National Institutes of Health.
NR 20
TC 4
Z9 4
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1720-8386
J9 J ENDOCRINOL INVEST
JI J. Endocrinol. Invest.
PD DEC
PY 2013
VL 36
IS 11
BP 1112
EP 1116
DI 10.3275/9067
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AG1BW
UT WOS:000335151000032
PM 23887034
ER
PT J
AU Calvo, E
Campos-Chagas, A
Oliveira, LF
Valenzuela, JG
Ribeiro, JMC
AF Calvo, Eric
Campos-Chagas, Andrezza
Oliveira, Luiz F.
Valenzuela, Jesus G.
Ribeiro, Jose M. C.
TI LUNDEP, A SALIVARY ENDONUCLEASE FROM SAND FLIES INCREASES LEISHMANIA
PARASITE SURVIVAL IN NEUTROPHILS
SO PATHOGENS AND GLOBAL HEALTH
LA English
DT Meeting Abstract
C1 [Calvo, Eric; Campos-Chagas, Andrezza; Oliveira, Luiz F.; Valenzuela, Jesus G.; Ribeiro, Jose M. C.] NIAID, NIH, Lab Malaria & Vector Res, Rockville, MD 20852 USA.
RI Ribeiro, Jose/J-7011-2015
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 2047-7724
EI 2047-7732
J9 PATHOG GLOB HEALTH
JI Pathog. Glob. Health
PD DEC
PY 2013
VL 107
IS 8
BP 407
EP 407
PG 1
WC Public, Environmental & Occupational Health; Parasitology; Tropical
Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
Medicine
GA AF9SZ
UT WOS:000335056200024
ER
PT J
AU Campos-Chagas, A
Ribeiro, J
Calvo, E
AF Campos-Chagas, Andrezza
Ribeiro, Jose
Calvo, Eric
TI SIMPLAGRIN, A SALIVARY COLLAGEN BINDING PROTEIN INHIBITS PLATELET
AGGREGATION AND ADHESION UNDER HIGH SHEAR STRESS
SO PATHOGENS AND GLOBAL HEALTH
LA English
DT Meeting Abstract
C1 [Campos-Chagas, Andrezza; Ribeiro, Jose; Calvo, Eric] NIAID, NIH, Lab Malaria & Vector Res, Rockville, MD 20852 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 2047-7724
EI 2047-7732
J9 PATHOG GLOB HEALTH
JI Pathog. Glob. Health
PD DEC
PY 2013
VL 107
IS 8
BP 407
EP 407
PG 1
WC Public, Environmental & Occupational Health; Parasitology; Tropical
Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
Medicine
GA AF9SZ
UT WOS:000335056200023
ER
PT J
AU Calvo, E
Chagas, A
Sa-Nunes, A
Kotsyfakis, M
Ribeiro, JMC
AF Calvo, Eric
Chagas, Andrezza
Sa-Nunes, Anderson
Kotsyfakis, Michail
Ribeiro, Jose M. C.
TI MOSQUITO SALIVARY SERPINS: PUTTING THE BREAKS ON BLOT CLOTTING
SO PATHOGENS AND GLOBAL HEALTH
LA English
DT Meeting Abstract
C1 [Calvo, Eric; Chagas, Andrezza; Ribeiro, Jose M. C.] NIAID, Vector Biol Sect, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA.
[Sa-Nunes, Anderson] Univ Sao Paulo, Dept Immunol, Inst Biomed Sci, BR-05508 Sao Paulo, Brazil.
[Kotsyfakis, Michail] Acad Sci Czech Republic, Inst Parasitol, Ctr Biol, CR-37005 Ceske Budejovice, Czech Republic.
RI Kotsyfakis, Michail/G-9525-2014; Sa-Nunes, Anderson/D-8667-2012
OI Kotsyfakis, Michail/0000-0002-7526-1876; Sa-Nunes,
Anderson/0000-0002-1859-4973
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 2047-7724
EI 2047-7732
J9 PATHOG GLOB HEALTH
JI Pathog. Glob. Health
PD DEC
PY 2013
VL 107
IS 8
BP 413
EP 414
PG 2
WC Public, Environmental & Occupational Health; Parasitology; Tropical
Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
Medicine
GA AF9SZ
UT WOS:000335056200040
ER
PT J
AU Chmelar, J
Calvo, E
Kotal, J
Andersen, J
Ribeiro, J
Pedra, J
Francischetti, I
Kotsyfakis, M
AF Chmelar, Jindrich
Calvo, Eric
Kotal, Jan
Andersen, John
Ribeiro, Jose
Pedra, Joao
Francischetti, Ivo
Kotsyfakis, Michail
TI THE ROLE OF PROTEOLYSIS IN ARTHROPOD VECTORIAL CAPACITY
SO PATHOGENS AND GLOBAL HEALTH
LA English
DT Meeting Abstract
C1 [Chmelar, Jindrich; Kotal, Jan; Kotsyfakis, Michail] Acad Sci Czech Republic, Inst Parasitol, Ctr Biol, Lab Genom & Prote Dis Vectors, CR-37005 Ceske Budejovice, Czech Republic.
[Calvo, Eric; Andersen, John; Ribeiro, Jose; Francischetti, Ivo] NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD USA.
[Pedra, Joao] Univ Calif Riverside, Ctr Dis Vector Res, Riverside, CA 92521 USA.
[Pedra, Joao] Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA.
RI Kotsyfakis, Michail/G-9525-2014; Ribeiro, Jose/J-7011-2015
OI Kotsyfakis, Michail/0000-0002-7526-1876;
NR 0
TC 0
Z9 0
U1 1
U2 2
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 2047-7724
EI 2047-7732
J9 PATHOG GLOB HEALTH
JI Pathog. Glob. Health
PD DEC
PY 2013
VL 107
IS 8
BP 413
EP 413
PG 1
WC Public, Environmental & Occupational Health; Parasitology; Tropical
Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
Medicine
GA AF9SZ
UT WOS:000335056200039
ER
PT J
AU Diabate, A
Niang, A
Sawadogo, S
Maiga, H
Dabire, R
Tripet, F
Lehmann, T
AF Diabate, Abdoulaye
Niang, Abdoulaye
Sawadogo, Simon
Maiga, Hamidou
Dabire, Roch
Tripet, Frederic
Lehmann, Tovi
TI ASSESSMENT OF THE ECOLOGICALLY DEPENDENT POSTMATING ISOLATION BETWEEN
THE MOLECULAR FORMS OF ANOPHELES GAMBIAE
SO PATHOGENS AND GLOBAL HEALTH
LA English
DT Meeting Abstract
C1 [Diabate, Abdoulaye; Niang, Abdoulaye; Sawadogo, Simon; Maiga, Hamidou; Dabire, Roch] IRSS Ctr Muraz, Bobo Dioulassso, Burkina Faso.
[Tripet, Frederic] Keele Univ, Keele, Staffs, England.
[Lehmann, Tovi] NIAID, LMVR, NIH, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU MANEY PUBLISHING
PI LEEDS
PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND
SN 2047-7724
EI 2047-7732
J9 PATHOG GLOB HEALTH
JI Pathog. Glob. Health
PD DEC
PY 2013
VL 107
IS 8
BP 449
EP 449
PG 1
WC Public, Environmental & Occupational Health; Parasitology; Tropical
Medicine
SC Public, Environmental & Occupational Health; Parasitology; Tropical
Medicine
GA AF9SZ
UT WOS:000335056200131
ER
PT J
AU Ison, CA
Deal, C
Unemo, M
AF Ison, Catherine A.
Deal, Carolyn
Unemo, Magnus
TI Current and future treatment options for gonorrhoea
SO SEXUALLY TRANSMITTED INFECTIONS
LA English
DT Article
DE antimicrobial resistance; Neisseria gonorrhoeae; cefixime; Gonorrhoea;
ceftriaxone; antimicrobial treatment
ID RESISTANT NEISSERIA-GONORRHOEAE; HIGH-LEVEL RESISTANCE; TREATMENT
FAILURE; PHARYNGEAL GONORRHEA; ANTIMICROBIAL SUSCEPTIBILITY;
AZITHROMYCIN RESISTANCE; UNTREATABLE GONORRHEA; CEFTRIAXONE; STRAINS;
EMERGENCE
AB The delivery of effective antimicrobial therapy is essential for public health control of gonorrhoea, in the absence of a suitable vaccine. The antimicrobial agent chosen should have high efficacy and quality, lack toxicity and give > 95% success when given empirically. Guidelines, which are informed by surveillance data, are used to aid clinicians in their choice of appropriate agent. Historically, gonorrhoea treatment has been delivered as a single, directly observed dose but this has resulted in failure of successive antimicrobial agents which have been replaced by a new antimicrobial to which resistance has been rare or non-existing. Following the drift towards decreased susceptibility and treatment failure to the extended spectrum cephalosporins, and the lack of 'new' alternative antimicrobials, the threat of difficult to treat or untreatable gonorrhoea has emerged. The challenge of maintaining gonorrhoea as a treatable infection has resulted in national, regional and global response or action plans. This review discusses different approaches to the future treatment of gonorrhoea including; use of ceftriaxone, the injectable cephalosporin at increased dosage; dual antimicrobial therapy; use of drugs developed for other infections and use of older agents, directed by rapid point of care tests, to susceptible infections. Finally, it is considered whether the time is right to readdress the possibility of developing an effective gonococcal vaccine, given the major advances in our understanding of natural infection, molecular pathogenesis and the revolution in molecular biology techniques.
C1 [Ison, Catherine A.] Publ Hlth England, Microbiol Serv, Sexually Transmitted Bacteria Reference Unit, London NW9 5EQ, England.
[Deal, Carolyn] NIAID, Bethesda, MD 20892 USA.
[Unemo, Magnus] Orebro Univ Hosp, Dept Lab Med, WHO Collaborating Ctr Gonorrhoea & Other STIs, Orebro, Sweden.
RP Ison, CA (reprint author), Publ Hlth England, Microbiol Serv, Sexually Transmitted Bacteria Reference Unit, 61 Colindale Ave, London NW9 5EQ, England.
EM Catherine.Ison@phe.gov.uk
FU Merck
FX CAI has received a grant from Merck to test alternative antimicrobial
agents to Neisseria gonorrhoeae.
NR 60
TC 18
Z9 18
U1 1
U2 15
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1368-4973
EI 1472-3263
J9 SEX TRANSM INFECT
JI Sex. Transm. Infect.
PD DEC
PY 2013
VL 89
IS 4
SU 4
BP 52
EP 56
DI 10.1136/sextrans-2012-050913
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA AE3VS
UT WOS:000333907100012
ER
PT J
AU Jerse, AE
Deal, CD
AF Jerse, Ann E.
Deal, Carolyn D.
TI Vaccine research for gonococcal infections: where are we?
SO SEXUALLY TRANSMITTED INFECTIONS
LA English
DT Article
DE VACCINATION; IMMUNOSUPPRESSION; GONORRHOEA; ANTIGEN; IMMUNOLOGY
ID OUTER-MEMBRANE PROTEIN; NEISSERIA-GONORRHOEAE; PATHOGENIC NEISSERIA;
EPITHELIAL-CELLS; SEROGROUP-B; ANTIBODIES; MENINGITIDIS; BINDING;
IDENTIFICATION; CANDIDATE
AB Gonorrhoea continues to seriously impact human society with an estimated 106 million new infections occurring annually. The consequence of gonorrhoea on reproductive and neonatal health is especially concerning as is its role in the spread of HIV. Current control measures rely on the identification and treatment of infected individuals and their sexual contacts. The success of this strategy, which is already inadequate, is lessened by poor diagnostic capabilities in many parts of the world and challenged by the rapid emergence of antibiotic-resistant strains. The potential of untreatable gonorrhoea is now real, and a gonorrhoea vaccine is seriously needed. Historically, gonorrhoea vaccine research has been hampered by the antigenic variability of the gonococcal surface, a lack of known protective mechanisms, and the absence of a small laboratory animal model for testing candidate vaccines and manipulating host responses. Here we discuss recent advances that have rekindled research efforts towards a gonorrhoea vaccine. Several conserved and semiconserved vaccine antigens have been identified that elicit bactericidal antibodies or inhibit target function. A mouse genital tract infection model is available for systematic testing of vaccines, and transgenic mice have been developed to relieve host restrictions. Additionally, several immunological advances have been made including the identification of mechanisms by which Neisseria gonorrhoeae suppresses the adaptive response and the demonstration that Th1 responses clear experimental infection in mice and induce a protective memory response. We also discuss important issues with respect to product development that must be considered when entering the vaccine pipeline.
C1 [Jerse, Ann E.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Microbiol & Immunol, Bethesda, MD 20814 USA.
[Deal, Carolyn D.] NIAID, Sexually Transmitted Dis Branch, NIH, Bethesda, MD 20892 USA.
RP Jerse, AE (reprint author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.
EM ann.jerse@usuhs.edu
FU National Institute of Health [U19 AI31496]
FX Funding for this work was provided to AEJ by grant number U19 AI31496
from the National Institute of Health.
NR 35
TC 6
Z9 8
U1 4
U2 15
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1368-4973
EI 1472-3263
J9 SEX TRANSM INFECT
JI Sex. Transm. Infect.
PD DEC
PY 2013
VL 89
IS 4
SU 4
BP 63
EP 68
DI 10.1136/sextrans-2013-051225
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA AE3VS
UT WOS:000333907100015
PM 24243883
ER
PT J
AU Fradkin, JE
Cowie, CC
Hanlon, MC
Rodgers, GP
AF Fradkin, Judith E.
Cowie, Catherine C.
Hanlon, Mary C.
Rodgers, Griffin P.
TI Celebrating 30 Years of Research Accomplishments of the Diabetes Control
and Complications Trial/Epidemiology of Diabetes Interventions and
Complications Study
SO DIABETES
LA English
DT Article
ID BLOOD-GLUCOSE CONTROL; PITTSBURGH EPIDEMIOLOGY; CARDIOVASCULAR-DISEASE;
COGNITIVE FUNCTION; GLYCEMIC CONTROL; RISK-FACTORS; TYPE-1; MELLITUS;
RETINOPATHY; THERAPY
C1 [Fradkin, Judith E.; Cowie, Catherine C.] Natl Inst Diabet & Digest & Kidney Dis, Div Diabet Endocrinol & Metab Dis, NIH, Bethesda, MD 20892 USA.
[Hanlon, Mary C.] Natl Inst Diabet & Digest & Kidney Dis, Off Sci Program & Policy Anal, NIH, Bethesda, MD USA.
[Rodgers, Griffin P.] Natl Inst Diabet & Digest & Kidney Dis, NIH, Bethesda, MD USA.
RP Fradkin, JE (reprint author), Natl Inst Diabet & Digest & Kidney Dis, Div Diabet Endocrinol & Metab Dis, NIH, Bethesda, MD 20892 USA.
EM fradkinj@mail.nih.gov
NR 50
TC 3
Z9 4
U1 2
U2 5
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD DEC
PY 2013
VL 62
IS 12
BP 3963
EP 3967
DI 10.2337/db13-1108
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AE1OJ
UT WOS:000333738500005
PM 24264393
ER
PT J
AU Piaggi, P
Krakoff, J
Bogardus, C
Thearle, MS
AF Piaggi, Paolo
Krakoff, Jonathan
Bogardus, Clifton
Thearle, Marie S.
TI Lower " Awake and Fed Thermogenesis" Predicts Future Weight Gain in
Subjects With Abdominal Adiposity
SO DIABETES
LA English
DT Article
ID MEAL-INDUCED THERMOGENESIS; GLUCOSE-INDUCED THERMOGENESIS;
ENERGY-EXPENDITURE; RESPIRATORY CHAMBER; OBESE SUBJECTS; POSTPRANDIAL
THERMOGENESIS; INDIRECT CALORIMETRY; PIMA-INDIANS; BODY-WEIGHT; FOOD
AB Awake and fed thermogenesis (AFT) is the energy expenditure (EE) of the nonactive fed condition above the minimum metabolic requirement during sleep and is composed of the thermic effect of food and the cost of being awake. AFT was estimated from whole-room 24-h EE measures in 509 healthy subjects (368 Native Americans and 141 whites) while subjects consumed a eucaloric diet. Follow-up data were available for 290 Native Americans (median follow-up time: 6.6 years). AFT accounted for approximate to 10% of 24-h EE and explained a significant portion of deviations from expected energy requirements. Energy intake was the major determinant of AFT. AFT, normalized as a percentage of intake, was inversely related to age and fasting glucose concentration and showed a nonlinear relationship with waist circumference and BMI. Spline analysis demonstrated that AFT becomes inversely related to BMI at an inflection point of 29 kg/m(2). The residual variance of AFT, after accounting for covariates, predicted future weight change only in subjects with a BMI >29 kg/m(2). AFT may influence daily energy balance, is reduced in obese individuals, and predicts future weight gain in these subjects. Once central adiposity develops, a blunting of AFT may occur that then contributes to further weight gain.
C1 [Piaggi, Paolo; Krakoff, Jonathan; Bogardus, Clifton; Thearle, Marie S.] Natl Inst Diabet & Digest & Kidney Dis, Obes & Diabet Clin Res Sect, NIH, Phoenix, AZ USA.
[Piaggi, Paolo] Univ Hosp Pisa, Endocrinol Unit, Obes Res Ctr, Pisa, Italy.
RP Piaggi, P (reprint author), Natl Inst Diabet & Digest & Kidney Dis, Obes & Diabet Clin Res Sect, NIH, Phoenix, AZ USA.
EM paolo.piaggi@gmail.com
OI Piaggi, Paolo/0000-0003-2774-9161
FU National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases
FX This work was supported by the Intramural Research Program of the
National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases.
NR 42
TC 10
Z9 10
U1 0
U2 2
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD DEC
PY 2013
VL 62
IS 12
BP 4043
EP 4051
DI 10.2337/db13-0785
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AE1OJ
UT WOS:000333738500020
PM 23974925
ER
PT J
AU von Wilamowitz-Moellendorff, A
Hunter, RW
Garcia-Rocha, M
Kang, L
Lopez-Soldado, I
Lantier, L
Patel, K
Peggie, MW
Martinez-Pons, C
Voss, M
Calbo, J
Cohen, PTW
Wasserman, DH
Guinovart, JJ
Sakamoto, K
AF von Wilamowitz-Moellendorff, Alexander
Hunter, Roger W.
Garcia-Rocha, Mar
Kang, Li
Lopez-Soldado, Iliana
Lantier, Louise
Patel, Kashyap
Peggie, Mark W.
Martinez-Pons, Carlos
Voss, Martin
Calbo, Joaquim
Cohen, Patricia T. W.
Wasserman, David H.
Guinovart, Joan J.
Sakamoto, Kei
TI Glucose-6-Phosphate-Mediated Activation of Liver Glycogen Synthase Plays
a Key Role in Hepatic Glycogen Synthesis
SO DIABETES
LA English
DT Article
ID INTRACELLULAR-DISTRIBUTION; INSULIN-RESISTANCE; RAT HEPATOCYTES;
IN-VIVO; GLUCOSE; METABOLISM; PHOSPHORYLATION; PROTEIN; MUSCLE;
MECHANISMS
AB The liver responds to an increase in blood glucose levels in the postprandial state by uptake of glucose and conversion to glycogen. Liver glycogen synthase (GYS2), a key enzyme in glycogen synthesis, is controlled by a complex interplay between the allosteric activator glucose-6-phosphate (G6P) and reversible phosphorylation through glycogen synthase kinase-3 and the glycogen-associated form of protein phosphatase 1. Here, we initially performed mutagenesis analysis and identified a key residue (Arg(582)) required for activation of GYS2 by G6P. We then used GYS2 Arg(582)Ala knockin (+/R582A) mice in which G6P-mediated GYS2 activation had been profoundly impaired (60-70%), while sparing regulation through reversible phosphorylation. R582A mutant-expressing hepatocytes showed significantly reduced glycogen synthesis with glucose and insulin or glucokinase activator, which resulted in channeling glucose/G6P toward glycolysis and lipid synthesis. GYS2(+/R582A) mice were modestly glucose intolerant and displayed significantly reduced glycogen accumulation with feeding or glucose load in vivo. These data show that G6P-mediated activation of GYS2 plays a key role in controlling glycogen synthesis and hepatic glucose-G6P flux control and thus whole-body glucose homeostasis.
C1 [von Wilamowitz-Moellendorff, Alexander; Hunter, Roger W.; Patel, Kashyap; Peggie, Mark W.; Voss, Martin; Cohen, Patricia T. W.; Sakamoto, Kei] Univ Dundee, Coll Life Sci, MRC, Prot Phosphorylat Unit, Dundee, Scotland.
[Garcia-Rocha, Mar; Lopez-Soldado, Iliana; Martinez-Pons, Carlos; Calbo, Joaquim; Guinovart, Joan J.] Univ Barcelona, Inst Res Biomed, Barcelona, Spain.
[Garcia-Rocha, Mar; Lopez-Soldado, Iliana; Martinez-Pons, Carlos; Calbo, Joaquim; Guinovart, Joan J.] Univ Barcelona, Dept Biochem & Mol Biol, Barcelona, Spain.
[Garcia-Rocha, Mar; Lopez-Soldado, Iliana; Martinez-Pons, Carlos; Calbo, Joaquim; Guinovart, Joan J.] CIBERDEM, Barcelona, Spain.
[Kang, Li; Lantier, Louise; Wasserman, David H.] Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37212 USA.
[Kang, Li; Lantier, Louise; Wasserman, David H.] Vanderbilt Univ, Sch Med, Mouse Metab Phenotyping Ctr, Nashville, TN 37212 USA.
RP Sakamoto, K (reprint author), Univ Dundee, Coll Life Sci, MRC, Prot Phosphorylat Unit, Dundee, Scotland.
EM kei.sakamoto@rd.nestle.com
OI Patel, Kashyap/0000-0002-9240-8104
FU Diabetes UK; British Heart Foundation; British Medical Research Council
(MRC); MRC; Wellcome Trust [093991/Z/10/Z]; National Institutes of
Health [R37 DK050277, U24 DK059637]; Ministry of Science and Innovation,
Spain [BFU2011-30554]; Autonomous Government of Catalonia
[2009SGR-1176]; Fundacion Marcelino Botin; CIBERDEM (Instituto de Salud
Carlos III); AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Merck
Co. Inc.; Merck KGaA; Pfizer
FX This study was supported by Diabetes UK (to K. S.), British Heart
Foundation (to K. S.), and British Medical Research Council (MRC). A. v.
W.-M. was supported by an MRC studentship, and K. P. was supported by
the Wellcome Trust PhD Programme for Clinicians (093991/Z/10/Z). D. H.
W. was supported by National Institutes of Health Grants R37 DK050277
and U24 DK059637. J.J.G. was supported by the Ministry of Science and
Innovation, Spain (BFU2011-30554); by the Autonomous Government of
Catalonia (2009SGR-1176); by a grant from the Fundacion Marcelino Botin;
and by CIBERDEM (Instituto de Salud Carlos III).; The authors also thank
the pharmaceutical companies supporting the Division of Signal
Transduction Therapy (DSTT) Unit (AstraZeneca, Boehringer Ingelheim,
GlaxoSmithKline, Merck & Co. Inc., Merck KGaA, and Pfizer) for financial
support (to K. S. and P. T. W. C.). No other potential conflicts of
interest relevant to this article were reported.
NR 36
TC 12
Z9 12
U1 2
U2 10
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD DEC
PY 2013
VL 62
IS 12
BP 4070
EP 4082
DI 10.2337/db13-0880
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AE1OJ
UT WOS:000333738500023
PM 23990365
ER
PT J
AU Wang, L
Teng, RF
Di, LJ
Rogers, H
Wu, H
Kopp, JB
Noguchi, CT
AF Wang, Li
Teng, Ruifeng
Di, Lijun
Rogers, Heather
Wu, Hong
Kopp, Jeffrey B.
Noguchi, Constance Tom
TI PPAR alpha and Sirt1 Mediate Erythropoietin Action in Increasing
Metabolic Activity and Browning of White Adipocytes to Protect Against
Obesity and Metabolic Disorders
SO DIABETES
LA English
DT Article
ID PANCREATIC BETA-CELLS; ADIPOSE-TISSUE; INSULIN-RESISTANCE; MITOCHONDRIAL
DYSFUNCTION; GLUCOSE-HOMEOSTASIS; ENDOTHELIAL-CELLS; ADULT HUMANS; FAT;
RECEPTOR; MICE
AB Erythropoietin (EPO) has shown beneficial effects in the regulation of obesity and metabolic syndrome; however, the detailed mechanism is still largely unknown. Here, we created mice with adipocyte-specific deletion of EPO receptor. These mice exhibited obesity and decreased glucose tolerance and insulin sensitivity, especially when fed a high-fat diet. Moreover, EPO increased oxidative metabolism, fatty acid oxidation, and key metabolic genes in adipocytes and in white adipose tissue from diet-induced obese wild-type mice. Increased metabolic activity by EPO is associated with induction of brown fat-like features in white adipocytes, as demonstrated by increases in brown fat gene expression, mitochondrial content, and uncoupled respiration. Peroxisome proliferator-activated receptor (PPAR) was found to mediate EPO activity because a PPAR antagonist impaired EPO-mediated induction of brown fat-like gene expression and uncoupled respiration. PPAR also cooperates with Sirt1 activated by EPO through modulating the NAD+ level to regulate metabolic activity. PPAR targets, including PPAR coactivator 1, uncoupling protein 1, and carnitine palmitoyltransferase 1, were increased by EPO but impaired by Sirt1 knockdown. Sirt1 knockdown also attenuated adipose response to EPO. Collectively, EPO, as a novel regulator of adipose energy homeostasis via these metabolism coregulators, provides a potential therapeutic strategy to protect against obesity and metabolic disorders.
C1 [Wang, Li; Teng, Ruifeng; Rogers, Heather; Noguchi, Constance Tom] NIDDK, Mol Med Branch, NIH, Bethesda, MD 20892 USA.
[Wang, Li; Di, Lijun] Univ Macau, Fac Hlth Sci, Macao, Peoples R China.
[Teng, Ruifeng] NIDDK, Mouse Metab Core Lab, NIH, Bethesda, MD 20892 USA.
[Wu, Hong] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA.
[Kopp, Jeffrey B.] NIDDK, Kidney Dis Branch, NIH, Bethesda, MD 20892 USA.
RP Noguchi, CT (reprint author), NIDDK, Mol Med Branch, NIH, Bethesda, MD 20892 USA.
EM connien@helix.nih.gov
RI Di, Li-jun/B-3352-2011
FU Intramural Research Program of the National Institute of Diabetes and
Digestive and Kidney Diseases; National Institutes of Health
FX This work was supported by the Intramural Research Program of the
National Institute of Diabetes and Digestive and Kidney Diseases and the
National Institutes of Health.
NR 52
TC 33
Z9 36
U1 0
U2 11
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0012-1797
EI 1939-327X
J9 DIABETES
JI Diabetes
PD DEC
PY 2013
VL 62
IS 12
BP 4122
EP 4131
DI 10.2337/db13-0518
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AE1OJ
UT WOS:000333738500028
PM 23990359
ER
PT J
AU Murata, M
Sanbe, A
Lee, JW
Nishigori, H
AF Murata, Masatoshi
Sanbe, Atushi
Lee, Jung Wha
Nishigori, Hideo
TI Laser-Induced Intrachoroidal Dexamethasone Drug Delivery System to
Posterior Eye Segment
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE dexamethasone; drug delivery system; intrachoroidal implantation;
photocoagulation; uveitis
ID CHORIORETINAL VENOUS ANASTOMOSIS; RETINAL VEIN OCCLUSION;
ENDOTOXIN-INDUCED UVEITIS; INDOCYANINE GREEN; SUBCONJUNCTIVAL INJECTION;
INTRAVITREAL INJECTION; SUBRETINAL SPACE; MACULAR EDEMA; GROWTH-FACTOR;
GLUCOCORTICOIDS
AB PURPOSE. To investigate the feasibility of laser-induced intrachoroidal dexamethasone (DEX) delivery as a potentially useful therapy for adjusting the most effective drug level to the posterior segment eye diseases.
METHODS. An implant was prepared by dissolving poly(DL-lactide) and DEX. In vitro release of DEX was evaluated at 7, 14, and 28 days by ELISA. In vivo, a DEX implant was inserted into a rabbit choroid, and 10, 50, or 200 burns of photocoagulation were applied at the implant lesion. After treatment, the vitreous humor was immediately aspirated and the DEX level was measured by liquid chromatography/mass spectrometry/mass spectrometry. Furthermore, the vitreous DEX level was measured at 1, 7, 14, and 28 days after implantation and 50 burns of photocoagulation. The toxicity of the laser-induced DEX implant was evaluated by ophthalmoscopy and light microscopy. Endotoxin-induced uveitis (EIU) was induced after DEX implantation and photocoagulation, and anti-inflammatory activities were evaluated by grading clinical signs, protein concentrations, and histopathologic studies.
RESULTS. Photocoagulation significantly increased the DEX release from the implant at 7 days in vitro. In vivo, the DEX implant exposed to 10, 50, and 200 burns of photocoagulation increased the vitreous DEX levels in a dose-dependent manner. The vitreous DEX level in the DEX implant applied to 50 burns of photocoagulation peaked 1 day after treatment. The laser-induced DEX implant showed no retinal abnormalities except the implantation site, and significantly inhibited the EIU.
CONCLUSIONS. Laser-induced intrachoroidal DEX delivery controls the DEX level in the vitreous humor and effectively prevents the experimental uveitis.
C1 [Murata, Masatoshi] Murata Eye Clin, Morioka, Iwate 0200122, Japan.
[Murata, Masatoshi; Sanbe, Atushi; Nishigori, Hideo] Iwate Med Univ, Sch Pharm, Dept Pharmacotherapeut, Yahaba, Iwate, Japan.
[Lee, Jung Wha] NEI, Retinal Cell & Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
RP Murata, M (reprint author), Murata Eye Clin, 5-8-30 Mitake, Morioka, Iwate 0200122, Japan.
EM murata-ganka@cap.ocn.ne.jp
NR 49
TC 2
Z9 2
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2013
VL 54
IS 13
BP 8317
EP 8324
DI 10.1167/iovs.13-13078
PG 8
WC Ophthalmology
SC Ophthalmology
GA AD1ZM
UT WOS:000333032200026
PM 24265021
ER
PT J
AU Young, NS
AF Young, Neal S.
TI Current concepts in the pathophysiology and treatment of aplastic anemia
SO HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
LA English
DT Article
ID RABBIT ANTITHYMOCYTE GLOBULIN; IMMUNOSUPPRESSIVE THERAPY; PLUS
CYCLOSPORINE; CELLS; MUTATIONS; SURVIVAL
AB Historically viewed in isolation as an odd, rare, and invariably fatal blood disease, aplastic anemia is now of substantial interest for its immune pathophysiology, its relationship to constitutional BM failure syndromes and leukemia, and the success of both stem cell transplantation and immunosuppressive therapies in dramatically improving survival of patients. Once relegated to a few presentations in the red cell and anemia sessions of the ASH, the Society now sponsors multiple simultaneous sessions and plenary and scientific committee presentations on these topics. This update emphasizes developments in our understanding of immune mechanisms and hematopoietic stem cell biology and new clinical approaches to stem cell stimulation as a therapy, alone and in combination with conventional suppression of the aberrant immune system.
C1 NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.
RP Young, NS (reprint author), NHLBI, Hematol Branch, NIH, CRC Bldg 10,Room 3E-5142,10 Ctr Dr, Bethesda, MD 20892 USA.
EM youngns@nih.mail.gov
NR 37
TC 32
Z9 34
U1 0
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 1520-4391
EI 1520-4383
J9 HEMATOL-AM SOC HEMAT
JI Hematol.-Am. Soc. Hematol. Educ. Program
PD DEC
PY 2013
BP 76
EP 81
PG 6
WC Education, Scientific Disciplines; Hematology
SC Education & Educational Research; Hematology
GA AB6LP
UT WOS:000331900300013
ER
PT J
AU Childs, RW
Berg, M
AF Childs, Richard W.
Berg, Maria
TI Bringing natural killer cells to the clinic: ex vivo manipulation
SO HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
LA English
DT Article
ID HEMATOPOIETIC STEM-CELLS; BLOOD MONONUCLEAR-CELLS; ACUTE
MYELOID-LEUKEMIA; HUMAN NK CELLS; MULTIPLE-MYELOMA; LARGE-SCALE;
TUMOR-CELLS; CELLULAR CYTOTOXICITY; ACTIVATING RECEPTORS;
GENETIC-MODIFICATION
AB Recently, there has been a substantial gain in our understanding of the role that natural killer (NK) cells play in mediating innate host immune responses against viruses and cancer. Although NK cells have long been known to be capable of killing cancer cells independently of antigen recognition, the full therapeutic potential of NK cell-based immunotherapy has yet to be realized. Here we review novel methods to activate and expand human NK cells ex vivo for adoptive transfer in humans, focusing on the important phenotypic and functional differences observed among freshly isolated, cytokine activated, and ex vivo-expanded NK populations.
C1 [Childs, Richard W.; Berg, Maria] NHLBI, Sect Transplantat Immunotherapy, Hematol Branch, NIH, Bethesda, MD 20892 USA.
RP Childs, RW (reprint author), NIH, Sect Transplantat Immunotherapy, Bldg 10 CRC,Rm 3-5330,10 Ctr Dr, Bethesda, MD 20892 USA.
EM childsr@nhlbi.nih.gov
NR 79
TC 28
Z9 28
U1 1
U2 15
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 1520-4391
EI 1520-4383
J9 HEMATOL-AM SOC HEMAT
JI Hematol.-Am. Soc. Hematol. Educ. Program
PD DEC
PY 2013
BP 234
EP 246
PG 13
WC Education, Scientific Disciplines; Hematology
SC Education & Educational Research; Hematology
GA AB6LP
UT WOS:000331900300033
ER
PT J
AU Fry, TJ
Mackall, CL
AF Fry, Terry J.
Mackall, Crystal L.
TI T-cell adoptive immunotherapy for acute lymphoblastic leukemia
SO HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
LA English
DT Article
ID ANTI-CD22 IMMUNOTOXIN; CHIMERIC RECEPTORS; CLINICAL-TRIAL; ZETA-CHAIN;
IN-VIVO; CD28; COSTIMULATION; PERSISTENCE; ACTIVATION; SURVIVAL
AB Substantial progress has been made in the treatment of precursor B-cell acute lymphoblastic leukemia (B-ALL), but recurrent disease remains a leading cause of death in children due to cancer and outcomes for adults with B-ALL remain poor. Recently, complete clinical responses have been observed in small numbers of patients with B-ALL treated with adoptive immunotherapy using T cells genetically engineered to express chimeric antigen receptors (CARs) targeting CD19, a cell surface molecule present in essentially all cases of B-ALL. Preclinical data suggest that CARs targeting CD22, another antigen present in the majority of B-ALL cases, are similarly potent. Several clinical studies already under way will soon more clearly define the rate of response to this novel therapy in B-ALL. Further work is needed to identify optimal platforms for CAR-based adoptive immunotherapy for leukemia, to establish guidelines for managing toxicity, and to determine whether the remissions induced by this approach can be rendered durable.
C1 [Fry, Terry J.; Mackall, Crystal L.] NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA.
RP Mackall, CL (reprint author), NCI, Ctr Canc Res, Bldg 10 Hatfield CRC,Room 1W-3750, Bethesda, MD 20892 USA.
EM mackallc@mail.nih.gov
NR 42
TC 12
Z9 12
U1 2
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 1520-4391
EI 1520-4383
J9 HEMATOL-AM SOC HEMAT
JI Hematol.-Am. Soc. Hematol. Educ. Program
PD DEC
PY 2013
BP 348
EP 353
PG 6
WC Education, Scientific Disciplines; Hematology
SC Education & Educational Research; Hematology
GA AB6LP
UT WOS:000331900300050
ER
PT J
AU Little, RF
Dunleavy, K
AF Little, Richard F.
Dunleavy, Kieron
TI Update on the treatment of HIV-associated hematologic malignancies
SO HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; NON-HODGKIN-LYMPHOMA; INFUSIONAL EPOCH
CHEMOTHERAPY; AIDS-RELATED LYMPHOMA; INTENSIVE CHEMOTHERAPY; INFECTED
PATIENTS; CODOX-M/IVAC; BURKITTS-LYMPHOMA; IMMUNODEFICIENCY; RITUXIMAB
AB HIV is associated with an excess cancer risk, particularly of lymphoid malignancies. Modern therapeutics has changed the landscape of HIV disease and typical opportunistic complications of AIDS are now largely avoided. Although the risk of lymphoma has decreased, it still remains high. Nevertheless, treatment outcomes have improved due both to improvements in HIV medicine and in cancer therapeutics for the common lymphomas occurring in those with HIV infection. Other hematologic malignancies are rarely seen in HIV-infected patients, but the standardized risk ratio for many of these cancers is higher than in the background population. Principles of cancer care and appreciation for HIV infection as a comorbid condition can guide physicians in setting realistic goals and treatment for this patient population. In many cases, expected outcomes are very similar to the HIV-unrelated patients and therapeutic planning should be based on this understanding. Treatment tolerance can be predicted based on the status of the HIV disease and the cancer therapy being administered. For those hematologic cancers in which transplantation is part of standard care, this modality should be considered an option in those with HIV infection.
C1 [Little, Richard F.; Dunleavy, Kieron] NCI, NIH, Bethesda, MD 20892 USA.
RP Little, RF (reprint author), NCI, NIH, 31 Ctr Dr,MSC 2062,Bldg 31,Rm B1-W30, Bethesda, MD 20892 USA.
EM littler@mail.nih.gov
NR 36
TC 13
Z9 13
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 1520-4391
EI 1520-4383
J9 HEMATOL-AM SOC HEMAT
JI Hematol.-Am. Soc. Hematol. Educ. Program
PD DEC
PY 2013
BP 382
EP 388
PG 7
WC Education, Scientific Disciplines; Hematology
SC Education & Educational Research; Hematology
GA AB6LP
UT WOS:000331900300055
ER
PT J
AU Gea-Banacloche, J
AF Gea-Banacloche, Juan
TI Evidence-based approach to treatment of febrile neutropenia in
hematologic malignancies
SO HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
LA English
DT Article
ID STEM-CELL TRANSPLANTATION; LIPOSOMAL AMPHOTERICIN-B; RANDOMIZED
CONTROLLED-TRIALS; EMPIRICAL ANTIFUNGAL THERAPY; CLINICAL-PRACTICE
GUIDELINE; INVASIVE FUNGAL-INFECTION; GRAM-POSITIVE INFECTIONS; ADULT
CANCER-PATIENTS; PERSISTENT FEVER; DOUBLE-BLIND
AB Applying the principles of evidence-based medicine to febrile neutropenia (FN) results in a more limited set of practices than expected. Hundreds of studies over the last 4 decades have produced evidence to support the following: (1) risk stratification allows the identification of a subset of patients who may be safely managed as outpatients given the right health care environment; (2) antibacterial prophylaxis for high-risk patients who remain neutropenic for >= 7 days prevents infections and decreases mortality; (3) the empirical management of febrile neutropenia with a single antipseudomonal beta-lactam results in the same outcome and less toxicity than combination therapy using aminoglycosides; (4) vancomycin should not be used routinely empirically either as part of the initial regimen or for persistent fever, but rather should be added when a pathogen that requires its use is isolated; (5) empirical antifungal therapy should be added after 4 days of persistent fever in patients at high risk for invasive fungal infection (IFI); the details of the characterization as high risk and the choice of agent remain debatable; and (6) preemptive antifungal therapy in which the initiation of antifungals is postponed and triggered by the presence, in addition to fever, of other clinical findings, computed tomography (CT) results, and serological tests for fungal infection is an acceptable strategy in a subset of patients. Many practical management questions remain unaddressed.
C1 NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Gea-Banacloche, J (reprint author), NCI, Ctr Canc Res, NIH, Bldg 10,Hatfield CRC,Room 3-3130, Bethesda, MD 20892 USA.
EM banacloj@mail.nih.gov
NR 64
TC 4
Z9 5
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 1520-4391
EI 1520-4383
J9 HEMATOL-AM SOC HEMAT
JI Hematol.-Am. Soc. Hematol. Educ. Program
PD DEC
PY 2013
BP 414
EP 422
PG 9
WC Education, Scientific Disciplines; Hematology
SC Education & Educational Research; Hematology
GA AB6LP
UT WOS:000331900300060
ER
PT J
AU Landgren, O
AF Landgren, Ola
TI Monoclonal gammopathy of undetermined significance and smoldering
multiple myeloma: biological insights and early treatment strategies
SO HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
LA English
DT Article
ID LENALIDOMIDE PLUS DEXAMETHASONE; INDEPENDENT RISK-FACTOR; LIGHT-CHAIN
RATIO; SIGNIFICANCE MGUS; MOLECULAR PATHOGENESIS; ZOLEDRONIC ACID;
SALVAGE THERAPY; EARLY-DIAGNOSIS; RAS MUTATIONS; WORKING GROUP
AB After decades of virtually no progress, multiple myeloma survival has improved significantly in the past 10 years. Indeed, multiple myeloma has perhaps seen more remarkable progress in treatment and patient outcomes than any other cancer during the last decade. Recent data show that multiple myeloma is consistently preceded by a precursor state (monoclonal gammopathy of undetermined significance [MGUS]/smoldering multiple myeloma [SMM]). This observation provides a framework for prospective studies focusing on transformation from precursor disease to multiple myeloma and for the development of treatment strategies targeting "early myeloma." This review discusses current biological insights in MGUS/SMM, provides an update on clinical management, and discusses how the integration of novel biological markers, molecular imaging, and clinical monitoring of MGUS/SMM could facilitate the development of early treatment strategies for high-risk SMM (early myeloma) patients in the future.
C1 [Landgren, Ola] NCI, Multiple Myeloma Sect, Metab Branch, Bethesda, MD 20892 USA.
RP Landgren, O (reprint author), NCI, Multiple Myeloma Sect, Metab Branch, Ctr Canc Res,NIH, 9000 Rockville Pike,Bldg 10 Room 13N240, Bethesda, MD 20892 USA.
EM landgreo@mail.nih.gov
FU National Cancer Institute of the National Institutes of Health
FX This work was supported by the Intramural Research Program of the
National Cancer Institute of the National Institutes of Health.
NR 80
TC 19
Z9 19
U1 0
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 1520-4391
EI 1520-4383
J9 HEMATOL-AM SOC HEMAT
JI Hematol.-Am. Soc. Hematol. Educ. Program
PD DEC
PY 2013
BP 478
EP 487
PG 10
WC Education, Scientific Disciplines; Hematology
SC Education & Educational Research; Hematology
GA AB6LP
UT WOS:000331900300069
ER
PT J
AU Wilson, WH
AF Wilson, Wyndham H.
TI Treatment strategies for aggressive lymphomas: what works?
SO HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
LA English
DT Article
ID B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; RANDOMIZED CONTROLLED-TRIAL;
3-WEEKLY CHOP CHEMOTHERAPY; SMALL-MOLECULE INHIBITOR; PLUS RITUXIMAB;
ELDERLY-PATIENTS; EPOCH-RITUXIMAB; YOUNG-PATIENTS; EXPRESSION
AB Over the past 30 years, many treatment platforms have been developed for diffuse large B-cell lymphoma, but none proved better than CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone/prednisolone). In the immunochemotherapy era, however, there is convincing evidence for superior chemotherapy platforms. A randomized study from the Groupe d'Etude des Lymphomes de l'Adulte showed that R-ACVBP (rituximab plus doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone) was superior to rituximab plus CHOP (R-DHOP) in patients under 60 years of age, but toxicity limits its use to younger patients. Studies also suggest that DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) is more effective in some subtypes of diffuse large B-cell lymphoma and a randomized comparison with R-CHOP is now nearing completion. The simplicity and safety of R-CHOP and the long history of failed contenders, however, has set a high bar for new approaches.
C1 [Wilson, Wyndham H.] NCI, Lymphoid Malignancy Branch, NIH, Bethesda, MD 20892 USA.
RP Wilson, WH (reprint author), NCI, Metab Branch, NIH, Bldg 10,Room 4N-115, Bethesda, MD 20892 USA.
EM wilsonw@mail.nih.gov
NR 43
TC 14
Z9 15
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 1520-4391
EI 1520-4383
J9 HEMATOL-AM SOC HEMAT
JI Hematol.-Am. Soc. Hematol. Educ. Program
PD DEC
PY 2013
BP 584
EP 590
PG 7
WC Education, Scientific Disciplines; Hematology
SC Education & Educational Research; Hematology
GA AB6LP
UT WOS:000331900300082
ER
PT J
AU Leitman, SF
AF Leitman, Susan F.
TI Hemochromatosis: the new blood donor
SO HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM
LA English
DT Article
ID HFE HEREDITARY HEMOCHROMATOSIS; IRON-OVERLOAD; GENETIC HEMOCHROMATOSIS;
PHLEBOTOMY THERAPY; LIVER-DISEASES; RISK; POPULATION; FERROPORTIN;
PENETRANCE; PREVALENCE
AB Hereditary hemochromatosis (HH) due to homozygosity for the C282Y mutation in the HEE gene is a corn on inherited iron overload disorder in whites of northern European descent. Hepcidin deficiency, the hallmark of the disorder, leads to dysregulated intestinal iron absorption and progressive iron deposition in the liver, heart, skin, endocrine glands and joints Survival is normal if organ damage is prevented by early institution of phlebotomy therapy. HH arthropathy is the symptom most affecting quality of life and can be debilitating. Genotype screening in large population studies has shown that the clinical penetrance of C282Y homozygosity is highly variable and can be very low, with up to 50% of women and 20% of men showing a silent phenotype. Targeted population screening for the HEE C282Y mutation is not recommended at present, but might be reconsidered as a cost-effective approach to management if counseling and care were better organized and standardized. Referral of patients to the blood center for phlebotomy therapy and use of HH donor blood for transfusion standardizes treatment minimizes treatment costs and may benefit society as a whole Physician practices should be amended such that H H subjects are more frequently referred to the blood center for therapy
C1 [Leitman, Susan F.] NIH, Dept Transfus Med, Bethesda, MD 20892 USA.
RP Leitman, SF (reprint author), NIH, Blood Serv Sect, Dept Transfus Med, Ctr Clin, Bldg 10,Room 1C0-711, Bethesda, MD 20892 USA.
EM sleitman@nih.gov
NR 39
TC 5
Z9 6
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 1520-4391
EI 1520-4383
J9 HEMATOL-AM SOC HEMAT
JI Hematol.-Am. Soc. Hematol. Educ. Program
PD DEC
PY 2013
BP 645
EP 650
PG 6
WC Education, Scientific Disciplines; Hematology
SC Education & Educational Research; Hematology
GA AB6LP
UT WOS:000331900300092
ER
PT J
AU Prentice, RL
Manson, JE
Anderson, GL
LaCroix, AZ
Shumaker, SA
Chlebowski, RT
Howard, BV
Stefanick, ML
Jackson, RD
Wactawski-Wende, J
Rossouw, JE
AF Prentice, Ross L.
Manson, JoAnn E.
Anderson, Garnet L.
LaCroix, Andrea Z.
Shumaker, Sally A.
Chlebowski, Rowan T.
Howard, Barbara V.
Stefanick, Marcia L.
Jackson, Rebecca D.
Wactawski-Wende, Jean
Rossouw, Jacques E.
TI WOMEN'S HEALTH INITIATIVE VIEW OF ESTROGEN AVOIDANCE AND ALL-CAUSE
MORTALITY
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Letter
ID RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL WOMEN; HYSTERECTOMY;
PROGESTIN; BENEFITS; OUTCOMES; RISKS
C1 [Prentice, Ross L.; Anderson, Garnet L.; LaCroix, Andrea Z.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA.
[Manson, JoAnn E.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA.
[Shumaker, Sally A.] Wake Forest Univ, Bowman Gray Sch Med, Dept Social Sci & Hlth Policy, Div Publ Hlth Sci, Winston Salem, NC USA.
[Chlebowski, Rowan T.] Univ Calif Med Ctr, Los Angeles Biomed Harbor, Div Med Oncol Hematol, Torrance, CA USA.
[Howard, Barbara V.] Medstar Res Inst, Hyattsville, MD USA.
[Stefanick, Marcia L.] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA.
[Jackson, Rebecca D.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
[Wactawski-Wende, Jean] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA.
[Rossouw, Jacques E.] NHLBI, NIH, Bethesda, MD 20892 USA.
RP Prentice, RL (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1100 Fairview Ave North,POB 19024, Seattle, WA 98109 USA.
EM rprentic@whi.org
OI Anderson, Garnet/0000-0001-5087-7837
NR 6
TC 1
Z9 1
U1 0
U2 2
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD DEC
PY 2013
VL 103
IS 12
BP E2
EP E2
DI 10.2105/AJPH.2013.301604
PG 1
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AA4CV
UT WOS:000331043200003
PM 24134350
ER
PT J
AU Thompson, RG
Wall, MM
Greenstein, E
Grant, BF
Hasin, DS
AF Thompson, Ronald G., Jr.
Wall, Melanie M.
Greenstein, Eliana
Grant, Bridget F.
Hasin, Deborah S.
TI Substance-Use Disorders and Poverty as Prospective Predictors of
First-Time Homelessness in the United States
SO AMERICAN JOURNAL OF PUBLIC HEALTH
LA English
DT Article
ID NATIONAL EPIDEMIOLOGIC SURVEY; ALCOHOL-USE DISORDER; PAST HOMELESSNESS;
RISK-FACTORS; COMORBIDITY; POPULATION; PREVALENCE; ABUSE; IV;
RELIABILITY
AB Objectives. We examined whether substance-use disorders and poverty predicted first-time homelessness over 3 years.
Methods. We analyzed longitudinal data from waves 1 (2001-2002) and 2 (2004-2005) of the National Epidemiologic Survey on Alcohol and Related Conditions to determine the main and interactive effects of wave 1 substance use disorders and poverty on first-time homelessness by wave 2, among those who were never homeless at wave 1 (n = 30 558). First-time homelessness was defined as having no regular place to live or having to live with others for 1 month or more as a result of having no place of one's own since wave 1.
Results. Alcohol-use disorders (adjusted odds ratio [AOR] = 1.34), drug-use disorders (AOR = 2.51), and poverty (AOR = 1.34) independently increased prospective risk for first-time homelessness, after adjustment for ecological variables. Substance-use disorders and poverty interacted to differentially influence risk for first-time homelessness (P < .05), before, but not after, adjustment for controls.
Conclusions. This study reinforces the importance of both substance-use disorders and poverty in the risk for first-time homelessness, and can serve as a benchmark for future studies. Substance abuse treatment should address financial status and risk of future homelessness.
C1 [Thompson, Ronald G., Jr.; Wall, Melanie M.; Hasin, Deborah S.] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA.
[Wall, Melanie M.; Greenstein, Eliana; Hasin, Deborah S.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Grant, Bridget F.] NIAAA, Lab Epidemiol & Biometry, Div Clin & Biol Res, NIH, Bethesda, MD USA.
RP Thompson, RG (reprint author), Columbia Univ Coll Phys & Surg, Dept Psychiat, 722 West 168th St,Suite 229C, New York, NY 10032 USA.
EM rgt2101@columbia.edu
FU National Institute on Drug Abuse [K23DA032323]; National Institute on
Alcohol Abuse and Alcoholism [U01AA018111, K05AA014223]; New York State
Psychiatric Institute
FX This study was supported by a grant from the National Institute on Drug
Abuse (grant K23DA032323), grants from the National Institute on Alcohol
Abuse and Alcoholism (grants U01AA018111 and K05AA014223), and by the
New York State Psychiatric Institute.
NR 32
TC 13
Z9 13
U1 2
U2 9
PU AMER PUBLIC HEALTH ASSOC INC
PI WASHINGTON
PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA
SN 0090-0036
EI 1541-0048
J9 AM J PUBLIC HEALTH
JI Am. J. Public Health
PD DEC
PY 2013
VL 103
SU 2
BP S282
EP S288
DI 10.2105/AJPH.2013.301302
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AA4NP
UT WOS:000331073100027
PM 24148043
ER
PT J
AU Oliver, VF
Franchina, M
Jaffe, AE
Branham, KE
Othman, M
Heckenlively, JR
Swaroop, A
Campochiaro, B
Vote, BJ
Craig, JE
Saffery, R
Mackey, DA
Qian, J
Zack, DJ
Hewitt, AW
Merbs, SL
AF Oliver, Verity F.
Franchina, Maria
Jaffe, Andrew E.
Branham, Kari E.
Othman, Mohammad
Heckenlively, John R.
Swaroop, Anand
Campochiaro, Betsy
Vote, Brendan J.
Craig, Jamie E.
Saffery, Richard
Mackey, David A.
Qian, Jiang
Zack, Donald J.
Hewitt, Alex W.
Merbs, Shannath L.
TI Hypomethylation of the IL17RC Promoter in Peripheral Blood Leukocytes Is
Not A Hallmark of Age-Related Macular Degeneration
SO CELL REPORTS
LA English
DT Article
ID DNA METHYLATION ANALYSIS; CANCER; EXPRESSION; METHYLTRANSFERASE;
HYPERMETHYLATION; TRANSCRIPTION; REVEALS; SMOKING; ISLANDS; PROTEIN
AB Age-related macular degeneration (AMD) is a leading cause of visual impairment worldwide. Aberrant DNA methylation within the promoter of IL17RC in peripheral blood mononuclear cells has recently been reported in AMD. To validate this association, we examined DNA methylation of the IL17RC promoter in peripheral blood. First, we used Illumina Human Methylation450 Bead Arrays, a widely accepted platform for measuring global DNA methylation. Second, methylation status at multiple sites within the IL17RC promoter was determined by bisulfite pyrosequencing in two cohorts. Third, a methylation-sensitive quantitative PCR-based assay was performed on a subset of samples. In contrast to previous findings, we did not find evidence of differential methylation between AMD cases and age-matched controls. We conclude that hypomethylation within the IL17RC gene promoter in peripheral blood is not suitable for use as a clinical biomarker of AMD. This study highlights the need for considerable replication of epigenetic association studies prior to clinical application.
C1 [Oliver, Verity F.; Campochiaro, Betsy; Qian, Jiang; Zack, Donald J.; Merbs, Shannath L.] Johns Hopkins Univ, Sch Med, Wilmer Inst, Dept Ophthalmol, Baltimore, MD 21287 USA.
[Franchina, Maria; Mackey, David A.; Hewitt, Alex W.] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia.
[Jaffe, Andrew E.] Lieber Inst Brain Dev, Baltimore, MD 21287 USA.
[Branham, Kari E.; Othman, Mohammad; Heckenlively, John R.] Univ Michigan, Dept Ophthalmol & Visual Sci, Kellogg Eye Ctr, Ann Arbor, MI 48105 USA.
[Swaroop, Anand] NEI, NIH, Bethesda, MD 20892 USA.
[Vote, Brendan J.] Univ Tasmania, Launceston Eye Inst, Launceston, Tas 7249, Australia.
[Craig, Jamie E.] Flinders Univ S Australia, Flinders Med Ctr, Dept Ophthalmol, Adelaide, SA 5042, Australia.
[Saffery, Richard] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Canc & Dis Epigenet, Melbourne, Vic 3052, Australia.
[Zack, Donald J.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Dept Mol Biol & Genet, Baltimore, MD 21287 USA.
[Zack, Donald J.] Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21287 USA.
[Zack, Donald J.] Univ Paris 06, Inst Vis, F-75012 Paris, France.
[Hewitt, Alex W.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia.
RP Hewitt, AW (reprint author), Univ Western Australia, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia.
EM hewitt.alex@gmail.com; smerbs@jhmi.edu
RI Oliver, Verity/K-7336-2012; Hewitt, Alex/D-1936-2013; Jaffe,
Andrew/L-3089-2016; Mackey, David/H-5340-2014;
OI Oliver, Verity/0000-0003-4786-8272; Hewitt, Alex/0000-0002-5123-5999;
Jaffe, Andrew/0000-0001-6886-1454; Mackey, David/0000-0001-7914-4709;
Zack, Don/0000-0002-7966-1973; Swaroop, Anand/0000-0002-1975-1141
FU Western Australian DNA Bank; Center for Inherited Disease Research
(Johns Hopkins University); Ophthalmic Research Institute of Australia;
American Health Assistance Foundation; Australian National Health;
Medical Research Council Centres of Research Excellence grant [1023911];
National Eye Institute (NEI) [EY016862, X01HG006605, R01EY020406];
generosity of Agnes Nixon; NEI core grant [P30EY001765]
FX The authors gratefully acknowledge the technical advice provided by Dr.
David Chandler and the assistance of the Western Australian DNA Bank and
the Center for Inherited Disease Research (Johns Hopkins University).
This work was supported by funding from the Ophthalmic Research
Institute of Australia and the American Health Assistance Foundation to
A. W. H. as well as from an Australian National Health and Medical
Research Council Centres of Research Excellence grant 1023911
(2012-2016) to J. E. C., D. A. M., and A. W. H. CERA receives
operational infrastructure support from the Victorian government.
Collection of the Michigan AMD-MMAP cohort was enabled by funding from
the National Eye Institute (NEI; grant EY016862) to A. S. and J. R. H.
Funding from the NEI (grant X01HG006605) to S. L. M. was used for the
analysis of samples on the Illumina Human Methylation 450K platform at
CIDR. Pyrosequencing validation was funded by NEI grant R01EY020406 (to
S. L. M.) and the generosity of Agnes Nixon (to S. L. M.) and aided by
NEI core grant P30EY001765.
NR 37
TC 11
Z9 13
U1 1
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD DEC
PY 2013
VL 5
IS 6
BP 1527
EP 1535
DI 10.1016/j.celrep.2013.11.042
PG 9
WC Cell Biology
SC Cell Biology
GA AA5PW
UT WOS:000331153100006
PM 24373284
ER
PT J
AU McGuigan, C
Bourdin, C
Derudas, M
Hamon, N
Hinsinger, K
Kandil, S
Madela, K
Meneghesso, S
Pertusati, F
Serpi, M
Slusarczyk, M
Chamberlain, S
Kolykhalov, A
Vernachio, J
Vanpouille, C
Introini, A
Margolis, L
Balzarini, J
AF McGuigan, Christopher
Bourdin, Claire
Derudas, Marco
Hamon, Nadege
Hinsinger, Karen
Kandil, Sahar
Madela, Karolina
Meneghesso, Silvia
Pertusati, Fabrizio
Serpi, Michaela
Slusarczyk, Magdalena
Chamberlain, Stanley
Kolykhalov, Alexander
Vernachio, John
Vanpouille, Christophe
Introini, Andrea
Margolis, Leonid
Balzarini, Jan
TI Design, synthesis and biological evaluation of phosphorodiamidate
prodrugs of antiviral and anticancer nucleosides
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Nucleoside analogs; Antiviral; Anticancer; Phosphorodiamidates; Prodrugs
ID HEPATITIS-C VIRUS; PHOSPHORAMIDATE PROTIDE TECHNOLOGY;
REVERSE-TRANSCRIPTASE; PHOSPHORYLATION; PHOSPHONATES; ACYCLOVIR;
TRIESTERS; DISCOVERY; DRUGS; CELLS
AB We herein report the application of the phosphorodiamidate phosphate prodrug approach to a series of thirteen nucleoside analogs with antiviral or anticancer activity. Twenty-five symmetrical phosphorodiamidates were synthesized, bearing esterified L-Alanine (and in one case L-Alanine) in the prodrug moiety, each as single stereoisomer. The presence of an achiral phosphorus represents a potential advantage over the phosphoramidate ProTide approach, where diastereoisomeric mixtures are routinely obtained, and different biological profiles may be expected from the diastereoisomers. Optimization of the synthetic pathway allowed us to identify two general methods depending on the particular nudeoside analogs. All the compounds were biologically evaluated in antiviral and anticancer assays and several showed improvement of activity compared to their parent nucleosides, as in the case of ddA, d4T, abacavir and acyclovir against HIV-1 and/or HIV-2. The biological results were supported by metabolism studies with carboxypeptidase Y monitored by P-31 NMR to investigate their bioactivation. This work further validates the phosphorodiamidate approach as a monophosphate prodrug motif with broad application in the antiviral and anticancer fields. (C) 2013 Elsevier Masson SAS. All rights reserved.
C1 [McGuigan, Christopher; Bourdin, Claire; Derudas, Marco; Hamon, Nadege; Hinsinger, Karen; Kandil, Sahar; Madela, Karolina; Meneghesso, Silvia; Pertusati, Fabrizio; Serpi, Michaela; Slusarczyk, Magdalena] Cardiff Univ, Sch Pharm & Pharmaceut Sci, Cardiff CF10 3NB, S Glam, Wales.
[Chamberlain, Stanley; Kolykhalov, Alexander; Vernachio, John] Inhibitex Inc, Alpharetta, GA 30004 USA.
[Vanpouille, Christophe; Introini, Andrea; Margolis, Leonid] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD 20892 USA.
[Balzarini, Jan] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP McGuigan, C (reprint author), Cardiff Univ, Sch Pharm & Pharmaceut Sci, King Edward 7 Ave, Cardiff CF10 3NB, S Glam, Wales.
EM mcguigan@cardiff.ac.uk
RI McGuigan, Chris/P-1580-2014; Serpi, Michaela/G-5557-2015; pertusaTI,
fabrizio/G-5560-2015; Kandil, Sahar/L-2458-2015;
OI McGuigan, Chris/0000-0001-8409-710X; Serpi,
Michaela/0000-0002-6162-7910; pertusaTI, fabrizio/0000-0003-4532-9101;
Kandil, Sahar/0000-0003-1806-9623; Introini, Andrea/0000-0002-9929-8964
FU Inhibitex; KU Leuven [GOA 10/014]
FX This work was supported by Inhibitex, and by a grant from the KU Leuven
to JB (GOA 10/014). The authors thank Ms. Helen Murphy for excellent
secretarial assistance and Mrs. Leentje Persoons, Mrs. Frieda De Meyer,
Mrs. Leen Ingels and Mrs. Lizette van Berckelaer for excellent technical
assistance.
NR 26
TC 10
Z9 10
U1 3
U2 48
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD DEC
PY 2013
VL 70
BP 326
EP 340
DI 10.1016/j.ejmech.2013.09.047
PG 15
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 301TG
UT WOS:000330554400028
PM 24177359
ER
PT J
AU Ulloora, S
Shabaraya, R
Ranganathan, R
Adhikari, AV
AF Ulloora, Shrikanth
Shabaraya, Ramakrishna
Ranganathan, Rajesh
Adhikari, Airody Vasudeva
TI Synthesis, anticonvulsant and anti-inflammatory studies of new
1,4-dihydropyridin-4-yl-phenoxyacetohydrazones
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Dihydropyridine; Hydrazone; Anticonvulsant; Anti-inflammatory;
Analgesic; Neurotoxicity
ID HYDRAZONE DERIVATIVES; CHANNEL; 1,4-DIHYDROPYRIDINES; DESIGN; AGENTS;
MICE; EPILEPSY; CELLS; RATS
AB The present work involves design and synthesis of new substituted 1,4-dihydropyridin-4-yl-phenoxyacetohydrazones (4a-s, 5a-h), starting from 4-hydroxybenzaldehyde. The final compounds were screened for their in vivo anticonvulsant activity by MES, scPTZ and 6 Hz methods, while their antiinflammatory screening was performed by Carrageenan induced Paw Edema method. The results indicated that compounds carrying electron donating groups are anticonvulsant active, while most of the tested compounds exhibited significant anti-inflammatory activity. Compounds 4k, 1, 4p-s, and 5c showed rapid anti-inflammatory activity within 30 min and appeared as lead compounds. Further, Neurotoxicity study revealed that all the tested compounds are non-toxic up to 300 mg/kg doses. Selected compounds were also subjected to analgesic screening following Tail immersion method and they exhibited good activity. (C) 2013 Elsevier Masson SAS. All rights reserved.
C1 [Ulloora, Shrikanth; Adhikari, Airody Vasudeva] Natl Inst Technol Karnataka, Dept Chem, Mangalore 575025, Karnataka, India.
[Shabaraya, Ramakrishna] Srinivas Coll Pharm, Mangalore, Karnataka, India.
[Ranganathan, Rajesh] NIH, Ctr Neurosci, Bethesda, MD 20892 USA.
RP Adhikari, AV (reprint author), Natl Inst Technol Karnataka, Dept Chem, Mangalore 575025, Karnataka, India.
EM avachem@gmail.com
FU National Institute of Technology Karnataka, Mangalore
FX The authors are thankful to National Institute of Technology Karnataka,
Mangalore for financial support and Indian Institute of Science,
Bangalore for NMR spectral facilities, SAIF Punjab and SAIF Shillong for
mass spectral facilities.
NR 43
TC 12
Z9 12
U1 1
U2 9
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD DEC
PY 2013
VL 70
BP 341
EP 349
DI 10.1016/j.ejmech.2013.10.010
PG 9
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 301TG
UT WOS:000330554400029
PM 24177360
ER
PT J
AU Farag, AA
Abd El Munim, HE
Graham, JH
Farag, AA
AF Farag, Amal A.
Abd El Munim, Hossam E.
Graham, James H.
Farag, Aly A.
TI A Novel Approach for Lung Nodules Segmentation in Chest CT Using Level
Sets
SO IEEE TRANSACTIONS ON IMAGE PROCESSING
LA English
DT Article
DE Lung nodules; level sets; shape modeling; shape based segmentation;
shape registration and alignment; optimization
ID SMALL PULMONARY NODULES; IMAGE SEGMENTATION; GROWTH-RATE; SHAPE; SCANS;
MODELS; REGISTRATION; INFORMATION; SIZE
AB A new variational level set approach is proposed for lung nodule segmentation in lung CT scans. A general lung nodule shape model is proposed using implicit spaces as a signed distance function. The shape model is fused with the image intensity statistical information in a variational segmentation framework. The nodule shape model is mapped to the image domain by a global transformation that includes inhomogeneous scales, rotation, and translation parameters. A matching criteria between the shape model and the image implicit representations is employed to handle the alignment process. Transformation parameters evolve through gradient descent optimization to handle the shape alignment process and hence mark the boundaries of the nodule "head." The embedding process takes into consideration the image intensity as well as prior shape information. A nonparametric density estimation approach is employed to handle the statistical intensity representation of the nodule and background regions. The proposed technique does not depend on nodule type or location. Exhaustive experimental and validation results are demonstrated on 742 nodules obtained from four different CT lung databases, illustrating the robustness of the approach.
C1 [Farag, Amal A.] NIH, Imaging Biomarkers & Comp Aided Diag Lab, Ctr Clin, Bethesda, MD 20892 USA.
[Graham, James H.; Farag, Aly A.] Univ Louisville, Dept Elect & Comp Engn, Louisville, KY 40292 USA.
[Abd El Munim, Hossam E.] Ain Shams Univ, Comp & Syst Engn Dept, Cairo 11566, Egypt.
RP Farag, AA (reprint author), NIH, Imaging Biomarkers & Comp Aided Diag Lab, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.
EM amal.aly1@gmail.com; hossameldin.hassan@eng.asu.edu.eg;
james.graham@louisville.edu; aly.farag@louisville.edu
NR 53
TC 15
Z9 16
U1 1
U2 17
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 1057-7149
EI 1941-0042
J9 IEEE T IMAGE PROCESS
JI IEEE Trans. Image Process.
PD DEC
PY 2013
VL 22
IS 12
BP 5202
EP 5213
DI 10.1109/TIP.2013.2282899
PG 12
WC Computer Science, Artificial Intelligence; Engineering, Electrical &
Electronic
SC Computer Science; Engineering
GA AA6IY
UT WOS:000331203200003
PM 24107934
ER
PT J
AU Han, MH
Jiao, S
Jia, JM
Chen, Y
Chen, CY
Gucek, M
Markey, SP
Li, Z
AF Han, Meng-Hsuan
Jiao, Song
Jia, Jie-Min
Chen, Yong
Chen, Cai Yun
Gucek, Marjan
Markey, Sanford P.
Li, Zheng
TI The Novel Caspase-3 Substrate Gap43 is Involved in AMPA Receptor
Endocytosis and Long-Term Depression
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID TANDEM MASS-SPECTROMETRY; PROTEIN GAP-43; SYNAPTIC PLASTICITY; PROTEOMIC
ANALYSIS; STATISTICAL-MODEL; MESSENGER-RNA; CELL-DEATH; SCHIZOPHRENIA;
APOPTOSIS; DATABASE
C1 [Han, Meng-Hsuan; Jiao, Song; Jia, Jie-Min; Chen, Cai Yun; Markey, Sanford P.; Li, Zheng] NIMH, Bethesda, MD 20892 USA.
[Chen, Yong; Gucek, Marjan] NHLBI, Bethesda, MD 20892 USA.
RP Li, Z (reprint author), NIMH, 35 Convent DR,RM 2C1010,MSC 3732, Bethesda, MD 20892 USA.
EM lizheng2@mail.nih.gov
RI chen, yong/E-2432-2011; Jia, Jie-Min/O-1150-2013; Li, Zheng/I-8016-2014;
Jiao, Song/L-2803-2015
OI Jia, Jie-Min/0000-0001-8446-3819; Li, Zheng/0000-0002-2978-2531; Jiao,
Song/0000-0003-0496-6454
FU Intramural Research Program of the National Institute of Mental Health
[1ZIAMH000274-35, 1ZIAMH00279-27, 1ZIAMH002881]
FX This work was supported by the Intramural Research Program of the
National Institute of Mental Health, project 1ZIAMH000274-35,
1ZIAMH00279-27 and 1ZIAMH002881.
NR 58
TC 12
Z9 12
U1 4
U2 14
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
EI 1535-9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD DEC
PY 2013
VL 12
IS 12
BP 3719
EP 3731
DI 10.1074/mcp.M113.030676
PG 13
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 293SI
UT WOS:000329993600023
PM 24023391
ER
PT J
AU Cservenak, M
Szabo, ER
Bodnar, L
Leko, A
Palkovits, M
Nagy, GM
Usdin, TB
Dobolyi, A
AF Cservenak, Melinda
Szabo, Eva R.
Bodnar, Lbolya
Leko, Andras
Palkovits, Miklos
Nagy, Gyoergy M.
Usdin, Ted B.
Dobolyi, Arpad
TI Thalamic neuropeptide mediating the effects of nursing on lactation and
maternal motivation
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Maternal behavior; Rat dams; Suckling; Prolactin release; Brain
circuitry; Preoptic area; Hypothalamus; Ascending neuronal pathway
ID INDUCED PROLACTIN-RELEASE; HORMONE 2 RECEPTOR;
TUBEROINFUNDIBULAR-PEPTIDE; 39 RESIDUES; PREOPTIC AREA;
PARATHYROID-HORMONE-2 RECEPTOR; LENTIVIRAL VECTORS; BRAIN-REGIONS;
FEMALE RATS; C-FOS
AB Nursing has important physiological and psychological consequences on mothers during the postpartum period. Tuberoinfundibular peptide of 39 residues (TIP39) may contribute to its effects on prolactin release and maternal motivation. Since TIP39-containing fibers and the receptor for TIP39, the parathyroid hormone 2 receptor (PTH2 receptor) are abundant in the arcuate nucleus and the medial preoptic area, we antagonized TIP39 action locally to reveal its actions. Mediobasal hypothalamic injection of a virus encoding an antagonist of the PTH2 receptor markedly decreased basal serum prolactin levels and the suckling-induced prolactin release. In contrast, injecting this virus into the preoptic area had no effect on prolactin levels, but did dampen maternal motivation, judged by reduced time in a pup-associated cage during a place preference test. In support of an effect of TIP39 on maternal motivation, we observed that TIP39 containing fibers and terminals had the same distribution within the preoptic area as neurons expressing Fos in response to suckling. Furthermore, TIP39 terminals closely apposed the plasma membrane of 82% of Fos-ir neurons. Retrograde tracer injected into the arcuate nucleus and the medial preoptic area labeled TIP39 neurons in the posterior intralaminar complex of the thalamus (PIL), indicating that these cells but not other groups of TIP39 neurons project to these hypothalamic regions. We also found that TIP39 mRNA levels in the PIL markedly increased around parturition and remained elevated throughout the lactation period, demonstrating the availability of the peptide in postpartum mothers. Furthermore, suckling, but not pup exposure without physical contact, increased Fos expression by PILTIP39 neurons. These results indicate that suckling activates TIP39 neurons in the PIL that affect prolactin release and maternal motivation via projections to the arcuate nucleus and the preoptic area, respectively. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Cservenak, Melinda; Szabo, Eva R.; Leko, Andras; Palkovits, Miklos; Dobolyi, Arpad] Semmelweis Univ, Dept Anat Histol & Embryol, Neuromorphol Lab, H-1094 Budapest, Hungary.
[Cservenak, Melinda; Szabo, Eva R.; Dobolyi, Arpad] Hungarian Acad Sci, Res Grp Mol & Syst Neurobiol, H-1051 Budapest, Hungary.
[Palkovits, Miklos] Semmelweis Univ, Human Brain Tissue Bank, H-1094 Budapest, Hungary.
[Palkovits, Miklos] Hungarian Acad Sci, H-1094 Budapest, Hungary.
[Bodnar, Lbolya; Nagy, Gyoergy M.] Semmelweis Univ, Dept Human Morphol & Dev Biol, Neuroendocrinol Lab, H-1094 Budapest, Hungary.
[Usdin, Ted B.] NIMH, Sect Fundamental Neurosci, Bethesda, MD 20892 USA.
RP Dobolyi, A (reprint author), Semmelweis Univ, Dept Anat Histol & Embryol, Neuromorphol Lab, Tuzolto 58, H-1094 Budapest, Hungary.
EM dobolyi.arpad@med.semmelweis-univ.hu
RI Leko, Andras/O-5974-2016;
OI Leko, Andras/0000-0001-7840-2622; Palkovits, Miklos/0000-0003-0578-0387
FU Hungarian Academy of Sciences; OTKA [K100319]; KTIA NAP Program; NIMH
IRP
FX Grant support was provided by the Bolyai Janos Fellowship Award of the
Hungarian Academy of Sciences, the OTKA K100319 research grant and the
KTIA NAP_2013 Program for AD, and NIMH IRP for TBU. The Funding sources
are all governmental. The agencies supported the science by providing
funds but did not contribute to the manuscript in any other way and did
not influence the authors in any way.
NR 50
TC 7
Z9 8
U1 1
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD DEC
PY 2013
VL 38
IS 12
BP 3070
EP 3084
DI 10.1016/j.psyneuen.2013.09.004
PG 15
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA AA0YX
UT WOS:000330824400025
PM 24094875
ER
PT J
AU Leggio, L
Schwandt, ML
Oot, EN
Dias, AA
Ramchandani, VA
AF Leggio, Lorenzo
Schwandt, Melanie L.
Oot, Emily N.
Dias, Alexandra A.
Ramchandani, Vijay A.
TI Fasting-induced increase in plasma ghrelin is blunted by intravenous
alcohol administration: A within-subject placebo-controlled study
SO PSYCHONEUROENDOCRINOLOGY
LA English
DT Article
DE Alcohol; Ghrelin; Insulin; GLP-1; PYY; Intravenous alcohol
administration
ID HORMONE SECRETAGOGUE RECEPTOR; FOOD-INTAKE; DEPENDENT PATIENTS; ACYLATED
PEPTIDE; ETHANOL INTAKE; MESSENGER-RNA; SERUM-LEVELS; SECRETION; RATS;
ENDOCRINE
AB Ghrelin is a 28-amino acid peptide produced mainly by mucosal neuroendocrine cells lining the fundus of the stomach. Preclinical and clinical studies suggest that ghrelin plays a role in alcoholism. Furthermore, human laboratory studies indicate that acute oral administration of alcohol results in reduced circulating ghrelin. As ghrelin is primarily produced in the stomach, one question never previously explored is whether alcohol administered intravenously (IV) results in similar decrease in ghrelin levels. Thus, this study analyzed the potential effects of IV alcohol administration on plasma ghrelin levels in healthy nonsmoking social drinkers (n = 44) who received either a 180-min IV infusion of 6% (v/v) alcohol or 0.9% normal saline in two separate counterbalanced sessions. At each session, participants arrived having fasted for similar to 7 h and received a light breakfast 60 min before the infusion. The percent change (%Delta) in ghrelin levels was 4.5-fold less in the alcohol condition than the saline condition. In fact, there was only a modest change in ghrelin levels from baseline in the IV alcohol condition (9.6%Delta ghrelin) while in the IV saline condition there was a robust change (43.4%Delta ghrelin). There was a trend toward significance in %Delta ghrelin in the alcohol condition compared to the placebo condition (F[1,33] = 3.3, p = 0.07). While the exact mechanisms by which alcohol influences ghrelin levels are unclear, alcohol may act directly in the stomach by inhibiting ghrelin secretion and/or release, and may also attenuate ghrelin levels systemically. Although IV alcohol did not reduce circulating ghrelin levels, as seen in previous studies with oral alcohol administration, the present findings suggest that, despite bypassing the stomach, alcohol still attenuated circulating ghrelin levels, i.e. the fasting-induced increase in circulating ghrelin was blunted by IV alcohol administration. These findings lead us to hypothesize that alcohol might affect ghrelin signaling not only via a local effect on the stomach mucosa, but also via a systemic effect. Published by Elsevier Ltd.
C1 [Leggio, Lorenzo; Oot, Emily N.; Dias, Alexandra A.] NIAAA, Sect Clin Psychoneuroendocrinol & Neuropsychophar, Lab Clin & Translat Studies, NIH, Bethesda, MD 20892 USA.
[Leggio, Lorenzo] NIDA, Intramural Res Program, NIH, Baltimore, MD USA.
[Leggio, Lorenzo] Brown Univ, Dept Behav & Social Sci, Providence, RI 02912 USA.
[Schwandt, Melanie L.] NIAAA, Lab Clin & Translat Studies, NIH, Bethesda, MD 20892 USA.
[Ramchandani, Vijay A.] NIAAA, Sect Human Psychopharmacol, Lab Clin & Translat Studies, NIH, Bethesda, MD 20892 USA.
RP Leggio, L (reprint author), NIAAA, Sect Clin Psychoneuroendocrinol & Neuropsychophar, 10 Ctr Dr 10CRC-15330 MSC 1108,Room 1-5429, Bethesda, MD 20892 USA.
EM lorenzo.leggio@nih.gov
RI Schwandt, Melanie/L-9866-2016; Leggio, Lorenzo/M-2972-2016
FU Division of Intramural Clinical and Biological Research of the National
Institute on Alcohol Abuse and Alcoholism (NIAAA); Intramural Research
Program of the National Institute on Drug Abuse (NIDA)
FX This work was supported by the Division of Intramural Clinical and
Biological Research of the National Institute on Alcohol Abuse and
Alcoholism (NIAAA) and the Intramural Research Program of the National
Institute on Drug Abuse (NIDA).
NR 50
TC 11
Z9 11
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4530
J9 PSYCHONEUROENDOCRINO
JI Psychoneuroendocrinology
PD DEC
PY 2013
VL 38
IS 12
BP 3085
EP 3091
DI 10.1016/j.psyneuen.2013.09.005
PG 7
WC Endocrinology & Metabolism; Neurosciences; Psychiatry
SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry
GA AA0YX
UT WOS:000330824400026
PM 24090583
ER
PT J
AU Rao, M
AF Rao, Mahendra
TI National Institutes of Health Center for Regenerative Medicine: Putting
Science into Practice
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID PERSONALIZED GENOMIC MEDICINE; PLURIPOTENT STEM-CELLS; CARDIOTOXICITY
AB The field of regenerative medicine has been revolutionized by breakthroughs in stem cell biology, gene engineering, and whole-genome sequencing. These advances are not only scientific or medical but have also advanced how we conceptualize regenerative medicine. The progenitive research that proceeded as well as a substantial part of the funding that supported these discoveries were provided by the National Institutes of Health (NIH). Now, perhaps more than ever, the NIH has a vital role to play in the translation of science into clinical practice. The NIH is uniquely positioned to coordinate interactions between the different institutes and other arms of the government, as well as international organizations. Efforts of researchers in the United States both within and without the NIH are supported by a number of mechanisms, including specialized workshops, and the support of developing small-scale industry. Additionally, the NIH has stepped up to provide necessary infrastructure in areas of regenerative medicine where the medical need might be apparent but might be currently infeasible or unattractive to private-sector investment. This article will discuss these perhaps lesser-known activities of the NIH, which I believe have continued and will continue to contribute to the role of stem cell research in translating science into regenerative medicine.
C1 NIH, Ctr Regenerat Med, Bethesda, MD 20892 USA.
RP Rao, M (reprint author), NIH, Ctr Regenerat Med, Bldg 10, Bethesda, MD 20892 USA.
EM mahendra.rao@nih.gov
NR 22
TC 1
Z9 1
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547-3287
EI 1557-8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD DEC 1
PY 2013
VL 22
SU 1
BP 4
EP 7
DI 10.1089/scd.2013.0437
PG 4
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
Experimental; Transplantation
SC Cell Biology; Hematology; Research & Experimental Medicine;
Transplantation
GA AA0CX
UT WOS:000330763800003
PM 24304067
ER
PT J
AU Tan, F
Wahdan-Alaswad, R
Yan, S
Thiele, CJ
Li, ZJ
AF Tan, Fei
Wahdan-Alaswad, Reema
Yan, Shuang
Thiele, Carol J.
Li, Zhijie
TI Dihydropyrimidinase-like protein 3 expression is negatively regulated by
MYCN and associated with clinical outcome in neuroblastoma
SO CANCER SCIENCE
LA English
DT Article
ID RESPONSE MEDIATOR PROTEIN-2; AXON OUTGROWTH INHIBITION; DEVELOPING
RAT-BRAIN; UNC-33; CELLS; GENE; IDENTIFICATION; CANCER; ACID;
DIFFERENTIATION
AB Dihydropyrimidinase-like proteins (DPYSLs) are a family of proteins developmentally regulated during maturation of the nervous system. Recently, members of the DPYSL family have been reported to be involved in cancer with low expression of DPYSL1 correlating with poor clinical outcomes in non-small cell lung cancer and functioning as a metastasis suppressor. Neuroblastoma (NB) is a tumor derived from precursor cells of the sympathetic nervous system and is the most common solid tumor in childhood. So far the biological functions of DPYSLs in NB remain elusive. Studying the potential roles of DPYSLs in NB may give us new insights into NB tumorigenesis. In the present study, using antibodies specific to different members of the DPYSL family, DPYSL1, DPYSL2 and DPYSL3, we investigated regulation of their expression and their subcellular distribution during retinoic acid (RA)-induced differentiation in NB cells. The correlation between DPYSLs and MYCN, a biomarker for poor prognosis of NB, was evaluated. We found that DPYSL3 levels increased during RA-induced cell differentiation. Downregulation of MYCN by small interfering RNA (siRNA) increased DPYSL3 levels, while upregulation of MYCN in non-MYCN NB cells decreased DPYSL3 levels. DPYSL1 and DPYSL2 expression didn't change during RA treatment or under different expression levels of MYCN. Moreover, a high level of DPYSL3 mRNA, but not that of DPYSL1 or DPYSL2 mRNA, was detected in tumors from advanced-stage NB that have a better survival. These data indicated that DPYSL3, not DPYSL1 or DPYSL2, is negatively regulated by MYCN and may be used as a potential biomarker for NB.
C1 [Tan, Fei] China Med Univ, Shengjing Hosp, Dept Neurol, Shenyang, Peoples R China.
[Tan, Fei; Wahdan-Alaswad, Reema; Yan, Shuang; Thiele, Carol J.; Li, Zhijie] NCI, Cell & Mol Biol Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA.
[Li, Zhijie] China Med Univ, Shengjing Hosp, Med Res Ctr, Shenyang, Peoples R China.
RP Tan, F (reprint author), China Med Univ, Shengjing Hosp, Dept Neurol, Shenyang, Peoples R China.
EM tanfei66@hotmail.com; lizhijie68@hotmail.com
FU NCI Intramural Research Program of Center for Cancer Research at the
National Cancer Institute in the National Institute of Health; National
Natural Science Foundation of China [81272538]; Society Development
Foundation of Liaoning Province [201225016]
FX We would like to thank Dr Geoff Krystal for the MYCN expression vector,
Dr Rogier Versteeg and Richard Volckmann (Academic Medical Center,
Department of Human Genetics, Amsterdam, the Netherlands) for making the
R2 bioinformatics database publicly available. This work was supported
by and performed at the NCI Intramural Research Program of Center for
Cancer Research at the National Cancer Institute in the National
Institute of Health, National Natural Science Foundation of China (No.
81272538) and Society Development Foundation of Liaoning Province (No.
201225016).
NR 42
TC 3
Z9 3
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD DEC
PY 2013
VL 104
IS 12
BP 1586
EP 1592
DI 10.1111/cas.12278
PG 7
WC Oncology
SC Oncology
GA 297GG
UT WOS:000330243200005
PM 24011394
ER
PT J
AU Proenca-Modena, JL
Martinez, M
Amarilla, AA
Espinola, EE
Galeano, ME
Farina, N
Russomando, G
Aquino, VH
Parra, GI
Arruda, E
AF Proenca-Modena, J. L.
Martinez, M.
Amarilla, A. A.
Espinola, E. E.
Galeano, M. E.
Farina, N.
Russomando, G.
Aquino, V. H.
Parra, G. I.
Arruda, E.
TI Viral load of human bocavirus-1 in stools from children with viral
diarrhoea in Paraguay
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Gastroenteritis; HBoV; norovirus; rotavirus; viral co-infections
ID PHYLOGENETIC ANALYSIS; ROTAVIRUS STRAINS; INFECTION; PARVOVIRUS;
FREQUENT; PCR
AB Since their discovery, four species of human bocavirus (HBoV) have been described in patients with respiratory and gastrointestinal diseases. However, a clear causal association between HBoV-1 and gastroenteritis has not been demonstrated. In this study, we describe the detection and quantification of HBoV-1 in stools from children with acute non-bacterial gastroenteritis using quantitative polymerase chain reaction. HBoV-1 genome was detected in 10.6% of stools with frequent association with rotavirus and norovirus. The median of HBoV-1 viral load was 1.88x10(4) genome/ml, lower than previously shown in secretions of patients with respiratory infections, without any obvious association between high viral load and presence of HBoV as single agent. Thus, although HBoV-1 was frequently detected in these patients, there is no clear causal association of this agent with diarrhoea. Indeed, HBoV-1 DNA in stools of patients with gastroenteritis without respiratory symptoms may be a remnant of previous infections or associated with prolonged shedding of virus in the respiratory or digestive tracts.
C1 [Proenca-Modena, J. L.; Arruda, E.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Biol Celular & Mol, BR-14049 Ribeirao Preto, SP, Brazil.
[Martinez, M.; Amarilla, A. A.; Espinola, E. E.; Galeano, M. E.; Russomando, G.; Parra, G. I.] Univ Nacl Asunc, Inst Invest Ciencias Salud, Dept Biol Mol & Genet, San Lorenzo, Paraguay.
[Amarilla, A. A.; Aquino, V. H.] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin Toxicol & Bromatol, BR-14049 Ribeirao Preto, SP, Brazil.
[Farina, N.] Univ Nacl Asunc, Inst Invest Ciencias Salud, Dept Anal Clin & Microbiol, San Lorenzo, Paraguay.
RP Parra, GI (reprint author), NIAID, Infect Dis Lab, NIH, 9000 Rockville Pike,Bldg 50,Room 6316, Bethesda, MD 20892 USA.
EM gabriel_parra@hotmail.com
RI Proenca-Modena, Jose/C-8231-2014; Arruda, Eurico/E-4101-2012;
OI Aquino, Victor Hugo/0000-0003-1910-0776; Espinola,
Emilio/0000-0001-6019-0588; Parra, Gabriel/0000-0002-1102-4740
FU Sustainable Science Institute; FAPESP; CNPq
FX This research was partially funded by Sustainable Science Institute (G.
I. P.), FAPESP and CNPq (J.L.P.M, V. H. A, E. A.). The funders had no
role in design, data collection, analysis, or interpretation of the
data.
NR 30
TC 5
Z9 5
U1 0
U2 8
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD DEC
PY 2013
VL 141
IS 12
BP 2576
EP 2580
DI 10.1017/S095026881300023X
PG 5
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 299BS
UT WOS:000330370300013
PM 23425775
ER
PT J
AU Gavino, AI
Ho, BLC
Wee, PAA
Marcelo, AB
Fontelo, P
AF Gavino, Alex I.
Ho, Beverly Lorraine C.
Wee, Pura Angela A.
Marcelo, Alvin B.
Fontelo, Paul
TI Information-seeking trends of medical professionals and students from
middle-income countries: a focus on the Philippines
SO HEALTH INFORMATION AND LIBRARIES JOURNAL
LA English
DT Article
DE information seeking behaviour; students; medical; doctors; Asia; South
East; Medline
ID PRIMARY-CARE PHYSICIANS; HEALTH INFORMATION; DEVELOPING-WORLD; CLINICAL
QUESTIONS; NATIONAL-SURVEY; NEEDS; BEHAVIOR; DOCTORS; INTERNET;
KNOWLEDGE
AB Background: Increased emphasis has been given to the practice of evidence-based medicine (EBM) worldwide. Access to quality health information is essential to the practice of EBM in developing countries.
Objectives: To understand the information needs and sources of information of physicians from low-and middle-income countries (LMICs).
Methods: Medical doctors and students participated in an 18-question online or paper study.
Results: Of the 156 respondents from six LMICs, 146 (94%) came from the Philippines. Eighty-eight per cent encountered at least one clinical question daily, while 58% were very likely to search for answers. A basic mobile phone was the most used device at home (94%) and at work (82%). More than half had Internet connectivity at home (62%) and just under half at work (46%). In decreasing order, short messaging services (SMS), email, instant messaging and multimedia messaging services (MMS) were the most commonly used messaging tools at home and at work. The primary source for medication questions was a formulary, but for diagnostic dilemmas, colleagues were consulted first. PubMed use was high for therapy and management questions.
Conclusion: The use of health information from the Internet through mobile devices may be increasing. Access to health information was higher at home than at work. These results may be useful when planning resources for healthcare givers in resource-poor settings.
C1 [Gavino, Alex I.; Fontelo, Paul] Natl Lib Med, Bethesda, MD 20894 USA.
[Ho, Beverly Lorraine C.; Wee, Pura Angela A.; Marcelo, Alvin B.] Univ Philippines Manila, Natl Telehlth Ctr, Manila, Philippines.
RP Gavino, AI (reprint author), Natl Lib Med, Off High Performance Comp & Commun, Bldg 38A,Room B1N28D,8600 Rockville Pike, Bethesda, MD 20894 USA.
EM gavinoai@mail.nih.gov
NR 65
TC 11
Z9 11
U1 5
U2 25
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1471-1834
EI 1471-1842
J9 HEALTH INFO LIBR J
JI Heatlth Info. Libr. J.
PD DEC
PY 2013
VL 30
IS 4
BP 303
EP 317
DI 10.1111/hir.12032
PG 15
WC Information Science & Library Science
SC Information Science & Library Science
GA 297IY
UT WOS:000330250300006
PM 24251892
ER
PT J
AU Sullivan, JM
Prasanna, PGS
Grace, MB
Wathen, LK
Wallace, RL
Koerner, JF
Coleman, CN
AF Sullivan, Julie M.
Prasanna, Pataje G. S.
Grace, Marcy B.
Wathen, Lynne K.
Wallace, Rodney L.
Koerner, John F.
Coleman, C. Norman
TI ASSESSMENT OF BIODOSIMETRY METHODS FOR A MASS-CASUALTY RADIOLOGICAL
INCIDENT: MEDICAL RESPONSE AND MANAGEMENT CONSIDERATIONS
SO HEALTH PHYSICS
LA English
DT Article
DE biodosimetry; cytogenetics; dose assessment; emergency planning
ID IN-VIVO EPR; GENE-EXPRESSION SIGNATURES; OPTICALLY STIMULATED
LUMINESCENCE; SPECTROMETRY-BASED METABOLOMICS; DICENTRIC CHROMOSOME
ANALYSIS; IONIZING-RADIATION EXPOSURE; EARLY DOSE ASSESSMENT; BIOLOGICAL
DOSIMETRY; NUCLEAR DETONATION; HUMAN-LYMPHOCYTES
AB Following a mass-casualty nuclear disaster, effective medical triage has the potential to save tens of thousands of lives. In order to best use the available scarce resources, there is an urgent need for biodosimetry tools to determine an individual's radiation dose. Initial triage for radiation exposure will include location during the incident, symptoms, and physical examination. Stepwise triage will include point of care assessment of less than or greater than 2 Gy, followed by secondary assessment, possibly with high throughput screening, to further define an individual's dose. Given the multisystem nature of radiation injury, it is unlikely that any single biodosimetry assay can be used as a standalone tool to meet the surge in capacity with the timeliness and accuracy needed. As part of the national preparedness and planning for a nuclear or radiological incident, the authors reviewed the primary literature to determine the capabilities and limitations of a number of biodosimetry assays currently available or under development for use in the initial and secondary triage of patients. Understanding the requirements from a response standpoint and the capability and logistics for the various assays will help inform future biodosimetry technology development and acquisition. Factors considered include: type of sample required, dose detection limit, time interval when the assay is feasible biologically, time for sample preparation and analysis, ease of use, logistical requirements, potential throughput, point-of-care capability, and the ability to support patient diagnosis and treatment within a therapeutically relevant time point.
C1 [Sullivan, Julie M.; Koerner, John F.; Coleman, C. Norman] US Dept HHS, Off Emergency Management, Off Assistant Secretary Preparedness & Response, Washington, DC 20201 USA.
[Prasanna, Pataje G. S.; Coleman, C. Norman] NCI, Radiat Res Program, Div Canc Treatment & Diag, Bethesda, MD 20892 USA.
[Grace, Marcy B.; Wathen, Lynne K.; Wallace, Rodney L.] US Dept HHS, Biomed Adv Res & Dev Author, Off Assistant Secretary Preparedness & Response, Washington, DC 20201 USA.
RP Sullivan, JM (reprint author), ASPR OEM CBRNE, 330 Independence Ave SW,Rm G644, Washington, DC 20201 USA.
EM julie.sullivan@hhs.gov
FU Intramural NIH HHS [Z99 CA999999]
NR 110
TC 37
Z9 37
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0017-9078
EI 1538-5159
J9 HEALTH PHYS
JI Health Phys.
PD DEC
PY 2013
VL 105
IS 6
BP 540
EP 554
DI 10.1097/HP.0b013e31829cf221
PG 15
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA 299BF
UT WOS:000330368900005
PM 24162058
ER
PT J
AU Martinelli, E
Veglia, F
Goode, D
Guerra-Perez, N
Aravantinou, M
Arthos, J
Piatak, M
Lifson, JD
Blanchard, J
Gettie, A
Robbiani, M
AF Martinelli, Elena
Veglia, Filippo
Goode, Diana
Guerra-Perez, Natalia
Aravantinou, Meropi
Arthos, James
Piatak, Michael, Jr.
Lifson, Jeffrey D.
Blanchard, James
Gettie, Agegnehu
Robbiani, Melissa
TI The Frequency of alpha(4)beta(high)(7) Memory CD4(+) T Cells Correlates
With Susceptibility to Rectal Simian Immunodeficiency Virus Infection
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV; SIV; mucosa transmission; integrin alpha-4 beta-7; susceptibility;
gut
ID ACUTE SIV INFECTION; INTESTINAL DENDRITIC CELLS; RHESUS MACAQUES;
INTEGRIN ALPHA(4)BETA(7); MUCOSAL TRANSMISSION; HIV-1 INFECTION;
ENVELOPE; RECEPTOR; LYMPHOCYTES; PHENOTYPE
AB Background: Integrin alpha(4)beta(7) (alpha(4)beta(7)) mediates the homing of CD4(+) T cells to gut-associated lymphoid tissues, which constitute a highly favorable environment for HIV expansion and dissemination. HIV and simian immunodeficiency virus (SIV) envelope proteins bind to and signal through alpha(4)beta(7) and during acute infection SIV preferentially infects alpha(4)beta(7) high CD4(+) T cells. We postulated that the availability of these cells at the time of challenge could influence mucosal SIV transmission and acute viral load (VL).
Methods: We challenged 17 rhesus macaques with 3000 TCID50 of SIVmac239 rectally and followed the subsets of alpha(4)beta(+)(7) T cells and dendritic cells (DCs) by flow cytometry in blood and tissues, before and after challenge.
Results: We found that the frequency of memory CD4(+) T cells that expressed high levels of alpha(4)beta(7) (alpha(4)beta(high)(7) memory CD4(+) T cells) in blood before challenge correlated strongly with susceptibility to infection and acute VL. Notably, not only at the time of challenge but also their frequency 3 weeks before challenge correlated with infection. This association extended to the rectal tissue as we observed a strong direct correlation between the frequency of alpha(4)beta(7) high memory CD4(+) T cells in blood and rectum before and after challenge. The frequency of alpha(4)beta(+)(7) myeloid DCs and alpha(4)beta(7) high CD80(+) DCs also correlated with infection and acute VL, whereas blood CCR5(+) and CD69(+) CD4(+) T cells could not be associated with infection.
Conclusions: Our results suggest that animals with higher frequency of alpha(4)beta(high)(7) CD4(+) T cells in circulation and in rectal tissue could be more susceptible to SIV rectal transmission.
C1 [Martinelli, Elena; Veglia, Filippo; Goode, Diana; Guerra-Perez, Natalia; Aravantinou, Meropi; Robbiani, Melissa] Populat Council, Ctr Biomed Res, New York, NY 10065 USA.
[Arthos, James] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA.
[Piatak, Michael, Jr.; Lifson, Jeffrey D.] SAIC Frederick Inc, AIDS & Canc Virus Program, NCI, Frederick, MD USA.
[Blanchard, James] Tulane Univ, Ctr Sci, Tulane Natl Primate Res Ctr, Covington, LA USA.
[Gettie, Agegnehu] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10021 USA.
RP Martinelli, E (reprint author), Populat Council, Ctr Biomed Res, 1188 York Ave, New York, NY 10065 USA.
EM emartinelli@popcouncil.org
RI Veglia, Fabrizio/K-1958-2016
OI Veglia, Fabrizio/0000-0002-9378-8874
FU NIH [R37 AI040877-15]
FX Supported by NIH Grant R37 AI040877-15.
NR 36
TC 16
Z9 17
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 1
PY 2013
VL 64
IS 4
BP 325
EP 331
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 300HE
UT WOS:000330454200001
PM 23797688
ER
PT J
AU Rodriguez, B
Asmuth, DM
Matining, RM
Spritzler, J
Jacobson, JM
Mailliard, RB
Li, XD
Martinez, AI
Tenorio, AR
Lori, F
Lisziewicz, J
Yesmin, S
Rinaldo, CR
Pollard, RB
AF Rodriguez, Benigno
Asmuth, David M.
Matining, Roy M.
Spritzler, John
Jacobson, Jeffrey M.
Mailliard, Robbie B.
Li, Xiao-Dong
Martinez, Ana I.
Tenorio, Allan R.
Lori, Franco
Lisziewicz, Julianna
Yesmin, Suria
Rinaldo, Charles R.
Pollard, Richard B.
TI Safety, Tolerability, and Immunogenicity of Repeated Doses of DermaVir,
a Candidate Therapeutic HIV Vaccine, in HIV-Infected Patients Receiving
Combination Antiretroviral Therapy: Results of the ACTG 5176 Trial
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE DermaVir; CTL responses; HIV therapeutic vaccines; HIV-specific immune
responses
ID T-CELL RESPONSES; SIMIAN IMMUNODEFICIENCY VIRUS; TYPE-1 HIV-1; DENDRITIC
CELLS; PLASMA VIREMIA; EX-VIVO; IMMUNIZATION; REPLICATION; MACAQUES;
LYMPHOCYTES
AB Background: HIV-specific cellular immune responses are associated with control of viremia and delayed disease progression. An effective therapeutic vaccine could mimic these effects and reduce the need for continued antiretroviral therapy. DermaVir, a topically administered plasmid DNA-nanomedicine expressing HIV (CladeB) virus-like particles consisting of 15 antigens, induces predominantly central memory T-cell responses.
Methods: Treated HIV-infected adults (HIV RNA <50 and CD4 >350) were randomized to placebo or escalating DermaVir doses (0.1 or 0.4 mg of plasmid DNA at weeks 1, 7, and 13 in the low-and intermediate-dose groups and 0.8 mg at weeks 0, 1, 6, 7, 12, and 13 in the high-dose group), n = 5-6 evaluable subjects per group. Immunogenicity was assessed by a 12-day cultured interferon-g enzyme-linked immunosorbent spot assay at baseline and at weeks 9, 17, and 37 using 1 Tat/Rev and 3 overlapping Gag peptide pools (p17, p24, and p15).
Results: Groups were comparable at baseline. The study intervention was well tolerated, without dose-limiting toxicities. Most responses were highest at week 17 (4 weeks after last vaccination) when Gag p24 responses were significantly greater among intermediate-dose group compared with control subjects [median (IQR): 67,600 (5633-74,368) versus 1194 (9-1667)] net spot-forming units per million cells, P = 0.032. In the intermediate-dose group, there was also a marginal Gag p15 response increase from baseline to week 17 [2859 (1867-56,933), P = 0.06], and this change was significantly greater than in the placebo group [0 (2713 to 297), P = 0.016].
Conclusions: DermaVir administration was associated with a trend toward greater HIV-specific, predominantly central memory T-cell responses. The intermediate DermaVir dose tended to show the greatest immunogenicity, consistent with previous studies in different HIV-infected patient populations.
C1 [Rodriguez, Benigno] Case Western Reserve Univ, Univ Hosp Cleveland, Div Infect Dis, Cleveland, OH 44106 USA.
[Rodriguez, Benigno] Case Western Reserve Univ, Univ Hosp Cleveland, Ctr AIDS Res, Cleveland, OH 44106 USA.
[Asmuth, David M.; Li, Xiao-Dong; Pollard, Richard B.] Univ Calif Davis, Med Ctr, Div Infect Dis, Sacramento, CA 95817 USA.
[Matining, Roy M.; Spritzler, John] Harvard Univ, Sch Publ Hlth, Stat & Data Anal Ctr, Boston, MA 02115 USA.
[Jacobson, Jeffrey M.] Drexel Univ, Coll Med, Div Infect Dis & HIV Med, Philadelphia, PA 19104 USA.
[Mailliard, Robbie B.; Rinaldo, Charles R.] Univ Pittsburgh, Pittsburgh, PA USA.
[Martinez, Ana I.] NIAID, Div Aids, Bethesda, MD 20892 USA.
[Tenorio, Allan R.] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA.
[Lori, Franco] ViroStat Srl, Sassari, Italy.
[Lisziewicz, Julianna] Genet Immun, Budapest, Hungary.
[Lisziewicz, Julianna] Genet Immun, Mclean, VA USA.
[Yesmin, Suria] Social & Sci Syst Inc, Silver Spring, MD USA.
RP Rodriguez, B (reprint author), Case Western Reserve Univ, Univ Hosp Cleveland, Div Infect Dis, 2061 Cornell Rd,Suite 401, Cleveland, OH 44106 USA.
EM rodriguez.benigno@clevelandactu.org
RI Rodriguez, Benigno/C-3365-2009;
OI Rodriguez, Benigno/0000-0001-9736-7957; Mailliard,
Robbie/0000-0001-5501-503X
FU Genetic Immunity; NIAID [AI-36219, AI-069501, AI-68636, AI-68634,
201IC001]; SSSS, Inc (ACTG Immunol. Support Lab) [U01 AI-069471];
National Office for Research and Technology (Hungary) [HIKC05, DVCLIN01]
FX F.L. is CEO of Virostatics srl; J.L. is CEO of Genetic Immunity; R. B.
P. is a consultant and has received financial compensation from Genetic
Immunity. NIAID: AI-36219 and AI-069501 (B. R.), AI-68636 and AI-68634
(R. B. M. and J.S.), and 201IC001. SSSS, Inc (ACTG Immunol. Support Lab,
D. M. A., X-D. L., and R. B. P.), U01 AI-069471 (A. R. T.). National
Office for Research and Technology (Hungary): HIKC05 and DVCLIN01
(J.L.).
NR 58
TC 14
Z9 15
U1 3
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 1
PY 2013
VL 64
IS 4
BP 351
EP 359
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 300HE
UT WOS:000330454200005
PM 24169120
ER
PT J
AU Ransom, CE
Huo, YL
Patel, K
Scott, GB
Watts, HD
Williams, P
Siberry, GK
Livingston, EG
AF Ransom, Carla E.
Huo, Yanling
Patel, Kunjal
Scott, Gwendolyn B.
Watts, Heather D.
Williams, Paige
Siberry, George K.
Livingston, Elizabeth G.
CA Int Maternal Pediat Adolescent
TI Infant Growth Outcomes After Maternal Tenofovir Disoproxil Fumarate Use
During Pregnancy
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article; Proceedings Paper
CT Conference of the International-AIDS-Society (IAS)
CY JUL 22-27, 2012
CL Washington, DC
SP Int AIDS Soc
DE tenofovir; mother-to-child transmission; infant growth; TDF; HIV;
pregnancy
ID RENAL-FAILURE; HIV-1-INFECTED WOMEN; FANCONI-SYNDROME; RHESUS MACAQUES;
MACACA-MULATTA; HIV; NEPHROTOXICITY; TRANSMISSION; PHARMACOKINETICS;
EXPOSURE
AB Objective: To determine whether maternal use of tenofovir disoproxil fumarate for treatment of HIV in pregnancy predicts fetal and infant growth.
Methods: The study population included HIV-uninfected live-born singleton infants of mothers enrolled in the International Maternal Pediatric Adolescent AIDS Clinical Trials Group protocol P1025 (born 2002-2011) in the United States and exposed in utero to a combined (triple or more) antiretroviral regimen. Infant weight at birth and 6 months was compared between infants exposed and unexposed to tenofovir in utero using 2-sample t test, chi(2) test, and multivariable linear and logistic regression models, including demographic and maternal characteristics.
Results: Among 2025 infants with measured birth weight, there was no difference between those exposed (N = 630, 31%) versus unexposed to tenofovir in mean birth weight (2.75 vs. 2.77 kg, P = 0.64) or mean gestational age-and sex-adjusted birth weight z-score (WASZ) (0.14 vs. 0.14, P = 0.90). Among 1496 infants followed for 6 months, there was no difference in mean weight at 6 months between tenofovir-exposed (N = 457, 31%) and tenofovir-unexposed infants (7.64 vs. 7.59 kg, P = 0.52) or in mean WASZ (0.29 vs. 0.26, P = 0.61). Tenofovir exposure during the second/third trimester, relative to no exposure, significantly predicted underweight (WASZ < 5%) at age 6 months [odds ratio (95% confidence interval): 2.06 (1.01 to 3.95), P = 0.04]. Duration of tenofovir exposure did not predict neonatal or infant growth.
Conclusions: By most measures, in utero exposure to tenofovir did not significantly predict infant birth weight or growth through 6 months of age.
C1 [Ransom, Carla E.] Vanderbilt Univ, Dept Obstet & Gynecol, Nashville, TN 37232 USA.
[Huo, Yanling; Patel, Kunjal; Williams, Paige] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA.
[Patel, Kunjal] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Scott, Gwendolyn B.] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA.
[Watts, Heather D.; Siberry, George K.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Maternal & Pediat Infect Dis Branch, NIH, Bethesda, MD 20892 USA.
[Livingston, Elizabeth G.] Duke Univ, Sch Med, Dept Obstet & Gynecol, Durham, NC USA.
RP Ransom, CE (reprint author), Vanderbilt Univ, Dept Obstet & Gynecol, B-1100 Med Ctr North, Nashville, TN 37232 USA.
EM carla.ransom@vanderbilt.edu
FU NCATS NIH HHS [UL1 TR000038, UL1 TR000154, UL1 TR000161, UL1 TR001082];
NCRR NIH HHS [UL1 RR024131]; NIAID NIH HHS [1 U01 AI068616, 5 U01
AI41110, U01 AI041110, U01 AI068616, U01 AI068632, UM1 AI068616, UM1
AI068632]; NICHD NIH HHS [HHSN267200800001C]; NIDDK NIH HHS
[HHSN267200800001G, N01-DK-9-001]
NR 22
TC 24
Z9 24
U1 1
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD DEC 1
PY 2013
VL 64
IS 4
BP 374
EP 381
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 300HE
UT WOS:000330454200008
PM 24169122
ER
PT J
AU Remaley, AT
AF Remaley, A. T.
TI Tomatoes, lysophosphatidic acid, and the small intestine: new pieces in
the puzzle of apolipoprotein mimetic peptides?
SO JOURNAL OF LIPID RESEARCH
LA English
DT Editorial Material
ID ABCA1-DEPENDENT CHOLESTEROL EFFLUX; APOA-I; ATHEROSCLEROSIS; PROMOTES;
INFLAMMATION; LIPOPROTEIN; AFFINITY; CANCER
C1 NHLBI, Lipoprot Metab Sect, Cardiopulm Branch, NIH, Bethesda, MD 20892 USA.
RP Remaley, AT (reprint author), NHLBI, Lipoprot Metab Sect, Cardiopulm Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM aremaley1@cc.nih.gov
NR 23
TC 5
Z9 5
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD DEC
PY 2013
VL 54
IS 12
BP 3223
EP 3226
DI 10.1194/jlr.E045054
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 301LX
UT WOS:000330534900001
PM 24146211
ER
PT J
AU Fang, ZZ
He, RR
Cao, YF
Tanaka, N
Jiang, CT
Krausz, KW
Qi, YP
Dong, PP
Ai, CZ
Sun, XY
Hong, M
Ge, GB
Gonzalez, FJ
Ma, XC
Sun, HZ
AF Fang, Zhong-Ze
He, Rong-Rong
Cao, Yun-Feng
Tanaka, Naoki
Jiang, Changtao
Krausz, Kristopher W.
Qi, Yunpeng
Dong, Pei-Pei
Ai, Chun-Zhi
Sun, Xiao-Yu
Hong, Mo
Ge, Guang-Bo
Gonzalez, Frank J.
Ma, Xiao-Chi
Sun, Hong-Zhi
TI A model of in vitro UDP-glucuronosyltransferase inhibition by bile acids
predicts possible metabolic disorders
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE cholestasis; endobiotics; structure-UDP-glucuronosyltransferase
inhibition relationship; xenobiotics
ID FARNESOID-X-RECEPTOR; HUMAN-LIVER; HYODEOXYCHOLIC ACID; NUCLEAR
RECEPTOR; GLUCURONIDATION; ENZYME; HEPATOCYTES; CHOLESTASIS; EXPRESSION;
INTESTINE
AB Increased levels of bile acids (BAs) due to the various hepatic diseases could interfere with the metabolism of xenobiotics, such as drugs, and endobiotics including steroid hormones. UDP-glucuronosyltransferases (UGTs) are involved in the conjugation and elimination of many xenobiotics and endogenous compounds. The present study sought to investigate the potential for inhibition of UGT enzymes by BAs. The results showed that taurolithocholic acid (TLCA) exhibited the strongest inhibition toward UGTs, followed by lithocholic acid. Structure-UGT inhibition relationships of BAs were examined and in vitro-in vivo extrapolation performed by using in vitro inhibition kinetic parameters (K-i) in combination with calculated in vivo levels of TLCA. Substitution of a hydrogen with a hydroxyl group in the R1, R3, R4, R5 sites of BAs significantly weakens their inhibition ability toward most UGTs. The in vivo inhibition by TLCA toward UGT forms was determined with following orders of potency: UGT1A4 > UGT2B7 > UGT1A3 > UGT1A1 similar to UGT1A7 similar to UGT1A10 similar to UGT2B15. In conclusion, these studies suggest that disrupted homeostasis of BAs, notably taurolithocholic acid, found in various diseases such as cholestasis, could lead to altered metabolism of xenobiotics and endobiotics through inhibition of UGT enzymes.
C1 [Fang, Zhong-Ze; Sun, Hong-Zhi] Liaoning Med Univ, Affiliated Hosp 1, Jinzhou 121001, Peoples R China.
[Fang, Zhong-Ze; Cao, Yun-Feng; Ai, Chun-Zhi; Sun, Xiao-Yu; Hong, Mo; Ge, Guang-Bo] Chinese Acad Sci, Dalian Inst Chem Phys, Joint Ctr Translat Med, Dalian 116023, Peoples R China.
Liaoning Med Univ, Affiliated Hosp 1, Dalian 116023, Peoples R China.
[Fang, Zhong-Ze; Tanaka, Naoki; Jiang, Changtao; Krausz, Kristopher W.; Qi, Yunpeng; Gonzalez, Frank J.] NCI, Lab Metab, Ctr Canc Res, Bethesda, MD 20892 USA.
[He, Rong-Rong] Jinan Univ, Coll Pharm, Guangzhou 510632, Guangdong, Peoples R China.
[Dong, Pei-Pei] Dalian Med Univ, Acad Integrat Med, Dalian 116044, Peoples R China.
[Ma, Xiao-Chi] Dalian Med Univ, Coll Pharm, Pharmacokinet & Drug Transport Key Lab, Dalian 116044, Peoples R China.
RP Ma, XC (reprint author), Dalian Med Univ, Coll Pharm, Pharmacokinet & Drug Transport Key Lab, Dalian 116044, Peoples R China.
EM cmushz@163.com; maxc1978@163.com
FU National Natural Science Foundation of China [81202586, 81274047,
81102507]; National Cancer Institute, Center for Cancer Research,
Intramural Research Program
FX This work was supported by the National Natural Science Foundation of
China (No. 81202586, 81274047 and No. 81102507) and the National Cancer
Institute, Center for Cancer Research, Intramural Research Program. The
authors have declared no conflicts of interest.
NR 34
TC 25
Z9 26
U1 3
U2 28
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD DEC
PY 2013
VL 54
IS 12
BP 3334
EP 3344
DI 10.1194/jlr.M040519
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 301LX
UT WOS:000330534900011
PM 24115227
ER
PT J
AU Tyor, W
Fritz-French, C
Nath, A
AF Tyor, William
Fritz-French, Cari
Nath, Avindra
TI Effect of HIV clade differences on the onset and severity of
HIV-associated neurocognitive disorders
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Review
DE HIVencephalitis; Encephalitis; HIV clades; HIV-associated neurocognitive
disorders
ID RAPID SCREENING-TEST; SUB-SAHARAN AFRICA; TAT PROTEIN; ANTIRETROVIRAL
THERAPY; COGNITIVE IMPAIRMENT; POSITIVE INDIVIDUALS; AIDS PATIENTS;
SOUTH-AFRICA; RISK-FACTORS; SUBTYPE D
AB The effects of evolutionary pressure on human immunodeficiency virus-1 (HIV) have resulted in a variety of clades and recombinants. The functional implications of HIV clades on disease onset and progression of HIV-associated neurocognitive disorders (HAND) have been suggested by clinical and basic science studies, which will be reviewed in detail. Some clinical studies suggest that patients infected with clade D show the greatest propensity for developing HIV-associated dementia (HAD) followed by clades B, C, and A, respectively. However, there are conflicting reports. This review summarizes clinical studies that have assessed behavioral abnormalities and HIV clade type in HAND patients, focusing on the clades stated above. The limitations include variations in testing used to define the cohorts, patient sample size, lack of HIV clade characterization, combination antiretroviral therapy (cART) availability, and other factors, which are highlighted and compared between clinical studies performed primarily in Africa and India. Basic science studies provide substantial evidence that HIV clade differences can result in varying degrees of neuropathology and are also reviewed in some detail. These studies indicate that there are a number of clade differences, most notably in Tat, that result in different degrees of neurovirulence or neuropathological effects in vitro and in a mouse model of HAND. In order to confirm the hypothesis that HIV clade differences are important determinants of HAND pathogenesis, larger, longitudinal studies that employ standard definitions of HAND and HIV clade testing must be performed. In a larger sense, HAND continues to be highly prevalent despite the advent of cART, and therefore, further studies into HAND pathogenesis are critical to develop better therapies.
C1 [Tyor, William; Fritz-French, Cari] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
[Nath, Avindra] NINDS, Sect Infect Nervous Syst, NIH, Bethesda, MD 20892 USA.
[Tyor, William] Atlanta VA Med Ctr, Neurol GEC, Decatur, GA 30033 USA.
RP Tyor, W (reprint author), Atlanta VA Med Ctr, Neurol GEC, 1670 Clairmont Rd, Decatur, GA 30033 USA.
EM william.tyor@va.gov
FU NINDS, NIH
FX Dr. Nath is supported by intramural funds from NINDS, NIH.
NR 49
TC 10
Z9 10
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1355-0284
EI 1538-2443
J9 J NEUROVIROL
JI J. Neurovirol.
PD DEC
PY 2013
VL 19
IS 6
BP 515
EP 522
DI 10.1007/s13365-013-0206-6
PG 8
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA 296WU
UT WOS:000330216900001
PM 24129908
ER
PT J
AU Howard, EN
Frierson, GM
Willis, BL
Haskell, WL
Powell-Wiley, TM
Defina, LF
AF Howard, Erica N.
Frierson, Georita M.
Willis, Benjamin L.
Haskell, William L.
Powell-Wiley, Tiffany M.
Defina, Laura F.
TI The Impact of Race and Higher Socioeconomic Status on Cardiorespiratory
Fitness
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Article
DE RACIAL/ETHNIC MINORITIES; DISPARITIES; PHYSICAL ACTIVITY
ID ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY PARTICIPATION;
AMERICAN-HEART-ASSOCIATION; EXERCISE CAPACITY; CARDIOVASCULAR-DISEASE;
AFRICAN-AMERICAN; DISTANCE RUNNERS; AEROBIC CAPACITY; NHANES 1999-2000;
UNITED-STATES
AB Purpose: Previous studies suggest that African Americans (AA) have lower levels of cardiorespiratory fitness (CRF) than their Caucasian (C) counterparts. However, the association between CRF and race/ethnicity in the context of higher socioeconomic status (SES) has not been explored. Methods: We evaluated 589 AA (309 men and 203 women) and 33,015 C (19,399 men and 8753 women) enrolled in the Cooper Center Longitudinal Study. Education years and access to a preventive health care examination were used as a proxy for higher SES. Data were collected from a questionnaire, maximal treadmill exercise stress test, and other clinical measures. The outcome variable was CRF, which was stratified into low fit (quintile 1 of CRF) and fit (quintiles 2-5). Multivariable regression was used to compare adjusted mean CRF between groups. P values were adjusted for unbalanced sample size and unequal variance between groups. Results: The mean education years were similar for AA and C men at 16 yr; however, AA women had more years of education than C (15.8 vs 15.2 yr, P = 0.0062). AA men and women had a significantly higher prevalence of being unfit compared with their C counterparts (men 26.7% vs 12.6%, P < 0.0001; women 21.3% vs 8.4%, P < 0.0001). The adjusted mean estimated maximal METs were 10.9 vs 11.7 and 8.8 vs 9.8 for AA and C men and women, respectively. Fully adjusted odds ratios revealed that AA men had more than twice the risk of being unfit compared with C men. A trend persisted for AA women to have a lower MET value than their counterparts. Conclusions: Despite comparable higher SES, lower CRF existed among AA men versus C men. These results suggest that CRF may not be mediated strictly by environmental factors related to SES.
C1 [Howard, Erica N.; Willis, Benjamin L.; Defina, Laura F.] Cooper Inst, Dallas, TX 75230 USA.
[Frierson, Georita M.] Howard Univ, Dept Psychol, Washington, DC 20059 USA.
[Haskell, William L.] Stanford Univ, Dept Med, Prevent Res Ctr, Palo Alto, CA 94304 USA.
[Powell-Wiley, Tiffany M.] NHLBI, Cardiovasc Pulm Branch, NIH, Bethesda, MD 20892 USA.
RP Howard, EN (reprint author), Cooper Inst, 12330 Preston Rd, Dallas, TX 75230 USA.
EM ehoward@cooperinst.org
FU Intramural NIH HHS [Z99 HL999999]
NR 39
TC 2
Z9 2
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD DEC
PY 2013
VL 45
IS 12
BP 2286
EP 2291
PG 6
WC Sport Sciences
SC Sport Sciences
GA 300LN
UT WOS:000330465500009
PM 23698239
ER
PT J
AU Insel, TR
Voon, V
Nye, JS
Brown, VJ
Altevogt, BM
Bullmore, ET
Goodwin, GM
Howard, RJ
Kupfer, DJ
Malloch, G
Marston, HM
Nutt, DJ
Robbins, TW
Stahl, SM
Tricklebank, MD
Williams, JH
Sahakian, BJ
AF Insel, T. R.
Voon, V.
Nye, J. S.
Brown, V. J.
Altevogt, B. M.
Bullmore, E. T.
Goodwin, G. M.
Howard, R. J.
Kupfer, D. J.
Malloch, G.
Marston, H. M.
Nutt, D. J.
Robbins, T. W.
Stahl, S. M.
Tricklebank, M. D.
Williams, J. H.
Sahakian, B. J.
TI Innovative solutions to novel drug development in mental health
SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
LA English
DT Editorial Material
DE Translation; Back-translation; Pharmacological tool box; Cognitive and
psychosocial treatments; Novel drug development; Biomarkers;
Neurobiological mechanisms; Neuropsychiatric disorders
ID D-ASPARTATE ANTAGONIST; RESEARCH DOMAIN CRITERIA; PLURIPOTENT
STEM-CELLS; TREAT SCHIZOPHRENIA; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX;
MOOD DISORDERS; RECEPTOR; COGNITION; ILLNESS
AB There are many new advances in neuroscience and mental health which should lead to a greater understanding of the neurobiological dysfunction in neuropsychiatric disorders and new developments for early, effective treatments. To do this, a biomarker approach combining genetic, neuroimaging, cognitive and other biological measures is needed. The aim of this article is to highlight novel approaches for pharmacological and non-pharmacological treatment development. This article suggests approaches that can be taken in the future including novel mechanisms with preliminary clinical validation to provide a toolbox for mechanistic studies and also examples of translation and back-translation. The review also emphasizes the need for clinician-scientists to be trained in a novel way in order to equip them with the conceptual and experimental techniques required, and emphasizes the need for private-public partnership and pre-competitive knowledge exchange. This should lead the way for important new holistic treatment developments to improve cognition, functional outcome and well-being of people with neuropsychiatric disorders. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Insel, T. R.] NIMH, NIH, Bethesda, MD 20892 USA.
[Voon, V.; Stahl, S. M.; Sahakian, B. J.] Univ Cambridge, Dept Psychiat, Cambridge, England.
[Voon, V.; Robbins, T. W.; Sahakian, B. J.] Univ Cambridge, MRC, Wellcome Trust Behav & Clin Neurosci Inst, Cambridge, England.
[Nye, J. S.] Johnson & Johnson, Janssen Pharmaceut, Titusville, NJ USA.
[Brown, V. J.] Univ St Andrews, Sch Psychol & Neurosci, St Andrews, Fife, Scotland.
[Altevogt, B. M.] Natl Acad Sci, Inst Med, Forum Neurosci & Nervous Syst Disorders, Washington, DC 20418 USA.
[Bullmore, E. T.] Addenbrookes Hosp, Clin Unit, Glaxo Smith Kline, Cambridge CB2 0QQ, England.
[Goodwin, G. M.] Univ Oxford, Dept Psychiat, Oxford, England.
[Howard, R. J.] Kings Coll London, Royal Coll Psychiatrists, London, England.
[Howard, R. J.] Kings Coll London, Inst Psychiat, London, England.
[Kupfer, D. J.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Malloch, G.] MRC, London W1N 4AL, England.
[Marston, H. M.] TPP Global Dev, Edinburgh, Midlothian, Scotland.
[Nutt, D. J.] Univ London Imperial Coll Sci Technol & Med, Div Expt Med, Ctr Pharmacol & Therapeut, London, England.
[Robbins, T. W.] Univ Cambridge, Dept Psychol, Cambridge, England.
[Stahl, S. M.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Tricklebank, M. D.] Eli Lilly & Co Ltd, Windlesham, Surrey, England.
[Williams, J. H.] Wellcome Trust Res Labs, Cambridge, England.
RP Sahakian, BJ (reprint author), Addenbrookes Hosp, Dept Psychiat, Box 189,Level E4, Cambridge CB2 0QQ, England.
EM bjs1001@cam.ac.uk
RI Brown, Verity/A-5235-2011;
OI Brown, Verity/0000-0001-5762-1797; Bullmore, Edward/0000-0002-8955-8283
FU Intramural NIH HHS [Z99 MH999999]; Medical Research Council [G0001354,
G1002226]; Wellcome Trust [089589/Z/09/Z]
NR 47
TC 37
Z9 37
U1 4
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0149-7634
EI 1873-7528
J9 NEUROSCI BIOBEHAV R
JI Neurosci. Biobehav. Rev.
PD DEC
PY 2013
VL 37
IS 10
SI SI
BP 2438
EP 2444
DI 10.1016/j.neubiorev.2013.03.022
PN 1
PG 7
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 300US
UT WOS:000330490100012
PM 23563062
ER
PT J
AU Timofeev, J
Reddy, UM
Huang, CC
Driggers, RW
Landy, HJ
Laughon, SK
AF Timofeev, Julia
Reddy, Uma M.
Huang, Chun-Chih
Driggers, Rita W.
Landy, Helain J.
Laughon, S. Katherine
TI Obstetric Complications, Neonatal Morbidity, and Indications for
Cesarean Delivery by Maternal Age
SO OBSTETRICS AND GYNECOLOGY
LA English
DT Article
ID PREGNANCY; OUTCOMES; WOMEN; CHILDBEARING; OLDER; RISK
AB OBJECTIVE; To delineate adverse obstetric and neonatal outcomes as well as indications for cesarean delivery by maternal age in a contemporaneous large national cohort.
METHODS; This was a retrospective analysis of electronic medical records from 12 centers and 203,517 (30,673 women aged 35 years or older) women with singleton gestations stratified by maternal age. Logistic regression was performed to investigate maternal and neonatal outcomes for each maternal age strata (referent group, age 25.0-29.9 years), adjusting for race, parity, body mass index, insurance, pre-existing medical conditions, substance and tobacco use, and site. Documented indications for cesarean delivery were analyzed.
RESULTS; Neonates born to women aged 25.0-29.9 years had the lowest risk of birth weight less than 2,500 g (7.2%; P<.001), admission to neonatal intensive care unit (11.5%; P<.001), and perinatal mortality (0.7%; P<.001). Hypertensive disorders of pregnancy were higher in women aged 35 years or older (cumulative rate 8.5% compared with 7.8%; 25.0-29.9 years; P<.001). Previous uterine scar was the leading indication for cesarean delivery in women aged 25.0 years or older (36.9%; P<.001). For younger women, failure to progress or cephalopelvic disproportion (37.0% for those younger than age 20.0 years and 31.1% for those aged 20.0 24.9-years; P<.001) and nonreassuring fetal heart tracing (28.7% for those younger than 20.0 years and 21.2% for those aged 20.0-24.9-years; P<.001) predominated as indications. Truly elective cesarean delivery rate was 20.2% for women aged 45.0 years or older (adjusted odds ratio 1.85 [99% confidence interval 1.03-3.32] compared with the referent age group of 25.0-29.9 years).
CONCLUSIONS; Maternal and obstetric complications differed by maternal age, as did rates of elective cesarean delivery. Women aged 25.0-29.9 years had the lowest rate of serious neonatal morbidity.
C1 MedStar Washington Hosp Ctr, Dept Obstet & Gynecol, Div Maternal Fetal Med, Washington, DC 20010 USA.
Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
MedStar Hlth Res Inst, Dept Biostat & Epidemiol, Hyattsville, MD USA.
RP Timofeev, J (reprint author), MedStar Washington Hosp Ctr, Dept Obstet & Gynecol, 110 Irving St NW,5B-63, Washington, DC 20010 USA.
EM jtimofe1@jhmi.edu
OI Grantz, Katherine/0000-0003-0276-8534
FU Intramural Research Program of the Eunice Kennedy Shriver National
Institute of Child Health and Human Development, National Institutes of
Health [HHSN267200603425C]; National Center for Research Resources
[UL1RR031975]; National Center for Advancing Translational Sciences,
National Institutes of Health, through the Clinical and Translational
Science Awards Program
FX The Consortium on Safe Labor was funded by the Intramural Research
Program of the Eunice Kennedy Shriver National Institute of Child Health
and Human Development, National Institutes of Health, through Contract
No. HHSN267200603425C. Funded in part with Federal funds (grant #
(UL1RR031975) from the National Center for Research Resources and the
National Center for Advancing Translational Sciences, National
Institutes of Health, through the Clinical and Translational Science
Awards Program, a trademark of Department of Health and Human Services,
part of the Roadmap Initiative, "Re-Engineering the Clinical Research
Enterprise."
NR 19
TC 15
Z9 18
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-7844
EI 1873-233X
J9 OBSTET GYNECOL
JI Obstet. Gynecol.
PD DEC
PY 2013
VL 122
IS 6
BP 1184
EP 1195
DI 10.1097/AOG.0000000000000017
PG 12
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 300FV
UT WOS:000330450700008
PM 24201681
ER
PT J
AU Hodge, JW
Kwilas, A
Ardiani, A
Gameiro, SR
AF Hodge, James W.
Kwilas, Anna
Ardiani, Andressa
Gameiro, Sofia R.
TI Attacking malignant cells that survive therapy Exploiting immunogenic
modulation
SO ONCOIMMUNOLOGY
LA English
DT Editorial Material
DE antigen-processing machinery; calreticulin; CTL-mediated lysis;
immunogenic modulation; immunotherapy; therapeutic cancer vaccine
ID CYTOTOXIC T-LYMPHOCYTES; COMBINATION THERAPY; TUMOR-CELLS; CHEMOTHERAPY;
RADIATION; DEATH
AB We have recently defined "immunogenic modulation," a mechanism whereby malignant cells that survive anticancer therapy, due to sublethal delivery or development of treatment resistance, become nonetheless more sensitive to killing by cytotoxic T lymphocytes. This mechanism can be exploited to identify which therapies will best synergize with immunotherapy, potentially maximizing patient clinical benefit.
C1 [Hodge, James W.; Kwilas, Anna; Ardiani, Andressa; Gameiro, Sofia R.] NCI, Tumor Immunol & Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Hodge, JW (reprint author), NCI, Tumor Immunol & Biol Lab, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM jh241d@nih.gov
RI Hodge, James/D-5518-2015
OI Hodge, James/0000-0001-5282-3154
NR 10
TC 16
Z9 16
U1 0
U2 0
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2162-4011
EI 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PD DEC
PY 2013
VL 2
IS 12
AR e26937
DI 10.4161/onci.26937
PG 4
WC Oncology; Immunology
SC Oncology; Immunology
GA 299VZ
UT WOS:000330425100031
ER
PT J
AU Madsen, DH
Bugge, TH
AF Madsen, Daniel H.
Bugge, Thomas H.
TI Imaging collagen degradation in vivo highlights a key role for
M2-polarized macrophages in extracellular matrix degradation
SO ONCOIMMUNOLOGY
LA English
DT Editorial Material
DE cathepsin; collagenase; collagen endocytosis; Endo180; interstitial
collagen degradation; in vivo imaging; lysosome; M2-polarized
macrophages; mannose receptor; matrix metalloproteinase; Mrc1; Mrc2;
tumor invasion; urokinase plasminogen activator receptor-associated
protein
ID CANCER; CARCINOMAS; GROWTH; CELLS
AB We have recently described an assay for imaging interstitial collagen degradation in vivo, which allows for the identification of cell types and molecules involved in collagen turnover in the course of pathological and physiological tissue remodeling. The assay revealed a dominant role of receptor-mediated intracellular collagen degradation by M2-polarized macrophages in extracellular matrix turnover.
C1 [Madsen, Daniel H.; Bugge, Thomas H.] Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Sect, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.
RP Bugge, TH (reprint author), Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Sect, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.
EM thomas.bugge@nih.gov
OI Madsen, Daniel Hargboel/0000-0002-3183-6201
NR 10
TC 5
Z9 5
U1 3
U2 4
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2162-4011
EI 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PD DEC
PY 2013
VL 2
IS 12
AR e27127
DI 10.4161/onci.27127
PG 3
WC Oncology; Immunology
SC Oncology; Immunology
GA 299VZ
UT WOS:000330425100037
ER
PT J
AU Shimbo, T
Du, Y
Grimm, SA
Dhasarathy, A
Mav, D
Shah, RR
Shi, HD
Wade, PA
AF Shimbo, Takashi
Du, Ying
Grimm, Sara A.
Dhasarathy, Archana
Mav, Deepak
Shah, Ruchir R.
Shi, Huidong
Wade, Paul A.
TI MBD3 Localizes at Promoters, Gene Bodies and Enhancers of Active Genes
SO PLOS GENETICS
LA English
DT Article
ID CHROMATIN REMODELER MI-2-BETA; STEM-CELL DIFFERENTIATION; CPG
BINDING-PROTEINS; HUMAN GENOME; DNA METHYLATION; IN-VIVO; MODIFYING
ENZYMES; LOCATION ANALYSIS; COMPLEX; EXPRESSION
AB The Mi-2/nucleosome remodeling and histone deacetylase (NuRD) complex is a multiprotein machine proposed to regulate chromatin structure by nucleosome remodeling and histone deacetylation activities. Recent reports describing localization of NuRD provide new insights that question previous models on NuRD action, but are not in complete agreement. Here, we provide location analysis of endogenous MBD3, a component of NuRD complex, in two human breast cancer cell lines (MCF-7 and MDA-MB-231) using two independent genomic techniques: DNA adenine methyltransferase identification (DamID) and ChIP-seq. We observed concordance of the resulting genomic localization, suggesting that these studies are converging on a robust map for NuRD in the cancer cell genome. MBD3 preferentially associated with CpG rich promoters marked by H3K4me3 and showed cell-type specific localization across gene bodies, peaking around the transcription start site. A subset of sites bound by MBD3 was enriched in H3K27ac and was in physical proximity to promoters in three-dimensional space, suggesting function as enhancers. MBD3 enrichment was also noted at promoters modified by H3K27me3. Functional analysis of chromatin indicated that MBD3 regulates nucleosome occupancy near promoters and in gene bodies. These data suggest that MBD3, and by extension the NuRD complex, may have multiple roles in fine tuning expression for both active and silent genes, representing an important step in defining regulatory mechanisms by which NuRD complex controls chromatin structure and modification status.
C1 [Shimbo, Takashi; Dhasarathy, Archana; Wade, Paul A.] NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA.
[Du, Ying; Grimm, Sara A.] NIEHS, Res Triangle Pk, NC 27709 USA.
[Mav, Deepak; Shah, Ruchir R.] SRA Int Inc, Durham, NC USA.
[Shi, Huidong] Georgia Hlth Sci Univ, Dept Biochem & Mol Biol, Augusta, GA USA.
RP Shimbo, T (reprint author), NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA.
EM wadep2@niehs.nih.gov
FU National Institute of Environmental Health Sciences, NIH [ZO1ES101965];
NIH [CA134304]; National Institute of Environmental Health Sciences
[HHSN291200555547C]; GSA [GS-00F-003L]
FX This work was supported in part by the Intramural Research Program of
the National Institute of Environmental Health Sciences, NIH (Project
number ZO1ES101965 to PAW) and by a grant from NIH (CA134304 to HS). DM
and RRS were supported in whole or in part with federal funds from the
National Institute of Environmental Health Sciences, under Delivery
Order Number HHSN291200555547C, GSA Contract Number GS-00F-003L. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 53
TC 32
Z9 33
U1 3
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD DEC
PY 2013
VL 9
IS 12
AR e1004028
DI 10.1371/journal.pgen.1004028
PG 15
WC Genetics & Heredity
SC Genetics & Heredity
GA 301LH
UT WOS:000330533300056
PM 24385926
ER
PT J
AU Dutta, S
Dlugosz, LS
Drew, DR
Ge, XP
Ababacar, D
Rovira, YI
Moch, JK
Shi, M
Long, CA
Foley, M
Beeson, JG
Anders, RF
Miura, K
Haynes, JD
Batchelor, AH
AF Dutta, Sheetij
Dlugosz, Lisa S.
Drew, Damien R.
Ge, Xiopeng
Ababacar, Diouf
Rovira, Yazmin I.
Moch, J. Kathleen
Shi, Meng
Long, Carole A.
Foley, Michael
Beeson, James G.
Anders, Robin F.
Miura, Kazutoyo
Haynes, J. David
Batchelor, Adrian H.
TI Overcoming Antigenic Diversity by Enhancing the Immunogenicity of
Conserved Epitopes on the Malaria Vaccine Candidate Apical Membrane
Antigen-1
SO PLOS PATHOGENS
LA English
DT Article
ID PLASMODIUM-FALCIPARUM MEROZOITES; GROWTH-INHIBITORY ANTIBODIES; CELL
INVASION; DOMAIN-III; IN-VITRO; APICOMPLEXAN PARASITES; NEUTRALIZING
ANTIBODY; ERYTHROCYTE INVASION; MEDIATED INHIBITION; MONOCLONAL-ANTIBODY
AB Malaria vaccine candidate Apical Membrane Antigen-1 (AMA1) induces protection, but only against parasite strains that are closely related to the vaccine. Overcoming the AMA1 diversity problem will require an understanding of the structural basis of cross-strain invasion inhibition. A vaccine containing four diverse allelic proteins 3D7, FVO, HB3 and W2mef (AMA1 Quadvax or QV) elicited polyclonal rabbit antibodies that similarly inhibited the invasion of four vaccine and 22 non-vaccine strains of P. falciparum. Comparing polyclonal anti-QV with antibodies against a strain-specific, monovalent, 3D7 AMA1 vaccine revealed that QV induced higher levels of broadly inhibitory antibodies which were associated with increased conserved face and domain-3 responses and reduced domain-2 response. Inhibitory monoclonal antibodies (mAb) raised against the QV reacted with a novel cross-reactive epitope at the rim of the hydrophobic trough on domain-1; this epitope mapped to the conserved face of AMA1 and it encompassed the 1e-loop. MAbs binding to the 1e-loop region (1B10, 4E8 and 4E11) were similar to 10-fold more potent than previously characterized AMA1-inhibitory mAbs and a mode of action of these 1e-loop mAbs was the inhibition of AMA1 binding to its ligand RON2. Unlike the epitope of a previously characterized 3D7-specific mAb, 1F9, the 1e-loop inhibitory epitope was partially conserved across strains. Another novel mAb, 1E10, which bound to domain-3, was broadly inhibitory and it blocked the proteolytic processing of AMA1. By itself mAb 1E10 was weakly inhibitory but it synergized with a previously characterized, strain-transcending mAb, 4G2, which binds close to the hydrophobic trough on the conserved face and inhibits RON2 binding to AMA1. Novel inhibition susceptible regions and epitopes, identified here, can form the basis for improving the antigenic breadth and inhibitory response of AMA1 vaccines. Vaccination with a few diverse antigenic proteins could provide universal coverage by redirecting the immune response towards conserved epitopes.
C1 [Dutta, Sheetij; Dlugosz, Lisa S.; Rovira, Yazmin I.; Moch, J. Kathleen; Shi, Meng; Haynes, J. David; Batchelor, Adrian H.] Walter Reed Army Inst Res, Silver Spring, MD 20910 USA.
[Drew, Damien R.; Beeson, James G.] Burnet Inst, Melbourne, Vic, Australia.
[Ge, Xiopeng; Foley, Michael; Anders, Robin F.] La Trobe Univ, Dept Biochem, Bundoora, Vic 3086, Australia.
[Ababacar, Diouf; Long, Carole A.; Miura, Kazutoyo] NIH, Lab Malaria & Vector Res, Rockville, MD USA.
RP Dutta, S (reprint author), Walter Reed Army Inst Res, Silver Spring, MD 20910 USA.
EM sheetij.dutta.civ@mail.mil
FU PATH Malaria Vaccine Initiative; US Agency for International Development
Malaria Vaccine Program; Institute National Health and Medical Research
Council of Australia; Australian Research Council; Victorian State
Government Operational Infrastructure Support grant; Intramural Program
of NIAID
FX The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript. Funding for the
WRAIR and La Trobe University was provided by PATH Malaria Vaccine
Initiative and US Agency for International Development Malaria Vaccine
Program. Burnet Institute was funded by Institute National Health and
Medical Research Council of Australia; Australian Research Council; and
a Victorian State Government Operational Infrastructure Support grant.
The NIH studies were supported in part by the Intramural Program of
NIAID and the PATH Malaria Vaccine Initiative.
NR 88
TC 35
Z9 35
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD DEC
PY 2013
VL 9
IS 12
AR e1003840
DI 10.1371/journal.ppat.1003840
PG 17
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 301MC
UT WOS:000330535400059
PM 24385910
ER
PT J
AU Guzzo, C
Fox, J
Lin, Y
Miao, HY
Cimbro, R
Volkman, BF
Fauci, AS
Lusso, P
AF Guzzo, Christina
Fox, Jamie
Lin, Yin
Miao, Huiyi
Cimbro, Raffaello
Volkman, Brian F.
Fauci, Anthony S.
Lusso, Paolo
TI The CD8-Derived Chemokine XCL1/Lymphotactin Is a Conformation-Dependent,
Broad-Spectrum Inhibitor of HIV-1
SO PLOS PATHOGENS
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD8(+) T-CELLS; LONG TERMINAL REPEAT;
INFECTION IN-VITRO; N-LINKED GLYCAN; ENVELOPE GLYCOPROTEIN;
MONOCLONAL-ANTIBODIES; SOLUBLE FACTORS; V2 DOMAIN; V3 LOOP
AB CD8+ T cells play a key role in the in vivo control of HIV-1 replication via their cytolytic activity as well as their ability to secrete non-lytic soluble suppressive factors. Although the chemokines that naturally bind CCR5 ( CCL3/MIP-1 alpha, CCL4/MIP-1 beta, CCL5/RANTES) are major components of the CD8-derived anti-HIV activity, evidence indicates the existence of additional, still undefined, CD8-derived HIV-suppressive factors. Here, we report the characterization of a novel anti-HIV chemokine, XCL1/lymphotactin, a member of the C-chemokine family that is produced primarily by activated CD8+ T cells and behaves as a metamorphic protein, interconverting between two structurally distinct conformations ( classic and alternative). We found that XCL1 inhibits a broad spectrum of HIV-1 isolates, irrespective of their coreceptor-usage phenotype. Experiments with stabilized variants of XCL1 demonstrated that HIV-1 inhibition requires access to the alternative, all-beta conformation, which interacts with proteoglycans but does not bind/activate the specific XCR1 receptor, while the classic XCL1 conformation is inactive. HIV-1 inhibition by XCL1 was shown to occur at an early stage of infection, via blockade of viral attachment and entry into host cells. Analogous to the recently described anti-HIV effect of the CXC chemokine CXCL4/PF4, XCL1-mediated inhibition is associated with direct interaction of the chemokine with the HIV-1 envelope. These results may open new perspectives for understanding the mechanisms of HIV-1 control and reveal new molecular targets for the design of effective therapeutic and preventive strategies against HIV-1.
C1 [Guzzo, Christina; Lin, Yin; Miao, Huiyi; Cimbro, Raffaello; Fauci, Anthony S.; Lusso, Paolo] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA.
[Fox, Jamie; Volkman, Brian F.] Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.
RP Guzzo, C (reprint author), NIAID, Immunoregulat Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM plusso@niaid.nih.gov
OI Cimbro, Raffaello/0000-0002-6251-5160
FU Canadian Institutes of Health Research (CIHR); Intramural AIDS Targeted
Antiviral Program (IATAP); NIAID, NIH
FX This study was supported by a Fellowship from the Canadian Institutes of
Health Research (CIHR) to CG, a research grant from the Intramural AIDS
Targeted Antiviral Program (IATAP), and the Intramural Research Program
of the NIAID, NIH. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 51
TC 9
Z9 9
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD DEC
PY 2013
VL 9
IS 12
AR e1003852
DI 10.1371/journal.ppat.1003852
PG 11
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 301MC
UT WOS:000330535400062
PM 24385911
ER
PT J
AU Kwon-Chung, KJ
Sugui, JA
AF Kwon-Chung, Kyung J.
Sugui, Janyce A.
TI Aspergillus fumigatus-What Makes the Species a Ubiquitous Human Fungal
Pathogen?
SO PLOS PATHOGENS
LA English
DT Article
ID INVASIVE ASPERGILLOSIS; CONIDIAL PIGMENT; GENES; IDENTIFICATION;
VIRULENCE; COMPOST; SPORES
C1 [Kwon-Chung, Kyung J.; Sugui, Janyce A.] NIAID, Mol Microbiol Sect, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA.
RP Kwon-Chung, KJ (reprint author), NIAID, Mol Microbiol Sect, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM JKCHUNG@niaid.nih.gov
FU National Institute of Allergy and Infectious Diseases, National
Institutes of Health (Bethesda, Maryland, USA)
FX This study was supported by funds from the intramural program of the
National Institute of Allergy and Infectious Diseases, National
Institutes of Health (Bethesda, Maryland, USA). The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 30
TC 46
Z9 46
U1 4
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD DEC
PY 2013
VL 9
IS 12
AR e1003743
DI 10.1371/journal.ppat.1003743
PG 4
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 301MC
UT WOS:000330535400002
PM 24348239
ER
PT J
AU VanBlargan, LA
Mukherjee, S
Dowd, KA
Durbin, AP
Whitehead, SS
Pierson, TC
AF VanBlargan, Laura A.
Mukherjee, Swati
Dowd, Kimberly A.
Durbin, Anna P.
Whitehead, Stephen S.
Pierson, Theodore C.
TI The Type-Specific Neutralizing Antibody Response Elicited by a Dengue
Vaccine Candidate Is Focused on Two Amino Acids of the Envelope Protein
SO PLOS PATHOGENS
LA English
DT Article
ID WEST-NILE-VIRUS; TICK-BORNE ENCEPHALITIS; RECOMBINANT SUBVIRAL
PARTICLES; HUMAN MONOCLONAL-ANTIBODIES; MEDIATED NEUTRALIZATION;
DOMAIN-III; CROSS-NEUTRALIZATION; CELLULAR CYTOTOXICITY;
ENDOPLASMIC-RETICULUM; DEPENDENT ENHANCEMENT
AB Dengue viruses are mosquito-borne flaviviruses that circulate in nature as four distinct serotypes (DENV1-4). These emerging pathogens are responsible for more than 100 million human infections annually. Severe clinical manifestations of disease are predominantly associated with a secondary infection by a heterotypic DENV serotype. The increased risk of severe disease in DENV-sensitized populations significantly complicates vaccine development, as a vaccine must simultaneously confer protection against all four DENV serotypes. Eliciting a protective tetravalent neutralizing antibody response is a major goal of ongoing vaccine development efforts. However, a recent large clinical trial of a candidate live-attenuated DENV vaccine revealed low protective efficacy despite eliciting a neutralizing antibody response, highlighting the need for a better understanding of the humoral immune response against dengue infection. In this study, we sought to identify epitopes recognized by serotype-specific neutralizing antibodies elicited by monovalent DENV1 vaccination. We constructed a panel of over 50 DENV1 structural gene variants containing substitutions at surface-accessible residues of the envelope (E) protein to match the corresponding DENV2 sequence. Amino acids that contribute to recognition by serotype-specific neutralizing antibodies were identified as DENV mutants with reduced sensitivity to neutralization by DENV1 immune sera, but not cross-reactive neutralizing antibodies elicited by DENV2 vaccination. We identified two mutations (E126K and E157K) that contribute significantly to type-specific recognition by polyclonal DENV1 immune sera. Longitudinal and cross-sectional analysis of sera from 24 participants of a phase I clinical study revealed a markedly reduced capacity to neutralize a E126K/E157K DENV1 variant. Sera from 77% of subjects recognized the E126K/E157K DENV1 variant and DENV2 equivalently (<3-fold difference). These data indicate the type-specific component of the DENV1 neutralizing antibody response to vaccination is strikingly focused on just two amino acids of the E protein. This study provides an important step towards deconvoluting the functional complexity of DENV serology following vaccination.
C1 [VanBlargan, Laura A.; Mukherjee, Swati; Dowd, Kimberly A.; Pierson, Theodore C.] NIAID, Viral Pathogenesis Sect, Viral Dis Lab, NIH, Bethesda, MD 20892 USA.
[Durbin, Anna P.] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA.
[Whitehead, Stephen S.] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
RP VanBlargan, LA (reprint author), NIAID, Viral Pathogenesis Sect, Viral Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM piersontc@mail.nih.gov
FU National Institute of Allergy and Infectious Diseases
FX This study was funded by the intramural research program of the National
Institute of Allergy and Infectious Diseases. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 107
TC 14
Z9 15
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD DEC
PY 2013
VL 9
IS 12
AR e1003761
DI 10.1371/journal.ppat.1003761
PG 14
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 301MC
UT WOS:000330535400007
PM 24348242
ER
PT J
AU Brinckman, DD
Keppler-Noreuil, KM
Blumhorst, C
Biesecker, LG
Sapp, JC
Johnston, JJ
Wiggs, EA
AF Brinckman, Danielle D.
Keppler-Noreuil, Kim M.
Blumhorst, Catherine
Biesecker, Leslie G.
Sapp, Julie C.
Johnston, Jennifer J.
Wiggs, Edythe A.
TI Cognitive, Sensory, and Psychosocial Characteristics in Patients With
Bardet-Biedl Syndrome
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE Bardet-Biedl syndrome; Intellectual disability; psychometric testing;
brain development; olfaction
ID HUMAN OBESITY SYNDROME; OLFACTORY FUNCTION; SYNDROME GENE;
IDENTIFICATION; BBS; MUTATIONS; PROTEINS; GENOMICS; CHILDREN; MRI
AB Forty-two patients with a clinical diagnosis of Bardet-Biedl syndrome ages 2-61 years were given a neuropsychological test battery to evaluate cognitive, sensory, and behavioral functioning. These tests included the Wechsler scales of intelligence, Rey Auditory Verbal Learning Test, Boston Naming Test, D-KEFS Verbal Fluency Test, D-KEFS Color-Word Interference Test, D-KEFS Sorting Test, Wide Range Achievement Test: Math and Reading Subtests, Purdue Pegboard, The University of Pennsylvania Smell Identification Test, Social Communication Questionnaire, Social Responsiveness Scale, and Behavior Assessment System for Children, Second Edition, Parent Rating Scale. On the age appropriate Wechsler scale, the mean Verbal Comprehension was 81 (n=36), Working Memory was 81 (n=36), Perceptual Reasoning was 78 (n=24) and Full Scale IQ was 75 (n=26). Memory for a word list (Rey Auditory Verbal Learning Test) was in the average range with a mean of 89 (n=19). Fine motor speed was slow on the Purdue with mean scores 3-4 standard deviations below norms. All subjects were microsmic on the University of Pennsylvania Smell Identification Test. Of these 42 patients, only 6 were able to complete all auditory and visual tests; 52% were unable to complete the visual tests due to impaired vision. A wide range of behavioral issues were endorsed on questionnaires given to parents. Most had social skill deficits but no pattern of either externalizing or internalizing problems. We identify a characteristic neuro-behavioral profile in our cohort comprised of reduced IQ, impaired fine-motor function, and decreased olfaction. (c) 2013 Wiley Periodicals, Inc.
C1 [Brinckman, Danielle D.; Blumhorst, Catherine; Biesecker, Leslie G.; Sapp, Julie C.; Johnston, Jennifer J.] NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA.
[Keppler-Noreuil, Kim M.] Univ Iowa, Dept Pediat, Div Med Genet, Childrens Hosp, Iowa City, IA 52242 USA.
[Wiggs, Edythe A.] NINDS, Off Clin Director, NIH, Bethesda, MD 20892 USA.
RP Brinckman, DD (reprint author), Drexel Univ, 3141 Chestnut St,Stratton Hall,Suite 123, Philadelphia, PA 19104 USA.
EM ddb55@drexel.edu
FU National Human Genome Research Institute
FX The authors are grateful to the participants in this study, to the
Laurence-Moon Bardet-Biedl Family Network for their enthusiastic support
of the NIH Clinical Study of BBS. This study was supported by the
Intramural Research Program of the National Human Genome Research
Institute. This project would not have been possible without the
contributions of Dr. Penelope Feuillan, who passed away during the
course of this study. We also thank Julia Fekecs for assistance with
graphic illustrations.
NR 41
TC 8
Z9 8
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
EI 1552-4833
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD DEC
PY 2013
VL 161
IS 12
BP 2964
EP 2971
DI 10.1002/ajmg.a.36245
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 294IF
UT WOS:000330038000004
PM 24194441
ER
PT J
AU Sanchez-Vega, F
Gotea, V
Petrykowska, HM
Margolin, G
Krivak, TC
DeLoia, JA
Bell, DW
Elnitski, L
AF Sanchez-Vega, Francisco
Gotea, Valer
Petrykowska, Hanna M.
Margolin, Gennady
Krivak, Thomas C.
DeLoia, Julie A.
Bell, Daphne W.
Elnitski, Laura
TI Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL
promoters across a wide spectrum of human solid epithelial tumors and
cancer cell lines
SO EPIGENETICS
LA English
DT Article
DE DNA methylation; cancer; pan-cancer; ZNF154; CASP8; VHL; epigenetics;
chromatin; serous ovarian cancer; endometrioid ovarian cancer;
endometrioid endometrial cancer; ovarian papillary serous tumors of low
malignant potential
ID COMPREHENSIVE GENOMIC CHARACTERIZATION; COLORECTAL-CANCER;
PROSTATE-CANCER; GENE-EXPRESSION; SUPPRESSOR GENE; HUMAN-DISEASE; HUMAN
COLON; CARCINOMA; IDENTIFICATION; BIOMARKERS
AB The study of aberrant DNA methylation in cancer holds the key to the discovery of novel biological markers for diagnostics and can help to delineate important mechanisms of disease. We have identified 12 loci that are differentially methylated in serous ovarian cancers and endometrioid ovarian and endometrial cancers with respect to normal control samples. The strongest signal showed hypermethylation in tumors at a CpG island within the ZNF154 promoter. We show that hypermethylation of this locus is recurrent across solid human epithelial tumor samples for 15 of 16 distinct cancer types from TCGA. Furthermore, ZNF154 hypermethylation is strikingly present across a diverse panel of ENCODE cell lines, but only in those derived from tumor cells. By extending our analysis from the Illumina 27K Infinium platform to the 450K platform, to sequencing of PCR amplicons from bisulfite treated DNA, we demonstrate that hypermethylation extends across the breadth of the ZNF154 CpG island. We have also identified recurrent hypomethylation in two genomic regions associated with CASP8 and VHL. These three genes exhibit significant negative correlation between methylation and gene expression across many cancer types, as well as patterns of DNaseI hypersensitivity and histone marks that reflect different chromatin accessibility in cancer vs. normal cell lines. Our findings emphasize hypermethylation of ZNF154 as a biological marker of relevance for tumor identification. Epigenetic modifications affecting the promoters of ZNF154, CASP8, and VHL are shared across a vast array of tumor types and may therefore be important for understanding the genomic landscape of cancer.
C1 [Sanchez-Vega, Francisco; Gotea, Valer; Petrykowska, Hanna M.; Margolin, Gennady; Elnitski, Laura] NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA.
[Krivak, Thomas C.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA.
[DeLoia, Julie A.] George Washington Univ, Sch Publ Hlth & Hlth Serv, Washington, DC USA.
[Bell, Daphne W.] NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA.
RP Elnitski, L (reprint author), NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA.
EM elnitski@mail.nih.gov
OI Gotea, Valer/0000-0001-7857-3309
FU National Human Genome Research Institute, National Institutes of Health
FX This work was supported by the Intramural Program of the National Human
Genome Research Institute, National Institutes of Health. We thank
Elaine Lewis, Alexandra Scott, and Kornel Schuebel for critical reading
of the manuscript. We also thank Meghan Rudd for technical assistance.
NR 76
TC 16
Z9 17
U1 0
U2 11
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD DEC 1
PY 2013
VL 8
IS 12
BP 1355
EP 1372
DI 10.4161/epi.26701
PG 18
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 298DO
UT WOS:000330304500011
PM 24149212
ER
PT J
AU Oksenhendler, E
Boutboul, D
Beldjord, K
Meignin, V
de Labarthe, A
Fieschi, C
Dossier, A
Agbalika, F
Parravicini, C
Tosato, G
Gerard, L
Galicier, L
AF Oksenhendler, Eric
Boutboul, David
Beldjord, Kheira
Meignin, Veronique
de Labarthe, Adrienne
Fieschi, Claire
Dossier, Antoine
Agbalika, Felix
Parravicini, Carlo
Tosato, Giovanna
Gerard, Laurence
Galicier, Lionel
TI Human herpesvirus 8+polyclonal IgM lambda B-cell lymphocytosis mimicking
plasmablastic leukemia/lymphoma in HIV-infected patients
SO EUROPEAN JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE multicentric Castleman disease; HIV; human herpesvirus-8; lymphoma
ID MULTICENTRIC CASTLEMAN-DISEASE; SARCOMA-ASSOCIATED HERPESVIRUS; PRIMARY
EFFUSION LYMPHOMA; KAPOSIS-SARCOMA; LYMPHOPROLIFERATIVE DISORDERS;
RITUXIMAB; INTERLEUKIN-10
AB PurposeMulticentric Castleman disease (MCD) is a distinct lymphoproliferative disorder characterized by inflammatory symptoms, lymphadenopathy, splenomegaly, and cytopenia. Kaposi's sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8), is the cause of virtually all cases of MCD occurring in patients with HIV infection. MCD lesions characteristically contain HHV-8-infected polyclonal IgM plasmablasts. A high frequency of HHV-8-related non-Hodgkin lymphoma has been reported in these patients.
Patients and methodsWe now report on three patients who presented with severe symptoms of MCD, extreme splenomegaly, and rapid expansion of B-cell lymphocytosis (44-81%) attributable to circulating HHV-8 positive plasmablasts.
ResultsThe circulating plasmablastic cells shared the phenotype (IgM, CD19+, CD20- CD138-) of HHV-8-infected cells from MCD lesions, mimicking the leukemic phase of large B-cell lymphoma occurring in HHV-8-related MCD. These patients displayed a very high HHV-8 viral load in blood (>7 logs HHV-8 DNA copies/ml) and high levels of serum vIL-6, the viral homolog of human interleukin 6. Serum IL-6 and IL-10 were also abnormally elevated. HHV-8-infected cells were demonstrated by immunoglobulin gene rearrangement analysis, to be polyclonal and likely represent an expansion of HHV-8-infected cells similar to those found in MCD lesions.
ConclusionThus, the spectrum of HHV-8-related plasmablastic lymphoproliferative disorders in patients with HIV infection is expanded to include HHV-8+ polyclonal IgM B-cell lymphocytosis. At onset, this lymphoproliferative disorder may mimic plasmablastic leukemia/lymphoma. Recognizing this unusual complication may have important implications in treatment decision avoiding unnecessary toxicity to the patients.
C1 [Oksenhendler, Eric; Boutboul, David; Dossier, Antoine; Gerard, Laurence; Galicier, Lionel] Hop St Louis, AP HP, Dept Clin Immunol, Paris, France.
[Oksenhendler, Eric; Boutboul, David; Meignin, Veronique; de Labarthe, Adrienne; Dossier, Antoine; Agbalika, Felix; Gerard, Laurence; Galicier, Lionel] Univ Paris Diderot, Sorbonne Paris Cite, Paris, France.
[Beldjord, Kheira; de Labarthe, Adrienne; Fieschi, Claire] Hop St Louis, AP HP, Hematol Lab, Paris, France.
[Beldjord, Kheira; Fieschi, Claire] Univ Paris 05, Sorbonne Paris Cite, Paris, France.
[Meignin, Veronique] Hop St Louis, AP HP, Dept Pathol, Paris, France.
[Agbalika, Felix] Hop St Louis, AP HP, Virol Lab, Paris, France.
[Parravicini, Carlo] Lugio Sacco Hosp, Dept Pathol, Milan, Italy.
[Tosato, Giovanna] NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
RP Oksenhendler, E (reprint author), Hop St Louis, Dept Clin Immunol, Paris, France.
EM eric.oksenhendler@sls.aphp.fr
FU National Institutes of Health, National Cancer Institute, Center for
Cancer Research
FX GT is a co-inventor on a patent describing the measurement of KSHV
vIL-6. This invention was made when GT was an employee of the US
Government under 45 Code of Federal Regulations Part 7. All rights,
title, and interest to this patent have been assigned to the US
Department of Health and Human Services. The government conveys a
portion of the royalties it receives to its employee inventors under the
Federal Technology Transfer Act of 1986 (P.L. 99-502). GT is supported
by the Intramural Research Program of the National Institutes of Health,
National Cancer Institute, Center for Cancer Research. The remaining
authors declare no competing financial interests.
NR 25
TC 1
Z9 3
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0902-4441
EI 1600-0609
J9 EUR J HAEMATOL
JI Eur. J. Haematol.
PD DEC
PY 2013
VL 91
IS 6
BP 497
EP 503
DI 10.1111/ejh.12191
PG 7
WC Hematology
SC Hematology
GA 295FK
UT WOS:000330101800004
PM 23992152
ER
PT J
AU Cao, GY
Yang, XW
Xu, W
Li, F
AF Cao, Gui-Yun
Yang, Xiu-Wei
Xu, Wei
Li, Fei
TI New inhibitors of nitric oxide production from the seeds of Myristica
fragrans
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Myristica fragrans; Nutmeg; Myrisfrageal A; Myrisfrageal B; Nitric
oxide; Inducible nitric oxide synthase
ID NUTMEG; EXTRACT; MACELIGNAN; NEOLIGNANS; LIGNANS; INJURY; PLANTS; CELLS
AB Six dihydrobenzofuran type neolignans were isolated from the dried ripe seeds of Myristica fragrans Houtt. (family: Myristicaceae) and their chemical structures were identified as licarin B (1), 3'-methoxylicarin B (2), myrisfrageal A (3), isodihydrocainatidin (4), dehydrodiisoeugenol (5), and myrisfrageal B (6), respectively, on the basis of spectroscopic data analyses. Among them, compounds 3 and 6 are new compounds. Compounds 1-6 showed inhibition of nitric oxide production in lipopolysaccharide-activated murine monocyte-macrophage RAW264.7 with IC50 values of 53.6, 48.7, 76.0, 36.0, 33.6, and 45.0 mu M, respectively. These values were compared to those of the positive controls, indomethacin and L-N-6-(1-iminoethyl)-lysine, which have IC50 values of 65.3 and 27.1 mu M, respectively. Further compounds 3, 5 and 6 suppressed LPS-induced iNOS mRNA expression in a does-dependent manner in RAW 264.7 cells assayed by real-time RT-PCR. Compounds 3,5 and 6 may inhibit NO overproduction via inhibition of iNOS mRNA expression. The results provided valuable information for further investigation of compounds 1-6 as anti-inflammatory and chemopreventive agents. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Cao, Gui-Yun; Yang, Xiu-Wei; Xu, Wei] Peking Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, Dept Nat Med,State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China.
[Li, Fei] NCI, NIH, Ctr Canc Res, Lab Metab, Bethesda, MD 20892 USA.
RP Yang, XW (reprint author), Peking Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM xwyang@bjmu.edu.cn
RI Li, Fei/F-6849-2013
FU National Natural Science Foundation of China [30973863]; National Key
Technology R & D Program of China [2011BAI07B08]
FX We thank the NIH Fellows Editorial Board (NIH, Bethesda) for editing the
manuscript. This research was partly supported by the National Natural
Science Foundation of China (30973863) and National Key Technology R & D
Program of China (2011BAI07B08).
NR 34
TC 10
Z9 11
U1 2
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD DEC
PY 2013
VL 62
BP 167
EP 171
DI 10.1016/j.fct.2013.08.046
PG 5
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA 293GW
UT WOS:000329960400022
PM 23994084
ER
PT J
AU Portnoy, DB
Han, PKJ
Ferrer, RA
Klein, WMP
Clauser, SB
AF Portnoy, David B.
Han, Paul K. J.
Ferrer, Rebecca A.
Klein, William M. P.
Clauser, Steven B.
TI Physicians' attitudes about communicating and managing scientific
uncertainty differ by perceived ambiguity aversion of their patients
SO HEALTH EXPECTATIONS
LA English
DT Article
DE ambiguity aversion; patient-provider communication; shared decision
making
ID SHARED DECISION-MAKING; HEALTH-PROFESSIONALS PERCEPTIONS;
CLINICAL-PRACTICE; CARE; POWER; RECOMMENDATIONS; FACILITATORS;
PREFERENCES; GUIDELINES; TOLERANCE
AB Background Medical interventions are often characterized by substantial scientific uncertainty regarding their benefits and harms. Physicians must communicate to their patients as part of the process of shared decision making, yet they may not always communicate scientific uncertainty for several reasons. One suggested by past research is individual differences in physicians' tolerance of uncertainty. Relatedly, an unexplored explanation is physicians' beliefs about their patients' tolerance of uncertainty. Design To test this possibility, we surveyed a sample of primary care physicians (N=1500) and examined the association between their attitudes about communicating and managing scientific uncertainty and their perceptions of negative reactions to uncertainty by their patients. Physician perceptions were measured by their propensity towards pessimistic appraisals of risk information and avoidance of decision making when risk information is ambiguous - of uncertain reliability, credibility or adequacy, known as ambiguity aversion'. Results Confirming past studies, physician demographics (e.g. medical specialty) predicted attitudes toward communicating scientific uncertainty. Additionally, physicians' beliefs about their patients' ambiguity aversion significantly predicted these preferences. Physicians who thought that more of their patients would have negative reactions to ambiguous information were more likely to think that they should decide what is best for their patients (=0.065, P=0.013), and to withhold an intervention that had uncertainty associated with it (=0.170, P<0.001). Discussion When faced with the task of communicating scientific uncertainty about medical tests and treatments, physicians' perce-ptions of their patients' ambiguity aversion may be related to their attitudes towards communicating uncertainty.
C1 [Portnoy, David B.] NCI, Canc Prevent Fellowship Program, Ctr Canc Training, Bethesda, MD 20892 USA.
[Portnoy, David B.; Klein, William M. P.] NCI, Behav Res Program, Bethesda, MD 20892 USA.
[Han, Paul K. J.] Maine Med Ctr, Ctr Outcomes Res & Evaluat, Portland, ME 04102 USA.
[Ferrer, Rebecca A.] NCI, Basic Biobehav & Psychol Sci Branch, Bethesda, MD 20892 USA.
[Clauser, Steven B.] NCI, Outcomes Res Branch, Appl Res Program, Bethesda, MD 20892 USA.
RP Portnoy, DB (reprint author), NCI, 6130 Execut Blvd,Room 4051B, Bethesda, MD 20892 USA.
EM portnoydb@mail.nih.gov
OI Portnoy, David/0000-0003-2175-9457; Han, Paul/0000-0003-0165-1940
FU National Cancer Institute
FX National Cancer Institute
NR 40
TC 8
Z9 8
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1369-6513
EI 1369-7625
J9 HEALTH EXPECT
JI Health Expect.
PD DEC
PY 2013
VL 16
IS 4
BP 362
EP 372
DI 10.1111/j.1369-7625.2011.00717.x
PG 11
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 296JF
UT WOS:000330180400014
PM 21838835
ER
PT J
AU Vella, S
Gnani, D
Crudele, A
Ceccarelli, S
De Stefanis, C
Gaspari, S
Nobili, V
Locatelli, F
Marquez, VE
Rota, R
Alisi, A
AF Vella, Serena
Gnani, Daniela
Crudele, Annalisa
Ceccarelli, Sara
De Stefanis, Cristiano
Gaspari, Stefania
Nobili, Valerio
Locatelli, Franco
Marquez, Victor E.
Rota, Rossella
Alisi, Anna
TI EZH2 Down-Regulation Exacerbates Lipid Accumulation and Inflammation in
in Vitro and in Vivo NAFLD
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE NAFLD; EZH2; DZNep; microRNAs
ID FATTY LIVER-DISEASE; HISTONE METHYLTRANSFERASE EZH2; HOMOLOG 2 EZH2;
INSULIN-RESISTANCE; DNA METHYLATION; CANCER; MICRORNAS; CELLS;
EPIGENETICS; EXPRESSION
AB Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent, chronic liver diseases, worldwide. It is a multifactorial disease caused by complex interactions between genetic, epigenetic and environmental factors. Recently, several microRNAs, some of which epigenetically regulated, have been found to be up- and/or down-regulated during NAFLD development. However, in NAFLD, the essential role of the Polycomb Group protein Enhancer of Zeste Homolog 2 (EZH2), which controls the epigenetic silencing of specific genes and/or microRNAs by trimethylating Lys27 on histone H3, still remains unknown. In this study, we demonstrate that the nuclear expression/activity of the EZH2 protein is down-regulated both in livers from NAFLD rats and in the free fatty acid-treated HepG2. The drop in EZH2 is inversely correlated with: (i) lipid accumulation; (ii) the expression of pro-inflammatory markers including TNF- and TGF-; and (iii) the expression of miR-200b and miR-155. Consistently, the pharmacological inhibition of EZH2 by 3-Deazaneplanocin A (DZNep) significantly reduces EZH2 expression/activity, while it increases lipid accumulation, inflammatory molecules and microRNAs. In conclusion, the results of this study suggest that the defective activity of EZH2 can enhance the NAFLD development by favouring steatosis and the de-repression of the inflammatory genes and that of specific microRNAs.
C1 [Vella, Serena; Gaspari, Stefania; Locatelli, Franco; Rota, Rossella] Bambino Gesu Pediat Hosp, IRCCS, Dept Oncohematol, I-00165 Rome, Italy.
[Gnani, Daniela; Crudele, Annalisa; Ceccarelli, Sara; De Stefanis, Cristiano; Alisi, Anna] Bambino Gesu Pediat Hosp, IRCCS, Liver Res Unit, I-00165 Rome, Italy.
[Nobili, Valerio] Bambino Gesu Pediat Hosp, IRCCS, Hepatometab Dis Unit, I-00165 Rome, Italy.
[Locatelli, Franco] Univ Pavia, Dept Pediat Hematol Oncol, I-27100 Pavia, Italy.
[Marquez, Victor E.] NCI, Biol Chem Lab, Frederick Natl Lab Canc Res, CCR,NIH, Frederick, MD 21702 USA.
RP Rota, R (reprint author), Bambino Gesu Pediat Hosp, IRCCS, Dept Oncohematol, I-00165 Rome, Italy.
EM serena.vella@opbg.net; daniela.gnani@yahoo.it;
annalisa.crudele@gmail.com; sara.ceccarelli@opbg.net;
cristiano.destefanis@opbg.net; stefania.gaspari@opbg.net;
nobili66@yahoo.it; franco.locatelli@opbg.net; marquezv@mail.nih.gov;
rossella.rota@opbg.net; anna.alisi@opbg.net
RI Vella, Stefano/D-4912-2015; Alisi, Anna/A-6469-2010; Vella,
Serena/K-6451-2016;
OI Vella, Stefano/0000-0003-2347-5984; Alisi, Anna/0000-0001-7241-6329;
Vella, Serena/0000-0001-9477-9294; Crudele,
Annalisa/0000-0001-8131-8229; Rota, Rossella/0000-0002-9408-7711;
Ceccarelli, Sara/0000-0001-6313-3247
FU AIRC [IG 10338, MFAG 12936]; Intramural Research Program of the NIH,
National Cancer Institute, Center for Cancer Research
FX This work was supported by grants from AIRC (IG 10338 to Rossella Rota
and MFAG 12936 to Anna Alisi) and it was partially funded by the
Intramural Research Program of the NIH, National Cancer Institute,
Center for Cancer Research.
NR 39
TC 13
Z9 13
U1 0
U2 26
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2013
VL 14
IS 12
BP 24154
EP 24168
DI 10.3390/ijms141224154
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA 296XX
UT WOS:000330219800064
PM 24351808
ER
PT J
AU Spira, AP
Gamaldo, AA
An, Y
Wu, MN
Simonsick, EM
Bilgel, M
Zhou, Y
Wong, DF
Ferrucci, L
Resnick, SM
AF Spira, Adam P.
Gamaldo, Alyssa A.
An, Yang
Wu, Mark N.
Simonsick, Eleanor M.
Bilgel, Murat
Zhou, Yun
Wong, Dean F.
Ferrucci, Luigi
Resnick, Susan M.
TI Self-reported Sleep and beta-Amyloid Deposition in Community-Dwelling
Older Adults
SO JAMA NEUROLOGY
LA English
DT Article
ID MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; ELDERLY SUBJECTS; MRI
DATA; DEMENTIA; BRAIN; QUALITY; EPIDEMIOLOGY; ASSOCIATION; PERFORMANCE
AB IMPORTANCE Older adults commonly report disturbed sleep, and recent studies in humans and animals suggest links between sleep and Alzheimer disease biomarkers. Studies are needed that evaluate whether sleep variables are associated with neuroimaging evidence of beta-amyloid (A beta) deposition.
OBJECTIVE To determine the association between self-reported sleep variables and A beta deposition in community-dwelling older adults.
DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study of 70 adults (mean age, 76 [range, 53-91] years) from the neuroimaging substudy of the Baltimore Longitudinal Study of Aging, a normative aging study.
EXPOSURE Self-reported sleep variables.
MAIN OUTCOMES AND MEASURES beta-Amyloid burden, measured by carbon 11-labeled Pittsburgh compound B positron emission tomography distribution volume ratios (DVRs).
RESULTS After adjustment for potential confounders, reports of shorter sleep duration were associated with greater A beta burden, measured by mean cortical DVR (B = 0.08 [95% CI, 0.03-0.14]; P = .005) and precuneus DVR (B = 0.11 [0.03-0.18]; P = .007). Reports of lower sleep quality were associated with greater A beta burden measured by precuneus DVR (B = 0.08 [0.01-0.15]; P = .03).
CONCLUSIONS AND RELEVANCE Among community-dwelling older adults, reports of shorter sleep duration and poorer sleep quality are associated with greater A beta burden. Additional studies with objective sleep measures are needed to determine whether sleep disturbance causes or accelerates Alzheimer disease.
C1 [Spira, Adam P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21205 USA.
[Gamaldo, Alyssa A.; Bilgel, Murat; Ferrucci, Luigi; Resnick, Susan M.] NIA, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
[Wu, Mark N.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
[Wu, Mark N.; Wong, Dean F.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.
[Bilgel, Murat] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.
[Zhou, Yun; Wong, Dean F.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA.
[Wong, Dean F.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA.
RP Spira, AP (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, 624 N Broadway,Hampton House,Room 794, Baltimore, MD 21205 USA.
EM aspira@jhsph.edu
FU Intramural Research Program, National Institute on Aging (NIA), National
Institutes of Health (NIH); Research and Development Contract, NIA
[HHSN-260-2004-00012C]; Synapses, Circuits and Cognitive Disorders Award
from The Johns Hopkins School of Medicine Brain Science Institute;
Mentored Research Scientist Development Award from the NIA
[1K01AG033195]; NIH, National Institute on Drug Abuse [K24 DA000412]
FX This study was supported in part by the Intramural Research Program,
National Institute on Aging (NIA), National Institutes of Health (NIH);
by Research and Development Contract HHSN-260-2004-00012C, NIA; by a
Synapses, Circuits and Cognitive Disorders Award from The Johns Hopkins
School of Medicine Brain Science Institute; by Mentored Research
Scientist Development Award 1K01AG033195 from the NIA (Dr Spira); and by
career award K24 DA000412 from the NIH, National Institute on Drug Abuse
(Dr Wong, 2000-2011).
NR 43
TC 81
Z9 83
U1 6
U2 16
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6149
EI 2168-6157
J9 JAMA NEUROL
JI JAMA Neurol.
PD DEC
PY 2013
VL 70
IS 12
BP 1537
EP 1543
DI 10.1001/jamaneurol.2013.4258
PG 7
WC Clinical Neurology
SC Neurosciences & Neurology
GA 295LS
UT WOS:000330118200011
PM 24145859
ER
PT J
AU Hong, SN
Gona, P
Fontes, JD
Oyama, N
Chan, RH
Kenchaiah, S
Tsao, CW
Yeon, SB
Schnabel, RB
Keaney, JF
O'Donnell, CJ
Benjamin, EJ
Manning, WJ
AF Hong, Susie N.
Gona, Philimon
Fontes, Joao D.
Oyama, Noriko
Chan, Raymond H.
Kenchaiah, Satish
Tsao, Connie W.
Yeon, Susan B.
Schnabel, Renate B.
Keaney, John F.
O'Donnell, Christopher J.
Benjamin, Emelia J.
Manning, Warren J.
TI Atherosclerotic Biomarkers and Aortic Atherosclerosis by Cardiovascular
Magnetic Resonance Imaging in the Framingham Heart Study
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE aorta; atherosclerosis; biomarkers; cardiovascular magnetic resonance
imaging
ID C-REACTIVE PROTEIN; CORONARY-ARTERY CALCIFICATION; CAROTID
ATHEROSCLEROSIS; RISK-FACTORS; INFLAMMATORY BIOMARKERS; DISEASE;
ASSOCIATION; MARKERS; MEN; PREDICTOR
AB Background-The relations between subclinical atherosclerosis and inflammatory biomarkers have generated intense interest but their significance remains unclear. We sought to determine the association between a panel of biomarkers and subclinical aortic atherosclerosis in a community-based cohort.
Methods and Results-We evaluated 1547 participants of the Framingham Heart Study Offspring cohort who attended the 7th examination cycle and underwent both cardiovascular magnetic resonance imaging (CMR) and assays for 10 biomarkers associated with atherosclerosis: high-sensitivity C-reactive protein, fibrinogen, intercellular adhesion molecule-1, interleukin-6, interleukin-18, lipoprotein-associated phospholipase-A2 activity and mass, monocyte chemoattractant protein-1, P-selectin, and tumor necrosis factor receptor-2. In logistic regression analysis, we found no significant association between the biomarker panel and the presence of aortic plaque (global P=0.53). Using Tobit regression with aortic plaque as a continuous variable, we noted a modest association between biomarker panel and aortic plaque volume in age-and sex-adjusted analyses (P=0.003). However, this association was attenuated after further adjustment for clinical covariates (P=0.09).
Conclusions-In our community-based cohort, we found no significant association between our multibiomarker panel and aortic plaque. Our results underscore the strengths and limitations of the use of biomarkers for the identification of subclinical atherosclerosis and the importance of traditional risk factors.
C1 [Hong, Susie N.; Oyama, Noriko; Chan, Raymond H.; Tsao, Connie W.; Yeon, Susan B.; Manning, Warren J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Cardiovasc, Dept Med,Sch Med, Boston, MA 02215 USA.
[Manning, Warren J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Radiol, Boston, MA 02215 USA.
[Gona, Philimon] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Div Biostat & Hlth Serv Res, Worcester, MA USA.
[Keaney, John F.] Univ Massachusetts, Sch Med, Dept Med, Div Cardiovasc Med, Worcester, MA USA.
[Kenchaiah, Satish; Benjamin, Emelia J.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Cardiol Sect, Boston, MA 02118 USA.
[Kenchaiah, Satish; Benjamin, Emelia J.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Prevent Med Sect,Dept Med, Boston, MA 02118 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[O'Donnell, Christopher J.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Gona, Philimon; Fontes, Joao D.; Kenchaiah, Satish; Tsao, Connie W.; Schnabel, Renate B.; O'Donnell, Christopher J.; Benjamin, Emelia J.] Boston Univ, Natl Heart Lung & Blood Inst, Framingham, MA USA.
[Gona, Philimon; Fontes, Joao D.; Kenchaiah, Satish; Tsao, Connie W.; Schnabel, Renate B.; O'Donnell, Christopher J.; Benjamin, Emelia J.] Boston Univ, Framingham Heart Study, Framingham, MA USA.
RP Hong, SN (reprint author), Beth Israel Deaconess Med Ctr, Div Cardiovasc, 330 Brookline Ave, Boston, MA 02215 USA.
EM snh7311@gmail.com
RI Kenchaiah, Satish/A-1519-2016;
OI Benjamin, Emelia/0000-0003-4076-2336
FU National Heart, Lung, and Blood Institute's [N01-HC-25195]; National
Institutes of Health (NIH) [RO1HL70279]; NIH [RO1 HL064753, HL076784,
AG028321]
FX The Framingham Heart Study (FHS) is supported by the National Heart,
Lung, and Blood Institute's Contract No. N01-HC-25195 and a subcontract
from the National Institutes of Health (NIH) (RO1HL70279). Additional
funding for this work supported by NIH grants RO1 HL064753, HL076784,
and AG028321 to Dr. Benjamin. Lipoprotein-associated phospholipase-A2
activity measurements were provided by Glaxo-SmithKline at no cost to
the FHS. The contents of this manuscript are solely the responsibility
of the authors and do not necessarily represent the official views of
the NIH.
NR 31
TC 8
Z9 8
U1 1
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD DEC
PY 2013
VL 2
IS 6
DI 10.1161/JAHA.113.000307
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 296IG
UT WOS:000330177900019
ER
PT J
AU Marder, W
Khalatbari, S
Myles, JD
Hench, R
Lustig, S
Yalavarthi, S
Parameswaran, A
Brook, RD
Kaplan, MJ
AF Marder, Wendy
Khalatbari, Shokoufeh
Myles, James D.
Hench, Rita
Lustig, Susan
Yalavarthi, Srilakshmi
Parameswaran, Aishwarya
Brook, Robert D.
Kaplan, Mariana J.
TI The Peroxisome Proliferator Activated Receptor-gamma Pioglitazone
Improves Vascular Function and Decreases Disease Activity in Patients
With Rheumatoid Arthritis
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE drugs; inflammation; rheumatoid arthritis; vasodilation
ID C-REACTIVE PROTEIN; CARDIOVASCULAR RISK-FACTORS; FLOW-MEDIATED
VASODILATION; ALL-CAUSE MORTALITY; PPAR-GAMMA; BRACHIAL-ARTERY;
15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); ENDOTHELIAL FUNCTION;
CONTROLLED-TRIAL; CLINICAL-TRIAL
AB Background-Rheumatoid arthritis (RA) is associated with heightened mortality due to atherosclerotic cardiovascular disease (CVD). Inflammatory pathways in RA negatively affect vascular physiology and promote metabolic disturbances that contribute to CVD. We hypothesized that the peroxisome proliferator activated receptor-gamma (PPAR-gamma) pioglitazone could promote potent vasculoprotective and anti-inflammatory effects in RA.
Methods and Results-One hundred forty-three non-diabetic adult RA patients (76.2% female, age 55.2 +/- 12.1 [mean +/- SD]) on stable RA standard of care treatment were enrolled in a randomized, double-blind placebo controlled crossover trial of 45 mg daily pioglitazone versus placebo, with a 3-month duration/arm and a 2-month washout period. Pulse wave velocity of the aorta (PWV), brachial artery flow mediated dilatation (FMD), nitroglycerin mediated dilatation (NMD), microvascular endothelial function (reactive hyperemia index [RHI]), and circulating biomarkers of inflammation, insulin resistance, and atherosclerosis risk all were quantified. RA disease activity was assessed with the 28-Joint Count Disease Activity Score (DAS-28) C-reactive protein (CRP) and the Short Form (36) Health Survey quality of life questionnaire. When added to standard of care RA treatment, pioglitazone significantly decreased pulse wave velocity (ie, aortic stiffness) (P=0.01), while FMD and RHI remained unchanged when compared to treatment with placebo. Further, pioglitazone significantly reduced RA disease activity (P=0.02) and CRP levels (P=0.001), while improving lipid profiles. The drug was well tolerated.
Conclusions-Addition of pioglitazone to RA standard of care significantly improves aortic elasticity and decreases inflammation and disease activity with minimal safety issues. The clinical implications of these findings remain to be established.
C1 [Marder, Wendy; Hench, Rita; Yalavarthi, Srilakshmi; Kaplan, Mariana J.] Univ Michigan, Sch Med, Div Rheumatol, Ann Arbor, MI USA.
[Lustig, Susan; Brook, Robert D.] Univ Michigan, Sch Med, Div Cardiol, Ann Arbor, MI USA.
[Khalatbari, Shokoufeh; Myles, James D.; Parameswaran, Aishwarya] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA.
[Khalatbari, Shokoufeh; Myles, James D.; Parameswaran, Aishwarya] Univ Michigan, Sch Med, Michigan Inst Clin Res, Ann Arbor, MI USA.
[Kaplan, Mariana J.] NIAMSD, Syst Autoimmun Branch, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
RP Kaplan, MJ (reprint author), NIAMSD, Syst Autoimmun Branch, Intramural Res Program, NIH, Bldg 10,6D47C,10 Ctr Dr,MSC 1560, Bethesda, MD 20892 USA.
EM mariana.kaplan@nih.gov
FU National Institutes of Health through PHS [RO1 HL086553]; Michigan
Diabetes Research and Training Center, University of Michigan; National
Institutes of Health [K12HD001438]; NIH [UL1TR000433]
FX This work was supported by the National Institutes of Health through PHS
grant RO1 HL086553 (to Kaplan) and by the Michigan Diabetes Research and
Training Center, University of Michigan. Marder was supported by
K12HD001438 from National Institutes of Health. Additional financial
support for statistical analysis was provided by NIH grant UL1TR000433.
Takeda Pharmaceuticals provided pioglitazone and placebo tablets.
NR 55
TC 11
Z9 12
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD DEC
PY 2013
VL 2
IS 6
AR e000441
DI 10.1161/JAHA.113.000441
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 296IG
UT WOS:000330177900029
PM 24252844
ER
PT J
AU McDermott, MM
Applegate, WB
Bonds, DE
Buford, TW
Church, T
Espeland, MA
Gill, TM
Guralnik, JM
Haskell, W
Lovato, LC
Pahor, M
Pepine, CJ
Reid, KF
Newman, A
AF McDermott, Mary M.
Applegate, William B.
Bonds, Denise E.
Buford, Thomas W.
Church, Timothy
Espeland, Mark A.
Gill, Thomas M.
Guralnik, Jack M.
Haskell, William
Lovato, Laura C.
Pahor, Marco
Pepine, Carl J.
Reid, Kieran F.
Newman, Anne
TI Ankle Brachial Index Values, Leg Symptoms, and Functional Performance
Among Community-Dwelling Older Men and Women in the Lifestyle
Interventions and Independence for Elders Study
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE aging; exercise; peripheral vascular disease
ID PERIPHERAL ARTERIAL-DISEASE; AMERICAN-HEART-ASSOCIATION; LOWER-EXTREMITY
FUNCTION; SUBSEQUENT DISABILITY; MEANINGFUL CHANGE; GAIT SPEED;
MORTALITY; ADULTS; PRESSURE; DISTANCE
AB Background-The prevalence and significance of low normal and abnormal ankle brachial index (ABI) values in a community-dwelling population of sedentary, older individuals is unknown. We describe the prevalence of categories of definite peripheral artery disease (PAD), borderline ABI, low normal ABI, and no PAD and their association with lower-extremity functional performance in the LIFE Study population.
Methods and Results-Participants age 70 to 89 in the LIFE Study underwent baseline measurement of the ABI, 400-m walk, and 4-m walking velocity. Participants were classified as follows: definite PAD (ABI <0.90), borderline PAD (ABI 0.90 to 0.99), low normal ABI (ABI 1.00 to 1.09), and no PAD (ABI 1.10 to 1.40). Of 1566 participants, 220 (14%) had definite PAD, 250 (16%) had borderline PAD, 509 (33%) had low normal ABI, and 587 (37%) had no PAD. Among those with definite PAD, 65% were asymptomatic. Adjusting for age, sex, race, body mass index, smoking, and comorbidities, lower ABI was associated with longer mean 400-m walk time: (definite PAD=533 seconds; borderline PAD=514 seconds; low normal ABI=503 seconds; and no PAD=498 seconds [P<0.001]). Among asymptomatic participants with and without PAD, lower ABI values were also associated with longer 400-m walk time (P<0.001) and slower walking velocity (P=0.042).
Conclusion-Among older community-dwelling men and women, 14% had PAD and 49% had borderline or low normal ABI values. Lower ABI values were associated with greater functional impairment, suggesting that lower extremity atherosclerosis may be a common preventable cause of functional limitations in older people.
C1 [McDermott, Mary M.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Applegate, William B.; Espeland, Mark A.; Lovato, Laura C.] Wake Forest Sch Med, Winston Salem, NC USA.
[Bonds, Denise E.] Natl Heart Lung & Blood Inst, Bethesda, MD USA.
[Buford, Thomas W.; Pahor, Marco; Pepine, Carl J.] Univ Florida, Gainesville, FL USA.
[Church, Timothy] Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA.
[Gill, Thomas M.] Yale Univ, Sch Med, New Haven, CT USA.
[Guralnik, Jack M.] Univ Maryland, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA.
[Haskell, William] Stanford Univ, Palo Alto, CA 94304 USA.
[Reid, Kieran F.] Tufts Univ, Boston, MA 02111 USA.
[Newman, Anne] Univ Pittsburgh, Pittsburgh, PA USA.
RP McDermott, MM (reprint author), 750 North Lake Shore Dr,10th Floor, Chicago, IL 60611 USA.
EM mdm608@northwestern.edu
RI Buford, Thomas /B-1111-2011; Newman, Anne/C-6408-2013
OI Buford, Thomas /0000-0002-9541-4358; Newman, Anne/0000-0002-0106-1150
FU National Institutes of Health/National Institute on Aging [UO1 AG22376];
National Heart, Lung and Blood Institute [3U01AG022376-05A2S];
Intramural Research Program, National Institute on Aging, NIH;
NIH/National Center for Advancing Translational Science Clinical and
Translational Science Award [UL1 TR000064]; US Department of Agriculture
[58-1950-7-707]; Boston Claude D. Pepper Older Americans Independence
Center [1P30AG031679]; University of Florida Claude D. Pepper Older
Americans Independence Center [1 P30 AG028740]; Pittsburgh Claude D.
Pepper Older Americans Independence Center [P30 AG024827]; Claude D.
Pepper Older Americans Independence Center [1 P30 AG21332, P30AG021342];
National Institute on Aging [K07AG043587]; Department of Veterans
Affairs
FX Funded by a National Institutes of Health/National Institute on Aging
Cooperative Agreement #UO1 AG22376 and a supplement from the National
Heart, Lung and Blood Institute 3U01AG022376-05A2S, and sponsored in
part by the Intramural Research Program, National Institute on Aging,
NIH. Supported in part by the NIH/National Center for Advancing
Translational Science Clinical and Translational Science Award to the
University of Florida UL1 TR000064. Dr Fielding's contribution is
partially supported by the US Department of Agriculture, under agreement
No. 58-1950-7-707. Any opinions, findings, conclusion, or
recommendations expressed in this publication are those of the author(s)
and do not necessarily reflect the view of the US Dept of Agriculture.
This research is also supported by the Boston Claude D. Pepper Older
Americans Independence Center (1P30AG031679). This research is partially
supported by the University of Florida Claude D. Pepper Older Americans
Independence Center (1 P30 AG028740). The Pittsburgh Field Center is
partially supported by the Pittsburgh Claude D. Pepper Older Americans
Independence Center (P30 AG024827). The Wake Forest University Field
Center is, in part, supported by the Claude D. Pepper Older Americans
Independence Center (1 P30 AG21332). Dr Gill is the recipient of an
Academic Leadership Award (K07AG043587) from the National Institute on
Aging. The Yale Field Center is partially supported by the Claude D.
Pepper Older Americans Independence Center (P30AG021342). Dr Fragoso is
the recipient of a Career Development Award from the Department of
Veterans Affairs.
NR 27
TC 14
Z9 15
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD DEC
PY 2013
VL 2
IS 6
AR e000257
DI 10.1161/JAHA.113.000257
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 296IG
UT WOS:000330177900032
PM 24222666
ER
PT J
AU Wong, TC
Piehler, KM
Zareba, KM
Lin, K
Phrampus, A
Patel, A
Moon, JC
Ugander, M
Valeti, U
Holtz, JE
Fu, B
Chang, CCH
Mathier, M
Kellman, P
Butler, J
Gheorghiade, M
Schelbert, EB
AF Wong, Timothy C.
Piehler, Kayla M.
Zareba, Karolina M.
Lin, Kathie
Phrampus, Ashley
Patel, Agam
Moon, James C.
Ugander, Martin
Valeti, Uma
Holtz, Jonathan E.
Fu, Bo
Chang, Chung-Chou H.
Mathier, Michael
Kellman, Peter
Butler, Javed
Gheorghiade, Mihai
Schelbert, Erik B.
TI Myocardial Damage Detected by Late Gadolinium Enhancement Cardiovascular
Magnetic Resonance Is Associated With Subsequent Hospitalization for
Heart Failure
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE late gadolinium enhancement; magnetic resonance imaging; myocardial
delayed enhancement; myocardial fibrosis; myocardial infarction
ID DILATED CARDIOMYOPATHY; EJECTION FRACTION; RISK PREDICTION; CONTRAST;
OUTCOMES; QUANTIFICATION; MULTICENTER; PERFORMANCE; DYSFUNCTION;
PREVALENCE
AB Background-Hospitalization for heart failure (HHF) is among the most important problems confronting medicine. Late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) robustly identifies intrinsic myocardial damage. LGE may indicate inherent vulnerability to HHF, regardless of etiology, across the spectrum of heart failure stage or left ventricular ejection fraction (LVEF).
Methods and Results-We enrolled 1068 consecutive patients referred for CMR where 448 (42%) exhibited LGE. After a median of 1.4 years (Q1 to Q3: 0.9 to 2.0 years), 57 HHF events occurred, 15 deaths followed HHF, and 43 deaths occurred without antecedent HHF (58 total deaths). Using multivariable Cox regression adjusting for LVEF, heart failure stage, and other covariates, LGE was associated with first HHF after CMR (HR: 2.70, 95% CI: 1.32 to 5.50), death (HR: 2.13, 95% CI: 1.08 to 4.21), or either death or HHF (HR: 2.52, 95% CI: 1.49 to 4.25). Quantifying LGE extent yielded similar results; more LGE equated higher risks. LGE improved model discrimination (IDI: 0.016, 95% CI: 0.005 to 0.028, P=0.002) and reclassification of individuals at risk (continuous NRI: 0.40, 95% CI: 0.05 to 0.70, P=0.024). Adjustment for competing risks of death that shares common risk factors with HHF strengthened the LGE and HHF association (HR: 4.85, 95% CI: 1.40 to 16.9).
Conclusions-The presence and extent of LGE is associated with vulnerability for HHF, including higher risks of HHF across the spectrum of heart failure stage and LVEF. Even when LVEF is severely decreased, those without LGE appear to fare reasonably well. LGE may enhance risk stratification for HHF and may enhance both clinical and research efforts to reduce HHF through targeted treatment.
C1 [Wong, Timothy C.; Piehler, Kayla M.; Zareba, Karolina M.; Lin, Kathie; Patel, Agam; Fu, Bo; Mathier, Michael; Schelbert, Erik B.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
[Wong, Timothy C.; Piehler, Kayla M.; Zareba, Karolina M.; Phrampus, Ashley; Patel, Agam; Holtz, Jonathan E.; Chang, Chung-Chou H.; Schelbert, Erik B.] UPMC, Pittsburgh, PA USA.
[Wong, Timothy C.; Piehler, Kayla M.; Zareba, Karolina M.; Patel, Agam; Holtz, Jonathan E.; Mathier, Michael; Schelbert, Erik B.] UPMC, Inst Heart & Vasc, Pittsburgh, PA USA.
[Moon, James C.] UCL, Heart Hosp, Imaging Ctr, London, England.
[Ugander, Martin] Karolinska Inst, Dept Clin Physiol, S-10401 Stockholm, Sweden.
[Ugander, Martin] Karolinska Univ Hosp, Stockholm, Sweden.
[Valeti, Uma] Univ Minnesota, Div Cardiol, Minneapolis, MN USA.
[Fu, Bo; Chang, Chung-Chou H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA.
[Fu, Bo; Chang, Chung-Chou H.; Schelbert, Erik B.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA.
[Kellman, Peter] NHLBI, Bethesda, MD 20892 USA.
[Butler, Javed] Emory Univ, Div Cardiol, Atlanta, GA 30322 USA.
[Gheorghiade, Mihai] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA.
RP Schelbert, EB (reprint author), Univ Pittsburgh, Sch Med, 200 Lothrop St,PUH A349, Pittsburgh, PA 15213 USA.
EM schelberteb@upmc.edu
RI Moon, James/F-1031-2014; FU, BO/J-4063-2015;
OI Moon, James/0000-0001-8071-1491; Wong, Timothy/0000-0002-1045-2698;
Ugander, Martin/0000-0003-3665-2038
FU Pittsburgh Foundation [M2009-0068]; American Heart Association
[09SDG2180083]; T. Franklin Williams Scholarship Award; Atlantic
Philanthropies, Inc; John A. Hartford Foundation; Association of
Specialty Professors; American Heart Association; Agency for Healthcare
Research and Quality [K12 HS19461-01]; UK National Institute for Health
Research University College London Hospitals Biomedical Research Centre;
National Center for Research Resources (NCRR), a component of the
National Institutes of Health (NIH), NIH Roadmap for Medical Research
[UL1 RR024153]
FX Dr Schelbert is supported by a grant from The Pittsburgh Foundation,
Grant M2009-0068, and an American Heart Association Scientist
Development grant (09SDG2180083) including a T. Franklin Williams
Scholarship Award; funding provided by: Atlantic Philanthropies, Inc,
the John A. Hartford Foundation, the Association of Specialty
Professors, and the American Heart Association. Dr Wong is supported by
grant K12 HS19461-01 from the Agency for Healthcare Research and
Quality. Dr Moon is supported by the UK National Institute for Health
Research University College London Hospitals Biomedical Research Centre.
This work was also supported by grant UL1 RR024153 from the National
Center for Research Resources (NCRR), a component of the National
Institutes of Health (NIH), NIH Roadmap for Medical Research.
NR 40
TC 12
Z9 12
U1 2
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD DEC
PY 2013
VL 2
IS 6
AR e000416
DI 10.1161/JAHA.113.000416
PG 13
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 296IG
UT WOS:000330177900048
PM 24249712
ER
PT J
AU Xanthakis, V
Larson, MG
Wollert, KC
Aragam, J
Cheng, S
Ho, J
Coglianese, E
Levy, D
Colucci, WS
Felker, GM
Benjamin, EJ
Januzzi, JL
Wang, TJ
Vasan, RS
AF Xanthakis, Vanessa
Larson, Martin G.
Wollert, Kai C.
Aragam, Jayashri
Cheng, Susan
Ho, Jennifer
Coglianese, Erin
Levy, Daniel
Colucci, Wilson S.
Felker, G. Michael
Benjamin, Emelia J.
Januzzi, James L.
Wang, Thomas J.
Vasan, Ramachandran S.
TI Association of Novel Biomarkers of Cardiovascular Stress With Left
Ventricular Hypertrophy and Dysfunction: Implications for Screening
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE biomarkers; echocardiography; heart failure; hypertrophy; screening
ID GROWTH-DIFFERENTIATION FACTOR-15; ACUTE HEART-FAILURE; HIGHLY SENSITIVE
ASSAY; NATRIURETIC PEPTIDE; TROPONIN-T; SYSTOLIC DYSFUNCTION;
MYOCARDIAL-INFARCTION; EJECTION FRACTION; CARDIAC TROPONIN;
FAMILY-MEMBER
AB Background-Currently available screening tools for left ventricular (LV) hypertrophy (LVH) and systolic dysfunction (LVSD) are either expensive (echocardiography) or perform suboptimally (B-type natriuretic peptide [BNP]). It is unknown whether newer biomarkers are associated with LVH and LVSD and can serve as screening tools.
Methods and Results-We studied 2460 Framingham Study participants (mean age 58 years, 57% women) with measurements of biomarkers mirroring cardiac biomechanical stress (soluble ST-2 [ST2], growth differentiation factor-15 [GDF-15] and high-sensitivity troponin I [hsTnI]) and BNP. We defined LVH as LV mass/height(2) >= the sex-specific 80th percentile and LVSD as mild/greater impairment of LV ejection fraction (LVEF) or a fractional shortening <0.29. Adjusting for standard risk factors in logistic models, BNP, GDF-15, and hsTnI were associated with the composite echocardiographic outcome (LVH or LVSD), odds ratios (OR) per SD increment in log-biomarker 1.29, 1.14, and 1.18 (95% CI: 1.15 to 1.44, 1.004 to 1.28, and 1.06 to 1.31), respectively. The C-statistic for the composite outcome increased from 0.765 with risk factors to 0.770 adding BNP, to 0.774 adding novel biomarkers. The continuous Net Reclassification Improvement was 0.212 (95% CI: 0.119 to 0.305, P<0.0001) after adding the novel biomarkers to risk factors plus BNP. BNP was associated with LVH and LVSD in multivariable models, whereas GDF-15 was associated with LVSD (OR 1.41, 95% CI: 1.16 to 1.70), and hsTnI with LVH (OR 1.22, 95% CI: 1.09 to 1.36). ST2 was not significantly associated with any outcome.
Conclusions-Our community-based investigation suggests that cardiac stress biomarkers are associated with LVH and LVSD but may have limited clinical utility as screening tools.
C1 [Xanthakis, Vanessa; Larson, Martin G.; Cheng, Susan; Ho, Jennifer; Levy, Daniel; Benjamin, Emelia J.; Vasan, Ramachandran S.] Framingham Heart Dis Epidemiol Study, Framingham, MA USA.
[Xanthakis, Vanessa] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Xanthakis, Vanessa; Benjamin, Emelia J.; Vasan, Ramachandran S.] Boston Univ, Sch Med, Sect Prevent Med & Epidemiol, Boston, MA 02118 USA.
[Ho, Jennifer; Colucci, Wilson S.; Benjamin, Emelia J.; Vasan, Ramachandran S.] Boston Univ, Sch Med, Cardiol Sect, Boston, MA 02118 USA.
[Januzzi, James L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Wollert, Kai C.] Hannover Med Sch, Dept Cardiol & Angiol, Div Mol & Translat Cardiol, Hannover, Germany.
[Aragam, Jayashri] Vet Adm Hosp, West Roxbury, MA USA.
[Aragam, Jayashri; Cheng, Susan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Cardiovasc Med, Boston, MA 02115 USA.
[Levy, Daniel] NHLBI, Ctr Populat Studies, Bethesda, MD 20892 USA.
[Larson, Martin G.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
[Coglianese, Erin] Loyola Univ, Div Cardiol, Chicago, IL 60611 USA.
[Felker, G. Michael] Duke Univ, Sch Med, Div Cardiol, Durham, NC USA.
[Wang, Thomas J.] Vanderbilt Univ, Div Med, Div Cardiovasc Med, Nashville, TN 37235 USA.
RP Xanthakis, V (reprint author), Boston Univ, Sch Med, Dept Med, Sect Prevent Med & Epidemiol, 801 Massachusetts Ave,Suite 470, Boston, MA 02118 USA.
EM vanessax@bu.edu
OI Ho, Jennifer/0000-0002-7987-4768
FU AHA Clinical Research Program award [13CRP14090010]; German Ministry of
Education and Research; Ellison Foundation; Roman W. DeSanctis Clinical
Scholar Endowment; [N01-HC-25915]; [R01-HL-08675]; [K99-HL-107642]
FX This work was supported by AHA Clinical Research Program award
13CRP14090010 (to Dr Xanthakis), by N01-HC-25915, and R01-HL-08675 and
K99-HL-107642. Dr Wollert was supported by the German Ministry of
Education and Research, Dr Cheng by the Ellison Foundation, and Dr
Januzzi by the Roman W. DeSanctis Clinical Scholar Endowment.
NR 49
TC 21
Z9 22
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD DEC
PY 2013
VL 2
IS 6
AR e000399
DI 10.1161/JAHA.113.000399
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 296IG
UT WOS:000330177900049
PM 24200688
ER
PT J
AU Southan, C
Sitzmann, M
Muresan, S
AF Southan, Christopher
Sitzmann, Markus
Muresan, Sorel
TI Comparing the Chemical Structure and Protein Content of ChEMBL,
DrugBank, Human Metabolome Database and the Therapeutic Target Database
SO MOLECULAR INFORMATICS
LA English
DT Article
DE Compounds; Proteins; Drugs; Drug targets; Databases; InChI
ID DISCOVERY; PATHWAYS; PANTHER
AB ChEMBL, DrugBank, Human Metabolome Database and the Therapeutic Target Database are resources of curated chemistry-to-protein relationships widely used in the chemogenomic arena. In this work we have extended an earlier analysis (PMID 22821596) by comparing chemistry and protein target content between 2010 and 2013. For the former, details are presented for overlaps and differences, statistics of stereochemistry as well as stereo representation and MW profiles between the four databases. For 2013 our results indicate quality improvements, major expansion, increased achiral structures and changes in MW distributions. An orthogonal comparison of chemical content with different sources inside PubChem highlights further interpretable differences. Expansion of protein content by UniProt IDs is also recorded for 2013 and Gene Ontology comparisons for human-only sets indicate differences. These emphasise the expanding complementarity of chemistry-to-protein relationships between sources, although different criteria are used for their capture.
C1 [Southan, Christopher] Univ Edinburgh, Queens Med Res Inst, Univ British Heart Fdn, Ctr Cardiovasc Sci,IUPHAR Database Guide PHARMACO, Edinburgh EH16 4TJ, Midlothian, Scotland.
[Sitzmann, Markus] Natl Canc Inst, NIH, Frederick Natl Lab Canc Res, Biol Chem Lab, Frederick, MD 21702 USA.
[Muresan, Sorel] Banats Univ Agr Sci & Vet Med, Food Control Dept, Timisoara 300645, Romania.
RP Southan, C (reprint author), Univ Edinburgh, Queens Med Res Inst, Univ British Heart Fdn, Ctr Cardiovasc Sci,IUPHAR Database Guide PHARMACO, Edinburgh EH16 4TJ, Midlothian, Scotland.
EM sorel.muresan@gmail.com
FU Wellcome Trust [099156/Z/12/Z]
FX We would like to express our appreciation of the four database teams
responsible for the resources analysed here. In addition, we thank Craig
Knox for assistance with DrugBank and HMDB protein data sets. During the
latter part of this work CS was supported by Biomedical Resources Grand
(099156/Z/12/Z) from the Wellcome Trust, who also funded the Open Access
charge.
NR 22
TC 7
Z9 7
U1 2
U2 8
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1868-1743
EI 1868-1751
J9 MOL INFORM
JI Mol. Inf.
PD DEC
PY 2013
VL 32
IS 11-12
SI SI
BP 881
EP 897
DI 10.1002/minf.201300103
PG 17
WC Chemistry, Medicinal; Computer Science, Interdisciplinary Applications;
Mathematical & Computational Biology
SC Pharmacology & Pharmacy; Computer Science; Mathematical & Computational
Biology
GA 295IJ
UT WOS:000330109500002
PM 24533037
ER
PT J
AU Carnie, A
Lin, J
Aicher, B
Leon, B
Courville, AB
Sebring, NG
de Jesus, J
DellaValle, DM
Fitzpatrick, BD
Zalos, G
Powell-Wiley, TM
Chen, KY
Cannon, RO
AF Carnie, A.
Lin, J.
Aicher, B.
Leon, B.
Courville, A. B.
Sebring, N. G.
de Jesus, J.
DellaValle, D. M.
Fitzpatrick, B. D.
Zalos, G.
Powell-Wiley, T. M.
Chen, K. Y.
Cannon, R. O., III
TI Randomized trial of nutrition education added to internet-based
information and exercise at the work place for weight loss in a racially
diverse population of overweight women
SO NUTRITION & DIABETES
LA English
DT Article
DE obesity; adiposity; weight loss program; racial disparity; women's
health
ID AFRICAN-AMERICAN WOMEN; LIFE-STYLE INTERVENTION; DISEASE RISK-FACTORS;
PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; LOSS PROGRAM; LOSS
MAINTENANCE; BLOOD-PRESSURE; OBESITY; HEALTH
AB OBJECTIVE: Obesity in the United States is highly prevalent, approaching 60% for black women. We investigated whether nutrition education sessions at the work place added to internet-based wellness information and exercise resources would facilitate weight and fat mass loss in a racially diverse population of overweight female employees.
METHODS: A total of 199 (average body mass index 33.9 +/- 6.3 kg m(-2)) nondiabetic women (57% black) at our institution were randomized to a 6-month program of either internet-based wellness information (WI) combined with dietitian-led nutrition education group sessions (GS) weekly for 3 months and then monthly with shift in emphasis to weight loss maintenance (n = 99) or to WI alone (n = 100). All were given access to exercise rooms convenient to their work site. Fat mass was measured by dual-energy X-ray absorptiometry.
RESULTS: WI + GS subjects lost more weight than WI subjects at 3 months (-2.2 +/- 2.8 vs -1.0 +/- 3.0 kg, P > 0.001). Weight (-2.7 +/- 3.9 vs -2.0 +/- 3.9 kg) and fat mass (-2.2 +/- 3.1 vs -1.7 +/- 3.7 kg) loss at 6 months was significant for WI + GS and WI groups (both P < 0.001), but without significant difference between groups (both P > 0.10); 27% of the WI + GS group achieved >= 5% loss of initial weight as did 18% of the WI group (P = 0.180). Blacks and whites similarly completed the study (67 vs 74%, P = 0.303), lost weight (-1.8 +/- 3.4 vs -3.3 +/- 5.2 kg, P = 0.255) and fat mass (-1.6 +/- 2.7 vs -2.5 +/- 4.3 kg, P = 0.532), and achieved >= 5% loss of initial weight (21 vs 32%, P = 0.189), irrespective of group assignment.
CONCLUSION: Overweight women provided with internet-based wellness information and exercise resources at the work site lost weight and fat mass, with similar achievement by black and white women. Additional weight loss benefit of nutrition education sessions, apparent at 3 months, was lost by 6 months and may require special emphasis on subjects who fail to achieve weight loss goals to show continued value.
C1 [Carnie, A.; Lin, J.; Aicher, B.; Leon, B.; de Jesus, J.; Zalos, G.; Powell-Wiley, T. M.; Cannon, R. O., III] NHLBI, Cardiovasc & Pulm Branch, NIH, Bethesda, MD 20892 USA.
[Courville, A. B.; Sebring, N. G.; DellaValle, D. M.; Fitzpatrick, B. D.] NIH, Dept Nutr, Ctr Clin, Bethesda, MD 20892 USA.
[Chen, K. Y.] Natl Inst Diabet & Digest & Kidney Dis, Diabet Endocrinol & Obes Branch, NIH, Bethesda, MD USA.
RP Cannon, RO (reprint author), NHLBI, NIH, Bldg 10-CRC Room 5-3330,10 Ctr Dr, Bethesda, MD 20892 USA.
EM cannonr@nih.gov
OI Chen, Kong/0000-0002-0306-1904
FU National Heart, Lung, and Blood Institute; National Institute of
Diabetes, and Digestive and Kidney Diseases; Clinical Center, National
Institutes of Health
FX This research was supported by the intramural research programs of the
National Heart, Lung, and Blood Institute, the National Institute of
Diabetes, and Digestive and Kidney Diseases, and the Clinical Center,
National Institutes of Health.
NR 49
TC 3
Z9 3
U1 2
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2044-4052
J9 NUTR DIABETES
JI Nutr. Diabetes
PD DEC
PY 2013
VL 3
AR e98
DI 10.1038/nutd.2013.39
PG 7
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 295OZ
UT WOS:000330126700002
PM 24366370
ER
PT J
AU Rossouw, JE
Howard, BV
AF Rossouw, Jacques E.
Howard, Barbara V.
TI Noakes misses the point
SO SAMJ SOUTH AFRICAN MEDICAL JOURNAL
LA English
DT Letter
ID DIETARY MODIFICATION TRIAL; RISK; PATTERN; INTERVENTION; DISEASE
C1 [Rossouw, Jacques E.] NHLBI, NIH, Bethesda, MD 20892 USA.
[Howard, Barbara V.] MedStar Hlth Res Inst, Hyattsville, MD USA.
RP Rossouw, JE (reprint author), NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM rossouwj@nih.gov
NR 7
TC 2
Z9 2
U1 0
U2 0
PU SA MEDICAL ASSOC
PI PRETORIA
PA BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
PRETORIA, 0002, SOUTH AFRICA
SN 0256-9574
EI 2078-5135
J9 SAMJ S AFR MED J
JI SAMJ S. Afr. Med. J.
PD DEC
PY 2013
VL 103
IS 12
BP 882
EP 882
DI 10.7196/SAMJ.7709
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 295UN
UT WOS:000330141700004
PM 24490206
ER
PT J
AU Keller, MJ
Buckley, N
Katzen, LL
Walsh, J
Friedland, B
Littlefield, S
Lin, J
Xue, XN
Cornelison, T
Herold, BC
Einstein, MH
AF Keller, Marla J.
Buckley, Niall
Katzen, Lauren L.
Walsh, Jennifer
Friedland, Barbara
Littlefield, Sarah
Lin, Juan
Xue, Xiaonan
Cornelison, Terri
Herold, Betsy C.
Einstein, Mark H.
TI Use of the Dye Stain Assay and Ultraviolet Light Test for Assessing
Vaginal Insertion of Placebo-Filled Applicators Before and After Sex
SO SEXUALLY TRANSMITTED DISEASES
LA English
DT Article
ID MICROBICIDE APPLICATORS; CLINICAL-TRIALS; SOUTH-AFRICA; ADHERENCE; GEL;
VALIDATION; EXPOSURE
AB Background: Applicator dye staining and ultraviolet (UV) light have been used in trials to measure adherence, but not in the setting of before and after sex gel dosing (BAT-24). This study was designed to determine if semen or presex gel dosing impacts the sensitivity and specificity of a dye stain assay (DSA) for measuring vaginal insertion of placebo-filled applicators with BAT-24 dosing.
Methods: Healthy monogamous couples received Microlax-type applicators (Tectubes, A Astorp, Sweden) filled with hydroxyethylcelluose placebo gel. Women were instructed to vaginally insert 1 dose of gel before and a second dose after sex and to return applicators within 48 hours after sex. Applicators were stained to detect semen, followed by UV then DSA, and scored by 2 readers. Positive and negative controls were randomly included in applicator batches.
Results: Fifteen couples completed the study. Each woman returned at least 6 applicators over a 30-day period. The sensitivity for insertion of postsex applicators was higher for UV (97%) compared with DSA (90%), and the specificity was similar (Q96%). For presex applicators, the sensitivity and specificity were higher for DSA (100%) compared with UV testing (87% sensitivity, 96% specificity). Among returned postsex applicators, 95% tested positive by UV compared with 87% by DSA. Agreement between readers was significantly better on the presex applicators for DSA than for UV, and for postsex readings, agreement was less than half that for UV, although the results were not statistically significant.
Conclusions: Applicator tests are feasible for measuring adherence in trials with gel dosing before and after sex.
C1 [Keller, Marla J.; Buckley, Niall; Walsh, Jennifer; Lin, Juan; Xue, Xiaonan; Herold, Betsy C.; Einstein, Mark H.] Albert Einstein Coll Med, Bronx, NY 10461 USA.
[Keller, Marla J.; Buckley, Niall; Walsh, Jennifer; Lin, Juan; Xue, Xiaonan; Herold, Betsy C.; Einstein, Mark H.] Montefiore Med Ctr, Bronx, NY 10467 USA.
[Katzen, Lauren L.; Friedland, Barbara; Littlefield, Sarah] Populat Council, New York, NY 10021 USA.
[Xue, Xiaonan; Einstein, Mark H.] Albert Einstein Canc Ctr, Bronx, NY USA.
[Cornelison, Terri] NCI, NIH, Bethesda, MD 20892 USA.
RP Keller, MJ (reprint author), Albert Einstein Coll Med, 1300 Morris Pk Ave,Harold & Muriel Block Bldg, Bronx, NY 10461 USA.
EM marla.keller@einstein.yu.edu
FU Population Council through grants from the United States Agency for
International Development; Swedish Ministry of Finance; NIH [R01
CA-148966]; Harold and Muriel Block Institute for Clinical and
Translational Research at Einstein and Montefiore [NCATS UL1 TR001073];
EinsteinMontefiore Center for AIDS Research [NIH AI-051519]
FX This study was supported in part by the Population Council through
grants from the United States Agency for International Development and
Swedish Ministry of Finance and funds from the NIH including R01
CA-148966, Harold and Muriel Block Institute for Clinical and
Translational Research at Einstein and Montefiore (NCATS UL1 TR001073),
and EinsteinMontefiore Center for AIDS Research (NIH AI-051519). None of
the authors declare any conflicts of interest.
NR 20
TC 5
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-5717
EI 1537-4521
J9 SEX TRANSM DIS
JI Sex. Transm. Dis.
PD DEC
PY 2013
VL 40
IS 12
BP 939
EP 943
DI 10.1097/OLQ.0000000000000040
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 297GB
UT WOS:000330242600008
PM 24220355
ER
PT J
AU Arscott, WT
Tandle, AT
Zhao, SP
Shabason, JE
Gordon, IK
Schlaff, CD
Zhang, GF
Tofilon, PJ
Camphausen, KA
AF Arscott, W. Tris
Tandle, Anita T.
Zhao, Shuping
Shabason, Jacob E.
Gordon, Ira K.
Schlaff, Cody D.
Zhang, Guofeng
Tofilon, Philip J.
Camphausen, Kevin A.
TI Ionizing Radiation and Glioblastoma Exosomes: Implications in Tumor
Biology and Cell Migration
SO TRANSLATIONAL ONCOLOGY
LA English
DT Article
ID BREAST-CANCER CELLS; FOCAL ADHESION KINASE; GROWTH-FACTOR; DIAGNOSTIC
BIOMARKERS; CANDIDATE BIOMARKER; THERAPEUTIC TARGET; GAMMA-H2AX FOCI;
PROSTATE-CANCER; RECIPIENT CELLS; MICROVESICLES
AB Exosomes are nanometer-sized lipid vesicles released ubiquitously by cells, which have been shown to have a normal physiological role, as well as influence the tumor microenvironment and aid metastasis. Recent studies highlight the ability of exosomes to convey tumor-suppressive and oncogenic mRNAs, microRNAs, and proteins to a receiving cell, subsequently activating downstream signaling pathways and influencing cellular phenotype. Here, we show that radiation increases the abundance of exosomes released by glioblastoma cells and normal astrocytes. Exosomes derived from irradiated cells enhanced the migration of recipient cells, and their molecular profiling revealed an abundance of molecules related to signaling pathways important for cell migration. In particular, connective tissue growth factor (CTGF) mRNA and insulin-like growth factor binding protein 2 (IGFBP2) protein levels were elevated, and coculture of nonirradiated cells with exosomes isolated from irradiated cells increased CTGF protein expression in the recipient cells. Additionally, these exosomes enhanced the activation of neurotrophic tyrosine kinase receptor type 1 (TrkA), focal adhesion kinase, Paxillin, and proto-oncogene tyrosine-protein kinase Src (Src) in recipient cells, molecules involved in cell migration. Collectively, our data suggest that radiation influences exosome abundance, specifically alters their molecular composition, and on uptake, promotes a migratory phenotype.
C1 [Arscott, W. Tris; Tandle, Anita T.; Zhao, Shuping; Shabason, Jacob E.; Gordon, Ira K.; Schlaff, Cody D.; Tofilon, Philip J.; Camphausen, Kevin A.] NCI, Radiat Oncol Branch, Bethesda, MD 20892 USA.
[Arscott, W. Tris] Univ Vermont, Coll Med, Burlington, VT USA.
[Arscott, W. Tris; Shabason, Jacob E.] NIH, Howard Hughes Med Inst, Res Scholars Program, Bethesda, MD 20892 USA.
[Shabason, Jacob E.] Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
[Zhang, Guofeng] Natl Inst Biomed Imaging & Bioengn, Bethesda, MD USA.
RP Camphausen, KA (reprint author), NCI, Radiat Oncol Branch, 10 Ctr Dr 3B42, Bethesda, MD 20892 USA.
EM camphauk@mail.nih.gov
FU Howard Hughes Medical Institute-National Institutes of Health Research
Scholars Program
FX Thanks to Andrew Byrnes and Gina Conenello (Food and Drug
Administration) for assistance with the NanoSight microscope and Mike
Kruhlak (National Institutes of Health) for assistance with confocal
microscopy. W.T.A. and J.S. received funding as part of the Howard
Hughes Medical Institute-National Institutes of Health Research Scholars
Program.
NR 52
TC 24
Z9 24
U1 2
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1944-7124
EI 1936-5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD DEC
PY 2013
VL 6
IS 6
BP 638
EP U254
DI 10.1593/tlo.13640
PG 13
WC Oncology
SC Oncology
GA 298RP
UT WOS:000330342400005
PM 24466366
ER
PT J
AU Mohammed, A
Janakiram, NB
Brewer, M
Ritchie, RL
Marya, A
Lightfoot, S
Steele, VE
Rao, CV
AF Mohammed, Altaf
Janakiram, Naveena B.
Brewer, Misty
Ritchie, Rebekah L.
Marya, Anuj
Lightfoot, Stan
Steele, Vernon E.
Rao, Chinthalapally V.
TI Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by
Targeting in Part Cancer Stem Cells and mTOR Signaling
SO TRANSLATIONAL ONCOLOGY
LA English
DT Article
ID PROTEIN-COUPLED RECEPTOR; DIABETIC-PATIENTS; MICE; CARCINOMA; GROWTH;
RISK; PROLIFERATION; INHIBITION; LESIONS; MODEL
AB Epidemiologic studies have shown that diabetes mellitus is associated positively with increased risk of pancreatic ductal adenocarcinoma (PDAC), and recent meta-analysis studies showed that metformin, reduces the risk of pancreatic cancer (PC). We tested the effects of metformin on pancreatic intraepithelial neoplasia (PanIN) and their progression to PDAC in p48Cre/+.LSL-KrasG12D/+ transgenic mice. Mice fed control diet showed 80% and 62% incidence of PDAC in males and females, respectively. Male mice showed 20% and 26%, and female mice showed 7% and 0% PDAC incidence with 1000- and 2000-ppm metformin treatments, respectively. Both doses of metformin decreased pancreatic tumor weights by 34% to 49% (P < 0.03-0.001). The drug treatment caused suppression of PanIN 3 (carcinoma in situ) lesions by 28% to 39% (P <.002) and significant inhibition of carcinoma spread in the pancreas. The pancreatic tissue and/or serum of mice fed metformin showed a significant inhibition of mammalian target of rapamycin (mTOR), extracellular signal-regulated kinases (ERK), phosphorylated extracellular signal-regulated kinases (pErk), and insulin-like growth factor 1 (IGF-1) with an increase in phosphorylated 5' adenosine monophosphate kinase (pAMPK), tuberous sclerosis complex 1 (TSC1, TSC2), C-protein and an autophagy related protein 2 (ATG2). The cancer stem cell (CSC) markers were significantly decreased (P < 0.04-0.0002) in the pancreatic tissue. These results suggest that biologic effects of metformin are mediated through decreased CSC markers cluster of differentiation 44 (CD44 and CD133), aldehyde dehydrogenase isoform 1 (ALDH1), and epithelial cell adhesion molecule (EPCAM) and modulation of the mTOR signaling pathway. Our preclinical data indicate that metformin has significant potential for use in clinical trials for PC chemoprevention.
C1 [Mohammed, Altaf; Janakiram, Naveena B.; Brewer, Misty; Ritchie, Rebekah L.; Marya, Anuj; Lightfoot, Stan; Rao, Chinthalapally V.] Univ Oklahoma, Hlth Sci Ctr, Ctr Canc Prevent & Drug Dev, Dept Med,Hematol Oncol Sect,Peggy & Charles Steph, Oklahoma City, OK 73104 USA.
[Steele, Vernon E.] NCI, Chemoprevent Agent Dev Res Grp, Canc Prevent Div, Bethesda, MD 20892 USA.
RP Rao, CV (reprint author), Univ Oklahoma, Hlth Sci Ctr, Ctr Canc Prevent & Drug Dev, 975 NE 10th St,BRC 2,Room 1203, Oklahoma City, OK 73104 USA.
EM altaf-mohammed@ouhsc.edu; cv-rao@ouhsc.edu
FU National Cancer Institute [N01CN-53300]; Kerley Cade Endowed Chair
FX We acknowledge support from the National Cancer Institute (N01CN-53300)
and Kerley Cade Endowed Chair.
NR 46
TC 43
Z9 49
U1 4
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1944-7124
EI 1936-5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD DEC
PY 2013
VL 6
IS 6
BP 649
EP U266
DI 10.1593/tlo.13556
PG 12
WC Oncology
SC Oncology
GA 298RP
UT WOS:000330342400006
PM 24466367
ER
PT J
AU Jadhav, V
Hackl, M
Druz, A
Shridhar, S
Chung, CY
Heffner, KM
Kreil, DP
Betenbaugh, M
Shiloach, J
Barron, N
Grillari, J
Borth, N
AF Jadhav, Vaibhav
Hackl, Matthias
Druz, Aliaksandr
Shridhar, Smriti
Chung, Cheng-Yu
Heffner, Kelley M.
Kreil, David P.
Betenbaugh, Mike
Shiloach, Joseph
Barron, Niall
Grillari, Johannes
Borth, Nicole
TI CHO microRNA engineering is growing up: Recent successes and future
challenges
SO BIOTECHNOLOGY ADVANCES
LA English
DT Review
DE MicroRNA engineering; Chinese Hamster Ovary cells; Bioprocess relevant
properties
ID HAMSTER OVARY CELLS; LACTATE DEHYDROGENASE-A; RECOMBINANT PROTEIN
THERAPEUTICS; MONOCLONAL-ANTIBODY PRODUCTION; ENDOPLASMIC-RETICULUM
STRESS; LACTIC-ACID FORMATION; INDUCED APOPTOSIS; MAMMALIAN-CELLS;
GENE-EXPRESSION; DOWN-REGULATION
AB microRNAs with their ability to regulate complex pathways that control cellular behavior and phenotype have been proposed as potential targets for cell engineering in the context of optimization of biopharmaceutical production cell lines, specifically of Chinese Hamster Ovary cells. However, until recently, research was limited by a lack of genomic sequence information on this industrially important cell line. With the publication of the genomic sequence and other relevant data sets for CHO cells since 2011, the doors have been opened for an improved understanding of CHO cell physiology and for the development of the necessary tools for novel engineering strategies. In the present review we discuss both knowledge on the regulatory mechanisms of microRNAs obtained from other biological models and proof of concepts already performed on CHO cells, thus providing an outlook of potential applications of microRNA engineering in production cell lines. (C) 2013 The Authors. Published by Elsevier Inc. All rights reserved.
C1 [Jadhav, Vaibhav; Hackl, Matthias; Shridhar, Smriti; Kreil, David P.; Grillari, Johannes; Borth, Nicole] Univ Nat Resources & Life Sci, Dept Biotechnol, Vienna, Austria.
[Druz, Aliaksandr; Shiloach, Joseph] NIDDK, Biotechnol Core Lab, NIH, Bethesda, MD 20892 USA.
[Druz, Aliaksandr; Chung, Cheng-Yu; Heffner, Kelley M.; Betenbaugh, Mike] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA.
[Kreil, David P.] Univ Warwick, Coventry CV4 7AL, W Midlands, England.
[Barron, Niall] Dublin City Univ, Natl Inst Cellular Biotechnol, Dublin 9, Ireland.
RP Grillari, J (reprint author), Univ Nat Resources & Life Sci, Dept Biotechnol, Vienna, Austria.
EM nicole.borth@boku.ac.at
RI Betenbaugh, Michael J./A-3252-2010; Jadhav, Vaibhav/A-1887-2016;
Grillari, Johannes/B-2967-2011; Kreil, D/O-1783-2013;
OI Betenbaugh, Michael J./0000-0002-6336-4659; Jadhav,
Vaibhav/0000-0002-1873-1894; Grillari, Johannes/0000-0001-5474-6332;
Kreil, D/0000-0001-7538-2056; Hackl, Matthias/0000-0002-4136-7293;
barron, niall/0000-0003-4602-326X
FU Biotop; Austrian Science Fund [W1224]; BOKU DOC grant; intramural
research program of the NIDDK/NIH; Science Foundation Ireland; Vienna
Science and Technology Fund (WWTF); Baxter AG; Austrian Research Centre
Seibersdorf; Austrian Centre of Biopharmaceutical Technology; Austrian
Center of Industrial Biotechnology, ACIB
FX VJ and SS were funded by Biotop, a PhD program funded by the Austrian
Science Fund, W1224. MH is the recipient of a BOKU DOC grant. AD and YS
acknowledge support by the intramural research program of the NIDDK/NIH.
NBarron is funded by the Science Foundation Ireland. DPK acknowledges
funding by the Vienna Science and Technology Fund (WWTF), the Baxter AG,
the Austrian Research Centre Seibersdorf and the Austrian Centre of
Biopharmaceutical Technology. NBorth acknowledges support by the
Austrian Center of Industrial Biotechnology, ACIB.
NR 207
TC 20
Z9 20
U1 2
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0734-9750
EI 1873-1899
J9 BIOTECHNOL ADV
JI Biotechnol. Adv.
PD DEC
PY 2013
VL 31
IS 8
BP 1501
EP 1513
DI 10.1016/j.biotechadv.2013.07.007
PG 13
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 281DW
UT WOS:000329081200029
PM 23916872
ER
PT J
AU Burgio, MR
Ioannidis, JPA
Kaminski, BM
DeRycke, E
Rogers, S
Khoury, MJ
Seminara, D
AF Burgio, Michael R.
Ioannidis, John P. A.
Kaminski, Brett M.
DeRycke, Eric
Rogers, Scott
Khoury, Muin J.
Seminara, Daniela
TI Collaborative Cancer Epidemiology in the 21st Century: The Model of
Cancer Consortia
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Review
ID GENOME-WIDE ASSOCIATION; BRCA2 MUTATION CARRIERS; BRAIN-TUMOR
CONSORTIUM; PROSTATE-CANCER; BREAST-CANCER; GENETIC EPIDEMIOLOGY; FAMILY
REGISTRY; INTERNATIONAL CONSORTIUM; COLON-CANCER; RISK
AB During the last two decades, epidemiology has undergone a rapid evolution toward collaborative research. The proliferation of multi-institutional, interdisciplinary consortia has acquired particular prominence in cancer research. Herein, we describe the characteristics of a network of 49 established cancer epidemiology consortia (CEC) currently supported by the Epidemiology and Genomics Research Program (EGRP) at the National Cancer Institute (NCI). This collection represents the largest disease-based research network for collaborative cancer research established in population sciences. We describe the funding trends, geographic distribution, and areas of research focus. The CEC have been partially supported by 201 grants and yielded 3,876 publications between 1995 and 2011. We describe this output in terms of interdisciplinary collaboration and translational evolution. We discuss challenges and future opportunities in the establishment and conduct of large-scale team science within the framework of CEC, review future prospects for this approach to large-scale, interdisciplinary cancer research, and describe a model for the evolution of an integrated Network of Cancer Consortia optimally suited to address and support 21st-century epidemiology. (C)2013 AACR.
C1 [Burgio, Michael R.; Kaminski, Brett M.; DeRycke, Eric; Rogers, Scott; Khoury, Muin J.; Seminara, Daniela] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Gen, Atlanta, GA USA.
[Burgio, Michael R.] Sci Consulting Grp Inc, Gaithersburg, MD USA.
[Ioannidis, John P. A.] Stanford Univ, Dept Med, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA.
[Ioannidis, John P. A.] Stanford Univ, Sch Med, Dept Publ Hlth & Policy, Stanford, CA 94305 USA.
[Ioannidis, John P. A.] Stanford Univ, Dept Stat, Sch Humanities & Sci, Stanford, CA 94305 USA.
RP Burgio, MR (reprint author), NCI, NIH, Div Canc Control & Populat Sci, Epidemiol & Genom Res Program, 9609 Med Ctr Dr,Rm 4E320,MSC 9763, Rockville, MD 20850 USA.
EM burgiom@mail.nih.gov
FU Intramural CDC HHS [CC999999]; Intramural NIH HHS [Z99 CA999999]
NR 64
TC 5
Z9 5
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD DEC
PY 2013
VL 22
IS 12
BP 2148
EP 2160
DI 10.1158/1055-9965.EPI-13-0591
PG 13
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 293ML
UT WOS:000329975700002
PM 24045926
ER
PT J
AU Cook, MB
Gamborg, M
Aarestrup, J
Sorensen, TIA
Baker, JL
AF Cook, Michael B.
Gamborg, Michael
Aarestrup, Julie
Sorensen, Thorkild I. A.
Baker, Jennifer L.
TI Childhood Height and Birth Weight in Relation to Future Prostate Cancer
Risk: A Cohort Study Based on the Copenhagen School Health Records
Register
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID BODY-MASS INDEX; ADULT HEIGHT; LEG LENGTH; TRUNK LENGTH; GROWTH;
CHILDREN; MORTALITY; ANTIGEN; AGE; TRENDS
AB Background: Adult height has been positively associated with prostate cancer risk. However, the exposure window of importance is currently unknown and assessments of height during earlier growth periods are scarce. In addition, the association between birth weight and prostate cancer remains undetermined. We assessed these relationships in a cohort of the Copenhagen School Health Records Register (CSHRR).
Methods: The CSHRR comprises 372,636 school children. For boys born between the 1930s and 1969, birth weight and annual childhood heights-measured between ages 7 and 13 years-were analyzed in relation to prostate cancer risk. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CI).
Results: There were 125,211 males for analysis, 2,987 of who were subsequently diagnosed with prostate cancer during 2.57 million person-years of follow-up. Height z-score was significantly associated with prostate cancer risk at all ages (HRs, 1.13 to 1.14). Height at age 13 years was more important than height change (P = 0.024) and height at age 7 years (P = 0.024), when estimates from mutually adjusted models were compared. Adjustment of birth weight did not alter the estimates. Birth weight was not associated with prostate cancer risk.
Conclusions: The association between childhood height and prostate cancer risk was driven by height at age 13 years.
Impact: Our findings implicate late childhood, adolescence, and adulthood growth periods as containing the exposure window(s) of interest that underlies the association between height and prostate cancer. The causal factor may not be singular given the complexity of both human growth and carcinogenesis. (C)2013 AACR.
C1 [Cook, Michael B.] NCI, Div Canc Epidemiol & Genet, NIH, DHHS, Bethesda, MD USA.
[Sorensen, Thorkild I. A.; Baker, Jennifer L.] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark.
RP Baker, JL (reprint author), Inst Prevent Med, Nordre Fasanvej 57, DK-2000 Frederiksberg, Denmark.
EM jennifer.lyn.baker@regionh.dk
RI Cook, Michael/A-5641-2009; Baker, Jennifer/F-1917-2010
OI Cook, Michael/0000-0002-0533-7302; Baker, Jennifer/0000-0002-9649-6615
FU Intramural Program of the National Cancer Institute, NIH; Department of
Health and Human Services; European Research Council under the European
Union's Seventh Framework Program/ERC grant [281418]
FX This work was supported by Intramural Program of the National Cancer
Institute, NIH, and Department of Health and Human Services. The
research leading to these results has received funding from the European
Research Council under the European Union's Seventh Framework Program
(FP/2007-2013)/ERC grant agreement no. 281418, child-growth2cancer.org
(to J.L. Baker).
NR 72
TC 9
Z9 9
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD DEC
PY 2013
VL 22
IS 12
BP 2232
EP 2240
DI 10.1158/1055-9965.EPI-13-0712
PG 9
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 293ML
UT WOS:000329975700008
PM 24089459
ER
PT J
AU Mir, MC
Stephenson, AJ
Grubb, RL
Black, A
Kibel, AS
Izmirlian, G
AF Mir, Maria C.
Stephenson, Andrew J.
Grubb, Robert L., III
Black, Amanda
Kibel, Adam S.
Izmirlian, Grant
TI Predicting Risk of Bladder Cancer Using Clinical and Demographic
Information from Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial Participants
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID SMOKING; HEMATURIA; MORTALITY
AB Background: Effective screening and prevention strategies for bladder cancer require accurate risk stratification models. We developed models to predict the risk of bladder cancer based on clinical and sociodemographic data on participants in the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) screening trial.
Methods: Baseline clinical and sociodemographic data were obtained from 149,542 PLCO participants, ages 55 to 74 years, without a prior history of bladder cancer. Cox proportional hazards models were used to predict the risk of all bladder cancers (ABC) and of high-grade bladder cancers (HGBC) from baseline information. We used the HGBC risk model to design a hypothetical bladder cancer mortality prevention trial.
Results: Over a median follow-up of 12 years, 1,124 men and 259 women developed bladder cancer (including 392 and 72 with HGBC, respectively). The incidence in men and in women was 133.6 and 29.6 cases per 100,000 person-years, respectively. Nomograms constructed for predicting the risk of ABC and HGBC had c-indices of 0.746 and 0.759, respectively. Age, race, education, smoking (intensity and duration), comorbidity, prostatitis, syphilis, and hormone replacement therapy use were statistically significant predictors in the models. We show that our risk model can be used to design a bladder cancer mortality prevention trial half the size of a trial designed without risk stratification.
Conclusion: Models to predict the risk of ABC and HGBC have been developed and validated.
Impact: Using the upper 40th percentile from the HGBC model, a suitable cohort for a screening or chemoprevention trial could be identified, although the size and follow-up of such a trial would be costly. (C)2013 AACR.
C1 [Mir, Maria C.; Stephenson, Andrew J.] Cleveland Clin, Glickman Urol & Kidney Inst, Ctr Urol Oncol, Cleveland, OH 44106 USA.
[Grubb, Robert L., III] Washington Univ, Sch Med, Div Urol Surg, St Louis, MO 63110 USA.
[Black, Amanda] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Izmirlian, Grant] NCI, Canc Prevent Div, Bethesda, MD 20892 USA.
[Kibel, Adam S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Urol, Boston, MA 02115 USA.
RP Izmirlian, G (reprint author), NCI, BG 9609 RM 5E130 MSC 9789,9609 Med Ctr Dr, Bethesda, MD 20892 USA.
EM izmirlig@mail.nih.gov
FU GlaxoSmithKline
FX R.L. Grubb III has other commercial research support from
GlaxoSmithKline. No potential conflicts of interest were disclosed by
the other authors.
NR 17
TC 5
Z9 5
U1 1
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD DEC
PY 2013
VL 22
IS 12
BP 2241
EP 2249
DI 10.1158/1055-9965.EPI-13-0632
PG 9
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 293ML
UT WOS:000329975700009
PM 24089460
ER
PT J
AU Yu, GQ
Murphy, G
Michel, A
Weinstein, SJ
Mannisto, S
Albanes, D
Pawlita, M
Stolzenberg-Solomon, RZ
AF Yu, Guoqin
Murphy, Gwen
Michel, Angelika
Weinstein, Stephanie J.
Mannisto, Satu
Albanes, Demetrius
Pawlita, Michael
Stolzenberg-Solomon, Rachael Z.
TI Seropositivity to Helicobacter pylori and Risk of Pancreatic Cancer
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID MULTIPLEX SEROLOGY; ASSOCIATION; INFECTION
AB Helicobacter pylori (H. pylori) seropositivity has been inconsistently associated with pancreatic cancer. We, therefore, investigated the association between H. pylori seropositivity and pancreatic cancer in a case-control study nested within Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC) cohort of Finnish male smokers. Pancreatic cancer cases (n = 353) and control subjects (n = 353) were matched on date of baseline serum collection, age at randomization, and follow-up time (up to 23.9 years). We used a multiplex serology assay to determine the sero-status of antibodies against 15 H. pylori-specific antigens in fasting serum samples. Conditional logistic regression was used to calculate the odds ratio (OR) and 95% confidence intervals (CI). Neither targeted H. pylori antigens in serum nor the combination of all was associated with development of pancreatic cancer (combination of all: OR, 0.85; 95% CI, 0.49-1.49). Our results suggest that H. pylori is not a risk factor for pancreatic cancer. (C) 2013 AACR.
C1 [Yu, Guoqin; Murphy, Gwen; Weinstein, Stephanie J.; Albanes, Demetrius; Stolzenberg-Solomon, Rachael Z.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Michel, Angelika; Pawlita, Michael] German Canc Res Ctr, Div Genome Modificat & Carcinogenesis, Res Program Infect & Canc, Heidelberg, Germany.
[Mannisto, Satu] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland.
RP Yu, GQ (reprint author), NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, 9609 Med Ctr Dr,Room 6E518 MSC 9704, Bethesda, MD 20892 USA.
EM yug3@mail.nih.gov
RI Albanes, Demetrius/B-9749-2015; Murphy, Gwen/G-7443-2015; Waterboer,
Tim/G-1252-2010;
OI Mannisto, Satu/0000-0002-8668-3046; Pawlita, Michael/0000-0002-4720-8306
FU Intramural Research Program of the NIH, Division of Cancer Epidemiology
and Genetics, National Cancer Institute, Department of Health and Human
Services
FX This research was supported by the Intramural Research Program of the
NIH, Division of Cancer Epidemiology and Genetics, National Cancer
Institute, Department of Health and Human Services.
NR 13
TC 12
Z9 12
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD DEC
PY 2013
VL 22
IS 12
BP 2416
EP 2419
DI 10.1158/1055-9965.EPI-13-0680
PG 4
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 293ML
UT WOS:000329975700028
PM 24089457
ER
PT J
AU Lee, D
Vandrey, R
Mendu, DR
Anizan, S
Milman, G
Murray, JA
Barnes, AJ
Huestis, MA
AF Lee, Dayong
Vandrey, Ryan
Mendu, Damodara R.
Anizan, Sebastien
Milman, Garry
Murray, Jeannie A.
Barnes, Allan J.
Huestis, Marilyn A.
TI Oral Fluid Cannabinoids in Chronic Cannabis Smokers during Oral
Delta(9)-Tetrahydrocannabinol Therapy and Smoked Cannabis Challenge
SO CLINICAL CHEMISTRY
LA English
DT Article
ID 2-DIMENSIONAL GAS-CHROMATOGRAPHY; MARIJUANA WITHDRAWAL; SIMULTANEOUS
QUANTIFICATION; PHARMACOKINETIC PROPERTIES; REMAINING CHALLENGES;
MASS-SPECTROMETRY; RECENT PROGRESS; DOUBLE-BLIND; THC; PLASMA
AB BACKGROUND: Oral Delta(9)-tetrahydrocannabinol (THC) is effective for attenuating cannabis withdrawal and may benefit treatment of cannabis use disorders. Oral fluid (OF) cannabinoid testing, increasing in forensic and workplace settings, could be valuable for monitoring during cannabis treatment.
METHODS: Eleven cannabis smokers resided on a closed research unit for 51 days and received daily 0, 30, 60, and 120 mg of oral THC in divided doses for 5 days. There was a 5-puff smoked cannabis challenge on the fifth day. Each medication session was separated by 9 days of ad libitum cannabis smoking. OF was collected the evening before and throughout oral THC sessions and analyzed by 2-dimensional GC-MS for THC, cannabidiol (CBD), cannabinol (CBN), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH).
RESULTS: During all oral THC administrations, THC OF concentrations decreased to <= 78.2, 33.2, and 1.4 mu g/L by 24, 48, and 72 h, respectively. CBN also decreased over time, with concentrations 10-fold lower than THC, with none detected beyond 69 h. CBD and 11-OH-THC were rarely detected, only within 19 and 1.6 h after smoking, respectively. THCCOOH OF concentrations were dose dependent and increased over time during 120-mg THC dosing. After cannabis smoking, THC, CBN, and THCCOOH concentrations showed a significant dose effect and decreased significantly over time.
CONCLUSIONS: Oral THC dosing significantly affected OFTHCCOOH but minimally contributed to THCOF concentrations; prior ad libitum smoking was the primary source of THC, CBD, and CBN. Higher cannabinoid concentrations following active oral THC administrations vs placebo suggest a compensatory effect of THC tolerance on smoking topography. (C) 2013 American Association for Clinical Chemistry
C1 [Lee, Dayong; Mendu, Damodara R.; Anizan, Sebastien; Milman, Garry; Barnes, Allan J.; Huestis, Marilyn A.] NIDA, Intramural Res Program, NIH, Baltimore, MD 21224 USA.
[Vandrey, Ryan; Murray, Jeannie A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
RP Huestis, MA (reprint author), NIDA, IRP, NIH, Biomed Res Ctr, 251 Bayview Blvd,Suite 200,Rm 05A721, Baltimore, MD 21224 USA.
EM mhuestis@intra.nida.nih.gov
FU Intramural NIH HHS; NIDA NIH HHS [R01 DA025044]
NR 37
TC 4
Z9 4
U1 3
U2 12
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
EI 1530-8561
J9 CLIN CHEM
JI Clin. Chem.
PD DEC
PY 2013
VL 59
IS 12
BP 1770
EP 1779
DI 10.1373/clinchem.2013.207316
PG 10
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 293MU
UT WOS:000329976700013
PM 23938457
ER
PT J
AU Himes, SK
Scheidweiler, KB
Beck, O
Gorelick, DA
Desrosiers, NA
Huestis, MA
AF Himes, Sarah K.
Scheidweiler, Karl B.
Beck, Olof
Gorelick, David A.
Desrosiers, Nathalie A.
Huestis, Marilyn A.
TI Cannabinoids in Exhaled Breath following Controlled Administration of
Smoked Cannabis
SO CLINICAL CHEMISTRY
LA English
DT Article
ID ORAL FLUID; HEPATIC MICROSOMES; DELTA(9)-TETRAHYDROCANNABINOL;
METABOLISM; USERS; DELTA-9-TETRAHYDROCANNABINOL; PHARMACOKINETICS;
HYDROLYSIS; MATRICES; DRUGS
AB BACKGROUND: Delta(9)-Tetrahydrocannabinol (THC), 11-nor-9- carboxy-THC (THCCOOH), and cannabinol (CBN) were measured in breath following controlled cannabis smoking to characterize the time course and windows of detection of breath cannabinoids.
METHODS: Exhaled breath was collected from chronic (>4 times per week) and occasional (= 65-yr-old subjects generated significantly more IL-1, TNF-alpha, and IL-6, but not IL-8 or IL-12, and significantly more ex-mRNAs for IL-6, TNF-alpha, and IL-12, but not for IL-8 or IL-1, than Ms from 20 matched 21- to 45-yr-old subjects. CD4-Tm generation of IL-2, IL-4, and IFN-gamma and, for young subjects, IL-10, but not IL-6, evoked by A beta was significantly lower than with anti-T-cell antigen receptor antibodies (Abs). Abs significantly increased all CD4-Tm ex-mRNAs, but only IL-2 and IL-6 ex-mRNAs were increased by A beta. There were no significant differences between cytokine and ex-mRNA responses of CD4-Tms from the old compared to the young subjects. M-derived serum exosomes from the old subjects had significantly higher IL-6 and IL-12 ex-mRNA levels than those from the young subjects, whereas there were no differences for CD4-Tm-derived serum exosomes. An A beta level relevant to neurodegeneration elicited broad M cytokine and ex-mRNA responses that were significantly greater in the old subjects, but only narrow and age-independent CD4-Tm responses.
C1 [Mitsuhashi, Masato] Hitachi Chem Res Ctr, Irvine, CA USA.
[Taub, Dennis D.; Kapogiannis, Dimitrios; Eitan, Erez; Zukley, Linda; Mattson, Mark P.; Ferrucci, Luigi; Goetzl, Edward J.] NIA, NIH, Baltimore, MD 21224 USA.
[Schwartz, Janice B.; Goetzl, Edward J.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Schwartz, Janice B.; Goetzl, Edward J.] Univ Calif San Francisco, Geriatr Res Labs, San Francisco, CA 94143 USA.
RP Goetzl, EJ (reprint author), UCSF Geriatr Res Ctr, 1719 Broderick St, San Francisco, CA 94115 USA.
EM edward.goetzl@ucsf.edu
FU Jewish Home of San Francisco; Intramural Research Program of the U.S.
National Institute on Aging; Edward A. Dickson Professorship at the
University of California, San Francisco
FX This research was supported by endowment fund income of the Jewish Home
of San Francisco, by the Intramural Research Program of the U.S.
National Institute on Aging, and by funds from the Edward A. Dickson
Professorship at the University of California, San Francisco. The
authors are grateful to Judith H. Goetzl for expert preparation of the
graphic illustrations. Dr. Charles Hesdorffer (Veterans Affairs Medical
Center, Washington, DC, USA) provided constant support for the research.
NR 40
TC 6
Z9 7
U1 1
U2 5
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD DEC
PY 2013
VL 27
IS 12
BP 5141
EP 5150
DI 10.1096/fj.13-238980
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA 293UK
UT WOS:000329999000046
PM 24014820
ER
PT J
AU De Matteis, S
Consonni, D
Lubin, JH
Tucker, M
Peters, S
Bertazzi, PA
Caporaso, NE
Pesatori, AC
Wacholder, S
Landi, MT
Vermeulen, RCH
Kromhout, H
AF De Matteis, Sara
Consonni, Dario
Lubin, Jay H.
Tucker, Margaret
Peters, Susan
Bertazzi, Pier Alberto
Caporaso, Neil E.
Pesatori, Angela C.
Wacholder, Sholom
Landi, Maria Teresa
Vermeulen, Roel C. H.
Kromhout, Hans
TI Authors' Response to: Comment upon the article: Impact of occupational
carcinogens on lung cancer risk in a general population
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Letter
ID EXPOSURE ASSESSMENT
C1 [De Matteis, Sara] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England.
[Consonni, Dario; Bertazzi, Pier Alberto; Pesatori, Angela C.] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Prevent Med, Epidemiol Unit, Milan, Italy.
[Consonni, Dario; Bertazzi, Pier Alberto; Pesatori, Angela C.] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
[Lubin, Jay H.; Tucker, Margaret; Caporaso, Neil E.; Wacholder, Sholom; Landi, Maria Teresa] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Peters, Susan; Vermeulen, Roel C. H.; Kromhout, Hans] Univ Utrecht, Environm Epidemiol Div, Inst Risk Assessment Sci, Utrecht, Netherlands.
[Peters, Susan] Univ Western Australia, Western Australian Inst Med Res, Nedlands, WA 6009, Australia.
RP Landi, MT (reprint author), NCI, Genet Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, 9609 Med Ctr Dr,Room 6E446,MSC 9769, Bethesda, MD 20892 USA.
EM landim@mail.nih.gov
RI Tucker, Margaret/B-4297-2015; Consonni, Dario/K-7943-2016; Vermeulen,
Roel/F-8037-2011; bertazzi, pietro alberto/D-5039-2017;
OI Consonni, Dario/0000-0002-8935-3843; Vermeulen,
Roel/0000-0003-4082-8163; bertazzi, pietro alberto/0000-0003-3475-2449;
Peters, Susan/0000-0001-5662-1971; pesatori, angela/0000-0002-0261-3252
NR 9
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
EI 1464-3685
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD DEC
PY 2013
VL 42
IS 6
BP 1895
EP 1896
DI 10.1093/ije/dyt176
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 291ZC
UT WOS:000329870400058
PM 24415626
ER
PT J
AU Glass, R
AF Glass, Roger
TI INTERNATIONAL RESEARCH ETHICS EDUCATION
SO JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS
LA English
DT Editorial Material
C1 [Glass, Roger] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
[Glass, Roger] NIH, Bethesda, MD USA.
RP Glass, R (reprint author), NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
EM Roger.Glass@nih.gov
NR 0
TC 3
Z9 3
U1 0
U2 3
PU UNIV CALIFORNIA PRESS
PI BERKELEY
PA C/O JOURNALS & DIGITAL PUBLISHING DIVISION, 2000 CENTER ST, STE 303,
BERKELEY, CA 94704-1223 USA
SN 1556-2646
EI 1556-2654
J9 J EMPIR RES HUM RES
JI J. Empir. Res. Hum. Res. Ethics
PD DEC
PY 2013
VL 8
IS 5
BP 1
EP 2
DI 10.1525/jer.2013.8.5.1
PG 2
WC Ethics; Medical Ethics
SC Social Sciences - Other Topics; Medical Ethics
GA 293GY
UT WOS:000329960600001
PM 24384511
ER
PT J
AU Millum, J
Grady, C
Keusch, G
Sina, B
AF Millum, Joseph
Grady, Christine
Keusch, Gerald
Sina, Barbara
TI INTRODUCTION: THE FOGARTY INTERNATIONAL RESEARCH ETHICS EDUCATION AND
CURRICULUM DEVELOPMENT PROGRAM IN HISTORICAL CONTEXT
SO JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS
LA English
DT Editorial Material
DE Fogarty International Center; research ethics; bioethics; training;
education; curriculum; history
ID HUMAN-IMMUNODEFICIENCY-VIRUS; INFORMED-CONSENT; CLINICAL-TRIALS;
RESEARCH PARTICIPANTS; DEVELOPING-COUNTRIES; GLOBALIZATION;
TRANSMISSION; WORLD
AB IN RESPONSE TO THE INCREASING NEED for research ethics expertise in low- and middle-income countries (LMICs), the NIH's Fogarty International Research Ethics Education and Curriculum Development Program has provided grants for the development of training programs in international research ethics for LMIC professionals since 2000. This collection of papers draws upon the combined expertise of Fogarty grantees, trainees, and other experts to assess the state of research ethics in LMICs, and the lessons learned over 12 years of international research ethics education; to assess future needs; and to chart a way forward to meet those needs. In this introductory paper we briefly sketch the evolution of research ethics as applied to LMIC research, the underpinning and evolution of the Fogarty bioethics program, and summarize key conclusions from the other papers in the collection.
C1 [Millum, Joseph] NIH, Bethesda, MD 20892 USA.
[Grady, Christine] NIH, Dept Bioeth, Ctr Clin, Bethesda, MD 20892 USA.
[Sina, Barbara] NIH, Int Res Eth Educ & Curriculum Dev Program, Div Int Training & Res, Fogarty Int Ctr, Bethesda, MD 20892 USA.
[Keusch, Gerald] Boston Univ, Natl Emerging Infect Dis Lab, Boston, MA 02215 USA.
RP Millum, J (reprint author), NIH, Ctr Clin, Dept Bioeth, Fogarty Int Ctr, Bldg 10,1C118,10 Ctr Dr, Bethesda, MD 20892 USA.
EM joseph.millum@nih.gov
FU Intramural NIH HHS [Z99 CL999999]
NR 38
TC 5
Z9 5
U1 0
U2 4
PU UNIV CALIFORNIA PRESS
PI BERKELEY
PA C/O JOURNALS & DIGITAL PUBLISHING DIVISION, 2000 CENTER ST, STE 303,
BERKELEY, CA 94704-1223 USA
SN 1556-2646
EI 1556-2654
J9 J EMPIR RES HUM RES
JI J. Empir. Res. Hum. Res. Ethics
PD DEC
PY 2013
VL 8
IS 5
BP 3
EP 16
DI 10.1525/jer.2013.8.5.3
PG 14
WC Ethics; Medical Ethics
SC Social Sciences - Other Topics; Medical Ethics
GA 293GY
UT WOS:000329960600002
PM 24384512
ER
PT J
AU Fix, J
Odell, J
Sina, B
Meslin, EM
Goodman, K
Upshur, R
AF Fix, Jonathan
Odell, Jere
Sina, Barbara
Meslin, Eric M.
Goodman, Ken
Upshur, Ross
TI A BIBLIOMETRIC ANALYSIS OF AN INTERNATIONAL RESEARCH ETHICS TRAINEE
PROGRAM
SO JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS
LA English
DT Article
DE bioethics education; bioethics scholarship; bibliometrics; citation
analysis
ID SCIENTIFIC LITERATURE; JOURNALS; BIOETHICS
AB WE USED BIBLIOMETRIC ANALYSIS TO evaluate the citations associated with publications by trainees in the Fogarty International Center's International Research Ethics Education and Curriculum Development program. Papers published between 2004 and 2008 were identified for analysis. The outcome measures were total citations, h-index, and i-10. A total of 328 manuscripts were identified, with a yearly average of 66 publications and 363 citations. The median number of citations per paper is 3 (IQR Q1-Q3:6). 12.6% (n = 53) of papers were cited over 10 times and the h-index is 22, indicating that 22 papers had been cited at least 22 times. The data indicate that trainees have been productive and contributed to the scholarly literature. Future studies to benchmark this performance with other bioethics education programs are required to make interpretation of citation analysis more meaningful.
C1 [Fix, Jonathan] Univ Maryland, College Pk, MD 20742 USA.
[Odell, Jere] Indiana Univ Purdue Univ, Indianapolis, IN USA.
[Sina, Barbara] NIH, Div Int Training & Res, Fogarty Int Ctr, Bethesda, MD USA.
[Meslin, Eric M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
[Goodman, Ken] Univ Miami, Sch Med, Dept Med, Bioeth Program, Coral Gables, FL 33124 USA.
[Upshur, Ross] Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada.
[Upshur, Ross] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M5S 1A1, Canada.
RP Upshur, R (reprint author), Univ Toronto, Dept Family & Community Med, Room 678,155 Coll St, Toronto, ON M5T 3M7, Canada.
EM ross.upshur@gmail.com
OI Upshur, Ross/0000-0003-1128-0557; Odell, Jere/0000-0001-5455-1471
NR 31
TC 3
Z9 3
U1 3
U2 10
PU UNIV CALIFORNIA PRESS
PI OAKLAND
PA 155 GRAND AVE, SUITE 400, OAKLAND, CA 94612-3758 USA
SN 1556-2646
EI 1556-2654
J9 J EMPIR RES HUM RES
JI J. Empir. Res. Hum. Res. Ethics
PD DEC
PY 2013
VL 8
IS 5
BP 75
EP 81
DI 10.1525/jer.2013.8.5.75
PG 7
WC Ethics; Medical Ethics
SC Social Sciences - Other Topics; Medical Ethics
GA 293GY
UT WOS:000329960600008
PM 24384518
ER
PT J
AU Miller, FG
Joffe, S
AF Miller, Franklin G.
Joffe, Steven
TI Phase 1 oncology trials and informed consent
SO JOURNAL OF MEDICAL ETHICS
LA English
DT Article
DE Informed Consent
ID I CANCER TRIALS; THERAPEUTIC MISCONCEPTION; CLINICAL-TRIALS; BENEFIT;
COMMUNICATION; PERCEPTIONS; PHYSICIANS
AB Ethical concerns have been raised about the quality of informed consent by participants in phase 1 oncology trials. Interview surveys indicate that substantial proportions of trial participants do not understand the purpose of these trialsevaluating toxicity and dosing for subsequent efficacy studiesand overestimate the prospect of therapeutic benefit that they offer. In this article we argue that although these data suggest the desirability of enhancing the process of information disclosure and assessment of comprehension of the implications of study participation, they do not necessarily invalidate consent by phase 1 trial participants.
C1 [Miller, Franklin G.] NIH, Dept Bioeth, Bethesda, MD 20892 USA.
[Joffe, Steven] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
RP Miller, FG (reprint author), NIH, Warren G Magnuson Clin Ctr, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.
EM fmiller@nih.gov
OI Joffe, Steven/0000-0002-0667-7384
NR 25
TC 7
Z9 7
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-6800
EI 1473-4257
J9 J MED ETHICS
JI J. Med. Ethics
PD DEC
PY 2013
VL 39
IS 12
BP 761
EP 764
DI 10.1136/medethics-2012-100832
PG 4
WC Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical
SC Social Sciences - Other Topics; Medical Ethics; Social Issues;
Biomedical Social Sciences
GA 291EG
UT WOS:000329809900011
PM 23161617
ER
PT J
AU Afonso, PV
Parent, CA
AF Afonso, Philippe V.
Parent, Carole A.
TI B-4 leucotriene A lipid at the heart of inflammation
SO M S-MEDECINE SCIENCES
LA French
DT News Item
ID NEUTROPHIL; RECRUITMENT; CHEMOTAXIS; MIGRATION; DISEASE; LTB4
C1 [Afonso, Philippe V.; Parent, Carole A.] NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Afonso, Philippe V.] Inst Pasteur, Dept Virol, Unite Epidemiol & Physiopathol Virus Oncogenes, F-75724 Paris 15, France.
[Afonso, Philippe V.] Inst Pasteur, CNRS, UMR3569, F-75724 Paris 15, France.
RP Afonso, PV (reprint author), NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, 37 Convent Dr,MSC 4256, Bethesda, MD 20892 USA.
EM parentc@mail.nih.gov
RI Afonso, Philippe/D-2234-2014
OI Afonso, Philippe/0000-0002-4828-3797
NR 11
TC 1
Z9 1
U1 2
U2 4
PU EDP SCIENCES S A
PI LES ULIS CEDEX A
PA 17, AVE DU HOGGAR, PA COURTABOEUF, BP 112, F-91944 LES ULIS CEDEX A,
FRANCE
SN 0767-0974
J9 M S-MED SCI
JI M S-Med. Sci.
PD DEC
PY 2013
VL 29
IS 12
BP 1083
EP 1085
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 294JQ
UT WOS:000330042100007
PM 24356134
ER
PT J
AU Donkervoort, S
Schindler, A
Tesi-Rocha, C
Schreiber, A
Leach, ME
Dastgir, J
Hu, Y
Mankodi, A
Wagner, KR
Friedman, NR
Bonnemann, CG
AF Donkervoort, Sandra
Schindler, Alice
Tesi-Rocha, Carolina
Schreiber, Allison
Leach, Meganne E.
Dastgir, Jahannaz
Hu, Ying
Mankodi, Ami
Wagner, Kathryn R.
Friedman, Neil R.
Boennemann, Carsten G.
TI 'Double trouble': Diagnostic challenges in Duchenne muscular dystrophy
in patients with an additional hereditary skeletal dysplasia
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Double trouble; Duchenne muscular dystrophy; Genetic counseling;
Ostoegenesis imperfecta
ID OSTEOGENESIS IMPERFECTA; DMD GENE; MUTATIONS
AB Duchenne muscular dystrophy (DMD) is caused by mutations in Dystrophin and affects 1 in 3600-6000 males. It is characterized by progressive weakness leading to loss of ambulation, respiratory insufficiency, cardiomyopathy, and scoliosis. We describe the unusual phenotype of 3 patients with skeletal dysplasias in whom an additional diagnosis of DMD was later established. Two unrelated boys presented with osteogenesis imperfecta due to point mutations in COL1A1 and were both subsequently found to have a 1 bp frameshift deletion in the Dystrophin gene at age 3 and age 15 years, respectively. The third patient had a diagnosis of pseudoachondroplasia caused by a mutation in the COMP gene and was found to have a deletion of exons 48-50 in Dystrophin at age 9. We discuss the atypical presentation caused by the concomitant presence of 2 conditions affecting the musculoskeletal system, emphasizing aspects that may confound the presentation of a well-characterized disease like DMD. Additional series of patients with DMD and a secondary inherited condition are necessary to establish the natural history in this "double trouble" population. The recognition and accurate diagnosis of patients with two independent genetic disease processes is essential for management, prognosis, genetic risk assessment, and discussion regarding potential therapeutic interventions. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Donkervoort, Sandra; Schindler, Alice; Leach, Meganne E.; Dastgir, Jahannaz; Hu, Ying; Mankodi, Ami; Boennemann, Carsten G.] Natl Inst Neurol Disorders & Stroke, NIH, Neurogenet Branch, Bethesda, MD 20892 USA.
[Tesi-Rocha, Carolina; Leach, Meganne E.] Childrens Natl Med Ctr, Dept Neurol, Washington, DC 20010 USA.
[Schreiber, Allison] Cleveland Clin, Genom Med Inst, Cleveland, OH 44106 USA.
[Wagner, Kathryn R.] Johns Hopkins Sch Med, Kennedy Krieger Inst, Ctr Genet Muscle Disorders, Baltimore, MD USA.
[Wagner, Kathryn R.] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA.
[Wagner, Kathryn R.] Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD USA.
[Friedman, Neil R.] Cleveland Clin, Ctr Pediat Neurol, Cleveland, OH 44106 USA.
RP Bonnemann, CG (reprint author), Natl Inst Neurol Disorders & Stroke, NIH, Porter Neurosci Res Ctr, 35 Convent Dr,Bldg 35,Room 2A-116, Bethesda, MD 20892 USA.
EM carsten.bonnemann@nih.gov
OI Friedman, Neil/0000-0002-7349-7981
FU Intramural NIH HHS [Z99 NS999999, ZIA NS003129-01, ZIA NS003129-02, ZIA
NS003129-03]
NR 29
TC 1
Z9 1
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD DEC
PY 2013
VL 23
IS 12
BP 955
EP 961
DI 10.1016/j.nmd.2013.08.003
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 293FP
UT WOS:000329957100001
PM 24070816
ER
PT J
AU Phelps, DL
Ward, RM
Williams, RL
Watterberg, KL
Laptook, AR
Wrage, LA
Nolen, TL
Fennell, TR
Ehrenkranz, RA
Poindexter, BB
Cotten, CM
Hallman, MK
Frantz, ID
Faix, RG
Zaterka-Baxter, KM
Das, A
Ball, MB
O'Shea, TM
Lacy, CB
Walsh, MC
Shankaran, S
Sanchez, PJ
Bell, EF
Higgins, RD
AF Phelps, Dale L.
Ward, Robert M.
Williams, Rick L.
Watterberg, Kristi L.
Laptook, Abbot R.
Wrage, Lisa A.
Nolen, Tracy L.
Fennell, Timothy R.
Ehrenkranz, Richard A.
Poindexter, Brenda B.
Cotten, C. Michael
Hallman, Mikko K.
Frantz, Ivan D., III
Faix, Roger G.
Zaterka-Baxter, Kristin M.
Das, Abhik
Ball, M. Bethany
O'Shea, T. Michael
Lacy, Conra Backstrom
Walsh, Michele C.
Shankaran, Seetha
Sanchez, Pablo J.
Bell, Edward F.
Higgins, Rosemary D.
CA Eunice Kennedy Shriver Natl Inst
TI Pharmacokinetics and safety of a single intravenous dose of myo-inositol
in preterm infants of 23-29 wk
SO PEDIATRIC RESEARCH
LA English
DT Article
ID RESPIRATORY-DISTRESS SYNDROME; INOSITOL SUPPLEMENTATION; SERUM
CONCENTRATION; PHOSPHOLIPIDS; METABOLISM; EVOLUTION; TERM
AB BACKGROUND: Myo-inositol given to preterm infants with respiratory distress has reduced death, increased survival without bronchopulmonary dysplasia, and reduced severe retinopathy of prematurity in two randomized trials. Pharmacokinetic (PK) studies in extremely preterm infants are needed before efficacy trials.
METHODS: Infants born in 23-29 wk of gestation were randomized to a single intravenous (i.v.) dose of inositol at 60 or 120 mg/kg or placebo. Over 96 h, serum levels (sparse sampling population PK) and urine inositol excretion were determined. Population PK models were fit using a nonlinear mixed-effects approach. Safety outcomes were recorded.
RESULTS: A single-compartment model that included factors for endogenous inositol production, allometric size based on weight, gestational age strata, and creatinine clearance fit the data best. The central volume of distribution was 0.5115 l/kg, the clearance was 0.0679 l/kg/h, endogenous production was 2.67 mg/kg/h, and the half-life was 5.22 h when modeled without the covariates. During the first 12 h, renal inositol excretion quadrupled in the 120 mg/kg group, returning to near-baseline value after 48 h. There was no diuretic side effect. No significant differences in adverse events occurred among the three groups (P > 0.05).
CONCLUSION: A single-compartment model accounting for endogenous production satisfactorily described the PK of i.v. inositol.
C1 [Phelps, Dale L.] Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA.
[Ward, Robert M.; Faix, Roger G.] Univ Utah, Sch Med, Dept Pediat, Div Neonatol, Salt Lake City, UT USA.
[Williams, Rick L.; Wrage, Lisa A.; Nolen, Tracy L.; Zaterka-Baxter, Kristin M.] RTI Int, Stat & Epidemiol Unit, Res Triangle Pk, NC USA.
[Watterberg, Kristi L.; Lacy, Conra Backstrom] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA.
[Laptook, Abbot R.] Brown Univ, Women & Infants Hosp, Dept Pediat, Providence, RI 02908 USA.
[Fennell, Timothy R.] RTI Int, Div Pharmacol & Toxicol, Res Triangle Pk, NC USA.
[Ehrenkranz, Richard A.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA.
[Poindexter, Brenda B.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA.
[Cotten, C. Michael] Duke Univ, Dept Pediat, Durham, NC 27706 USA.
[Hallman, Mikko K.] Univ Oulu, Dept Pediat, SF-90100 Oulu, Finland.
[Hallman, Mikko K.] Oulu Univ Hosp, Oulu, Finland.
[Frantz, Ivan D., III] Tufts Med Ctr, Floating Hosp Children, Dept Pediat, Div Newborn Med, Boston, MA USA.
[Das, Abhik] RTI Int, Stat & Epidemiol Unit, Rockville, MD USA.
[Ball, M. Bethany] Stanford Univ, Sch Med, Div Neonatal & Dev Med, Dept Pediat,Lucile Packard Childrens Hosp, Palo Alto, CA 94304 USA.
[O'Shea, T. Michael] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA.
[Walsh, Michele C.] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA.
[Shankaran, Seetha] Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA.
[Sanchez, Pablo J.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA.
[Bell, Edward F.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.
[Higgins, Rosemary D.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA.
RP Phelps, DL (reprint author), Univ Rochester, Sch Med & Dent, Rochester, NY 14627 USA.
EM dale_phelps@urmc.rochester.edu
FU National Institutes of Health through the Eunice Kennedy Shriver
National Institute of Child Health and Human Development's (NICHD)
Neonatal Research Network; Pediatric Pharmacology Research Units
Network; National Eye Institute; National Center for Research Resources;
National Center for Advancing Translational Sciences
FX The National Institutes of Health provided grant support through the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development's (NICHD) Neonatal Research Network and the Pediatric
Pharmacology Research Units Network, with cofunding from the National
Eye Institute and with support from the National Center for Research
Resources, and the National Center for Advancing Translational Sciences.
NR 27
TC 10
Z9 10
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
EI 1530-0447
J9 PEDIATR RES
JI Pediatr. Res.
PD DEC
PY 2013
VL 74
IS 6
BP 721
EP 729
DI 10.1038/pr.2013.162
PG 9
WC Pediatrics
SC Pediatrics
GA 287RN
UT WOS:000329560000014
PM 24067395
ER
PT J
AU Bailey, RL
Gahche, JJ
Thomas, PR
Dwyer, JT
AF Bailey, Regan L.
Gahche, Jaime J.
Thomas, Paul R.
Dwyer, Johanna T.
TI Why US children use dietary supplements
SO PEDIATRIC RESEARCH
LA English
DT Article
ID UNITED-STATES; NATIONAL-HEALTH; ADULTS; ADOLESCENTS; SAMPLE
AB BACKGROUND: Dietary supplements are used by one-third of children. We examined motivations for supplement use in children, the types of products used by motivations, and the role of physicians and health care practitioners in guiding choices about supplements.
METHODS: We examined motivations for dietary supplement use reported for children (from birth to 19 y of age; n = 8,245) using the National Health and Nutrition Examination Survey 2007-2010.
RESULTS: Dietary supplements were used by 31% of children; many different reasons were given as follows: to "improve overall health" (41%), to "maintain health" (37%), for "supplementing the diet" (23%), to "prevent health problems" (20%), and to "boost immunity" (14%). Most children (similar to 90%) who use dietary supplements use a multivitamin-mineral or multivitamin product. Supplement users tend to be non-Hispanic white, have higher family incomes, report more physical activity, and have health insurance. Only a small group of supplements used by children (15%) were based on the recommendation of a physician or other health care provider.
CONCLUSION: Most supplements used by children are not under the recommendation of a health care provider. The most common reasons for use of supplements in children are for health promotion, yet little scientific data support this notion in nutrient-replete children.
C1 [Bailey, Regan L.; Thomas, Paul R.; Dwyer, Johanna T.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA.
[Gahche, Jaime J.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA.
[Dwyer, Johanna T.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
[Dwyer, Johanna T.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Dwyer, Johanna T.] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.
RP Bailey, RL (reprint author), NIH, Off Dietary Supplements, Bldg 10, Bethesda, MD 20892 USA.
EM baileyr@mail.nih.gov
OI Dwyer, Johanna/0000-0002-0783-1769
FU Office of Dietary Supplements at the National Institutes of Health
FX This work was supported in part by resources from the Office of Dietary
Supplements at the National Institutes of Health.
NR 14
TC 8
Z9 8
U1 3
U2 9
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0031-3998
EI 1530-0447
J9 PEDIATR RES
JI Pediatr. Res.
PD DEC
PY 2013
VL 74
IS 6
BP 737
EP 741
DI 10.1038/pr.2013.160
PG 5
WC Pediatrics
SC Pediatrics
GA 287RN
UT WOS:000329560000016
PM 24002333
ER
PT J
AU Stansfield, L
Hughes, TE
Walsh-Chocolaad, TL
AF Stansfield, Lindsay
Hughes, Thomas E.
Walsh-Chocolaad, Tracey L.
TI Bosutinib: A Second-Generation Tyrosine Kinase Inhibitor for Chronic
Myelogenous Leukemia
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Review
DE bosutinib; tyrosine kinase inhibitor; CML
ID CHRONIC MYELOID-LEUKEMIA; IMATINIB; THERAPY; RECOMMENDATIONS;
RESISTANCE; DASATINIB; NILOTINIB; SKI-606; SAFETY
AB Objective: To review clinical trials and main characteristics of bosutinib, a second-generation tyrosine kinase inhibitor (TKI) for treatment of chronic myelogenous leukemia (CML). Data Sources: Pertinent data were identified through a search of PubMed (January 1990-April 2013) using the primary search terms SKI-606, bosutinib, and CML. Additionally, preliminary reports published in abstract form by the American Society of Clinical Oncology and American Society of Hematology (January 1990-April 2013) were screened for inclusion. Study Selection and Data Extraction: Clinical Phase 1, 2, and 3 studies reported in English evaluating the safety and efficacy of bosutinib in patients with CML were reviewed. Data Synthesis: Bosutinib is a TKI of the breakpoint cluster region/Abelson murine leukemia (BCR-ABL) gene approved by the Food and Drug Administration on September 4, 2012, for second-line treatment of chronic phase, accelerated phase, and blast phase CML. In the second-line setting, bosutinib is effective in some patients with CML resistant or intolerant to imatinib, dasatinib, and/or nilotinib, but it is not effective in patients whose disease expresses the T315I point mutation in BCR-ABL. Bosutinib also has been compared with imatinib, the standard first-line treatment, in 502 patients with newly diagnosed chronic phase CML in a Phase 3 trial. Complete cytogenetic response at 12 months, the primary efficacy end point, is similar between bosutinib and imatinib (p = 0.601); therefore, bosutinib is not indicated in the first-line setting. Common adverse events associated with bosutinib include diarrhea, nausea, and vomiting. Grade 3 and 4 adverse events reported in at least 5% of bosutinib-treated patients include elevated serum lipase and liver aminotransferases, anemia, thrombocytopenia, neutropenia, and diarrhea. Conclusions: Currently available clinical trials suggest that bosutinib is generally a safe and effective treatment option for patients with CML who have failed first-line TKIs and who do not express the T315I mutation; however, tolerability may be problematic for some patients.
C1 [Stansfield, Lindsay; Hughes, Thomas E.; Walsh-Chocolaad, Tracey L.] NIH, Ctr Clin, Bethesda, MD 20892 USA.
RP Stansfield, L (reprint author), NIH, Dept Pharm, Ctr Clin, Bldg 10, Bethesda, MD 20892 USA.
EM lindsay.stansfield@nih.gov
NR 28
TC 4
Z9 4
U1 2
U2 11
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1060-0280
EI 1542-6270
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD DEC
PY 2013
VL 47
IS 12
BP 1703
EP 1711
DI 10.1177/1060028013503124
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 287SU
UT WOS:000329563300013
PM 24396109
ER
PT J
AU Arterberry, ME
Bornstein, MH
Blumenstyk, JB
AF Arterberry, Martha E.
Bornstein, Marc H.
Blumenstyk, Julia B.
TI Categorization of two-dimensional and three-dimensional stimuli by
18-month-old infants
SO INFANT BEHAVIOR & DEVELOPMENT
LA English
DT Article
DE Categorization; 2D and 3D perception; Dual representation
ID YOUNG-CHILDREN; 3-MONTH-OLD INFANTS; PICTURE PERCEPTION; OBJECTS;
DISCRIMINATION; PHOTOGRAPHS; ATTRIBUTES; LEVEL; MODEL; REAL
AB In two experiments, 18-month-old infants' categorization of 3D replicas and 2D photographs of the same animals and vehicles were compared to explore infants' flexibility in categorization across different object representations. Using a sequential touching procedure, infants completed one superordinate and two basic-level categorization tasks with 3D replicas, 2D cut out photographs, or 2D images on photo cubes ("20 cubes"). For superordinate sets, 3D replicas elicited longer mean run lengths than 2D cut outs, and 3D replicas elicited equivalent mean run lengths as 2D cubes. For basic-level sets, infants categorized high-contrast animal sets when presented with 3D replicas, but they failed to categorize any of the 20 photograph sets. Categorization processes appear to differ for 3D and 2D stimuli, and infants' discovery of object properties over time while manipulating objects may facilitate categorization, as least at the superordinate level. These findings are discussed in the context of infants' representation abilities and the integration of perception and action. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Arterberry, Martha E.; Blumenstyk, Julia B.] Colby Coll, Dept Psychol, Waterville, ME 04901 USA.
[Bornstein, Marc H.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Dept Hlth & Human Serv, Bethesda, MD USA.
RP Arterberry, ME (reprint author), Colby Coll, Dept Psychol, 5553 Mayflower Hill, Waterville, ME 04901 USA.
EM Martha.Arterberry@colby.edu
FU Intramural NIH HHS [Z99 HD999999, ZIA HD001119-22]
NR 38
TC 0
Z9 0
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0163-6383
EI 1879-0453
J9 INFANT BEHAV DEV
JI Infant Behav. Dev.
PD DEC
PY 2013
VL 36
IS 4
BP 786
EP 795
DI 10.1016/j.infbeh.2013.09.008
PG 10
WC Psychology, Developmental
SC Psychology
GA 287OF
UT WOS:000329551400034
PM 24120992
ER
PT J
AU Pugach, MK
Suggs, C
Li, Y
Wright, JT
Kulkarni, AB
Bartlett, JD
Gibson, CW
AF Pugach, M. K.
Suggs, C.
Li, Y.
Wright, J. T.
Kulkarni, A. B.
Bartlett, J. D.
Gibson, C. W.
TI M180 Amelogenin Processed by MMP20 is Sufficient for Decussating Murine
Enamel
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE matrix metalloproteinase-20; knockout mouse; transgenic mouse;
amelogenesis; imperfecta; ameloblasts; tooth calcification
ID NULL MOUSE ENAMEL; DENTAL ENAMEL; IMPERFECTA PHENOTYPE; MICE DISPLAY;
MMP-20; MATRIX; EXPRESSION; PROTEINS; CLEAVAGE; RESCUE
AB Amelogenin (AMELX) and matrix metalloproteinase-20 (MMP20) are essential for proper enamel development. Amelx and Mmp20 mutations cause amelogenesis imperfecta. MMP20, a protease secreted by ameloblasts, is responsible for processing enamel proteins, including AMELX, during the secretory stage of enamel formation. Of at least 16 different amelogenin splice products, the most abundant isoform found in murine ameloblasts and developing enamel is the M180 protein. To understand the role of MMP20 processing of M180 AMELX, we generated AmelxKO/Mmp20KO (DKO) mice with an amelogenin (M180Tg) transgene. We analyzed the enamel phenotype by SEM to determine enamel structure and thickness, mu CT, and by nanoindentation to quantify enamel mechanical properties. M180Tg/DKO mouse enamel had 37% of the hardness of M180Tg/AmelxKO teeth and demonstrated a complete lack of normal prismatic architecture. Although molar enamel of M180Tg/AmelxKO mice was thinner than WT, it had similar mechanical properties and decussating enamel prisms, which were abolished by the loss of MMP20 in the M180Tg/DKO mice. Retention of the C-terminus or complete lack of this domain is unable to rescue amelogenin null enamel. We conclude that among amelogenins, M180 alone is sufficient for normal enamel mechanical properties and prism patterns, but that additional amelogenin splice products are required to restore enamel thickness.
C1 [Pugach, M. K.; Li, Y.; Gibson, C. W.] Univ Penn, Sch Dent Med, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA.
[Suggs, C.; Wright, J. T.] Univ N Carolina, Sch Dent, Chapel Hill, NC 27599 USA.
[Kulkarni, A. B.] Natl Inst Dent & Craniofacial Res, Funct Genom Sect, Lab Cell & Dev Biol, NIH, Bethesda, MD 20892 USA.
[Pugach, M. K.; Bartlett, J. D.] Harvard Univ, Sch Dent Med, Dept Mineralized Tissue Biol, Forsyth Inst, Cambridge, MA 02142 USA.
[Pugach, M. K.; Bartlett, J. D.] Harvard Univ, Sch Dent Med, Dept Dev Biol, Cambridge, MA 02142 USA.
RP Pugach, MK (reprint author), Univ Penn, Sch Dent Med, Dept Anat & Cell Biol, 240 S 40th St, Philadelphia, PA 19104 USA.
EM mpugach@forsyth.org
FU National Institutes of Health (NIDCR) [DE019968, DE011089, DE016276,
DE022624]
FX The authors thank Hui Xue from the University of Pennsylvania for
assistance with protein analysis and Zhorro Nikolov from the Centralized
Research Facilities at Drexel University for assistance with
nanoindentation. This research was supported by the National Institutes
of Health (NIDCR grants DE019968, DE011089, DE016276, DE022624). The
authors declare no potential conflicts of interest with respect to the
authorship and/or publication of this article.
NR 32
TC 4
Z9 5
U1 2
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-0345
EI 1544-0591
J9 J DENT RES
JI J. Dent. Res.
PD DEC
PY 2013
VL 92
IS 12
BP 1118
EP 1122
DI 10.1177/0022034513506444
PG 5
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 286SZ
UT WOS:000329490300012
PM 24072097
ER
PT J
AU Glaser, RL
Dimitrakakis, C
AF Glaser, Rebecca L.
Dimitrakakis, Constantine
TI Reduced breast cancer incidence in women treated with subcutaneous
testosterone, or testosterone with anastrozole: A prospective,
observational study
SO MATURITAS
LA English
DT Article
DE Testosterone; Anastrozole; Breast cancer; Prevention; Implants
ID SURGICALLY MENOPAUSAL WOMEN; ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL
WOMEN; ANDROGEN RECEPTOR; RANDOMIZED-TRIAL; HORMONE-THERAPY; SEXUAL
DESIRE; CELL-LINES; IN-SITU; RISK
AB Objectives: There is evidence that androgens are breast protective and that testosterone therapy treats many symptoms of hormone deficiency in both pre and postmenopausal patients. However, unlike estrogen and progestins, there is a paucity of data regarding the incidence of breast cancer in women treated with testosterone therapy. This study was designed to investigate the incidence of breast cancer in women treated with subcutaneous testosterone therapy in the absence of systemic estrogen therapy.
Study design: This is a 5-year interim analysis of a 10-year, prospective, observational, IRB approved study investigating the incidence of breast cancer in women presenting with symptoms of hormone deficiency treated with subcutaneous testosterone (T) implants or, T combined with the aromatase inhibitor anastrozole (A), i.e., T+A implants. Breast cancer incidence was compared with that of historical controls reported in the literature, age specific Surveillance Epidemiology and End
Results (SEER) incidence rates, and a representative, similar age group of our patients used as a 'control' group. The effect of adherence to T therapy was also evaluated. Results: Since March 2008, 1268 pre and post menopausal women have been enrolled in the study and eligible for analysis. As of March 2013, there have been 8 cases of invasive breast cancer diagnosed in 5642 person-years of follow up for an incidence of 142 cases per 100 000 person-years, substantially less than the age-specific SEER incidence rates (293/100 000), placebo arm of Women's Health Initiative Study (300/100000), never users of hormone therapy from the Million Women Study (325/100 000) and our control group (390/100 000). Unlike adherence to estrogen therapy, adherence to T therapy further decreased the incidence of breast cancer (73/100 000).
Conclusion: T and/or T+A, delivered subcutaneously as a pellet implant, reduced the incidence of breast cancer in pre and postmenopausal women. Evidence supports that breast cancer is preventable by maintaining a T to estrogen ratio in favor of T and, in particular, by the use of continuous T or, when indicated, T+A. This hormone therapy should be further investigated for the prevention and treatment of breast cancer. (C) 2013 The Authors. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Glaser, Rebecca L.] Millennium Wellness Ctr, Dayton, OH 45458 USA.
[Glaser, Rebecca L.] Wright State Univ, Boonshoft Sch Med, Dept Surg, Dayton, OH 45435 USA.
[Dimitrakakis, Constantine] Univ Athens, Sch Med, Dept Ob Gyn 1, Athens 11528, Greece.
[Dimitrakakis, Constantine] NICHD, NIH, Bethesda, MD 20892 USA.
RP Glaser, RL (reprint author), Millennium Wellness Ctr, 228 E Spring Valley Rd, Dayton, OH 45458 USA.
EM rglaser@woh.rr.com
NR 62
TC 9
Z9 9
U1 0
U2 2
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0378-5122
EI 1873-4111
J9 MATURITAS
JI Maturitas
PD DEC
PY 2013
VL 76
IS 4
BP 342
EP 349
DI 10.1016/j.maturitas.2013.08.002
PG 8
WC Geriatrics & Gerontology; Obstetrics & Gynecology
SC Geriatrics & Gerontology; Obstetrics & Gynecology
GA 283UQ
UT WOS:000329272900010
PM 24028858
ER
PT J
AU Siu, FM
Pommier, Y
AF Siu, Fung-Ming
Pommier, Yves
TI Sequence selectivity of the cleavage sites induced by topoisomerase I
inhibitors: a molecular dynamics study
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID FREE-ENERGY DECOMPOSITION; N-TERMINAL DOMAIN; CAMPTOTHECIN DERIVATIVES;
DNA CLEAVAGE; LINKER DOMAIN; CRYSTAL-STRUCTURES; DRUG-RESISTANCE;
ANTICANCER DRUG; SINGLE MUTATION; ENZYME-ACTIVITY
AB Topoisomerase IB (Top1) inhibitors, such as camptothecin (CPT), stabilize the Top1-DNA cleavage complex in a DNA sequence-dependent manner. The sequence selectivity of Top1 inhibitors is important for targeting specific genomic sequences of therapeutic value. However, the molecular mechanisms underlying this selectivity remain largely unknown. We performed molecular dynamics simulations to delineate structural, dynamic and energetic features that contribute to the differential sequence selectivity of the Top1 inhibitors. We found the sequence selectivity of CPT to be highly correlated with the drug binding energies, dynamic and structural properties of the linker domain. Chemical insights, gained by per-residue binding energy analysis revealed that the non-polar interaction between CPT and nucleotide at the +1 position of the cleavage site was the major (favorable) contributor to the total binding energy. Mechanistic insights gained by a potential of mean force analysis implicated that the drug dissociation step was associated with the sequence selectivity. Pharmaceutical insights gained by our molecular dynamics analyses explained why LMP-776, an indenoisoquinoline derivative under clinical development at the National Institutes of Health, displays different sequence selectivity when compared with camptothecin and its clinical derivatives.
C1 [Siu, Fung-Ming] Chinese Acad Sci, Ctr High Performance Comp, Inst Adv Comp & Digital Engn, Shenzhen Inst Adv Technol, Shenzhen 518055, Peoples R China.
[Siu, Fung-Ming] Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China.
[Siu, Fung-Ming] Univ Hong Kong, Inst Mol Technol Drug Discovery & Synth, State Key Lab Synthet Chem, Hong Kong, Hong Kong, Peoples R China.
[Pommier, Yves] NCI, Mol Pharmacol Lab, Ctr Canc Res, Bethesda, MD 20892 USA.
RP Siu, FM (reprint author), Chinese Acad Sci, Ctr High Performance Comp, Inst Adv Comp & Digital Engn, Shenzhen Inst Adv Technol, 1068 Xueyuan Blvd, Shenzhen 518055, Peoples R China.
EM xiao.fm@siat.ac.cn; pommier@nih.gov
FU Center of Cancer Research, National Cancer Institute Intramural Program
at the National Institutes of Health (US Government); National Science
Foundation of China (NSFC) [21203237]; Shenzhen Basic Research Grant;
Committee on Research and Conference Grants (CRCR) of the University of
Hong Kong [JCYJ20130401170306875]; Areas of Excellence Scheme
[AoE/P-10/01]; Innovation and Technology Fund [ITF-Tier 2]
[ITS/134/09FP]; National Key Basic Research Program of China
[2013CB834802]; Special Equipment Grant [SEG HKU09]; University
Development Fund; Strategic Research Fund; Shenzhen Institutes of
Advanced Technology, Chinese Academy of Sciences; NSFC [21203237];
Shenzhen Basic Research Grant [JCYJ20130401170306875]
FX Center of Cancer Research, National Cancer Institute Intramural Program
at the National Institutes of Health (US Government); National Science
Foundation of China (NSFC), [21203237] and Shenzhen Basic Research
Grant; [JCYJ20130401170306875] seed funding from the Committee on
Research and Conference Grants (CRCR) of the University of Hong Kong;
the Areas of Excellence Scheme administrated by the University Grants
Committee of the Hong Kong Special Administrative Region, China
[AoE/P-10/01], Innovation and Technology Fund [ITF-Tier 2,
ITS/134/09FP]; National Key Basic Research Program of China
[2013CB834802]; Special Equipment Grant [SEG HKU09]; University
Development Fund and Strategic Research Fund. Funding for open access
charge: Shenzhen Institutes of Advanced Technology, Chinese Academy of
Sciences; NSFC [21203237]; and Shenzhen Basic Research Grant
[JCYJ20130401170306875].
NR 78
TC 7
Z9 7
U1 0
U2 19
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD DEC
PY 2013
VL 41
IS 22
BP 10010
EP 10019
DI 10.1093/nar/gkt791
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 292AQ
UT WOS:000329874400009
PM 24021629
ER
PT J
AU Lormand, JD
Buncher, N
Murphy, CT
Kaur, P
Lee, MY
Burgers, P
Wang, H
Kunkel, TA
Opresko, PL
AF Lormand, Justin D.
Buncher, Noah
Murphy, Connor T.
Kaur, Parminder
Lee, Marietta Y.
Burgers, Peter
Wang, Hong
Kunkel, Thomas A.
Opresko, Patricia L.
TI DNA polymerase delta stalls on telomeric lagging strand templates
independently from G-quadruplex formation
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID WERNER-SYNDROME HELICASE; ATOMIC-FORCE MICROSCOPY;
SACCHAROMYCES-CEREVISIAE; MAMMALIAN TELOMERES; REPLICATION FORK;
STRUCTURAL BASIS; FRAGILE SITES; BLM HELICASE; HUMAN-CELLS; SEQUENCE
AB Previous evidence indicates that telomeres resemble common fragile sites and present a challenge for DNA replication. The precise impediments to replication fork progression at telomeric TTAGGG repeats are unknown, but are proposed to include G-quadruplexes (G4) on the G-rich strand. Here we examined DNA synthesis and progression by the replicative DNA polymerase d/proliferating cell nuclear antigen/replication factor C complex on telomeric templates that mimic the leading C-rich and lagging G-rich strands. Increased polymerase stalling occurred on the G-rich template, compared with the C-rich and nontelomeric templates. Suppression of G4 formation by substituting Li+ for K+ as the cation, or by using templates with 7-deaza-G residues, did not alleviate Pol delta pause sites within the G residues. Furthermore, we provide evidence that G4 folding is less stable on single-stranded circular TTAGGG templates where ends are constrained, compared with linear oligonucleotides. Artificially stabilizing G4 structures on the circular templates with the G4 ligand BRACO-19 inhibited Pol d progression into the G-rich repeats. Similar results were obtained for yeast and human Pol d complexes. Our data indicate that G4 formation is not required for polymerase stalling on telomeric lagging strands and suggest that an
C1 [Lormand, Justin D.; Buncher, Noah; Murphy, Connor T.; Opresko, Patricia L.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15219 USA.
[Kaur, Parminder; Wang, Hong] N Carolina State Univ, Dept Phys, Raleigh, NC 27695 USA.
[Lee, Marietta Y.] New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.
[Burgers, Peter] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.
[Kunkel, Thomas A.] NIEHS, Mol Genet Lab, NIH, DHHS, Res Triangle Pk, NC 27709 USA.
[Kunkel, Thomas A.] NIEHS, Struct Biol Lab, NIH, DHHS, Res Triangle Pk, NC 27709 USA.
RP Opresko, PL (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, 100 Technol Dr, Pittsburgh, PA 15219 USA.
EM plo4@pitt.edu
RI Wang, Hong/F-3164-2014;
OI Wang, Hong/0000-0003-0165-3559; Opresko, Patricia/0000-0002-6470-2189
FU NIH [R01ES0515052, R01GM032431, R00ES016758, R01GM031973]; Division of
Intramural Research of the National Institutes of Health, NIEHS [Z01
ES065070]
FX NIH [R01ES0515052 to P.L.O., R01GM032431 to P. M. B., R00ES016758 to H.
W., R01GM031973 to M.Y.L.] (in part); Division of Intramural Research of
the National Institutes of Health, NIEHS [Z01 ES065070 to T. A. K.].
Funding for open access charge: Scaife Foundation through the Center for
Nucleic Acids Science and Technology at Carnegie Mellon University (to
P.L.O.).
NR 62
TC 12
Z9 12
U1 2
U2 21
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD DEC
PY 2013
VL 41
IS 22
BP 10323
EP 10333
DI 10.1093/nar/gkt813
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 292AQ
UT WOS:000329874400032
PM 24038470
ER
PT J
AU Barabas, O
Nemeth, V
Bodor, A
Perczel, A
Rosta, E
Kele, Z
Zagyva, I
Szabadka, Z
Grolmusz, VI
Wilmanns, M
Vertessy, BG
AF Barabas, Orsolya
Nemeth, Veronika
Bodor, Andrea
Perczel, Andras
Rosta, Edina
Kele, Zoltan
Zagyva, Imre
Szabadka, Zoltan
Grolmusz, Vince I.
Wilmanns, Matthias
Vertessy, Beata G.
TI Catalytic mechanism of alpha-phosphate attack in dUTPase is revealed by
X-ray crystallographic snapshots of distinct intermediates, P-31-NMR
spectroscopy and reaction path modelling
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID INFECTIOUS-ANEMIA VIRUS; DEOXYURIDINE TRIPHOSPHATASE INHIBITORS;
PLASMODIUM-FALCIPARUM DUTPASE; PHOSPHORYL TRANSFER-REACTION;
ESCHERICHIA-COLI DUTPASE; FREE-ENERGY CALCULATIONS; ACTIVE-SITE;
CRYSTAL-STRUCTURE; SUBSTRATE-ANALOG; KINETIC CHARACTERIZATION
AB Enzymatic synthesis and hydrolysis of nucleoside phosphate compounds play a key role in various biological pathways, like signal transduction, DNA synthesis and metabolism. Although these processes have been studied extensively, numerous key issues regarding the chemical pathway and atomic movements remain open for many enzymatic reactions. Here, using the Mason-Pfizer monkey retrovirus dUTPase, we study the dUTPase-catalyzed hydrolysis of dUTP, an incorrect DNA building block, to elaborate the mechanistic details at high resolution. Combining mass spectrometry analysis of the dUTPase-catalyzed reaction carried out in (H2O)-O-18 and quantum mechanics/molecular mechanics (QM/MM) simulation, we show that the nucleophilic attack occurs at the a-phosphate site. Phosphorus-31 NMR spectroscopy (P-31-NMR) analysis confirms the site of attack and shows the capability of dUTPase to cleave the dUTP analogue alpha,beta-imido-dUTP, containing the imido linkage usually regarded to be non-hydrolyzable. We present numerous X-ray crystal structures of distinct dUTPase and nucleoside phosphate complexes, which report on the progress of the chemical reaction along the reaction coordinate. The presently used combination of diverse structural methods reveals details of the nucleophilic attack and identifies a novel enzyme-product complex structure.
C1 [Barabas, Orsolya; Nemeth, Veronika; Zagyva, Imre; Vertessy, Beata G.] Hungarian Acad Sci, Res Ctr Nat Sci, Inst Enzymol, Lab Genome Metab, H-1113 Budapest, Hungary.
[Barabas, Orsolya] NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
[Barabas, Orsolya] European Mol Biol Lab, Struct & Computat Biol Unit, D-69117 Heidelberg, Germany.
[Bodor, Andrea; Perczel, Andras] Eotvos Lorand Univ, Inst Chem, Lab Struct Chem & Biol, H-1117 Budapest, Hungary.
[Perczel, Andras] Eotvos Lorand Univ, Inst Chem, Prot Modelling Grp MTA ELTE, H-1117 Budapest, Hungary.
[Rosta, Edina] Kings Coll London, Dept Chem, London SE1 1UL, England.
[Kele, Zoltan] Univ Szeged, Dept Med Chem, Szeged, Hungary.
[Szabadka, Zoltan; Grolmusz, Vince I.] Eotvos Lorand Univ, Dept Comp Sci, Budapest, Hungary.
[Wilmanns, Matthias] Hamburg Outstn, European Mol Biol Lab, D-22603 Hamburg, Germany.
[Vertessy, Beata G.] Budapest Univ Technol & Econ, Dept Appl Biotechnol & Food Sci, Budapest, Hungary.
RP Vertessy, BG (reprint author), Hungarian Acad Sci, Res Ctr Nat Sci, Inst Enzymol, Lab Genome Metab, H-1113 Budapest, Hungary.
EM barabas@embl.de; vertessy@enzim.hu
RI Barabas, Orsolya/F-3961-2012; Vertessy, Beata/H-6202-2012;
OI Barabas, Orsolya/0000-0002-2873-5872; Wilmanns,
Matthias/0000-0002-4643-5435; Rosta, Edina/0000-0002-9823-4766
FU Hungarian Scientilic Research Fund [OTKA K68229, OTKA-A08 CK78646, OTKA
NK-84008]; New Hungary Development Plan
[TAMOP-4.2.1/B-09/1/KMR-2010-0002]; Baross ID:3DSTRUCT [OMFB-00266/2010
REG-KM-09-1-2009-0050]; Howard Hughes Medical Institutes [55005628,
55000342]; Bolyai fellowship; EU [OTKA NK101072]; NIDDK; NIH; European
Molecular Biology Laboratory; [HPMT-CT-20000-00174]
FX Supported by the Hungarian Scientilic Research Fund [OTKA K68229,
OTKA-A08 CK78646, OTKA NK-84008]; the New Hungary Development Plan
[TAMOP-4.2.1/B-09/1/KMR-2010-0002 and Baross ID:3DSTRUCT,
OMFB-00266/2010 REG-KM-09-1-2009-0050]; the Howard Hughes Medical
Institutes [#55005628 and #55000342, USA, to B.G.V.]; Bolyai fellowship
(to B.A.); [HPMT-CT-20000-00174. EU, to O.B., OTKA NK101072 to A.P.]:
and the Intramural Program of the NIDDK, NIH (to O.B. and E.R.). Funding
for open access charge: European Molecular Biology Laboratory.
NR 91
TC 6
Z9 6
U1 0
U2 24
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD DEC
PY 2013
VL 41
IS 22
BP 10542
EP 10555
DI 10.1093/nar/gkt756
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 292AQ
UT WOS:000329874400050
PM 23982515
ER
PT J
AU Li, XT
Thomason, LC
Sawitzke, JA
Costantino, N
Court, DL
AF Li, Xin-tian
Thomason, Lynn C.
Sawitzke, James A.
Costantino, Nina
Court, Donald L.
TI Positive and negative selection using the tetA-sacB cassette:
recombineering and P1 transduction in Escherichia coli
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID COMPLETE GENOME SEQUENCE; BACILLUS-SUBTILIS; HOMOLOGOUS RECOMBINATION;
TETRACYCLINE RESISTANCE; STRUCTURAL GENE; CHROMOSOME; EFFICIENT;
LEVANSUCRASE; BACTERIA; EXCHANGE
AB The two-step process of selection and counter-selection is a standard way to enable genetic modification and engineering of bacterial genomes using homologous recombination methods. The tetA and sacB genes are contained in a DNA cassette and confer a novel dual counter-selection system. Expression of tetA confers bacterial resistance to tetracycline (Tc-R) and also causes sensitivity to the lipophillic chelator fusaric acid; sacB causes sensitivity to sucrose. These two genes are introduced as a joint DNA cassette into Escherichia coli by selection for Tc-R. A medium containing both fusaric acid and sucrose has been developed, in which, coexpression of tetA-sacB is orders of magnitude more sensitive as a counter-selection agent than either gene alone. In conjunction with the homologous recombination methods of recombineering and P1 transduction, this powerful system has been used to select changes in the bacterial genome that cannot be directly detected by other counter-selection systems.
C1 [Li, Xin-tian; Thomason, Lynn C.; Sawitzke, James A.; Costantino, Nina; Court, Donald L.] NCI, Mol Control & Genet Sect, NIH, Frederick, MD 21702 USA.
[Thomason, Lynn C.] Leidos Biomed Res Inc, Frederick Natl Lab, Frederick, MD 21702 USA.
RP Court, DL (reprint author), NCI, Mol Control & Genet Sect, NIH, Frederick, MD 21702 USA.
EM courtd@mail.nih.gov
FU NIH, National Cancer Institute, Center for Cancer Research; National
Cancer Institute, National Institutes of Health [HHSN261200800001E];
Intramural Research Program of the NIH, National Cancer Institute,
Center for Cancer Research
FX Intramural Research Program of the NIH, National Cancer Institute,
Center for Cancer Research (in part); federal funds from the National
Cancer Institute, National Institutes of Health, under contract
[HHSN261200800001E] (in part); The content of this publication does not
necessarily reflect the views or policies of the Department of Health
and Human Services, nor does mention of trade names, commercial products
or organizations imply endorsement by the US Government. Funding for
open access charge: This research is funded by the Intramural Research
Program of the NIH, National Cancer Institute, Center for Cancer
Research.
NR 31
TC 15
Z9 18
U1 4
U2 28
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD DEC
PY 2013
VL 41
IS 22
AR e204
DI 10.1093/nar/gkt1075
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 292AQ
UT WOS:000329874400003
PM 24203710
ER
PT J
AU Cui, Y
Gao, YT
Cai, QY
Qu, SM
Cai, H
Li, HL
Wu, J
Ji, BT
Yang, G
Chow, WH
Shu, XO
Zheng, W
AF Cui, Yong
Gao, Yu-Tang
Cai, Qiuyin
Qu, Shimian
Cai, Hui
Li, Hong-Lan
Wu, Jie
Ji, Bu-Tian
Yang, Gong
Chow, Wong-Ho
Shu, Xiao-Ou
Zheng, Wei
TI Associations of leukocyte telomere length with body anthropometric
indices and weight change in chinese women
SO OBESITY
LA English
DT Article
ID CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; RISK-FACTORS; OBESITY;
ADIPOSITY; GAIN
AB Objective: This study evaluated associations of telomere length with various anthropometric indices of general and abdominal obesity, as well as weight change. Design and Methods: The study included 2,912 Chinese women aged 40-70 years. Monochrome multiplex quantitative polymerase chain reaction was applied to measure relative telomere length. Results: Telomere length was inversely associated with body mass index (BMI), waist circumference, waist-to-height ratio, weight, and hip circumference (Ptrend = 0.005, 0.004, 0.004, 0.010, and 0.026, respectively), but not waist-to-hip ratio (Ptrend = 0.116) or height (Ptrend = 0.675). Weight change since age 50 was further evaluated among women over age 55. Women who maintained their weight within +/- 5% since age 50, particularly within a normal range (BMI = 18.5-24.9 kg/m2), or reduced their weight from overweight (BMI = 25-29.9 kg/m2) or obesity (BMI 30 kg/m2) to normal range, had a longer mean of current telomere length than women who gained weight since age 50 (Ptrend = 0.025), particularly those who stayed in obesity or gained weight from normal range or overweight to obesity (P = 0.023). Conclusion: Our findings show that telomere shortening is associated with obesity and that maintaining body weight within a normal range helps maintain telomere length.
C1 [Cui, Yong; Cai, Qiuyin; Qu, Shimian; Cai, Hui; Wu, Jie; Yang, Gong; Shu, Xiao-Ou; Zheng, Wei] Vanderbilt Univ, Med Ctr, Dept Med, Div Epidemiol, Nashville, TN 37203 USA.
[Cui, Yong; Cai, Qiuyin; Qu, Shimian; Cai, Hui; Wu, Jie; Yang, Gong; Shu, Xiao-Ou; Zheng, Wei] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Gao, Yu-Tang; Li, Hong-Lan] Shanghai Canc Inst, Dept Epidemiol, Shanghai, Peoples R China.
[Chow, Wong-Ho] NCI, Occupat Epidemiol Branch, NIH, Bethesda, MD 20892 USA.
RP Zheng, W (reprint author), Vanderbilt Univ, Med Ctr, Dept Med, Div Epidemiol, Nashville, TN 37203 USA.
EM wei.zheng@vanderbilt.edu; wei.zheng@vanderbilt.edu
FU NIH [R37 CA 070867]
FX Funding support for this work was provided by NIH grant (R37 CA 070867).
NR 29
TC 7
Z9 7
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD DEC
PY 2013
VL 21
IS 12
BP 2582
EP 2588
DI 10.1002/oby.20321
PG 7
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 288LT
UT WOS:000329614200059
PM 23408544
ER
PT J
AU Mason, C
Risques, RA
Xiao, LR
Duggan, CR
Imayama, I
Campbell, KL
Kong, A
Foster-Schubert, KE
Wang, CY
Alfano, CM
Blackburn, GL
Rabinovitch, PS
McTiernan, A
AF Mason, Caitlin
Risques, Rosa-Ana
Xiao, Liren
Duggan, Catherine R.
Imayama, Ikuyo
Campbell, Kristin L.
Kong, Angela
Foster-Schubert, Karen E.
Wang, C. Y.
Alfano, Catherine M.
Blackburn, George L.
Rabinovitch, Peter S.
McTiernan, Anne
TI Independent and combined effects of dietary weight loss and exercise on
leukocyte telomere length in postmenopausal women
SO OBESITY
LA English
DT Article
ID CARDIOVASCULAR-DISEASE; OXIDATIVE STRESS; ASSOCIATION; CANCER; RISK;
POPULATION; MORTALITY; OBESITY; ADULTS; HEART
AB Objective Investigate the effects of 12 months of dietary weight loss and/or aerobic exercise on leukocyte telomere length in postmenopausal women. Design and Methods Four hundred and thirty nine overweight or obese women (50-75 years) were randomized to: (i) dietary weight loss (N = 118); (ii) aerobic exercise (N = 117), (iii) diet + exercise (N = 117), or (iv) control (N = 87). The diet intervention was a group-based program with a 10% weight loss goal. The exercise intervention was 45 min day-1, 5 days week-1 of moderate-to-vigorous aerobic activity. Fasting blood samples were taken at baseline and 12 months. DNA was extracted from isolated leukocytes and telomere length was measured by quantitative-polymerase chain reaction (qPCR). Mean changes were compared between groups (intent-to-treat) using generalized estimating equations. Results Baseline telomere length was inversely associated with age (r = -0.12 P < 0.01) and positively associated with maximal oxygen uptake (r = 0.11, P = 0.03), but not with BMI or %body fat. Change in telomere length was inversely correlated with baseline telomere length (r = -0.47, P < 0.0001). No significant difference in leukocyte telomere length was detected in any intervention group compared to controls, nor was the magnitude of weight loss associated with telomere length at 12 months. Conclusions Twelve months of dietary weight loss and exercise did not change telomere length in postmenopausal women.
C1 [Mason, Caitlin; Xiao, Liren; Duggan, Catherine R.; Imayama, Ikuyo; Wang, C. Y.; McTiernan, Anne] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
[Risques, Rosa-Ana; Wang, C. Y.; Rabinovitch, Peter S.; McTiernan, Anne] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Campbell, Kristin L.] Univ British Columbia, Dept Phys Therapy, Vancouver, BC V5Z 1M9, Canada.
[Kong, Angela] Univ Illinois, Sch Publ Hlth, Inst Hlth Res & Policy, Chicago, IL USA.
[Foster-Schubert, Karen E.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA.
[Alfano, Catherine M.] NCI, Off Canc Survivorship, Bethesda, MD 20892 USA.
[Blackburn, George L.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Nutr, Boston, MA 02215 USA.
RP Mason, C (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA.
RI Duggan, Catherine/F-9414-2015
OI Duggan, Catherine/0000-0001-7369-4021
FU National Cancer Institute at the National Institutes of Health [R01
CA102504, U54-CA116847, 5KL2RR025015-03, R25 CA94880, 2R25CA057699-16];
Canadian Institutes of Health Research
FX This work was supported by the National Cancer Institute at the National
Institutes of Health (grant number: R01 CA102504, U54-CA116847,
5KL2RR025015-03 to K.F.S, R25 CA94880 and 2R25CA057699-16 to A.K.); and
the Canadian Institutes of Health Research (Fellowship to K.L.C & C.M).
None of the funding agencies were involved in the trial design or
conduct. While working on the trial, Dr. Alfano was employed at The Ohio
State University, and located to NCI following completion of her effort
on the NEW trial.
NR 34
TC 17
Z9 17
U1 0
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD DEC
PY 2013
VL 21
IS 12
BP E549
EP E554
DI 10.1002/oby.20509
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 288LT
UT WOS:000329614200004
PM 23640743
ER
PT J
AU Perkins, TA
Scott, TW
Le Menach, A
Smith, DL
AF Perkins, T. Alex
Scott, Thomas W.
Le Menach, Arnaud
Smith, David L.
TI Heterogeneity, Mixing, and the Spatial Scales of Mosquito-Borne Pathogen
Transmission
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID MALARIA TRANSMISSION; POPULATION-DYNAMICS; ANOPHELES-GAMBIAE; HUMAN
MOVEMENT; SIMULATION-MODEL; FOREST MALARIA; WESTERN KENYA; DENGUE;
CULICIDAE; DIPTERA
AB The Ross-Macdonald model has dominated theory for mosquito-borne pathogen transmission dynamics and control for over a century. The model, like many other basic population models, makes the mathematically convenient assumption that populations are well mixed; i.e., that each mosquito is equally likely to bite any vertebrate host. This assumption raises questions about the validity and utility of current theory because it is in conflict with preponderant empirical evidence that transmission is heterogeneous. Here, we propose a new dynamic framework that is realistic enough to describe biological causes of heterogeneous transmission of mosquito-borne pathogens of humans, yet tractable enough to provide a basis for developing and improving general theory. The framework is based on the ecological context of mosquito blood meals and the fine-scale movements of individual mosquitoes and human hosts that give rise to heterogeneous transmission. Using this framework, we describe pathogen dispersion in terms of individual-level analogues of two classical quantities: vectorial capacity and the basic reproductive number, R-0. Importantly, this framework explicitly accounts for three key components of overall heterogeneity in transmission: heterogeneous exposure, poor mixing, and finite host numbers. Using these tools, we propose two ways of characterizing the spatial scales of transmissionpathogen dispersion kernels and the evenness of mixing across scales of aggregationand demonstrate the consequences of a model's choice of spatial scale for epidemic dynamics and for estimation of R-0, both by a priori model formulas and by inference of the force of infection from time-series data.
C1 [Perkins, T. Alex; Scott, Thomas W.; Smith, David L.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA.
[Perkins, T. Alex; Scott, Thomas W.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA.
[Le Menach, Arnaud; Smith, David L.] Ctr Dis Dynam Econ & Policy, Washington, DC USA.
[Smith, David L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
RP Perkins, TA (reprint author), NIH, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA.
EM taperkins@ucdavis.edu
FU Research and Policy for Infectious Disease Dynamics (RAPIDD) program of
the Science and Technology Directory; Department of Homeland Security;
Fogarty International Center, National Institutes of Health; Bill and
Melinda Gates Foundation [49446, OPP52250]; Bloomberg Family Foundation
FX This work was supported by the Research and Policy for Infectious
Disease Dynamics (RAPIDD) program of the Science and Technology
Directory, Department of Homeland Security, and Fogarty International
Center, National Institutes of Health. DLS and ALM (49446) and TWS
(OPP52250) acknowledge funding from the Bill and Melinda Gates
Foundation. DLS (U19AI089674) and TWS (R01 AI069341) acknowledge funding
from the NIH/NIAID. DLS acknowledges funding from the Bloomberg Family
Foundation. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 86
TC 37
Z9 37
U1 3
U2 32
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD DEC
PY 2013
VL 9
IS 12
AR e1003327
DI 10.1371/journal.pcbi.1003327
PG 16
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA 285AM
UT WOS:000329364800006
PM 24348223
ER
PT J
AU Xue, X
Hall, MD
Zhang, Q
Wang, PC
Gottesman, MM
Liang, XJ
AF Xue, Xue
Hall, Matthew D.
Zhang, Qiang
Wang, Paul C.
Gottesman, Michael M.
Liang, Xing-Jie
TI Nanoscale Drug Delivery Platforms Overcome Platinum-Based Resistance in
Cancer Cells Due to Abnormal Membrane Protein Trafficking
SO ACS NANO
LA English
DT Review
DE cancer; cisplatin; drug resistance; nanoscale drug delivery platforms;
membrane trafficking; nanotechnology; chemotherapy; abnormal membrane
proteins
ID PLGA-PEG NANOPARTICLES; DNA-DAMAGING AGENTS; CISPLATIN-RESISTANCE;
MULTIDRUG-RESISTANCE; COPPER TRANSPORTER; TUMOR-CELLS; PT(IV) PRODRUG;
P-GLYCOPROTEIN; BREAST-CANCER; LUNG-CANCER
AB The development of cellular resistance to platinum-based chemotherapies is often associated with reduced intracellular platinum concentrations. In some models, this reduction is due to abnormal membrane protein trafficking, resulting in reduced uptake by transporters at the cell surface. Given the central role of platinum drugs in the clinic, it is critical to overcome cisplatin resistance by bypassing the plasma membrane barrier to significantly increase the intracellular cisplatin concentration enough to inhibit the proliferation of cisplatin-resistant cells. Therefore, rational design of appropriate nanoscale drug delivery platforms (nDDPs) loaded with cisplatin or other platinum analogues as payloads is a possible strategy to solve this problem. This review will focus on the known mechanism of membrane trafficking in cisplatin-resistant cells and the development and employment of nDDPs to improve cell uptake of cisplatin.
C1 [Xue, Xue; Liang, Xing-Jie] Natl Ctr Nanosci & Technol China, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China.
[Xue, Xue; Zhang, Qiang] Peking Univ, Sch Pharmaceut Sci, Dept Pharmaceut, Beijing 100191, Peoples R China.
[Hall, Matthew D.; Gottesman, Michael M.] NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Wang, Paul C.] Howard Univ, Dept Radiol, Mol Imaging Lab, Washington, DC 20060 USA.
RP Gottesman, MM (reprint author), NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bldg 37, Bethesda, MD 20892 USA.
EM mgottesman@nih.gov; liangxj@nanoctr.cn
FU National Natural Science Foundation for Distinguished Young Scholars of
China [31225009]; National Science and Technology support program
[2012BAF13B05]; National Natural Science Foundation of China [81171455];
National Key Basic Research Program of China [2009CB930200]; Chinese
Academy of Sciences (CAS) "Hundred Talents Program"; Intramural Research
Program of the National Institutes of Health, National Cancer Institute
FX This work was financially supported in part by grants from the National
Natural Science Foundation for Distinguished Young Scholars of China
(No.31225009), National Science and Technology support program (No.
2012BAF13B05), National Natural Science Foundation of China project (No.
81171455), National Key Basic Research Program of China (2009CB930200),
and the Chinese Academy of Sciences (CAS) "Hundred Talents Program".
This research was also partially supported by the Intramural Research
Program of the National Institutes of Health, National Cancer Institute.
We thank George Leiman for editorial assistance. We would also like to
thank Dr. Teni Boulikas for allowing us to adapt her figure for Figure
2B. We also thank Dr. Juan Liu to advance the TOC and Figure 2.
NR 144
TC 35
Z9 35
U1 92
U2 526
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD DEC
PY 2013
VL 7
IS 12
BP 10452
EP 10464
DI 10.1021/nn405004f
PG 13
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 281YO
UT WOS:000329137100004
PM 24219825
ER
PT J
AU Gomez, PMS
Amano, M
Yashchuk, S
Mizuno, A
Das, D
Ghosh, AK
Mitsuya, H
AF Gomez, Pedro Miguel Salcedo
Amano, Masayuki
Yashchuk, Sofiya
Mizuno, Akira
Das, Debananda
Ghosh, Arun K.
Mitsuya, Hiroaki
TI GRL-04810 and GRL-05010, Difluoride-Containing Nonpeptidic HIV-1
Protease Inhibitors (PIs) That Inhibit the Replication of
Multi-PI-Resistant HIV-1 In Vitro and Possess Favorable Lipophilicity
That May Allow Blood-Brain Barrier Penetration
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM; ACTIVE
ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; DRUG-RESISTANCE;
NEUROCOGNITIVE DISORDERS; POTENT; VARIANTS; RESERVOIRS; LIGAND
AB We designed, synthesized, and identified two novel nonpeptidic human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs), GRL-04810 and GRL-05010, containing the structure-based designed privileged cyclic ether-derived nonpeptide P2 ligand, bis-tetrahydrofuranylurethane (bis-THF), and a difluoride moiety, both of which are active against the laboratory strain HIV-1(LAI) (50% effective concentrations [EC(50)s], 0.0008 and 0.003 mu M, respectively) with minimal cytotoxicity (50% cytotoxic concentrations [CC(50)s], 17.5 and 37.0 mu M, respectively, in CD4(+) MT-2 cells). The two compounds were active against multi-PI-resistant clinical HIV-1 variants isolated from patients who had no response to various antiviral regimens. GRL-04810 and GRL-05010 also blocked the infectivity and replication of each of the HIV-1NL4-3 variants selected by up to 5 mu M lopinavir (EC(50)s, 0.03 and 0.03 mu M, respectively) and atazanavir (EC(50)s, 0.02 and 0.04 mu M, respectively). Moreover, they were active against darunavir (DRV)-resistant variants (EC50 in 0.03 to 0.034 mu M range for GRL-04810 and 0.026 to 0.043 mu M for GRL-05010), while DRV had EC(50)s between 0.02 and 0.174 mu M. GRL-04810 had a favorable lipophilicity profile as determined with the partition (log P) and distribution (log D) coefficients of -0.14 and -0.29, respectively. The in vitro blood-brain barrier (BBB) permeability assay revealed that GRL-04810 and GRL-05010 may have a greater advantage in terms of crossing the BBB than the currently available PIs, with apparent penetration indexes of 47.8 x 10(-6) and 61.8 x 10(-6) cm/s, respectively. The present data demonstrate that GRL-04810 and GRL-05010 exert efficient activity against a wide spectrum of HIV-1 variants in vitro and suggest that two fluorine atoms added to their bis-THF moieties may well enhance their penetration across the BBB.
C1 [Gomez, Pedro Miguel Salcedo; Amano, Masayuki; Mitsuya, Hiroaki] Kumamoto Univ, Sch Med, Dept Infect Dis, Kumamoto 860, Japan.
[Gomez, Pedro Miguel Salcedo; Amano, Masayuki; Mitsuya, Hiroaki] Kumamoto Univ, Sch Med, Dept Hematol, Kumamoto 860, Japan.
[Yashchuk, Sofiya; Mizuno, Akira; Ghosh, Arun K.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
[Yashchuk, Sofiya; Mizuno, Akira; Ghosh, Arun K.] Purdue Univ, Dept Med Chem, W Lafayette, IN 47907 USA.
[Das, Debananda; Mitsuya, Hiroaki] NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA.
RP Amano, M (reprint author), Kumamoto Univ, Sch Med, Dept Infect Dis, Kumamoto 860, Japan.
EM mamano@kumamoto-u.ac.jp
RI Amano, Masayuki/N-7407-2016
OI Amano, Masayuki/0000-0003-0516-9502
FU Monbu-Kagakusho; Promotion of AIDS Research from the Ministry of Health,
Welfare, and Labor of Japan; Monbu-Kagakusho [78]; Intramural Research
Program of Center for Cancer Research, National Cancer Institute,
National Institutes of Health; National Institutes of Health [GM53386]
FX The present work was supported in part by a grant for global education
and a research center aiming at the control of AIDS (Global Center of
Excellence supported by Monbu-Kagakusho), the Promotion of AIDS Research
from the Ministry of Health, Welfare, and Labor of Japan, a grant to the
Cooperative Research Project on Clinical and Epidemiological Studies of
Emerging and Re-emerging Infectious Diseases (Renkei Jigyo: number 78,
Kumamoto University) of Monbu-Kagakusho (H. M.), the Intramural Research
Program of Center for Cancer Research, National Cancer Institute,
National Institutes of Health (H. M.), and a grant from the National
Institutes of Health (GM53386 to A.K.G.).
NR 55
TC 8
Z9 8
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD DEC
PY 2013
VL 57
IS 12
BP 6110
EP 6121
DI 10.1128/AAC.01420-13
PG 12
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 279KW
UT WOS:000328959900037
ER
PT J
AU Kirby, KA
Michailidis, E
Fetterly, TL
Steinbach, MA
Singh, K
Marchand, B
Leslie, MD
Hagedorn, AN
Kodama, EN
Marquez, VE
Hughes, SH
Mitsuya, H
Parniak, MA
Sarafianos, SG
AF Kirby, Karen A.
Michailidis, Eleftherios
Fetterly, Tracy L.
Steinbach, Musetta A.
Singh, Kamalendra
Marchand, Bruno
Leslie, Maxwell D.
Hagedorn, Ariel N.
Kodama, Eiichi N.
Marquez, Victor E.
Hughes, Stephen H.
Mitsuya, Hiroaki
Parniak, Michael A.
Sarafianos, Stefan G.
TI Effects of Substitutions at the 4 ' and 2 Positions on the Bioactivity
of 4 '- Ethynyl-2-Fluoro-2 '-Deoxyadenosine
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HIV-1 REVERSE-TRANSCRIPTASE; IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEOSIDE
ANALOG INHIBITORS; SUGAR RING CONFORMATION; ADENOSINE-DEAMINASE;
CARBOCYCLIC NUCLEOSIDES; MITOCHONDRIAL TOXICITY; IN-VITRO; DEOXYCYTIDINE
KINASE; MOLECULAR-MECHANISMS
AB Nucleos(t) ide reverse transcriptase inhibitors (NRTIs) form the backbone of most anti-HIV therapies. We have shown that 4 '-ethynyl- 2-fluoro-2 '-deoxyadenosine (EFdA) is a highly effective NRTI; however, the reasons for the potent antiviral activity of EFdA are not well understood. Here, we use a combination of structural, computational, and biochemical approaches to examine how substitutions in the sugar or adenine rings affect the incorporation of dA-based NRTIs like EFdA into DNA by HIV RT and their susceptibility to deamination by adenosine deaminase (ADA). Nuclear magnetic resonance (NMR) spectroscopy studies of 4 '-substituted NRTIs show that ethynyl or cyano groups stabilize the sugar ring in the C-2 '-exo/C-3 '-endo (north) conformation. Steady-state kinetic analysis of the incorporation of 4 '-substituted NRTIs by RT reveals a correlation between the north conformation of the NRTI sugar ring and efficiency of incorporation into the nascent DNA strand. Structural analysis and the kinetics of deamination by ADA demonstrate that 4 '-ethynyl and cyano substitutions decrease the susceptibility of adenosinebased compounds to ADA through steric interactions at the active site. However, the major determinant for decreased susceptibility to ADA is the 2-halo substitution, which alters the pK(a) of N1 on the adenine base. These results provide insight into how NRTI structural attributes affect their antiviral activities through their interactions with the RT and ADA active sites.
C1 [Kirby, Karen A.; Michailidis, Eleftherios; Fetterly, Tracy L.; Steinbach, Musetta A.; Singh, Kamalendra; Marchand, Bruno; Leslie, Maxwell D.; Hagedorn, Ariel N.; Sarafianos, Stefan G.] Univ Missouri, Christopher Bond Life Sci Ctr, Columbia, MO 65211 USA.
[Kirby, Karen A.; Michailidis, Eleftherios; Fetterly, Tracy L.; Steinbach, Musetta A.; Singh, Kamalendra; Marchand, Bruno; Leslie, Maxwell D.; Hagedorn, Ariel N.; Sarafianos, Stefan G.] Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA.
[Kodama, Eiichi N.] Tohoku Univ, Sch Med, Div Emerging Infect Dis, Sendai, Miyagi 980, Japan.
[Marquez, Victor E.] NCI, Biol Chem Lab, Ctr Canc Res, Frederick, MD 21701 USA.
[Hughes, Stephen H.] NCI, HIV Drug Resistance Program, Frederick, MD 21701 USA.
[Mitsuya, Hiroaki] Kumamoto Univ, Sch Med, Dept Internal Med, Kumamoto 860, Japan.
[Mitsuya, Hiroaki] NIH, Expt Retrovirol Sect, HIV AIDS Malignancy Branch, Bethesda, MD 20892 USA.
[Parniak, Michael A.] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA USA.
[Sarafianos, Stefan G.] Univ Missouri, Dept Biochem, Columbia, MO USA.
RP Sarafianos, SG (reprint author), Univ Missouri, Christopher Bond Life Sci Ctr, Columbia, MO 65211 USA.
EM sarafianoss@missouri.edu
RI Kodama, Eiichi /C-4032-2009;
OI Kodama, Eiichi /0000-0002-6622-2752; Sarafianos, Stefan
G/0000-0002-5840-154X; Kirby, Karen A./0000-0003-2468-4796
FU NSF [CHE-89-08304]; NIH/NCRR [S10 RR022341-01]; National Institutes of
Health [AI076119, AI099284, AI100890, GM103368, AI079801]; Intramural
Research Program of the National Institutes of Health (NIH); National
Cancer Institute, Center for Cancer Research; Ministry of Knowledge and
Economy, Bilateral International Collaborative R&D Program, Republic of
Korea; Mathilde Krim Fellowship; Canadian Institutes of Health Research
(CIHR) Fellowship
FX The 500-MHz NMR spectrometer is supported by NSF grant CHE-89-08304 and
NIH/NCRR grant S10 RR022341-01 (cold probe). This work was supported, in
whole or in part, by National Institutes of Health grants AI076119,
AI099284, AI100890, and GM103368 (S.G.S.) and AI079801 (M.A.P.). This
study was supported in part by the Intramural Research Program of the
National Institutes of Health (NIH), National Cancer Institute, Center
for Cancer Research. We also acknowledge support from Ministry of
Knowledge and Economy, Bilateral International Collaborative R&D
Program, Republic of Korea. B.M. is a recipient of the amfAR Mathilde
Krim Fellowship and a Canadian Institutes of Health Research (CIHR)
Fellowship. E.N.K. and H.M. are coinventors of EFdA.
NR 71
TC 7
Z9 7
U1 1
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD DEC
PY 2013
VL 57
IS 12
BP 6254
EP 6264
DI 10.1128/AAC.01703-13
PG 11
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 279KW
UT WOS:000328959900054
PM 24100493
ER
PT J
AU Wong, SY
Javid, B
Addepalli, B
Piszczek, G
Strader, MB
Limbach, PA
Barry, CE
AF Wong, Sharon Y.
Javid, Babak
Addepalli, Balasubrahmanyam
Piszczek, Grzegorz
Strader, Michael Brad
Limbach, Patrick A.
Barry, Clifton E., III
TI Functional Role of Methylation of G518 of the 16S rRNA 530 Loop by GidB
in Mycobacterium tuberculosis
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID LEVEL STREPTOMYCIN RESISTANCE; GENETIC-CODE; PROTEIN; MISTRANSLATION;
ACCURACY; SUBUNIT; COLI; BIOGENESIS; MUTATIONS; MECHANISM
AB Posttranscriptional modifications of bacterial rRNA serve a variety of purposes, from stabilizing ribosome structure to preserving its functional integrity. Here, we investigated the functional role of one rRNA modification in particular-the methylation of guanosine at position 518 (G518) of the 16S rRNA in Mycobacterium tuberculosis. Based on previously reported evidence that G518 is located 5 angstrom; from proline 44 of ribosomal protein S12, which interacts directly with the mRNA wobble position of the codon: anticodon helix at the A site during translation, we speculated that methylation of G518 affects protein translation. We transformed reporter constructs designed to probe the effect of functional lesions at one of the three codon positions on translational fidelity into the wild-type strain, H37Rv, and into a Delta gidB mutant, which lacks the methyltransferase (GidB) that methylates G518. We show that mistranslation occurs less in the Delta gidB mutant only in the construct bearing a lesion in the wobble position compared to H37Rv. Thus, the methylation of G518 allows mistranslation to occur at some level in order for translation to proceed smoothly and efficiently. We also explored the role of methylation at G518 in altering the susceptibility of M. tuberculosis to streptomycin (SM). Using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), we confirmed that G518 is not methylated in the Delta gidB mutant. Furthermore, isothermal titration calorimetry experiments performed on 70S ribosomes purified from wild-type and Delta gidB mutant strains showed that methylation significantly enhances SM binding. These results provide a mechanistic explanation for the low-level, SM-resistant phenotype observed in M. tuberculosis strains that contain a gidB mutation.
C1 [Wong, Sharon Y.; Barry, Clifton E., III] NIAID, TB Res Sect, Lab Clin Infect Dis, NIH, Bethesda, MD 20892 USA.
[Javid, Babak] Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China.
[Addepalli, Balasubrahmanyam; Limbach, Patrick A.] Univ Cincinnati, Dept Chem, Rieveschl Labs Mass Spectrometry, Cincinnati, OH 45221 USA.
[Piszczek, Grzegorz] NHLBI, Biophys Facil, NIH, Bethesda, MD 20892 USA.
[Strader, Michael Brad] NIMH, Lab Neurotoxicol, NIH, Bethesda, MD 20892 USA.
[Javid, Babak] Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China.
RP Barry, CE (reprint author), NIAID, TB Res Sect, Lab Clin Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM cbarry@mail.nih.gov
RI Barry, III, Clifton/H-3839-2012; Limbach, Patrick/A-9188-2009
OI Limbach, Patrick/0000-0003-1526-4546
FU Intramural Research Program of the NIH; NIAID; NIH [GM58843]
FX Funding for this work was provided by the Intramural Research Program of
the NIH, by NIAID, and by NIH grant GM58843 to P.A.L.
NR 31
TC 8
Z9 8
U1 1
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD DEC
PY 2013
VL 57
IS 12
BP 6311
EP 6318
DI 10.1128/AAC.00905-13
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 279KW
UT WOS:000328959900062
PM 24100503
ER
PT J
AU Alvarenga, PH
Xu, XQ
Oliveira, F
Chagas, AC
Nascimento, CR
Francischetti, IMB
Juliano, MA
Juliano, L
Scharfstein, J
Valenzuela, JG
Ribeiro, JMC
Andersen, JF
AF Alvarenga, Patricia H.
Xu, Xueqing
Oliveira, Fabiano
Chagas, Andrezza C.
Nascimento, Clarissa R.
Francischetti, Ivo M. B.
Juliano, Maria A.
Juliano, Luiz
Scharfstein, Julio
Valenzuela, Jesus G.
Ribeiro, Jose M. C.
Andersen, John F.
TI Novel Family of Insect Salivary Inhibitors Blocks Contact Pathway
Activation by Binding to Polyphosphate, Heparin, and Dextran Sulfate
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE blood coagulation factor inhibitors; bradykinin; factor XI; factor XII;
inflammation; kallikreins; leishmania
ID FLY LUTZOMYIA-LONGIPALPIS; KININ SYSTEM INHIBITOR;
VON-WILLEBRAND-FACTOR; BLOOD-FEEDING INSECT; FORMATION IN-VIVO; SAND
FLY; FACTOR-XII; THROMBUS FORMATION; LIGAND-BINDING; MAST-CELLS
AB Objective Polyphosphate and heparin are anionic polymers released by activated mast cells and platelets that are known to stimulate the contact pathway of coagulation. These polymers promote both the autoactivation of factor XII and the assembly of complexes containing factor XI, prekallikrein, and high-molecular-weight kininogen. We are searching for salivary proteins from blood-feeding insects that counteract the effect of procoagulant and proinflammatory factors in the host, including elements of the contact pathway.
Approach and Results Here, we evaluate the ability of the sand fly salivary proteins, PdSP15a and PdSP15b, to inhibit the contact pathway by disrupting binding of its components to anionic polymers. We attempt to demonstrate binding of the proteins to polyphosphate, heparin, and dextran sulfate. We also evaluate the effect of this binding on contact pathway reactions. We also set out to determine the x-ray crystal structure of PdSP15b and examine the determinants of relevant molecular interactions. Both proteins bind polyphosphate, heparin, and dextran sulfate with high affinity. Through this mechanism they inhibit the autoactivation of factor XII and factor XI, the reciprocal activation of factor XII and prekallikrein, the activation of factor XI by thrombin and factor XIIa, the cleavage of high-molecular-weight kininogen in plasma, and plasma extravasation induced by polyphosphate. The crystal structure of PdSP15b contains an amphipathic helix studded with basic side chains that forms the likely interaction surface.
Conclusions The results of these studies indicate that the binding of anionic polymers by salivary proteins is used by blood feeders as an antihemostatic/anti-inflammatory mechanism.
C1 [Alvarenga, Patricia H.; Xu, Xueqing; Oliveira, Fabiano; Chagas, Andrezza C.; Francischetti, Ivo M. B.; Valenzuela, Jesus G.; Ribeiro, Jose M. C.; Andersen, John F.] NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.
[Alvarenga, Patricia H.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Lab Bioquim Resposta Ao Estresse, Rio De Janeiro, Brazil.
[Alvarenga, Patricia H.] Univ Fed Rio de Janeiro, INCT EM, Rio De Janeiro, Brazil.
[Nascimento, Clarissa R.; Scharfstein, Julio] Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, Brazil.
[Juliano, Maria A.; Juliano, Luiz] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil.
RP Andersen, JF (reprint author), NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD 20852 USA.
EM jandersen@niaid.nih.gov
RI Juliano, Luiz/D-7204-2012; Oliveira, Fabiano/B-4251-2009; Ribeiro,
Jose/J-7011-2015;
OI Oliveira, Fabiano/0000-0002-7924-8038; Ribeiro, Jose/0000-0002-9107-0818
FU National Institute of Allergy and Infectious Diseases (NIAID), National
Institutes of Health; Fundacao de Amparo a Pesquisa do Rio de Janeiro
Carlos Chagas Filho; Conselho Nacional de Desenvolvimento Cientifico e
Tecnologico; US Department of Energy, Office of Science, Office of Basic
Energy Sciences [W-31-109-Eng-38]
FX This work was supported by the intramural research program of the
National Institute of Allergy and Infectious Diseases (NIAID), National
Institutes of Health. P.H. Alvarenga was supported, in part, by a grant
from the Fundacao de Amparo a Pesquisa do Rio de Janeiro Carlos Chagas
Filho and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico.
Use of the Advanced Photon Source beamlines was supported by the US
Department of Energy, Office of Science, Office of Basic Energy
Sciences, under contract no. W-31-109-Eng-38.
NR 53
TC 12
Z9 12
U1 3
U2 22
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
EI 1524-4636
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD DEC
PY 2013
VL 33
IS 12
BP 2759
EP 2770
DI 10.1161/ATVBAHA.113.302482
PG 12
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 283YW
UT WOS:000329283900012
PM 24092749
ER
PT J
AU Patel, S
AF Patel, Sejal
TI The Benevolent Tyranny of Biostatistics: Public Administration and the
Promotion of Biostatistics at the National Institutes of Health,
1946-1970
SO BULLETIN OF THE HISTORY OF MEDICINE
LA English
DT Article
DE biostatistics; National Institutes of Health; biomedical research
policy; public administration; biometry
ID UNITED-STATES; EPIDEMIOLOGY; NIH; CONVERSATION; FRAMINGHAM; TRIALS
AB This article explores the central role of the National Institutes of Health (NIH) in developing and promoting biostatistics in American biomedical research between the late 1940s and the late 1960s. During this period, the NIH invested in the training of both intramural and extramural biostatisticians and was considered the single largest user of biostatisticians in the country. In addition to helping meet the scientific needs of NIH investigators, this article argues that biostatisticians played a critical role in aligning NIH-funded scientific endeavors with new public administration mandates and policies. In particular, it argues that the changing expectations of federal oversight and management played a central, though largely unrecognized, role in the growing presence of biostatisdcs at the NIH and in American health and biomedical research during the 1960s.
C1 [Patel, Sejal] Univ Wisconsin, Madison, WI 53706 USA.
[Patel, Sejal] NIH, Off Hist, Bethesda, MD USA.
RP Patel, S (reprint author), Mitre Corp, Bedford, MA 01730 USA.
NR 67
TC 1
Z9 1
U1 0
U2 2
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 0007-5140
EI 1086-3176
J9 B HIST MED
JI Bull. Hist. Med.
PD WIN
PY 2013
VL 87
IS 4
BP 622
EP 647
PG 26
WC Health Care Sciences & Services; History & Philosophy Of Science
SC Health Care Sciences & Services; History & Philosophy of Science
GA 280IB
UT WOS:000329020800008
PM 24362278
ER
PT J
AU Reznick, JS
AF Reznick, Jeffrey S.
TI War's Waste: Rehabilitation in World War I America
SO BULLETIN OF THE HISTORY OF MEDICINE
LA English
DT Book Review
C1 [Reznick, Jeffrey S.] US Natl Lib Med, Bethesda, MD USA.
RP Reznick, JS (reprint author), US Natl Lib Med, Bethesda, MD USA.
NR 1
TC 0
Z9 0
U1 0
U2 1
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 0007-5140
EI 1086-3176
J9 B HIST MED
JI Bull. Hist. Med.
PD WIN
PY 2013
VL 87
IS 4
BP 703
EP 704
PG 2
WC Health Care Sciences & Services; History & Philosophy Of Science
SC Health Care Sciences & Services; History & Philosophy of Science
GA 280IB
UT WOS:000329020800022
ER
PT J
AU Miyajima, N
Tsutsumi, S
Sourbier, C
Beebe, K
Mollapour, M
Rivas, C
Yoshida, S
Trepel, JB
Huang, Y
Tatokoro, M
Shinohara, N
Nonomura, K
Neckers, L
AF Miyajima, Naoto
Tsutsumi, Shinji
Sourbier, Carole
Beebe, Kristin
Mollapour, Mehdi
Rivas, Candy
Yoshida, Soichiro
Trepel, Jane B.
Huang, Ying
Tatokoro, Manabu
Shinohara, Nobuo
Nonomura, Katsuya
Neckers, Len
TI The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor
Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor
Models
SO CANCER RESEARCH
LA English
DT Article
ID CELL LUNG-CANCER; PAPILLARY RENAL-CARCINOMAS; HEPATOCYTE GROWTH-FACTOR;
TYROSINE KINASE; C-MET; ACTIVATING MUTATIONS; ACQUIRED-RESISTANCE;
ANTITUMOR-ACTIVITY; SOMATIC MUTATIONS; TARGETING HSP90
AB The proto-oncogene MET is aberrantly activated via overexpression or mutation in numerous cancers, making it a prime anticancer molecular target. However, the clinical success of MET-directed tyrosine kinase inhibitors (TKI) has been limited due, in part, to mutations in the MET kinase domain that confer therapeutic resistance. Circumventing this problem remains a key challenge to improving durable responses in patients receiving MET-targeted therapy. MET is an HSP90-dependent kinase, and in this report we show that HSP90 preferentially interacts with and stabilizes activated MET, regardless of whether the activation is ligand-dependent or is a consequence of kinase domain mutation. In contrast, many MET-TKI show a preference for the inactive form of the kinase, and activating mutations in MET can confer resistance. Combining the HSP90 inhibitor ganetespib with the MET-TKI crizotinib achieves synergistic inhibition of MET, its downstream signaling pathways, and tumor growth in both TKI-sensitive and -resistant MET-driven tumor models. These data suggest that inclusion of an HSP90 inhibitor can partially restore TKI sensitivity to previously resistant MET mutants, and they provide the foundation for clinical evaluation of this therapeutic combination in patients with MET-driven cancers. (C)2013 AACR.
C1 [Miyajima, Naoto; Tsutsumi, Shinji; Sourbier, Carole; Beebe, Kristin; Mollapour, Mehdi; Rivas, Candy; Yoshida, Soichiro; Huang, Ying; Tatokoro, Manabu; Neckers, Len] NCI, Urol Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Trepel, Jane B.] NCI, Med Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Mollapour, Mehdi] SUNY Upstate Med Univ, Canc Res Inst, Dept Urol, Syracuse, NY 13210 USA.
[Mollapour, Mehdi] SUNY Upstate Med Univ, Canc Res Inst, Dept Biochem, Syracuse, NY 13210 USA.
[Mollapour, Mehdi] SUNY Upstate Med Univ, Canc Res Inst, Dept Mol Biol, Syracuse, NY 13210 USA.
[Miyajima, Naoto; Shinohara, Nobuo; Nonomura, Katsuya] Hokkaido Univ, Grad Sch Med, Dept Urol, Sapporo, Hokkaido, Japan.
RP Neckers, L (reprint author), NCI, Urol Oncol Branch, Bldg 10-CRC,Room 1-5940,9000 Rockville Pike, Bethesda, MD 20892 USA.
EM neckersl@mail.nih.gov
FU Intramural Research Program, National Cancer Institute, Center for
Cancer Research
FX This work was financially supported by funds from the Intramural
Research Program, National Cancer Institute, Center for Cancer Research.
NR 50
TC 21
Z9 21
U1 4
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 1
PY 2013
VL 73
IS 23
BP 7022
EP 7033
DI 10.1158/0008-5472.CAN-13-1156
PG 12
WC Oncology
SC Oncology
GA 279DS
UT WOS:000328941200017
PM 24121490
ER
PT J
AU Rimmerman, N
Ben-Hail, D
Porat, Z
Juknat, A
Kozela, E
Daniels, MP
Connelly, PS
Leishman, E
Bradshaw, HB
Shoshan-Barmatz, V
Vogel, Z
AF Rimmerman, N.
Ben-Hail, D.
Porat, Z.
Juknat, A.
Kozela, E.
Daniels, M. P.
Connelly, P. S.
Leishman, E.
Bradshaw, H. B.
Shoshan-Barmatz, V.
Vogel, Z.
TI Direct modulation of the outer mitochondrial membrane channel,
voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel
mechanism for cannabinoid-induced cell death
SO CELL DEATH & DISEASE
LA English
DT Article
DE cancer; cannabidiol; cell death; microglia; mitochondria;
voltage-dependent anion channel 1
ID BV-2 MICROGLIAL CELLS; INDUCED APOPTOSIS; PERMEABILITY TRANSITION;
OXIDATIVE STRESS; LEUKEMIA-CELLS; LIPID RAFTS; EXPRESSION; ACTIVATION;
PROTEIN; MICE
AB Cannabidiol (CBD) is a non-psychoactive plant cannabinoid that inhibits cell proliferation and induces cell death of cancer cells and activated immune cells. It is not an agonist of the classical CB1/CB2 cannabinoid receptors and the mechanism by which it functions is unknown. Here, we studied the effects of CBD on various mitochondrial functions in BV-2 microglial cells. Our findings indicate that CBD treatment leads to a biphasic increase in intracellular calcium levels and to changes in mitochondrial function and morphology leading to cell death. Density gradient fractionation analysis by mass spectrometry and western blotting showed colocalization of CBD with protein markers of mitochondria. Single-channel recordings of the outer-mitochondrial membrane protein, the voltage-dependent anion channel 1 (VDAC1) functioning in cell energy, metabolic homeostasis and apoptosis revealed that CBD markedly decreases channel conductance. Finally, using microscale thermophoresis, we showed a direct interaction between purified fluorescently labeled VDAC1 and CBD. Thus, VDAC1 seems to serve as a novel mitochondrial target for CBD. The inhibition of VDAC1 by CBD may be responsible for the immunosuppressive and anticancer effects of CBD.
C1 [Rimmerman, N.; Juknat, A.; Kozela, E.; Vogel, Z.] Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, Dr Miriam & Sheldon G Adelson Ctr Biol Addict Dis, IL-6997801 Tel Aviv, Israel.
[Ben-Hail, D.; Shoshan-Barmatz, V.] Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel.
[Ben-Hail, D.; Shoshan-Barmatz, V.] Ben Gurion Univ Negev, Natl Inst Biotechnol Negev, IL-84105 Beer Sheva, Israel.
[Porat, Z.] Weizmann Inst Sci, Flow Cytometry Unit, IL-76100 Rehovot, Israel.
[Daniels, M. P.; Connelly, P. S.] NHLBI, Bethesda, MD 20892 USA.
[Leishman, E.; Bradshaw, H. B.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN USA.
RP Rimmerman, N (reprint author), Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, Miriam & Sheldon G Adelson Ctr Biol Addict Dis, IL-6997801 Tel Aviv, Israel.
EM Neta.rimmerman@weizmann.ac.il
OI Leishman, Emma/0000-0002-8310-1821; Ben-Hail, Danya/0000-0002-8210-3446;
Porat, Ziv/0000-0003-3059-181X
FU Dr. Miriam and Sheldon G Adelson Medical Research Foundation; Israeli
Ministry for Absorption in Science
FX This work was supported by the Dr. Miriam and Sheldon G Adelson Medical
Research Foundation. AJ is supported by the Israeli Ministry for
Absorption in Science. We thank Dr. Or Golan and Professor Asher
Shainberg from The Cancer Research Center, Bar Ilan University, Ramat
Gan, Israel, for the preliminary experiments on mitochondrial membrane
potential.
NR 60
TC 13
Z9 16
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD DEC
PY 2013
VL 4
AR e949
DI 10.1038/cddis.2013.471
PG 11
WC Cell Biology
SC Cell Biology
GA 282HM
UT WOS:000329161300010
PM 24309936
ER
PT J
AU Rudolph, A
Hein, R
Lindstrom, S
Beckmann, L
Behrens, S
Liu, J
Aschard, H
Bolla, MK
Wang, J
Truong, T
Cordina-Duverger, E
Menegaux, F
Bruning, T
Harth, V
Severi, G
Baglietto, L
Southey, M
Chanock, SJ
Lissowska, J
Figueroa, JD
Eriksson, M
Humpreys, K
Darabi, H
Olson, JE
Stevens, KN
Vachon, CM
Knight, JA
Glendon, G
Mulligan, AM
Ashworth, A
Orr, N
Schoemaker, M
Webb, PM
Guenel, P
Brauch, H
Giles, G
Garcia-Closas, M
Czene, K
Chenevix-Trench, G
Couch, FJ
Andrulis, IL
Swerdlow, A
Hunter, DJ
Flesch-Janys, D
Easton, DF
Hall, P
Nevanlinna, H
Kraft, P
Chang-Claude, J
AF Rudolph, Anja
Hein, Rebecca
Lindstroem, Sara
Beckmann, Lars
Behrens, Sabine
Liu, Jianjun
Aschard, Hugues
Bolla, Manjeet K.
Wang, Jean
Truong, Therese
Cordina-Duverger, Emilie
Menegaux, Florence
Bruening, Thomas
Harth, Volker
Severi, Gianluca
Baglietto, Laura
Southey, Melissa
Chanock, Stephen J.
Lissowska, Jolanta
Figueroa, Jonine D.
Eriksson, Mikael
Humpreys, Keith
Darabi, Hatef
Olson, Janet E.
Stevens, Kristen N.
Vachon, Celine M.
Knight, Julia A.
Glendon, Gord
Mulligan, Anna Marie
Ashworth, Alan
Orr, Nicholas
Schoemaker, Minouk
Webb, Penny M.
Guenel, Pascal
Brauch, Hiltrud
Giles, Graham
Garcia-Closas, Montserrat
Czene, Kamila
Chenevix-Trench, Georgia
Couch, Fergus J.
Andrulis, Irene L.
Swerdlow, Anthony
Hunter, David J.
Flesch-Janys, Dieter
Easton, Douglas F.
Hall, Per
Nevanlinna, Heli
Kraft, Peter
Chang-Claude, Jenny
CA GENICA Network
KConFab Investigators
AOCS Management Grp
Breast Canc Association Consortium
TI Genetic modifiers of menopausal hormone replacement therapy and breast
cancer risk: a genome-wide interaction study
SO ENDOCRINE-RELATED CANCER
LA English
DT Article
DE breast cancer; genetic variation; menopausal hormone therapy;
genome-wide
ID ENVIRONMENT INTERACTIONS; PHOSPHOLIPASE C-GAMMA-2; ASSOCIATION;
SUSCEPTIBILITY; FGFR2; POLYMORPHISMS; METAANALYSIS; RECEPTORS;
NUTRITION; HAPLOTYPE
AB Women using menopausal hormone therapy (MHT) are at increased risk of developing breast cancer (BC). To detect genetic modifiers of the association between current use of MHT and BC risk, we conducted a meta-analysis of four genome-wide case-only studies followed by replication in 11 case-control studies. We used a case-only design to assess interactions between single-nucleotide polymorphisms (SNPs) and current MHT use on risk of overall and lobular BC. The discovery stage included 2920 cases (541 lobular) from four genome-wide association studies. The top 1391 SNPs showing P values for interaction (Pint) < 3.0 x 10(-3) were selected for replication using pooled case-control data from 11 studies of the Breast Cancer Association Consortium, including 7689 cases (676 lobular) and 9266 controls. Fixed-effects meta-analysis was used to derive combined Pint. No SNP reached genome-wide significance in either the discovery or combined stage. We observed effect modification of current MHT use on overall BC risk by two SNPs on chr13 near POMP (combined P-int <= 8.9 x 10(-6)), two SNPs in SLC25A21 (combined P-int <= 4.8 x 10(-5)), and three SNPs in PLCG2 (combined P-int <= 4.5 x 10(-5)). The association between lobular BC risk was potentially modified by one SNP in TMEFF2 (combined P-int <= 2.7 x 10(-5)), one SNP in CD80 (combined P-int <= 8.2 x 10(-6)), three SNPs on chr17 near TMEM132E (combined P-int <= 2.2 x 10(-6)), and two SNPs on chr18 near SLC25A52 (combined P-int <= 4.6 x 10(-5)). In conclusion, polymorphisms in genes related to solute transportation in mitochondria, transmembrane signaling, and immune cell activation are potentially modifying BC risk associated with current use of MHT. These findings warrant replication in independent studies.
C1 [Rudolph, Anja; Hein, Rebecca; Beckmann, Lars; Behrens, Sabine; Chang-Claude, Jenny] German Canc Res Ctr, Div Canc Epidemiol, D-69120 Heidelberg, Germany.
[Hein, Rebecca] Univ Cologne, PMV Res Grp, Dept Child & Adolescent Psychiat & Psychotherapy, D-50931 Cologne, Germany.
[Lindstroem, Sara; Aschard, Hugues; Hunter, David J.; Kraft, Peter] Harvard Univ, Sch Publ Hlth, Program Mol & Genet Epidemiol, Boston, MA 02115 USA.
[Lindstroem, Sara; Aschard, Hugues; Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Beckmann, Lars] Fdn Qual & Efficiency Hlth Care IQWIG, Cologne, Germany.
[Liu, Jianjun] Genome Inst Singapore, Singapore, Singapore.
[Bolla, Manjeet K.; Wang, Jean; Easton, Douglas F.] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Publ Hlth & Primary Care, Cambridge, England.
[Truong, Therese; Cordina-Duverger, Emilie; Menegaux, Florence; Guenel, Pascal] INSERM, Natl Inst Hlth & Med Res, CESP Ctr Res Epidemiol & Populat Hlth, U1018, Villejuif, France.
[Truong, Therese; Cordina-Duverger, Emilie; Menegaux, Florence; Guenel, Pascal] Univ Paris Sud, Unite Mixte Rech Sci UMRS 1018, Villejuif, France.
[Bruening, Thomas; Harth, Volker] Inst Ruhr Univ Bochum IPA, Inst Prevent & Occupat Med German Social Accid In, Bochum, Germany.
[Harth, Volker] Univ Med Ctr Hamburg Eppendorf, Inst Occupat Med & Maritime Med, Hamburg, Germany.
Evangel Kliniken Bonn GGmbH, Johanniter Krankenhaus, Dept Internal Med, Bonn, Germany.
Univ Bonn, Inst Pathol, Bonn, Germany.
German Canc Res Ctr, D-69120 Heidelberg, Germany.
[Brauch, Hiltrud; GENICA Network] Univ Tubingen, Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany.
[Severi, Gianluca; Baglietto, Laura; Giles, Graham] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
[Severi, Gianluca; Baglietto, Laura; Giles, Graham] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia.
[Southey, Melissa] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia.
[Chanock, Stephen J.; Figueroa, Jonine D.; Garcia-Closas, Montserrat] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA.
[Lissowska, Jolanta] M Sklodowska Curie Mem Canc Ctr, Dept Canc Epidemiol & Prevent, Warsaw, Poland.
[Lissowska, Jolanta] Inst Oncol, Warsaw, Poland.
[Eriksson, Mikael; Humpreys, Keith; Darabi, Hatef; Czene, Kamila; Hall, Per] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
[Olson, Janet E.; Stevens, Kristen N.; Vachon, Celine M.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
[Knight, Julia A.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
[Knight, Julia A.] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Epidemiol, Toronto, ON, Canada.
[Glendon, Gord] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Ontario Canc Genet Network, Toronto, ON M5G 1X5, Canada.
[Mulligan, Anna Marie] Univ Toronto, Univ Hlth Network, Dept Lab Med & Pathobiol, Lab Med Program, Toronto, ON, Canada.
[Ashworth, Alan; Orr, Nicholas; Schoemaker, Minouk] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England.
[Ashworth, Alan; Orr, Nicholas; Schoemaker, Minouk; Swerdlow, Anthony] Inst Canc Res, Div Breast Canc Res, Sutton, Surrey, England.
[Webb, Penny M.; Chenevix-Trench, Georgia] Queensland Inst Med Res, Brisbane, Qld 4006, Australia.
[KConFab Investigators; AOCS Management Grp] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Garcia-Closas, Montserrat] Inst Canc Res, Epidemiol Sect, London SW3 6JB, England.
[Garcia-Closas, Montserrat] Inst Canc Res, Genet Sect, London SW3 6JB, England.
[Garcia-Closas, Montserrat] Breakthrough Breast Canc Res Ctr, London, England.
[Couch, Fergus J.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
[Andrulis, Irene L.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Fred A Litwin Ctr Canc Genet, Ontario Canc Genet Network, Toronto, ON M5G 1X5, Canada.
[Andrulis, Irene L.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
[Swerdlow, Anthony] Inst Canc Res, Div Genet & Epidemiol, Sutton, Surrey, England.
[Flesch-Janys, Dieter] Univ Clin Hamburg Eppendorf, Dept Canc Epidemiol, Clin Canc Registry, Hamburg, Germany.
[Flesch-Janys, Dieter] Univ Clin Hamburg Eppendorf, Inst Med Biometr & Epidemiol, Hamburg, Germany.
[Easton, Douglas F.] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Oncol, Cambridge, England.
[Nevanlinna, Heli] Univ Helsinki, Dept Obstet & Gynecol, Helsinki, Finland.
[Nevanlinna, Heli] Univ Helsinki, Cent Hosp, Helsinki, Finland.
[Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
RP Chang-Claude, J (reprint author), German Canc Res Ctr, Div Canc Epidemiol, Neuenheimer Feld 581, D-69120 Heidelberg, Germany.
EM j.chang-claude@dkfz.de
RI Bruning, Thomas/G-8120-2015; Whiteman, David/P-2728-2014; Andrulis,
Irene/E-7267-2013; Knight, Julia/A-6843-2012; Li, Jingmei/I-2904-2012;
Gonzalez-Neira, Anna/C-5791-2015; Garcia-Closas, Montserrat
/F-3871-2015; Brinton, Louise/G-7486-2015; Szeszenia-Dabrowska,
Neonila/F-7190-2010; Bowtell, David/H-1007-2016;
OI Bruning, Thomas/0000-0001-9560-5464; Whiteman,
David/0000-0003-2563-9559; Schoemaker, Minouk/0000-0001-8403-2234;
Czene, Kamila/0000-0002-3233-5695; Eeles, Rosalind/0000-0002-3698-6241;
Webb, Penelope/0000-0003-0733-5930; Li, Jingmei/0000-0001-8587-7511;
Garcia-Closas, Montserrat /0000-0003-1033-2650; Brinton,
Louise/0000-0003-3853-8562; Bowtell, David/0000-0001-9089-7525;
Nevanlinna, Heli/0000-0002-0916-2976; Dunning, Alison
Margaret/0000-0001-6651-7166; Giles, Graham/0000-0003-4946-9099
FU European Community's Seventh Framework Program [223175,
HEALTH-F2-2009-223175]; (COGS), Cancer Research UK [C1287/A10118,
C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007,
C5047/A10692]; National Institutes of Health [CA128978]; Post-Cancer
GWAS initiative [1U19 CA148537, 1U19 CA148065, 1U19 CA148112]; GAME-ON
initiative; Department of Defence [W81XWH-10-1-0341]; Canadian
Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks
of Breast Cancer; Komen Foundation for the Cure; Breast Cancer Research
Foundation; Ovarian Cancer Research Fund; European Union COST program
[BM0606]; Fondation de France; French National Institute of Cancer
(INCa); National League against Cancer; National Agency for
Environmental and Occupational Health and Food Safety (ANSES); National
Agency for Research (ANR); Association for Research against Cancer
(ARC); Federal Ministry of Education and Research (BMBF) Germany
[01KW9975/5, 01KW9976/8, 01KW9977/0, 01KW0114, 01KH0401, 01KH0410,
01KH0411, 01KH0402]; Robert Bosch Foundation, Stuttgart; Deutsches
Krebsforschungszentrum (DKFZ), Heidelberg; Institute for Prevention and
Occupational Medicine of the German Social Accident Insurance (IPA);
Department of Internal Medicine; Evangelische Kliniken Bonn gGmbH;
Johanniter Krankenhaus, Bonn, Germany; Deutsche Krebshilfe e.V
[70-2892-BR I]; Hamburg Cancer Society; German Cancer Research Center;
NIH [CA128978, CA122340]; Specialized Program of Research Excellence
(SPORE) in Breast Cancer [CA116201]; VicHealth; Cancer Council Victoria;
Australian NHMRC [209057, 251553, 504711]; US NIH (National Institute of
Health) [CA65725, CA87969, CA49449, CA67262, CA50385, 5UO1CA098233];
National Cancer Institute. [UM1 CA164920]; Intramural Research Funds of
the National Cancer Institute; Department of Health and Human Services,
USA; National Breast Cancer Foundation; NHMRC [145684, 288704, 454508,
199600]; Queensland Cancer Fund, the Cancer Councils of New South Wales,
Victoria, Tasmania and South Australia; Cancer Foundation of Western
Australia; AOCS was provided by the United States Army Medical Research
and Materiel Command [DAMD17-01-1-0729]; Cancer Council of Tasmania and
Cancer Foundation of Western Australia; NHMRC Senior Research
Fellowship; Breast Cancer and the Institute of Cancer Research (ICR);
NIHR Biomedical Research Centre
FX Funding for the iCOGS infrastructure came from: the European Community's
Seventh Framework Program under grant agreement n degrees 223175
(HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118,
C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007,
C5047/A10692), the National Institutes of Health CA128978) and
Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065, and 1U19
CA148112 - the GAME-ON initiative), the Department of Defence
(W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR)
for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation
for the Cure, the Breast Cancer Research Foundation, and the Ovarian
Cancer Research Fund. Meetings of the BCAC have been funded by the
European Union COST program (BM0606). D F Easton is a Principal Research
Fellow of CR-UK. The CECILE study was funded by the Fondation de France;
the French National Institute of Cancer (INCa); The National League
against Cancer; the National Agency for Environmental and Occupational
Health and Food Safety (ANSES), the National Agency for Research (ANR),
and the Association for Research against Cancer (ARC). GENICA was funded
by the Federal Ministry of Education and Research (BMBF) Germany grants
01KW9975/5, 01KW9976/8, 01KW9977/0, and 01KW0114 as well as 01KH0401,
01KH0410, 01KH0411, the Robert Bosch Foundation, Stuttgart, Deutsches
Krebsforschungszentrum (DKFZ), Heidelberg, Institute for Prevention and
Occupational Medicine of the German Social Accident Insurance (IPA),
Bochum, as well as the Department of Internal Medicine, Evangelische
Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. The MARIE
study was supported by the Deutsche Krebshilfe e.V. (70-2892-BR I), the
Hamburg Cancer Society, the German Cancer Research Center and genotype
work in part by the Federal Ministry of Education and Research (BMBF)
Germany (01KH0402). The MCBCS was supported by the NIH grants (CA122340,
CA128978) and a Specialized Program of Research Excellence (SPORE) in
Breast Cancer (CA116201). MCCS cohort recruitment was funded by
VicHealth and Cancer Council Victoria. The MCCS was further supported by
Australian NHMRC grants 209057, 251553, and 504711 and by infrastructure
provided by Cancer Council Victoria. The Nurses' Health Studies are
supported by US NIH (National Institute of Health) grants CA65725,
CA87969, CA49449, CA67262, CA50385, and 5UO1CA098233. OFBCR was
supported by grant UM1 CA164920 from the National Cancer Institute. The
content of this manuscript does not necessarily reflect the views or
policies of the National Cancer Institute or any of the collaborating
centers in the Breast Cancer Family Registry (BCFR), nor does mention of
trade names, commercial products, or organizations imply endorsement by
the US Government or the BCFR. The PBCS was funded by Intramural
Research Funds of the National Cancer Institute, Department of Health
and Human Services, USA. kConFab is supported by grants from the
National Breast Cancer Foundation, the NHMRC, the Queensland Cancer
Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and
South Australia and the Cancer Foundation of Western Australia. The
kConFab Clinical Follow-Up Study was funded by the NHMRC (145684,
288704, 454508). Financial support for the AOCS was provided by the
United States Army Medical Research and Materiel Command
(DAMD17-01-1-0729), the Cancer Council of Tasmania and Cancer Foundation
of Western Australia and the NHMRC (199600). ABS is supported by an
NHMRC Senior Research Fellowship.; The Breakthrough Generations Study
investigators thank Breakthrough Breast Cancer and the Institute of
Cancer Research (ICR) for support and funding of the Breakthrough
Generations Study. The ICR acknowledge NHS funding to the NIHR
Biomedical Research Centre.
NR 47
TC 7
Z9 7
U1 2
U2 11
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 1351-0088
EI 1479-6821
J9 ENDOCR-RELAT CANCER
JI Endocr.-Relat. Cancer
PD DEC
PY 2013
VL 20
IS 6
BP 875
EP 887
DI 10.1530/ERC-13-0349
PG 13
WC Oncology; Endocrinology & Metabolism
SC Oncology; Endocrinology & Metabolism
GA 282WZ
UT WOS:000329206500016
PM 24080446
ER
PT J
AU Gluick, T
Yuan, ZQ
Libutti, SK
Marx, SJ
AF Gluick, Thomas
Yuan, Ziqiang
Libutti, Steven K.
Marx, Stephen J.
TI Mutations in CDKN2C (p18) and CDKN2D (p19) may cause sporadic
parathyroid adenoma
SO ENDOCRINE-RELATED CANCER
LA English
DT Letter
ID TUMOR-SUPPRESSOR P16(INK4A); KINASE INHIBITOR GENES; ANKYRIN-REPEAT;
MECHANISMS; GERMLINE
C1 [Gluick, Thomas; Marx, Stephen J.] Natl Inst Diabet & Digest & Kidney Dis, Genet & Endocrinol Sect, Metab Dis Branch, NIH, Bethesda, MD 20892 USA.
[Yuan, Ziqiang; Libutti, Steven K.] Albert Einstein Coll Med, Dept Surg, Bronx, NY 10461 USA.
[Yuan, Ziqiang; Libutti, Steven K.] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10461 USA.
RP Marx, SJ (reprint author), Natl Inst Diabet & Digest & Kidney Dis, Genet & Endocrinol Sect, Metab Dis Branch, NIH, Bld 10,Room 9C-103,10 Ctr Dr, Bethesda, MD 20892 USA.
EM marxs@mail.nih.gov
NR 13
TC 4
Z9 4
U1 0
U2 4
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 1351-0088
EI 1479-6821
J9 ENDOCR-RELAT CANCER
JI Endocr.-Relat. Cancer
PD DEC
PY 2013
VL 20
IS 6
BP L27
EP L29
DI 10.1530/ERC-13-0445
PG 3
WC Oncology; Endocrinology & Metabolism
SC Oncology; Endocrinology & Metabolism
GA 282WZ
UT WOS:000329206500002
PM 24127162
ER
PT J
AU Gudlaugsson, J
Gudnason, V
Aspelund, T
Olafsdottir, AS
Jonsson, PV
Arngrimsson, SA
Harris, TB
Johannsson, E
AF Gudlaugsson, J.
Gudnason, V.
Aspelund, T.
Olafsdottir, A. S.
Jonsson, P. V.
Arngrimsson, S. A.
Harris, T. B.
Johannsson, E.
TI Effects of exercise training and nutrition counseling on body
composition and cardiometabolic factors in old individuals
SO EUROPEAN GERIATRIC MEDICINE
LA English
DT Article
DE Physical activity; Body composition; Cardiometabolic factors; Exercise
training and nutrition counseling; Older people
ID METABOLIC SYNDROME; PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE;
SEASONAL-VARIATION; GLUCOSE-TOLERANCE; ASSOCIATION; RISK; AGE;
INTERVENTION; CHOLESTEROL
AB Background: Regular physical activity (PA) and nutritional counseling can reduce weight and trunk fat accumulation and influence cardiometabolic factors.
Methods: This study was an exercise training and nutritional counseling intervention, conducted in two 6-month phases. Participants were assessed at baseline and at 6 and 12 months. Participants (54 males and 63 females aged 71-90) were randomized into immediate exercise training group (Group 1) and delayed exercise training group (Group 2). At time-point 2, the groups crossed over.
Results: After the exercise training-phase by Group 1, a statistically significant increase (P < 0.05) was seen in physical activity (PA), energy intake, and total lean mass. A significant decrease was seen in weight, total fat mass, trunk fat mass, waist circumference, and blood pressure. At the 6-month follow-up, Group 1 saw a significant decrease in PA, energy intake, total lean mass and blood pressure. A significant increase was seen in waist circumference and total fat mass. After the 6-month control phase by Group 2, a significant decrease was measured in PA, systolic blood pressure, total fat mass, fat mass of the trunk and waist circumference. After a delayed 6-month exercise training-phase by Group 2, a significant increase was measured in PA, and a decrease in weight, total fat mass, trunk fat mass, waist circumference, blood pressure and triglyceride.
Conclusion: Our findings suggest that positive improvements in body composition and cardiometabolic factors in old people may be achieved by systematic exercise training in combination with nutrition counseling. This should be considered as an integral part of the health care system. (C) 2013 Elsevier Masson SAS and European Union Geriatric Medicine Society. All rights reserved.
C1 [Gudlaugsson, J.; Olafsdottir, A. S.; Arngrimsson, S. A.; Johannsson, E.] Univ Iceland, Ctr Res Sport & Hlth Sci, IS-840 Laugarvatn, Iceland.
[Gudnason, V.; Aspelund, T.; Jonsson, P. V.] Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland.
[Jonsson, P. V.] Univ Hosp, Landspitali, Dept Geriatr, Reykjavik, Iceland.
[Harris, T. B.] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, Bethesda, MD 20892 USA.
RP Gudlaugsson, J (reprint author), Univ Iceland, Ctr Res Sport & Hlth Sci, IS-840 Laugarvatn, Iceland.
EM janus@hi.is
RI Aspelund, Thor/C-5983-2008; Gudnason, Vilmundur/K-6885-2015;
Olafsdottir, Anna/A-8804-2013
OI Aspelund, Thor/0000-0002-7998-5433; Gudnason,
Vilmundur/0000-0001-5696-0084; Olafsdottir, Anna/0000-0002-7258-1727
FU Icelandic Centre for Research; University of Iceland Research Fund;
Ministry of Education, Science and Culture Sport Fund; Association of
Municipalities in the Capital Area; Fitness Centre Laugar; Public Health
Institute of Iceland; Icelandic Heart Association
FX This research project was supported by The Icelandic Centre for
Research, The University of Iceland Research Fund, The Ministry of
Education, Science and Culture Sport Fund, The Association of
Municipalities in the Capital Area, The Fitness Centre Laugar, The
Public Health Institute of Iceland and The Icelandic Heart Association.
NR 35
TC 2
Z9 2
U1 0
U2 10
PU ELSEVIER MASSON
PI MILANO
PA VIA PALEOCAPA 7, 20121 MILANO, ITALY
SN 1878-7649
EI 1878-7657
J9 EUR GERIATR MED
JI Eur. Geriatr. Med.
PD DEC
PY 2013
VL 4
IS 6
BP 431
EP 437
DI 10.1016/j.eurger.2013.09.005
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 285VG
UT WOS:000329422500018
ER
PT J
AU Chandler, RJ
Ashok, AA
Varshney, GK
LaFave, MC
Wu, W
Elkahloun, AG
Burgess, SM
Venditti, CP
AF Chandler, R. J.
Ashok, A. A.
Varshney, G. K.
LaFave, M. C.
Wu, W.
Elkahloun, A. G.
Burgess, S. M.
Venditti, C. P.
TI Genotoxicity following AAV gene therapy for Methylmalonic Acidemia (MMA)
in mice
SO HUMAN GENE THERAPY
LA English
DT Meeting Abstract
CT Collaborative Congress of the European-Society-for-Gene-and-Cell-Therapy
and the Spanish-Society-for-Gene-and-Cell-Therapy
CY OCT 25-28, 2013
CL Madrid, SPAIN
SP European Soc Gene & Cell Therapy, Spanish Soc Gene & Cell Therapy
C1 [Chandler, R. J.] NIH, Bethesda, MD 20892 USA.
RI Varshney, Gaurav/L-5261-2014
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
EI 1557-7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD DEC 1
PY 2013
VL 24
IS 12
BP A149
EP A149
PG 1
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA 271UU
UT WOS:000328417900451
ER
PT J
AU Uchiyama, T
Horino, S
So, T
Jagadeesh, GJ
Ishii, N
Candotti, F
AF Uchiyama, T.
Horino, S.
So, T.
Jagadeesh, G. J.
Ishii, N.
Candotti, F.
TI Gene therapy models of X-linked severe combined immunodeficiency and
Wiskott-Aldrich Syndrome using foamy virus vectors
SO HUMAN GENE THERAPY
LA English
DT Meeting Abstract
CT Collaborative Congress of the European-Society-for-Gene-and-Cell-Therapy
and the Spanish-Society-for-Gene-and-Cell-Therapy
CY OCT 25-28, 2013
CL Madrid, SPAIN
SP European Soc Gene & Cell Therapy, Spanish Soc Gene & Cell Therapy
C1 [Uchiyama, T.; Jagadeesh, G. J.; Candotti, F.] NHGRI, Genet & Mol Biol Branch, Bethesda, MD USA.
[Horino, S.; So, T.; Ishii, N.] Tohoku Univ, Sch Med, Dept Microbiol & Immunol, Sendai, Miyagi 980, Japan.
[Uchiyama, T.; Horino, S.] Tohoku Univ, Sch Med, Dept Pediat, Sendai, Miyagi 980, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
EI 1557-7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD DEC 1
PY 2013
VL 24
IS 12
BP A150
EP A150
PG 1
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA 271UU
UT WOS:000328417900453
ER
PT J
AU Efroni, S
Meerzaman, D
Schaefer, CF
Greenblum, S
Soo-Lyu, M
Hu, Y
Cultraro, C
Meshorer, E
Buetow, KH
AF Efroni, Sol
Meerzaman, Daoud
Schaefer, Carl F.
Greenblum, Sharon
Soo-Lyu, Myung
Hu, Ying
Cultraro, Constance
Meshorer, Eran
Buetow, Kenneth H.
TI Systems analysis utilising pathway interactions identifies sonic
hedgehog pathway as a primary biomarker and oncogenic target in
hepatocellular carcinoma
SO IET SYSTEMS BIOLOGY
LA English
DT Article
DE bioinformatics; cancer; cellular biophysics; genetics; liver; molecular
biophysics; RNA; systems analysis; tumours; biomedical informatics;
human liver cancer; network underpinning HCC aetiology; liver cancer
cell line; cell proliferation; SHH gene expression; siRNA-mediated
silencing; CDK7 levels; phosphorylated cyclin B1; Western blot analysis;
in silico findings; SHH pathway; human hepatocellular carcinoma;
tumour-adjacent samples; gene network; integrated computational
approach; oncogenic drivers; biologic processes; cancer development;
biological networks; cancer progression; oncogenic target; primary
biomarker; sonic hedgehog pathway; pathway interactions; systems
analysis
ID SIGNALING PATHWAY; PROTEIN NETWORKS; GENE-EXPRESSION; CANCER;
MICROARRAY; PROLIFERATION; PREDICTION; CELLS
AB The development and progression of cancer is associated with disruption of biological networks. Historically studies have identified sets of signature genes involved in events ultimately leading to the development of cancer. Identification of such sets does not indicate which biologic processes are oncogenic drivers and makes it difficult to identify key networks to target for interventions. Using a comprehensive, integrated computational approach, the authors identify the sonic hedgehog (SHH) pathway as the gene network that most significantly distinguishes tumour and tumour-adjacent samples in human hepatocellular carcinoma (HCC). The analysis reveals that the SHH pathway is commonly activated in the tumour samples and its activity most significantly differentiates tumour from the non-tumour samples. The authors experimentally validate these in silico findings in the same biologic material using Western blot analysis. This analysis reveals that the expression levels of SHH, phosphorylated cyclin B1, and CDK7 levels are much higher in most tumour tissues as compared to normal tissue. It is also shown that siRNA-mediated silencing of SHH gene expression resulted in a significant reduction of cell proliferation in a liver cancer cell line, SNU449 indicating that SHH plays a major role in promoting cell proliferation in liver cancer. The SHH pathway is a key network underpinning HCC aetiology which may guide the development of interventions for this most common form of human liver cancer.
C1 [Efroni, Sol] Bar Ilan Univ, Mina & Everard Goodman Life Sci Fac, Ramat Gan, Israel.
[Meerzaman, Daoud; Soo-Lyu, Myung; Hu, Ying; Cultraro, Constance; Buetow, Kenneth H.] NIH, Lab Populat Genet, Bethesda, MD 20892 USA.
[Schaefer, Carl F.; Greenblum, Sharon; Buetow, Kenneth H.] NCI, Ctr Biomed Informat, NIH, Rockville, MD 20852 USA.
[Meshorer, Eran] Hebrew Univ Jerusalem, Dept Genet, IL-91904 Jerusalem, Israel.
[Buetow, Kenneth H.] Arizona State Univ, Tempe, AZ 85287 USA.
[Buetow, Kenneth H.] Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA.
RP Efroni, S (reprint author), Bar Ilan Univ, Mina & Everard Goodman Life Sci Fac, Ramat Gan, Israel.
EM kenneth.buetow@asu.edu
FU NIH, National Cancer Institute
FX This research was supported by the Intramural Research Program of the
NIH, National Cancer Institute.
NR 28
TC 2
Z9 3
U1 0
U2 3
PU INST ENGINEERING TECHNOLOGY-IET
PI HERTFORD
PA MICHAEL FARADAY HOUSE SIX HILLS WAY STEVENAGE, HERTFORD SG1 2AY, ENGLAND
SN 1751-8849
EI 1751-8857
J9 IET SYST BIOL
JI IET Syst. Biol.
PD DEC
PY 2013
VL 7
IS 6
BP 243
EP 251
DI 10.1049/iet-syb.2010.0078
PG 9
WC Cell Biology; Mathematical & Computational Biology
SC Cell Biology; Mathematical & Computational Biology
GA 284YH
UT WOS:000329357800002
PM 24712101
ER
PT J
AU Stratakis, CA
AF Stratakis, Constantine A.
TI An Aroma of Complexity: How the Unique Genetics of Aromatase (CYP19A1)
Explain Diverse Phenotypes From Hens and Hyenas to Human Gynecomastia,
and Testicular and Other Tumors
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Editorial Material
ID TISSUE-SPECIFIC EXPRESSION; PEUTZ-JEGHERS-SYNDROME; PREPUBERTAL
GYNECOMASTIA; EXCESS SYNDROME; POSTMENOPAUSAL WOMEN; BREAST-CANCER;
DOMINANT TRANSMISSION; ESTROGEN BIOSYNTHESIS; FAMILIAL GYNECOMASTIA;
SEBRIGHT BANTAM
C1 [Stratakis, Constantine A.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Endocrinol & Genet, Program Dev Endocrinol & Genet, Bethesda, MD 20892 USA.
[Stratakis, Constantine A.] NIH, Interinst Pediat Endocrinol Training Program, Bethesda, MD 20892 USA.
RP Stratakis, CA (reprint author), NICHHD, East Labs, Sect Endocrinol & Genet, Program Dev Endocrinol & Genet,NIH, Room 1-3330,Bldg 10 CRC,10 Ctr Dr, Bethesda, MD 20892 USA.
EM stratakc@mail.nih.gov
FU Intramural NIH HHS
NR 73
TC 3
Z9 3
U1 0
U2 6
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD DEC
PY 2013
VL 98
IS 12
BP 4676
EP 4681
DI 10.1210/jc.2013-3990
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 272RF
UT WOS:000328477200038
PM 24311795
ER
PT J
AU Guettier, JM
Lungu, A
Goodling, A
Cochran, C
Gorden, P
AF Guettier, Jean-Marc
Lungu, Andreea
Goodling, Anne
Cochran, Craig
Gorden, Phillip
TI The Role of Proinsulin and Insulin in the Diagnosis of Insulinoma: A
Critical Evaluation of the Endocrine Society Clinical Practice Guideline
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID ISLET CELL TUMORS; CIRCULATING INSULIN; PLASMA PROINSULIN; COMPONENT
AB Context: An end of fast insulin >= 3 mu IU/mL and a proinsulin concentration >= 5 pmol/L have been suggested as useful cutoffs for the diagnosis of insulinoma.
Objective: The main objective was to evaluate the diagnostic performance of an end of fast insulin concentration >= 3 mu IU/mL and an end of fast proinsulin concentration >= 5 pmol/L.
Design: The design was a case-control series.
Setting: The setting was a tertiary-care center.
Patients: Fifty-six subjects with a positive 48-hour supervised fast had an insulinoma between June 2000 and April 2011. During this same time period, a diagnosis of insulinoma was excluded in 29 subjects who underwent a supervised fast.
Intervention: 48-hour supervised fast.
Main Outcome Measure: The main outcome measures were serum insulin concentration and plasma proinsulin concentration.
Results: Ninety-one percent of the patients with an insulinoma had a measured insulin concentration >= 5 mu IU/mL at the end of fast. The sensitivity increased to 98% if the threshold to define inadequate insulin suppression was lowered to >= 3 mu IU/mL. The median (interquartile range) end of fast proinsulin was 100 (53-270) pmol/L for cases and 6.8 (4.2-12.0) pmol/L for controls. An end of fast proinsulin value of >5 pmol/L could not distinguish cases from controls (59% false positive rate). All patients with an insulinoma (sensitivity 100%) and none of the control subject (specificity 100%) had end of fast proinsulin concentration >= 27 pmol/L.
Conclusions: Using a current insulin assay 9% of insulinoma cases end the supervised fast with an insulin concentration below 5 mu IU/mL. Inadequate insulin suppression defined using a threshold of >= 3 mu IU/mL increases the sensitivity of the test. The value of the proinsulin test lies in its unique ability to distinguish cases from controls. A proinsulin concentration of >= 22 pmol/L best discriminates cases from controls. Reliance on an end of fast proinsulin cutoff value of 5 pmol/L does not augment sensitivity but greatly reduces specificity of the test.
C1 [Guettier, Jean-Marc; Lungu, Andreea; Goodling, Anne; Cochran, Craig; Gorden, Phillip] NIDDK, NIH, Bethesda, MD 20892 USA.
[Guettier, Jean-Marc] US FDA, Div Metab & Endocrinol Prod, Silver Spring, MD 20903 USA.
RP Guettier, JM (reprint author), Bldg 10 CRC,Room 6-5952,10 Ctr Dr, Bethesda, MD 20892 USA.
EM Jean-Marc.Guettier@fda.hhs.gov
FU National Institute of Diabetes and Digestive and Kidney Diseases at the
National Institutes of Health
FX This work was supported by the Intramural Research Program of the
National Institute of Diabetes and Digestive and Kidney Diseases at the
National Institutes of Health.
NR 16
TC 14
Z9 15
U1 0
U2 3
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD DEC
PY 2013
VL 98
IS 12
BP 4752
EP 4758
DI 10.1210/jc.2013-2182
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 272RF
UT WOS:000328477200047
PM 24081736
ER
PT J
AU Schlogl, M
Piaggi, P
Thiyyagura, P
Reiman, EM
Chen, KW
Lutrin, C
Krakoff, J
Thearle, MS
AF Schloegl, Mathias
Piaggi, Paolo
Thiyyagura, Pradeep
Reiman, Eric M.
Chen, Kewei
Lutrin, Calvin
Krakoff, Jonathan
Thearle, Marie S.
TI Overfeeding Over 24 Hours Does Not Activate Brown Adipose Tissue in
Humans
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID THERMOGENIC RESPONSES; OBESITY; FAT
AB Context: Human brown adipose tissue (BAT) is activated with cold exposure, but it is unknown whether overfeeding activates BAT.
Objective: We determined BAT activation with cold, fasting, and overfeeding and the relationship of BAT activation with future weight change.
Design, Setting, Participants, and Interventions: Sixteen healthy adults were evaluated during energy balance, fasting, and 24 hours of 200% overfeeding. All subjects had a fluorodeoxyglucose-positron emission tomography (PET) scan after exposure to 16 degrees C to determine cold-induced BAT activity (CIBA). The first six subjects had a second PET scan after 36 hours of fasting to establish the lack of BAT activation at 22 degrees C. The other subjects' second PET scan occurred after 24 hours of overfeeding at 22 degrees C but only if they demonstrated CIBA. Twelve subjects returned at 6 months for reassessment of body composition.
Main Outcome Measures: BAT was defined in cool scans as voxels with a standardized uptake value (SUV) of 2.0 or greater and Hounsfield units between -250 and -10. Body composition was assessed by dual-energy x-ray absorptiometry.
Results: Although 75% of the subjects demonstrated visible CIBA, none had visual BAT activity after overfeeding. CIBA was greater than that observed in the same defined BAT voxels after fasting (n = 6; 2.9 +/- 0.5 vs 1.2 +/- 0.2; Delta = -1.7; 95% confidence interval -2.4, -1.0 SUV; P < .01). In the second cohort, CIBA was also higher than observed BAT voxel activity after 24 hours overfeeding (n = 8; 3.5 +/- 0.7 vs 0.9 +/- 0.2; Delta = -2.6; 95% confidence interval -3.2, -1.9 SUV; P < .01). Baseline CIBA negatively correlated with changes in fat mass after 6 months (r = -0.72, P = .009).
Conclusions: BAT may be important in weight regulation unrelated to the response to overeating.
C1 [Schloegl, Mathias; Piaggi, Paolo; Krakoff, Jonathan; Thearle, Marie S.] NIDDK, Phoenix Epidemiol & Clin Res Branch, NIH, Phoenix, AZ 85016 USA.
[Thiyyagura, Pradeep; Reiman, Eric M.; Chen, Kewei] Banner Alzheimers Inst Phoenix, Phoenix, AZ 85006 USA.
[Thiyyagura, Pradeep; Reiman, Eric M.; Chen, Kewei; Lutrin, Calvin] Banner Good Samaritan Med Ctr Phoenix, Phoenix, AZ 85006 USA.
RP Schlogl, M (reprint author), NIDDK, Obes & Diabet Clin Res Sect, NIH, 4212 North 16th St,5th Floor, Phoenix, AZ 85016 USA.
EM mathias.schlogl@nih.gov
RI Chen, kewei/P-6304-2015;
OI Chen, kewei/0000-0001-8497-3069; Piaggi, Paolo/0000-0003-2774-9161
FU Intramural Research Program of the National Institute of Diabetes and
Digestive and Kidney Diseases, National Institutes of Health
FX This work was supported by the Intramural Research Program of the
National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health.
NR 20
TC 12
Z9 12
U1 0
U2 6
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD DEC
PY 2013
VL 98
IS 12
BP E1956
EP E1960
DI 10.1210/jc.2013-2387
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 272RF
UT WOS:000328477200012
PM 24081739
ER
PT J
AU Drwal, MN
Agama, K
Pommier, Y
Griffith, R
AF Drwal, Malgorzata N.
Agama, Keli
Pommier, Yves
Griffith, Renate
TI Development of purely structure-based pharmacophores for the
topoisomerase I-DNA-ligand binding pocket
SO JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
LA English
DT Article
DE Structure-based pharmacophores; LUDI; Virtual screening; DNA
topoisomerase I
ID DRUG DISCOVERY; COVALENT COMPLEX; POSE PREDICTION; FORCE-FIELD;
INHIBITORS; PERSPECTIVE; VALIDATION; CHALLENGES; ALGORITHM; MECHANISM
AB Purely structure-based pharmacophores (SBPs) are an alternative method to ligand-based approaches and have the advantage of describing the entire interaction capability of a binding pocket. Here, we present the development of SBPs for topoisomerase I, an anticancer target with an unusual ligand binding pocket consisting of protein and DNA atoms. Different approaches to cluster and select pharmacophore features are investigated, including hierarchical clustering and energy calculations. In addition, the performance of SBPs is evaluated retrospectively and compared to the performance of ligand- and complex-based pharmacophores. SBPs emerge as a valid method in virtual screening and a complementary approach to ligand-focussed methods. The study further reveals that the choice of pharmacophore feature clustering and selection methods has a large impact on the virtual screening hit lists. A prospective application of the SBPs in virtual screening reveals that they can be used successfully to identify novel topoisomerase inhibitors.
C1 [Drwal, Malgorzata N.; Griffith, Renate] Univ New S Wales, Dept Pharmacol, Sch Med Sci, Sydney, NSW 2052, Australia.
[Agama, Keli; Pommier, Yves] NCI, Mol Pharmacol Lab, Ctr Canc Res, Bethesda, MD 20892 USA.
RP Griffith, R (reprint author), Univ New S Wales, Dept Pharmacol, Sch Med Sci, Sydney, NSW 2052, Australia.
EM r.griffith@unsw.edu.au
RI Griffith, Renate/A-3584-2015; Drwal, Malgorzata/B-6461-2015
OI Griffith, Renate/0000-0001-7739-5686;
FU Intramural Research Program of the National Institutes of Health,
National Cancer Institute, Center for Cancer Research; University of New
South Wales, Australia; Translational Cancer Research Network (TCRN)
Australia
FX This research was supported in part by the Intramural Research Program
of the National Institutes of Health, National Cancer Institute, Center
for Cancer Research. The authors gratefully acknowledge the NCI
Developmental Therapeutics Program (http://dtp.cancer.gov) for providing
compound samples. The authors acknowledge Tom Dupree for the use of his
script to superimpose proteins by tethers. M. D. acknowledges financial
assistance from the University of New South Wales, Australia, in
providing a PhD scholarship in the form of a University International
Postgraduate Award (UIPA), as well as the Translational Cancer Research
Network (TCRN) Australia for providing a Postgraduate Research
Scholarship Top-up in 2012.
NR 37
TC 3
Z9 3
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-654X
EI 1573-4951
J9 J COMPUT AID MOL DES
JI J. Comput.-Aided Mol. Des.
PD DEC
PY 2013
VL 27
IS 12
BP 1037
EP 1049
DI 10.1007/s10822-013-9695-x
PG 13
WC Biochemistry & Molecular Biology; Biophysics; Computer Science,
Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Computer Science
GA 283HX
UT WOS:000329238200003
PM 24293134
ER
PT J
AU Chang, L
Shoptaw, S
Normand, J
AF Chang, Linda
Shoptaw, Steven
Normand, Jacques
TI Brain abnormalities in HIV and stimulant users: Interventions and
prevention
SO JOURNAL OF FOOD AND DRUG ANALYSIS
LA English
DT Article; Proceedings Paper
CT International Conference on Global Health (ICGH)
CY APR 17-19, 2013
CL Taipei, TAIWAN
DE Brain abnormalities; HIV prevention; Neurocognitive disorder; Stimulant
use
ID METABOLITES
AB The session, "HIV and other Infectious Diseases," was chaired by Dr. Jacques Normand, Director of the AIDS Research Program of the US National Institute on Drug Abuse. The two presenters (and their presentation topics) were: Dr. Linda Chang ("Neural Correlates of Cognitive Deficits and Training Effects on Brain Function in HIV-infected Individuals") and Dr. Steven Shoptaw ("HIV Prevention in Substance Users"). Copyright (C) 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan LLC. All rights reserved.
C1 [Chang, Linda] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96813 USA.
[Shoptaw, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Behav & Addict Med, Dept Family Med, Los Angeles, CA 90095 USA.
[Normand, Jacques] Natl Inst Drug Abuse, AIDS Res Program, Bethesda, MD USA.
RP Chang, L (reprint author), Univ Hawaii, John A Burns Sch Med, Dept Med, 1356 Lusitana St,Univ Tower,7th Floor, Honolulu, HI 96813 USA.
EM lchang@hawaii.edu
FU NIDA NIH HHS [R13 DA035084, P30 DA016383]; NIMH NIH HHS [P30 MH058107]
NR 8
TC 1
Z9 1
U1 0
U2 1
PU FOOD & DRUG ADMINSTRATION
PI TAIPEI
PA 161-2 KUNYANG STREET, NANGANG, TAIPEI, 00000, TAIWAN
SN 1021-9498
J9 J FOOD DRUG ANAL
JI J. Food Drug Anal.
PD DEC
PY 2013
VL 21
SU 4
BP S7
EP S9
DI 10.1016/j.jfda.2013.09.021
PG 3
WC Food Science & Technology; Pharmacology & Pharmacy
SC Food Science & Technology; Pharmacology & Pharmacy
GA 285VJ
UT WOS:000329422800005
PM 25264417
ER
PT J
AU Hser, YI
Chang, LD
Wang, GJ
Li, MD
Rawson, R
Shoptaw, S
Normand, J
Tai, B
AF Hser, Yih-Ing
Chang, Linda
Wang, Gene-Jack
Li, Ming D.
Rawson, Richard
Shoptaw, Steven
Normand, Jacques
Tai, Betty
TI Capacity building and collaborative research on cross-national studies
in the Asian region
SO JOURNAL OF FOOD AND DRUG ANALYSIS
LA English
DT Article; Proceedings Paper
CT International Conference on Global Health (ICGH)
CY APR 17-19, 2013
CL Taipei, TAIWAN
DE Asia; Capacity building; Collaborative research; Cross-national studies
ID NICOTINE DEPENDENCE; JAPANESE POPULATION; APOLIPOPROTEIN-E; RECEPTOR;
BRAIN; ASSOCIATION; GENE; PSYCHOSIS; VARIANTS; EXPOSURE
AB To build capacity and collaborative research for future cross-national studies in the Asian and Pacific Islander (API) region, priority research topics were identified and discussed at the April 2013 Conference to Promote Global Health in Taipei. These topics included: (1) neuroscience on human immunodeficiency virus (HIV)/hepatitis C virus (HCV) and amphetamine-type stimulants (ATS), led by Drs Linda Chang, Gene-Jack Wang, and Betty Tai; (2) ATS and mental health disorders, led by Drs Richard Rawson and Wilson Compton; and (3) HIV/HCV transmission and social networks, led by Drs Steven Shoptaw and Jacques Normand. Potential genetic studies spanning these topical areas as well as the importance of smoking cessation were further discussed, led by Dr Ming Li. Additional priority research topics were also identified: (4) drug use prevention; and (5) family involvement to improve treatment adherence and recovery. Workgroups on these topics will be formed to prioritize research questions within the respective topical area and to determine the next steps. The ultimate goal of these workgroups is to stimulate collaboration that will eventually lead to research studies addressing critical issues related to the rising substance abuse and HIV infection rates in many Asian countries and, at the same time, to advance the scientific knowledge of substance abuse and HIV infection. Copyright (C) 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan LLC. All rights reserved.
C1 [Hser, Yih-Ing; Rawson, Richard] Univ Calif Los Angeles, Integrated Substance Abuse Programs, Dept Psychiat & Biobehav Sci, David Geffen Sch Med, Los Angeles, CA 90025 USA.
[Chang, Linda] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA.
[Wang, Gene-Jack] SUNY Stony Brook, Stony Brook, NY 11794 USA.
[Li, Ming D.] Univ Virginia, Sch Med, Dept Psychiat & Neurobehav Sci, Charlottesville, VA 22908 USA.
[Shoptaw, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, Ctr Behav & Addict Med, Los Angeles, CA 90025 USA.
[Normand, Jacques] NIDA, AIDS Res Program, Bethesda, MD 20892 USA.
[Tai, Betty] NIDA, Ctr Clin Trials Network, Bethesda, MD 20892 USA.
[Hser, Yih-Ing] China Med Univ, Dept Publ Hlth, Taichung, Taiwan.
RP Hser, YI (reprint author), Univ Calif Los Angeles, Integrated Substance Abuse Programs, 11075 Santa Monica Blvd,Suite 100, Los Angeles, CA 90025 USA.
EM yhser@ucla.edu
FU US National Institute,on Drug Abuse (NIDA) [R13 DA 035084-01/PA10-071,
P30DA016383]; NIDA Asian American and Pacific Islander (AAPI) Workgroup
[API-AS.NET201303]
FX Funding for this conference was made possible (in part) by grant R13 DA
035084-01/PA10-071 and P30DA016383 (Center for Advancing Longitudinal
Drug Abuse Research, or CALDAR) from the US National Institute,on Drug
Abuse (NIDA). This special edition is partially supported by the NIDA
Asian American and Pacific Islander (AAPI) Workgroup project
API-AS.NET201303. The views expressed in written conference materials or
publications and by the speakers and moderators do not necessarily
reflect the official policies of the US Department of Health and Human
Services, nor does the mention of trade names, commercial practices, or
organizations imply endorsement by the US government. The authors thank
Dr Wilson Compton for his contributions as a workgroup leader and
conference presenter.
NR 25
TC 2
Z9 2
U1 1
U2 7
PU FOOD & DRUG ADMINSTRATION
PI TAIPEI
PA 161-2 KUNYANG STREET, NANGANG, TAIPEI, 00000, TAIWAN
SN 1021-9498
J9 J FOOD DRUG ANAL
JI J. Food Drug Anal.
PD DEC
PY 2013
VL 21
SU 4
BP S117
EP S122
DI 10.1016/j.jfda.2013.09.048
PG 6
WC Food Science & Technology; Pharmacology & Pharmacy
SC Food Science & Technology; Pharmacology & Pharmacy
GA 285VJ
UT WOS:000329422800032
PM 24567700
ER
PT J
AU Hser, YI
Tsay, WI
Wang, Y
Tai, B
AF Hser, Yih-Ing
Tsay, Wen-Ing
Wang, Yun
Tai, Betty
TI Introduction to the Special Issue: Promoting global health-Treatment and
prevention of substance abuse and HIV in Asia
SO JOURNAL OF FOOD AND DRUG ANALYSIS
LA English
DT Editorial Material
C1 [Hser, Yih-Ing] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Integrated Substance Abuse Programs, Los Angeles, CA 90095 USA.
[Tsay, Wen-Ing] Food & Drug Adm, Div Controlled Drugs, Minist Hlth & Welf, Taipei, Taiwan.
[Wang, Yun] Natl Hlth Res Inst, Ctr Neuropsychiat Res, Miaoli, Taiwan.
[Tai, Betty] Natl Inst Drug Abuse, Ctr Clin Trials Network, Bethesda, MD USA.
RP Hser, YI (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Integrated Substance Abuse Programs, Los Angeles, CA 90095 USA.
FU NIDA NIH HHS [R13 DA035084, P30 DA016383]
NR 0
TC 0
Z9 0
U1 0
U2 2
PU FOOD & DRUG ADMINSTRATION
PI TAIPEI
PA 161-2 KUNYANG STREET, NANGANG, TAIPEI, 00000, TAIWAN
SN 1021-9498
J9 J FOOD DRUG ANAL
JI J. Food Drug Anal.
PD DEC
PY 2013
VL 21
SU 4
BP S3
EP S3
DI 10.1016/j.jfda.2013.09.019
PG 1
WC Food Science & Technology; Pharmacology & Pharmacy
SC Food Science & Technology; Pharmacology & Pharmacy
GA 285VJ
UT WOS:000329422800003
PM 25278733
ER
EF